PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bennett, HJ				Bennett, HJ			Apgar scores for dads	BRITISH MEDICAL JOURNAL			English	Article											Bennett, HJ (corresponding author), 9 Avalon Court, Bethesda, MD 20816 USA.							APGAR V, 1953, ANESTH ANALG CLEVE, V32, P260, DOI DOI 10.1213/00000539-195301000-00041; FERGUSON L, 1997, J DUBIOUS INVEST, V39, P658; RANDOLPH D, 1996, ARCH UTERUS, V43, P127	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1712	1712		10.1136/bmj.317.7174.1712	http://dx.doi.org/10.1136/bmj.317.7174.1712			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857138	Green Published			2022-12-28	WOS:000077742300028
J	Wills-Karp, M; Luyimbazi, J; Xu, XY; Schofield, B; Neben, TY; Karp, CL; Donaldson, DD				Wills-Karp, M; Luyimbazi, J; Xu, XY; Schofield, B; Neben, TY; Karp, CL; Donaldson, DD			Interleukin-13: Central mediator of allergic asthma	SCIENCE			English	Article							EOSINOPHILIC INFLAMMATION; AIRWAY HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; T-LYMPHOCYTES; TRENDS; HOSPITALIZATION; EXPRESSION; IL-13; MICE	The worldwide incidence, morbidity, and mortality of allergic asthma are increasing. The pathophysiological features of allergic asthma are thought to result from the aberrant expansion of CD4(+) T cells producing the type 2 cytokines interleukin-4 (IL-4) and IL-5, although a necessary role for these cytokines in allergic asthma has not been demonstrable. The type 2 cytokine IL-13, which shares a receptor component and signaling pathways with IL-4, was found to be necessary and sufficient for the expression of allergic asthma. IL-13 induces the pathophysiological features of asthma in a manner that is independent of immunoglobulin E and eosinophils. Thus, IL-13 is critical to allergen-induced asthma but operates through mechanisms other than those that are classically implicated in allergic responses.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Genet Inst, Dept Immunol, Cambridge, MA 02140 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wills-Karp, M (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.	mkarp@welchlink.welch.jhu.edu		Karp, Christopher/0000-0002-0832-2659	NHLBI NIH HHS [HL58527] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058527] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FRIEDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Goebeler M, 1997, IMMUNOLOGY, V91, P450, DOI 10.1046/j.1365-2567.1997.00263.x; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HERSHEY GK, 1977, NEW ENGL J MED, V337, P1720; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; JACKSON R, 1988, CHEST, V94, P914, DOI 10.1378/chest.94.5.914; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; LUYIMBAZI J, UNPUB; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; PAUWELS R, 1989, CLIN EXP ALLERGY, V19, P395, DOI 10.1111/j.1365-2222.1989.tb02404.x; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosenwasser LJ, 1997, NEW ENGL J MED, V337, P1766, DOI 10.1056/NEJM199712113372412; SLY RM, 1984, ANN ALLERGY, V53, P20; TESSLER DC, 1991, GENE, V2, P177; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; VOLLMER WM, 1992, J CLIN EPIDEMIOL, V45, P999, DOI 10.1016/0895-4356(92)90115-4; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	43	2201	2326	2	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2258	2261		10.1126/science.282.5397.2258	http://dx.doi.org/10.1126/science.282.5397.2258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856949				2022-12-28	WOS:000077645800047
J	Chervitz, SA; Aravind, L; Sherlock, G; Ball, CA; Koonin, EV; Dwight, SS; Harris, MA; Dolinski, K; Mohr, S; Smith, T; Weng, S; Cherry, JM; Botstein, D				Chervitz, SA; Aravind, L; Sherlock, G; Ball, CA; Koonin, EV; Dwight, SS; Harris, MA; Dolinski, K; Mohr, S; Smith, T; Weng, S; Cherry, JM; Botstein, D			Comparison of the complete protein sets of worm and yeast: Orthology and divergence	SCIENCE			English	Review							NEMATODE CAENORHABDITIS-ELEGANS; CELL-LINEAGE; GENES; IDENTIFICATION; GENERATION; CEREVISIAE; SEQUENCES; DOMAINS; HOMOLOG; CYCLE	Comparative analysis of predicted protein sequences encoded by the genomes of Caenorhabditis elegans and Saccharomyces cerevisiae suggests that most of the core biological functions are carried out by orthologous proteins (proteins of different species that can be traced back to a common ancestor) that occur in comparable numbers. The specialized processes of signal transduction and regulatory control that are unique to the multicellular worm appear to use novel proteins, many of which re-use conserved domains. Major expansion of the number of some of these domains seen in the worm may have contributed to the advent of multicellularity, The proteins conserved in yeast and worm are Likely to have orthologs throughout eukaryotes; in contrast, the proteins unique to the worm may well define metazoans.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02115 USA	Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Boston University	Chervitz, SA (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.		Sherlock, Gavin J/B-1831-2009; Sherlock, Gavin J/E-9110-2012; Dolinski, Kara/GPP-4026-2022	Harris, Midori/0000-0003-4148-4606; Dolinski, Kara/0000-0002-7010-0264; Cherry, J. Michael/0000-0001-9163-5180; Aravind, L/0000-0003-0771-253X; Sherlock, Gavin/0000-0002-1692-4983	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U41HG001315, P41HG001315, K22HG000044, T32HG000044] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG000044, K22 HG000044, U24 HG001315, P41 HG001315-16, U41 HG001315, P41 HG001315, HG 00044, HG01315] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHERRY JJ, UNPUB; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; GALPERIN MY, 1998, SILICO BIOL, V1, P7; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HALL TM, 1996, CELL, V91, P85; HENNIKOF S, 1997, SCIENCE, V278, P609; HERMAN RK, 1982, GENETICS, V102, P379; HESCHL MFP, 1990, COMP BIOCHEM PHYS B, V96, P633, DOI 10.1016/0305-0491(90)90206-9; HORVITZ HR, 1980, GENETICS, V96, P435; Karatsuba A. A., 1985, USP MAT NAUK, V40, P19; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MARSH L, 1988, COLD SPRING HARB SYM, V53, P557, DOI 10.1101/SQB.1988.053.01.064; MORI H, 1994, MOL GEN GENET, V245, P781, DOI 10.1007/BF00297285; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OKIMOTO R, 1994, J MOL EVOL, V39, P598, DOI 10.1007/BF00160405; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; ROGALSKI TM, 1988, GENETICS, V118, P61; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sternberg P.W., 1990, Advances in Genetics, V27, P63; Sternberg PW, 1997, CURR OPIN GENET DEV, V7, P543, DOI 10.1016/S0959-437X(97)80084-6; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	40	346	354	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2022	2028		10.1126/science.282.5396.2022	http://dx.doi.org/10.1126/science.282.5396.2022			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851918	Green Accepted			2022-12-28	WOS:000077467100036
J	Yano, S; Tokumitsu, H; Sodeling, TR				Yano, S; Tokumitsu, H; Sodeling, TR			Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway	NATURE			English	Article							MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; DEATH; AKT; CASCADE; PHOSPHORYLATION; CALMODULIN; BAD; DEPOLARIZATION; 3-KINASE	The protection against apoptosis provided by growth factors in several cell lines is due to stimulation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway, which results in activation of protein kinase B-1,B-2 (PKB; also known as c-Akt and Rac) and phosphorylation and sequestration to protein 14-3-3 of the pro-apoptotic Bcl-2-family member BAD(3-7). A modest increase in intracellular Ca2+ concentration also promotes survival of some cultured neurons(8,9) through a pathway that requires calmodulin but is independent of PI(3)K and the MAP kinases(10,11), Here we report that Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK) activates PKB directly, resulting in phosphorylation of BAD on serine residue 136 and the interaction of BAD with protein 14-3-3, Serum withdrawal induced a three- to fourfold increase in cell death of NG108 neuroblastoma cells, and this apoptosis was largely blocked by increasing the intracellular Ca2+ concentration with NMDA (N-methyl-D-aspartate) or KCl or by transfection with constitutively active CaM-KK. The effect of NMDA on cell survival was blocked by transfection with dominant-negative forms of CaM-KK or PKB. These results identify a Ca2+-triggered signalling cascade in which CaM-KK activates PKB, which in turn phosphorylates BAD and protects cells from apoptosis.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Sodeling, TR (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.	soderlit@ohsu.edu	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FURBER S, 1987, J NEUROSCI, V7, P1816; GALLO V, 1987, J NEUROSCI, V7, P2203; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SEBERT MA, 1995, J BIOL CHEM, V270, P17616; Soler RM, 1998, J NEUROSCI, V18, P1230; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	28	527	552	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					584	587		10.1038/25147	http://dx.doi.org/10.1038/25147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859994				2022-12-28	WOS:000077466800060
J	Matsukawa, Y; Nishinarita, S; Horie, T; Naruse, S				Matsukawa, Y; Nishinarita, S; Horie, T; Naruse, S			Anaphylaxis induced by gabexate mesylate	BRITISH MEDICAL JOURNAL			English	Letter									Nihon Univ, Sch Med, Itabashi Ku, Tokyo 173, Japan	Nihon University	Matsukawa, Y (corresponding author), Nihon Univ, Sch Med, Itabashi Ku, Tokyo 173, Japan.							BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165; Cavallini G, 1996, NEW ENGL J MED, V335, P919, DOI 10.1056/NEJM199609263351302; Novelli G P, 1995, Minerva Anestesiol, V61, P509	3	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1563	1563		10.1136/bmj.317.7172.1563	http://dx.doi.org/10.1136/bmj.317.7172.1563			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836656	Green Submitted, Green Published			2022-12-28	WOS:000077451700026
J	Moss, S; Cuckle, H				Moss, S; Cuckle, H			Trial of mammography in women under 50 is ethical	BRITISH MEDICAL JOURNAL			English	Letter									Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England; Univ Leeds, Leeds LS2 9NZ, W Yorkshire, England	University of London; Institute of Cancer Research - UK; University of Leeds	Moss, S (corresponding author), Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England.							Kmietowicz Z, 1998, BRIT MED J, V316, P1628	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1589	1590		10.1136/bmj.317.7172.1589	http://dx.doi.org/10.1136/bmj.317.7172.1589			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836674				2022-12-28	WOS:000077451700050
J	Peltola, H; Leinikki, P				Peltola, H; Leinikki, P			Rubella gene sequencing as a clinician's tool	LANCET			English	Editorial Material							INFECTION; OUTBREAK		Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.							Adams MS, 1997, EPIDEMIOL INFECT, V118, P253, DOI 10.1017/S0950268897007450; Bellini WJ, 1998, EMERG INFECT DIS, V4, P29, DOI 10.3201/eid0401.980105; Frenkel LM, 1996, CLIN INFECT DIS, V22, P287, DOI 10.1093/clinids/22.2.287; Frey TK, 1998, J INFECT DIS, V178, P642, DOI 10.1086/515370; Liitsola K, 1998, AIDS, V12, P1907, DOI 10.1097/00002030-199814000-00023; MELLINGER AK, 1995, PEDIATR INFECT DIS J, V14, P573, DOI 10.1097/00006454-199507000-00004; Mulders MN, 1997, J INFECT DIS, V176, P617, DOI 10.1086/514081; PELTOLA H, 1998, 38 INT C ANT AG CHEM; POYRY T, 1990, J GEN VIROL, V71, P2535, DOI 10.1099/0022-1317-71-11-2535; ZgorniakNowosielska I, 1996, EUR J EPIDEMIOL, V12, P303, DOI 10.1007/BF00145421	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1799	1800		10.1016/S0140-6736(05)79885-8	http://dx.doi.org/10.1016/S0140-6736(05)79885-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851377				2022-12-28	WOS:000077337900005
J	Gat, U; DasGupta, R; Degenstein, L; Fuchs, E				Gat, U; DasGupta, R; Degenstein, L; Fuchs, E			De novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin	CELL			English	Article							DROSOPHILA PATCHED GENE; GARDNERS-SYNDROME; SONIC HEDGEHOG; HUMAN HOMOLOG; STEM-CELLS; PROTEIN; APC; CARCINOGENESIS; ACTIVATION; MUTATIONS	An effector of intercellular adhesion, beta-catenin also functions in Wnt signaling, associating with Lef-1/Tcf DNA-binding proteins to form a transcription factor. We report that this pathway operates in keratinocytes and that mice expressing a stabilized beta-catenin controlled by an epidermal promoter undergo a process resembling de novo hair morphogenesis. The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. As in embryologically initiated hair germs, transgenic follicles induce Lef-1, but follicles are disoriented and defective in sonic hedgehog polarization. Additionally, proliferation continues unchecked, resulting in two types of tumors also found in humans. Our findings suggest that transient beta-catenin stabilization may be a key player in the long-sought epidermal signal reading to hair development and implicate aberrant beta-catenin activation in hair tumors.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Dasgupta, Ramanuj/0000-0001-9015-3729	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011921] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR31737] Funding Source: Medline; NIDCR NIH HHS [5P50-DE11921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COOPER PH, 1983, J AM ACAD DERMATOL, V8, P639, DOI 10.1016/S0190-9622(83)70071-X; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fitzpatrick TB, 1987, DERMATOLOGY GEN MED, P1841; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hardy M.H., 1992, TRENDS GENET, V8, P159; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LEPPARD BJ, 1976, CLIN EXP DERMATOL, V1, P75, DOI 10.1111/j.1365-2230.1976.tb01400.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; Manabe M, 1996, INT J DERMATOL, V35, P325, DOI 10.1111/j.1365-4362.1996.tb03632.x; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NARISAWA Y, 1995, J CUTAN PATHOL, V22, P115, DOI 10.1111/j.1600-0560.1995.tb01392.x; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; SENGEL P, 1990, International Journal of Developmental Biology, V34, P33; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZHOU P, 1995, GENE DEV, V9, P570	43	897	994	2	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					605	614		10.1016/S0092-8674(00)81631-1	http://dx.doi.org/10.1016/S0092-8674(00)81631-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845363	Bronze			2022-12-28	WOS:000077253700008
J	Black, AJ; McLeod, HL; Capell, HA; Powrie, RH; Matowe, LK; Pritchard, SC; Collie-Duguid, ESR; Reid, DM				Black, AJ; McLeod, HL; Capell, HA; Powrie, RH; Matowe, LK; Pritchard, SC; Collie-Duguid, ESR; Reid, DM			Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine	ANNALS OF INTERNAL MEDICINE			English	Article							HEART-TRANSPLANT RECIPIENT; INDUCED MYELOSUPPRESSION	Background: Substantial hematologic toxicity limits the use of azathioprine. Objective: To evaluate 1) polymorphic inactivation of azathioprine by thiopurine methyltransferase and 2) clinical toxicity. Design: Prospective cohort study. Setting: Two rheumatology units. Patients: 67 patients for whom azathioprine was prescribed as second-line therapy for rheumatic disease. Measurements: Polymerase chain reaction-based assays were used to detect mutations in thiopurine methyltransferase. The primary end point was discontinuation of azathioprine therapy because of toxicity. Results: Six of 67 patients (9%) were heterozygous for mutant thiopurine methyltransferase alleles. Five of the 6 patients discontinued therapy within 1 month of starting treatment because of low leukocyte counts. The sixth patient did not adhere to treatment. Patients with wild-type thiopurine methyltransferase alleles received therapy longer than did patients with mutant alleles (median duration of therapy, 39 weeks [range, 6 to 180 weeks] and 2 weeks [range, 2 to 4 weeks], respectively; P = 0.018). Conclusion: Analysis of thiopurine methyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine.	Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Aberdeen Royal Hosp Trust, Aberdeen, Scotland; Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland	University of Aberdeen; University of Glasgow	McLeod, HL (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland.	h.l.mcleod@abdn.ac.uk	McLeod, Howard/ABD-8364-2021; Collie-Duguid, Elaina S R/A-4432-2017	McLeod, Howard/0000-0002-9004-9232; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLARY S, 1995, ANN INTERN MED, V123, P32, DOI 10.7326/0003-4819-123-1-199507010-00004; Bergan S, 1997, THER DRUG MONIT, V19, P318, DOI 10.1097/00007691-199706000-00013; COLLIEDUGUID ES, IN PRESS PHARMACOGEN; GomezReino JJ, 1996, LANCET, V347, P343, DOI 10.1016/S0140-6736(96)90531-0; HOLLANDER AAMJ, 1995, LANCET, V345, P610, DOI 10.1016/S0140-6736(95)90520-0; KERSTENS PJSM, 1993, LANCET, V342, P1245, DOI 10.1016/0140-6736(93)92231-H; MCLEOD HL, 1995, BLOOD, V85, P1897, DOI 10.1182/blood.V85.7.1897.bloodjournal8571897; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; Palace J, 1997, LANCET, V350, P261, DOI 10.1016/S0140-6736(97)24030-4; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003	14	290	304	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					716	718		10.7326/0003-4819-129-9-199811010-00007	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841604				2022-12-28	WOS:000076785200006
J	Bridge, DT; Gilbert, J				Bridge, DT; Gilbert, J			An international work exchange: better than a midlife crisis	BRITISH MEDICAL JOURNAL			English	Article									Royal Perth Hosp, Perth, WA 6001, Australia; Exeter & Dist Hospice, Exeter EX2 5JJ, Devon, England	Royal Perth Hospital; University of Western Australia	Bridge, DT (corresponding author), Royal Perth Hosp, X2213, Perth, WA 6001, Australia.							FEEHALLY J, 1994, J ROY COLL PHYS LOND, V28, P372; HANDYSIDES S, 1994, BRIT MED J, V308, P114, DOI 10.1136/bmj.308.6921.114; JARECKY RK, 1986, J MED EDUC, V61, P803; VEALE D, 1992, BRIT J HOSP MED, V48, P671; Vickman L, 1996, ANN EMERG MED, V27, P668, DOI 10.1016/S0196-0644(96)70174-9; WOOD JB, 1994, BRIT MED J, V308, P1029, DOI 10.1136/bmj.308.6935.1029	6	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1709	1710		10.1136/bmj.317.7174.1709	http://dx.doi.org/10.1136/bmj.317.7174.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857136	Green Published			2022-12-28	WOS:000077742300024
J	Deary, IJ				Deary, IJ			Differences in mental abilities	BRITISH MEDICAL JOURNAL			English	Review							INTELLIGENCE		Univ Edinburgh, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland	University of Edinburgh	Deary, IJ (corresponding author), Univ Edinburgh, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				Bouchard TJ, 1998, HUM BIOL, V70, P257; Carroll J. B., 1993, HUMAN COGNITIVE ABIL, DOI DOI 1017/CBO9780511571312; Carroll JB, 1995, INTELLIGENCE, V21, P121, DOI 10.1016/0160-2896(95)90022-5; Deary IJ, 1997, TRENDS NEUROSCI, V20, P365, DOI 10.1016/S0166-2236(97)01070-9; Gould S. J., 1996, MISMEASURE MAN; GUSTAFSSON JE, 1984, INTELLIGENCE, V8, P179, DOI 10.1016/0160-2896(84)90008-4; Herrnstein R., 1994, BELL CURVE INTELLIGE; Hobbes T., 1651, LEVIATHAN; Jensen A. R., 1982, CONT ED REV, V1, P121; McClearn GE, 1997, SCIENCE, V276, P1560, DOI 10.1126/science.276.5318.1560; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; SCHALEKW, 1996, INTELLECTUAL DEV ADU; SCHWARTZMAN AE, 1987, CAN J PSYCHOL, V41, P244, DOI 10.1037/h0084155	13	8	9	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1701	1703		10.1136/bmj.317.7174.1701	http://dx.doi.org/10.1136/bmj.317.7174.1701			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151VX	9857133	Green Submitted, Green Published			2022-12-28	WOS:000077742300020
J	Martyn, C				Martyn, C			Snapshots from the decade of the brain - Exciting, but no cause for triumphalism	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1673	1673		10.1136/bmj.317.7174.1673	http://dx.doi.org/10.1136/bmj.317.7174.1673			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857118	Green Published			2022-12-28	WOS:000077742300004
J	Blackburn, N; Fenchel, T; Mitchell, J				Blackburn, N; Fenchel, T; Mitchell, J			Microscale nutrient patches in planktonic habitats shown by chemotactic bacteria	SCIENCE			English	Article							MARINE-BACTERIA; PHYTOPLANKTON GROWTH; NATURAL ASSEMBLAGES; MOTILITY; ZOOPLANKTON; RESPONSES	Are nutrients available to microbial communities in micropatches Long enough to influence growth and competition? And what are the sources of such patches? To answer these questions, the swimming behavior of chemotactic bacteria in seawater samples was examined. Clusters of bacteria formed in conjunction with cell Lysis and excretion by protozoa, These point sources of nutrients spread into spherical patches a few millimeters in diameter and sustained swarms of bacteria for about 10 minutes. Within that time, a large proportion of the nutrients was encountered by bacteria, chemotactic and nonchemotactic alike. Chemotaxis is advantageous for bacteria using patches over a certain size.	Univ Copenhagen, Marine Biol Lab, DK-3000 Helsingor, Denmark; Flinders Univ S Australia, Sch Biol, Adelaide, SA 5001, Australia	University of Copenhagen; Flinders University South Australia	Blackburn, N (corresponding author), Univ Copenhagen, Marine Biol Lab, Strandpromenaden 5, DK-3000 Helsingor, Denmark.		Fenchel, Tom/F-8979-2011	Fenchel, Tom/0000-0003-0023-2402; Mitchell, Jim/0000-0002-8445-0935				ANDERSSON A, 1985, MAR ECOL PROG SER, V23, P99, DOI 10.3354/meps023099; Azam F., 1984, FLOWS ENERGY MAT MAR, P345, DOI [10.1007/978-1-4757-0387-0_14, DOI 10.1007/978-1-4757-0387-0_14]; Barbara GM, 1996, APPL ENVIRON MICROB, V62, P3985, DOI 10.1128/AEM.62.11.3985-3990.1996; BELL W, 1972, BIOL BULL, V143, P265, DOI 10.2307/1540052; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; Blackburn N, 1997, LIMNOL OCEANOGR, V42, P613, DOI 10.4319/lo.1997.42.4.0613; BLACKBURN N, UNPUB; BOWEN JD, 1992, J FLUID MECH, V236, P95, DOI 10.1017/S0022112092001356; BROWN D A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1388, DOI 10.1073/pnas.71.4.1388; CURRIE DJ, 1984, J PLANKTON RES, V6, P591, DOI 10.1093/plankt/6.4.591; FENCHEL T, 1994, MICROBIOL-UK, V140, P3109, DOI 10.1099/13500872-140-11-3109; GOLDMAN JC, 1984, B MAR SCI, V35, P462; JACKSON GA, 1980, NATURE, V284, P439, DOI 10.1038/284439a0; JACKSON GA, 1987, LIMNOL OCEANOGR, V32, P1253, DOI 10.4319/lo.1987.32.6.1253; JUMARS PA, 1989, DEEP-SEA RES, V36, P483, DOI 10.1016/0198-0149(89)90001-0; KarpBoss L, 1996, OCEANOGR MAR BIOL, V34, P71; LEHMAN JT, 1982, P NATL ACAD SCI-BIOL, V79, P5001, DOI 10.1073/pnas.79.16.5001; MITCHELL JG, 1995, APPL ENVIRON MICROB, V61, P4436, DOI 10.1128/AEM.61.12.4436-4440.1995; MITCHELL JG, 1985, NATURE, V316, P58, DOI 10.1038/316058a0; Mitchell JG, 1996, APPL ENVIRON MICROB, V62, P3716, DOI 10.1128/AEM.62.10.3716-3721.1996; MITCHELL JG, 1995, APPL ENVIRON MICROB, V61, P877, DOI 10.1128/AEM.61.3.877-882.1995; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; Wheeler PA, 1983, NITROGEN MARINE ENV; WILLIAMS PJL, 1981, ECOHYDRODYNAMICS, P209	24	237	246	2	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2254	2256		10.1126/science.282.5397.2254	http://dx.doi.org/10.1126/science.282.5397.2254			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856947				2022-12-28	WOS:000077645800045
J	Paxton, LA; Kiwanuka, N; Nalugoda, F; Gray, R; Wawer, MJ				Paxton, LA; Kiwanuka, N; Nalugoda, F; Gray, R; Wawer, MJ		Rakai Project Study Grp	Community based study of treatment seeking among subjects with symptoms of sexually transmitted disease in rural Uganda	BRITISH MEDICAL JOURNAL			English	Article									Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY 10032 USA; Uganda Virus Res Inst, Rakai Project, Entebbe, Uganda; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	Columbia University; Uganda Virus Research Institute; Johns Hopkins University	Paxton, LA (corresponding author), Ctr Dis Control & Prevent, Mailstop E45,1600 Clifton Rd, Atlanta, GA 30333 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI34826] Funding Source: Medline; NICHD NIH HHS [5P30HD06826] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Hayes R, 1997, GENITOURIN MED, V73, P432; *MIN HLTH, 1996, REP BAS SURV SEX TRA; Wawer MJ, 1998, AIDS, V12, P1211, DOI 10.1097/00002030-199810000-00014; *WHO, 1997, WHOGPASTD951	4	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1630	1631		10.1136/bmj.317.7173.1630	http://dx.doi.org/10.1136/bmj.317.7173.1630			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848902	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000077602100026
J	Ben-Tovim, DI; Esterman, A				Ben-Tovim, DI; Esterman, A			Zero progress with hypochondriasis	LANCET			English	Editorial Material							CONTROLLED TRIAL		Flinders Med Ctr, Dept Psychiat, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Dept Clin Epidemiol & Hlth Outcomes, Bedford Pk, SA 5042, Australia	Flinders Medical Centre; Flinders Medical Centre	Ben-Tovim, DI (corresponding author), Flinders Med Ctr, Dept Psychiat, Bedford Pk, SA 5042, Australia.		Esterman, Adrian J/D-1042-2009	Esterman, Adrian/0000-0001-7324-9171				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Balint M., 1964, DOCTOR HIS PATIENT I; Barsky AJ, 1996, PSYCHOSOMATICS, V37, P48, DOI 10.1016/S0033-3182(96)71598-0; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; Fallon BA, 1996, PSYCHOPHARMACOL BULL, V32, P607; LEFF GP, 1988, PSYCHIAT GLOBAL TRAN; Mayou RA, 1997, PSYCHOL MED, V27, P1021, DOI 10.1017/S0033291797005254; Papageorgiou C, 1998, PSYCHOL MED, V28, P193, DOI 10.1017/S0033291797005825; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1798	1799		10.1016/S0140-6736(05)79884-6	http://dx.doi.org/10.1016/S0140-6736(05)79884-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851376				2022-12-28	WOS:000077337900004
J	Hutchison, G				Hutchison, G			Words to the wise - Muscling in	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1582	1582		10.1136/bmj.317.7172.1582	http://dx.doi.org/10.1136/bmj.317.7172.1582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836667	Green Published			2022-12-28	WOS:000077451700037
J	Kuznetsov, G; Nigam, SK				Kuznetsov, G; Nigam, SK			Mechanisms of disease - Folding of secretory and membrane proteins	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; NEWLY SYNTHESIZED GLYCOPROTEINS; NEPHROGENIC DIABETES-INSIPIDUS; CYSTIC-FIBROSIS; MOLECULAR CHAPERONES; QUALITY-CONTROL; INTRACELLULAR-TRANSPORT; DISULFIDE-ISOMERASE		Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Eisai Res Inst, Andover, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Eisai Co Ltd	Nigam, SK (corresponding author), Harvard Univ, Sch Med, Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NIDDK NIH HHS [DK5121] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; AOYAMA T, 1993, HUM MOL GENET, V2, P2135, DOI 10.1093/hmg/2.12.2135; Arbini AA, 1996, BLOOD, V87, P5085, DOI 10.1182/blood.V87.12.5085.bloodjournal87125085; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLANK CA, 1994, ANN ALLERGY, V72, P305; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BUSH KT, 1994, BIOCHEM J, V303, P705, DOI 10.1042/bj3030705; BUSH KT, 1995, BIOCHEM J, V305, P1031; Bush KT, 1997, J BIOL CHEM, V272, P9086; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Djordjevic JT, 1996, EUR J BIOCHEM, V239, P214, DOI 10.1111/j.1432-1033.1996.0214u.x; DOCTOR RB, 1994, AM J PHYSIOL, V266, pC1803, DOI 10.1152/ajpcell.1994.266.6.C1803; Elliott JG, 1997, J BIOL CHEM, V272, P20312; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fra A, 1993, Subcell Biochem, V21, P143; FREEDMAN RB, 1995, METHOD ENZYMOL, V251, P397, DOI 10.1016/0076-6879(95)51143-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; KATO A, 1992, BLOOD, V79, P3212; Katsumi A, 1996, BLOOD, V87, P4164, DOI 10.1182/blood.V87.10.4164.bloodjournal87104164; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LYONS SE, 1992, J BIOL CHEM, V267, P4424; MARQUARDT T, 1995, EUR J CELL BIOL, V66, P268; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; MedeirosNeto G, 1996, J CLIN INVEST, V98, P2838, DOI 10.1172/JCI119112; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OCKNER RK, 1993, PROGR LIVER DIS, V11, P139; Oksche A, 1996, MOL PHARMACOL, V50, P820; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1997, CURR BIOL, V7, pR67, DOI 10.1016/S0960-9822(06)00038-8; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WAGAR G, 1974, ACTA ENDOCRINOL-COP, V77, P64, DOI 10.1530/acta.0.0770064; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	71	107	117	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1688	1695		10.1056/NEJM199812033392307	http://dx.doi.org/10.1056/NEJM199812033392307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834307				2022-12-28	WOS:000077294800007
J	Hahn, S				Hahn, S			The role of TAFs in RNA polymerase II transcription	CELL			English	Review							PROMOTER SELECTIVITY; ACTIVATION; DROSOPHILA; RESOLUTION; TAF(II)S; YEAST		Howard Hughes Med Inst, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Howard Hughes Medical Institute; Fred Hutchinson Cancer Center	Hahn, S (corresponding author), Howard Hughes Med Inst, Seattle, WA 98109 USA.			Hahn, Steven/0000-0001-7240-2533				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; Lee D, 1998, NATURE, V393, P389, DOI 10.1038/30770; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SAUER F, 1998, CELL, V95; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	25	81	82	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					579	582		10.1016/S0092-8674(00)81625-6	http://dx.doi.org/10.1016/S0092-8674(00)81625-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845358	Bronze			2022-12-28	WOS:000077253700002
J	Roper, WL; Mays, GP				Roper, WL; Mays, GP			The changing managed care - Public health interface	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAID; PLANS		Univ N Carolina, Sch Publ Hlth, Off Dean, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Hlth Policy & Adm, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Roper, WL (corresponding author), Rosenau Hall,CB 7400, Chapel Hill, NC 27599 USA.							[Anonymous], 1995, MMWR Recomm Rep, V44, P1; BAKER EL, 1994, JAMA-J AM MED ASSOC, V272, P1276, DOI 10.1001/jama.272.16.1276; Dowd B E, 1982, Inquiry, V19, P68; FeltLisk S, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.5.125; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; Goldberg BW, 1998, ANNU REV PUBL HEALTH, V19, P527, DOI 10.1146/annurev.publhealth.19.1.527; Gunn RA, 1998, JAMA-J AM MED ASSOC, V279, P680, DOI 10.1001/jama.279.9.680; Halverson PK, 1997, MILBANK Q, V75, P113, DOI 10.1111/1468-0009.00046; HURLEY RE, 1998, MEDICAID COMMERCIAL; KILBORN P, 1998, NY TIMES        1005, pA1; Lasker RD., 1997, MED PUBLIC HLTH POWE; Moran DW, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.6.7; Roper W L, 1994, Front Health Serv Manage, V10, P32; Roper WL, 1998, HEALTH AFFAIR, V17, P152, DOI 10.1377/hlthaff.17.2.152; Rosenbaum S, 1997, HEALTH AFFAIR, V16, P266, DOI 10.1377/hlthaff.16.4.266; Schauffler HH, 1998, AM J PREV MED, V14, P240; Showstack J, 1996, JAMA-J AM MED ASSOC, V276, P1071, DOI 10.1001/jama.276.13.1071; Wall S, 1998, HEALTH AFFAIR, V17, P64, DOI 10.1377/hlthaff.17.3.64; [No title captured]	19	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1739	1740		10.1001/jama.280.20.1739	http://dx.doi.org/10.1001/jama.280.20.1739			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842939				2022-12-28	WOS:000077081400013
J	Sneader, W				Sneader, W			The discovery of heroin	LANCET			English	Article									Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Sneader, W (corresponding author), Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland.							*BIBL I AG, 1966, FREMDW, V5, P271; Crum-Brown A., 1868, T R SOC EDINBURGH, V25, P151; DERIDDER M, 1994, J PSYCHOACTIVE DRUGS, V26, P65, DOI 10.1080/02791072.1994.10472603; DOT DB, 1888, YB PHARM, P349; DRESER H, 1898, THERAP MONATSCH, V12, P509; DRESER H, 1898, ARCH GES PHYSL, V72, P485; Dreser H., 1898, DEUT MED WOCHENSCHR, V24, P185; EDDY NB, 1953, B NAC, V5, P43; EICHENGRUN A, 1949, PHARMAZIE, V4, P582; GIRMAUX E, 1881, CR HEBD ACAD SCI, V92, P1140; HESSE O, 1884, LIEBIGS ANN CHEM, V222, P206; HIGBY GJ, 1986, NEW YORK STATE J MED, V86, P137; LEO H, 1899, DEUT MED WOCHENSCHR, V25, P186; MANGES M, 1900, NY MED J, V71, P51; MANGES M, 1900, NY MED J, V71, P79; Matthiessen A, 1869, P ROY SOC LOND B BIO, V17, P455, DOI [10.1098/rspl.1868.0094, DOI 10.1098/RSPL.1868.0094]; Ministry of Health, 1926, ROLL REP; MUSTO DF, 1973, AM DREAM, P91; *PHARM SOC, 1907, BRIT PHARM COD, P8; Philips J, 1912, J AMER MED ASSOC, V59, P2146; Pierce F., 1874, J CHEM SOC, V27, P1043; Pierce F., 1875, PRACTITIONER, V14, P437; SCHADEWALDT H, 1990, STROKE S4, V21, P15; SIEBEL W, 1892, THERAP MONATSH, V6, P31; Sneader W., 1996, DRUG PROTOTYPES THEI, P185; Sneader W., 1997, PHARM J, V259, P614; Stockman R., 1890, BRIT MED J, V2, P189; VERG E, 1988, MILESTONES; von Issekutz B., 1911, ARCH GES PHYSL, V142, P255; VonMering J., 1898, MERCK REPORT, V7, P5; Wright C.A., 1874, J CHEM SOC, V27, P1031, DOI [10.1039/JS8742701031, DOI 10.1039/JS8742701031]; 1973, BRIT PHARM COD, P153; 1954, BRIT PHARM COD, P236; 1934, BRIT PHARM COD, P390; 1911, BRIT PHARM CODEX, P8; 1963, BRIT PHARM COD, P243	36	42	44	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1697	1699		10.1016/S0140-6736(98)07115-3	http://dx.doi.org/10.1016/S0140-6736(98)07115-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853457				2022-12-28	WOS:000077110300044
J	Hellman, S				Hellman, S			Tales of the unnatural: Return from the dean(d)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1657	1658		10.1001/jama.280.19.1657	http://dx.doi.org/10.1001/jama.280.19.1657			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831985				2022-12-28	WOS:000076980700013
J	Curtis, E				Curtis, E			Child health and the international monetary fund: the Nicaraguan experience	LANCET			English	Editorial Material							STRUCTURAL ADJUSTMENT; MORTALITY RATES		Newcastle City Hlth NHS Trust, Child & Adolescent Hlth Programme, Community Paediat Serv Delivery Unit, Arthurs Hill Clin, Newcastle Upon Tyne NE4 6BT, Tyne & Wear, England	Newcastle University - UK	Curtis, E (corresponding author), Newcastle City Hlth NHS Trust, Child & Adolescent Hlth Programme, Community Paediat Serv Delivery Unit, Arthurs Hill Clin, Arthurs Hill, Newcastle Upon Tyne NE4 6BT, Tyne & Wear, England.							Bower H, 1998, LANCET, V351, P43, DOI 10.1016/S0140-6736(05)78078-8; Chomsky N., 1994, WORLD ORDERS OLD NEW; EVANS T, 1995, STRUCTURAL ADJUSTMEN; GARFIELD R, 1989, HLTH REVOLUTION NICA; GARFIELD RM, 1992, AM J PUBLIC HEALTH, V82, P1291, DOI 10.2105/AJPH.82.9.1291; George Susan, 1989, FATE WORSE DEBT; Hanlon, 1996, PEACE PROFIT IMF BLO; *JUBL 2000, 1997, DEBT CUTT HDB; Logie DE, 1998, LANCET, V351, P982; Lundy P, 1996, SOC SCI MED, V42, P313, DOI 10.1016/0277-9536(95)00153-0; Peabody JW, 1996, SOC SCI MED, V43, P823, DOI 10.1016/0277-9536(96)00127-X; SANDIFORD P, 1991, AM J PUBLIC HEALTH, V81, P30, DOI 10.2105/AJPH.81.1.30; *WITN PEAC, 1995, BITT MED STRUCT ADJ; YUILL H, 1997, LOBBYING ESAF DEBT R	14	14	14	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1622	1624		10.1016/S0140-6736(98)03248-6	http://dx.doi.org/10.1016/S0140-6736(98)03248-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138XT	9843123				2022-12-28	WOS:000076998900047
J	Carlezon, WA; Thome, J; Olson, VG; Lane-Ladd, SB; Brodkin, ES; Hiroi, N; Duman, RS; Neve, RL; Nestler, EJ				Carlezon, WA; Thome, J; Olson, VG; Lane-Ladd, SB; Brodkin, ES; Hiroi, N; Duman, RS; Neve, RL; Nestler, EJ			Regulation of cocaine reward by CREB	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; KAPPA-OPIOID RECEPTOR; NUCLEAR-PROTEIN CBP; MESSENGER-RNA; DOPAMINE; RAT; EXPRESSION; SENSITIZATION; AMPHETAMINE; MORPHINE	Cocaine regulates the transcription factor CREB (adenosine 3',5'-monophosphate response element binding protein) in rat nucleus accumbens, a brain region that is important for addiction. Overexpression of CREB in this region decreases the rewarding effects of cocaine and makes Low doses of the drug aversive. Conversely, overexpression of a dominant-negative mutant CREB increases the rewarding effects of cocaine. Altered transcription of dynorphin Likely contributes to these effects: Its expression is increased by overexpression of CREB and decreased by overexpression of mutant CREB. Moreover, blockade of kappa opioid receptors ton which dynorphin acts) antagonizes the negative effect of CREB on cocaine reward. These results identify an intracellular cascade-culminating in gene expression-through which exposure to cocaine modifies subsequent responsiveness to the drug.	Yale Univ, Sch Med, Ctr Genes & Behav, Div Mol Psychiat, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Genet, Belmont, MA 02178 USA	Yale University; Harvard University; McLean Hospital	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Ctr Genes & Behav, Div Mol Psychiat, 34 Pk St, New Haven, CT 06508 USA.		Hiroi, Noboru/E-2215-2013; Jansen, Heiko T./A-5770-2008	Hiroi, Noboru/0000-0002-6846-5969; Jansen, Heiko T./0000-0003-0178-396X; /0000-0002-4162-3947				BALSKUBIK R, 1993, J PHARMACOL EXP THER, V264, P489; Bartlett E, 1997, NEUROPSYCHOPHARMACOL, V16, P77, DOI 10.1016/S0893-133X(96)00164-9; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Carlezon WA, 1996, J NEUROSCI, V16, P3112; CARLEZON WA, 1995, PSYCHOPHARMACOLOGY, V122, P194, DOI 10.1007/BF02246095; CARR GD, 1989, NEUROPHARMACOLOGICAL; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; DAUNAIS JB, 1993, NEUROREPORT, V4, P453; DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HURD YL, 1993, SYNAPSE, V13, P357, DOI 10.1002/syn.890130408; HURD YL, 1992, MOL BRAIN RES, V13, P165, DOI 10.1016/0169-328X(92)90058-J; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; Lim F, 1996, BIOTECHNIQUES, V20, P460; LOH EA, 1990, PSYCHOPHARMACOLOGY, V101, P262, DOI 10.1007/BF02244137; Mendelson JH, 1998, NEUROPSYCHOPHARMACOL, V18, P263; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0; RICHARDSON NR, 1991, LIFE SCI, V49, P833, DOI 10.1016/0024-3205(91)90248-A; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Self DW, 1998, J NEUROSCI, V18, P1848; Shippenberg TS, 1997, PHARMACOL BIOCHEM BE, V57, P449, DOI 10.1016/S0091-3057(96)00450-9; SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205; SPANAGEL R, 1993, NEUROSCI LETT, V153, P232, DOI 10.1016/0304-3940(93)90329-J; SPANGLER R, 1993, MOL BRAIN RES, V19, P323, DOI 10.1016/0169-328X(93)90133-A; STEINER H, 1995, J COMP NEUROL, V353, P200, DOI 10.1002/cne.903530204; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; Unterwald EM, 1996, EUR J PHARMACOL, V318, P31, DOI 10.1016/S0014-2999(96)00841-2; WISE RA, 1989, NEUROPHARMACOLOGICAL; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	38	571	590	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2272	2275		10.1126/science.282.5397.2272	http://dx.doi.org/10.1126/science.282.5397.2272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856954				2022-12-28	WOS:000077645800052
J	Wulfing, C; Davis, MM				Wulfing, C; Davis, MM			A receptor/cytoskeletal movement triggered by costimulation during T cell activation	SCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CO-STIMULATION; COMPLEXES; ANTIGEN; LFA-1; REQUIREMENTS; RESPONSES; CD28; MICE; CYTOSKELETON	During T cell activation, the engagement of costimulatory molecules is often crucial to the development of an effective immune response, but the mechanism by which this is achieved is not known. Here, it is shown that beads attached to the surface of a T cell translocate toward the interface shortly after the start of T cell activation. This movement appears to depend on myosin motor proteins and requires the engagement of the major costimulatory receptor pairs, B7-CD28 and ICAM-1-LFA-1. This suggests that the engagement of costimulatory receptors triggers an active accumulation of molecules at the interface of the T cell and the antigen-presenting cell, which then increases the overall amplitude and duration of T cell signaling.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Davis, MM (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Wuelfing, Christoph/0000-0002-6156-9861; Davis, Mark/0000-0001-6868-657X				Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Blair PJ, 1997, BIOCHEM SOC T, V25, P651, DOI 10.1042/bst0250651; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; BROWER RC, 1994, MOL IMMUNOL, V31, P1285, DOI 10.1016/0161-5890(94)90079-5; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40; Delon J, 1998, J EXP MED, V188, P1473, DOI 10.1084/jem.188.8.1473; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEATH JP, 1993, SYM SOC EXP BIOL, V47, P35; HOLIFIELD BF, 1990, J CELL BIOL, V111, P2499, DOI 10.1083/jcb.111.6.2499; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Maciver SK, 1996, BIOESSAYS, V18, P179, DOI 10.1002/bies.950180304; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; SAGERSTROM CG, 1993, P NATL ACAD SCI USA, V90, P8987, DOI 10.1073/pnas.90.19.8987; SCHLICHTER LC, 1992, J PHARMACOL EXP THER, V261, P438; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHEETS ED, 1995, CURR OPIN CELL BIOL, V7, P707, DOI 10.1016/0955-0674(95)80113-8; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; Sykulev Y, 1996, IMMUNITY, V4, P565, DOI 10.1016/S1074-7613(00)80483-5; TAKEI F, 1985, J IMMUNOL, V134, P1403; TING AE, 1990, J BIOL CHEM, V265, P5337; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; vanKooyk Y, 1997, BIOCHEM SOC T, V25, P515, DOI 10.1042/bst0250515; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; WULFING C, UNPUB; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95; YANO H, 1993, J BIOL CHEM, V268, P25846	47	532	547	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2266	2269		10.1126/science.282.5397.2266	http://dx.doi.org/10.1126/science.282.5397.2266			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856952				2022-12-28	WOS:000077645800050
J	Wildman, M				Wildman, M			Quality and the invisible man	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1667	1667		10.1136/bmj.317.7173.1667	http://dx.doi.org/10.1136/bmj.317.7173.1667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848934	Green Published			2022-12-28	WOS:000077602100080
J	Dieterich, DT				Dieterich, DT			Testosterone replacement therapy for HIV-related wasting - Abstracts and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University	Dieterich, DT (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.							Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Grinspoon S, 1998, ANN INTERN MED, V129, P18, DOI 10.7326/0003-4819-129-1-199807010-00005; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; PORETSKY L, 1995, METABOLISM, V44, P946, DOI 10.1016/0026-0495(95)90250-3; SUTTMANN U, 1995, J ACQ IMMUN DEF SYND, V8, P239, DOI 10.1097/00042560-199503010-00004	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1959	1960		10.1001/jama.280.22.1959	http://dx.doi.org/10.1001/jama.280.22.1959			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851485				2022-12-28	WOS:000077364500044
J	Tomlinson, J				Tomlinson, J			ABC of sexual health - Taking a sexual history	BRITISH MEDICAL JOURNAL			English	Review									Mens Hlth Clin, Winchester, Hants, England; London Bridge Hosp, London, England		Tomlinson, J (corresponding author), Mens Hlth Clin, Winchester, Hants, England.							BANCROFT J, 1998, HUMAN SEXUALITY ITS; GREGOIRE A, 1993, IMPOTENCE INTEGRATED; MORRIS D, 1980, MAN WATCHING	3	46	47	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1573	1576		10.1136/bmj.317.7172.1573	http://dx.doi.org/10.1136/bmj.317.7172.1573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836664	Green Published			2022-12-28	WOS:000077451700031
J	Yao, S; Ghosh, I; Zutshi, R; Chmielewski, J				Yao, S; Ghosh, I; Zutshi, R; Chmielewski, J			Selective amplification by auto- and cross-catalysis in a replicating peptide system	NATURE			English	Article							SELF-REPLICATION; HEXADEOXYNUCLEOTIDE; SEQUENCE; LINKAGE	Self-replication has been demonstrated in synthetic chemical systems based on oligonucleotides(1-7), peptides(8-12) and complementary molecules without natural analogues(13-16). However, within a living cell virtually no molecule catalyses its own formation, and the search for chemical systems in which both auto- and cross-catalysis can occur has therefore attracted wide interest(17). One such system, consisting of two self-replicating peptides that catalyse each other's production, has been reported(10). Here we describe a four-component peptide system that is capable of auto- and cross-catalysis and allows for the selective amplification of one or more of the products by changing the reaction conditions. The ability of this system selectively to amplify one or more molecules in response to changes in environmental conditions such as pH or salt concentration supports the suggestions that self-replicating peptides may have played a role in the origin of life.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chmielewski, J (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.		Yao, Shao Q/B-8825-2008	Zutshi, Reena/0000-0002-2582-1484				ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; KRAMER FR, 1974, J MOL BIOL, V89, P719, DOI 10.1016/0022-2836(74)90047-3; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee DH, 1997, NATURE, V390, P591, DOI 10.1038/37569; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; Severin K, 1997, NATURE, V389, P706, DOI 10.1038/39556; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; WINTNER EA, 1995, J ORG CHEM, V60, P7997, DOI 10.1021/jo00129a046; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; Yao S, 1998, ANGEW CHEM INT EDIT, V37, P478, DOI 10.1002/(SICI)1521-3773(19980302)37:4<478::AID-ANIE478>3.0.CO;2-V; Yao S, 1997, J AM CHEM SOC, V119, P10559, DOI 10.1021/ja9710619; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	20	124	128	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					447	450		10.1038/24814	http://dx.doi.org/10.1038/24814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853750				2022-12-28	WOS:000077370100048
J	Mullan, F; Deitch, S				Mullan, F; Deitch, S			Selma Deitch, MD, MPH: Children first	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hlth Affairs, Bethesda, MD 20814 USA		Mullan, F (corresponding author), Hlth Affairs, 7500 Old Georgetown Rd,Suite 600, Bethesda, MD 20814 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1867	1871		10.1001/jama.280.21.1867	http://dx.doi.org/10.1001/jama.280.21.1867			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846785				2022-12-28	WOS:000077176600036
J	Rowbotham, M; Harden, N; Stacey, B; Bernstein, P; Magnus-Miller, L				Rowbotham, M; Harden, N; Stacey, B; Bernstein, P; Magnus-Miller, L		Gabapentin Postherpetic Neuralgia Study Grp	Gabapentin for the treatment of postherpetic neuralgia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POST-HERPETIC NEURALGIA; NEUROPATHIC PAIN; AMITRIPTYLINE; MANAGEMENT; THERAPY	Context.-Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes tester (shingles) that eludes effective treatment in many patients. Objective.-To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain. Design.-Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997. Setting.-Sixteen US outpatient clinical centers. Participants.-A total of 229 subjects were randomized. Intervention.-A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study. Main Outcome Measures.-The primary efficacy measure was change in the average daily pain score based on an Ii-point Likert scale (0, no pain; 10, worst possible pain) from baseline week to the final week of therapy, Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF-36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events. Results.-One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P<.001). Secondary measures of pain as well as changes in pain and sleep interference showed improvement with gabapentin (P<.001), Many measures within the SF-36 and POMS also significantly favored gabapentin (P less than or equal to.01). Somnolence, dizziness, ataxia, peripheral edema, and infection were all more frequent in the gabapentin group, but withdrawals were comparable in the 2 groups (15 [13.3%] in the gabapentin group vs 11 [9.5%] in the placebo group). Conclusions.-Gabapentin is effective in the treatment of pain and sleep interference associated with PHN. Mood and quality of life also improve with gabapentin therapy.	Univ Calif San Francisco, Pain Clin Res Ctr, San Francisco, CA 94115 USA; Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Oregon Hlth Sci Univ, Dept Anesthesiol, Portland, OR 97201 USA; Parke Davis, Dept Biometr, Morris Plains, NJ USA; Parke Davis, Dept Med Res, Morris Plains, NJ USA	University of California System; University of California San Francisco; Shirley Ryan AbilityLab; Oregon Health & Science University; Pfizer; Pfizer	Rowbotham, M (corresponding author), Univ Calif San Francisco, Pain Clin Res Ctr, 1701 Divisadero St,Suite 480, San Francisco, CA 94115 USA.		Rowbotham, Michael/AAA-3606-2019					ATTAL N, 1997, 16 ANN SCI M AM PAIN; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bowsher D, 1996, J PAIN SYMPTOM MANAG, V12, P290, DOI 10.1016/S0885-3924(96)00180-7; BRUNI J, 1991, Neurology, V41, P330; CHADWICK D, 1990, LANCET, V335, P1114; GERSON GR, 1977, POSTGRAD MED J, V53, P104; Gillin S, 1998, ANESTH ANALG, V86, P111, DOI 10.1097/00000539-199801000-00022; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; Gobel H, 1997, DRUGS, V53, P34; Herne K, 1996, DRUG AGING, V8, P97, DOI 10.2165/00002512-199608020-00004; Hwang JH, 1997, REGION ANESTH, V22, P249, DOI 10.1016/S1098-7339(06)80010-6; JOHNSON RW, 1996, RAIN REV, V3, P117; Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3; KISHOREKUMAR R, 1990, CLIN PHARMACOL THER, V47, P305, DOI 10.1038/clpt.1990.33; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; MAX MB, 1994, ANN NEUROL, V35, pS50, DOI 10.1002/ana.410350715; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; MCQUAY H, 1995, BRIT MED J, V311, P1047, DOI 10.1136/bmj.311.7012.1047; MELLICK GA, 1995, J PAIN SYMPTOM MANAG, V10, P265, DOI 10.1016/0885-3924(95)00001-F; OOMMEN K, 1993, NEUROLOGY, V43, P2292; Rosenberg JM, 1997, CLIN J PAIN, V13, P251, DOI 10.1097/00002508-199709000-00011; Rosner H, 1996, CLIN J PAIN, V12, P56, DOI 10.1097/00002508-199603000-00010; Singh L, 1996, PSYCHOPHARMACOLOGY, V127, P1, DOI 10.1007/BF02805968; STACEY BR, 1996, REGION ANESTH, V21, pS65; TAKEDA Y, 1988, SKIN RES, V30, P33; Volmink J, 1996, FAM PRACT, V13, P84, DOI 10.1093/fampra/13.1.84; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; WATSON CPN, 1993, CLIN THER, V15, P510; Watson CPN, 1995, NEUROLOGY, V45, pS58, DOI 10.1212/WNL.45.12_Suppl_8.S58; WATSON CPN, 1985, PAIN, V23, P387, DOI 10.1016/0304-3959(85)90009-0; WATSON CPN, 1992, PAIN, V48, P29, DOI 10.1016/0304-3959(92)90128-X; XIAO WH, 1996, PAIN, V2, P267	32	1030	1078	0	63	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1837	1842		10.1001/jama.280.21.1837	http://dx.doi.org/10.1001/jama.280.21.1837			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846778	Bronze			2022-12-28	WOS:000077176600029
J	March, JS; Biederman, J; Wolkow, R; Safferman, A; Mardekian, J; Cook, EH; Cutler, NR; Dominguez, R; Ferguson, J; Muller, B; Riesenberg, R; Rosenthal, M; Sallee, FR; Wagner, KD				March, JS; Biederman, J; Wolkow, R; Safferman, A; Mardekian, J; Cook, EH; Cutler, NR; Dominguez, R; Ferguson, J; Muller, B; Riesenberg, R; Rosenthal, M; Sallee, FR; Wagner, KD			Sertraline in children and adolescents with obsessive-compulsive disorder - A multicenter randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; CLOMIPRAMINE TREATMENT; PLACEBO; DESIPRAMINE; INHIBITORS; FLUOXETINE	Context.-The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than far adults. Objective.-To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design.-Randomized, double-blind, placebo-controlled trial. Patients.-One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting.-Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention.-Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 move weeks. Control patients received placebo. Main Outcome Measures.-The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), the National institute of Mental Health Global Obsessive ;Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results.-In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P = .005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42% of patients receiving sertraline and 26% of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia, nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13%) of 92 sertraline-treated patients and 3 (3.2%) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P =.02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion.-Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.	Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Psychol, Durham, NC 27710 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Pfizer Inc, New York, NY USA; Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; Univ Chicago, Dept Psychol, Chicago, IL 60637 USA; Calif Clin Trials, Beverly Hills, CA USA; Univ Miami, Dept Psychiat, Miami, FL 33152 USA; Tulane Univ, Dept Psychiat, New Orleans, LA 70118 USA; Biobehav Res Ctr, Decatur, GA USA; Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA; Univ Texas, Med Branch, Dept Psychiat, Galveston, TX 77550 USA	Duke University; Duke University; Harvard University; Massachusetts General Hospital; Pfizer; University of Chicago; University of Chicago; University of Miami; Tulane University; Medical University of South Carolina; University of Texas System; University of Texas Medical Branch Galveston	March, JS (corresponding author), Duke Univ, Med Ctr, Dept Psychiat, Box 3527, Durham, NC 27710 USA.	jsmarch@acpub.duke.edu		Cook, Edwin/0000-0002-5848-5114				*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P417; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; CHOUINARD G, 1990, PSYCHOPHARMACOL BULL, V26, P279; DEVEAUGHGEISS J, 1992, J AM ACAD CHILD PSY, V31, P45, DOI 10.1097/00004583-199201000-00008; ELLIOTT GR, 1991, J CHILD ADOL PSYCHOP, V1, P187; Feighner J.P., 1991, INT CLIN PSYCHOPHARM, V6, P126; FISCH C, 1985, J CLIN PSYCHIAT, V46, P42; FLAMENT MF, 1988, J AM ACAD CHILD PSY, V27, P764, DOI 10.1097/00004583-198811000-00018; FLAMENT MF, 1985, ARCH GEN PSYCHIAT, V42, P977; Goodman Wayne K., 1994, P431; GOODMAN WK, 1992, PSYCHIAT CLIN N AM, V15, P861; GREIST J, 1995, ARCH GEN PSYCHIAT, V52, P289; GREIST JH, 1995, ARCH GEN PSYCHIAT, V52, P53; GREIST JH, 1995, INT CLIN PSYCHOPHARM, V10, P57, DOI 10.1097/00004850-199506000-00001; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; KATZ RJ, 1990, BIOL PSYCHIAT, V28, P401, DOI 10.1016/0006-3223(90)90408-T; LEONARD H, 1996, SYNOPSIS TREATMENTS, P143; LEONARD HL, 1989, ARCH GEN PSYCHIAT, V46, P1088; Leonard HL, 1997, J AM ACAD CHILD PSY, V36, P725, DOI 10.1097/00004583-199706000-00008; LEONARD HL, 1995, J AM ACAD CHILD PSY, V34, P1460, DOI 10.1097/00004583-199511000-00012; MARCH J, IN PRESS TXB PEDIAT; March JS, 1996, J AM ACAD CHILD PSY, V35, P1265, DOI 10.1097/00004583-199610000-00012; March JS, 1998, OCD CHILDREN ADOLESC; MARCH JS, 1995, CHILD ADOLESC PSYCHI, V4, P217; Marchal IS, 1997, VET IMMUNOL IMMUNOP, V58, P1; Murphy DL, 1982, BEHAVIOR PSYCHIATRIC, P335; RASMUSSEN S, IN PRESS AM J PSYCHI; RIDDLE MA, 1992, J AM ACAD CHILD PSY, V31, P1062, DOI 10.1097/00004583-199211000-00011; RIDDLE MA, 1996, CONTROLLED TRIAL FLU; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; SCHROEDER JS, 1989, J AM ACAD CHILD PSY, V28, P376, DOI 10.1097/00004583-198905000-00012; TOLLEFSON GD, 1994, ARCH GEN PSYCHIAT, V51, P559; WHEADON DE, 1993, ANN M AM COLL NEUR D	33	310	316	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1752	1756		10.1001/jama.280.20.1752	http://dx.doi.org/10.1001/jama.280.20.1752			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842950				2022-12-28	WOS:000077081400030
J	Tamura, N; Lottspeich, F; Baumeister, W; Tamura, T				Tamura, N; Lottspeich, F; Baumeister, W; Tamura, T			The role of Tricorn protease and its aminopeptidase-interacting factors in cellular protein degradation	CELL			English	Article							TRIPEPTIDYL PEPTIDASE-II; ESCHERICHIA-COLI; THERMOPLASMA-ACIDOPHILUM; PROCESSIVE DEGRADATION; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; PROTEOLYSIS; MUTANTS; COMPLEX; 20S		Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Baumeister, W (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	tamura@biochem.mpg.de	Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; BALOW RM, 1986, J BIOL CHEM, V261, P2409; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; CAPRIOGLIO DR, 1993, J BIOL CHEM, V268, P14310; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIRSCH HH, 1988, EUR J BIOCHEM, V173, P589, DOI 10.1111/j.1432-1033.1988.tb14040.x; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kratzer R, 1998, ELECTROPHORESIS, V19, P1910, DOI 10.1002/elps.1150191109; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MACPHERSON E, 1987, BIOCHEM J, V248, P259, DOI 10.1042/bj2480259; Mason R W, 1996, Subcell Biochem, V27, P159; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Medrano FJ, 1998, EMBO J, V17, P1, DOI 10.1093/emboj/17.1.1; MILLER CG, 1975, ANNU REV MICROBIOL, V29, P485, DOI 10.1146/annurev.mi.29.100175.002413; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; Osmulski PA, 1998, CURR BIOL, V8, P1023, DOI 10.1016/S0960-9822(07)00423-X; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; Roberts D.V., 1977, ENZYME KINETICS; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Ruepp A, 1998, FEBS LETT, V425, P87, DOI 10.1016/S0014-5793(98)00205-1; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; Tamura T, 1996, FEBS LETT, V398, P101, DOI 10.1016/S0014-5793(96)01163-5; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; YEN C, 1980, J MOL BIOL, V143, P21, DOI 10.1016/0022-2836(80)90122-9; YEN C, 1980, J MOL BIOL, V143, P35, DOI 10.1016/0022-2836(80)90123-0	45	95	100	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					637	648		10.1016/S0092-8674(00)81634-7	http://dx.doi.org/10.1016/S0092-8674(00)81634-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845366	Bronze			2022-12-28	WOS:000077253700011
J	Butterworth, RF				Butterworth, RF			Excitatory neurons and schizophrenia	LANCET			English	Editorial Material							HIPPOCAMPUS		Univ Montreal, Dept Med, Neurosci Res Unit, St Lucia, Qld H2X 3J4, Australia		Butterworth, RF (corresponding author), Univ Montreal, Dept Med, Neurosci Res Unit, St Lucia, Qld H2X 3J4, Australia.							DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Porter RHP, 1997, BRAIN RES, V751, P217, DOI 10.1016/S0006-8993(96)01404-7; Zaidel DW, 1997, AM J PSYCHIAT, V154, P812	4	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1643	1643		10.1016/S0140-6736(05)61442-0	http://dx.doi.org/10.1016/S0140-6736(05)61442-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853431				2022-12-28	WOS:000077110300003
J	Murray, AW				Murray, AW			Chromosome structure - How to compact DNA	SCIENCE			English	Editorial Material							CONDENSATION; PROTEIN		Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Murray, AW (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	amurray@socrates.ucsf.edu						Boveri T, 1903, VERHANDLUNGEN PHYSIK, V35, P67; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062	12	18	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					425	+		10.1126/science.282.5388.425	http://dx.doi.org/10.1126/science.282.5388.425			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9841400				2022-12-28	WOS:000076479600038
J	Pickering, WG				Pickering, WG			Medical omniscience	BRITISH MEDICAL JOURNAL			English	Article																		Martin IG, 1997, BMJ-BRIT MED J, V314, P467, DOI 10.1136/bmj.314.7079.467; Pickering WG, 1996, LANCET, V347, P379, DOI 10.1016/S0140-6736(96)90544-9	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1729	1730		10.1136/bmj.317.7174.1729	http://dx.doi.org/10.1136/bmj.317.7174.1729			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857151	Green Published			2022-12-28	WOS:000077742300042
J	Kawasaki, H; Springett, GM; Mochizuki, N; Toki, S; Nakaya, M; Matsuda, M; Housman, DE; Graybiel, AM				Kawasaki, H; Springett, GM; Mochizuki, N; Toki, S; Nakaya, M; Matsuda, M; Housman, DE; Graybiel, AM			A family of cAMP-binding proteins that directly activate Rap1	SCIENCE			English	Article							LONG-TERM POTENTIATION; CYCLIC-AMP; KINASE-A; SIGNALING PATHWAY; MAP KINASE; SITE-A; RAS; HIPPOCAMPUS; LTP; PHOSPHORYLATION	cAMP (3',5' cyclic adenosine monophosphate) is a second messenger that in eukaryotic cells induces physiological responses ranging from growth, differentiation, and gene expression to secretion and neurotransmission. Most of these effects have been attributed to the binding of cAMP to cAMP-dependent protein kinase A (PKA). Here, a family of cAMP-binding proteins that are differentially distributed in the mammalian brain and body organs and that exhibit both cAMP-binding and guanine nucleotide exchange factor (GEF) domains is reported. These cAMP-regulated GEFs (cAMP-GEFs) bind cAMP and selectively activate the Ras superfamily guanine nucleotide binding protein Rap1A in a cAMP-dependent but PKA-independent manner. Our findings suggest the need to reformulate concepts of cAMP-mediated signaling to include direct coupling to Ras superfamily signaling.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); National Center for Global Health & Medicine - Japan	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, Bldg E25,Room 618, Cambridge, MA 02139 USA.	arng@wccf.mit.edu		Matsuda, Michiyuki/0000-0002-5876-9969; Graybiel, Ann/0000-0002-4326-7720	NCI NIH HHS [P01 CA42063] Funding Source: Medline; NHLBI NIH HHS [P01 HL41484] Funding Source: Medline; NICHD NIH HHS [R01 HD28341] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028341] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BINU JO, 1998, SCIENCE, V280, P1082; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1997, FEBS LETT, V410, P59, DOI 10.1016/S0014-5793(97)00324-4; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BROWN EE, 1992, J NEUROSCI, V12, P4112; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GALLISTEL CR, 1985, J NEUROSCI, V5, P1246; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU FC, 1995, J NEUROSCI, V15, P2367, DOI 10.1523/JNEUROSCI.15-03-02367.1995; LONDON ED, 1985, EUR J PHARMACOL, V110, P391, DOI 10.1016/0014-2999(85)90572-2; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; OGREID D, 1988, J BIOL CHEM, V263, P17397; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SANDYK R, 1991, INT J NEUROSCI, V61, P189, DOI 10.3109/00207459108990738; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	47	1118	1158	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2275	2279		10.1126/science.282.5397.2275	http://dx.doi.org/10.1126/science.282.5397.2275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856955				2022-12-28	WOS:000077645800053
J	Stallard, P; Velleman, R; Baldwin, S				Stallard, P; Velleman, R; Baldwin, S			Prospective study of post-traumatic stress disorder in children involved in road traffic accidents	BRITISH MEDICAL JOURNAL			English	Article							CONSEQUENCES; EVENTS; SCALE	Objective To determine the prevalence of severe psychological trauma-that is, post-traumatic stress disorder-in children involved in everyday road traffic accidents. Design 12 month prospective study. Setting Accident and emergency department, Royal United Hospital Bath. Subjects 119 children aged 5-18 years involved in road traffic accidents and 66 children who sustained sports injuries. Main outcome measure Presence of appreciable psychological distress; fulfilment of diagnostic criteria for post-traumatic stress disorder. Results Post-traumatic stress disorder was found in 41 (34.5%) children involved in road traffic accidents but only two (3.0%) who sustained sports injuries. The presence of post-traumatic stress disorder was not related to the type of accident, age of the child, or the nature of injuries but was significantly associated with sex, previous experience of trauma, and subjective appraisal of threat to rife, None of the children had received any psychological help at the lime of assessment. Conclusions One in three children involved in road traffic accidents was found to suffer from post-traumatic stress disorder when they were assessed 6 weeks after their accident The psychological needs of such children after such accidents remain largely unrecognised.	Royal United Hosp, Bath Mental Hlth Care Trust, Dept Child & Family Psychiat, Bath BA1 3NG, Avon, England		Stallard, P (corresponding author), Royal United Hosp, Bath Mental Hlth Care Trust, Dept Child & Family Psychiat, Bath BA1 3NG, Avon, England.		Velleman, Richard/P-3697-2018					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BIRLESON P, 1981, J CHILD PSYCHOL PSYC, V22, P73, DOI 10.1111/j.1469-7610.1981.tb00533.x; BLANCHARD EB, 1995, BEHAV RES THER, V33, P369, DOI 10.1016/0005-7967(94)00067-T; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; CANTERBURY R, 1996, AFTERMATH ROAD ACCID; Casswell G., 1997, CLIN CHILD PSYCHOL P, V2, P517; *CHILD ACC PREV TR, 1996, HEAL HIDD HURT EM EF; Curle CE, 1996, BRIT J CLIN PSYCHOL, V35, P297, DOI 10.1111/j.2044-8260.1996.tb01183.x; *DEP ENV TRANSP RE, 1997, ROAD ACC GREAT BRIT; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DiGallo A, 1996, BRIT J PSYCHIAT, V169, P405, DOI 10.1192/bjp.169.4.405; GARMEZY N, 1986, CHILD ADOLESCENT PSY; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JONES RW, 1993, J FAM PRACTICE, V36, P223; JOSEPH S, 1997, UNDERSTANDING POST T; Mackway-Jones K, 1997, EMERGENCY TRIAGE; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; NADER KO, CLIN ADM PTSD SCALE; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; STALLARD P, 1993, BRIT J PSYCHIAT, V163, P660, DOI 10.1192/bjp.163.5.660; STALLARD P, 1994, CHILDREN SOC, V8, P89; THOMPSON A, 1993, BRIT MED J, V307, P1282, DOI 10.1136/bmj.307.6914.1282-c; UDWIN O, 1993, J CHILD PSYCHOL PSYC, V34, P115, DOI 10.1111/j.1469-7610.1993.tb00974.x; YULE W, 1989, NEWSLETTER ASS CHILD, V11, P3	24	135	138	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1619	1623		10.1136/bmj.317.7173.1619	http://dx.doi.org/10.1136/bmj.317.7173.1619			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149JW	9848900	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000077602100023
J	Lo, YMD; Hjelm, NM; Fidler, C; Sargent, IL; Murphy, MF; Chamberlain, PF; Poon, PMK; Redman, CWG; Wainscoat, JS				Lo, YMD; Hjelm, NM; Fidler, C; Sargent, IL; Murphy, MF; Chamberlain, PF; Poon, PMK; Redman, CWG; Wainscoat, JS			Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA AMPLIFICATION; PERIPHERAL-BLOOD; CELLS; POLYPEPTIDE; CLONING; SERUM; PCR	Background The ability to determine fetal RhD status noninvasively is useful in the treatment of RhD-sensitized pregnant women whose partners are heterozygous for the RhD gene. The recent demonstration of fetal DNA in maternal plasma raises the possibility that fetal RhD genotyping may be possible with the use of maternal plasma. Methods We studied 57 RhD-negative pregnant women and their singleton fetuses. DNA extracted from maternal plasma was analyzed for the RhD gene with a fluorescence-based polymerase-chain-reaction (PCR) test sensitive enough to detect the RhD gene in a single cell. Fetal RhD status was determined directly by serologic analysis of cord blood or PCR analysis of amniotic fluid. Results Among the 57 RhD-negative women, 12 were in their first trimester of pregnancy, 30 were in their second trimester, and 15 were in their third trimester. Thirty-nine fetuses were RhD-positive, and 18 were RhD-negative. In the samples obtained from women in their second or third trimester of pregnancy, the results of RhD PCR analysis of maternal plasma DNA were completely concordant with the results of serologic analysis. Among the maternal plasma samples collected in the first trimester, 2 contained no RhD DNA, but the fetuses were RhD-positive; the results in the other 10 samples were concordant (7 were RhD-positive, and 3 RhD-negative). Conclusions Noninvasive fetal RhD genotyping can be performed rapidly and reliably with the use of maternal plasma beginning in the second trimester of pregnancy. (N Engl J Med 1998;339:1734-8.) (C) 1998, Massachusetts Medical Society.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; John Radcliffe Hosp, Dept Hematol, Oxford OX3 9DU, England; John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	Chinese University of Hong Kong; Prince of Wales Hospital; University of Oxford; University of Oxford	Lo, YMD (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Rm 38023,Clin Sci Bldg,30-32 Ngan Shing St, Hong Kong, Peoples R China.		Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293				Aubin JT, 1997, BRIT J HAEMATOL, V98, P356, DOI 10.1046/j.1365-2141.1997.2193040.x; BENNETT PR, 1993, NEW ENGL J MED, V329, P607, DOI 10.1056/NEJM199308263290903; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; BLAKEMORE KJ, 1986, AM J OBSTET GYNECOL, V155, P988, DOI 10.1016/0002-9378(86)90332-7; Chen XQ, 1996, NAT MED, V2, P1033; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; CLARKE CA, 1987, BRIT MED J, V294, P1001, DOI 10.1136/bmj.294.6578.1001; COLIN Y, 1991, BLOOD, V78, P2747; Dildy GA, 1996, OBSTET GYNECOL, V88, P207, DOI 10.1016/0029-7844(96)00143-3; GeifmanHoltzman O, 1996, AM J OBSTET GYNECOL, V174, P818, DOI 10.1016/S0002-9378(96)70306-X; HAMERTON JL, 1989, LANCET, V1, P1; Hamlington J, 1997, LANCET, V349, P540, DOI 10.1016/S0140-6736(97)80090-6; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KWOK S, 1989, NATURE, V339, P490; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; LO YMD, 1994, ANN NY ACAD SCI, V731, P204, DOI 10.1111/j.1749-6632.1994.tb55772.x; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MOLLISON PL, 1993, BLOOD TRANSFUSION CL, P204; Robson SC, 1998, BRIT J OBSTET GYNAEC, V105, P129, DOI 10.1111/j.1471-0528.1998.tb10039.x; Schumacher B, 1996, OBSTET GYNECOL, V88, P137, DOI 10.1016/0029-7844(96)00113-5; Sekizawa A, 1996, OBSTET GYNECOL, V87, P501, DOI 10.1016/0029-7844(95)00496-3; TABOR A, 1987, BRIT J OBSTET GYNAEC, V94, P528, DOI 10.1111/j.1471-0528.1987.tb03145.x; Toth T, 1998, J REPROD MED, V43, P219	28	496	606	1	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1734	1738		10.1056/NEJM199812103392402	http://dx.doi.org/10.1056/NEJM199812103392402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845707				2022-12-28	WOS:000077459700002
J	Delwart, E				Delwart, E			A new HIV-1 group - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA		Delwart, E (corresponding author), Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.			Delwart, Eric/0000-0002-6296-4484				Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1960	1960		10.1001/jama.280.22.1960	http://dx.doi.org/10.1001/jama.280.22.1960			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851486				2022-12-28	WOS:000077364500045
J	McManus, RJ; Wilson, S; Delaney, BC; Fitzmaurice, DA; Hyde, CJ; Tobias, RS; Jowett, S; Hobbs, FDR				McManus, RJ; Wilson, S; Delaney, BC; Fitzmaurice, DA; Hyde, CJ; Tobias, RS; Jowett, S; Hobbs, FDR			Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Aggress Res Intelligence Facil, Birmingham B16 9PA, W Midlands, England	University of Birmingham	McManus, RJ (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	r.j.mcmanus@bhaam.ac.uk	Jowett, Sue/AAO-4198-2021; Delaney, Brendan C/C-5578-2008	Jowett, Sue/0000-0001-8936-3745; hobbs, richard/0000-0001-7976-7172; Delaney, Brendan/0000-0002-3518-0131; Christopher, Hyde/0000-0002-7349-0616				CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DICKERSIN K, 1995, SYSTEMATIC REV; HOBBS FDR, 1997, HLTH TECHNOL ASSESSM, V1; JADAD AR, 1993, BMJ-BRIT MED J, V307, P66, DOI 10.1136/bmj.307.6895.66-a; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389	5	124	125	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1562	1563		10.1136/bmj.317.7172.1562	http://dx.doi.org/10.1136/bmj.317.7172.1562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836655	Green Submitted, Green Published			2022-12-28	WOS:000077451700025
J	Sundar, S; Rosenkaimer, F; Makharia, MK; Goyal, AK; Mandal, AK; Voss, A; Hilgard, P; Murray, HW				Sundar, S; Rosenkaimer, F; Makharia, MK; Goyal, AK; Mandal, AK; Voss, A; Hilgard, P; Murray, HW			Trial of oral miltefosine for visceral leishmaniasis	LANCET			English	Article							KALA-AZAR; HEXADECYLPHOSPHOCHOLINE; AMPHOTERICIN; ANTIMONY; MICE	Background There is no effective oral treatment for visceral leishmaniasis (kala-azar), a disseminated intracellular protozoal infection that occurs worldwide. Miltefosine, an alkyl phospholipid developed as an oral antineoplastic agent, is active against visceral infection in animal models. We tested safety, tolerance, and efficacy of miltefosine in kala-azar. Methods Oral doses of miltefosine were given to six groups of five Indian men for 28 days: 50 mg every second day (group 1), 100 mg every second day (group 2), 100 mg/day (group 3), 150 mg/day (group 4), 200 mg/day (group 5), and 250 mg/day (group 6), Assessment for apparent cure-taken as an afebrile state with decreased spleen size and a splenic-aspirate parasite-density score of 0-was done on days 14 and 28. Definitive cure at 8 months required a parasite-free bone-marrow aspirate and no clinical evidence of relapse. Findings 21 of 30 patients were apparently cured on day 14. Transient episodes of vomiting and diarrhoea, were common during weeks 1-2 and were seen in 22 patients. Four other patients in groups 5 and 6 had miltefosine withdrawn after 7-10 days because of vomiting. One patient in group 6 developed renal insufficiency and severe diarrhoea and died on day 21. On day 28, all 29 remaining patients were apparently cured. By 8 months, seven of ten patients in groups 1 and 2 had relapsed; however, 18 of 19 patients treated daily (groups 3-6) appeared to be cured. Among the 21 definitive cures were the four patients treated for 10 days or less and 12 for whom previous therapy with pentavalent antimony had failed. Interpretation Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection.	Banaras Hindu Univ, Inst Med Sci, Kala Azar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India; ASTA Med, Frankfurt, Germany; Cornell Univ Med Coll, Dept Med, New York, NY USA	Banaras Hindu University (BHU); Cornell University	Murray, HW (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Box 130,525 E 68th St, New York, NY 10021 USA.		Murray, Heather/GQY-8016-2022; Voss, A./H-8111-2014					*ASTA MED, 1995, INV BROCH MILT; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; BREISER A, 1987, LIPIDS, V22, P925, DOI 10.1007/BF02535556; Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041; DANHAUSERRIEDL S, 1991, ONKOLOGIE, V14, P392; Davidson RN, 1996, CLIN INFECT DIS, V22, P938, DOI 10.1093/clinids/22.6.938; GRADONI L, 1995, B WORLD HEALTH ORGAN, V73, P191; HOCHHUTH CH, 1992, CELL IMMUNOL, V141, P161, DOI 10.1016/0008-8749(92)90135-C; Jha TK, 1998, BRIT MED J, V316, P1200, DOI 10.1136/bmj.316.7139.1200; KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630, DOI 10.1128/AAC.36.8.1630; MISHRA M, 1994, LANCET, V344, P1599, DOI 10.1016/S0140-6736(94)90406-5; MISHRA M, 1992, LANCET, V340, P1256, DOI 10.1016/0140-6736(92)92952-C; OLLIARO PL, 1993, PARASITOL TODAY, V9, P323, DOI 10.1016/0169-4758(93)90231-4; SHERWOOD JA, 1994, CLIN INFECT DIS, V19, P1034, DOI 10.1093/clinids/19.6.1034; Sundar S, 1996, LANCET, V348, P614, DOI 10.1016/S0140-6736(05)64828-3; SUNDAR S, 1990, LANCET, V336, P1582, DOI 10.1016/0140-6736(90)93358-V; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; Sundar S, 1997, ANN INTERN MED, V127, P133, DOI 10.7326/0003-4819-127-2-199707150-00007; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; ZEISIG R, 1995, J CANCER RES CLIN, V121, P69, DOI 10.1007/BF01202215	20	187	194	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1821	1823		10.1016/S0140-6736(98)04367-0	http://dx.doi.org/10.1016/S0140-6736(98)04367-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851383	hybrid			2022-12-28	WOS:000077337900011
J	Yujiri, T; Sather, S; Fanger, CR; Johnson, GL				Yujiri, T; Sather, S; Fanger, CR; Johnson, GL			Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption	SCIENCE			English	Article							KINASE KINASE KINASE; PROTEIN-KINASE; DOMAIN; RAS	Targeted disruption of the gene encoding MEK kinase 1 (MEKK1), a mitogen-activated protein kinase (MAPK) kinase kinase, defined its function in the regulation of MAPK pathways and cell survival. MEKK1(-/-) embryonic stem cells from mice had Lost or altered responses of the c-Jun amino-terminal kinase (INK) to microtubule disruption and cold stress but activated JNK normally in response to heat shock, anisomycin, and ultraviolet irradiation. Activation of JNK was Lost and that of extracellular signal-regulated protein kinase (ERK) was diminished in response to hyperosmolarity and serum factors in MEKK1(-/-) cells. Loss of MEKK1 expression resulted in a greater apoptotic response of cells to hyperosmolarity and microtubule disruption. When activated by specific stresses that alter cell shape and the cytoskeleton, MEKK1 Signals to protect cells from apoptosis.	Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA.	johnsong@njc.org	Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456	NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FANGER GR, UNPUB; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ishizuka T, 1996, J BIOL CHEM, V271, P12762, DOI 10.1074/jbc.271.22.12762; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLESINGER TK, UNPUB; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; WIDMANN C, UNPUB	17	281	289	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1911	1914		10.1126/science.282.5395.1911	http://dx.doi.org/10.1126/science.282.5395.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836645				2022-12-28	WOS:000077338100055
J	Migaud, M; Charlesworth, P; Dempster, M; Webster, LC; Watabe, AM; Makhinson, M; He, Y; Ramsay, MF; Morris, RGM; Morrison, JH; O'Dell, TJ; Grant, SGN				Migaud, M; Charlesworth, P; Dempster, M; Webster, LC; Watabe, AM; Makhinson, M; He, Y; Ramsay, MF; Morris, RGM; Morrison, JH; O'Dell, TJ; Grant, SGN			Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein	NATURE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; SYNAPTIC PLASTICITY; GUANYLATE KINASES; PSD-95 FAMILY; K+ CHANNELS; IN-VIVO; MEMBRANE; SYNAPSES; HIPPOCAMPUS	Specific patterns of neuronal firing induce changes in synaptic strength that may contribute to learning and memory. If the postsynaptic NMDA (N-methyl-D-aspartate) receptors are blocked, long-term potentiation (LTP) and long-term depression (LTD) of synaptic transmission and the learning of spatial information are prevented. The NMDA receptor can bind a protein known as postsynaptic density-95 (PSD-95), which may regulate the localization of and/or signalling by the receptor, In mutant mice lacking PSD-95, the frequency function of NMDA-dependent LTP and LTD is shifted to produce strikingly enhanced LTP at different frequencies of synaptic stimulation. In keeping with neural-network models that Incorporate bidirectional learning rules, this frequency shift is accompanied by severely impaired spatial learning. Synaptic NMDA-receptor currents, subunit expression, localization and synaptic morphology are all unaffected in the mutant mice. PSD-95 thus appears to be important in coupling the NMDA receptor to pathways that control bidirectional synaptic plasticity and learning.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Edinburgh, Ctr Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	University of Edinburgh; University of Edinburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Grant, SGN (corresponding author), Univ Edinburgh, Ctr Genome Res, Roger Land Bldg,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.		Morris, Richard G M/C-9982-2013; Morrison, John/F-9229-2012	Grant, Seth/0000-0001-8732-8735; Migaud, Martine/0000-0002-9496-0517	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allison DW, 1998, J NEUROSCI, V18, P2423; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Hancock PJB, 1991, NEURAL COMPUT, V3, P201, DOI 10.1162/neco.1991.3.2.201; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Hunt CA, 1996, J NEUROSCI, V16, P1380; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morrison BM, 1998, J COMP NEUROL, V395, P523; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1997, J NEUROSCI, V17, P5687; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P314; Niethammer M, 1996, J NEUROSCI, V16, P2157; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; RAYPORT S, 1992, J NEUROSCI, V12, P4264; SEJNOWSKI TJ, 1977, J THEOR BIOL, V69, P387; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wang JH, 1997, J NEUROPHYSIOL, V78, P2707, DOI 10.1152/jn.1997.78.5.2707; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	38	921	959	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					433	439		10.1038/24790	http://dx.doi.org/10.1038/24790			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853749				2022-12-28	WOS:000077370100044
J	Haworth, CS; Selby, PL; Webb, AK; Mawer, EB; Adams, JE; Freemont, TJ				Haworth, CS; Selby, PL; Webb, AK; Mawer, EB; Adams, JE; Freemont, TJ			Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis	LANCET			English	Article							OSTEOPOROSIS		Wythenshawe Hosp, Adult Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England; Univ Manchester, Dept Med, Manchester M13 9PL, Lancs, England; Univ Manchester, Dept Diagnost Radiol, Manchester, Lancs, England; Univ Manchester, Dept Osteoarticular Pathol, Manchester, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; University of Manchester; University of Manchester	Webb, AK (corresponding author), Wythenshawe Hosp, Adult Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England.		Freemont, Tony J/A-9000-2015	Freemont, Tony J/0000-0002-9780-208X; Selby, Peter/0000-0001-9465-9268				Aris RM, 1998, ANN INTERN MED, V128, P186, DOI 10.7326/0003-4819-128-3-199802010-00004; GALLACHER SJ, 1992, THORAX, V47, P932, DOI 10.1136/thx.47.11.932; GIBBENS TG, 1988, J PEDIATR, V295, P300; *NOV PHARM, 1996, AR DRY POWD SUMM PRO; THIEBAUD D, 1994, OSTEOPOROSIS INT, V4, P76, DOI 10.1007/BF01623227	5	49	49	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1753	1754		10.1016/S0140-6736(05)79826-3	http://dx.doi.org/10.1016/S0140-6736(05)79826-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848356				2022-12-28	WOS:000077246500015
J	Kandela, P				Kandela, P			Sketches from the Lancet	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1793	1793		10.1016/S0140-6736(05)79880-9	http://dx.doi.org/10.1016/S0140-6736(05)79880-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848392				2022-12-28	WOS:000077246500070
J	Sokal, EM; Melchior, M; Cornu, C; Vandenbroucke, AT; Buts, JP; Cohen, BJ; Burtonboy, G				Sokal, EM; Melchior, M; Cornu, C; Vandenbroucke, AT; Buts, JP; Cohen, BJ; Burtonboy, G			Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children	LANCET			English	Article							LIVER-FAILURE; HYBRIDIZATION ASSAY; DNA; ARTHROPATHY; PERSISTENCE	Background The cause of fulminant hepatitis (FH) in children is unexplained in up to 50% of cases. We report parvovirus B19 as an agent associated with FH in children and compare clinical characteristics of these patients with those of age-matched patients with FH of other origin. Methods 45 patients presented with FH. No cause was apparent in 21 patients. Parvovirus B19 genome was retrospectively sought by PCR in serum collected admission in 41 patients. Findings Parvovirus B19 genome was detected in serum from four of 21 patients with unexplained FH (four of 11 younger than 5 years). No B19 DNA was detected in serum from patients with other types of FH or from 82 patients with biliary atresia. Parvovirus B19 IgM was detected in one of the four patients. Patients with parvovirus B19 infection had significantly lower bilirubin concentrations than age-matched patients with FH due to hepatitis A (nine) or other causes (nine) (poisoning with amanita excluded). All patients with parvovirus B19 survived without orthotopic liver transplantation, with restoration of normal liver function within 17 days. Interpretation In patients younger than 5 years with FH of unexplained origin, evidence of acute parvovirus B19 was associated with a distinct clinical pattern. In particular, low bilirubin concentrations and rapid recovery of liver function without transplantation were distinctive features.	Clin Univ St Luc, Dept Pediat, B-1200 Brussels, Belgium; Clin Univ St Luc, Dept Virol, B-1200 Brussels, Belgium; Publ Hlth Lab Serv, Div Virus Reference, London NW9 5EQ, England	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Public Health England	Sokal, EM (corresponding author), Clin Univ St Luc, Dept Pediat, 10-1301 Av Hippocrate, B-1200 Brussels, Belgium.	sokal@pedi.ucl.ac.be		Sokal, Etienne/0000-0001-5597-4708				BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CAMES B, 1992, J PEDIATR-US, V120, P33, DOI 10.1016/S0022-3476(05)80593-1; Clewley Jonathan P., 1993, P367; COHEN B, 1995, BMJ-BRIT MED J, V311, P1549, DOI 10.1136/bmj.311.7019.1549; Debray D, 1997, HEPATOLOGY, V26, P1018, DOI 10.1053/jhep.1997.v26.pm0009328329; DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1002/hep.1840160509; Durand P, 1996, PRESSE MED, V25, P1501; FOTO F, 1993, J INFECT DIS, V167, P744, DOI 10.1093/infdis/167.3.744; HICKS KE, 1995, J CLIN MICROBIOL, V33, P2473, DOI 10.1128/JCM.33.9.2473-2475.1995; Hillingso JG, 1998, LANCET, V351, P955, DOI 10.1016/S0140-6736(00)80016-1; Langnas AN, 1995, HEPATOLOGY, V22, P1661, DOI 10.1002/hep.1840220608; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; MORI J, 1989, J CLIN MICROBIOL, V27, P459, DOI 10.1128/JCM.27.3.459-464.1989; Soderlund M, 1997, LANCET, V349, P1063, DOI 10.1016/S0140-6736(96)09110-6; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; Yoto Y, 1996, LANCET, V347, P868, DOI 10.1016/S0140-6736(96)91348-3; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	17	90	94	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1739	1741		10.1016/S0140-6736(98)06165-0	http://dx.doi.org/10.1016/S0140-6736(98)06165-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848349				2022-12-28	WOS:000077246500008
J	van Dongen, JJM; Seriu, T; Panzer-Grumayer, ER; Biondi, A; Pongers-Willemse, MJ; Corral, L; Stolz, F; Schrappe, M; Masera, G; Kamps, WA; Gadner, H; van Wering, ER; Ludwig, WD; Basso, G; de Bruijn, MAC; Cazzaniga, G; Hettinger, A; van der Does-van den Berg, A; Hop, WCJ; Riehm, H; Bartram, CR				van Dongen, JJM; Seriu, T; Panzer-Grumayer, ER; Biondi, A; Pongers-Willemse, MJ; Corral, L; Stolz, F; Schrappe, M; Masera, G; Kamps, WA; Gadner, H; van Wering, ER; Ludwig, WD; Basso, G; de Bruijn, MAC; Cazzaniga, G; Hettinger, A; van der Does-van den Berg, A; Hop, WCJ; Riehm, H; Bartram, CR			Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CELL RECEPTOR GENES; IMMUNOLOGICAL MARKER ANALYSIS; T-CELL; ACUTE-LEUKEMIA; SUBSEQUENT RELAPSE; IMMUNOGLOBULIN; CHEMOTHERAPY; PERSISTENCE; DIAGNOSIS	Background Sensitive techniques for detection of minimal residual disease (MRD) at degrees of one leukaemic cell per 10(3)-10(6) cells (10(-3)-10(-6)) during follow-up of children with acute lymphoblastic leukaemia (ALL) can provide insight into the effectiveness of cytotoxic treatment. However, it is not yet clear how information on MRD can be applied to treatment protocols. Methods We monitored 240 patients with childhood ALL who were treated according to national protocols of the International BFM Study Group. 60 patients relapsed and the patients in continuous complete remission (CCR) had a median event-free follow-up of 48 months. Bone-marrow samples were collected at up to nine time points during and after treatment. Standardised PCR analysis of patient-specific immunoglobulin and T-cell receptor gene rearrangements and TALI deletions were used as targets for semiquantitative estimation of MRD. Amount of MRD was classed as 10(-2) or more, 10(-3), and 10(-4) or less. Findings MRD negativity at the various follow-up times was associated with low relapse rates (3-15% at 3 years), but five-fold to ten-fold higher relapse rates (39-86% at 3 years) were found in MRD-positive patients. The distinct degrees of MRD appeared to have independent prognostic value (p [trend]<0.001) at all separate time points, especially at the first two time points (at the end of induction treatment and before consolidation treatment). At these two time points a high degree of MRD (greater than or equal to 10(-2)) was associated with a three-fold higher relapse rate when compared with patients with a low degree of MRD (less than or equal to 10(-4)). At later time points (including the end of treatment) even a low degree of MRD was associated with a poor outcome. Positivity in patients in CCR after treatment was rare (<1%). With the combined MRD information from the first two follow-up time points, it was possible to recognise three different risk groups-55 (43%) were in a low-risk group and had a 3-year relapse rate of only 2% (95% CI 0.05-12%); 19 (15%) were in a high-risk group and had a relapse rate of 75% (55-95%); and 55 (43%) were in an intermediate-risk group and had a 3-year relapse rate of 23% (13-36%). Interpretation Our collaborative MRD study shows that monitoring patients with childhood ALL at consecutive time points gives clinically relevant insight into the effectiveness of treatment. Combined information on MRD from the first 3 months of treatment distinguishes patients with good prognoses from those with poor prognoses, and this helps in decisions whether and how to modify treatment.	Erasmus Univ, Univ Rotterdam Hosp, Dept Immunol, Rotterdam, Netherlands; Univ Heidelberg, Inst Human Genet, Heidelberg, Germany; St Anna Childrens Hosp, Childrens Canc Res Inst, Dept Pediat, A-1090 Vienna, Austria; Univ Milan, Osped San Gerardo, Dept Pediat, Monza, Italy; Med Hsch Hannover, Dept Pediat, Hannover, Germany; Dutch Childhood Leukaemia Study Grp, The Hague, Netherlands; Univ Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; Humboldt Univ, Robert Rossle Clin, Dept Hematol Oncol & Tumour Immunol, Berlin, Germany; Univ Turin, Dept Pediat, I-10124 Turin, Italy; Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Ruprecht Karls University Heidelberg; Saint Anna Children's Hospital; San Gerardo Hospital; University of Milan; Hannover Medical School; University of Groningen; Humboldt University of Berlin; University of Turin; Erasmus University Rotterdam	van Dongen, JJM (corresponding author), Erasmus Univ, Dept Immunol, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Biondi, Andrea/K-9997-2016; Biondi, Andrea/AAX-1865-2020; Schrappe, Martin/A-8109-2010; van Dongen, Jacques J.M./F-8537-2015; Schrappe, Martin/ABA-6144-2020; Cazzaniga, Giovanni/K-6338-2016	Biondi, Andrea/0000-0002-6757-6173; van Dongen, Jacques J.M./0000-0001-7686-0021; van Dongen, Jacques J.M./0000-0002-3650-7087; BASSO, GIUSEPPE/0000-0002-2634-9302; Cazzaniga, Giovanni/0000-0003-2955-4528				ADRIAANSEN HJ, 1993, LEUKEMIA, V7, P472; BARTRAM CR, 1993, CLIN CHIM ACTA, V217, P75, DOI 10.1016/0009-8981(93)90239-Z; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BEISHUIZEN A, 1991, LEUKEMIA, V5, P657; BEISHUIZEN A, 1994, LEUKEMIA, V8, P2228; Beishuizen A, 1997, LEUKEMIA, V11, P2200, DOI 10.1038/sj.leu.2400904; BIONDI A, 1992, LEUKEMIA, V6, P282; BREIT TM, 1993, BLOOD, V82, P3063; BREIT TM, 1993, LEUKEMIA, V7, P2004; Brisco MJ, 1997, BRIT J HAEMATOL, V99, P314, DOI 10.1046/j.1365-2141.1997.3723186.x; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAVE H, 1994, BLOOD, V83, P1892; Childhood A, 1996, LANCET, V347, P1783, DOI DOI 10.1016/S0140-6736(96)91615-3; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GAJJAR A, 1995, BLOOD, V86, P1292, DOI 10.1182/blood.V86.4.1292.bloodjournal8641292; GHALI DW, 1995, BLOOD, V85, P2795, DOI 10.1182/blood.V85.10.2795.bloodjournal85102795; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; PONGERSWILLEMSE MJ, IN PRESS LEUKEMIA; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; SANMIGUEL JF, 1995, EUROPEAN UNION BIOME, P372; SERIU T, 1995, LEUKEMIA, V9, P316; STEENBERGEN EJ, 1995, LEUKEMIA, V9, P1726; STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; vanDongen JJM, 1996, CYTOKINES MOL THER, V2, P121; VANDONGEN JJM, 1992, LEUKEMIA, V6, P47; VANDONGEN JJM, 1986, MINIMAL RESIDUAL DIS, P113; VanDongenMelman JEWM, 1997, LEUKEMIA, V11, P1799, DOI 10.1038/sj.leu.2400830; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911	34	731	766	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1731	1738		10.1016/S0140-6736(98)04058-6	http://dx.doi.org/10.1016/S0140-6736(98)04058-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848348				2022-12-28	WOS:000077246500007
J	Zheng, P; Guo, Y; Niu, QT; Levy, DE; Dyck, JA; Lu, SL; Sheiman, LA; Liu, Y				Zheng, P; Guo, Y; Niu, QT; Levy, DE; Dyck, JA; Lu, SL; Sheiman, LA; Liu, Y			Proto-oncogene PML controls genes devoted to MHC class I antigen presentation	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; EXPRESSION; T(15-17); CELLS; TRANSLOCATION; ADENOVIRUS-12; INTERFERON; MOLECULES; PATHWAY	Fragments of foreign antigens associated with class I molecules of the major histocompatibility complex (MHC) are presented at the cell surface to elicit an immune response. This presentation requires the coordinated expression of several genes contained in the MHC1-5, including those encoding the MHC class I heavy chain, the proteins LMP-2 and LMP-7, which are involved in the proteasomal degradation of cytosolic antigens into peptide fragments that are destined for association with MHC class I molecules, and TAP-1 and TAP-2, which transport these fragments across the membrane of the endoplasmic reticulum at the start of their journey to the cell surface. In many virus-transformed cell lines(6,7) and spontaneous tumours(8-10), these genes are simultaneously repressed. However, the key factor(s) that are essential for their expression and repression have not been identified. Here we report that the proto-oncogene product PML induces expression of LMP-2, LMP-7, TAP-1 and TAF-2 in an MHC-class I-negative, recurrent tumour, leading to the re-expression of cell-surface MHC in tumours and to rejection of the tumours. PML also regulates MHC expression in untransformed fibroblasts. We conclude that malfunction of PML may enable a tumour to evade the immune defence of its host.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	New York University; New York University; University of California System; University of California San Diego	Liu, Y (corresponding author), NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA.	liu-3@medctr.osu.edu	Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022; Zheng, Pan/E-8691-2011	Levy, David/0000-0002-7320-7788; Zheng, Pan/0000-0003-2598-3544; Liu, Yang/0000-0002-9442-700X				BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Gambacorta M, 1996, AM J PATHOL, V149, P2023; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo Y, 1996, J EXP MED, V184, P955, DOI 10.1084/jem.184.3.955; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Korkolopoulou P, 1996, BRIT J CANCER, V73, P148, DOI 10.1038/bjc.1996.28; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1995, ONCOGENE, V11, P871; MATINEZ CK, 1991, NATURE, V353, P554; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; RAMARATHINAM L, 1994, J EXP MED, V179, P1205, DOI 10.1084/jem.179.4.1205; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VEGH Z, 1993, CANCER RES, V53, P2416; Whitley EA, 1996, J EXP THEOR ARTIF IN, V8, P365, DOI 10.1080/095281396147375; Yoshida H, 1996, CANCER RES, V56, P2945	30	145	149	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					373	376		10.1038/24628	http://dx.doi.org/10.1038/24628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845074				2022-12-28	WOS:000077204000051
J	Owen, WF; Chertow, GM; Lazarus, JM; Lowrie, EG				Owen, WF; Chertow, GM; Lazarus, JM; Lowrie, EG			Dose of hemodialysis and survival - Differences by race and sex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UREA REDUCTION RATIO; DIALYSIS TREATMENT; MORTALITY; PREDICTORS; ADEQUACY; DEATH	Context.-Although blacks receive lower doses of hemodialysis than whites, their survival when receiving dialysis treatment is better than that for whites. Previous studies of the relationship between the dose of dialysis and patient survival have not controlled for differences in patient characteristics. Objective.-To examine the association of mortality with the lose of hemodialysis for clusters of patients categorized by race and sex. Design.-Retrospective analysis of laboratory data and mortality outcomes from 1994, using a national database of hemodialysis patients. Patients.-A total of 18144 black and white patients receiving hemodialysis 3 times weekly who either lived the entire year receiving hemodialysis or died. Main Outcome Measures.-The fractional reduction of urea in a single dialysis session as the measured hemodialysis dose (urea reduction ratio [URR]) after controlling for race, sex, age, and diabetes mellitus. Mortality was determined by strata of URRs and albumin and creatinine levels. Results.-Across all age categories, blacks had lower URRs than whites, and men had lower URRs than women. In an age-adjusted model for evaluating interactions among URRs, race, sex, and diabetes, the association of URR with mortality risk was weak among blacks, particularly black men. After adjustment for age and diabetes, death probability curves were most steep for white women with URR values less than 60%. The death probability curves were least steep for black men. There was no meaningful difference between death probability and albumin or creatinine concentration among the race by sex clusters. Conclusion.-Using URR, the usual measure of hemodialysis dose, the assumption that the association between dialysis dose and survival is uniform across demographic groups appears incorrect. Comparisons of the quality of dialysis patient cave should not rely on URR alone to predict patient survival.	Brigham & Womens Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA; Fresenius Med Care N Amer, Lexington, MA USA	Harvard University; Brigham & Women's Hospital	Owen, WF (corresponding author), Brigham & Womens Hosp, Dept Med, Div Nephrol, 75 Francis St, Boston, MA 02115 USA.	wfowen@bics.bwh.harvard.edu		Chertow, Glenn/0000-0002-7599-0534	NIDDK NIH HHS [DK520521] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acchiardo S R, 1992, ASAIO J, V38, pM282, DOI 10.1097/00002480-199207000-00038; *AM ASS KIDN PAT, 1995, AM ASS KIDN PAT ADV, P1; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Chertow GM, 1997, KIDNEY INT, V51, P1578, DOI 10.1038/ki.1997.216; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; *DEP HLTH HUM SERV, 1995, KNOW YOUR NUMB; *DEP HLTH HUM SERV, 1997, ESRD COR IND PROJ 19; DEPNER TA, 1993, SEMIN DIALYSIS, V6, P242, DOI 10.1111/j.1525-139X.1993.tb00152.x; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Eknoyan G, 1996, SEMIN DIALYSIS, V9, P24, DOI 10.1111/j.1525-139X.1996.tb00897.x; FINESTEIN AR, 1996, MULTIVARIABLE ANAL, P164; Gotch FA, 1990, CLIN DIALYSIS, P118; HAKIM RM, 1990, KIDNEY INT, V37, P822, DOI 10.1038/ki.1990.52; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HAKIM RM, 1992, AM J KIDNEY DIS, V20, P107, DOI 10.1016/S0272-6386(12)80538-5; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; *HEM AD WORK GROUP, 1997, AM J KIDNEY DIS S, V30, pS15; *HLTH CAR FIN ADM, 1997, HCFA PUBL A B, V60; HORNBERGER JC, 1993, J AM SOC NEPHROL, V4, P1004; HOSMER DW, 1989, APPL LOGISTIC REGRES; IFUDU O, 1995, DIALYSIS TRANSPLANT, V24, P292; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 1997, SEMIN DIALYSIS, V10, P115, DOI 10.1111/j.1525-139X.1997.tb00865.x; LOWRIE EG, 1994, DEV NEPHROL, V35, P121; LOWRIE EG, 1994, AM J KIDNEY DIS, V24, P255, DOI 10.1016/S0272-6386(12)80191-0; Lowrie EG, 1996, SEMIN NEPHROL, V16, P242; LOWRIE EG, 1991, CONT DIAL NEPHROL, V2, P11; LOWRIE EG, 1992, KIDNEY INT, V42, P22; Owen WF, 1998, KIDNEY INT, V54, P627, DOI 10.1046/j.1523-1755.1998.00032.x; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; OWEN WF, 1997, ADV RENAL REPLACE TH, V4, P3; PARKER TF, 1994, AM J KIDNEY DIS, V23, P670, DOI 10.1016/S0272-6386(12)70277-9; *REN PHYS ASS WORK, 1993, CLIN PRACT GUID, V1; SHERMAN RA, 1995, KIDNEY INT, V47, P319, DOI 10.1038/ki.1995.41; *US REN DAT SYST, 1996, USRDS 1997 ANN DAT R	37	170	173	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1764	1768		10.1001/jama.280.20.1764	http://dx.doi.org/10.1001/jama.280.20.1764			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842952				2022-12-28	WOS:000077081400032
J	Nutt, D				Nutt, D			Substance-P antagonists: a new treatment for depression?	LANCET			English	Editorial Material									Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS9 1TD, Avon, England	University of Bristol	Nutt, D (corresponding author), Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS9 1TD, Avon, England.							Bell CJ, 1998, BRIT J PSYCHIAT, V172, P465, DOI 10.1192/bjp.172.6.465; Davidson JRT, 1998, J CLIN PSYCHIAT, V59, P47; DELGADO PL, 1994, ARCH GEN PSYCHIAT, V51, P865; Hokfelt Tomas G. M., 1995, P483; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Rasmussen S, 1997, INT CLIN PSYCHOPHARM, V12, P309, DOI 10.1097/00004850-199711000-00003; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323	8	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1644	1646		10.1016/S0140-6736(05)61444-4	http://dx.doi.org/10.1016/S0140-6736(05)61444-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853433				2022-12-28	WOS:000077110300005
J	Powell, JT; Brady, AR; Brown, LC; Forbes, JF; Fowkes, FGR; Greenhalgh, RM; Ruckley, CV; Thompson, SG				Powell, JT; Brady, AR; Brown, LC; Forbes, JF; Fowkes, FGR; Greenhalgh, RM; Ruckley, CV; Thompson, SG		UK Small Aneurysm Trial Participants	Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms	LANCET			English	Article							POPULATION; MANAGEMENT	Background Early elective surgery may prevent rupture of abdominal aortic aneurysms, but mortality is 5-6%. The risk of rupture seems to be low for aneurysms smaller than 5 cm. We investigated whether prophylactic open surgery decreased long-term mortality risks for small aneurysms. Methods We randomly assigned 1090 patients aged 60-76 years, with symptomless abdominal aortic aneurysms 4.0-5.5 cm in diameter to undergo early elective open surgery (n=563) or ultrasonographic surveillance (n=527). Patients were followed up for a mean of 4.6 years. If the diameter of aneurysms in the surveillance group exceeded 5 5 cm, surgical repair was recommended. The primary endpoint was death. Mortality analyses were done by intention to treat. Findings The two groups had similar cardiovascular risk factors at baseline. 93% of patients adhered to the assigned treatment. 309 patients died during follow-up. The overall hazard ratio for all-cause mortality in the early-surgery group compared with the surveillance group was 0.94 (95% CI 0.75-1.17, p=0.56). The 30-day operative mortality in the early-surgery group was 5.8%, which led to a survival disadvantage for these patients early in the trial. Mortality did not differ significantly between groups at 2 years, 4 years, or 6 years. Age, sex, or initial aneurysm size did not modify the overall hazard ratio. Interpretation Ultrasonographic surveillance for small abdominal aortic aneurysms is safe, and early surgery does not provide a long-term survival advantage. Our results do not support a policy of open surgical repair for abdominal aortic aneurysms of 4 0-5.5 cm in diameter.	Charing Cross Hosp, Imperial Coll Sch Med, Dept Vasc Surg, London W6 8RF, England; Royal United Hosp, Bath, Avon, England; Bristol Royal Infirm, Bristol, Avon, England; Derriford Hosp, Plymouth, Devon, England; Dorset Cty Hosp, Dorchester, England; Frenchay Hosp, Bristol, Avon, England; Gloucester Royal Infirm, Gloucester, England; Morriston Hosp, Swansea, W Glam, Wales; Neville Hall Hosp, Abergavenny, Wales; New Royal Bournemouth Gen Hosp, Bournemouth, Dorset, England; N Devon Dist Gen Hosp, Barnstaple, England; Princess Wales Hosp, Bridgend, Wales; Princess Margaret Hosp, Swindon, Wilts, England; Southampton Gen Hosp, Southampton, Hants, England; Southmead Hosp, Bristol, Avon, England; Torbay Hosp, Torquay, England; Yeovil Dist Gen Hosp, Yeovil, England; Aberdeen Royal Infirm, Aberdeen, Scotland; Ayr Hosp, Ayr, Scotland; Dryburn Hosp, Durham, England; Dumfries & Galloway Royal Infirm, Dumfries, Scotland; Dumfermline & W Fife Hosp, Falkirk, Scotland; Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England; Gartnavel Gen Hosp, Glasgow, Lanark, Scotland; Ninewells Hosp, Dundee, Scotland; Royal Perth Infirm, Perth, WA, Australia; Queen Elizabeth Hosp, London, England; Royal Victoria Infirm, Newcastle Upon Tyne, Tyne & Wear, England; Leicester Royal Infirm, Leicester, Leics, England; Derbyshire Royal Infirm, Derby, England; Glenfield Gen Hosp, Leicester, Leics, England; Kettering & Gen Dist Hosp, Kettering, England; Kidderminster Gen Hosp, Kidderminster, England; Leicester Gen Hosp, Leicester, Leics, England; Northampton Gen Hosp, Northampton, England; No Gen Hosp, Sheffield, S Yorkshire, England; Nottingham Queens Med Ctr, Nottingham, England; Royal Hallamshire Hosp, Sheffield, S Yorkshire, England; Sandwell Dist Gen Hosp, W Bromwich, England; Worcester Royal Infirm, Worcester, England; Charing Cross Hosp, London, England; Colchester Gen Hosp, Colchester, Essex, England; Epsom Dist Hosp, Epsom, Surrey, England; Guys Hosp, London, England; Hillingdon Hosp, Uxbridge, Middx, England; Ipswich Hosp, Ipswich, Suffolk, England; Joyce Green Hosp, Dartford, England; Lewisham Hosp, London, England; Medway Hosp, Gillingham, England; Newham Gen Hosp, London, England; Princess Alexandra Hosp, Woolloongabba, Qld, Australia; Royal Free Hosp, London, England; Royal Hampshire Cty Hosp, Winchester, Hants, England; Royal Surrey Cty Hosp, Guildford, Surrey, England; St Georges Hosp, London, England; St Peters Hosp, Surrey, England; St Thomas Hosp, London, England; Univ Coll Hosp, London, England; W Middlesex Hosp, Isleworth, England; W Norwich Hosp, Norwich, Norfolk, England; Wexham Pk Hosp, Slough, Berks, England; Whipps Cross Hosp, Leeds, W Yorkshire, England; Univ Hosp S Manchester, Manchester, Lancs, England; Arrowe Pk Hosp, Liverpool, Merseyside, England; Blackburn Royal Infirm, Blackburn, Lancs, England; Victoria Hosp, London, England; Burnley Gen Hosp, Burnley, Lancs, England; Clatterbridge Hosp, Wirral, Merseyside, England; Cumberland Infirm, Carlisle, England; Grimsby Dist Gen Hosp, Grimsby, England; Hull Royal Infirm, Hull, N Humberside, England; Leeds Dist Gen Hosp, Leeds, W Yorkshire, England; Leigh Infirm, Lancaster, England; Macclesfield Gen Hosp, Macclesfield, Cheshire, England; Manchester Royal Infirm, Manchester, Lancs, England; Oldham Royal Hosp, Oldham, England; Pontefract Gen Infirm, Pontefract, England; Royal Preston Hosp, Preston, Lancs, England; Royal Lancaster Infirm, Lancaster, England; Stafford Gen Hosp, Stafford, England; Telford Gen Hosp, Telford, Shrops, England; Infirm Rochdale, Rochdale, England; York Dist Hosp, York, N Yorkshire, England; Glan Clwyd Hosp, Rhyl, Wales; Stoke City Gen Hosp, Stoke On Trent, Staffs, England; Royal Edinburgh Infirm, Edinburgh, Midlothian, Scotland	Imperial College London; Bristol Royal Infirmary; Derriford Hospital; Morriston Hospital; University of Southampton; Southmead Hospital; University of Aberdeen; Newcastle Freeman Hospital; University of Dundee; Royal Perth Hospital; Newcastle University - UK; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University Hospitals of Leicester NHS Trust; Leicester General Hospital; Northern General Hospital; University of Sheffield; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Ipswich Hospital NHS Trust; Ipswich Hospital; Medway Maritime Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Royal Surrey County Hospital; St Georges University London; Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Imperial College London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; Royal Preston Hospital; Royal Infirmary of Edinburgh	Powell, JT (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Dept Vasc Surg, London W6 8RF, England.	j.powell@ic.ac.uk	Forbes, John F/L-2558-2013; Powell, Janet/AAW-8669-2021	Forbes, John F/0000-0002-8255-3762; Powell, Janet/0000-0002-3905-1468; Brady, Tony/0000-0003-4751-7616				Bradbury AW, 1997, BRIT J SURG, V84, P1705, DOI 10.1046/j.1365-2168.1997.02868.x; Bradbury AW, 1998, BRIT J SURG, V85, P645; BUDD JS, 1995, EUR J VASC ENDOVASC, V9, P176, DOI 10.1016/S1078-5884(05)80087-5; COLLIN J, 1988, LANCET, V2, P613; DARLING RC, 1970, AM J SURG, V119, P397, DOI 10.1016/0002-9610(70)90140-6; *DEP HLTH, 1997, HOSP EP STAT 1989 19; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; Glimaker H, 1991, Eur J Vasc Surg, V5, P125, DOI 10.1016/S0950-821X(05)80675-9; GREENHALGH RM, 1995, EUR J VASC ENDOVASC, V9, P42; HALLETT JW, 1993, J VASC SURG, V18, P684, DOI 10.1016/0741-5214(93)90078-Z; JOHNSTON KW, 1994, J VASC SURG, V19, P888, DOI 10.1016/S0741-5214(94)70015-X; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; LEDERLE FA, 1994, J VASC SURG, V20, P296, DOI 10.1016/0741-5214(94)90019-1; LUCAROTTI ME, 1992, BRIT J SURG, V79, P641, DOI 10.1002/bjs.1800790714; MACSWEENEY STR, 1994, LANCET, V344, P651, DOI 10.1016/S0140-6736(94)92087-7; Manfredini R, 1996, J CLIN EPIDEMIOL, V49, P865, DOI 10.1016/0895-4356(96)00114-X; May J, 1998, J VASC SURG, V27, P213, DOI 10.1016/S0741-5214(98)70352-0; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POWELL JT, 1993, LANCET, V342, P1473, DOI 10.1016/0140-6736(93)92939-Q; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SMITH FCT, 1993, BRIT J SURG, V80, P1406, DOI 10.1002/bjs.1800801117; Woodburn KR, 1998, BRIT J SURG, V85, P435	23	832	853	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1649	1655						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853436				2022-12-28	WOS:000077110300008
J	Wechsler, H; Rigotti, NA; Gledhill-Hoyt, J; Lee, H				Wechsler, H; Rigotti, NA; Gledhill-Hoyt, J; Lee, H			Increased levels of cigarette use among college students - A cause for national concern	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SMOKING; PREVALENCE; INITIATION; DRINKING	Context.-Adolescent smoking prevalence is tracked annually and has increased since 1991. In contrast, little is known about trends in smoking among college students, a group that has previously been more resistant to tobacco use than other young adults. Objective.-To examine changes in cigarette smoking among college students between 1993 and 1997 and among different types of students and colleges. Design.-Seif-administered survey (Harvard School of Public Health College Alcohol Study). Setting.-One hundred sixteen nationally representative 4-year colleges. Subjects.-A total of 15 103 randomly selected students in 1993 (70% response rate) and 14 251 students in 1997 (60% response rate). Main Outcome Measures.-Self-reports of cigarette smoking in the past 30 days and in the past year, age at smoking first cigarette, and number of attempts to quit. Results.-Over 4 years, the prevalence of current (30-day) cigarette smoking rose by 27.8%, from 22.3% to 28.5% (P<.001). The increase was observed in 99 of 116 colleges and was statistically significant(P<.05) in 27 (23%) of them. Current smoking increased across all student subgroups (defined by sex, race/ ethnicity, and year in school) and in all types of colleges. Smoking is rising faster in public schools (from 22.0% to 29.3%) than in private schools (from 22.9% to 26.8%). Eleven percent of college smokers had their first cigarette and 28% began to smoke regularly at or after age 19 years, by which time most were already in college. Half of current smokers tried to quit in the previous year; 18% had made 5 or more attempts to quit. Conclusions.-Cigarette use is increasing on campuses nationwide in all subgroups and types of colleges. Substantial numbers of college students are both starting to smoke regularly and trying to stop. National efforts to reduce smoking should be extended to college students.	Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Div Gen Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Calif Los Angeles, Ctr Vaccine Res, Los Angeles, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	Wechsler, H (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, 677 Huntington Ave, Boston, MA 02115 USA.							*BARR ED SER INC, 1996, BARR PROF AM COLL; Breslau N, 1996, AM J PUBLIC HEALTH, V86, P214, DOI 10.2105/AJPH.86.2.214; CARABALLO RS, 1998, ANN M SOC RES NIC TO; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Emmons KM, 1998, AM J PUBLIC HEALTH, V88, P104, DOI 10.2105/AJPH.88.1.104; ESCOBEDO LG, 1990, JAMA-J AM MED ASSOC, V264, P1550, DOI 10.1001/jama.264.12.1550; Escobedo LG, 1996, AM J PUBLIC HEALTH, V86, P231, DOI 10.2105/AJPH.86.2.231; FRIER ME, 1991, N3291CHF; GRAY NL, 1993, J DRUG EDUC, V23, P117, DOI 10.2190/7W66-52X5-LY0B-AE6R; JOHNSON LD, 1996, US DEP HHS NIH PUBLI, V1; JOHNSON LD, 1996, US DEP HHS NIH PUBL, V2; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; *NAT CTR ED STAT, 1996, NCES PUBL US DEP ED; SAS Institute, 1990, SAS STAT US GUID VER; SAS INSTITUTE INC, 1990, SAS STAT US GUID VER, V1; SCHOTTE U, 1994, J PHYS-CONDENS MAT, V6, P10105, DOI 10.1088/0953-8984/6/46/026; Stephens T, 1997, AM J PUBLIC HEALTH, V87, P1519, DOI 10.2105/AJPH.87.9.1519; U. S. Department of Health Human Services, 1994, MMWR-MORBID MORTAL W, V43, P1; *US BUR CENS, 1996, 1966 STAT ABSTR US; *US DEP ED, 1997, DIG ED STAT; *US DEP HHS, 1998, MMWR-MORBID MORTAL W, V47, P229; *US DEP HHS, 1995, MMWR-MORBID MORTAL W, V46, P1217; *US DEP HHS, 1994, PREV TOB US YOUNG PE; *US DEP HHS, 1989, DHHS PUBL; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P433; WECHSLER H, 1992, JAMA-J AM MED ASSOC, V267, P2929; WECHSLER H, 1994, JAMA-J AM MED ASSOC, V272, P1672, DOI 10.1001/jama.272.21.1672; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; [No title captured]	29	322	325	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1673	1678		10.1001/jama.280.19.1673	http://dx.doi.org/10.1001/jama.280.19.1673			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138PD	9831998	Bronze			2022-12-28	WOS:000076980700032
J	Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M				Hira, K; Fukui, T; Endoh, A; Rahman, M; Maekawa, M			Influence of superstition on the date of hospital discharge and medical cost in Japan: retrospective and descriptive study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd Asian-Pacific Congress of Epidemiology	JAN   28, 1998	TOKYO, JAPAN				PLACEBO	Objectives To determine the influence of superstition about Taian (a lucky day)-Butsumetsu tan unlucky day) on decision to leave hospital. To estimate the costs of the effect of this superstition. Design Retrospective and descriptive study. Setting University hospital in Kyoto,Japan. Subjects Patients who were discharged alive from Kyoto University Hospital from 1 April 1992 to 31 March 1995, Main outcome measures Mean number, age, and hospital stay of patients discharged on each day of six day cycle. Results The mean number, age, and hospital stay of discharged patients were highest on Taian and lowest on Butsumetsu (25.5 v 19.3 patients/day, P = 0.0001; 43.9 v 41.4 years, P = 0.0001; and 43.1 v 33.3 days, P = 0.0001 respectively). The effect of this difference on the hospital's costs was estimated to be 7.4 million yen (pound 31 000). Conclusion The superstition influenced the decision to leave hospital, contributing to higher medical care costs in Japan. Although hospital stays need to be kept as short as possible to minimise costs, doctors should not ignore the possible psychological effects on patients' health caused by dismissing the superstition.	Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Human & Environm Studies, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hira, K (corresponding author), Kyoto Univ, Dept Gen Med & Clin Epidemiol, Sakyo Ku, Kyoto 6068507, Japan.							BLACHER RS, 1983, GEN HOSP PSYCHIAT, V5, P279, DOI 10.1016/0163-8343(83)90007-5; DOBRILLA G, 1994, DIGEST DIS, V12, P368, DOI 10.1159/000171471; EDWARD A, 1990, HUM BEHAV, P64; KAKU K, 1975, AM J PUBLIC HEALTH, V65, P170, DOI 10.2105/AJPH.65.2.170; KAKU K, 1972, SOC BIOL, V19, P60, DOI 10.1080/19485565.1972.9987966; KAKU K, 1975, ANN HUM BIOL, V2, P391, DOI 10.1080/03014467500001011; KAKU K, 1975, ANN HUM BIOL, V2, P111, DOI 10.1080/03014467500000651; KIM YS, 1979, J BIOSOC SCI, V11, P457, DOI 10.1017/S0021932000012530; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; OH VMS, 1994, BRIT MED J, V309, P69, DOI 10.1136/bmj.309.6947.69; *ORG EC COOP DEV, 1993, OECD HLTH SYST FACTS, P215; REISS RE, 1988, OBSTET GYNECOL, V71, P270; SCANLON TJ, 1993, BRIT MED J, V307, P1584, DOI 10.1136/bmj.307.6919.1584; SCOTT R, 1994, BRIT MED J, V309, P1691, DOI 10.1136/bmj.309.6970.1691; *STAT INF DEP, 1993, PAT SURV, P566; *SURV DEP I SOC IN, 1997, DRUG TAR; UCHIDA M, 1991, CALENDARS TALE 12 MO, P106	17	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1680	1683		10.1136/bmj.317.7174.1680	http://dx.doi.org/10.1136/bmj.317.7174.1680			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151VX	9857123	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077742300009
J	Lasky, T; Terracciano, GJ; Magder, L; Koski, CL; Ballesteros, M; Nash, D; Clark, S; Haber, P; Stolley, PD; Schonberger, LB; Chen, RT				Lasky, T; Terracciano, GJ; Magder, L; Koski, CL; Ballesteros, M; Nash, D; Clark, S; Haber, P; Stolley, PD; Schonberger, LB; Chen, RT			The Guillain-Barre syndrome and the 1993 and 1993-1994 influenza vaccines	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; VACCINATION; ASSOCIATION	Background The number of reports of influenza-vaccine-associated Guillain-Barre syndrome to the national Vaccine Adverse Event Reporting System increased from 37 in 1992-1993 to 74 in 1993-1994, arousing concern about a possible increase in vaccine-associated risk. Methods Patients given a diagnosis of the Guillain-Barre syndrome in the 1992-1993 and 1993-1994 influenza-vaccination seasons were identified in the hospital-discharge data bases of four states. Vaccination histories were obtained by telephone interviews during 1995-1996 and were confirmed by the vaccine providers. Disease with an onset within six weeks after vaccination was defined as vaccine-associated. Vaccine coverage in the population was measured through a random-digit-dialing telephone survey. Results We interviewed 180 of 273 adults with the Guillain-Barre syndrome; 15 declined to participate, and the remaining 78 could not be contacted. The vaccine providers confirmed influenza vaccination in the six weeks before the onset of Guillain-Barre syndrome for 19 patients. The relative risk of the Guillain-Barre syndrome associated with vaccination, adjusted for age, sex, and vaccine season, was 1.7 (95 percent confidence interval, 1.0 to 2.8; P=0.04). The adjusted relative risks were 2.0 for the 1992-1993 season (95 percent confidence interval, 1.0 to 4.3) and 1.5 for the 1993-1994 season (95 percent confidence interval, 0.8 to 2.9). In 9 of the 19 vaccine-associated cases, the onset was in the second week after vaccination, all between day 9 and day 12. Conclusions There was no increase in the risk of vaccine-associated Guillain-Barre syndrome from 1992-1993 to 1993-1994. For the two seasons combined, the adjusted relative risk of 1.7 suggests slightly more than one additional case of Guillain-Barre syndrome per million persons vaccinated against influenza. (N Engl J Med 1998;339:1797-802.) (C) 1998, Massachusetts Medical Society.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Ctr Dis Control & Prevent, Vaccine Safety & Dev Act Epidemiol & Surveillance, Natl Immunizat Program, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Lasky, T (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St, Baltimore, MD 21201 USA.		Lasky, Tamar/AAR-3410-2021; Nash, Denis/AFI-7485-2022; Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; Nash, Denis/0000-0002-3280-5386	PHS HHS [U50/CCU 300860-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; ASBURY AK, 1981, ANN NEUROL, V9, P1, DOI 10.1002/ana.410090703; BREMAN JG, 1984, AM J EPIDEMIOL, V119, P880, DOI 10.1093/oxfordjournals.aje.a113810; Chen R, 1992, POST MARKETING SURVE, V6, P5; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; CHEN RT, 1994, PHARMACOEPIDEM DR S, P581; *DHHS, 1980, DHHS PUBL, V1; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; HURWITZ ES, 1981, NEW ENGL J MED, V304, P1557, DOI 10.1056/NEJM198106253042601; Johnston Jr RB, 1994, ADVERSE EVENTS ASS C, P464; KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698; KOOBATIAN TJ, 1991, ANN NEUROL, V30, P618, DOI 10.1002/ana.410300418; KOSKI CL, 1992, NEUROL CLIN, V10, P629, DOI 10.1016/S0733-8619(18)30201-9; KOSKI CL, 1994, SEMIN NEUROL, V14, P123, DOI 10.1055/s-2008-1041069; LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809; *MACR INT, 1995, RAP ASS INFL VACC US; MARKS JS, 1980, JAMA-J AM MED ASSOC, V243, P2490, DOI 10.1001/jama.243.24.2490; Ropper AH., 1991, CONT NEUROLOGY SERIE, P73; ROSCELLI JD, 1991, AM J EPIDEMIOL, V133, P952, DOI 10.1093/oxfordjournals.aje.a115974; RUBIN DB, 1986, J AM STAT ASSOC, V81, P366, DOI 10.2307/2289225; SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; *US BUR CENS, 1992, RPOTU REG STAT SEL A; *US BUR CENS, 1993, RPOTU REG STAT SEL A; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; 1997, MMWR MORB MORTAL WKL, V46, P913; 1997, MMWR MORB MORTAL WKL, V46, P974	30	356	372	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1797	1802		10.1056/NEJM199812173392501	http://dx.doi.org/10.1056/NEJM199812173392501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854114	Green Published			2022-12-28	WOS:000077545800001
J	Lund, E; Dahlberg, JE				Lund, E; Dahlberg, JE			Proofreading and aminoacylation of tRNAs before export from the nucleus	SCIENCE			English	Article							PRECURSOR TRANSFER-RNAS; SACCHAROMYCES-CEREVISIAE; NONSENSE MUTATIONS; YEAST MUTANT; PROTEIN; TRANSPORT; SYNTHETASE; MECHANISM; SIGNALS; LAEVIS	After synthesis and processing in the nucleus, mature transfer RNAs (tRNAs) are exported to the cytoplasm in a Ran.guanosine triphosphate-dependent manner. Export of defective or immature tRNAs is avoided by monitoring both structure and function of tRNAs in the nucleus, and only tRNAs with mature 5' and 3' ends are exported. ALL tRNAs examined can be aminoacylated in nuclei of Xenopus oocytes, thereby providing a possible mechanism for functional proofreading of newly made tRNAs. Inhibition of aminoacylation of a specific tRNA retards its appearance in the cytoplasm, indicating that nuclear aminoacylation promotes efficient export.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahlberg, JE (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	dahlberg@facstaff.wisc.edu			NIGMS NIH HHS [GM30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman Sidney, 1995, P67; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; ARTS GJ, IN PRESS EMBO J; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P262; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Dahlberg JE, 1997, SEMIN CELL DEV BIOL, V8, P65, DOI 10.1006/scdb.1996.0123; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Deutscher Murray P., 1995, P51; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DREHER TW, IN PRESS J BIOL CHEM; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1980, CELL, V19, P741, DOI 10.1016/S0092-8674(80)80050-X; HURT DJ, 1987, MOL CELL BIOL, V7, P1208, DOI 10.1128/MCB.7.3.1208; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUGLER W, 1995, NUCLEIC ACIDS RES, V23, P413, DOI 10.1093/nar/23.3.413; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LUND E, UNPUB; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MULLER F, 1980, CELL, V19, P345, DOI 10.1016/0092-8674(80)90509-7; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; Pasquinelli AE, 1995, RNA, V1, P957; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SANDERS J, 1996, J CELL SCI, V109, P113; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1080, P126, DOI 10.1016/0167-4838(91)90138-P; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; WOLIN SL, INPRESS GENES DEV; WSTAWAY SK, 1995, TRNA STRUCTURE BIOSY, P79; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272	45	258	266	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2082	2085		10.1126/science.282.5396.2082	http://dx.doi.org/10.1126/science.282.5396.2082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851929				2022-12-28	WOS:000077467100047
J	Kemp, M				Kemp, M			Kendrew constructs; Geis gazes	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					525	525		10.1038/25019	http://dx.doi.org/10.1038/25019			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859985				2022-12-28	WOS:000077466800036
J	Nurminsky, DI; Nurminskaya, MV; De Aguiar, D; Hartl, DL				Nurminsky, DI; Nurminskaya, MV; De Aguiar, D; Hartl, DL			Selective sweep of a newly evolved sperm-specific gene in Drosophila	NATURE			English	Article							MELANOGASTER; TRANSFORMATION; DIVERGENCE; EVOLUTION; RATES	The pattern of genetic variation across the genome of Drosophila melanogaster is consistent with the occurrence of frequent 'selective sweeps' in which new favourable mutations become incorporated into the species so quickly that linked alleles can 'hitchhike' and also become fixed(1). Because of the hitchhiking of linked genes, it is generally difficult to identify the target of any putative selective sweep. Here, however, we identify a new gene in D. melanogaster that codes for a sperm-specific axonemal dynein subunit. The gene has a new testes-specific promoter derived from a protein-coding region in a gene encoding the cell-adhesion protein annexin X (AnnX), and it contains a new protein-coding exon derived from an intron in a gene encoding a cytoplasmic dynein intermediate chain (Cdic). The new transcription unit, designated Sdic (for sperm-specific dynein intermediate chain), has been duplicated about tenfold in a tandem array. Consistent with the selective sweep of this gene, the level of genetic polymorphism near Sdic is unusually low. The discovery of this gene supports other results that point to the rapid molecular evolution of male reproductive functions(2-4).	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA	Harvard University; Tufts University	Nurminsky, DI (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.							BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; BENEVOLENSKAYA EV, 1994, DNA CELL BIOL, V14, P349; CACCONE A, 1988, GENETICS, V118, P671; Civetta A, 1998, MOL BIOL EVOL, V15, P901, DOI 10.1093/oxfordjournals.molbev.a025994; COULTHART MB, 1988, MOL BIOL EVOL, V5, P182; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; Long MY, 1995, P NATL ACAD SCI USA, V92, P12495, DOI 10.1073/pnas.92.26.12495; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; Nurminsky DI, 1996, MOL BIOL EVOL, V13, P132, DOI 10.1093/oxfordjournals.molbev.a025551; Nurminsky DI, 1998, MOL CELL BIOL, V18, P6816, DOI 10.1128/MCB.18.11.6816; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534	17	209	215	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					572	575		10.1038/25126	http://dx.doi.org/10.1038/25126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859991				2022-12-28	WOS:000077466800057
J	Jenks, PJ				Jenks, PJ			Science, medicine, and the future - Microbial genome sequencing-beyond the double helix	BRITISH MEDICAL JOURNAL			English	Review							BACTERIAL VIRULENCE GENES; HAEMOPHILUS-INFLUENZAE; IDENTIFICATION; SELECTION; RD		Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Jenks, PJ (corresponding author), Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, 28 Rue Dr Roux, F-75724 Paris 15, France.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Hood DW, 1996, P NATL ACAD SCI USA, V93, P11121, DOI 10.1073/pnas.93.20.11121; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; Roberts TC, 1997, J CLIN MICROBIOL, V35, P268, DOI 10.1128/JCM.35.1.268-269.1997; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x	16	5	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1568	1571		10.1136/bmj.317.7172.1568	http://dx.doi.org/10.1136/bmj.317.7172.1568			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836662	Green Published			2022-12-28	WOS:000077451700029
J	Sandler, RS				Sandler, RS			Appendicectomy and ulcerative colitis	LANCET			English	Editorial Material							INFLAMMATORY BOWEL-DISEASE; CROHNS-DISEASE; APPENDECTOMY; TONSILLECTOMY; RISK		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Sandler, RS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							Breslin NP, 1997, INFLAMM BOWEL DIS, V3, P1, DOI 10.1002/ibd.3780030102; Duggan AE, 1998, GUT, V43, P494, DOI 10.1136/gut.43.4.494; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; Minocha A, 1997, DIGEST DIS SCI, V42, P1567, DOI 10.1023/A:1018847617560; Mizoguchi A, 1996, J EXP MED, V184, P707, DOI 10.1084/jem.184.2.707; RATH HC, IN PRESS GASTROENTER; Russel MG, 1997, GASTROENTEROLOGY, V113, P377, DOI 10.1053/gast.1997.v113.pm9247453; RUTGEERTS P, 1994, GASTROENTEROLOGY, V106, P1251, DOI 10.1016/0016-5085(94)90016-7; SMITHSON JE, 1995, J CLIN GASTROENTEROL, V21, P283, DOI 10.1097/00004836-199512000-00006; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342	11	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1797	1798		10.1016/S0140-6736(05)79883-4	http://dx.doi.org/10.1016/S0140-6736(05)79883-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851375				2022-12-28	WOS:000077337900003
J	Marra, PP; Hobson, KA; Holmes, RT				Marra, PP; Hobson, KA; Holmes, RT			Linking winter and summer events in a migratory bird by using stable-carbon isotopes	SCIENCE			English	Article							REDSTARTS SETOPHAGA-RUTICILLA; BODY SIZE; ARRIVAL; EVOLUTION; CONSEQUENCES; DIMORPHISM; FINCHES; GROUNDS; DATE; TIME	For migratory birds, early arrival and physical condition on the breeding grounds are important determinants of reproductive success and fitness. Differences in arrival times often exceed a month, and Later arriving individuals are often in poorer condition. Habitat-specific isotopic signatures indicate that the quality of winter habitats occupied by American redstarts (Setophaga ruticilla) determines their physical condition and spring departure dates, which in turn result in variable arrival schedules and condition on temperate breeding grounds. These findings link events in tropical winter grounds with those in temperate breeding areas for a migratory songbird and provide evidence that winter habitats may be limiting.	Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA; Canadian Wildlife Serv, Prairie & No Wildlife Res Ctr, Saskatoon, SK S7N OX4, Canada	Dartmouth College; Environment & Climate Change Canada; Canadian Wildlife Service	Marra, PP (corresponding author), Smithsonian Inst, Natl Zool Pk, Smithsonian Migratory Bird Ctr, Washington, DC 20008 USA.	pmarra@nzp.si.edu	Hobson, Keith/Q-9306-2019	Marra, Peter/0000-0002-0508-7577				Chamberlain CP, 1997, OECOLOGIA, V109, P132, DOI 10.1007/s004420050067; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; DOWNHOWER JF, 1976, NATURE, V263, P558, DOI 10.1038/263558a0; FRANCIS CM, 1986, AUK, V103, P548; Gauthreaux S.A. Jr, 1978, Perspectives in Ethology, V3, P17; HOBSON KA, 1992, CONDOR, V94, P181, DOI 10.2307/1368807; Hobson KA, 1997, OECOLOGIA, V109, P142, DOI 10.1007/s004420050068; Lajtha K, 1994, STABLE ISOTOPES ECOL, P1; Loneragan NR, 1997, MAR BIOL, V130, P289, DOI 10.1007/s002270050248; Lozano GA, 1996, J AVIAN BIOL, V27, P164, DOI 10.2307/3677146; MARRA PP, 1993, AUK, V110, P565, DOI 10.2307/4088420; Marra PP, 1998, OECOLOGIA, V116, P284, DOI 10.1007/s004420050590; MARRA PP, 1998, THESIS DARTMOUTH COL; MOLLER AP, 1994, BEHAV ECOL SOCIOBIOL, V35, P115, DOI 10.1007/BF00171501; MURPHY MT, 1986, AUK, V103, P465, DOI 10.1093/auk/103.3.465; NEWTON I, 1984, J ANIM ECOL, V53, P809, DOI 10.2307/4661; ORNAT AL, 1990, AUK, V107, P539; PARRISH JD, 1994, AUK, V111, P38, DOI 10.2307/4088503; PERRINS CM, 1970, IBIS, V112, P242, DOI 10.1111/j.1474-919X.1970.tb00096.x; PRICE T, 1988, SCIENCE, V240, P798, DOI 10.1126/science.3363360; PRICE TD, 1984, AM NAT, V123, P500, DOI 10.1086/284219; Ramenofsky M., 1990, P214; ROBBINS CS, 1989, P NATL ACAD SCI USA, V86, P7658, DOI 10.1073/pnas.86.19.7658; ROWE L, 1994, AM NAT, V143, P698, DOI 10.1086/285627; Sandberg R, 1996, OIKOS, V77, P577, DOI 10.2307/3545949; *SAS I, 1995, JMP STAT GRAPH GUID; Sherry Thomas W., 1997, Birds of North America, V0, P1; STOLT BO, 1995, ORNIS FENNICA, V72, P14; Tieszen LL, 1988, STABLE ISOTOPES ECOL, P167; VANDERMERWE NJ, 1982, AM SCI, V70, P596; Verboven N, 1998, OIKOS, V81, P511, DOI 10.2307/3546771	31	779	806	7	207	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1884	1886		10.1126/science.282.5395.1884	http://dx.doi.org/10.1126/science.282.5395.1884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836637				2022-12-28	WOS:000077338100047
J	Narayan, SS; Temchin, AN; Recio, A; Ruggero, MA				Narayan, SS; Temchin, AN; Recio, A; Ruggero, MA			Frequency tuning of basilar membrane and auditory nerve fibers in the same cochleae	SCIENCE			English	Article							OUTER HAIR-CELLS; GUINEA-PIG; RECEPTOR POTENTIALS; MECHANICAL RESPONSES; HYDRODYNAMIC-FORCES; MOSSBAUER TECHNIQUE; CHINCHILLA-COCHLEA; BASE; MICROMECHANICS; SENSITIVITY	Responses to tones of a basilar membrane site and of auditory nerve fibers innervating neighboring inner hair cells were recorded in the same cochleae in chinchillas. At near-threshold stimulus Levels, the frequency tuning of auditory nerve fibers closely paralleled that of basilar membrane displacement modified by high-pass filtering, indicating that only relatively minor signal transformations intervene between mechanical vibration and auditory nerve excitation. This finding establishes that cochlear frequency selectivity in chinchillas (and probably in mammals in general) is fully expressed in the vibrations of the basilar membrane and renders unnecessary additional ("second") filters, such as those present in the hair cells of the cochleae of reptiles.	Northwestern Univ, Dept Commun Sci & Disorders, Audiol & Hearing Sci Program, Hugh Knowles Ctr, Evanston, IL 60208 USA; Northwestern Univ, Inst Neurosci, Evanston, IL 60208 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	Northwestern University; Northwestern University; University of Wisconsin System; University of Wisconsin Madison	Ruggero, MA (corresponding author), Northwestern Univ, Dept Commun Sci & Disorders, Audiol & Hearing Sci Program, Hugh Knowles Ctr, Evanston, IL 60208 USA.	mruggero@nwu.edu	Recio-Spinoso, Alberto/F-7744-2013; Ruggero, Mario A/A-9860-2009	Recio-Spinoso, Alberto/0000-0003-1909-832X; Ruggero, Mario A/0000-0001-8240-3644	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P50DC000110, F32DC000419, P01DC000110, R01DC000419] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000419, DC-00419, F32 DC000419, P50 DC000110, DC-00110] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLEN JB, 1993, J ACOUST SOC AM, V94, P809, DOI 10.1121/1.408182; ALLEN JB, 1992, PHYS TODAY, V45, P40, DOI 10.1063/1.881349; ALLEN JB, 1980, J ACOUST SOC AM, V68, P1660, DOI 10.1121/1.385198; ART JJ, 1987, J PHYSIOL-LONDON, V385, P207, DOI 10.1113/jphysiol.1987.sp016492; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; BRAUN M, 1994, HEARING RES, V78, P98, DOI 10.1016/0378-5955(94)90048-5; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; Cheatham MA, 1998, J ACOUST SOC AM, V104, P356, DOI 10.1121/1.423245; COOPER NP, 1992, HEARING RES, V63, P163, DOI 10.1016/0378-5955(92)90083-Y; CRAWFORD AC, 1981, J PHYSIOL-LONDON, V312, P377, DOI 10.1113/jphysiol.1981.sp013634; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; ELDREDGE DH, 1981, J ACOUST SOC AM, V69, P1091, DOI 10.1121/1.385688; EVANS EF, 1972, J PHYSIOL-LONDON, V226, P263, DOI 10.1113/jphysiol.1972.sp009984; EVANS EF, 1975, SCIENCE, V190, P1218, DOI 10.1126/science.1198110; FREEMAN DM, 1990, HEARING RES, V48, P17, DOI 10.1016/0378-5955(90)90196-V; FREEMAN DM, 1990, HEARING RES, V48, P31, DOI 10.1016/0378-5955(90)90197-W; GREENWOOD DD, 1990, J ACOUST SOC AM, V87, P2592, DOI 10.1121/1.399052; HARRIS GG, 1970, SCIENCE, V167, P76, DOI 10.1126/science.167.3914.76; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; KHANNA SM, 1982, SCIENCE, V215, P305, DOI 10.1126/science.7053580; LIBERMAN MC, 1978, J ACOUST SOC AM, V63, P442, DOI 10.1121/1.381736; Murugasu E, 1996, J NEUROSCI, V16, P325; NEELY ST, 1983, HEARING RES, V9, P123, DOI 10.1016/0378-5955(83)90022-9; Nuttall AL, 1996, J ACOUST SOC AM, V99, P1556, DOI 10.1121/1.414732; Patuzzi R., 1996, COCHLEA, P186; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUGGERO MA, 1990, J ACOUST SOC AM, V87, P1612, DOI 10.1121/1.399409; RUGGERO MA, 1991, HEARING RES, V51, P215, DOI 10.1016/0378-5955(91)90038-B; RUGGERO MA, 1991, J NEUROSCI, V11, P1057; RUGGERO MA, 1986, J ACOUST SOC AM, V79, P1491, DOI 10.1121/1.393763; Ruggero MA, 1996, AUDIT NEUROSCI, V2, P159; RUGGERO MA, 1995, ACTIVE HEARING, P321; RUSSELL IJ, 1983, J PHYSIOL-LONDON, V338, P179, DOI 10.1113/jphysiol.1983.sp014668; RUSSELL IJ, 1986, NATURE, V321, P517, DOI 10.1038/321517a0; Russell IJ, 1995, ADV HEARING RES, P136; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SPOENDLIN H, 1971, ARCH KLIN EXP OHR, V200, P275, DOI 10.1007/BF00373310; WILSON JP, 1992, ADV BIOSCI, V83, P71; ZWISLOCKI JJ, 1979, SCIENCE, V204, P639, DOI 10.1126/science.432671; ZWISLOCKI JJ, 1982, AM J OTOLARYNG, V3, P48, DOI 10.1016/S0196-0709(82)80032-X; ZWISLOCKI JJ, 1986, HEARING RES, V22, P155, DOI 10.1016/0378-5955(86)90091-2	46	153	158	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1882	1884		10.1126/science.282.5395.1882	http://dx.doi.org/10.1126/science.282.5395.1882			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836636	Green Accepted			2022-12-28	WOS:000077338100046
J	Raymond, RS; Fallon, MB; Abrams, GA				Raymond, RS; Fallon, MB; Abrams, GA			Oral thymic extract for chronic hepatitis C in patients previously treated with interferon - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							HORMONES	Background: Hepatitis C is an important cause of chronic liver disease. It is claimed that Complete Thymic Formula, an over-the-counter herbal dietary supplement, is beneficial for patients with hepatitis C. Objective: To evaluate the efficacy and safety of Complete Thymic Formula. Design: Randomized, double-blind, placebo-controlled trial. Setting: Tertiary referral center. Patients: 38 patients with hepatitis C who did not respond to or were intolerant of interferon therapy. Intervention: Complete Thymic Formula for 3 to 6 months or placebo for 3 months. Measurements: Serial measurements of hepatitis C virus (HCV) RNA titers. Results: No differences were noted at 3 months between the placebo group (n = 13) and the treatment group (n = 19) in mean HCV RNA titers (4.06 +/- 1.52 x 10(6) copies/mL compared with 3.48 +/- 1.92 x 10(6) copies/mL; P > 0.2). The 19 patients who completed 6 months of treatment with Complete Thymic Formula remained positive for HCV, and their mean HCV RNA titers were similar at 6 months and at baseline (2.78 +/- 1.96 x 10(6) copies/ml compared with 3.12 +/- 1.94 x 10(6) copies/mL; P > 0.2). Conclusions: Complete Thymic Formula did not benefit patients who had previously received interferon therapy. Patients should be advised about use of this over-the-counter compound.	Univ Alabama Birmingham, Birmingham Liver Ctr, Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Abrams, GA (corresponding author), Univ Alabama Birmingham, Birmingham Liver Ctr, Div Gastroenterol & Hepatol, 401 Zeigler Res Bldg,703 S 19th St, Birmingham, AL 35294 USA.		Abrams, Gary/AAC-4099-2019					Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; BURGSTINER CB, COMPLETE THYMIC FORM; Carithers RL, 1997, HEPATOLOGY, V26, pS83, DOI 10.1002/hep.510260715; Davis G. L., 1997, Hepatology, V26, p247A; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; JOUET P, 1994, GASTROENTEROLOGY, V106, P686, DOI 10.1016/0016-5085(94)90703-X; LOW TLK, 1984, THYMUS, V6, P27; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; *MED EC, 1993, PHYS DESK REF, P2404; Rasi G, 1996, GUT, V39, P679, DOI 10.1136/gut.39.5.679; REZKOVIC I, 1993, HEPATOLOGY, V18, pA252; SERRATE SA, 1987, J IMMUNOL, V139, P2338; Sherman K. E., 1996, Hepatology, V24, p402A; SZTEIN MB, 1986, SPRINGER SEMIN IMMUN, V9, P1	16	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					797	800		10.7326/0003-4819-129-10-199811150-00009	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841585				2022-12-28	WOS:000076984800005
J	Kandela, P				Kandela, P			Sketches from The Lancet - Readers' digestions	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1639	1639						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843146				2022-12-28	WOS:000076998900076
J	Powsner, SM; Wyatt, JC; Wright, P				Powsner, SM; Wyatt, JC; Wright, P			Opportunities for and challenges of computerisation	LANCET			English	Article							CLINICAL-DATA SYSTEMS; WORLD-WIDE-WEB; INFORMATION-SYSTEM; PERFORMANCE; QUALITY; IMPACT; CARE	Information technology offers many potential advantages over paper for the storage and retrieval of patients' data. Enthusiasts predict that soon all records will be stored and viewed on computer, but others are more sceptical. The failure of some computer-based records may be due to poor information design. This paper explores how computers broaden the range of design options but points out that more attention to design is required for computer-based than for paper-based records.	UCL, Sch Publ Policy, London WC1H 9EZ, England; Yale Univ, Dept Psychiat, New Haven, CT 06520 USA; Yale Univ, Ctr Med Informat, New Haven, CT USA; Univ Cardiff, Sch Psychol, Cardiff, S Glam, Wales	University of London; University College London; Yale University; Yale University; Cardiff University	Wyatt, JC (corresponding author), UCL, Sch Publ Policy, 29 Tavistock Sq, London WC1H 9EZ, England.	jeremy.wyatt@ucl.ac.uk	Wyatt, Jeremy/F-8160-2010	Wyatt, Jeremy/0000-0001-7008-1473				BARNETT GO, 1978, MED CARE, V16, P962, DOI 10.1097/00005650-197811000-00007; CHERNOFF H, 1973, J AM STAT ASSOC, V68, P361, DOI 10.2307/2284077; COLE WG, 1994, METHOD INFORM MED, V33, P390; CRUICKSHANK PJ, 1984, J ROY COLL GEN PRACT, V34, P77; HARRISON GSM, 1991, BRIT J UROL, V67, P532, DOI 10.1111/j.1464-410X.1991.tb15201.x; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Johnson J. A., 1993, Communications of the ACM, V36, P40, DOI 10.1145/255950.153576; Kohane IS, 1996, J AM MED INFORM ASSN, V3, P191, DOI 10.1136/jamia.1996.96310633; Kushniruk AW, 1996, M D COMPUT, V13, P406; MASSARO TA, 1993, ACAD MED, V68, P20, DOI 10.1097/00001888-199301000-00003; McConnell J, 1998, LANCET, V351, P3; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MUTER P, 1991, BEHAV INFORM TECHNOL, V10, P257, DOI 10.1080/01449299108924288; NIELSEN J, 1994, COMMUN ACM, V37, P66, DOI 10.1145/175276.175282; Nygren E, 1998, LANCET, V352, P1462, DOI 10.1016/S0140-6736(97)08307-4; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; ROGERS JL, 1979, MED CARE, V17, P618, DOI 10.1097/00005650-197906000-00006; SMITH MF, 1994, BMJ-BRIT MED J, V308, P612, DOI 10.1136/bmj.308.6929.612; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; vanOverbeeke JJ, 1996, INT J BIOMED COMPUT, V42, P91, DOI 10.1016/0020-7101(96)01185-3; Verheij R, 1997, METHOD INFORM MED, V36, P11; Wright P, 1998, LANCET, V352, P1539, DOI 10.1016/S0140-6736(98)08308-1; Wyatt J C, 1993, Proc Annu Symp Comput Appl Med Care, P834; WYATT JC, 1995, BRIT MED J, V311, P175, DOI 10.1136/bmj.311.6998.175; WYATT JC, 1994, LANCET, V344, P1682, DOI 10.1016/S0140-6736(94)90463-4; WYATT JC, 1994, LANCET, V344, P1609, DOI 10.1016/S0140-6736(94)90409-X; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	34	76	76	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1617	1622		10.1016/S0140-6736(98)08309-3	http://dx.doi.org/10.1016/S0140-6736(98)08309-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843122	hybrid			2022-12-28	WOS:000076998900046
J	Schlechte, JA; Kreisberg, R				Schlechte, JA; Kreisberg, R			Update in endocrinology	ANNALS OF INTERNAL MEDICINE			English	Article							HYPERPARATHYROIDISM		Univ Iowa, Clin Res Ctr, Iowa City, IA 52242 USA; Baptist Hlth Ctr, Birmingham, AL USA	University of Iowa	Schlechte, JA (corresponding author), Univ Iowa, Clin Res Ctr, Room 157 MRF,200 Hawkins Dr, Iowa City, IA 52242 USA.			Schlechte, Janet/0000-0002-4089-0445				FUJIWARA S, 1992, RADIAT RES, V130, P372, DOI 10.2307/3578384; PEDERSEN TR, 1994, LANCET, V344, P1383; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; Walsh BW, 1998, JAMA-J AM MED ASSOC, V279, P1445, DOI 10.1001/jama.279.18.1445	4	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					719	725		10.7326/0003-4819-129-9-199811010-00008	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841605				2022-12-28	WOS:000076785200007
J	Lester, BM; LaGasse, LL; Seifer, R				Lester, BM; LaGasse, LL; Seifer, R			Drug abuse - Cocaine exposure and children: The meaning of subtle effects	SCIENCE			English	Editorial Material							PRESCHOOL-AGE; MOTHERS		Brown Univ, Sch Med, Providence, RI 02905 USA	Brown University	Lester, BM (corresponding author), Brown Univ, Sch Med, Providence, RI 02905 USA.	barry_lester@brown.edu		Seifer, Ronald/0000-0003-4879-2839	NATIONAL INSTITUTE ON DRUG ABUSE [U10DA024119] Funding Source: NIH RePORTER; NIDA NIH HHS [U10 DA024119] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AZUMA SD, 1993, PEDIATRICS, V92, P396; Bender SL, 1995, J DEV BEHAV PEDIATR, V16, P418; Cohen J., 1988, STAT POWER ANAL SOCI, V2; HAWLEY TL, 1995, AM J ORTHOPSYCHIAT, V65, P364, DOI 10.1037/h0079693; Jensen A.R., 1980, BIAS MENTAL TESTING; Lester BM, 1997, J DRUG ISSUES, V27, P487, DOI 10.1177/002204269702700304; LESTER BM, 1998, ANN NY ACAD SCI, V846, P295; MALAKOFF ME, 1994, AM J ADDICTION, V3, P346; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; *NAT I DRUG AB, 1996, NIH PUBL; NULMAN I, 1994, CAN MED ASSOC J, V151, P1591; Richardson GA, 1996, NEUROTOXICOL TERATOL, V18, P627, DOI 10.1016/S0892-0362(96)00121-3; Rosenthal R., 1991, ESSENTIALS BEHAV RES, V2nd Edn; ROTHOLZ DA, 1995, ED TREATMENT CHILDRE, V18, P1; *US GEN ACC OFF, 1990, DRUG EXP INF GEN RIS; *US NAT CTR ED STA, 1996, PATT SPEC ED SERV DE; VANBAAR A, 1994, DEV MED CHILD NEUROL, V36, P1063	17	166	167	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					633	634		10.1126/science.282.5389.633	http://dx.doi.org/10.1126/science.282.5389.633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AM	9841414				2022-12-28	WOS:000076607500025
J	Bongaarts, J				Bongaarts, J			Global population growth - Demographic consequences of declining fertility	SCIENCE			English	Editorial Material																		BONGAARTS J, 1994, SCIENCE, V263, P771, DOI 10.1126/science.8303293; Bongaarts J, 1998, POPUL DEV REV, V24, P271, DOI 10.2307/2807974; Coleman D, 1996, EUROPES POPULATION 1; *COUNC EUR, 1996, REC DEM DEV EUR; DEMENY P, 1997, P EXP GROUP M REPL F; Eberstadt N, 1997, PUBLIC INTEREST, P3; *UN POP DIV, 1997, P EXP GROUP M REPL F; UN (United Nations), 1998, WORLD POP PROJ 2150; UNITED NATIONS, 1997, WORLD POP PROSP 1996; WATTENBERG B, 1997, NY TIMES        1123, P61	10	34	36	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					419	420		10.1126/science.282.5388.419	http://dx.doi.org/10.1126/science.282.5388.419			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	129TT	9841398				2022-12-28	WOS:000076479600033
J	Tabara, H; Grishok, A; Mello, CC				Tabara, H; Grishok, A; Mello, CC			RNAi in C-elegans: Soaking in the genome sequence	SCIENCE			English	Editorial Material							EMBRYOS		Univ Massachusetts, Sch Med, Dept Cell Biol, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Ctr Canc, 373 Plantat St, Worcester, MA 01605 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD33769-01] Funding Source: Medline; NIDDK NIH HHS [DK32520-15] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSHER J, COMMUNICATIN; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GRISHOK A, UNPUB; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Korf I, 1998, DEVELOPMENT, V125, P2469; MELLO CC, UNPUB; MONTGOMERY M, COMMUNICATION; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; TABARA H, UNPUB; TIMMONS L, IN PRESS NATURE; Wagner RW, 1998, NATURE, V391, P744, DOI 10.1038/35750	13	453	583	4	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					430	431		10.1126/science.282.5388.430	http://dx.doi.org/10.1126/science.282.5388.430			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9841401				2022-12-28	WOS:000076479600040
J	Signore, F				Signore, F			From the other side	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1741	1741		10.1136/bmj.317.7174.1741	http://dx.doi.org/10.1136/bmj.317.7174.1741			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857164	Green Published			2022-12-28	WOS:000077742300059
J	Ganguly, A				Ganguly, A			Current concepts - Primary aldosteronism	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM; CALCIUM-CHANNEL BLOCKADE; PLASMA-RENIN ACTIVITY; ADRENAL ADENOMA; DIFFERENTIAL-DIAGNOSIS; BILATERAL HYPERPLASIA; COMPUTED-TOMOGRAPHY; CLINICAL SPECTRUM; HYPERTENSION; SPIRONOLACTONE		James A Haley Vet Affairs Hosp, Med Serv, Tampa, FL USA; Univ S Florida, Coll Med, Tampa, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida	Ganguly, A (corresponding author), Vet Affairs Hosp 111M, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.							BIGLIERI EG, 1979, J CLIN ENDOCR METAB, V49, P87, DOI 10.1210/jcem-49-1-87; BLUMENFELD JD, 1994, ANN INTERN MED, V121, P877, DOI 10.7326/0003-4819-121-11-199412010-00010; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1986, HYPERTENSION, V8, P191; BROWN JJ, 1972, BMJ-BRIT MED J, V2, P729, DOI 10.1136/bmj.2.5816.729; CAIN JP, 1972, AM J MED, V53, P627, DOI 10.1016/0002-9343(72)90158-1; CAREY RM, 1981, ARCH INTERN MED, V141, P1594, DOI 10.1001/archinte.141.12.1594; CONN JW, 1955, J LAB CLIN MED, V45, P3; CONN JW, 1976, J LAB CLIN MED, V88, P841; DLUHY RG, 1994, ENDOCRIN METAB CLIN, V23, P285, DOI 10.1016/S0889-8529(18)30098-7; DOPPMAN JL, 1992, RADIOLOGY, V184, P677, DOI 10.1148/radiology.184.3.1509049; DUNNICK NR, 1982, RADIOLOGY, V142, P429, DOI 10.1148/radiology.142.2.7054832; Fallo F, 1997, AM J HYPERTENS, V10, P476; FARGE D, 1987, AM J MED, V83, P635, DOI 10.1016/0002-9343(87)90891-6; FELTYNOWSKI T, 1994, CLIN ENDOCRINOL, V41, P309, DOI 10.1111/j.1365-2265.1994.tb02550.x; GANGULY A, 1990, AM J MED, V88, P321, DOI 10.1016/0002-9343(90)90483-T; GANGULY A, 1981, NEW ENGL J MED, V305, P991, DOI 10.1056/NEJM198110223051706; GANGULY A, 1980, J CLIN ENDOCR METAB, V51, P1190, DOI 10.1210/jcem-51-5-1190; GANGULY A, 1973, J CLIN ENDOCR METAB, V37, P765, DOI 10.1210/jcem-37-5-765; GANGULY A, 1983, J UROLOGY, V129, P241, DOI 10.1016/S0022-5347(17)52033-9; GANGULY A, 1981, CLIN PHARMACOL THER, V30, P246, DOI 10.1038/clpt.1981.155; GANGULY A, 1992, CLIN INVESTIGATOR, V70, P392; GANGULY A, 1979, AM HEART J, V98, P642, DOI 10.1016/0002-8703(79)90292-8; GANGULY A, 1977, J CLIN ENDOCR METAB, V44, P775, DOI 10.1210/jcem-44-4-775; GANGULY A, 1981, J CLIN ENDOCR METAB, V53, P1040, DOI 10.1210/jcem-53-5-1040; GANGULY A, 1976, SYSTEMIC EFFECTS ANT, P383; GORDON RD, 1994, LANCET, V344, P240, DOI 10.1016/S0140-6736(94)93003-1; GREGOIRE JR, 1994, MAYO CLIN PROC, V69, P1108, DOI 10.1016/S0025-6196(12)61380-9; GRIFFING GT, 1983, J CLIN ENDOCR METAB, V56, P218, DOI 10.1210/jcem-56-2-218; GUAZZONI G, 1994, J UROLOGY, V152, P1375, DOI 10.1016/S0022-5347(17)32424-2; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; HOEFNAGELS WHL, 1980, CLIN PHARMACOL THER, V27, P317, DOI 10.1038/clpt.1980.42; Inoue H, 1997, AM J ROENTGENOL, V168, P1241, DOI 10.2214/ajr.168.5.9129420; IRONY I, 1990, AM J HYPERTENS, V3, P576, DOI 10.1093/ajh/3.7.576; JECK T, 1994, CLIN INVESTIGATOR, V72, P979, DOI 10.1007/BF00577740; KONO T, 1981, J CLIN ENDOCR METAB, V52, P1009, DOI 10.1210/jcem-52-5-1009; LI JT, 1994, EUR J PEDIATR, V153, P715, DOI 10.1007/BF01954485; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LUETSCHER JA, 1974, CIRC RES, V34, pI175; LYONS DF, 1983, J CLIN ENDOCR METAB, V57, P892, DOI 10.1210/jcem-57-5-892; MA JTC, 1986, Q J MED, V61, P1021; MCLEOD MK, 1989, SURGERY, V106, P1161; NADLER JL, 1985, J CLIN ENDOCR METAB, V60, P896, DOI 10.1210/jcem-60-5-896; RADIN DR, 1992, AM J ROENTGENOL, V158, P553, DOI 10.2214/ajr.158.3.1738993; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; ROSSI GP, 1993, J HUM HYPERTENS, V7, P357; RUSSELL RP, 1972, MEDICINE, V51, P211, DOI 10.1097/00005792-197205000-00007; SARUTA T, 1987, ACTA ENDOCRINOL-COP, V116, P229, DOI 10.1530/acta.0.1160229; SCHALEKAMP MADH, 1981, CLIN ENDOCRINOL META, V10, P397, DOI 10.1016/S0300-595X(81)80005-9; SHENKER Y, 1989, ENDOCRIN METAB CLIN, V18, P415, DOI 10.1016/S0889-8529(18)30377-3; SPARK RF, 1968, ANN INTERN MED, V69, P685, DOI 10.7326/0003-4819-69-4-685; STREETEN DHP, 1979, AM J MED, V67, P403, DOI 10.1016/0002-9343(79)90786-1; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; TAKEDA M, 1994, SURGERY, V115, P621; TAKEDA Y, 1994, ENDOCR J, V41, P483, DOI 10.1507/endocrj.41.483; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; ULICK S, 1993, J CLIN ENDOCR METAB, V76, P873, DOI 10.1210/jc.76.4.873; Vallotton MB, 1996, CLIN ENDOCRINOL, V45, P53, DOI 10.1111/j.1365-2265.1996.tb02060.x; WEINBERGER MH, 1993, ARCH INTERN MED, V153, P2125, DOI 10.1001/archinte.153.18.2125; WEINBERGER MH, 1979, ANN INTERN MED, V90, P386, DOI 10.7326/0003-4819-90-3-386; WISGERHOF M, 1981, J CLIN ENDOCR METAB, V52, P195, DOI 10.1210/jcem-52-2-195; Young WF, 1996, SURGERY, V120, P913, DOI 10.1016/S0039-6060(96)80033-X; YOUNG WF, 1990, MAYO CLIN PROC, V65, P96, DOI 10.1016/S0025-6196(12)62114-4; 1979, LANCET, V2, P1221	64	234	251	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1828	1834		10.1056/NEJM199812173392507	http://dx.doi.org/10.1056/NEJM199812173392507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854120				2022-12-28	WOS:000077545800007
J	Veeken, H				Veeken, H			Colombia: the winner takes all	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands	Doctors Without Borders	Veeken, H (corresponding author), Med Sans Frontieres, POB 10014, NL-1001 EA Amsterdam, Netherlands.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1649	1650		10.1136/bmj.317.7173.1649	http://dx.doi.org/10.1136/bmj.317.7173.1649			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848912	Green Published			2022-12-28	WOS:000077602100035
J	Nguyen, JT; Turck, CW; Cohen, FE; Zuckermann, RN; Lim, WA				Nguyen, JT; Turck, CW; Cohen, FE; Zuckermann, RN; Lim, WA			Exploiting the basis of proline recognition by SH3 and WW domains: Design of n-substituted inhibitors	SCIENCE			English	Article							PHAGE DISPLAY; PEPTIDE LIGANDS; RICH PEPTIDES; BINDING; SRC; IDENTIFICATION; SPECIFICITY; LIBRARIES; PROTEINS; AFFINITY	Src homology 3 (SH3) and WW protein interaction domains bind specific proline-rich sequences. However, instead of recognizing critical prolines on the basis of side chain shape or rigidity, these domains broadly accepted amide N-substituted residues. Proline is apparently specifically selected in vivo, despite Low complementarity, because it is the only endogenous N-substituted amino acid. This discriminatory mechanism explains how these domains achieve specific but Low-affinity recognition, a property that is necessary for transient signaling interactions. The mechanism can be exploited: screening a series of Ligands in which key prolines were replaced by nonnatural N-substituted residues yielded a Ligand that selectively bound the Grb2 SH3 domain with 100 times greater affinity.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Novartis	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu	Zuckermann, Ronald/P-3436-2019; Zuckermann, Ronald N/A-7606-2014	Zuckermann, Ronald/0000-0002-3055-8860; Zuckermann, Ronald N/0000-0002-3055-8860				BRUNER AT, 1996, XPLOR; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Figliozzi GM, 1996, METHOD ENZYMOL, V267, P437; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; NGUYEN J, UNPUB; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; SICHERI F, 1997, NATURE, V385, P595; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	36	265	275	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2088	2092		10.1126/science.282.5396.2088	http://dx.doi.org/10.1126/science.282.5396.2088			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851931				2022-12-28	WOS:000077467100049
J	Rambukkana, A; Yamada, H; Zanazzi, G; Mathus, T; Salzer, JL; Yurchenco, PD; Campbell, KP; Fischetti, VA				Rambukkana, A; Yamada, H; Zanazzi, G; Mathus, T; Salzer, JL; Yurchenco, PD; Campbell, KP; Fischetti, VA			Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae	SCIENCE			English	Article							DYSTROPHIN-GLYCOPROTEIN COMPLEX; PERIPHERAL-NERVE; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX; AGRIN RECEPTOR; CHAIN GENE; LAMININ; MEROSIN; MEMBRANE	alpha-Dystroglycan (alpha-DG) is a component of the dystroglycan complex, which is involved in early development and morphogenesis and in the pathogenesis of muscular dystrophies. Here, alpha-DG was shown to serve as a Schwann cell receptor for Mycobacterium leprae, the causative organism of leprosy. Mycobacterium leprae specifically bound to alpha-DG only in the presence of the G domain of the alpha 2 chain of laminin-2. Native alpha-DG competitively inhibited the lminin-2-mediated M. leprae binding to primary Schwann cells. Thus, M. leprae may use Linkage between the extracellular matrix and cytoskeleton through lminin-2 and alpha-DG for its interaction with Schwann cells.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Phys & Biophys, Iowa City, IA 52242 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Robert Wood Johnson Med Sch, Dept Pathol, Piscataway, NJ 08854 USA	Rockefeller University; University of Iowa; University of Iowa; New York University; New York University; New York University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rambukkana, A (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.	rambuka@rockvax.rockefeller.edu		Campbell, Kevin/0000-0003-2066-5889; Yurchenco, Peter/0000-0003-0387-2317; rambukkana, anura/0000-0002-6286-9145; Salzer, James/0000-0001-9126-7197	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JOB CK, 1989, INT J LEPROSY, V57, P532; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; RAMBUKKANA A, UNPUB; RUTKOWSKI JL, 1991, EXP BIOL M, P343; STONER GL, 1979, LANCET, V2, P994; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; *WHO, 1995, WEEKLY EPIDEMIO 0920, P269; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yamada H., UNPUB; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	38	186	191	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2076	2079		10.1126/science.282.5396.2076	http://dx.doi.org/10.1126/science.282.5396.2076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851927				2022-12-28	WOS:000077467100045
J	Chelala, C				Chelala, C			Saturdays are radio days for psychiatric patients in Argentina	LANCET			English	Editorial Material											Chelala, C (corresponding author), 390 W Broadway, New York, NY 10012 USA.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1867	1867		10.1016/S0140-6736(05)79942-6	http://dx.doi.org/10.1016/S0140-6736(05)79942-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851426				2022-12-28	WOS:000077337900075
J	Clark, RE				Clark, RE			Bone-marrow donation by mentally incapable adults	LANCET			English	Article							VOLUNTEERING CHILDREN		Univ Liverpool, Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Clark, RE (corresponding author), Univ Liverpool, Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England.							BAILEYHARRIS R, 1997, FAMILY LAW       FEB, P91; Delany L, 1996, BRIT MED J, V312, P240; Gratwohl A, 1997, BONE MARROW TRANSPL, V19, P407, DOI 10.1038/sj.bmt.1700694; Kent G, 1996, BRIT MED J, V313, P49, DOI 10.1136/bmj.313.7048.49b; *LAW COMM, 1995, 231 LAW COMM; Luttrell S, 1997, LANCET, V350, P950, DOI 10.1016/S0140-6736(97)00001-9; RE F, 1990, MENTAL PATIENT STERI; RE Y, 1996, MENTAL INCAPACITY BO, P287	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1847	1848		10.1016/S0140-6736(98)04378-5	http://dx.doi.org/10.1016/S0140-6736(98)04378-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851401				2022-12-28	WOS:000077337900047
J	Freer, R				Freer, R			Human rights in the USA: land of the free?	LANCET			English	Editorial Material									Amnesty Int, USA Team, London WC1X 8DJ, England		Freer, R (corresponding author), Amnesty Int, USA Team, 1 Easton St, London WC1X 8DJ, England.							*AMR, 1998, 515798 AMR; TIMBERG C, 1998, WASHINGTON POST 1016	2	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1853	1854		10.1016/S0140-6736(05)79917-7	http://dx.doi.org/10.1016/S0140-6736(05)79917-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851404				2022-12-28	WOS:000077337900050
J	Elia, M				Elia, M			Oral or parenteral therapy for B12 deficiency	LANCET			English	Editorial Material							COBALAMIN DEFICIENCY; ELDERLY POPULATION; PERNICIOUS-ANEMIA; HOMOCYSTEINE; PREVALENCE		Dunn Clin Nutr Ctr, Cambridge CB2 2DH, England		Elia, M (corresponding author), Dunn Clin Nutr Ctr, Cambridge CB2 2DH, England.							BERLIN H, 1968, ACTA MED SCAND, V184, P247; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; HATHCOCK JN, 1991, JAMA-J AM MED ASSOC, V265, P96, DOI 10.1001/jama.265.1.96; Hurwitz A, 1997, JAMA-J AM MED ASSOC, V278, P659, DOI 10.1001/jama.278.8.659; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; Kuzminski AM, 1998, BLOOD, V92, P1191, DOI 10.1182/blood.V92.4.1191.416k15_1191_1198; LEDERLE FA, 1991, JAMA-J AM MED ASSOC, V265, P94, DOI 10.1001/jama.265.1.94; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; MIDDLETON J, 1985, BRIT MED J, V290, P1254, DOI 10.1136/bmj.290.6477.1254; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; Riggs KM, 1996, AM J CLIN NUTR, V63, P306, DOI 10.1093/ajcn/63.3.306; van Asselt DZB, 1998, AM J CLIN NUTR, V68, P328, DOI 10.1093/ajcn/68.2.328	12	86	88	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1721	1722		10.1016/S0140-6736(05)79821-4	http://dx.doi.org/10.1016/S0140-6736(05)79821-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848344				2022-12-28	WOS:000077246500003
J	Dominguez, M; de Celis, JF				Dominguez, M; de Celis, JF			A dorsal/ventral boundary established by Notch controls growth and polarity in the Drosophila eye	NATURE			English	Article							DORSAL; EXPRESSION; FRINGE; GENE	In the Drosophila compound eye the dorsal and ventral fields of eye units (ommatidia) meet along the dorsoventral midline, forming a line of mirror image symmetry called the equator(1), The molecular mechanism establishing the equator is not fully understood, but it involves the transcription factors' encoded by the Iroquois gene complex(3), The Iroquois genes are expressed in the dorsal half of the eye(2) and here we show that they regulate the expression of the secreted molecule Fringe. A boundary between fringe-expressing and fringe-non-expressing cells is essential, from the time of the second larval instar, for eye growth and formation of the equator. Boundaries of fringe expression determine where the transmembrane receptor Notch is activated(4,5). We find that Notch is activated at the dorsoventral midline, where it is required to promote growth and set up the axis of mirror symmetry. As boundaries of fringe expression and Notch activation are also important during Drosophila wing formation(6) and vertebrate somitogenesis(7-9), we suggest that these boundaries constitute a general mechanism that directs growth and patterning of large fields of cells.	Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	de Celis, JF (corresponding author), Univ Cambridge, Dept Genet, Downing St, Cambridge CB2 3EH, England.	jdc@mole.bio.cam.ac.uk	de+Celis, Jose/AAE-8142-2019; Dominguez, Maria/G-2171-2014	Dominguez, Maria/0000-0002-3329-7862; de Celis, Jose F./0000-0003-4808-9844	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAKER WK, 1978, DEV BIOL, V62, P447, DOI 10.1016/0012-1606(78)90227-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; CAMPOSORTEGA JA, 1978, DEV BIOL, V184, P155; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; de Celis JF, 1998, DEVELOPMENT, V125, P4617; DIAZBENJUMEA G, 1993, CELL, V75, P742; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; Heberlein U, 1998, DEVELOPMENT, V125, P567; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Klein T, 1997, DEV BIOL, V189, P123, DOI 10.1006/dbio.1997.8564; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Reifegerste R, 1997, MECH DEVELOP, V68, P69, DOI 10.1016/S0925-4773(97)00127-5; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WOLFF T, 1993, PATTERN FORMATION DR, P1277; Zeller R, 1997, BIOESSAYS, V19, P541, DOI 10.1002/bies.950190703; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	25	207	208	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					276	278		10.1038/24402	http://dx.doi.org/10.1038/24402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834035				2022-12-28	WOS:000077110400050
J	Mejicano, GC; Maki, DG				Mejicano, GC; Maki, DG			Infections acquired during cardiopulmonary resuscitation: Estimating the risk and defining strategies for prevention	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; HEPATITIS-C VIRUS; TO-MOUTH RESUSCITATION; CREUTZFELDT-JAKOB-DISEASE; HOSPITAL CARDIAC-ARREST; AIDS-RELATED COMPLEX; B IMMUNE GLOBULIN; OCCUPATIONAL RISK; CYTOMEGALO-VIRUS	Purpose: To estimate the risk for acquiring an infectious disease during cardiopulmonary resuscitation (CPR) or CPR training and to identify strategies to minimize that risk. Data Sources: English-language articles published since 1965 were identified through a search of the MEDLINE database and selected bibliographies. Study Selection: Studies that contained information about transmission of infectious organisms, particularly HIV and other bloodborne viruses that might be transmitted through mouth-to-mouth ventilation, contact exposures, and needlesticks during CPR. Data Extraction: Descriptive and analytic data from each study. Data Synthesis: Fear of acquiring infection, especially HIV infection, can delay prompt initiation of mouth-to-mouth ventilation. Although pathogens can be isolated from the saliva of infected persons, salivary transmission of bloodborne viruses is unusual and transmission of infection has been rare: Only 15 documented cases have been reported. Most of these cases involved a bacterial pathogen, such as Neisseria meningitidis. Transmission of hepatitis B virus, hepatitis C virus, or cytomegalovirus during CPR has not been reported; all three reported cases of HIV infection acquired during resuscitation of an infected patient resulted from high-risk cutaneous exposures. There have been no reports of infection acquired during CPR training. Simple infection-control measures, including use of barrier devices, can reduce the risk for acquisition of an infectious disease during CPR and CPR training. Postexposure protocols can further protect potential rescuers and trainees. Conclusions: The benefit of initiating lifesaving resuscitation in a patient in cardiopulmonary arrest greatly outweighs the risk for secondary infection in the rescuer or the patient. Nevertheless, use of simple infection-control measures during CPR and CPR training can reduce a very low level of risk even further.	Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Maki, DG (corresponding author), Univ Wisconsin Hosp & Clin, 600 Highland Ave, Madison, WI 53792 USA.							ABE K, 1991, LANCET, V337, P248, DOI 10.1016/0140-6736(91)92222-N; ACHONG MR, 1980, AM HEART J, V100, P759, DOI 10.1016/0002-8703(80)90248-3; ADLER SP, 1986, PEDIATR INFECT DIS J, V5, P239, DOI 10.1097/00006454-198603000-00016; AHLFORS K, 1981, ACTA PAEDIATR SCAND, V70, P819, DOI 10.1111/j.1651-2227.1981.tb06233.x; AHMAD F, 1990, LANCET, V335, P787, DOI 10.1016/0140-6736(90)90898-F; AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1996, Med Lett Drugs Ther, V38, P35; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, JAMA-J AM MED ASSOC, V268, P2184, DOI DOI 10.1001/JAMA.1992.03490160054025; [Anonymous], [No title captured]; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BALLARD JL, 1986, PEDIATR INFECT DIS J, V5, P198, DOI 10.1097/00006454-198603000-00007; Ballew KA, 1997, BRIT MED J, V314, P1462, DOI 10.1136/bmj.314.7092.1462; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Becker LB, 1997, ANN EMERG MED, V30, P654, DOI 10.1016/S0196-0644(97)70085-4; Berg RA, 1997, CIRCULATION, V95, P1635; BERGER JR, 1993, NEUROLOGY, V43, P205, DOI 10.1212/WNL.43.1_Part_1.205; BERNOULLI C, 1977, LANCET, V1, P478; Bierens JJLM, 1996, RESUSCITATION, V32, P185, DOI 10.1016/0300-9572(96)00943-4; BLENKHARN JI, 1990, RESUSCITATION, V19, P151, DOI 10.1016/0300-9572(90)90038-G; BLUMENFIELD M, 1987, GEN HOSP PSYCHIAT, V9, P58, DOI 10.1016/0163-8343(87)90103-4; BRADY MT, 1986, AM J INFECT CONTROL, V14, P197, DOI 10.1016/0196-6553(86)90117-3; BRADY MT, 1987, INFECT CONT HOSP EP, V8, P329, DOI 10.1017/S0195941700066431; Brenner B, 1996, RESUSCITATION, V32, P5, DOI 10.1016/0300-9572(96)00966-5; BRENNER B, 1994, RESUSCITATION, V28, P185, DOI 10.1016/0300-9572(94)90063-9; Brenner BE, 1996, RESUSCITATION, V31, P17, DOI 10.1016/0300-9572(95)00905-1; BRENNER BE, 1993, ARCH INTERN MED, V153, P1763, DOI 10.1001/archinte.153.15.1763; BRETTLER DB, 1992, BLOOD, V80, P540; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUDDINGH GJ, 1953, PEDIATRICS, V11, P595; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; Cardo DM, 1997, INFECT DIS CLIN N AM, V11, P331, DOI 10.1016/S0891-5520(05)70359-7; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CAVALCANTE N J F, 1991, AIDS Care, V3, P311, DOI 10.1080/09540129108253078; *CDC, 1978, 42 CDC, P34; Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P101; CHANDRA NC, 1994, INSTRUCTORS MANUAL B; COHEN HJ, 1985, ANN INTERN MED, V102, P136, DOI 10.7326/0003-4819-102-1-136_2; COMROE JH, 1979, AM REV RESPIR DIS, V119, P1025; CONTE JE, 1983, NEW ENGL J MED, V309, P740, DOI 10.1056/NEJM198309223091228; COUZIGOU P, 1993, GUT, V324, pS59; CREANGE A, 1995, ANN NEUROL, V38, P269, DOI 10.1002/ana.410380223; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V262, P2732; CURREY CJ, 1990, ACAD MED, V65, P472, DOI 10.1097/00001888-199007000-00015; CYDULKA R K, 1991, Journal of Emergency Medicine, V9, P317, DOI 10.1016/0736-4679(91)90373-N; DAVIS GE, 1978, J MAINE MED ASSOC, V69, P214; DEMMLER GJ, 1986, PEDIATR INFECT DIS J, V5, P605, DOI 10.1097/00006454-198609000-00032; DRUMMOND JA, 1986, JAMA-J AM MED ASSOC, V256, P2342, DOI 10.1001/jama.1986.03380170058010; DUFFY P, 1974, NEW ENGL J MED, V290, P692; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; DWORSKY ME, 1983, NEW ENGL J MED, V309, P950, DOI 10.1056/NEJM198310203091604; *ECRI, 1992, ECRI HEALTHC HAZ MAT, P5; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EMBIL JA, 1975, CAN MED ASSOC J, V113, P627; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FELDMAN HA, 1972, J AMER MED ASSOC, V220, P1107, DOI 10.1001/jama.220.8.1107; Figura N, 1996, LANCET, V347, P1342, DOI 10.1016/S0140-6736(96)90996-4; FINKELHOR RS, 1980, JAMA-J AM MED ASSOC, V243, P650; FLOWERS RH, 1988, INFECT CONT HOSP EP, V9, P491, DOI 10.2307/30146544; FONS MP, 1994, J AM DENT ASSOC, V125, P713, DOI 10.14219/jada.archive.1994.0114; FRIED MW, 1992, GASTROENTEROLOGY, V102, P1306; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Gerberding J L, 1989, Infect Dis Clin North Am, V3, P735; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GLASER JB, 1985, ARCH INTERN MED, V145, P1653, DOI 10.1001/archinte.145.9.1653; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; GREENBERG MD, 1983, ANN EMERG MED, V12, P194, DOI 10.1016/S0196-0644(83)80576-9; GROOPMAN JE, 1984, SCIENCE, V226, P447, DOI 10.1126/science.6093247; HART CA, 1993, J MED MICROBIOL, V39, P3, DOI 10.1099/00222615-39-1-3; HATHERLEY LI, 1986, INFECT CONT HOSP EP, V7, P452, DOI 10.1017/S0195941700064948; HEILMAN KM, 1965, NEW ENGL J MED, V273, P1035, DOI 10.1056/NEJM196511042731908; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1995, PRINCIPLES PRACTICE, P2632; HENDERSON DK, 1993, PREVENTION CONTROL N, P42; HENDRICKS AA, 1980, JAMA-J AM MED ASSOC, V243, P257, DOI 10.1001/jama.243.3.257; HEPTONSTALL J, 1995, OCCUPATIONAL HIV SUM; HESS D, 1990, Respiratory Care, V35, P800; HO DD, 1985, NEW ENGL J MED, V313, P1606; HO M, 1990, REV INFECT DIS, V12, pS701; Hodgin L, 1992, Occup Health Saf, V61, P58; HODGIN L, 1992, OCCUP HEALTH SAF, V61, P58; HOLLINGER FB, 1992, GASTROENTEROLOGY, V102, P1426, DOI 10.1016/0016-5085(92)90791-V; Holmes SJ, 1996, J NEUROL NEUROSUR PS, V60, P333, DOI 10.1136/jnnp.60.3.333; Idris AH, 1996, ANN EMERG MED, V27, P569, DOI 10.1016/S0196-0644(96)70159-2; IDRIS AH, 1994, CIRCULATION, V90, P3063, DOI 10.1161/01.CIR.90.6.3063; IDRIS AH, 1994, RESUSCITATION, V28, P143, DOI 10.1016/0300-9572(94)90087-6; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; JACOBSON JA, 1976, JAMA-J AM MED ASSOC, V236, P1053; Juip M, 1988, Nursing, V18, P48; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; Khajotia RR, 1997, ARCH INTERN MED, V157, P1901, DOI 10.1001/archinte.157.16.1901; KHAN AH, 1979, JAMA-J AM MED ASSOC, V241, P2701; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN R, 1993, LANCET, V341, P768, DOI 10.1016/0140-6736(93)90549-V; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LAWRENCE PJ, 1985, MED J AUSTRALIA, V143, P443, DOI 10.5694/j.1326-5377.1985.tb123133.x; Lee KH, 1996, CRIT CARE MED, V24, P2046, DOI 10.1097/00003246-199612000-00019; LEWANDOWSKI C, 1992, ANN EMERG MED, V21, P1353, DOI 10.1016/S0196-0644(05)81901-8; LIFSON AR, 1988, JAMA-J AM MED ASSOC, V259, P1353, DOI 10.1001/jama.259.9.1353; LIOU TC, 1992, J MED VIROL, V37, P197, DOI 10.1002/jmv.1890370309; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LOCKE CJ, 1995, ARCH INTERN MED, V155, P938, DOI 10.1001/archinte.155.9.938; LUCHT E, 1993, J MED VIROL, V39, P156, DOI 10.1002/jmv.1890390213; MACQUARRIE MB, 1974, JAMA-J AM MED ASSOC, V230, P723; Madama V C, 1991, Occup Health Saf, V60, P64; MADAMA VC, 1991, OCCUP HEALTH SAF, V60, P64; MADAMA VC, 1991, OCCUP HEALTH SAF, V60, P58; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARDER MZ, 1985, ORAL SURG ORAL MED O, V60, P372, DOI 10.1016/0030-4220(85)90258-0; MARTINEZLAGE JF, 1994, J NEUROL NEUROSUR PS, V57, P1091, DOI 10.1136/jnnp.57.9.1091; Mason M, 1991, Can J Cardiovasc Nurs, V2, P23; MCCORMICK JB, 1975, ANN INTERN MED, V83, P883, DOI 10.7326/0003-4819-83-6-883; MCCORMICK RD, 1991, AM J MED, V91, pS301, DOI 10.1016/0002-9343(91)90386-C; MCCORMICK RD, 1981, AM J MED, V70, P928, DOI 10.1016/0002-9343(81)90558-1; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCDONALD GB, 1976, GASTROINTEST ENDOSC, V22, P168, DOI 10.1016/S0016-5107(76)73735-0; McHugh M, 1990, Nurs Manage, V21, P37; MCNEIL EL, 1989, RESUSCITATION, V18, P1, DOI 10.1016/0300-9572(89)90107-X; MEMON AM, 1982, ANN EMERG MED, V11, P322, DOI 10.1016/S0196-0644(82)80135-2; MICHAEL AD, 1992, AM J EMERG MED, V10, P156; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MORRIS IM, 1975, LANCET, V2, P1152; MOSLEY JW, 1975, NEW ENGL J MED, V293, P729, DOI 10.1056/NEJM197510092931501; MURPH JR, 1991, JAMA-J AM MED ASSOC, V265, P603, DOI 10.1001/jama.265.5.603; NAKANO I, 1992, AM J GASTROENTEROL, V87, P1522; Newcombe RL, 1996, MED J AUSTRALIA, V164, P603, DOI 10.5694/j.1326-5377.1996.tb122203.x; NICKALLS RWD, 1986, BRIT MED J, V292, P1350, DOI 10.1136/bmj.292.6532.1350; NICKLIN G, 1980, JAMA-J AM MED ASSOC, V244, P2046, DOI 10.1001/jama.1980.03310180016016; NUMATA N, 1993, J MED VIROL, V41, P120, DOI 10.1002/jmv.1890410207; *OCC SAF HLTH ADM, 1993, POL PROC OCC EXP TUB; ORNATO JP, 1990, ANN EMERG MED, V19, P151, DOI 10.1016/S0196-0644(05)81800-1; ORNATO JP, 1989, J EMERGENCY CARE TRA, V18, P45; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PERRILLO RP, 1979, GASTROENTEROLOGY, V76, P1319; Pinkerton SD, 1997, ARCH INTERN MED, V157, P1972, DOI 10.1001/archinte.157.17.1972; POWELL E, 1985, AUST NZ J MED, V15, P717; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; PROSSER RL, 1990, JAMA-J AM MED ASSOC, V263, P3025, DOI 10.1001/jama.1990.03440220047025; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PUCHHAMMERSTOCKL E, 1994, J MED VIROL, V43, P143, DOI 10.1002/jmv.1890430208; Reed Elizabeth, 1993, Journal of Emergency Medicine, V11, P9, DOI 10.1016/0736-4679(93)90003-P; RICHMAN KM, 1993, J ACQ IMMUN DEF SYND, V6, P402; ROBERT LM, 1994, INFECT DIS CLIN N AM, V8, P319; ROSSI R, 1991, RESUSCITATION, V21, P103, DOI 10.1016/0300-9572(91)90082-A; SAHDEV P, 1994, ANN EMERG MED, V23, P823, DOI 10.1016/S0196-0644(94)70321-3; SANDE MA, 1986, NEW ENGL J MED, V314, P380, DOI 10.1056/NEJM198602063140609; SAVITEER SM, 1985, NEW ENGL J MED, V313, P1606; SCHUPFER PC, 1986, PEDIATR INFECT DIS J, V5, P677, DOI 10.1097/00006454-198611000-00015; SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; Sepkowitz KA, 1996, ANN INTERN MED, V125, P917, DOI 10.7326/0003-4819-125-11-199612010-00008; Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007; Sheard T, 1990, Nursing, V20, P43; SMITH JL, 1976, J INFECT DIS, V133, P705, DOI 10.1093/infdis/133.6.705; STEELMAN VM, 1994, AM J INFECT CONTROL, V22, P312, DOI 10.1016/0196-6553(94)90019-1; Stern A, 1994, JEMS, V19, P85; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; SUN D, 1995, SEMIN DERMATOL, V14, P205, DOI 10.1016/S1085-5629(05)80020-3; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; Teplow L, 1973, J Occup Med, V15, P427; Thomas DL, 1996, AM J MED, V100, P41, DOI 10.1016/S0002-9343(96)90009-1; TODD MA, 1980, JAMA-J AM MED ASSOC, V243, P331; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TOOKEY P, 1991, ARCH DIS CHILD, V66, P1009, DOI 10.1136/adc.66.9.1009; TSOUKAS CM, 1988, J ACQ IMMUN DEF SYND, V1, P505; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; TURNER R, 1982, PEDIATRICS, V70, P547; TYLER K, 1995, PRINCIPLES PRACTICE, P1674; VALENZUELA TD, 1991, ANN EMERG MED, V20, P90, DOI 10.1016/S0196-0644(05)81129-1; VANDYKE RB, 1984, PEDIATR INFECT DIS J, V3, P153, DOI 10.1097/00006454-198403000-00019; Vidmar L, 1996, LANCET, V347, P1762, DOI 10.1016/S0140-6736(96)90838-7; VILLAREJOS VM, 1974, NEW ENGL J MED, V291, P1375, DOI 10.1056/NEJM197412262912602; WAHN V, 1986, LANCET, V2, P694; WANG JT, 1992, J MED VIROL, V36, P28, DOI 10.1002/jmv.1890360106; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; Weiss SH, 1997, MED CLIN N AM, V81, P555, DOI 10.1016/S0025-7125(05)70531-9; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; West K, 1990, Occup Health Saf, V59, P28; Weston CFM, 1997, RESUSCITATION, V34, P27, DOI 10.1016/S0300-9572(96)01031-3; Wickham EA, 1996, BRIT MED J, V312, P988, DOI 10.1136/bmj.312.7037.988; YEAGER AS, 1975, J CLIN MICROBIOL, V2, P448; Yeager M, 1990, Occup Health Saf, V59, P51; YOUNG KC, 1993, J MED VIROL, V41, P55, DOI 10.1002/jmv.1890410112; 1997, MMWR MORB MORTAL WKL, V46, P620; 1995, MMWR MORB MORTAL WKL, V44, P929; 1997, MMWR MORB MORTAL WKL, V46, P1066; 1992, CLIN INFECT DIS, V14, P1179; 1987, MMWR MORB MORTAL WKL, V36, P285; 1990, MMWR MORB MORTAL WKL, V39, P17; 1990, CMAJ, V143, P1007; 1989, MMWR MORB MORTAL  S6, V38, P1; 1997, MMWR MORB MORTAL WKL, V46, P21; 1989, JAMA, V262, P2714; 1986, NURS LIFE, V6, P23; 1978, MMWR MORB MORTAL WKL, V27, P247; 1988, MMWR MORB MORTAL WKL, V37, P377; 1987, MMWR MORB MORTAL S2, V36, pS3; 1988, ANN EMERG MED, V17, P1249; 1984, INFECT CONTROL, V5, P242; 1982, MMWR MORB MORTAL WKL, V31, P577; 1996, MMWR MORB MORTAL WKL, V45, P468; 1996, MMWR MORB MORTAL WKL, V45, P295; 1990, CMAJ, V142, P547; 1978, MMWR MORB MORTAL WKL, V27, P132; 1992, JAMA, V268, P2171	214	68	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					813	828		10.7326/0003-4819-129-10-199811150-00014	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00014			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841588				2022-12-28	WOS:000076984800008
J	Johnston, C				Johnston, C			Platinum alone for chemotherapy for ovarian cancer?	LANCET			English	Editorial Material							CISPLATIN		Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Johnston, C (corresponding author), Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA.							AHERN RP, 1995, J CLIN ONCOL, V13, P726, DOI 10.1200/JCO.1995.13.3.726; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; DUBOIS A, 1998, P AN M AM SOC CLIN, V17, P361; Jakobsen A, 1997, J CLIN ONCOL, V15, P193, DOI 10.1200/JCO.1997.15.1.193; Kaye SB, 1996, J CLIN ONCOL, V14, P2113, DOI 10.1200/JCO.1996.14.7.2113; KNOPF K, 1998, P ASCO, V17, P359; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MUGGIA FM, 1997, P AN M AM SOC CLIN, V16, P352; *OV CTR MET PROJ, 1991, J CLIN ONCOL, V9, P168; STEWART LA, 1991, BRIT MED J, V303, P884; STUART G, 1998, P AN M AM SOC CLIN, V17, P361	12	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1567	1568		10.1016/S0140-6736(05)61037-9	http://dx.doi.org/10.1016/S0140-6736(05)61037-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843097				2022-12-28	WOS:000076998900003
J	Sabin, JE				Sabin, JE			Fairness as a problem of love and the heart: a clinician's perspective on priority setting	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd International Conference on Priorities in Health Care	OCT 08-10, 1998	LONDON, ENGLAND				CARE		Harvard Pilgrim Hlth Care, Ctr Eth Managed Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Sabin, JE (corresponding author), Harvard Pilgrim Hlth Care, Ctr Eth Managed Care, Boston, MA 02215 USA.							ABRAMS HS, 1993, PSYCH Q, V64, P12; Berwick D, 1997, BRIT MED J, V315, P1633, DOI 10.1136/bmj.315.7123.1633; Blendon RJ, 1998, HEALTH AFFAIR, V17, P80, DOI 10.1377/hlthaff.17.4.80; Bobbitt P., 1978, TRAGIC CHOICES; Collins J., 1997, BUILT LAST SUCCESSFU; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Kassirer JP, 1998, NEW ENGL J MED, V339, P397, DOI 10.1056/NEJM199808063390608; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; MECHANIC D, 1995, BRIT MED J, V310, P1655, DOI 10.1136/bmj.310.6995.1655; SABIN JE, 1994, BEHAV SCI LAW, V12, P317, DOI 10.1002/bsl.2370120403; SABIN JE, 1992, BRIT MED J, V305, P514, DOI 10.1136/bmj.305.6852.514	11	21	21	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1002	1004						3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9841022				2022-12-28	WOS:000076449300031
J	Daniels, AM				Daniels, AM			The promise of the neurosciences	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, W Midlands Poisons Unit, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Daniels, AM (corresponding author), City Hosp, W Midlands Poisons Unit, Birmingham B18 7QH, W Midlands, England.							Broberg G., 1996, EUGENICS WELFARE STA; Carter R, 2004, MAPPING MIND; Kramer PD, 1994, LISTENING PROZAC; MOIR A, 1995, MIND CRIME	4	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1728	1728		10.1136/bmj.317.7174.1728	http://dx.doi.org/10.1136/bmj.317.7174.1728			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857150	Green Published			2022-12-28	WOS:000077742300041
J	Supparatpinyo, K; Perriens, J; Nelson, KE; Sirisanthana, T				Supparatpinyo, K; Perriens, J; Nelson, KE; Sirisanthana, T			A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS	Background In Southeast Asia, disseminated infection with Penicillium marneffei is common among patients with human immunodeficiency virus (HIV) infection. Even after successful primary treatment, the relapse rate for this potentially fatal systemic fungal infection is about 50 percent. Methods We conducted a double-blind trial in Thailand to evaluate itraconazole as secondary prophylaxis against P. marneffei infection in patients with the acquired immunodeficiency syndrome (AIDS) who were in complete remission after treatment for culture-proved P. marneffei infection. The patients were randomly assigned to receive either oral itraconazole (200 mg daily) or placebo as maintenance therapy. Results Of the 72 HIV-infected patients who completed initial treatment for P. marneffei infection, 71 were enrolled in the maintenance study. None of the 36 patients assigned to itraconazole had a relapse of P. marneffei infection within one year, whereas 20 of the 35 patients assigned to placebo (57 percent) had relapses (P<0.001). Among the 20 patients who had relapses, P, marneffei was cultured from blood (15 patients), lymph-node tissue (3 patients), skin (3 patients), and sputum (1 patient). The median time to relapse was 24 weeks after the completion of the initial treatment (95 percent confidence interval, 19.0 to 36,1). Survival and toxic effects were similar in the two groups. Conclusions In patients infected with HIV who have completed successful primary treatment of FI marneffei infection, secondary prophylaxis with oral itraconazole is well tolerated and prevents relapses of this opportunistic infection. (N Engl J Med 1998;339:1739-43.) (C) 1998, Massachusetts Medical Society.	Chiang Mai Univ, Fac Med, Dept Med, Chiang Mai 50000, Thailand; Joint UN Program HIV AIDS, Geneva, Switzerland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Chiang Mai University; Johns Hopkins University	Sirisanthana, T (corresponding author), Chiang Mai Univ, Fac Med, Dept Med, Chiang Mai 50000, Thailand.							BENNETT J E, 1990, P1165; BORRADORI L, 1994, J AM ACAD DERMATOL, V31, P843, DOI 10.1016/S0190-9622(94)70242-X; CHANG CC, 1995, J FORMOS MED ASSOC, V94, P572; Duong TA, 1996, CLIN INFECT DIS, V23, P125, DOI 10.1093/clinids/23.1.125; HILMARSDOTTIR I, 1994, CLIN INFECT DIS, V19, P357, DOI 10.1093/clinids/19.2.357; KOK I, 1994, NETH J MED, V44, P18; Lee SS, 1996, CHINESE MED J-PEKING, V109, P70; Leung R, 1996, DIGEST DIS SCI, V41, P1212, DOI 10.1007/BF02088239; REMADI S, 1995, ACTA CYTOL, V39, P798; Rokiah I, 1995, Med J Malaysia, V50, P101; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P170; Sobottka I, 1996, EUR J CLIN MICROBIOL, V15, P256, DOI 10.1007/BF01591368; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; SUPPARATPINYO K, 1994, LANCET, V344, P110, DOI 10.1016/S0140-6736(94)91287-4; SUPPARATPINYO K, 1993, ANTIMICROB AGENTS CH, V37, P2407, DOI 10.1128/AAC.37.11.2407; Supparatpinyo K., 1994, JAMA SE ASIA S3, V10, P208; Supparatpinyo Khuanchai, 1992, Journal of the Medical Association of Thailand, V75, P688	17	111	130	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1739	1743		10.1056/NEJM199812103392403	http://dx.doi.org/10.1056/NEJM199812103392403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845708	Bronze			2022-12-28	WOS:000077459700003
J	He, J; Whelton, PK; Vu, B; Klag, MJ				He, J; Whelton, PK; Vu, B; Klag, MJ			Aspirin and risk of hemorrhagic stroke - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-DOSE ASPIRIN; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ACETYLSALICYLIC-ACID; CEREBRAL-ISCHEMIA; ATRIAL-FIBRILLATION; CLINICAL-TRIAL; DOUBLE-BLIND; ODDS RATIO; DIPYRIDAMOLE	Context.-Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke. Objective-To estimate the risk of hemorrhagic stroke associated with aspirin treatment. Data Sources.-Studies were retrieved using MEDLINE (search terms, aspirin, cerebrovascular disorders, and stroke), bibliographies of the articles retrieved, and the authors' reference files. Study Selection.-All trials published in English-language journals before July 1997 in which participants were randomized to aspirin or a control treatment for at least 1 month and in which the incidence of stroke subtype was reported. Data Extraction.-Information on country of origin, sample size, duration, study design, aspirin dosage, participant characteristics, and outcomes was abstracted independently by 2 authors who used a standardized protocol, Data Synthesis.-Data from 16 trials with 55 462 participants and 108 hemorrhagic stroke cases were analyzed. The mean dosage of aspirin was 273 mg/d and mean duration of treatment was 37 months. Aspirin use was associated with an absolute risk reduction in myocardial infarction of 137 events per 10 000 persons (95% confidence interval [CI], 107-167; P<.001) and in ischemic stroke, a reduction of 39 events per 10 000 persons (95% CI, 17-61; P<.001), However, aspirin treatment was also associated with an absolute risk increase in hemorrhagic stroke of 12 events per In 000 persons (95% CI, 5-20; P<.001). This risk did not differ by participant or study design characteristics. Conclusions.-These results indicate that aspirin therapy increases the risk of hemorrhagic stroke; However, the overall benefit of aspirin use on myocardial infarction and ischemic stroke may outweigh its adverse effects on risk of hemorrhagic stroke in mast populations.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat & Epidemiol, New Orleans, LA 70112 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA	Tulane University; Johns Hopkins University; Johns Hopkins University	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat & Epidemiol, 1430 Tulane Ave,SL 18, New Orleans, LA 70112 USA.	jhe@mailhost.tcs.tulane.edu			NHLBI NIH HHS [R29HL60300] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; *AM HEART ASS, 1997, AM HEART ASS HEART S; [Anonymous], 1987, Lancet, V2, P1351; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1976, J CHRON DIS, V29, P625; *ASP MYOC INF STUD, 1980, CIRCULATION S5, V62, P79; Begg C., 1994, HDB RES SYNTHESIS, P399; Blackshear JL, 1996, LANCET, V348, P633; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; BRESLOW N, 1981, BIOMETRIKA, V68, P73, DOI 10.1093/biomet/68.1.73; BRITTON M C H, 1987, Stroke, V18, P325; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; CANDELISE L, 1995, LANCET, V346, P1509; CANDELISE L, 1982, STROKE, V13, P175, DOI 10.1161/01.STR.13.2.175; CAPPELLERI JC, 1995, ONLINE J CURR CLIN T, V14; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; COTE R, 1995, ANN INTERN MED, V123, P649, DOI 10.7326/0003-4819-123-9-199511010-00002; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; ELWOOD PC, 1979, LANCET, V2, P1313; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1985, STROKE, V16, P406; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; FINDLAY JM, 1985, J NEUROSURG, V63, P693, DOI 10.3171/jns.1985.63.5.0693; Fleiss J.L., 1994, HDB RES SYNTHESIS, P245; Fuster V, 1997, LANCET, V350, P389; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HE J, 1995, STROKE, V26, P2222, DOI 10.1161/01.STR.26.12.2222; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HERSKOVITS E, 1981, RES CLIN LAB, V11, P257; HUME AL, 1993, ANN PHARMACOTHER, V27, P442, DOI 10.1177/106002809302700409; Julian DG, 1996, BMJ-BRIT MED J, V313, P1429, DOI 10.1136/bmj.313.7070.1429; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; Kahn HA, 1989, STAT METHODS EPIDEMI; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KROL WF, 1980, CIRCULATION, V62, P449; Lee T K, 1990, J Formos Med Assoc, V89, P635; Lee TK, 1997, THROMB RES, V87, P215, DOI 10.1016/S0049-3848(97)00121-7; LINDBLAD B, 1993, STROKE, V24, P1125, DOI 10.1161/01.STR.24.8.1125; MARUYAMA S, 1995, ANGIOLOGY, V46, P999, DOI 10.1177/000331979504601104; MATIASGUIU J, 1987, ACTA NEUROL SCAND, V76, P413, DOI 10.1111/j.1600-0404.1987.tb03596.x; MAYO NE, 1991, STROKE, V22, P1213, DOI 10.1161/01.STR.22.9.1213; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MEYER JS, 1989, J AM GERIATR SOC, V37, P549, DOI 10.1111/j.1532-5415.1989.tb05688.x; NORRVING B, 1991, LANCET, V338, P1345; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PETERSEN P, 1989, LANCET, V1, P175; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Puddey IB, 1996, ATHEROSCLEROSIS, V119, P1, DOI 10.1016/0021-9150(95)05634-3; RANKE C, 1993, CIRCULATION, V87, P1873, DOI 10.1161/01.CIR.87.6.1873; REEVES MJ, 1997, MMWR-MORBID MORTAL W, V46, P498; Sandercock P, 1997, LANCET, V349, P1569; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; Shahar E, 1996, AM HEART J, V131, P915, DOI 10.1016/S0002-8703(96)90173-8; SILAGY CA, 1993, CLIN PHARMACOL THER, V54, P84, DOI 10.1038/clpt.1993.115; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; SIVENIUS J, 1992, STROKE, V23, P851, DOI 10.1161/01.STR.23.6.851; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; VANDEWERF F, 1994, CIRCULATION, V89, P588; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALTER SD, 1991, BIOMETRICS, V47, P795, DOI 10.2307/2532640; WILLARD JE, 1992, NEW ENGL J MED, V327, P175	67	353	375	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1930	1935		10.1001/jama.280.22.1930	http://dx.doi.org/10.1001/jama.280.22.1930			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851479				2022-12-28	WOS:000077364500038
J	Lyckholm, LJ				Lyckholm, LJ			Should physicians accept gifts from patients?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Virginia Commonwealth Univ, Dept Internal Med, Div Hematol Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Lyckholm, LJ (corresponding author), Virginia Commonwealth Univ, Dept Internal Med, Div Hematol Oncol, Box 980230, Richmond, VA 23298 USA.	llyckhol@hsc.vcu.edu		Lyckholm, Laurel/0000-0003-0963-3675				Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; CHEAL D, 1988, GIFT EC, P9; COHEN L, 1987, CAN MED ASSOC J, V136, P408; Davidoff F, 1998, ANN INTERN MED, V128, P572, DOI 10.7326/0003-4819-128-7-199804010-00011; DREW J, 1983, SOC SCI MED, V17, P399, DOI 10.1016/0277-9536(83)90343-X; EMERSON RW, 1990, ESSAYS 1 2 SERIES, P306; GABBARD GO, 1995, JAMA-J AM MED ASSOC, V273, P1445, DOI 10.1001/jama.273.18.1445; GOSS B, 1998, CANC COMBAT CANC SUR, P105; HAINER BL, 1982, J FAM PRACTICE, V14, P47; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Koven SJ, 1998, JAMA-J AM MED ASSOC, V279, P1607, DOI 10.1001/jama.279.20.1607; LEVENE MI, 1980, BRIT MED J, V281, P1685, DOI 10.1136/bmj.281.6256.1685; MAUSS M, 1990, GIFT FORM REASON EXC, P65	13	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1944	1946		10.1001/jama.280.22.1944	http://dx.doi.org/10.1001/jama.280.22.1944			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851481				2022-12-28	WOS:000077364500040
J	Hutcheon, ID; Krot, AN; Keil, K; Phinney, DL; Scott, ERD				Hutcheon, ID; Krot, AN; Keil, K; Phinney, DL; Scott, ERD			Mn-53-Cr-53 dating of fayalite formation in the CV3 chondrite mokoia: Evidence for asteroidal alteration	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; HIGH-TEMPERATURE CONDENSATION; PARENT BODY; AQUEOUS ALTERATION; ALLENDE METEORITE; CARBONACEOUS CHONDRITES; NEBULA; OLIVINE; AL-26; KABA	Fayalite grains in chondrules in the oxidized, aqueously altered CV3 chondrite Mokoia have large excesses of radiogenic chromium-53. These excesses indicate the in situ decay of short-lived manganese-53 (half-Life = 3.7 million years) and define an initial Mn-53/Mn-55 ratio of 2.32 (+/-0.18) x 10(-6). This ratio is comparable to values for carbonates in CI and CM chondrites and for several classes of differentiated meteorites. Mokoia fayalites formed 7 to 16 million years after Allende calcium-aluminum-rich inclusions, during hydrothermal activity on a geologically active asteroid after chondritic components had ceased forming in the solar nebula.	Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Hawaii System; University of Hawaii Manoa	Hutcheon, ID (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.			Scott, Edward/0000-0002-5137-3830				BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; BIRCK JL, 1985, GEOPHYS RES LETT, V12, P745, DOI 10.1029/GL012i011p00745; Brearley A, 1997, SCIENCE, V278, P76, DOI 10.1126/science.278.5335.76; Brearley AJ, 1997, SCIENCE, V276, P1103, DOI 10.1126/science.276.5315.1103; BROWNING L, UNPUB; CAMERON AGW, 1995, METEORITICS, V30, P133, DOI 10.1111/j.1945-5100.1995.tb01110.x; EBER DS, 1997, METEORL PLANET SCI, V32, pA37; Endress M, 1996, NATURE, V379, P701, DOI 10.1038/379701a0; GROSSMAN L, 1980, ANNU REV EARTH PL SC, V8, P559, DOI 10.1146/annurev.ea.08.050180.003015; Hohenberg CM, 1998, METEORIT PLANET SCI, V33, pA69; Housley R. M., 1983, CHONDRULES THEIR ORI, P145; HUA X, 1988, GEOCHIM COSMOCHIM AC, V52, P1389, DOI 10.1016/0016-7037(88)90210-4; HUA X, 1995, GEOCHIM COSMOCHIM AC, V59, P563, DOI 10.1016/0016-7037(94)00383-W; HUTCHEON ID, 1997, 9702 LUN PLAN I 1, P27; HUTCHEON ID, 1992, LUNAR PLANET SCI, V23, P565; HUTCHEON ID, 1981, LUNAR PLANET SCI, V12, P491; KELLER LP, 1990, GEOCHIM COSMOCHIM AC, V54, P2113, DOI 10.1016/0016-7037(90)90274-O; KELLER LP, 1991, SCIENCE, V252, P946, DOI 10.1126/science.252.5008.946; Kerridge JF., 1988, METEORITES EARLY SOL; KIMUR M, 1997, ANTARCT MET RES, V10, P217; Kojima T, 1996, GEOCHIM COSMOCHIM AC, V60, P2651, DOI 10.1016/0016-7037(96)00116-0; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; Krot AN, 1998, METEORIT PLANET SCI, V33, pA89; KROT AN, 1997, 9702 LPI 1, P34; Lawson WA, 1996, MON NOT R ASTRON SOC, V280, P1071; Lugmair G. W., 1992, LUNAR PLANET SCI, VXXIII, P823; LUGMAIR GW, 1994, METEORITICS, V29, P493; LUGMAIR GW, 1997, LUNAR PLANET SCI, V27, P851; MACDOUGALL JD, 1984, NATURE, V307, P249, DOI 10.1038/307249a0; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MACPHERSON GJ, 1997, 9702 LUN PLAN I 1, P42; MCSWEEN HY, 1977, GEOCHIM COSMOCHIM AC, V41, P1777, DOI 10.1016/0016-7037(77)90210-1; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; PALME H, 1990, EARTH PLANET SC LETT, V101, P180, DOI 10.1016/0012-821X(90)90152-N; PECK JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1503, DOI 10.1016/0016-7037(87)90332-2; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; Richardson S. M., 1978, Meteoritics, V13, P141, DOI 10.1111/j.1945-5100.1978.tb00803.x; Rubin A. E., 1988, METEORITES EARLY SOL, P488; RUSSELL SS, 1997, 9702 LUN PLAN I 1, P54; SHIELDS WR, 1966, J RES NBS A PHYS CH, VA 70, P193, DOI 10.6028/jres.070A.016; SHUKOLYUKOV A, 1998, LUNAR PLANET SCI, V29, P1208; Strom S. E., 1993, PROTOSTARS PLANETS, P837; TOMEOKA K, 1982, NATURE, V299, P327, DOI 10.1038/299327a0; TOMEOKA K, 1997, WORKSH PAR BOD NEB 1, P61; TORNEOKA K, 1990, GEOCHIM COSMOCHIM AC, V54, P1745; WADHWA M, 1998, LUNAR PLANET SCI, V29, P1480; WADHWA M, 1998, LUNAR PLANET SCI, V29, P1484; WEINBRUCH S, 1990, METEORITICS, V25, P115, DOI 10.1111/j.1945-5100.1990.tb00983.x; WEINBRUCH S, 1994, GEOCHIM COSMOCHIM AC, V58, P1019, DOI 10.1016/0016-7037(94)90523-1; Weisberg MK, 1997, METEORIT PLANET SCI, V32, pA138; WEISBERG MK, 1997, METEORIT PLANET SCI, V32, P719; WOOD JA, 1988, ANNU REV EARTH PL SC, V16, P53; WOOD JA, 1993, GEOCHIM COSMOCHIM AC, V57, P2377, DOI 10.1016/0016-7037(93)90575-H; ZOLENSKY ME, 1997, 9702 LUN PLAN I 2; ZOLENSKY ME, 1997, 9702 LUN PLAN I 1; [No title captured]; [No title captured]	58	65	66	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1865	1867		10.1126/science.282.5395.1865	http://dx.doi.org/10.1126/science.282.5395.1865			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836631				2022-12-28	WOS:000077338100041
J	Burlingham, WJ; Grailer, AP; Heisey, DM; Claas, FHJ; Norman, D; Mohanakumar, T; Brennan, DC; De Fijter, H; Van Gelder, T; Pirsch, JD; Sollinger, HW; Bean, MA				Burlingham, WJ; Grailer, AP; Heisey, DM; Claas, FHJ; Norman, D; Mohanakumar, T; Brennan, DC; De Fijter, H; Van Gelder, T; Pirsch, JD; Sollinger, HW; Bean, MA			The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							T-CELL; INDUCTION; UNRESPONSIVENESS; TRANSFUSIONS; RECIPIENTS; REPERTOIRE; RESPONSES; MIGRATION; IMMUNITY	Background During pregnancy and nursing, a baby's developing immune system is intimately exposed to the mother's antigens. To determine whether this exposure is of clinical benefit to patients who later receive an allograft as an adult, we analyzed the outcome of primary renal transplantations from sibling donors. Methods We retrospectively studied graft survival and rejection episodes in 205 patients who had received renal transplants at nine centers between 1966 and 1996 from sibling donors bearing maternal or paternal HLA antigens not inherited by the recipient. The sibling donors were categorized by analysis of family HLA-typing data. Results In the multicenter analysis, graft survival was higher 5 years and 10 years after transplantation in recipients of kidneys from siblings expressing maternal HLA antigens not inherited by the recipient than in recipients of kidneys from siblings expressing paternal HLA antigens not inherited by the recipient (86 percent vs. 67 percent at 5 years and 77 percent vs. 49 percent at 10 years, P = 0.006 for both comparisons). Paradoxically, there was a higher incidence of early rejection in the former group, suggesting that fetal and neonatal exposure to maternal antigens results in immunologic priming. Pretransplantation transfusions of donor blood reduced the incidence of acute rejection while preserving the beneficial effect of tolerance to noninherited maternal antigens on graft survival. Since 1986, new immunosuppressive drugs have lessened the shortterm, but not the long-term, survival advantage of grafts expressing maternal HLA antigens not inherited by the recipient. Conclusions In the transplantation of a kidney from a sibling donor who is mismatched with the recipient for one HLA haplotype, graft survival is higher when the donor has maternal HLA antigens not inherited by the recipient than when the donor has paternal HLA antigens not inherited by the recipient. (N Engl J Med 1998;339:1657-64.) (C)1998. Massachusetts Medical Society.	Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53792 USA; Leiden Univ, Med Ctr, Dept Immunohematol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; Oregon Hlth & Sci Univ, Lab Immunogenet & Transplantat, Portland, OR 97201 USA; Washington Univ, Dept Pathol, St Louis, MO 63130 USA; Washington Univ, Dept Med, St Louis, MO 63130 USA; Univ Hosp Dijkzigt, NL-3015 GD Rotterdam, Netherlands; Dendreon Corp, Mountain View, CA USA	University of Wisconsin System; University of Wisconsin Madison; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Oregon Health & Science University; Washington University (WUSTL); Washington University (WUSTL); Erasmus University Rotterdam; Erasmus MC; Dendreon	Burlingham, WJ (corresponding author), Univ Wisconsin, Sch Med, Dept Surg, H4-748 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.				NIAID NIH HHS [K02-AI01452] Funding Source: Medline; NIDDK NIH HHS [R01-DK32253, R01-DK50954] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050954, R01DK032253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAN MA, 1990, TRANSPLANTATION, V49, P382, DOI 10.1097/00007890-199002000-00031; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bishop GA, 1997, TRANSPLANTATION, V64, P1377, DOI 10.1097/00007890-199711270-00001; BURLINGHAM WJ, 1995, TRANSPLANTATION, V59, P1147, DOI 10.1097/00007890-199504270-00013; BURLINGHAM WJ, IN PRESS IMMUNOLOGY; Cecka J M, 1997, Pediatr Transplant, V1, P55; Chen NX, 1995, TRANSPLANTATION, V60, P1187; CLAAS FHJ, 1988, SCIENCE, V241, P1815, DOI 10.1126/science.3051377; DALESSANDRO AM, 1995, ANN SURG, V222, P353, DOI 10.1097/00000658-199509000-00012; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HADLEY GA, 1990, HUM IMMUNOL, V28, P373, DOI 10.1016/0198-8859(90)90032-K; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Neu A, 1996, J AM SOC NEPHROL, V7, pA3352; NEWTON WT, 1973, SURGERY, V74, P430; OCONNELL PJ, IN PRESS TRANSPLANTA; Opelz G, 1990, Clin Transpl, P63; OWEN RD, 1954, P NATL ACAD SCI USA, V40, P420, DOI 10.1073/pnas.40.6.420; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; ROELEN DL, 1995, TRANSPLANTATION, V59, P1728, DOI 10.1097/00007890-199506270-00015; RUSSELL PS, 1994, J IMMUNOL, V152, P5135; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; Singh RR, 1996, J EXP MED, V183, P1613, DOI 10.1084/jem.183.4.1613; Smits JMA, 1998, TRANSPLANT INT, V11, P82, DOI 10.1111/j.1432-2277.1998.tb00781.x; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STEINMULLER D, 1967, SCIENCE, V158, P127, DOI 10.1126/science.158.3797.127; Terasaki P I, 1996, Clin Transpl, P443; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; Wagner J E, 1997, Cancer Treat Res, V77, P187; ZHANG L, 1994, J IMMUNOL, V152, P2222; ZHANG L, 1993, TRANSPLANTATION, V56, P918, DOI 10.1097/00007890-199310000-00027	34	195	200	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1657	1664		10.1056/NEJM199812033392302	http://dx.doi.org/10.1056/NEJM199812033392302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834302				2022-12-28	WOS:000077294800002
J	Kramer, MS; Platt, R; Yang, H; Joseph, KS; Wen, SW; Morin, L; Usher, RH				Kramer, MS; Platt, R; Yang, H; Joseph, KS; Wen, SW; Morin, L; Usher, RH			Secular trends in preterm birth - A hospital-based cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFANT-MORTALITY RATES; GESTATIONAL-AGE; WEIGHT; FRANCE	Context.-Canada and the United States have reported a recent increase in the incidence of preterm birth, but the reasons for this increase are unknown. Objective.-To assess secular trends in preterm birth and its potential determinants. Design.-Hospital-based cohort study. Setting.-Canadian tertiary care university teaching hospital, 1978-1996. Participants.-A total of 65 574 nonreferred live births and stillbirths. Main Outcome Measures.-Changes in occurrence of preterm birth, before and after adjustment for changes in method of gestational age assessment, obstetric intervention, registration of births weighing less than 500 g, and sociodemographic, behavioral, and clinical determinants. Results.-A crude secular increase in preterm births was seen for births less than 37, 34, and 32 completed weeks using 3 alternative gestational age estimation methods, Based on an algorithm incorporating both menstrual and early ultrasound gestational age estimates, rates increased from 6.6% to 9.8% for births at less than 37 weeks' gestation, 1.7% to 2.3% at less than 34 weeks, and 1.0% to 1.2% at less than 32 weeks. Exclusion of births weighing less than 500 g and those with induction or preterm cesarean delivery without labor before each of the corresponding gestational age cutoffs eliminated the secular trends for births before 34 and 32 weeks and attenuated the trend for births before 37 weeks. Nearly half of the remaining trend for births before 37 weeks was accounted for by the increasing use of early ultrasound dating. The residual trend was eliminated after controlling for secular increases in unmarried status and the proportion of women aged 35 years or older. These factors, combined with a decrease in alcohol consumption and increases in histological chorioamnionitis and cocaine use, appear to have counteracted a reduction in preterm birth since the mid-1980s that otherwise would have been observed. Conclusions.-This hospital's increase in preterm births since 1978 parallels increases reported in population-based national studies from the United States and Canada. This trend appears largely attributable to the increasing use of early ultrasound dating, preterm induction and preterm cesarean delivery without labor, and changes in sociodemographic and behavioral factors.	McGill Univ, Fac Med, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Med, Dept Obstet & Gynecol, Montreal, PQ H3A 2T5, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Hlth Canada, Lab Ctr Dis Control, Bur Reprod & Child Hlth, Ottawa, ON K1A 0L2, Canada	McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital; Health Canada	Kramer, MS (corresponding author), 1020 Pine Ave, W Montreal, PQ H3A 1A2, Canada.			Joseph, K.S./0000-0003-2317-5607; Platt, Robert/0000-0002-5981-8443				[Anonymous], 1985, PREV LOW BIRTHW; BREART G, 1995, PAEDIATR PERINAT EP, V9, P296, DOI 10.1111/j.1365-3016.1995.tb00146.x; DOLLFUS C, 1990, PEDIATRICS, V86, P176; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V160, P462, DOI 10.1016/0002-9378(89)90473-0; Joseph KS, 1997, CAN MED ASSOC J, V157, P535; Joseph KS, 1998, NEW ENGL J MED, V339, P1434, DOI 10.1056/NEJM199811123392004; Joseph KS, 1996, CAN MED ASSOC J, V155, P1047; KLIEGMAN RM, 1995, AM J PUBLIC HEALTH, V85, P909, DOI 10.2105/AJPH.85.7.909; KRAMER M, 1987, B WORLD HEALTH ORGAN, V65, P665; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; LEE KS, 1980, AM J PUBLIC HEALTH, V70, P15, DOI 10.2105/AJPH.70.1.15; Martin J A, 1995, Stat Bull Metrop Insur Co, V76, P10; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MORRISON JC, 1990, OBSTET GYNECOL, V76, P55; *NAT CTR CHRON DIS, 1994, MMWR-MORBID MORTAL W, V43, P335; OLSEN P, 1995, AM J EPIDEMIOL, V142, P1184, DOI 10.1093/oxfordjournals.aje.a117577; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; SMITH LP, 1982, ACTA OBSTET GYNECO S, V109, P49	21	122	124	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1849	1854		10.1001/jama.280.21.1849	http://dx.doi.org/10.1001/jama.280.21.1849			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846780				2022-12-28	WOS:000077176600031
J	Rexrode, KM; Carey, VJ; Hennekens, CH; Walters, EE; Colditz, GA; Stampfer, MJ; Willett, WC; Manson, JAE				Rexrode, KM; Carey, VJ; Hennekens, CH; Walters, EE; Colditz, GA; Stampfer, MJ; Willett, WC; Manson, JAE			Abdominal adiposity and coronary heart disease in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-FAT DISTRIBUTION; CARDIOVASCULAR RISK-FACTORS; POSTMENOPAUSAL WOMEN; PROSPECTIVE COHORT; DIABETES-MELLITUS; NATIONAL-HEALTH; OLDER WOMEN; HIP RATIO; MEN; FOLLOW	Context.-Obesity is a well-established risk factor for coronary heart disease (CHD), but whether regional fat distribution contributes independently to risk remains unclear. Objective.-To compare waist-hip ratio (WHR) and waist circumference in determining risk of CHD in women. Design and Setting.-Prospective cohort study among US female registered nurses participating in the Nurses' Health Study conducted between 1986, when the nurses completed a questionnaire, and follow-up in June 1994. Participants.-A total of 44 702 women aged 40 to 65 years who provided waist and hip circumferences and were free of prior CHD, stroke, or cancer in 1986. Main Outcome Measures.-Incidence of CHD (nonfatal myocardial infarction or CHD death). Results.-During 8 years of follow-up 320 CHD events (251 myocardial infarctions and 69 CHD deaths) were documented. Higher WHR and greater waist circumference were independently associated with a significantly increased age-adjusted risk of CHD. After adjusting for body mass index (BMI) (defined as weight in kilograms divided by the square of height in meters) and other cardiac risk factors, women with a WHR of 0.88 or higher had a relative risk (RR) of 3.25 (95% confidence interval [CI], 1.78-5.95) for CHD compared with women with a WHR of less than 0.72. A waist circumference of 96.5 cm (38 in) or more was associated with an RR of 3.06 (95% CI, 1.54-6.10). The WHR and waist circumference were independently strongly associated with increased risk of CHD also among women with a BMI of 25 kg/m(2) or less. After adjustment for reported hypertension, diabetes, and high cholesterol level, a WHR of 0.76 or higher or waist circumference of 76.2 cm (30 in) or more was associated with more than a 2-fold higher risk of CHD. Conclusions.-The WHR and waist circumference are independently associated with risk of CHD in women.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Rexrode, KM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009; Rexrode, Kathryn M/I-1177-2018	Colditz, Graham/0000-0002-7307-0291; Rexrode, Kathryn/0000-0003-3387-8429	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; CURB JD, 1991, AM J CLIN NUTR, V53, pS1612, DOI 10.1093/ajcn/53.6.1612S; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DONAHUE RP, 1987, LANCET, V1, P821; DUCIMETIERE P, 1986, INT J OBESITY, V10, P229; Duncan Bruce B., 1995, Annals of Epidemiology, V5, P192, DOI 10.1016/1047-2797(94)00106-4; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; FRASER GE, 1992, CIRCULATION, V86, P406, DOI 10.1161/01.CIR.86.2.406; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; HAFFNER SM, 1991, INT J OBESITY, V15, P471; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; KANNEL WB, 1991, J CLIN EPIDEMIOL, V44, P183, DOI 10.1016/0895-4356(91)90265-B; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; PEIRIS AN, 1987, INT J OBESITY, V11, P581; Prineas R J, 1993, Ann Epidemiol, V3, P35, DOI 10.1016/1047-2797(93)90007-Q; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033; SVENDSEN OL, 1993, AM J MED, V95, P131, DOI 10.1016/0002-9343(93)90253-L; TERRY RB, 1992, INT J OBESITY, V16, P417; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WING RR, 1995, INT J OBESITY, V19, P67; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250	34	802	829	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1843	1848		10.1001/jama.280.21.1843	http://dx.doi.org/10.1001/jama.280.21.1843			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846779	Bronze			2022-12-28	WOS:000077176600030
J	Binion, DG; West, GA; Volk, EE; Drazba, JA; Ziats, NP; Petras, RE; Fiocchi, C				Binion, DG; West, GA; Volk, EE; Drazba, JA; Ziats, NP; Petras, RE; Fiocchi, C			Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease	LANCET			English	Article							RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; ADHESION MOLECULES; CROHNS-DISEASE; CELL-ADHESION; T-CELLS; ACTIVATION; EXPRESSION; FIBROBLASTS; ICAM-1	Background Endothelial cells that line microvascular blood vessels have an important role in inflammation through their ability to bind and recruit circulating leucocytes. Endothelial cells from the intestines of patients with chronically inflamed Crohn's disease and ulcerative colitis-the two forms of inflammatory bowel disease-display an increased leucocyte-binding capacity in vitro. We investigated whether this enhanced leucocyte binding is a primary or an acquired defect. Methods We cultured human intestinal microvascular endothelial cells (HIMEC) from the uninvolved intestine and chronically inflamed bower of three patients with inflammatory bower disease (two Crohn's disease, one ulcerative colitis). We assessed HIMEC binding to polymorphonuclear leucocytes and U937 cells by means of an adhesion assay. Findings After activation with interleukin-la or lipopolysaccharide, HIMEC from the chronically inflamed tissue in all three patients with inflammatory bowel disease bound as many polymorphonuclear cells as endothelial cells from twice U937 leucocytes and uninvolved tissue. Interpretation Enhanced leucocyte binding by HIMEC from chronically inflamed tissue in patients with inflammatory bowel disease is an acquired defect since it is not found in the uninvolved intestinal segments from the same individuals. Because interaction between endothelial cells and leucocytes is a key regulatory step in the inflammatory process, this enhanced binding may contribute to the pathophysiology of chronic intestinal inflammation.	Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Inst Res, Cleveland, OH 44195 USA	Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Binion, DG (corresponding author), Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030399, R01DK050984, R01DK030399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02417, DK30399, DK50984] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; BURGIO VL, 1995, GASTROENTEROLOGY, V109, P1029; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CASH JM, 1994, NEW ENGL J MED, V330, P1368; DAVIS LS, 1995, J IMMUNOL, V154, P3525; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Fiocchi C, 1997, INFLAMM BOWEL DIS, V3, P133, DOI 10.1002/ibd.3780030209; GAULDIE J, 1992, AM REV RESPIR DIS, V145, pS14, DOI 10.1164/ajrccm/145.2_Pt_2.S14; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Ina K, 1996, GASTROENTEROLOGY, V110, pA930; KOIZUMI M, 1992, GASTROENTEROLOGY, V103, P840, DOI 10.1016/0016-5085(92)90015-Q; KOOPMAN WJ, 1993, RHEUM DIS CLIN N AM, V19, P107; Markowitz J, 1998, GASTROENTEROLOGY, V114, pA1032, DOI 10.1016/S0016-5085(98)84200-5; Musso A, 1996, GASTROENTEROLOGY, V110, pA977; NAKAMURA S, 1993, LAB INVEST, V69, P77; NIELSEN OH, 1994, DIGEST DIS SCI, V420, P403; OHTANI H, 1992, VIRCHOWS ARCH A, V420, P403, DOI 10.1007/BF01600511; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; SALMI M, 1994, GASTROENTEROLOGY, V106, P596, DOI 10.1016/0016-5085(94)90691-2; SchulzeKoops H, 1996, CLIN EXP IMMUNOL, V106, P190, DOI 10.1046/j.1365-2249.1996.d01-828.x; SOUTO JC, 1995, DIGEST DIS SCI, V40, P1883, DOI 10.1007/BF02208650; WAKEFIELD AJ, 1991, DIGEST DIS SCI, V36, P1147, DOI 10.1007/BF01297463; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4	26	83	86	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1742	1746		10.1016/S0140-6736(98)05050-8	http://dx.doi.org/10.1016/S0140-6736(98)05050-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848350				2022-12-28	WOS:000077246500009
J	Shao, DL; Rangwala, SM; Bailey, ST; Krakow, SL; Reginato, MJ; Lazar, MA				Shao, DL; Rangwala, SM; Bailey, ST; Krakow, SL; Reginato, MJ; Lazar, MA			Interdomain communication regulating ligand binding by PPAR-gamma	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; ESTROGEN-RECEPTOR; ADIPOCYTE DIFFERENTIATION; PROTEIN-KINASE; PROLIFERATOR; PHOSPHORYLATION; HORMONE; ALPHA; THIAZOLIDINEDIONES; TRANSCRIPTION	Binding to receptors in the cell nucleus is crucial for the action of lipophilic hormones and ligands. PPAR-gamma (for peroxisome proliferator-activated receptor) is a nuclear hormone receptor that mediates adipocyte differentiation(1,2) and modulates insulin sensitivity(3), cell proliferation(4) and inflammatory processes(5,6). PPAR-gamma ligands have been implicated in the development of atherogenic foam cells(7) and as potential cancer treatments(8). Transcriptional activity of PPAR-gamma is induced by binding diverse ligands, including natural fatty acid derivatives(9-11), antidiabetic thiazolidinediones(12), and non-steroidal anti-inflammatory drugs(13). Ligand binding by PPAR-gamma, as well as by the entire nuclear-receptor superfamily, is an independent property of the carboxy-terminal ligand-binding domain (LBD) of the receptor(14,15). Here we show that ligand binding by PPAR-gamma is regulated by intramolecular communication between its amino-terminal A/B domain and its carboxy-terminal LED. Modification of the A/B domain, for example by physiological phosphorylation by MAP kinase, reduces ligand-binding affinity, thus negatively regulating the transcriptional and biological functions of PPAR-gamma. The ability of the A/B domain to regulate ligand binding has important implications for the evaluation and mechanism of action of potentially therapeutic ligands that bind PPAR-gamma and that are likely to extend to other members of the nuclear-receptor superfamily.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Bailey, Shannon/B-8045-2014; Lazar, Mitchell A/AAF-3738-2019; Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAMP HS, 1997, J BIOL CHEM, V272, P13452; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	30	294	308	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					377	380		10.1038/24634	http://dx.doi.org/10.1038/24634			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845075				2022-12-28	WOS:000077204000052
J	Luther, A; Brandsch, R; von Kiedrowski, G				Luther, A; Brandsch, R; von Kiedrowski, G			Surface-promoted replication and exponential amplification of DNA analogues	NATURE			English	Article							PEPTIDE SELF-REPLICATION; CHEMICAL LIGATION; SYSTEM; EVOLUTION; OLIGOMERS; TEMPLATES; GROWTH; LIFE	Self-replicating chemical systems have been designed and studied to identify the minimal requirements for molecular replication(1), to translate the principle into synthetic supramolecular systems(2) and to derive a better understanding of the scope and limitations of self-organization processes(3) that are believed to be relevant to the origin of life on Earth(4). Current implementations make use of oligonucleotide analogues(5-12), peptides(13-17), and other molecules(18-24) as templates and are based either on autocatalytic, cross-catalytic, or collectively catalytic pathways for template formation. A common problem of these systems is product inhibition, leading to parabolic instead of exponential amplification(25). The fatter is the dynamic prerequisite for selection in the darwinian sense(26,27). We here describe an iterative, stepwise procedure for chemical replication which permits an exponential increase in the concentration of oligonucleotide analogues. The procedure employs the surface of a solid support and is called SPREAD (surface-promoted replication and exponential amplification of DNA analogues). Copies are synthesized from precursor fragments by chemical ligation on immobilized templates, and then Liberated and immobilized to become new templates. The process is repeated iteratively. The role of the support is to separate complementary templates which would form stable duplexes in solution. SPREAD combines the advantages of solid-phase chemistry with chemical replication, and can be further developed for the non-enzymatic and enzymatic amplification of RNA, peptides and other templates as well as for studies of in vitro evolution and competition in artificial chemical systems. Similar processes may also have played a role in the origin of life on Earth, because the earliest replication systems may have proliferated by spreading on mineral surfaces(28-33).	Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, D-44780 Bochum, Germany	Ruhr University Bochum	von Kiedrowski, G (corresponding author), Ruhr Univ Bochum, Lehrstuhl Bioorgan Chem, Univ Str 150 NC 2-173, D-44780 Bochum, Germany.	kiedro@ernie.orch.ruhr-uni-bochum.de						ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; BERNAL JD, 1951, PHYSICAL BASE LIFE; DOLINNAYA NG, 1991, NUCLEIC ACIDS RES, V19, P3073, DOI 10.1093/nar/19.11.3073; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FENG Q, 1992, SCIENCE, V256, P1179, DOI 10.1126/science.256.5060.1179; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; James KD, 1997, CHEM BIOL, V4, P595, DOI 10.1016/S1074-5521(97)90245-3; Joyce GF., 1994, ORIGINS LIFE CENTRAL; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; KUHN H, 1981, ANGEW CHEM INT EDIT, V20, P500, DOI 10.1002/anie.198105001; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; Lee DH, 1997, NATURE, V390, P591, DOI 10.1038/37569; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MARTIN B, 1997, HELV CHIM ACTA, V80, P1901; Orgel LE, 1998, ORIGINS LIFE EVOL B, V28, P227, DOI 10.1023/A:1006595411403; ORGEL LE, 1995, ACCOUNTS CHEM RES, V28, P109, DOI 10.1021/ar00051a004; PIETERS RJ, 1994, ANGEW CHEM INT EDIT, V33, P1579, DOI 10.1002/anie.199415791; Reinhoudt DN, 1996, J AM CHEM SOC, V118, P6880, DOI 10.1021/ja960324g; Severin K, 1998, ANGEW CHEM INT EDIT, V37, P126, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<126::AID-ANIE126>3.0.CO;2-4; Severin K, 1997, CHEM-EUR J, V3, P1017, DOI 10.1002/chem.19970030706; SIEVERS D, 1994, NATO ADV SCI INST SE, V446, P45; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; Sievers D, 1998, CHEM-EUR J, V4, P629, DOI 10.1002/(SICI)1521-3765(19980416)4:4<629::AID-CHEM629>3.0.CO;2-0; SZATHMARY E, 1989, J THEOR BIOL, V138, P55, DOI 10.1016/S0022-5193(89)80177-8; Szathmary E, 1997, J THEOR BIOL, V187, P555, DOI 10.1006/jtbi.1996.0389; TERFORT A, 1992, ANGEW CHEM INT EDIT, V31, P654, DOI 10.1002/anie.199206541; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; vonKiedrowski G, 1996, NATURE, V381, P20, DOI 10.1038/381020a0; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; Wang B, 1997, CHEM COMMUN, P1495, DOI 10.1039/a701573i; WILLS RW, 1997, 9707065; WILLS RW, IN PRESS B MATH BIOL; WINTNER EA, 1994, ACCOUNTS CHEM RES, V27, P198, DOI 10.1021/ar00043a003; Yao S, 1998, ANGEW CHEM INT EDIT, V37, P478, DOI 10.1002/(SICI)1521-3773(19980302)37:4<478::AID-ANIE478>3.0.CO;2-V; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0; [No title captured]	40	198	219	0	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					245	248		10.1038/24343	http://dx.doi.org/10.1038/24343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834031				2022-12-28	WOS:000077110400041
J	Rhee, KH; Morriss, EP; Barber, J; Kuhlbrandt, W				Rhee, KH; Morriss, EP; Barber, J; Kuhlbrandt, W			Three-dimensional structure of the plant photosystem II reaction centre at 8 angstrom resolution	NATURE			English	Article							PHOTOSYNTHETIC REACTION-CENTER; PURPLE MEMBRANE; MODEL; DONOR; POLYPEPTIDES	Photosystem II is a multisubunit enzyme complex involved in plant photosynthesis. It uses solar energy to catalyse the breakdown of water to reducing equivalents and molecular oxygen(1). Native photosystem II comprises more than 25 different subunits, and has a relative molecular mass of more than 600K. Here we report the three-dimensional structure of a photosystem II subcomplex, containing the proteins D1, D2, CP47 and cytochrome b-559, determined by electron crystallography. This CP47 reaction centre, which has a relative molecular mass of 160K, can perform light-mediated energy and electron-transfer reactions but is unable to oxidize water(2). The complex contains 23 transmembrane alpha-helices, of which 16 have been assigned to the D1, D2 and CP47 proteins. The arrangement of these helices is remarkably similar to that of the helices in the reaction centres of purple bacteria and of plant photosystem I, indicating a common evolutionary origin for these assemblies. The map suggests that redox cofactors in the D1-D2 complex are located in positions analogous to those in the bacterial reaction centre, but the distance between the chlorophylls corresponding to the bacterial 'special pair' is significantly larger.	Max Planck Inst Biophys, Abt Strukt Biol, D-60528 Frankfurt, Germany; European Mol Biol Lab, Struct Biol Programme & Biocomp Unit, D-69117 Heidelberg, Germany; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Wolfson Labs, London SW7 2AY, England	Max Planck Society; European Molecular Biology Laboratory (EMBL); Imperial College London	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Abt Strukt Biol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.			Kuhlbrandt, Werner/0000-0002-2013-4810				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; Bianchetti M, 1998, J BIOL CHEM, V273, P16128, DOI 10.1074/jbc.273.26.16128; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DURRANT JR, 1995, P NATL ACAD SCI USA, V92, P4798, DOI 10.1073/pnas.92.11.4798; Fromme P, 1996, BBA-BIOENERGETICS, V1275, P76, DOI 10.1016/0005-2728(96)00053-9; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; MATHIS P, 1990, BIOCHIM BIOPHYS ACTA, V1018, P163, DOI 10.1016/0005-2728(90)90240-5; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MOSKALENKO AA, 1992, FEBS LETT, V314, P271, DOI 10.1016/0014-5793(92)81487-7; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Nitschke W., 1998, P285; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; Rhee KH, 1997, NATURE, V389, P522, DOI 10.1038/39103; Rutherford A. W., 1996, P143; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122	29	283	296	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					283	286		10.1038/24421	http://dx.doi.org/10.1038/24421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834037				2022-12-28	WOS:000077110400052
J	Hunt, SA				Hunt, SA			Current status of cardiac transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; TOTAL LYMPHOID IRRADIATION; HEART-TRANSPLANTATION; ALLOGRAFT-REJECTION; SYMPATHETIC REINNERVATION; IMMUNOSUPPRESSIVE THERAPY; INTRACORONARY ULTRASOUND; CYTOMEGALOVIRUS DISEASE; EXERCISE CAPACITY; RECIPIENTS	Cardiac transplantation, first introduced 30 years ago, has become a widely used and increasingly important procedure for treatment of truly end-stage heart disease. Current use is limited strictly by donor supply, making selection of appropriate recipients an important ethical and societal issue. Survival rates after transplantation rose in the 1980s with the use of cyclosporine and have remained relatively consistent since then, although recipients older than 65 years or younger than 1 year have lower survival rates than recipients of other ages. Although immunosuppressive drugs have helped establish cardiac transplantation as a successful procedure, risks of opportunistic infection and rejection, as well as coronary arteriopathy, have led to development of new immunosuppressive agents currently under study. Future alternatives to the current technology of cardiac allotransplantation may include xenotransplantation and/ or nonbiological replacement of the heart with mechanical devices.	Stanford Univ, Ctr Med, Stanford, CA 94305 USA	Stanford University	Hunt, SA (corresponding author), Stanford Univ, Ctr Med, Falk Cardiovasc Res Bldg, Stanford, CA 94305 USA.							ARMITAGE JM, 1991, TRANSPLANT P, V23, P1149; Bach FH, 1998, NAT MED, V4, P141, DOI 10.1038/nm0298-141; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Billingham M E, 1990, J Heart Transplant, V9, P587; BOUCHART F, 1993, J HEART LUNG TRANSPL, V12, P427; BURKE MN, 1995, CIRCULATION, V91, P72, DOI 10.1161/01.CIR.91.1.72; BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110; Callard P, 1975, Adv Nephrol Necker Hosp, V5, P333; CAVES PK, 1974, LANCET, V1, P821; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; COSTANZONORDIN MR, 1988, CIRCULATION, V78, P47; COSTANZONORDIN MR, 1992, TRANSPLANTATION, V53, P808, DOI 10.1097/00007890-199204000-00021; DELEUZE PH, 1995, J THORAC CARDIOV SUR, V109, P731, DOI 10.1016/S0022-5223(95)70355-1; DEVRIES WC, 1984, NEW ENGL J MED, V310, P273, DOI 10.1056/NEJM198402023100501; DREYFUS G, 1991, ANN THORAC SURG, V52, P1181, DOI 10.1016/0003-4975(91)91311-I; EHRMAN J, 1992, J APPL PHYSIOL, V73, P260, DOI 10.1152/jappl.1992.73.1.260; Gag SZ, 1996, J AM COLL CARDIOL, V28, P673, DOI 10.1016/0735-1097(96)00201-X; GAO SZ, 1989, AM J CARDIOL, V64, P1093, DOI 10.1016/0002-9149(89)90858-8; GAO SZ, 1989, CIRCULATION, V80, P100; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; GILBERT EM, 1987, AM J MED, V82, P202, DOI 10.1016/0002-9343(87)90056-8; Givertz MM, 1997, CIRCULATION, V96, P232; Grady KL, 1996, J HEART LUNG TRANSPL, V15, P749; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GREGORY CR, 1993, TRANSPLANT P, V25, P770; GRIFFITH BP, 1988, ANN SURG, V208, P371, DOI 10.1097/00000658-198809000-00015; GRIFFITH BP, 1989, NEW ENGL J MED, V47, P142; GRINYO J, 1995, LANCET, V345, P1321; HALLE AA, 1995, J AM COLL CARDIOL, V26, P120, DOI 10.1016/0735-1097(95)00124-I; HANTO DW, 1981, TRANSPLANT P, V13, P756; HANTO DW, 1995, ANNU REV MED, V46, P381; HOSENPUD JD, 1994, JAMA-J AM MED ASSOC, V271, P1844, DOI 10.1001/jama.271.23.1844; Hosenpud JD, 1998, J HEART LUNG TRANSPL, V17, P656; Hunt SA, 1993, J AM COLL CARDIOL, V22, P1; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Keogh A, 1996, J HEART LUNG TRANSPL, V15, P231; KEOGH AM, 1992, J HEART LUNG TRANSPL, V11, P892; Keown P, 1996, TRANSPLANTATION, V61, P1029; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KORMOS RL, 1994, ANN THORAC SURG, V57, P51, DOI 10.1016/0003-4975(94)90364-6; KRAKAUER H, 1995, TRANSPLANTATION, V59, P840, DOI 10.1097/00007890-199503270-00007; LEVIN B, 1989, TRANSPLANT P, V21, P1793; LOWER R R, 1960, Surg Forum, V11, P18; LOWER RR, 1962, AM J SURG, V104, P302, DOI 10.1016/0002-9610(62)90332-X; LUDWIG J, 1987, HEPATOLOGY, V7, P476, DOI 10.1002/hep.1840070311; Mancini D, 1997, CIRCULATION, V96, P6; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; *MED PROGR, 1987, FED REGISTER, V52, P10935; MEHRA MR, 1995, J HEART LUNG TRANSPL, V14, P632; MEISER BM, 1994, TRANSPLANTATION, V57, P563; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; NEUHAUS P, 1994, LANCET, V344, P423; OLIVARI MT, 1989, CIRCULATION, V80, P111; OLSEN SL, 1990, J HEART TRANSPLANT, V9, pA20; OYER PE, 1983, TRANSPLANT P, V15, P1247; Park JW, 1996, J HEART LUNG TRANSPL, V15, P572; PFLUGFELDER PW, 1987, J AM COLL CARDIOL, V10, P336, DOI 10.1016/S0735-1097(87)80016-5; PHAM SM, 1996, J THORAC CARDIOV SUR, V111, P1; Platt JL, 1997, AM J MED SCI, V313, P315, DOI 10.1097/00000441-199705000-00012; POPE SE, 1980, AM J CARDIOL, V46, P213, DOI 10.1016/0002-9149(80)90060-0; PORTNER PM, 1989, ANN THORAC SURG, V47, P142, DOI 10.1016/0003-4975(89)90256-7; Rickenbacher PR, 1996, TRANSPLANTATION, V61, P46, DOI 10.1097/00007890-199601150-00011; SAVIN WM, 1982, HEART TRANSPLANTATIO, V1, P72; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; STARK RP, 1991, NEW ENGL J MED, V324, P1791, DOI 10.1056/NEJM199106203242507; STARNES VA, 1989, CIRCULATION, V80, P79; STARZL TE, 1984, LANCET, V1, P583; STEVENSON LW, 1990, CIRCULATION, V81, P78, DOI 10.1161/01.CIR.81.1.78; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; STGOAR FG, 1992, CIRCULATION, V85, P979, DOI 10.1161/01.CIR.85.3.979; THOMPSON G, 1995, LANCET, V346, P766; TILNEY NL, 1991, TRANSPLANTATION, V52, P389, DOI 10.1097/00007890-199109000-00001; Trento A, 1996, Semin Thorac Cardiovasc Surg, V8, P126; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; VALANTINE HA, 1995, TRANSPLANT P, V27, P49; Valantine Hannah A., 1995, Journal of Heart and Lung Transplantation, V14, pS58; WILSON RF, 1991, CIRCULATION, V83, P1210, DOI 10.1161/01.CIR.83.4.1210; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	79	72	74	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1692	1698		10.1001/jama.280.19.1692	http://dx.doi.org/10.1001/jama.280.19.1692			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9832002	Bronze			2022-12-28	WOS:000076980700036
J	Golden, BL; Gooding, AR; Podell, ER; Cech, TR				Golden, BL; Gooding, AR; Podell, ER; Cech, TR			A preorganized active site in the crystal structure of the Tetrahymena ribozyme	SCIENCE			English	Article							GROUP-I INTRON; SELF-SPLICING INTRONS; BINDING-SITE; CATALYTIC CORE; METAL-ION; ELECTRON-MICROSCOPY; TERTIARY STRUCTURE; DIFFRACTION DATA; GAAA TETRALOOP; RNA CATALYSIS	Group I introns possess a single active site that catalyzes the two sequential reactions of self-splicing. An RNA comprising the two domains of the Tetrahymena thermophila group I intron catalytic core retains activity, and the 5.0 angstrom crystal structure of this 247-nucleotide ribozyme is now described. Close packing of the two domains forms a shallow cleft capable of binding the short helix that contains the 5' splice site. The helix that provides the binding site for the guanosine substrate deviates significantly from A-form geometry, providing a tight binding pocket. The binding pockets for both the 5' splice site helix and guanosine are formed and oriented in the absence of these substrates. Thus, this large ribozyme is largely preorganized for catalysis, much Like a globular protein enzyme.	Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Golden, BL (corresponding author), Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Campus Box 215, Boulder, CO 80309 USA.	bgolden@petunia.colorado.edu; Cech@colorado.edu		Golden, Barbara/0000-0002-9741-882X				ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Berens C, 1998, CHEM BIOL, V5, P163, DOI 10.1016/S1074-5521(98)90061-8; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BRUNGER AT, IN PRESS ACTA CRYS D; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; CAPRARA MG, 1994, GENE, V143, P29, DOI 10.1016/0378-1119(94)90600-9; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1993, RNA WORLD, P239; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CHRISTIAN EL, 1992, J MOL BIOL, V228, P743, DOI 10.1016/0022-2836(92)90861-D; Cohen SB, 1997, J AM CHEM SOC, V119, P6259, DOI 10.1021/ja9707421; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; Downs WD, 1996, RNA, V2, P718; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GEWIRTH D, 1994, HKL MANUAL DESCRIPTI; Golden BL, 1997, J MOL BIOL, V270, P711, DOI 10.1006/jmbi.1997.1155; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MCCONNELL T, 1995, THESIS U COLORADO; McKay DB, 1996, RNA, V2, P395; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NAKAMURA TM, 1995, EMBO J, V14, P4849, DOI 10.1002/j.1460-2075.1995.tb00166.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ortoleva-Donnelly L, 1998, RNA, V4, P498, DOI 10.1017/S1355838298980086; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT, P80; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sclavi B, 1998, SCIENCE, V279, P1940, DOI 10.1126/science.279.5358.1940; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; Szewczak AA, 1997, RNA, V3, P838; Tanner MA, 1997, SCIENCE, V275, P847, DOI 10.1126/science.275.5301.847; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WARING RB, 1985, CELL, V40, P371, DOI 10.1016/0092-8674(85)90151-5; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	59	279	288	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					259	264		10.1126/science.282.5387.259	http://dx.doi.org/10.1126/science.282.5387.259			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9841391				2022-12-28	WOS:000076370200037
J	Banks, M				Banks, M			How to do it - Get your book published	BRITISH MEDICAL JOURNAL			English	Article									BMJ Publishing Grp, BMJ Books, London WC1H 9JR, England	BMJ Publishing Group Ltd	Banks, M (corresponding author), BMJ Publishing Grp, BMJ Books, London WC1H 9JR, England.							TURNER B, 1997, WRITERS HDB; 1998, WRITERS ARTISTS YB; 1998, WHITAKERS BOOKS PRIN	3	1	1	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1715	1718		10.1136/bmj.317.7174.1715	http://dx.doi.org/10.1136/bmj.317.7174.1715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857141	Green Published			2022-12-28	WOS:000077742300031
J	Smith, GCS; Smith, MFS; McNay, MB; Fleming, JEE				Smith, GCS; Smith, MFS; McNay, MB; Fleming, JEE			First-trimester growth and the risk of low birth weight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CROWN-RUMP LENGTH; AGE	Background Previous studies have demonstrated a correlation between first-trimester size and birth weight. it is not known, however, whether low birth weight is related to first-trimester growth. We sought to determine whether the risk of low birth weight and birth weight that was low for gestational age is related to the size of the embryo or the fetus in the first trimester. Methods From a data base of ultrasound records of more than 30,000 pregnancies, We identified women who had no important medical problems, a normal menstrual history, and a first-trimester ultrasound scan in which the crown-rump length of the embryo or fetus had been measured. We examined the relation between the outcome of 4229 pregnancies and the difference between the measured and the expected crown-rump length in the first trimester, expressed as equivalent days of growth. Results A first-trimester crown-rump length that was two to six days smaller than expected was associated with an increased risk las compared with a normal or slightly larger than expected crown-rump length) of a birth weight below 2500 g (relative risk, 1.8; 95 percent confidence interval, 1.3 to 2.4), a birth weight below 2500 g at term (relative risk, 2.3; 95 percent confidence interval, 1.4 to 3.8), a birth weight below the fifth percentile for gestational age (relative risk, 3.0; 95 percent confidence interval, 2.0 to 4.4), and delivery between 24 and 32 weeks of gestation (relative risk, 2.1; 95 percent confidence interval, 1.1 to 4.0), but not with delivery between 33 and 36 weeks (relative risk, 1.0; 95 percent confidence interval, 0.7 to 1.5). Conclusions Suboptimal first-trimester growth may be associated with low birth weight, low birthweight percentile, and premature delivery. (N Engl J Med 1998;339:1817-22.) (C) 1998, Massachusetts Medical Society.	Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA; Univ Glasgow, Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow, Lanark, Scotland	Cornell University; University of Glasgow	Smith, GCS (corresponding author), Cornell Univ, Coll Vet Med, Dept Physiol, Lab Pregnancy & Newborn Res, Ithaca, NY 14853 USA.		Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAM AH, 1979, BRIT J OBSTET GYNAEC, V86, P521, DOI 10.1111/j.1471-0528.1979.tb10803.x; Aitken D. A., 1995, P12; Barker DJP, 1992, FETAL INFANT ORIGINS; BUCK GM, 1989, AM J EPIDEMIOL, V129, P874, DOI 10.1093/oxfordjournals.aje.a115221; Campbell S., 1989, RCOG STUD GROUP P FE, P251; DAYA S, 1993, AM J OBSTET GYNECOL, V168, P903, DOI 10.1016/S0002-9378(12)90842-X; DICKEY RP, 1993, HUM REPROD, V8, P331, DOI 10.1093/oxfordjournals.humrep.a138046; EVANS E, 1990, CLIN APPL ULTRASONIC; FORBES JF, 1983, BRIT J OBSTET GYNAEC, V90, P297, DOI 10.1111/j.1471-0528.1983.tb08913.x; GLUCKMAN PD, 1984, FETAL PHYSL MED BASI, V6, P511; HOLST K, 1989, AM J PERINAT, V6, P258, DOI 10.1055/s-2007-999588; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KUSTERMANN A, 1992, BRIT J OBSTET GYNAEC, V99, P38, DOI 10.1111/j.1471-0528.1992.tb14389.x; LENTON EA, 1985, CLIN REPROD ENDOCRIN, P81; Luke B, 1998, PRENAT NEONAT MED, V3, P32; NOVY MJ, 1995, CLIN OBSTET GYNECOL, V38, P790, DOI 10.1097/00003081-199538040-00013; ROBINSON HP, 1975, BRIT J OBSTET GYNAEC, V82, P702, DOI 10.1111/j.1471-0528.1975.tb00710.x; ROSSAVIK IK, 1988, FERTIL STERIL, V49, P1012	18	253	257	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1817	1822		10.1056/NEJM199812173392504	http://dx.doi.org/10.1056/NEJM199812173392504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854117				2022-12-28	WOS:000077545800004
J	Ruvkun, G; Hobert, O				Ruvkun, G; Hobert, O			The taxonomy of developmental control in Caenorhabditis elegans	SCIENCE			English	Review							C-ELEGANS; GENE ENCODES; DROSOPHILA; PROTEIN; PATHWAY; FAMILY; HEDGEHOG; MESODERM; NEURONS; MEMBER	The Caenorhabditis elegans genome sequence was surveyed for transcription factor and signaling gene families that have been shown to regulate development in a variety of species. About 10 to 25 percent of the genes in most of the gene families already have been genetically analyzed in C. elegans, about half of the genes detect probable orthologs in other species, and about 10 to 25 percent of the genes are, at present, unique to C. elegans. Caenorhabditis elegans is also missing genes that are found in vertebrates and other invertebrates. Thus the genome sequence reveals universals in developmental control that are the Legacy of metazoan complexity before the Cambrian explosion, as well as genes that have been more recently invented or Lost in particular phylogenetic lineages.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Genet,Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Ruvkun, G (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Genet,Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@frodo.mgh.harvard.edu		Hobert, Oliver/0000-0002-7634-2854				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Antebi A, 1998, DEVELOPMENT, V125, P1191; AWGULEWITSCH A, 1992, NATURE, V358, P341, DOI 10.1038/358341a0; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Colavita A, 1998, SCIENCE, V281, P706, DOI 10.1126/science.281.5377.706; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREENWALD I, 1998, GENE DEV, V12, P1751; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Harfe BD, 1998, GENE DEV, V12, P2623, DOI 10.1101/gad.12.16.2623; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Hou XS, 1997, TRENDS GENET, V13, P105, DOI 10.1016/S0168-9525(97)01006-8; INOUE T, COMMUNICATION; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Korf I, 1998, DEVELOPMENT, V125, P2469; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Kostrouchova M, 1998, DEVELOPMENT, V125, P1617; KUWABARA P, COMMUNICATION; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MEYER BJ, 1997, C ELEGANS, V2, P209; MILLER DM, 1992, NATURE, V355, P841, DOI 10.1038/355841a0; MORGAN WR, 1993, MOL CELL BIOL, V13, P7133, DOI 10.1128/MCB.13.11.7133; Mushegian AR, 1998, GENOME RES, V8, P590, DOI 10.1101/gr.8.6.590; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; PADGETT P, COMMUNICATION; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D, 1997, ELEGANS, VII; RIDDLE DL, COMMUNICATION; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schnabel R., 1997, C ELEGANS, P361; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Slack F, 1997, ANNU REV GENET, V31, P611, DOI 10.1146/annurev.genet.31.1.611; SLUDER A, IN PRESS GENOME RES; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; TEHRING W, 1994, ANNU REV BIOCHEM, V63, P487; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WOOD WB, 1988, NEMATODE C; WOOD WB, COMMUNICATION; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; [No title captured]	63	261	305	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2033	2041		10.1126/science.282.5396.2033	http://dx.doi.org/10.1126/science.282.5396.2033			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851920				2022-12-28	WOS:000077467100038
J	Song, HB; Endow, SA				Song, HB; Endow, SA			Decoupling of nucleotide- and microtubule-binding sites in a kinesin mutant	NATURE			English	Article							MOTOR DOMAIN; CRYSTAL-STRUCTURE; MITOTIC SPINDLE; PROTEIN; MYOSIN; KAR3; NCD; PURIFICATION; POLYMERASE	Molecular motors require ATP to move along microtubules or actin filaments. To understand how molecular motors function, it is crucial to know how binding of the motor to its filamentous track stimulates the hydrolysis of ATP by the motor, enabling it to move along the filament. A mechanism for the enhanced ATP hydrolysis has not been elucidated, but it is generally accepted that conformational changes in the motor proteins(1-3) occur when they bind to microtubules or actin filaments, facilitating the release of ADP. Here we report that a mutation in the motor domain of the microtubule motor proteins Kar3 and Ncd uncouples nucleotide- and microtubule-binding by the proteins, preventing activation of the motor ATPase by microtubules. Unlike the wild-type motors, the mutants bind tightly to both ADP and microtubules, indicating that interactions between the nucleotide- and microtubule-binding sites are blocked. The region of the motor that includes the mutated amino arid could transmit or undergo a conformational change required to convert the motor ATPase into a microtubule-stimulated state.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Endow, SA (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.			Endow, Sharyn A./0000-0002-0907-8889	NIGMS NIH HHS [R01 GM046225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BascomSlack CA, 1997, J CELL BIOL, V139, P459, DOI 10.1083/jcb.139.2.459; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYT MA, 1993, GENETICS, V135, P35; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; Song H, 1996, BIOCHEMISTRY-US, V35, P11203, DOI 10.1021/bi960997b; Song H, 1997, BIOTECHNIQUES, V22, P82, DOI 10.2144/97221bm18; Song H, 1997, P NATL ACAD SCI USA, V94, P322, DOI 10.1073/pnas.94.1.322; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	23	51	52	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					587	590		10.1038/25153	http://dx.doi.org/10.1038/25153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859995				2022-12-28	WOS:000077466800061
J	Koch, H				Koch, H			Dipsticks and convulsions	LANCET			English	Article							SULFITE OXIDASE DEFICIENCY; EXCRETION		St Marienhosp, Klin Kinder & Jugendmed, D-49375 Vechta, Germany	St. Marien Hospital	Koch, H (corresponding author), St Marienhosp, Klin Kinder & Jugendmed, D-49375 Vechta, Germany.							DURAN M, 1981, CLIN CHIM ACTA, V111, P47, DOI 10.1016/0009-8981(81)90419-8; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; VANDERKLEIVANMOORSEL JM, 1991, EUR J PEDIATR, V150, P196, DOI 10.1007/BF01963565	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1824	1824		10.1016/S0140-6736(98)09360-X	http://dx.doi.org/10.1016/S0140-6736(98)09360-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851384				2022-12-28	WOS:000077337900012
J	Polleux, F; Giger, RJ; Ginty, DD; Kolodkin, AL; Ghosh, A				Polleux, F; Giger, RJ; Ginty, DD; Kolodkin, AL; Ghosh, A			Patterning of cortical efferent projections by semaphorin-neuropilin interactions	SCIENCE			English	Article							EXPRESSION; RECEPTOR; GROWTH		Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Ghosh, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Polleux, Franck/H-9948-2014	Polleux, Franck/0000-0003-4313-0481	NINDS NIH HHS [NS534814, NS36176, NS35165] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036176, R01NS035165, R37NS035165] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; Catalano SM, 1998, MOL CELL NEUROSCI, V11, P173, DOI 10.1006/mcne.1998.0687; Chedotal A, 1998, DEVELOPMENT, V125, P4313; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GIGER RJ, UNPUB; GIGER RJ, IN PRESS NEURON; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; POLLEUX F, UNPUB; Skaliora I, 1998, EUR J NEUROSCI, V10, P1215, DOI 10.1046/j.1460-9568.1998.00128.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1	17	207	211	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1904	1906		10.1126/science.282.5395.1904	http://dx.doi.org/10.1126/science.282.5395.1904			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836643				2022-12-28	WOS:000077338100053
J	Dorsky, RI; Moon, RT; Raible, DW				Dorsky, RI; Moon, RT; Raible, DW			Control of neural crest cell fate by the Wnt signalling pathway	NATURE			English	Article							XENOPUS EMBRYOS; NERVOUS-SYSTEM; BETA-CATENIN; ZEBRAFISH; EXPRESSION; DIFFERENTIATION; RESTRICTIONS; LINEAGE	Environmental signals are important in the development of neural crest, during which process multipotent progenitor must choose from several fates(1-3). However, the nature of these environmental signals is unknown. A previous fate map of zebrafish cranial neural crest showed that lineage-restricted clones of pigment cells arise hom medial cells near the neural keel, and that clones of neurons arise from lateral cells farther from the neural keel(4), Wnt-1 and Wnt-3a are candidate genes for influencing neural crest fate, as they are expressed next to medial, but not lateral, crest cells. Here we determine the role of Wnt signals in modulating the fate of neural crest by injecting messenger RNAs into single, premigratory neural crest cells of zebrafish, Lineage analysis of injected cells shows that activation of Wnt signalling by injection of mRNA encoding cytoplasmic beta-catenin promotes pigment-cell formation at the expense of neurons and glia. Conversely, inhibition of the Wnt pathway, by injection of mRNAs encoding either a truncated form of the transcription factor Tcf-3 or a dominant-negative Wnt, promotes neuronal fates at the expense of pigment cells. We conclude that endogenous Wnt signalling normality promotes pigment-cell formation by medial crest cells and thereby contributes to the diversity of neural crest cell fates.	Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Dorsky, RI (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.		Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; Raible, David/0000-0002-5342-5841				Appel B, 1995, DEVELOPMENT, V121, P4117; Baker CVH, 1997, DEVELOPMENT, V124, P3077; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chang CB, 1998, DEV BIOL, V194, P129, DOI 10.1006/dbio.1997.8820; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; FRASER MB, 1991, DEVELOPMENT S, V2, P17; Henion PD, 1997, DEVELOPMENT, V124, P4351; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; HOPPLER S, 1996, GENE DEV, V10, P3805; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; Kozopas KM, 1998, GENE DEV, V12, P1155, DOI 10.1101/gad.12.8.1155; KRAUSS S, 1992, DEVELOPMENT, V116, P249; LaBonne C, 1998, DEVELOPMENT, V125, P2403; LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012-1606(74)90291-7; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Odenthal J, 1998, DEV GENES EVOL, V208, P245, DOI 10.1007/s004270050179; Raible DW, 1996, DEVELOPMENT, V122, P501; Reissmann E, 1996, DEVELOPMENT, V122, P2079; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SCHILLING TF, 1994, DEVELOPMENT, V120, P483; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	26	381	394	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					370	373		10.1038/24620	http://dx.doi.org/10.1038/24620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845073				2022-12-28	WOS:000077204000050
J	Kinoshita, S; Chen, BK; Kaneshima, H; Nolan, GP				Kinoshita, S; Chen, BK; Kaneshima, H; Nolan, GP			Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYCLOSPORINE-A; TRANSCRIPTION FACTORS; NONDIVIDING CELLS; CYCLOPHILIN-A; DNA-SYNTHESIS; TYPE-1 DNA; KAPPA-B; INFECTION; LYMPHOCYTES	Post HIV-1 entry, productive HIV-1 infection of primary T cells requires overcoming several cellular blocks to provirus establishment and replication. Activation of unknown host intracellular events overcomes such inhibitory steps and is concomitant with HIV-1 replication. We show that the transcription factor NFATc was sufficient as a cellular factor to induce a highly permissive state for HIV-1 replication in primary CD4(+) T cells. NFATc overcame a blockade at reverse transcription and permitted active HIV-1 replication. Pharmacologic blockade of endogenous NFAT activity by FK506 or CsA inhibited synthesis of reverse transcription and also potently blocked HIV-1 replication. T cells therefore can become competent for HIV-1 replication by control of regulated host factors such as the NFATc transcription factor. The host mechanisms regulated by such permissivity factors are potential targets for anti-HIV-1 therapy.	Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Rockefeller Univ, New York, NY 10021 USA; Systemix Inc, Palo Alto, CA 94303 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Rockefeller University; Novartis	Nolan, GP (corresponding author), Stanford Univ, Med Ctr, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	gnolan@CMGM.stanford.edu	Nolan, Garry/AAE-7903-2019	Chen, Benjamin K/0000-0002-5404-1997; Nolan, Garry/0000-0002-8862-9043	NIAID NIH HHS [P01-AI39646, AI27666] Funding Source: Medline; NIAMS NIH HHS [AR44565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039646, U01AI027666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; Borvak J, 1996, J INFECT DIS, V174, P850, DOI 10.1093/infdis/174.4.850; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOLKS T, 1986, J IMMUNOL, V136, P4049; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GRILLI M, 1993, INT REV CYTOL, V143, P1; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; JAIN JN, 1993, J IMMUNOL, V151, P837; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LI GR, 1993, J VIROL, V67, P3969, DOI 10.1128/JVI.67.7.3969-3977.1993; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sinoussi F. B., 1983, SCIENCE, V220, P868; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMSON AW, 1995, ADV EXP MED BIOL, V374, P211; TOBA K, 1995, J IMMUNOL METHODS, V182, P193, DOI 10.1016/0022-1759(95)00050-K; VANDEKERCKHOVE BAE, 1992, J EXP MED, V175, P1033, DOI 10.1084/jem.175.4.1033; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	40	192	195	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					595	604		10.1016/S0092-8674(00)81630-X	http://dx.doi.org/10.1016/S0092-8674(00)81630-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845362	Bronze			2022-12-28	WOS:000077253700007
J	Litvan, I				Litvan, I			Parkinsonian features - When are they Parkinson disease?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-DIAGNOSIS; ACCURACY		Henry M Jackson Fdn, Def & Vet Head Injury Program, Neuropharmacol Unit, Bethesda, MD USA; NINDS, NIH, Bethesda, MD 20892 USA	Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Litvan, I (corresponding author), Fed Bldg,Room 714, Bethesda, MD 20892 USA.	Litvan1@helix.nih.gov	Litvan, Irene/X-9319-2018	Litvan, Irene/0000-0002-3485-3445				Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; KOLLER WC, 1992, NEUROLOGY, V42, P6; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; Rajput A H, 1997, Parkinsonism Relat Disord, V3, P159, DOI 10.1016/S1353-8020(97)00030-8; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; Shoulson I, 1998, ANN NEUROL, V43, P318; WARD CD, 1990, ADV NEUROL, V53, P245; Wenning GK, 1998, J NEUROL NEUROSUR PS, V64, P184, DOI 10.1136/jnnp.64.2.184	12	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1654	1655		10.1001/jama.280.19.1654	http://dx.doi.org/10.1001/jama.280.19.1654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831984				2022-12-28	WOS:000076980700012
J	Hall, W; Solowij, N				Hall, W; Solowij, N			Adverse effects of cannabis	LANCET			English	Article							NON-TOBACCO CIGARETTES; DRUG-USE; MARIJUANA SMOKING; SWEDISH CONSCRIPTS; GENERAL-POPULATION; COCAINE USE; SCHIZOPHRENIA; ADOLESCENCE; IMPACT; RISK	Cannabis is the most widely used illicit drug in many developed societies. Its health and psychological effects are not well understood and remain the subject of much debate, with opinions on its risks polarised along the lines of proponents' views on what its legal status should be. An unfortunate consequence of this polarisation of opinion has been the absence of any consensus on what health information the medical profession should give to patients who are users or potential users of cannabis. There is conflicting evidence about many of the effects of cannabis use, so we summarise the evidence on the most probable adverse health and psychological consequences of acute and chronic use. This uncertainty, however, should not prevent medical practitioners from advising patients about the most likely ill-effects of their cannabis use. Here we make some suggestions about the advice doctors can give to patients who use, or are contemplating the use, of this drug.	Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Hall, W (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096; Solowij, Nadia/0000-0002-5222-5637				ABEL EL, 1985, NIDA RES MONOGRAPH, V59; Adams IB, 1996, ADDICTION, V91, P1585, DOI 10.1111/j.1360-0443.1996.tb02264.x; ALLEBECK P, 1991, PHYSIOPATHOLOGY ILLI; ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; ANDREASSON S, 1990, SCAND J SOC MED, V18, P9; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Bachman J. G, 1997, SMOKING DRINKING DRU; Bloch E, 1983, CANNABIS HLTH HAZARD; BLOOM JW, 1987, BMJ-BRIT MED J, V295, P1516, DOI 10.1136/bmj.295.6612.1516; British Medical Association, 1997, THER US CANN; CAPLAN GA, 1990, CANCER, V66, P1005, DOI 10.1002/1097-0142(19900901)66:5<1005::AID-CNCR2820660535>3.0.CO;2-H; Chait L.D., 1992, MARIJUANA CANNABINOI; CHANNABASAVANNA S, 1998, HLTH EFFECTS CANNABI; CHEN K, 1995, AM J PUBLIC HEALTH, V85, P41, DOI 10.2105/AJPH.85.1.41; CHESHER G, 1995, EFFECTS DRUGS OTHER, P67; CHOPRA GS, 1974, ARCH GEN PSYCHIAT, V30, P24; COATES RA, 1990, AM J EPIDEMIOL, V132, P717, DOI 10.1093/oxfordjournals.aje.a115713; COMPTON DR, 1990, ADV ALCOHOL SUBST AB, V9, P128; COMPTON DR, 1993, PHARM ASPECTS DRUG D; DER G, 1990, LANCET, V335, P513, DOI 10.1016/0140-6736(90)90745-Q; Fergusson DM, 1997, ADDICTION, V92, P279; Fletcher JM, 1996, ARCH GEN PSYCHIAT, V53, P1051; Fligiel SEG, 1997, CHEST, V112, P319, DOI 10.1378/chest.112.2.319; FRIED PA, 1995, LIFE SCI, V56, P2159, DOI 10.1016/0024-3205(95)00203-I; FRIED PA, 1993, CLIN OBSTET GYNECOL, V36, P319, DOI 10.1097/00003081-199306000-00011; FRIED PA, 1996, NIDA RES MONOGRAPH, V164; GRUFFERMAN S, 1993, CANCER CAUSE CONTROL, V4, P217; HALL W, 1998, HLTH EFFECTS CANNABI; Hall W, 1994, NATL DRUG STRATEGY M, V25; HARTEL C, 1998, HLTH EFFECTS CANNABI; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; JONES RT, 1981, J CLIN PHARMACOL, V21, pS143, DOI 10.1002/j.1552-4604.1981.tb02589.x; KALANT H, 1998, HLTH EFFECTS CANNABI; KANDEL DB, 1988, DRUGS SOC, V3, P55; KANDEL DB, 1992, VULNERABILITY DRUG A; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KLEIN TW, 1998, HLTH EFFECTS CANNABI; KUITJEN RR, 1992, CANCER RES, V52, P782; LEUCHTENBERGER C, 1983, CANNABIS HLTH HAZARD; LINSZEN DH, 1990, SCHIZOPHRENIA B, V16, P87; MUNSON AE, 1983, CANNABIS HLTH HAZARD; *NAT I DRUG AB, 1997, REP POSS MED US MAR; NEWCOMBE T, 1988, CONSEQUENCES ADOLESC; OSGOOD DW, 1988, AM SOCIOL REV, V53, P81, DOI 10.2307/2095734; Pertwee R. G, 1995, CANNABINOID RECEPTOR; POPE HG, 1995, DRUG ALCOHOL DEPEN, V38, P25, DOI 10.1016/0376-8716(95)01097-I; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Programme on Substance Abuse, 1997, CANN HLTH PERSP RES; RICHARDSON GA, 1993, CLIN OBSTET GYNECOL, V36, P302, DOI 10.1097/00003081-199306000-00010; Robbe H.W.J., 1994, INFLUENCE MARIJUANA; ROBISON LL, 1989, CANCER, V63, P1904; SHERRILL DL, 1991, INT J EPIDEMIOL, V20, P132, DOI 10.1093/ije/20.1.132; SHIONO PH, 1995, AM J OBSTET GYNECOL, V172, P19, DOI 10.1016/0002-9378(95)90078-0; Sidney S, 1997, AM J PUBLIC HEALTH, V87, P585, DOI 10.2105/AJPH.87.4.585; Smiley A., 1998, HLTH EFFECTS CANNABI; Solowij N., 1998, CANNABIS COGNITIVE F; SRIDHAR KS, 1994, J PSYCHOACTIVE DRUGS, V26, P285, DOI 10.1080/02791072.1994.10472442; STEPHENS RS, 1993, ADDICTIVE BEHAV LIFE; STEPHENS RS, 1993, J CONSULT CLIN PSYCH, V61, P1110; TASHKIN D, 1998, HLTH EFFECTS CANNABI; Tashkin DP, 1997, AM J RESP CRIT CARE, V155, P141, DOI 10.1164/ajrccm.155.1.9001303; TASHKIN DP, 1993, WESTERN J MED, V158, P635; TASHKIN DP, 1990, NATL I DRUG ABUSE RE, V99; TAYLOR FM, 1988, SOUTHERN MED J, V81, P1213, DOI 10.1097/00007611-198810000-00003; Terhune KW, 1986, ALCOHOL DRUGS DRIVIN, V2, P1; THOMAS HUW, 1993, BRIT J PSYCHIAT, V163, P141, DOI 10.1192/bjp.163.2.141; THORNICROFT G, 1990, BRIT J PSYCHIAT, V157, P25, DOI 10.1192/bjp.157.1.25; TIEN AY, 1990, J NERV MENT DIS, V178, P473, DOI 10.1097/00005053-199017880-00001; TURNER WM, 1990, SCHIZOPHRENIA BULL, V16, P87, DOI 10.1093/schbul/16.1.87; WEISBECK GA, 1996, ADDICTION, V91, P1469; Wickelgren I, 1997, SCIENCE, V276, P1967, DOI 10.1126/science.276.5321.1967; WU TC, 1988, NEW ENGL J MED, V318, P347, DOI 10.1056/NEJM198802113180603; YAMAGUCHI K, 1984, AM J PUBLIC HEALTH, V74, P668, DOI 10.2105/AJPH.74.7.668; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	75	500	512	3	154	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1611	1616		10.1016/S0140-6736(98)05021-1	http://dx.doi.org/10.1016/S0140-6736(98)05021-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138XT	9843121				2022-12-28	WOS:000076998900045
J	Lee, KM; Chuang, E; Griffin, M; Khattri, R; Hong, DK; Zhang, WG; Straus, D; Samelson, LE; Thompson, CB; Bluestone, JA				Lee, KM; Chuang, E; Griffin, M; Khattri, R; Hong, DK; Zhang, WG; Straus, D; Samelson, LE; Thompson, CB; Bluestone, JA			Molecular basis of T cell inactivation by CTLA-4	SCIENCE			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLATION; RECEPTOR; ACTIVATION; KINASES; ZETA; EXPRESSION; SUBUNIT; COMPLEX; DOMAIN	CTLA-4, a negative regulator of T cell function, was found to associate with the T cell receptor (TCR) complex zeta chain in primary T cells, The association of TCR zeta with CTLA-4, reconstituted in 293 transfectants, was enhanced by p56(lck)- induced tyrosine phosphorylation. Coexpression of the CTLA-4-associated tyrosine phosphatase, SHP-2, resulted in dephosphorylation of TCR zeta bound to CTLA-4 and abolished the p56(lck)-inducible TCR zeta-CTLA-4 interaction. Thus, CTLA-4 inhibits TCR signal transduction by binding to TCR zeta and inhibiting tyrosine phosphorylation after T cell activation. These findings have broad implications for the negative regulation of T cell function and T cell tolerance.	Univ Chicago, Ben May Inst Canc Res, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Pathol & Med, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Chicago	Bluestone, JA (corresponding author), Univ Chicago, Ben May Inst Canc Res, Howard Hughes Med Inst, Chicago, IL 60637 USA.		Griffin, Matthew/A-1688-2009	Griffin, Matthew/0000-0002-8701-8056; Lee, Kyung-Mi/0000-0002-5378-9258; Hong, David/0000-0003-3152-0618	NIAID NIH HHS [P01 AI35294-6] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035294] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1995, J IMMUNOL, V154, P985; Blair PJ, 1998, J IMMUNOL, V160, P12; Bluestone JA, 1997, J IMMUNOL, V158, P1989; Bradshaw JD, 1997, BIOCHEMISTRY-US, V36, P15975, DOI 10.1021/bi971762i; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Chuang E, 1997, J IMMUNOL, V159, P144; CHUANG E, IN PRESS J IMMUNOL; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GRIFFIN MCA, UNPUB; HOULDEN BA, 1988, J IMMUNOL, V141, P3753; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; KUPFER A, 1988, P NATL ACAD SCI USA, V85, P8216, DOI 10.1073/pnas.85.21.8216; Lee K. T., UNPUB; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALLACE PM, 1994, TRANSPLANTATION, V58, P602, DOI 10.1097/00007890-199409150-00013; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	28	507	530	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2263	2266		10.1126/science.282.5397.2263	http://dx.doi.org/10.1126/science.282.5397.2263			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856951				2022-12-28	WOS:000077645800049
J	Sizmann, N; Korting, HC				Sizmann, N; Korting, HC			Drug points - Prolonged urticaria with 17-1A antibody	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CARCINOMA		Univ Munich, Klinikum Innenstadt, Dept Dermatol, D-80337 Munich, Germany	University of Munich	Sizmann, N (corresponding author), Univ Munich, Klinikum Innenstadt, Dept Dermatol, D-80337 Munich, Germany.							FAGERBERG J, 1995, P NATL ACAD SCI USA, V92, P4773, DOI 10.1073/pnas.92.11.4773; FAGERBERG J, 1985, CANC IMMUNOL IMMUNOT, V42, P81; HALLER DG, 1995, EUR J CANCER, V31A, P1255, DOI 10.1016/0959-8049(95)00258-K; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1998	317	7173					1631	1631		10.1136/bmj.317.7173.1631	http://dx.doi.org/10.1136/bmj.317.7173.1631			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848903	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077602100027
J	Rougier, GW; Wible, JR; Novacek, MJ				Rougier, GW; Wible, JR; Novacek, MJ			Implications of Deltatheridium specimens for early marsupial history	NATURE			English	Article							MAMMALS; AMERICA; ORIGIN	We describe here two new specimens of the mammal Deltatheridium pretrituberculare from the Late Cretaceous period of Mongolia. These specimens provide information on tooth replacement in basal therian mammals and on lower jaw and basicranial morphology. Deltatheroidans, known previously from isolated teeth, partial rostra and jaws from the late Cretaceous of Asia(1-4) and possibly North America(5,6), have been identified variously as eutherians(1,7,8), as basal metatherians (the stem-based dade formed by marsupials and their extinct relatives)(3,9-11) or as an outgroup to both eutherians and metatherians(2,12-15). Resolution of these conflicting hypotheses and understanding of the early evolution of the therian lineage have been hampered by a sparse fossil record for basal therians. The new evidence supports metatherian affinities for deltatheroidans and allows a comprehensive phylogenetic analysis of basal metatherians and marsupials, The presence of specialized marsupial patterns of tooth replacement and cranial vascularization in Deltatheridium and the basal phylogenetic position of this taxon indicate that these features are characteristic of Metatheria as a whole. Other morphological transformations recognized here secure the previously elusive diagnosis of Metatheria(3,14,15). The new specimens of Deltatheridium illustrate the effectiveness of fairly complete fossil specimens in determining the nature of early evolutionary events.	Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Amer Museum Nat Hist, Dept Vertebrate Paleontol, New York, NY 10024 USA; Carnegie Museum Nat Hist, Sect Mammals, Pittsburgh, PA 15206 USA	University of Louisville; American Museum of Natural History (AMNH)	Rougier, GW (corresponding author), Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.	grougier@louisville.edu						Averianov AO, 1997, ACTA PALAEONTOL POL, V42, P243; BISCOE CHT, 1987, REPROD PHYSL MARSUPI; BUTLER PM, 1973, NATURE, V245, P105, DOI 10.1038/245105a0; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P332; CIFELLI RL, 1993, P NATL ACAD SCI USA, V90, P9413, DOI 10.1073/pnas.90.20.9413; Cifelli RL, 1998, CR ACAD SCI II A, V326, P215, DOI 10.1016/S1251-8050(00)89038-2; Cifelli RL, 1996, NATURE, V379, P715, DOI 10.1038/379715a0; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; deMuizon C, 1997, NATURE, V389, P486, DOI 10.1038/39029; FOX RC, 1974, NATURE, V249, P392, DOI 10.1038/249392a0; FOX RC, 1975, CAN J EARTH SCI, V12, P412, DOI 10.1139/e75-037; Gregory WK, 1926, AM MUS NOVIT, V225, P7; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hershkovitz Philip, 1995, Bonner Zoologische Beitraege, V45, P153; Kielan-Jaworowska Z., 1979, P182; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P103; KIELANJAWOROWSKA Z, 1990, LETHAIA, V23, P1, DOI 10.1111/j.1502-3931.1990.tb01776.x; Kirsch JAW, 1997, AUST J ZOOL, V45, P211, DOI 10.1071/ZO96030; LUCKETT WP, 1993, MAMMAL PHYLOGENY, P182; MAIER W, 1993, MAMMAL PHYLOGENY, P165; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; Martin Thomas, 1997, Journal of Mammalian Evolution, V4, P1, DOI 10.1023/A:1027300726126; MCKENNA M C, 1971, Journal of Paleontology, V45, P441; Sanchez-Villagra Marcelo R., 1997, Journal of Mammalian Evolution, V4, P119, DOI 10.1023/A:1027318213347; SLAUGHTER BH, 1974, J MAMMAL, V55, P115, DOI 10.2307/1379261; Springer Mark S., 1997, P129; Szalay F. S., 1994, EVOLUTIONARY HIST MA; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; Wible J.R., 1990, Journal of Vertebrate Paleontology, V10, P183	30	205	216	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					459	463		10.1038/24856	http://dx.doi.org/10.1038/24856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853752				2022-12-28	WOS:000077370100052
J	Nightingale, SL				Nightingale, SL			New FDA web site for health care professionals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-28	WOS:000077176600005
J	Mocroft, A; Vella, S; Benfield, TL; Chiesi, A; Miller, V; Gargalianos, P; Monforte, AD; Yust, I; Bruun, JN; Phillips, AN; Lundgren, JD				Mocroft, A; Vella, S; Benfield, TL; Chiesi, A; Miller, V; Gargalianos, P; Monforte, AD; Yust, I; Bruun, JN; Phillips, AN; Lundgren, JD		EuroSIDA Study Grp	Changing patterns of mortality across Europe in patients infected with HIV-1	LANCET			English	Article							CD4 CELL COUNTS; CUBIC MILLIMETER; PREMATURE MORTALITY; AIDS; COMBINATION; ZIDOVUDINE; THERAPY; IMPACT; ADULTS; TRIAL	Background The introduction of combination antiretroviral therapy and protease inhibitors has led to reports of falling mortality rates among people infected with HIV-1. We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens. Methods We analysed data from EuroSIDA, which is a prospective, observational, European, multicentre cohort of 4270 HIV-1-infected patients. We compared death rates in each 6 month period from September, 1994, to March, 1998. Findings By March, 1998, 1215 patients had died. The mortality rate from March to September, 1995, was 23.3 deaths per 100 person-years of follow-up (95% CI 20.6-26.0), and fell to 4.1 per 100 person-years of follow-up (2.3-5.9) between September, 1997, and March, 1998. From March to September, 1997, the death rate was 65.4 per 100 person-years of follow-up for those on no treatment, 7.5 per 100 person-years of follow-up for patients on dual therapy, and 3.4 per 100 person-years of follow-up for patients on triple-combination therapy. Compared with patients who were followed up from September, 1994, to March, 1995, patients seen between September, 1997, and March, 1998, had a relative hazard of death of 0.16 (0.08-0.32), which rose to 0.90 (0.50-1.64) after adjustment for treatment. Interpretation Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the begining of 1998 were less than a fifth of their previous level. A large proportion of the reduction in mortality could be explained by new treatments or combinations of treatments.	UCL, Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Inst Super Sanita, Rome, Italy; Hvidovre Univ Hosp, Copenhagen, Denmark; Univ Frankfurt Klinikum, Zentrum Inneren Med, D-6000 Frankfurt, Germany; Gen Hosp Athens, Athens, Greece; Clin Malattie Infett, Milan, Italy; Ichilov Hosp, Tel Aviv, Israel	University of London; University College London; University of London; University College London; Istituto Superiore di Sanita (ISS); University of Copenhagen; Goethe University Frankfurt; Goethe University Frankfurt Hospital; General Hospital of N. Ionia Agia Olga; Tel Aviv University	Mocroft, A (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, Royal Free Campus, London NW3 2PF, England.	amanda@rfhsm.ac.uk	Phillips, Andrew N/B-4427-2008; VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; Mocroft, Amanda/C-1527-2008; Lundgren, Jens/AAE-6876-2019; VELLA, STEFANO/V-8440-2019; Mocroft, Amanda/G-8748-2011	Phillips, Andrew N/0000-0003-2384-4807; VELLA, STEFANO/0000-0003-2347-5984; Mocroft, Amanda/0000-0001-8316-1122; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100; Chiesi, Antonio/0000-0002-6892-8142				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BARBARA JC, 1993, AIDS, V7, P1099, DOI 10.1097/00002030-199308000-00012; BINDELS PJE, 1994, AIDS, V8, P233, DOI 10.1097/00002030-199402000-00011; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P861; CHAISSON MA, 1997, 4 C RETR OPP INF WAS; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DUNCANSAUNDERS L, 1990, J ACQ IMMUN DEF SYND, V3, P921; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; GULLICK RM, 1997, NEW ENGL J MED, V337, P734; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; KIRK O, IN PRESS AIDS; LELEZARI J, 1996, 11 INT C AIDS VANC J; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MANN JM, 1992, J INFECT DIS, V165, P245, DOI 10.1093/infdis/165.2.245; MCCORMICK A, 1991, BRIT MED J, V302, P1375, DOI 10.1136/bmj.302.6789.1375; Montaner JSG, 1996, JAMA-J AM MED ASSOC, V275, P598, DOI 10.1001/jama.275.8.598; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Phillips AN, 1998, J ACQ IMMUN DEF SYND, V17, P239, DOI 10.1097/00042560-199803010-00009; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SELIK RM, 1993, JAMA-J AM MED ASSOC, V269, P2991, DOI 10.1001/jama.269.23.2991; Williams IG, 1997, GENITOURIN MED, V73, P429	30	1043	1068	2	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1998	352	9142					1725	1730		10.1016/S0140-6736(98)03201-2	http://dx.doi.org/10.1016/S0140-6736(98)03201-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848347				2022-12-28	WOS:000077246500006
J	Rose, DN				Rose, DN			Short-course prophylaxis against tuberculosis in HIV-infected persons - A decision and cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculosis; human immunodeficiency virus infections; cost-benefit analysis; isoniazid; rifampin	HUMAN-IMMUNODEFICIENCY-VIRUS; ISONIAZID PREVENTIVE THERAPY; UNITED-STATES; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; HEPATITIS; PROGRESSION; RIFAMPIN; COHORT	Background: Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality. Recent clinical trials have found that some short-course regimens also effectively prevent tuberculosis. Objective: To compare the benefits, risks, and cost-effectiveness of isoniazid prophylaxis and short-course prophylaxis regimens. Design: Decision and cost-effectiveness analysis. Setting: United States. Patients: Hypothetical patients who are HIV-infected and have CD4 counts of 200 cells/mm(3) or less and positive results on tuberculin skin tests. Interventions: Isoniazid prophylaxis lasting 12 months and six short-course prophylaxis regimens of isoniazid, rifampin, and pyrazinamide alone or in combination. Measurements: 5-year survival rate, life expectancy, lifetime incidence of tuberculosis, and cost per quality-adjusted life-year saved. Results: Compared with no prophylaxis, the 12-month isoniazid regimen increased 5-year survival rates by 9% and life expectancy by 8.7 months, decreased incidence of tuberculosis by 27%, and saved 4 medical care dollars for every 1 spent on prophylaxis. Regimens of isoniazid for 6 months, isoniazid and rifampin for 3 months, and rifampin and pyrazinamide for 2 months had similar results: 6.2- to 8.6-month increases in life expectancy, 19% to 26% reductions in incidence of tuberculosis, and 1 to 7 medical care dollars saved for every 1 spent on prophylaxis. A 3-month regimen of isoniazid, rifampin, and pyrazinamide resulted in fewer clinical benefits and was the only regimen tested that did not save medical care dollars. Conclusions: Prophylaxis decreases the incidence of tuberculosis and increases life expectancy for HIV-infected patients. Some regimens save medical care dollars, and some short-course regimens have clinical and economic benefits similar to those of the 12-month isoniazid regimen. Short-course prophylaxis is a reasonable alternative to the 12-month isoniazid regimen.	Long Isl Jewish Med Ctr, Div Gen Internal Med & Primary Care, New Hyde Pk, NY 11042 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Northwell Health; Yeshiva University; Albert Einstein College of Medicine	Rose, DN (corresponding author), Long Isl Jewish Med Ctr, Div Gen Internal Med & Primary Care, 410 Lakeville Rd,Suite 105, New Hyde Pk, NY 11042 USA.							ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; CHAISSON RE, 1998, 12 WORLD AIDS C GEN; COMSTOCK GW, 1979, AM REV RESPIR DIS, V119, P827; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; Garrait V, 1997, J IMMUNOL, V159, P2824; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; Goletti D, 1996, J IMMUNOL, V157, P1271; GORDIN F, 1998, C RETROVIR OPPO 0201, P223; Gourevitch MN, 1998, INT J TUBERC LUNG D, V2, P531; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Holtgrave DR, 1997, J ACQ IMMUN DEF SYND, V16, P54, DOI 10.1097/00042560-199709010-00009; HORWITZ O, 1974, AM J EPIDEMIOL, V99, P333, DOI 10.1093/oxfordjournals.aje.a121618; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189; Leroy V, 1997, AM J EPIDEMIOL, V145, P293; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; *MED EC, 1997, RED BOOK; Moreno S, 1997, ARCH INTERN MED, V157, P1729, DOI 10.1001/archinte.157.15.1729; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; MORRIS L, 1998, 5 C RETR OPP INF CHI; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; OBRIEN RJ, 1995, AIDS, V9, P665, DOI 10.1097/00002030-199507000-00001; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; Rose DN, 1998, JAMA-J AM MED ASSOC, V279, P160, DOI 10.1001/jama.279.2.160; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; SALPETER SR, 1993, WESTERN J MED, V159, P560; Salpeter SR, 1997, ANN INTERN MED, V127, P1051, DOI 10.7326/0003-4819-127-12-199712150-00001; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SNIDER DE, 1992, AM REV RESPIR DIS, V145, P494, DOI 10.1164/ajrccm/145.2_Pt_1.494; STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465; Tacconelli E, 1997, INT J TUBERC LUNG D, V1, P582; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WADHAWAN D, 1993, INT C AIDS 6 11 JUN, V9, P321; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; *WHO, 1993, WKLY EPIDEMIOL REC, V68, P361; 1997, ANN INTERN MED, V127, P922; 1989, MMWR MORB MORTAL WKL, V38, P236; 1989, MMWR MORB MORTAL WKL, V38, P243; 1990, MMWR MORB MORTAL WKL, V39, P9	52	43	44	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					779	+		10.7326/0003-4819-129-10-199811150-00005	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841583				2022-12-28	WOS:000076984800003
J	Bloch, KC; Zwerling, L; Pletcher, MJ; Hahn, JA; Gerberding, JL; Ostroff, SM; Vugia, DJ; Reingold, AL				Bloch, KC; Zwerling, L; Pletcher, MJ; Hahn, JA; Gerberding, JL; Ostroff, SM; Vugia, DJ; Reingold, AL			Incidence and clinical implications of isolation of Mycobacterium kansasii: Results of a 5-year, population-based study	ANNALS OF INTERNAL MEDICINE			English	Article						Mycobacterium kansasii; human immunodeficiency virus infections; socioeconomic factors; population surveillance; comorbidity	HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; SAN-FRANCISCO; INFECTION; DISEASE; WATER; AIDS; INTRACELLULARE; TRANSMISSION; EPIDEMIOLOGY	Background: Mycobacterium kansasii, an unusual pathogen in the pre-AIDS era, is increasingly reported to cause infection among patients with HIV infection. Little is known about the epidemiology and clinical implications of M. kansasii infection in the AIDS era. Objective: To compare the incidence, demographic characteristics, and clinical features of M. kansasii infection in HIV-positive and HIV-negative persons. Design: Population-based laboratory surveillance. Setting: Three counties in northern California. Patients: All persons who had a positive culture for M. kansasii between 1 January 1992 and 31 December 1996. Measurements: Cumulative incidence rates were calculated for each year by dividing the number of adult patients by the annual estimated adult population. Demographic and socioeconomic data for a single county were obtained by linkage with the 1990 U.S. Census report. Results: 270 patients (69.3% of whom were HIV positive) were identified, for an incidence of 2.4 cases per 100 000 adults per year (95% Cl, 2.1 to 2.7), 115 cases per 100 000 HIV-positive persons per year (Cl, 99 to 133), and 647 cases per 100 000 persons with AIDS per year (Cl, 554 to 751). Indicators of lower socioeconomic status were common among patients: Median incomes were $32 317 in census tracts in which cases were identified and $38 048 in census tracts without cases (P = 0.001), and 35.7% of patients had unstable housing situations. Ninety-four percent of cases were from respiratory isolates, and 87.5% of patients had evidence of infection. Persons with HIV infection differed from those without HIV infection with respect to mycobacteremia (9.6% compared with 0%; P = 0.001), need for hospitalization (77.4% compared with 51.9%; P < 0.001), and smear positivity (41.7% compared with 20.7%; P = 0.005). Chronic diseases were common among HIV-negative persons; however, 40.3% had no predisposing medical condition. Conclusions: Mycobacterium kansasii isolation is more common in HIV-positive persons, but most patients with M. kansasii infection have clinical and radiologic evidence of infection regardless of HIV status. Persons infected with HIV and M. kansasii have a higher rate of hospitalization and a greater burden of organisms. A possible association with poverty suggests mechanisms of transmission and requires further study.	Univ Calif Berkeley, Berkeley, CA 94720 USA; Calif Dept Hlth Serv, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; California Department of Health Care Services; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Bloch, KC (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, A-3310 MCN, Nashville, TN 37212 USA.		Hahn, Judith/J-5813-2014; Bloch, Karen/AAE-1479-2020	Hahn, Judith/0000-0002-2697-8264; 	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459, MH 19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHN CH, 1982, AM REV RESPIR DIS, V125, P388; AHN CH, 1979, CHEST, V75, P120, DOI 10.1378/chest.75.2.120; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BAMBERGER DR, 1994, CLIN INFECT DIS, V18, P395, DOI 10.1093/clinids/18.3.395; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BENNETT C, 1986, AM J MED, V80, P891, DOI 10.1016/0002-9343(86)90634-0; Bittner MJ, 1996, CLIN INFECT DIS, V22, P1109, DOI 10.1093/clinids/22.6.1109; Bor D H, 1991, Semin Respir Infect, V6, P194; Campo RE, 1997, CLIN INFECT DIS, V24, P1233, DOI 10.1086/513666; CHAISSON RE, 1991, ANN INTERN MED, V115, P496; *DEP FIN STAT CA, 1993, P3 DEP FIN STAT CAL; ENGEL HWB, 1980, TUBERCLE, V61, P21, DOI 10.1016/0041-3879(80)90055-0; Evans AJ, 1996, THORAX, V51, P1243, DOI 10.1136/thx.51.12.1243; Evans SA, 1996, THORAX, V51, P1248, DOI 10.1136/thx.51.12.1248; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; GOOD RC, 1982, J INFECT DIS, V146, P829, DOI 10.1093/infdis/146.6.829; GOSLEE S, 1976, AM REV RESPIR DIS, V113, P287; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; JOYNSON DHM, 1979, TUBERCLE, V60, P77, DOI 10.1016/0041-3879(79)90039-4; Kubalek I, 1996, EUR J EPIDEMIOL, V12, P471, DOI 10.1007/BF00143998; LEVINE B, 1991, ANN INTERN MED, V114, P861, DOI 10.7326/0003-4819-114-10-861; LILLO M, 1990, REV INFECT DIS, V12, P760; Maniar A C, 1976, Can J Public Health, V67, P59; MCSWIGGAN D A, 1974, Tubercle, V55, P291, DOI 10.1016/0041-3879(74)90038-5; OBRIEN RJ, 1987, AM REV RESPIR DIS, V135, P1007; ONSTAD GD, 1969, AM REV RESPIR DIS, V99, P426; PENNY ME, 1982, TUBERCLE, V63, P129, DOI 10.1016/S0041-3879(82)80050-0; Picardeau M, 1997, J CLIN MICROBIOL, V35, P25, DOI 10.1128/JCM.35.1.25-32.1997; POWELL BL, 1981, J CLIN MICROBIOL, V13, P969, DOI 10.1128/JCM.13.5.969-975.1981; PRINCE DS, 1989, NEW ENGL J MED, V321, P863, DOI 10.1056/NEJM198909283211304; Roberts GD, 1991, MANUAL CLIN MICROBIO, P304; SCHRAUFNAGEL DE, 1986, BRIT J DIS CHEST, V80, P131, DOI 10.1016/0007-0971(86)90033-1; SHAFER RW, 1992, CLIN INFECT DIS, V15, P161, DOI 10.1093/clinids/15.1.161; SINGLETON J, 1995, HIV AIDS UPDATE, P1; Singleton JA, 1996, WESTERN J MED, V164, P122; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; TABNAK F, 1997, HIV AIDS UPDATE, P1; VALAINIS GT, 1991, ANN INTERN MED, V115, P496, DOI 10.7326/0003-4819-115-6-496; WALLACE RJ, 1990, AM REV RESPIR DIS, V142, P940, DOI 10.1164/ajrccm/142.4.940; Wallace RJ, 1997, AM J RESP CRIT CARE, V156, pS1, DOI 10.1164/ajrccm.156.2.atsstatement; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; WITZIG RS, 1995, CLIN INFECT DIS, V21, P77, DOI 10.1093/clinids/21.1.77; WITZIG RS, 1993, ANTIMICROB AGENTS CH, V37, P1997, DOI 10.1128/AAC.37.9.1997; WOLINSKY E, 1992, CLIN INFECT DIS, V15, P1, DOI 10.1093/clinids/15.1.1; WOLINSKY E, 1981, REV INFECT DIS, V3, P1025; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; WOODS GL, 1987, REV INFECT DIS, V9, P275; 1997, MMWR MORB MORTAL WKL, V46, P861; 1997, MMWR MORB MORTAL WKL, V46, P695	52	109	111	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					698	+		10.7326/0003-4819-129-9-199811010-00004	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841601				2022-12-28	WOS:000076785200003
J	Oren, M; Herman, J; Elbaum, J				Oren, M; Herman, J; Elbaum, J			Men with no spleens and carved-out feet: What is the meaning in the words?	ANNALS OF INTERNAL MEDICINE			English	Article									Rebecca Sieff Govt Hosp, Dept Surg, Safed, Israel; Assia Community Hlth Ctr, Netivot, Israel; Hebrew Univ Jerusalem, Dept Hebrew Literature, Jerusalem, Israel	Ziv Medical Center; Hebrew University of Jerusalem	Herman, J (corresponding author), 24 Megadim St, IL-96185 Jerusalem, Israel.							AVINERY H, 1985, HEICHAL RASHI, P100; BISHOP WJ, 1960, EARLY HIST SURG, P43; BUXTON JT, 1922, AM J SURG, V36, P312; GOLDIN HE, 1962, ETHIC FATHERS, P9; Henry PH, 1998, HARRISONS PRINCIPLES, P345; HYMAN A, 1987, BIOGRAPHIES TANNAIM, P542; JASTROW M, 1971, DICT TARGUMIM TALMUD, P497; KHOULY J, 1978, YALKUT MEAM LOEZ; Lyons AS, 1978, MED ILLUSTRATED HIST; NEWMAN JR, 1956, WORLD MATH, P75; PREUSS J, 1978, J PREUSS BIBLICAL TA; Pugh H.L, 1946, INT ABSTRACTS SURG, V83, P209; Rosner Fred, 1977, MED BIBLE TALMUD SEL; SPIRO HM, 1977, CLIN GASTROENTEROLOG, P519; STEINSALTZ A, 1974, BABYLONIAN TALMUD TR, pA22; YEHIEL NB, 1955, ARUCH COMPLETUM; 1994, ENGLISH HEBREW HEBRE	17	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					756	758		10.7326/0003-4819-129-9-199811010-00044	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841628				2022-12-28	WOS:000076785200037
J	Berg, P; Singer, M				Berg, P; Singer, M			Inspired choices	SCIENCE			English	Editorial Material									Stanford Univ, Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA; Carnegie Inst Washington, Washington, DC 20005 USA	Stanford University; Carnegie Institution for Science	Berg, P (corresponding author), Stanford Univ, Beckman Ctr Mol & Genet Med, Stanford, CA 94305 USA.								0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					873	874		10.1126/science.282.5390.873	http://dx.doi.org/10.1126/science.282.5390.873			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9841431				2022-12-28	WOS:000076727300017
J	Williams, N; Amato, I; Glanz, J; Malakoff, D				Williams, N; Amato, I; Glanz, J; Malakoff, D			Nobel Prizes - Nine scientists get the call to Stockholm	SCIENCE			English	Editorial Material																			0	14	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					610	+		10.1126/science.282.5389.610	http://dx.doi.org/10.1126/science.282.5389.610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841408				2022-12-28	WOS:000076607500011
J	Wilson, S; Cooke, M				Wilson, S; Cooke, M			Double bandaging of sprained ankles	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; FUNCTIONAL TREATMENT; LIGAMENT; IMMOBILIZATION; MOBILIZATION; RUPTURE; BRACE		Univ Birmingham, Div Primary Care Publ & Occupat Hlth, Dept Gen Practice, Emergency Med Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Cooke, M (corresponding author), Univ Birmingham, Div Primary Care Publ & Occupat Hlth, Dept Gen Practice, Emergency Med Res Grp, Birmingham B15 2TT, W Midlands, England.							*BRIT MED ASS ROYA, 1998, BRIT NAT FORM; BROOKS SC, 1981, BMJ-BRIT MED J, V282, P606, DOI 10.1136/bmj.282.6264.606; DETTORI JR, 1994, MIL MED, V159, P15, DOI 10.1093/milmed/159.1.15; EIFF MP, 1994, AM J SPORT MED, V22, P83, DOI 10.1177/036354659402200115; Gleeson AP, 1996, J BONE JOINT SURG BR, V78B, P484, DOI 10.1302/0301-620X.78B3.0780484; GRONMARK T, 1980, INJURY, V11, P215, DOI 10.1016/S0020-1383(80)80046-5; Holmer P, 1991, Ugeskr Laeger, V153, P430; Karlsson J, 1996, SCAND J MED SCI SPOR, V6, P341; KLEIN J, 1991, UNFALLCHIRURG, V94, P99; Leanderson J, 1995, ACTA ORTHOP SCAND, V66, P529, DOI 10.3109/17453679509002308; MUWANGA CL, 1986, INJURY, V17, P380, DOI 10.1016/0020-1383(86)90075-6; SCHAAP GR, 1989, ARCH ORTHOP TRAUM SU, V108, P273, DOI 10.1007/BF00932312; VILJAKKA T, 1983, ANN CHIR GYNAECOL, V72, P66; ZWIPP H, 1989, ORTHOPADE, V18, P336	14	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1722	1723		10.1136/bmj.317.7174.1722	http://dx.doi.org/10.1136/bmj.317.7174.1722			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857146	Green Published			2022-12-28	WOS:000077742300036
J	Dave, AS; Yu, AC; Margoliash, D				Dave, AS; Yu, AC; Margoliash, D			Behavioral state modulation of auditory activity in a vocal motor system	SCIENCE			English	Article							ADULT ZEBRA FINCHES; WHITE-CROWNED SPARROW; SONG CONTROL NUCLEI; AUTOGENOUS SONG; FOREBRAIN; NEURONS; SLEEP; MAINTENANCE; PERCEPTION; PATHWAYS	Neurons of the song motor control nucleus robustus archistriatalis (RA) exhibited far weaker auditory responses in awake than in anesthetized zebra finches, Remarkably, sleep induced complex patterns of bursts in ongoing activity and uncovered vigorous auditory responses of RA neurons. Local injections of norepinephrine suggested that the changes in response strength occur through neuromodulatory control of the sensorimotor nucleus HVc, which projects to RA, Thus, motor access to auditory feedback, which zebra finches require for song Learning and maintenance, may be regulated through neuromodulation, During sleep, the descending motor system may gain access to sensorimotor song memories represented as bursting patterns of activity.	Univ Chicago, Comm Neurobiol, Dept Organismal Biol & Anat, Chicago, IL 60637 USA	University of Chicago	Margoliash, D (corresponding author), Univ Chicago, Comm Neurobiol, Dept Organismal Biol & Anat, 1027 E 57th St, Chicago, IL 60637 USA.	dan@bigbird.uchicago.edu	Galantucci, Bruno/E-5770-2010		NINDS NIH HHS [NS25677] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025677] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL GF, 1990, HORMONES BRAIN BEHAV, V1, P148; BOTTJER SW, 1984, SCIENCE, V224, P901, DOI 10.1126/science.6719123; DAVE AS, IN PRESS METHODS SIM; DOUPE AJ, 1991, P NATL ACAD SCI USA, V88, P11339, DOI 10.1073/pnas.88.24.11339; Doupe AJ, 1997, J NEUROSCI, V17, P1147; FORTUNE ES, 1995, J COMP NEUROL, V360, P413, DOI 10.1002/cne.903600305; KELLEY DB, 1979, J COMP NEUROL, V183, P455, DOI 10.1002/cne.901830302; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; Li R, 1997, BRAIN RES, V763, P239, DOI 10.1016/S0006-8993(97)00417-4; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; LIVINGSTONE MS, 1981, NATURE, V291, P554, DOI 10.1038/291554a0; Margoliash D, 1997, J NEUROBIOL, V33, P671, DOI 10.1002/(SICI)1097-4695(19971105)33:5<671::AID-NEU12>3.0.CO;2-C; MARGOLIASH D, 1985, P NATL ACAD SCI USA, V82, P5997, DOI 10.1073/pnas.82.17.5997; MARGOLIASH D, 1986, J NEUROSCI, V6, P1643; MARGOLIASH D, 1983, J NEUROSCI, V3, P1039; MCCASLAND JS, 1981, P NATL ACAD SCI-BIOL, V78, P7815, DOI 10.1073/pnas.78.12.7815; MCCASLAND JS, 1987, J NEUROSCI, V7, P23; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; NORDEEN KW, 1993, BEHAV NEURAL BIOL, V59, P79, DOI 10.1016/0163-1047(93)91215-9; NORDEEN KW, 1992, BEHAV NEURAL BIOL, V57, P58, DOI 10.1016/0163-1047(92)90757-U; Perkel D. J., 1994, Society for Neuroscience Abstracts, V20, P165; SAKAGUCHI H, 1989, DEV BRAIN RES, V47, P313, DOI 10.1016/0165-3806(89)90189-2; SAKAGUCHI H, 1991, DEV BRAIN RES, V62, P223, DOI 10.1016/0165-3806(91)90169-J; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; SUTTER ML, 1994, J NEUROPHYSIOL, V72, P2105, DOI 10.1152/jn.1994.72.5.2105; TAUBER ES, 1974, ADV SLEEP RES, V1, P133; Vates GE, 1996, J COMP NEUROL, V366, P613, DOI 10.1002/(SICI)1096-9861(19960318)366:4<613::AID-CNE5>3.0.CO;2-7; VICARIO DS, 1993, J NEUROBIOL, V24, P488, DOI 10.1002/neu.480240407; WILLIAMS H, 1985, SCIENCE, V229, P279, DOI 10.1126/science.4012321; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871	33	187	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2250	2254		10.1126/science.282.5397.2250	http://dx.doi.org/10.1126/science.282.5397.2250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856946				2022-12-28	WOS:000077645800044
J	Cummings, JH; Bingham, SA				Cummings, JH; Bingham, SA			Fortnightly review - Diet and the prevention of cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BETA-CAROTENE; CARDIOVASCULAR-DISEASE; COLON-CANCER; RISK; EXPLAIN; WEIGHT; MODEL; MEAT		MRC, Dunn Clin Nutr Ctr, Cambridge CB2 2DH, England		Cummings, JH (corresponding author), MRC, Dunn Clin Nutr Ctr, 100 Tennis Court Rd, Cambridge CB2 2DH, England.	john.cummings@mrc-dunn.cam.ac.uk	Cummings, John H/H-3538-2011; Cummings, John/AAC-2007-2019					*ALPH TOC BET CAR, 1994, NEW ENGL J MED, V300, P1029; Bingham SA, 1998, BRIT J NUTR, V79, P393, DOI 10.1079/BJN19980068; Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515; Charlton J, 1997, HLTH ADULT BRITAIN 1; *CHIEF MED OFF COM, 1998, DEP HLTH REP HLTH SO, V48; CUMMINGS JH, 1992, GASTROENTEROLOGY, V103, P1783, DOI 10.1016/0016-5085(92)91435-7; CUMMINGS JH, 1995, HUMAN COLONIC BACTER, P101; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; EASTON DF, 1994, BRIT MED BULL, V50, P527, DOI 10.1093/oxfordjournals.bmb.a072908; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORMAN D, 1991, J NATL CANCER I, V83, P1702, DOI 10.1093/jnci/83.23.1702; Hague A, 1996, P NUTR SOC, V55, P937, DOI 10.1079/PNS19960090; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LIN RS, 1981, JAMA-J AM MED ASSOC, V245, P147; *OFF NAT STAT, 1996, 1996 MORT STAT C DH2, V23; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PARKIN DM, 1992, IARC SCI PUBL, V120; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; RIBOLI E, 1992, ANN ONCOL, V3, P783, DOI 10.1093/oxfordjournals.annonc.a058097; RobertsThomson IC, 1996, LANCET, V347, P1372, DOI 10.1016/S0140-6736(96)91012-0; SCHORAH CJ, 1991, AM J CLIN NUTR, V53, pS287, DOI 10.1093/ajcn/53.1.287S; Selley S, 1997, HLTH TECHNOLOGY ASSE, V1, P1; Shuker DEG, 1997, BIOMARKERS, V2, P265, DOI 10.1080/135475097231490; SILVESTER KR, 1995, NUTR CANCER, V24, P279, DOI 10.1080/01635589509514417; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; SNYDERWINE EG, 1994, CANCER, V74, P1070, DOI 10.1002/1097-0142(19940801)74:3+<1070::AID-CNCR2820741515>3.0.CO;2-7; Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.1289/ehp.95103s8165; *WORLD CANC RES FU, 1994, DIET CANC REV LIT GE; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC	31	122	124	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1998	317	7173					1636	1640		10.1136/bmj.317.7173.1636	http://dx.doi.org/10.1136/bmj.317.7173.1636			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848907	Green Published			2022-12-28	WOS:000077602100029
J	Hurtig, AK; Nicoll, A; Carne, C; Lissauer, T; Connor, N; Webster, JP; Ratcliffe, L				Hurtig, AK; Nicoll, A; Carne, C; Lissauer, T; Connor, N; Webster, JP; Ratcliffe, L			Syphilis in pregnant women and their children in the United Kingdom: results from national clinician reporting surveys 1994-7	BRITISH MEDICAL JOURNAL			English	Article								Objective To measure the incidence of syphilis detected in pregnancy and congenital syphilis in the United Kingdom. Design Surveys through consultants in genitourinary medicine and paediatricians with active surveillance. Setting United Kingdom, 1994-7. Subjects Women treated for syphilis in pregnancy, and children with early congenital syphilis born in the United Kingdom. Results Over 3 years 139 women were diagnosed with and treated for syphilis in pregnancy; 121 were detected through antenatal screening. Thirty one had confirmed or probable congenitally transmissible syphilis, putting their pregnancies at risk These were minimum figures but are compatible with the 90 to 100 women newly diagnosed annually as having infectious or early latent syphilis. A universal screening policy would require 18 600 and 55 700 women (maximum numbers) to be screened, respectively, to detect one woman needing treatment and to prevent one case of congenital syphilis. Nine presumptive cases of children with congenital syphilis born in the United Kingdom were reported. Mothers requiring treatment for syphilis were found in almost every health region but were more prevalent in London and the south east Being born abroad and belonging to an ethnic minority group were strong risk factors, but 14% (19 of 121) of cases treated and six of 31 definite or probably transmissible cases occurred in white women born in the United Kingdom. Conclusions Congenitally transmissible syphilis continues to occur among pregnant women in the United Kingdom. Cases would be missed and stillbirths and congenitally infected babies would occur if antenatal screening was abandoned.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, STD Sect, HIV & STD Div, London NW9 5EQ, England; Addenbrookes Hosp, Dept Genitourinary Med, British Cooperat Clin Grp, Cambridge CB2 2QQ, England; St Marys Hosp, Dept Paediat, London W2 1NY, England	Public Health England; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, STD Sect, HIV & STD Div, London NW9 5EQ, England.							[Anonymous], MMWR; Calman K, 1994, J Med Screen, V1, P101; *CDCP, 1998, MMWR, V47; *COMM DIS SURV CTR, 1997, CDR WEEKLY, V7, P192; NICOLL A, 1994, BRIT MED J, V308, P1253, DOI 10.1136/bmj.308.6939.1253; SCHWARTZ DA, 1995, HUM PATHOL, V26, P784, DOI 10.1016/0046-8177(95)90228-7; *STD SECT HIV STD, 1998, REP NAT SCREEN COMM; 1998, CDR WEEKLY, V8, P413; 1998, CDR WEEKLY, V8, P416	9	35	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1617	1619		10.1136/bmj.317.7173.1617	http://dx.doi.org/10.1136/bmj.317.7173.1617			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848899	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077602100022
J	Moreno, J; Caplan, AL; Wolpe, PR				Moreno, J; Caplan, AL; Wolpe, PR		Human Res Ethics Grp	Updating protections for human subjects involved in research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL RESEARCH; CONSENT; ETHICS; DEBATE	For decades, all federally funded research involving human subjects has been subject to regulations that require the informed consent of the subject and oversight by the local institution. These regulations last underwent major revision in 1981 and have remained unchanged despite significant changes in the nature of clinical science, the financial sources of research support, and the institutional environment in which clinical research is conducted. In the intervening years, doubt has evolved as to whether the regulations currently in place adequately protect the welfare and rights of research subjects in today's clinical research environment and whether the costs, in terms of time, bureaucracy, and delay, are justified by the level of protection afforded. The Human Research Ethics Group, administered by the Center for Bioethics at the University of Pennsylvania Health System, extensively reviewed the status of existing human subjects protections with the aim of making recommendations to improve and reform the regulations. Here, we present recommendations constituting a consensus of the group members for reform in 3 key areas: protecting subject populations with special needs and vulnerabilities, oversight by institutional review boards, and regulatory policy.	Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania	Caplan, AL (corresponding author), Univ Penn Hlth Syst, Ctr Bioeth, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA.	caplan@mail.med.upenn.edu	Wolpe, Paul/A-1032-2007	Sugarman, Jeremy/0000-0001-7022-8332				*ADV COMM HUM RAD, 1996, HUM RAD EXP; [Anonymous], 1986, HIST THEORY INFORM C; Appelbaum Paul S, 1996, IRB, V18, P1, DOI 10.2307/3563910; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Backlar P, 1996, COMMUNITY MENT HLT J, V32, P321, DOI 10.1007/BF02249450; Blumenthal D, 1996, ACAD MED, V71, P1291, DOI 10.1097/00001888-199612000-00010; BROCK DW, 1996, CHILDREN RES SUBJECT, P81; CAPLAN A, 1998, AM I MY BROTHERS KEE; Clarke M, 1998, LANCET, V351, P286; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Gordon Valery M, 1998, IRB, V20, P1, DOI 10.2307/3564020; GRAY BH, 1978, SCIENCE, V201, P1094, DOI 10.1126/science.356268; Hewlett S, 1996, J MED ETHICS, V22, P232, DOI 10.1136/jme.22.4.232; Hilts Philip J, 1998, N Y Times Web, pB3; *I MED, 1995, REV FIAL FIAU CLIN T; Ivy EJ, 1996, PLAST RECONSTR SURG, V98, P1135, DOI 10.1097/00006534-199612000-00001; JONES J, 1981, BAD BLOOD TUSKEGEE S, P26; JOS PH, 1995, J LAW MED ETHICS, V23, P120, DOI 10.1111/j.1748-720X.1995.tb01341.x; Karlawish JHT, 1997, J AM GERIATR SOC, V45, P474, DOI 10.1111/j.1532-5415.1997.tb05174.x; Kodish E, 1996, ACAD MED, V71, P1287, DOI 10.1097/00001888-199612000-00009; KRUZEWSKI MG, 1996, HASTINGS CENT REP, V26, P30; LEVINE C, 1996, IRB, V13, P1; Levine C, 1996, ETHICS RES INVOLVING, P105; LEVINE RJ, 1986, ETHICS REGULATION CL; MERTON V, 1994, WOMEN HLTH RES ETHIC; Moreno JD, 1996, J AM COLL NUTR, V15, pS35, DOI 10.1080/07315724.1996.10720474; Robertson JA, 1995, HASTINGS CENT REP, V25, P13, DOI 10.2307/3527835; RODWIN MA, 1993, MONEY MED MORALS; Schaeffer MH, 1996, AM J MED, V100, P261, DOI 10.1016/S0002-9343(97)89483-1; SPECE RT, 1986, CONFLICTS INTEREST C; *US DEP HHS, 1998, PUBL US DEP HLTH HUM; *US FDA, 1996, FED REG         1002, V61, P51497; *US GEN ACC OFF, 1998, PUBL US GEN ACC OFF; 1991, FED REG         0618, V56, P28002	34	86	86	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1951	1958		10.1001/jama.280.22.1951	http://dx.doi.org/10.1001/jama.280.22.1951			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	145HF	9851484				2022-12-28	WOS:000077364500043
J	Barnes, N				Barnes, N			Bristol again: (Very) short service on the Bristol inquiry	BRITISH MEDICAL JOURNAL			English	Article									Addenbrookes Hosp, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Barnes, N (corresponding author), Addenbrookes Hosp, Hills Rd, Cambridge CB2 2QQ, England.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1577	+		10.1136/bmj.317.7172.1577	http://dx.doi.org/10.1136/bmj.317.7172.1577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836665	Green Published			2022-12-28	WOS:000077451700032
J	Loff, B; Cordner, S				Loff, B; Cordner, S			Learning a culture of respect for human rights	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Southbank, Vic 3006, Australia; Monash Univ, Dept Forens Med, Southbank, Vic 3006, Australia	Monash University; Monash University	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Southbank, Vic 3006, Australia.		Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503				[Anonymous], 1998, REP TRUTH REC COMM; Commonwealth of Australia, 1997, BRING THEM HOM NAT I; Johnston E., 1991, ROYAL COMMISSION ABO	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1800	1800		10.1016/S0140-6736(05)79886-X	http://dx.doi.org/10.1016/S0140-6736(05)79886-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851378				2022-12-28	WOS:000077337900006
J	Thompson, LG; Davis, ME; Mosley-Thompson, E; Sowers, TA; Henderson, KA; Zagorodnov, VS; Lin, PN; Mikhalenko, VN; Campen, RK; Bolzan, JF; Cole-Dai, J; Francou, B				Thompson, LG; Davis, ME; Mosley-Thompson, E; Sowers, TA; Henderson, KA; Zagorodnov, VS; Lin, PN; Mikhalenko, VN; Campen, RK; Bolzan, JF; Cole-Dai, J; Francou, B			A 25,000-year tropical climate history from Bolivian ice cores	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; SOUTH-AMERICA; POLAR ICE; RECORDS; DEGLACIATION; GREENLAND; PERU; GISP2; MODEL; CYCLE	Ice cores that were recovered from the summit of Sajama mountain in Bolivia provide carbon-14-dated tropical records and extend to the Late Glacial Stage (LGS). Oxygen isotopic ratios of the ice decreased 5.4 per mil between the early Holocene and the Last Glacial Maximum, which is consistent with values from other ice cores, The abrupt onset and termination of a Younger Dryas-type event suggest atmospheric processes as the probable drivers. Regional accumulation increased during the LGS, during deglaciation, and over the past 3000 years, which is concurrent with higher water levels in regional paleolakes. Unlike polar cores, Sajama glacial ice contains eight times Less dust than the Holocene ice, which reflects wetter conditions and extensive snow cover.	Ohio State Univ, Dept Geol Sci, Byrd Polar Res Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Geog, Byrd Polar Res Ctr, Columbus, OH 43210 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Russian Acad Sci, Inst Geog, Moscow 109017, Russia; ORSTOM, Quito, Ecuador	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Institute of Geography, Russian Academy of Sciences; Russian Academy of Sciences; Institut de Recherche pour le Developpement (IRD)	Thompson, LG (corresponding author), Ohio State Univ, Dept Geol Sci, Byrd Polar Res Ctr, Columbus, OH 43210 USA.		Mosley-Thompson, Ellen S/Z-2100-2018; Mikhalenko, Vladimir N/A-4253-2014; Campen, R. Kramer/M-2996-2013; Cole-Dai, Jihong/B-2510-2009	Campen, R. Kramer/0000-0002-7091-2991; Cole-Dai, Jihong/0000-0003-0921-5916				Abbott MB, 1997, QUATERNARY RES, V47, P169, DOI 10.1006/qres.1997.1881; Alley RB, 1997, J GEOPHYS RES-OCEANS, V102, P26367, DOI 10.1029/96JC03837; ASHWORTH AC, 1989, REV CHIL HIST NAT, V62, P61; Bard E, 1998, GEOCHIM COSMOCHIM AC, V62, P2025, DOI 10.1016/S0016-7037(98)00130-6; BARD E, 1987, NATURE, V328, P791, DOI 10.1038/328791a0; Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; BENDER M, 1994, NATURE, V372, P663, DOI 10.1038/372663a0; BENDER M, 1995, J GEOPHYS RES-ATMOS, V100, P18651, DOI 10.1029/94JD02212; BENSON L V, 1991, Journal of Paleolimnology, V5, P115; BENSON LV, 1981, QUATERNARY RES, V16, P390, DOI 10.1016/0033-5894(81)90018-1; BRADLEY RS, 1996, NATO ASI SER 1, V41, P603; BROECKER WS, 1990, QUATERNARY SCI REV, V9, P305, DOI 10.1016/0277-3791(90)90026-7; Broecker WS, 1998, QUATERNARY RES, V50, P12, DOI 10.1006/qres.1998.1973; BUDD WF, 1983, CLIMATIC RECORD POLA, P167; CLAPPERTON CM, 1993, PALAEOGEOGR PALAEOCL, V101, P189, DOI 10.1016/0031-0182(93)90012-8; Clapperton CM, 1997, QUATERN INT, V38-9, P49, DOI 10.1016/S1040-6182(96)00020-1; CLAPPERTON CM, 1993, QUATERNARY GEOLOGY G, P498; *CLIMAP, 1981, GEOL SOC AM MAP CHAR; Crowley TJ, 1997, J GEOPHYS RES-ATMOS, V102, P16463, DOI 10.1029/97JD00536; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; HAMMER CU, 1985, GREENLAND ICE CORE, V33, P77; Hardy DR, 1998, B AM METEOROL SOC, V79, P1899, DOI 10.1175/1520-0477(1998)079<1899:AADMCA>2.0.CO;2; Harrison S.P, 1984, GEOPHYS MONOGR SER, V29, P118; HERD DG, 1974, GEOLOGY, V2, P603; HERRON MM, 1980, J GLACIOL, V25, P373, DOI 10.3189/S0022143000015239; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; JOUZEL J, 1987, NATURE, V329, P403, DOI 10.1038/329403a0; KESSLER A, 1963, ERDKUNDE, V22, P275; Klein A.G., 1995, B I FRANCAIS ETUDES, V24, P607; LOWELL TV, 1995, SCIENCE, V269, P1541, DOI 10.1126/science.269.5230.1541; MARKGRAF V, 1991, BOREAS, V20, P63; McIntyre A., 1976, Science, V191, P1131, DOI 10.1126/science.191.4232.1131; Minchin J., 1882, P ROYAL GEOGRAPHICAL, V4, P67; OSMASTON H, 1965, THESIS OXFORD U; Paillard D., 1996, EOS T AM GEOPHYS UN, V77, P379, DOI 10.1029/96EO00259; Porter SC., 1979, GEOL SOC AM BULL, V90, P980; RAYMOND CF, 1983, J GLACIOL, V29, P357, DOI 10.3189/S0022143000030288; Rind D, 1998, J GEOPHYS RES-ATMOS, V103, P5943, DOI 10.1029/97JD03649; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; RIND D, COMMUNICATION; SELTZER GO, 1990, QUATERNARY SCI REV, V9, P137, DOI 10.1016/0277-3791(90)90015-3; SELTZER GO, 1994, BOREAS, V23, P105; SELTZER GO, 1992, J QUATERNARY SCI, V7, P87, DOI 10.1002/jqs.3390070202; SERVANT M, 1978, CAHIERS ORSTOM G, V14, P15; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; SOWERS T, 1995, SCIENCE, V269, P210, DOI 10.1126/science.269.5221.210; SOWERS T, 1989, J GEOPHYS RES-ATMOS, V94, P5137, DOI 10.1029/JD094iD04p05137; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; TAYLOR KC, 1993, NATURE, V361, P432, DOI 10.1038/361432a0; Thompson LG, 1997, SCIENCE, V276, P1821, DOI 10.1126/science.276.5320.1821; THOMPSON LG, 1989, SCIENCE, V246, P474, DOI 10.1126/science.246.4929.474; THOMPSON LG, 1981, SCIENCE, V212, P812, DOI 10.1126/science.212.4496.812; THOMPSON LG, 1985, SCIENCE, V229, P971, DOI 10.1126/science.229.4717.971; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Vuille M, 1998, J GEOPHYS RES-ATMOS, V103, P11191, DOI 10.1029/98JD00681; Webb RS, 1997, NATURE, V385, P695, DOI 10.1038/385695a0; WIRRMANN D, 1995, QUATERNARY RES, V43, P344, DOI 10.1006/qres.1995.1040; Wirrmann D., 1988, QUATERNARY S AM ANTA, V6, P89; Wolff T, 1998, GEOLOGY, V26, P675, DOI 10.1130/0091-7613(1998)026<0675:OIVCKT>2.3.CO;2	65	508	538	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1858	1864		10.1126/science.282.5395.1858	http://dx.doi.org/10.1126/science.282.5395.1858			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836630				2022-12-28	WOS:000077338100040
J	Kaffman, A; Rank, NM; O'Neill, EM; Huang, LS; O'Shea, EK				Kaffman, A; Rank, NM; O'Neill, EM; Huang, LS; O'Shea, EK			The receptor Msn5 exports the phosphorylated transcription factor Pho4 out of the nucleus	NATURE			English	Article							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; RNA TRANSPORT; SIGNALS; PHO80-PHO85; INHIBITOR; PATHWAY; KINASE; CRM1	The movement of many transcription factors, kinases and replication factors between the nucleus and cytoplasm is important in regulating their activity(1). In some cases, phosphorylation of a protein regulates its entry into the nucleus(2); in others, it causes the protein to be exported to the cytoplasm(3-6). The mechanism by which phosphorylation promotes protein export from the nucleus is poorly understood. Here we investigate how the export of the yeast transcription factor Pho4 is regulated in response to changes in phosphate availability. We show that phosphorylation of Pho4 by a nuclear complex of a cyclin with a cyclin-dependent kinase, Pho80-Pho85, triggers its export from the nucleus. We also find that the shuttling receptor used by Pho4 for nuclear export is the importin-beta-family member Msn5 (refs 7, 8), which is required for nuclear export of Pho4 in vivo and binds only to phosphorylated Pho4 in the presence of the GTP-bound form of yeast Ran in vitro. Our results reveal a simple mechanism by which phosphorylation can control the nuclear export of a protein.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Huang, Linda/C-9903-2014	Huang, Linda/0000-0002-9033-4391	NIGMS NIH HHS [F32 GM017494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CHENEVERT J, 1994, GENETICS, V136, P1287; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OGAWA N, 1995, MOL CELL BIOL, V15, P997; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691	30	275	280	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					482	486		10.1038/24898	http://dx.doi.org/10.1038/24898			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853758				2022-12-28	WOS:000077370100058
J	Kemp, M				Kemp, M			Julesz's joyfulness	NATURE			English	Editorial Material									Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					419	419		10.1038/24753	http://dx.doi.org/10.1038/24753			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853746				2022-12-28	WOS:000077370100034
J	Nightingale, SL				Nightingale, SL			New professional labeling for aspirin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-28	WOS:000077176600006
J	Thiele, TE; Marsh, DJ; Ste Marie, L; Bernstein, IL; Palmiter, RD				Thiele, TE; Marsh, DJ; Ste Marie, L; Bernstein, IL; Palmiter, RD			Ethanol consumption and resistance are inversely related to neuropeptide Y levels	NATURE			English	Article							INBRED MOUSE STRAINS; FOOD-INTAKE; ALCOHOL; RATS; BEHAVIOR; SEIZURES; MICE; SENSITIVITY; INHIBITION; RECEPTORS	Genetic linkage analysis of rats that were selectively bred for alcohol preference identified a chromosomal region that includes the neuropeptide Y (NPY) gene(I). Alcohol-preferring rats have lower levels of NPY in several brain regions compared with alcohol-non-preferring rats(2). We therefore studied alcohol consumption by mice that completely lack NPYas a result of targeted gene disruption(3). Here we report that NPY-deficient mice show increased consumption, compared with wild-type mice, of solutions containing 6%, 10% and 20% (v/v) ethanol. NPY-deficient nice are also less sensitive to the sedative/hypnotic effects of ethanol, as shown by more rapid recovery from ethanol-induced sleep, even though plasma ethanol concentrations do not differ significantly from those of controls, In contrast, transgenic mice that overexpress a marked NPY gene in neurons that usually express it have a lower preference for ethanol and are more sensitive to the sedative/hypnotic effects of this drug than controls. These data are direct evidence that alcohol consumption and resistance are inversely related to NPY levels in the brain.	Univ Washington, Dept Psychol, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Thiele, TE (corresponding author), Univ Washington, Dept Psychol, Box 351525, Seattle, WA 98195 USA.							BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P503, DOI 10.1007/BF02244901; Carr LG, 1998, ALCOHOL CLIN EXP RES, V22, P884, DOI 10.1097/00000374-199806000-00017; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; COLMER WF, 1993, BIOL NEUROPEPTIDE Y; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EHLERS CL, IN PRESS ALCOHOL CLI; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; HEILIG M, 1995, CRIT REV NEUROBIOL, V9, P115; HEILIG M, 1992, REGUL PEPTIDES, V41, P61, DOI 10.1016/0167-0115(92)90514-U; HEILIG M, 1993, NEUROPSYCHOPHARMACOL, V8, P357, DOI 10.1038/npp.1993.35; Kim JJ, 1997, P NATL ACAD SCI USA, V94, P5929, DOI 10.1073/pnas.94.11.5929; Kurtz DL, 1996, PHARMACOL BIOCHEM BE, V53, P585, DOI 10.1016/0091-3057(95)02055-1; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LI TK, 1993, BEHAV GENET, V23, P163, DOI 10.1007/BF01067421; MELO JA, 1996, NAT GENET, V13, P137; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Palmiter RD, 1998, RECENT PROG HORM RES, V53, P163; RODGERS RJ, 1993, PSYCHOPHARMACOLOGY, V113, P237, DOI 10.1007/BF02245704; Ryabinin AE, 1997, MOL PSYCHIATR, V2, P32, DOI 10.1038/sj.mp.4000206; Self DW, 1998, J NEUROSCI, V18, P1848; STEWART RB, 1993, ALCOHOL, V10, P1, DOI 10.1016/0741-8329(93)90046-Q; Woldbye DPD, 1996, BRAIN RES, V737, P162, DOI 10.1016/0006-8993(96)00730-5; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; Yamada K, 1996, BRAIN RES, V725, P272, DOI 10.1016/S0006-8993(96)00405-2	30	376	385	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					366	369		10.1038/24614	http://dx.doi.org/10.1038/24614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845072				2022-12-28	WOS:000077204000049
J	Begg, CB; Cramer, LD; Hoskins, WJ; Brennan, MF				Begg, CB; Cramer, LD; Hoskins, WJ; Brennan, MF			Impact of hospital volume on operative mortality for major cancer surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; BREAST-CANCER; PANCREATIC RESECTION; SURVIVAL; CARE; MORBIDITY; PATTERNS; QUALITY	Context.-Hospitals that treat a relatively high volume of patients for selected surgical oncology procedures report lower surgical in-hospital mortality rates than hospitals with a low volume of the procedures, but the reports do not take into account length of stay or adjust for case mix. Objective.-To determine whether hospital volume was inversely associated with 30-day operative mortality, after adjusting for case mix. Design and Setting.-Retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database in which the hypothesis was prospectively specified. Surgeons determined in advance the surgical oncology procedures for which the experience of treating a larger volume of patients was most likely to lead to the knowledge or technical expertise that might offset surgical fatalities. Patients.-All 5013 patients in the SEER registry aged 65 years or older at cancer diagnosis who underwent pancreatectomy, esophagectomy, pneumonectomy, liver resection, or pelvic exenteration, using incident cancers of the pancreas, esophagus, lung, colon, and rectum, and various genitourinary cancers diagnosed between 1984 and 1993. Main Outcome Measure.-Thirty-day mortality in relation to procedure volume, adjusted for comorbidity, patient age, and cancer stage. Results.-Higher volume was linked with lower mortality for pancreatectomy (P=.004), esophagectomy (P<.001), liver resection (P=.04), and pelvic exenteration (P=.04), but not for pneumonectomy (P=.32). The most striking results were for esophagectomy, for which the operative mortality rose to 17.3% in low-volume hospitals, compared with 3.4% in high-volume hospitals, and for pancreatectomy, for which the corresponding rates were 12.9% vs 5.8%. Adjustments for case mix and other patient factors did not change the finding that low volume was strongly associated with excess mortality. Conclusions.-These data support the hypothesis that when complex surgical oncologic procedures are provided by surgical teams in hospitals with specialty expertise, mortality rates are lower.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Begg, CB (corresponding author), 1275 York Ave,Box 44, New York, NY 10021 USA.							ANDRENSANDBERG A, 1983, ANN SURG, V198, P605, DOI 10.1097/00000658-198311000-00008; ARMITAGE P, 1994, STAT METHODS MED RES, P464; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Choti M A, 1998, J Gastrointest Surg, V2, P11, DOI 10.1016/S1091-255X(98)80098-X; EDGE SB, 1993, CANCER-AM CANCER SOC, V71, P3502, DOI 10.1002/1097-0142(19930601)71:11<3502::AID-CNCR2820711107>3.0.CO;2-N; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Glasgow RE, 1996, WESTERN J MED, V165, P294; GORDON TA, 1995, ANN SURG, V221, P43, DOI 10.1097/00000658-199501000-00005; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Janes RH, 1996, ANN SURG, V223, P261, DOI 10.1097/00000658-199603000-00006; KOSARY CL, NIH PUBL; LIEBERMAN MD, 1995, ANN SURG, V222, P638, DOI 10.1097/00000658-199511000-00006; Ma M, 1997, BRIT J CANCER, V75, P1652, DOI 10.1038/bjc.1997.281; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; Nattinger AB, 1997, J CLIN EPIDEMIOL, V50, P939, DOI 10.1016/S0895-4356(97)00099-1; NGUYEN HN, 1993, CANCER, V72, P8663; PELLEGRINI CA, 1989, ARCH SURG-CHICAGO, V124, P778; POTOSKY AL, 1993, MED CARE, V31, P732; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9	23	1308	1318	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1747	1751		10.1001/jama.280.20.1747	http://dx.doi.org/10.1001/jama.280.20.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842949	Bronze			2022-12-28	WOS:000077081400029
J	Drici, MD; Knollmann, BC; Wang, WX; Woosley, RL				Drici, MD; Knollmann, BC; Wang, WX; Woosley, RL			Cardiac actions of erythromycin - Influence of female sex	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORSADES-DE-POINTES; LONG QT SYNDROME; INTERVAL; GENDER; PROLONGATION; HEART; AGE	Context.-Erythromycin is a widely used antibiotic that infrequently causes QT-prolongation and torsades de pointes cardiac arrhythmias. For antiarrhythmic drugs, women are at a higher risk for these cardiac arrhythmias, but few other classes of drugs have been studied. Objectives.-To determine whether female sex is a risk factor for cardiac arrhythmias associated with erythromycin, and if this can be correlated with in vitro measurements of the QT-response to erythromycin in male and female rabbit hearts. Design.-Food and Drug Administration (FDA) MEDWATCH database analysis and in vitro experiment. Main Outcome Measures.-Cardiac arrhythmia reports associated with erythromycin from 1970 until 1996 classified by patient sex and age, and effect: of female sex on erythromycin-induced QT-prolongation in isolated perfused rabbit hearts. Results.-We observed a sex difference in cardiac arrhythmias associated with administration of erythromycin. A total of 346 cases were found in the FDA database: 201 females (58%), 110 males (32%), and 35 unspecified (10%). Forty-nine were life-threatening ventricular arrhythmias and deaths directly related to intravenous erythromycin lactobionate: 33 women (67%) and 16 men (33%) (P = .03). During the same period, no sex imbalance was present in the prescription pattern for intravenous erythromycin lacobionate (men 47%, women 49%, unspecified 4%). Perfusion with erythromycin caused significantly greater QT-prolongation in female rabbit hearts (mean [SD], 11.8% [2.3%]) than in male hearts (6.9% [2.1%]; P = .03). Conclusions.-As has been shown in reports of antiarrhythmic drugs, we found a female predominance in the FDA reports of erythromycin-associated cardiac arrhythmias. Based on in vitro experiments, a sex difference in cardiac repolarization response to erythromycin isa potential contributing factor.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Woosley, RL (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X; Knollmann, Bjorn/0000-0003-4956-9735	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054590] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54590] Funding Source: Medline; NIGMS NIH HHS [GM08386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antzelevitch C, 1996, J AM COLL CARDIOL, V28, P1836, DOI 10.1016/S0735-1097(96)00377-4; AUSTIN KL, 1980, BRIT J CLIN PHARMACO, V10, P273, DOI 10.1111/j.1365-2125.1980.tb01755.x; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Burke JH, 1997, AM J CARDIOL, V79, P178, DOI 10.1016/S0002-9149(96)00707-2; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; FREEDMAN RA, 1987, AM J CARDIOL, V59, P168, DOI 10.1016/S0002-9149(87)80096-6; Lehmann MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8; Lehmann Michael H., 1996, Circulation, V94, P2534; Locati EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MCCOMB JM, 1984, AM J CARDIOL, V54, P922, DOI 10.1016/S0002-9149(84)80237-4; OBERG KC, 1995, PHARMACOTHERAPY, V15, P687; PONSONNAILLE J, 1988, ARCH MAL COEUR VAISS, V81, P1001; RAUTAHARJU PM, 1992, CAN J CARDIOL, V8, P690; Vogt AW, 1997, ANESTH ANALG, V85, P1011, DOI 10.1097/00000539-199711000-00010	15	136	143	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1774	1776		10.1001/jama.280.20.1774	http://dx.doi.org/10.1001/jama.280.20.1774			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842954	Bronze			2022-12-28	WOS:000077081400034
J	Engelgau, MM; Narayan, KMV; Thompson, TJ; Boyle, JP; Williamson, DF; Manninen, DL; Dong, FB; Orians, CE; Dasbach, EJ; Teutsch, SM; Eastman, R; Herman, WH; Songer, TJ				Engelgau, MM; Narayan, KMV; Thompson, TJ; Boyle, JP; Williamson, DF; Manninen, DL; Dong, FB; Orians, CE; Dasbach, EJ; Teutsch, SM; Eastman, R; Herman, WH; Songer, TJ		CDC Diabetes Cost-Effect Study Grp	The cost-effectiveness of screening for type 2 diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-DIAGNOSIS; NIDDM; COMPLICATIONS; MELLITUS; PREVALENCE; ROCHESTER; HEALTH; TRIAL; ONSET; RETINOPATHY	Context.-Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it. Objective.-To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes. Design.-A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice. Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans. Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed. Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars. Setting.-Single-payer health care system. Participants.-Hypothetical cohort of 10000 persons with newly diagnosed diabetes from the general US population. Main Outcome Measures.-Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained. Results.-The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236 449 per life-year gained and $56 649 per QALY gained. Screening is more cost-effective among younger people and among African Americans. The benefits of early detection and treatment accrue more from postponement of complications and the resulting improvement in quality of life than from additional life-years. Conclusions.-Early diagnosis and treatment through opportunistic screening of type 2 diabetes may reduce the lifetime incidence of major microvascular complications and result in gains in both life-years and QALYs. Incremental increases in costs attributable to screening and earlier treatment are incurred but may well be in the range of acceptable cost-effectiveness for US health care systems, especially for younger adults and for some subpopulations (eg, minorities) who are at relatively high risk of developing the major complications of type 2 diabetes. Although current recommendations are that screening begin at age 45 years, these results suggest that screening is more cost-effective at younger ages. The selection of appropriate target populations for screening should consider factors in addition to the prevalence of diabetes.	Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Emory Univ, Sch Publ Hlth, Div Epidemiol, Atlanta, GA USA; Ctr Publ Hlth Res, Seattle, WA USA; Merck & Co Inc, Blue Bell, PA USA; Merck & Co Inc, West Point, PA USA; NIDDKD, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	Centers for Disease Control & Prevention - USA; Emory University; Merck & Company; Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Engelgau, MM (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-10,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	mxe1@cdc.gov	Narayan, K.M. Venkat/J-9819-2012; Dasbach, Erik/AAP-6801-2021	Narayan, K.M. Venkat/0000-0001-8621-5405; 				ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; *AM HEART ASS, 1995, HEART STROK FACTS ST; American Diabetes Association, 1998, DIABETES CARE S1, V12, pS20, DOI DOI 10.2337/DIACARE.21.1.S20; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; [Anonymous], 1995, DIABETES CARE, V18, P1510; [Anonymous], 1995, DIABETES, V44, P968; BALKIN SW, 1995, JAMA-J AM MED ASSOC, V273, P185, DOI 10.1001/jama.1995.03520270019016; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1013; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COPPLESON LW, 1976, AM J OBSTET GYNECOL, V125, P153, DOI 10.1016/0002-9378(76)90585-8; DASBACH EJ, 1992, MED DECIS MAKING, V12, P4; DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468; DONG F, 1997, DIABETES S1, V46, pA77; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; EASTMAN R, 1997, AM DIAB ASS ANN M JU; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P721; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; FERTIG BJ, 1995, NIH PUBLICATION; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gold MR, 1996, COST EFFECTIVENESS H; Granata AV, 1998, ANN INTERN MED, V128, P56, DOI 10.7326/0003-4819-128-1-199801010-00009; HARRIS MI, 1994, DIABETES CARE, V17, P440, DOI 10.2337/diacare.17.5.440; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Herman WH, 1995, DIABETIC MED, V12, P1126, DOI 10.1111/j.1464-5491.1995.tb00432.x; *HLTH CAR FIN ADM, 1996, RES REP END STAG REN; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; HUMPHREY LL, 1994, ARCH INTERN MED, V154, P885, DOI 10.1001/archinte.154.8.885; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; KLEIN R, 1995, ARCH INTERN MED, V155, P745, DOI 10.1001/archinte.155.7.745; KLEIN R, 1993, DIABETES CARE, V16, P1325, DOI 10.2337/diacare.16.10.1325; KNOWLER WC, 1994, DIABETES CARE, V17, P445, DOI 10.2337/diacare.17.5.445; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; McDowell A, 1981, Vital Health Stat 1, P1; *MED EC, 1996, RED BOOK; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; NATHAN DM, 1994, NEW ENGL J MED, V330, P642; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; Stern MP, 1997, DIABETES CARE, V20, P1501, DOI 10.2337/diacare.20.10.1501; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; Thompson TJ, 1996, DIABETIC MED, V13, P337, DOI 10.1002/(SICI)1096-9136(199604)13:4<337::AID-DIA71>3.0.CO;2-A; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; TURNER RC, 1991, DIABETOLOGIA, V34, P877; WEI M, 1997, DIABETES S1, V46, pA137; 1993, NATL HLTH INTERVIEW	54	177	181	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1757	1763						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842951				2022-12-28	WOS:000077081400031
J	Haber, JE				Haber, JE			The many interfaces of Mre11	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; RAD50; REPAIR; YEAST; MUTATIONS; SYNAPSIS; PATHWAYS; PROTEIN; XRS2		Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Haber, JE (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.			Haber, James/0000-0002-1878-0610				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1998, GENETICS, V150, P591; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; IVANOV EL, 1992, GENETICS, V132, P651; Kironmai KM, 1997, GENES CELLS, V2, P443; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; RATTRAY AJ, 1995, GENETICS, V139, P45; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985	24	352	359	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					583	586		10.1016/S0092-8674(00)81626-8	http://dx.doi.org/10.1016/S0092-8674(00)81626-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845359	Bronze			2022-12-28	WOS:000077253700003
J	Fu, XB; Shen, ZY; Chen, YL; Xie, JH; Guo, ZR; Zhang, ML; Sheng, ZY				Fu, XB; Shen, ZY; Chen, YL; Xie, JH; Guo, ZR; Zhang, ML; Sheng, ZY			Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns	LANCET			English	Article							WOUND REPAIR; DIFFERENTIATION; PROLIFERATION; CHILDREN; EGF	Background Wound healing is a dynamic process that could be accelerated by growth factors. We investigated the effect of recombinant bovine basic fibroblast growth factor (rbFGF) on burn healing in a randomised placebo-controlled trial. Methods We recruited 600 patients with superficial or deep second-degree burns. Patients received 150 AU/cm(2) daily topical rbFGF (n=300) or placebo (n=300) plus vehicle. We assessed healing by photography, punch-biopsy, and clinical examination. Findings All patients treated with rbFGF had faster granulation tissue formation and epidermal regeneration than those in the placebo group. Superficial and deep second-degree burns treated with rbFGF healed in a mean of 9 9 (SD 2.5) days and 17.0 (4.6) days, respectively, compared with 12.4 (2.7) and 21.2 (4.9) days (p=0.0008 and p=0.0003, respectively). No adverse effects were seen locally or systemically with rbFGF. Interpretation rbFGF effectively decreased healing time and improved healing quality. Clinical benefits would be shorter hospital slays and the patient's skin quickly becoming available for harvesting and grafting.	Postgrad Med Coll, Ctr Trauma, 304th Hosp, Wound Healing Unit, Beijing 100037, Peoples R China; Jishuitan Hosp, Burn Unit, Beijing, Peoples R China; Chanhai Hosp, Burn Unit, Shanghai, Peoples R China; Zhongshan Med Univ, Guangzhou, Peoples R China	Chinese People's Liberation Army General Hospital; Sun Yat Sen University	Fu, XB (corresponding author), Postgrad Med Coll, Ctr Trauma, 304th Hosp, Wound Healing Unit, Beijing 100037, Peoples R China.							APPLETON I, 1994, J ROY SOC MED, V87, P500; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; Cohen IK, 1997, SERONO SYMP, P3; DANILENKO DM, 1995, AM J PATHOL, V147, P1261; FU XB, 1995, CHIN J TRAUMA, V11, P134; FU XB, 1996, WOUND REPAIR REGEN, V4, P385; FU XB, 1996, J MILIT SURG, V8, P31; Fu Xiaobing, 1996, Wound Repair and Regeneration, V4, P297, DOI 10.1046/j.1524-475X.1996.40219.x; GIBRAN NS, 1994, J SURG RES, V56, P226, DOI 10.1006/jsre.1994.1036; GILPIN DA, 1994, ANN SURG, V220, P19, DOI 10.1097/00000658-199407000-00004; GOSPODAROWICZ D, 1990, J CELL PHYSIOL, V142, P325, DOI 10.1002/jcp.1041420215; HOPPENREIJS VPT, 1994, INVEST OPHTH VIS SCI, V35, P931; HUNT T K, 1984, Journal of Trauma, V24, pS39; HUNT TK, 1988, TRAUMA SEPSIS SHOCK, P443; LAZARUS GS, 1994, ARCH DERMATOL, V130, P489, DOI 10.1001/archderm.130.4.489; LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; NANNEY LB, 1990, J INVEST DERMATOL, V94, P624, DOI 10.1111/1523-1747.ep12876204; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; PRUITT BA, 1992, WORLD J SURG, V16, P1, DOI 10.1007/BF02067106; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROESEL JF, 1995, J SURG RES, V58, P449, DOI 10.1006/jsre.1995.1071; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; VILLASCHI S, 1993, AM J PATHOL, V143, P181	29	136	180	3	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1661	1664		10.1016/S0140-6736(98)01260-4	http://dx.doi.org/10.1016/S0140-6736(98)01260-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853438				2022-12-28	WOS:000077110300010
J	Raju, TNK				Raju, TNK			The Nobel Chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	20	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1714	1714		10.1016/S0140-6736(05)61500-0	http://dx.doi.org/10.1016/S0140-6736(05)61500-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853480				2022-12-28	WOS:000077110300071
J	Roberts, E; Wales, JM; Brett, MM; Bradding, P				Roberts, E; Wales, JM; Brett, MM; Bradding, P			Cranial-nerve palsies and vomiting	LANCET			English	Article							BOTULISM		Glenfield Gen Hosp, Dept Med, Leicester LE3 9QP, Leics, England; PHLS Cent Publ Hlth Lab, Food Hyg Lab, London, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Bradding, P (corresponding author), Glenfield Gen Hosp, Dept Med, Leicester LE3 9QP, Leics, England.	braddph@hotmail.com		Bradding, Peter/0000-0001-8403-0319				Cherington M, 1998, MUSCLE NERVE, V21, P701, DOI 10.1002/(SICI)1097-4598(199806)21:6<701::AID-MUS1>3.0.CO;2-B; HUGHES JM, 1981, ANN INTERN MED, V95, P442, DOI 10.7326/0003-4819-95-4-442; McPartland JM, 1997, AM FAM PHYSICIAN, V55, P1797; Tonello F, 1996, ADV EXP MED BIOL, V389, P251; 1998, COMMUN DIS REP CDR W, V8, P159	5	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1674	1674		10.1016/S0140-6736(98)09468-9	http://dx.doi.org/10.1016/S0140-6736(98)09468-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853441				2022-12-28	WOS:000077110300013
J	King, TE				King, TE			Update in pulmonary medicine	ANNALS OF INTERNAL MEDICINE			English	Article									San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center	King, TE (corresponding author), San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Room 5H22, San Francisco, CA 94110 USA.							ANDREWS BE, 1987, Q J MED, V62, P195; Bartlett JG, 1998, ANN INTERN MED, V129, P464, DOI 10.7326/0003-4819-129-6-199809150-00008; Baumgartner KB, 1997, AM J RESP CRIT CARE, V155, P242, DOI 10.1164/ajrccm.155.1.9001319; Hall WJ, 1998, ANN INTERN MED, V129, P387, DOI 10.7326/0003-4819-129-5-199809010-00008; Levinson W, 1998, ANN INTERN MED, V129, P212, DOI 10.7326/0003-4819-129-3-199808010-00010; Marrie T J, 1990, Semin Respir Infect, V5, P260; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418	7	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					806	812		10.7326/0003-4819-129-10-199811150-00012	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841587				2022-12-28	WOS:000076984800007
J	Horton, R				Horton, R			Yesterday's doctors	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							*DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Horton R, 1998, LANCET, V351, P1900; Horton R, 1998, LANCET, V352, P1166, DOI 10.1016/S0140-6736(05)60528-4; *SEN SURG GREAT BR, 1998, 5 SEN SURG	4	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1566	1567		10.1016/S0140-6736(98)00063-4	http://dx.doi.org/10.1016/S0140-6736(98)00063-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843096				2022-12-28	WOS:000076998900002
J	Lewis, SJ; Moye, LA; Sacks, FM; Johnstone, DE; Timmis, G; Mitchell, J; Limacher, M; Kell, S; Glasser, SP; Grant, J; Davis, BR; Pfeffer, MA; Braunwald, E				Lewis, SJ; Moye, LA; Sacks, FM; Johnstone, DE; Timmis, G; Mitchell, J; Limacher, M; Kell, S; Glasser, SP; Grant, J; Davis, BR; Pfeffer, MA; Braunwald, E		CARE Investigators	Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range - Results of the cholesterol and recurrent events (CARE) trial	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; pravastatin; age factors; coronary disease; cerebrovascular disorders; cholesterol	CORONARY HEART-DISEASE; HIGH BLOOD CHOLESTEROL; SECONDARY PREVENTION; ELDERLY PATIENTS; FOLLOW-UP; ARTERY DISEASE; DRUG-TREATMENT; RISK-FACTORS; A-I; MORTALITY	Background: A majority of all myocardial infarctions occur in patients who are 65 years of age or older and have average cholesterol levels, but little information is available on whether cholesterol lowering in such patients reduces the rate of recurrent cardiovascular disease. Objective: To determine whether pravastatin reduces the rate of recurrent cardiovascular events in older patients. Design: Subset analysis of a randomized, controlled trial. Setting: 80 hospitals and affiliates in the United States and Canada. Patients: 1283 patients aged 65 to 75 years who had had myocardial infarction and had a plasma total cholesterol level less than 6.2 mmol/L (240 mg/dL) and a low-density lipoprotein cholesterol level of 3.0 to 4.5 mmol/L (115 to 174 mg/dL). Intervention: Pravastatin, 40 mg/d, or placebo. Measurements: Five-year event rates of major coronary events (coronary death, nonfatal myocardial infarction, angioplasty, or bypass surgery) and stroke. Results: Major coronary events occurred in 28.1% of placebo recipients and 19.7% of pravastatin recipients (difference, 9.0 percentage points [95% CI, 4 to 13 percentage points]; relative risk reduction, 32%; P < 0.001). Coronary death occurred in 10.3% of the placebo group and in 5.8% of the pravastatin group (difference, 4.6 percentage points [CI, 1.9 to 6.5 percentage points]; relative risk reduction, 45%; P = 0.004). Stroke incidence was 7.3% in the placebo group and 4.5% in the pravastatin group (absolute reduction, 2.9 percentage points [CI, 0.3 to 4.5 percentage points]; relative reduction, 40%; P = 0.03). The numbers of older patients needed to treat for 5 years were 11 (CI, 8 to 24) to prevent a major coronary event and 22 (CI, 15 to 53) to prevent a coronary death. For every 1000 older patients treated, 225 cardiovascular hospitalizations would be prevented compared with 121 hospitalizations in 1000 younger patients. Conclusions: In older patients with myocardial infarction and cholesterol levels in the average range, pravastatin is associated with a clinically important reduction in risk for major coronary events and stroke. Given the high cardiovascular event rate in older patients, the potential for absolute benefit in this age group is substantial.	Portland Cardiovasc Inst, Legacy Hlth Syst, Portland, OR 97210 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; William Beaumont Hosp, Royal Oak, MI 48072 USA; Univ Florida, Gainesville, FL USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Calgary, Calgary, AB, Canada	Legacy Health; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Queen Elizabeth II Health Sciences Centre; Beaumont Health; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; University of Calgary	Lewis, SJ (corresponding author), Portland Cardiovasc Inst, Legacy Hlth Syst, 2222 NW Lovejoy St, Portland, OR 97210 USA.		Glasser, Stephen P/S-5996-2019	Glasser, Stephen P/0000-0001-9620-6406				ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BEARDEN DM, 1992, DRUG THERAPEUTICS, V22, P1; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BILHEIMER DW, 1991, ATHEROSCLEROSIS, V91, pS35, DOI 10.1016/0021-9150(91)90205-H; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; Corti MC, 1997, ANN INTERN MED, V126, P753, DOI 10.7326/0003-4819-126-10-199705150-00001; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DEVLIN W, 1995, AM J CARDIOL, V75, P573, DOI 10.1016/S0002-9149(99)80619-5; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GORDON DJ, 1989, AM J CARDIOL, V63, pH48; Graves E J, 1991, Vital Health Stat 13, P1; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Hazzard W R, 1992, Clin Geriatr Med, V8, P89; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; Krumholz HM, 1996, ANN INTERN MED, V124, P292, DOI 10.7326/0003-4819-124-3-199602010-00002; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; KRUMHOLZ HM, 1993, ANN INTERN MED, V119, P1084, DOI 10.7326/0003-4819-119-11-199312010-00005; LEAF DA, 1994, GERIATRICS, V49, P35; LEE ET, 1992, STATISTICAL METHODS, P250; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; Miettinen TA, 1997, CIRCULATION, V96, P4211; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; Paul SD, 1996, AM HEART J, V131, P710, DOI 10.1016/S0002-8703(96)90275-6; Qizilbash N, 1995, LANCET, V346, P1647; Rich MW, 1996, CLIN GERIATR MED, V12, P141, DOI 10.1016/S0749-0690(18)30250-7; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SACKS FM, 1991, AM J CARDIOL, V68, P1436, DOI 10.1016/0002-9149(91)90276-Q; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SHEPHERD J, 1998, DRUGS AFFECTING LIPI, P108; Snedecor GW, 1980, STATISTICAL METHODS, P64; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; TIKKANEN MJ, 1988, EUR HEART J, V9, P79, DOI 10.1093/eurheartj/9.suppl_D.79; *US PHS, 1984, DHHS PUB PHS	49	306	320	1	60	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					681	+		10.7326/0003-4819-129-9-199811010-00002	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841599				2022-12-28	WOS:000076785200001
J	Ohkusa, T; Takashimizu, I; Fujiki, K; Suzuki, S; Shimoi, K; Horiuchi, T; Sakurazawa, T; Ariake, K; Ishii, K; Kumagai, J; Tanizawa, T				Ohkusa, T; Takashimizu, I; Fujiki, K; Suzuki, S; Shimoi, K; Horiuchi, T; Sakurazawa, T; Ariake, K; Ishii, K; Kumagai, J; Tanizawa, T			Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							GASTRIC POLYPS; MALIGNANT TRANSFORMATION; INFECTION; CANCER	Background: Helicobacter pylori infection is common in patients with hyperplastic gastric polyps. Objective: To study the effect of eradication of H. pylori on the clinical course of patients with hyperplastic gastric polyps. Design: Single-blind, randomized, controlled trial. Setting: University-based gastroenterology outpatient clinic. Patients: 35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter. Intervention: Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment. Measurements: Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured. Results: In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 +/- 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01). Conclusions: Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.	Tokyo Med & Dent Univ, Sch Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU)	Ohkusa, T (corresponding author), Tokyo Med & Dent Univ, Sch Med, Dept Internal Med 1, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	ohmed1@med.tmd.ac.jp	大草, 敏史/HGD-2376-2022					Asaka M, 1997, GASTROENTEROLOGY, V113, pS56, DOI 10.1016/S0016-5085(97)80013-3; BOLAND CR, 1991, TXB GASTROENTEROLOGY, P1373; Bonilla Palacios J. J., 1994, Acta Gastroenterologica Latinoamericana, V24, P77; DAIBO M, 1987, AM J GASTROENTEROL, V82, P1016; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Ginsberg GG, 1996, AM J GASTROENTEROL, V91, P714; MOCEK FW, 1994, ANN INTERN MED, V120, P1007, DOI 10.7326/0003-4819-120-12-199406150-00006; NEIMARK S, 1982, AM J GASTROENTEROL, V77, P585; Ohkusa T, 1997, J CLIN GASTROENTEROL, V25, P317, DOI 10.1097/00004836-199707000-00004; REMMELE W, 1978, ENDOSCOPY, V10, P63, DOI 10.1055/s-0028-1098265; RUBEN C, 1991, TXB GASTROENTEROLOGY, P2479; SAITO Y, 1992, EUR J GASTROEN HEPAT, V4, pS89; SOBHANI I, 1993, GASTROENTEROLOGY, V105, P22; Sugiyama A, 1998, CANCER RES, V58, P2067; Suzuki S, 1997, GASTROINTEST ENDOSC, V46, P566, DOI 10.1016/S0016-5107(97)70020-8; Waldum HL, 1996, GUT, V39, P649, DOI 10.1136/gut.39.5.649; WAUTERS GV, 1990, AM J GASTROENTEROL, V85, P1395; Yasunaga Y, 1996, GUT, V39, P787, DOI 10.1136/gut.39.6.787; 1988, GASTROINTEST ENDO S3, V34, P18	19	98	103	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					712	715		10.7326/0003-4819-129-9-199811010-00006	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841603				2022-12-28	WOS:000076785200005
J	Hatch, T				Hatch, T			Genome sequencing - Chlamydia: Old ideas crushed, new mysteries bared	SCIENCE			English	Editorial Material									Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Hatch, T (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA.	thatch@utmem1.utmem.edu						Bannantine JP, 1998, MOL MICROBIOL, V28, P1017, DOI 10.1046/j.1365-2958.1998.00867.x; Bavoil PM, 1998, MOL MICROBIOL, V28, P860, DOI 10.1046/j.1365-2958.1998.00861.x; EVERETT KDE, 1995, J BACTERIOL, V177, P877, DOI 10.1128/jb.177.4.877-882.1995; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Grayston J T, 1997, Cardiologia, V42, P1145; Gura T, 1998, SCIENCE, V281, P35, DOI 10.1126/science.281.5373.35; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hsia RC, 1997, MOL MICROBIOL, V25, P351, DOI 10.1046/j.1365-2958.1997.4701834.x; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Longbottom D, 1998, INFECT IMMUN, V66, P1317, DOI 10.1128/IAI.66.4.1317-1324.1998; MATSUMOTO A, 1982, J BACTERIOL, V150, P358, DOI 10.1128/JB.150.1.358-364.1982; MATSUMOTO A, 1998, MICROBIOLOGY CHLAMYD, P21; McClarty Grant, 1994, Trends in Microbiology, V2, P157, DOI 10.1016/0966-842X(94)90665-3; MOULDER JW, 1993, INFECT AGENT DIS, V2, P87; STEPHENS R, COMMUNICATION; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754	16	20	22	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					638	639		10.1126/science.282.5389.638	http://dx.doi.org/10.1126/science.282.5389.638			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841415				2022-12-28	WOS:000076607500029
J	Lee, IM; Paffenbarger, RS				Lee, IM; Paffenbarger, RS			Life is sweet: candy consumption and longevity	BRITISH MEDICAL JOURNAL			English	Article							CHOCOLATE		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Lee, IM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.				NCI NIH HHS [CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doll R, 1997, BRIT MED J, V315, P1664, DOI 10.1136/bmj.315.7123.1664; Krummel DA, 1996, CRIT REV FOOD SCI, V36, P31, DOI 10.1080/10408399609527717; *NAT CONF ASS, CHOC MAN ASS; Sanbongi C, 1997, CELL IMMUNOL, V177, P129, DOI 10.1006/cimm.1997.1109; Waterhouse AL, 1996, LANCET, V348, P834, DOI 10.1016/S0140-6736(05)65262-2	5	25	26	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1683	1684		10.1136/bmj.317.7174.1683	http://dx.doi.org/10.1136/bmj.317.7174.1683			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857124	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000077742300010
J	Smith, R				Smith, R			BMJ bans anniversaries - We promise our readers no more boring anniversaries	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1674	1674		10.1136/bmj.317.7174.1674	http://dx.doi.org/10.1136/bmj.317.7174.1674			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857120	Green Published			2022-12-28	WOS:000077742300006
J	Willis, J				Willis, J			The accelerating pace of change	BRITISH MEDICAL JOURNAL			English	Article									Alton Hlth Ctr, Alton GU34 2QX, Hants, England		Willis, J (corresponding author), Alton Hlth Ctr, Alton GU34 2QX, Hants, England.							ABBIE A, 1897, SCOTTISH STUDENTS SO, P220; KARR A, 1849, GUEPES           JAN, P305; TENNYSON A, 1981, EVERYMANS BOOK ENGLI; Willis J, 1995, PARADOX PROGR	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1731	1732		10.1136/bmj.317.7174.1731	http://dx.doi.org/10.1136/bmj.317.7174.1731			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857153	Green Published			2022-12-28	WOS:000077742300044
J	Hudson, PJ; Dobson, AP; Newborn, D				Hudson, PJ; Dobson, AP; Newborn, D			Prevention of population cycles by parasite removal	SCIENCE			English	Article							RED GROUSE	The regular cyclic fluctuations in vertebrate numbers have intrigued scientists for more than 70 years, and yet the cause of such cycles has not been clearly demonstrated. Red grouse populations in Britain exhibit cyclic fluctuations in abundance, with periodic crashes. The hypothesis that these fluctuations are caused by the impact of a nematode parasite on host fecundity was tested by experimentally reducing parasite burdens in grouse. Treatment of the grouse population prevented population crashes, demonstrating that parasites were the cause of the cyclic fluctuations.	Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Game Conservancy Trust, Swaledale DL8 3HG, N Yorkshire, England	University of Stirling; Princeton University	Hudson, PJ (corresponding author), Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland.		Hudson, Peter/AAB-8080-2020	Hudson, Peter/0000-0003-0468-3403				DOBSON AP, 1992, J ANIM ECOL, V61, P487, DOI 10.2307/5339; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; Hudson P. J., 1985, Ecology and genetics of host-parasite interactions. International symposium, Keele University, 12-13 July 1984, P77; Hudson P.J., 1992, GROUSE SPACE TIME; HUDSON PJ, 1986, J ANIM ECOL, V55, P85, DOI 10.2307/4694; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; MAY RM, 1973, COMPLEXITY STABILITY; MOSS R, 1991, IBIS, V133, P113, DOI 10.1111/j.1474-919X.1991.tb07674.x; POTTS GR, 1986, J ANIM ECOL, V55, P21	9	650	675	1	264	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2256	2258		10.1126/science.282.5397.2256	http://dx.doi.org/10.1126/science.282.5397.2256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856948				2022-12-28	WOS:000077645800046
J	Weiner, JM; Abramson, MJ; Puy, RM				Weiner, JM; Abramson, MJ; Puy, RM			Intranasal corticosteroids versus oral H-1, receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AQUEOUS NASAL SPRAY; BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; TERFENADINE TABLETS; HAY-FEVER; PERENNIAL RHINITIS; TRIAMCINOLONE ACETONIDE; PROPHYLACTIC TREATMENT; BUDESONIDE; LORATADINE	Objective To determine whether intranasal corticosteroids are superior to oral H-1 receptor antagonists (antihistamines) in the treatment of allergic rhinitis. Design Meta-analysis of randomised controlled trials comparing intranasal corticosteroids with oral antihistamines. Setting Randomised controlled trials conducted worldwide and published between 1966 and 1997. Subjects 2267 subjects with allergic rhinitis in 16 randomised controlled trials. Main outcome measures Nasal blockage, nasal discharge, sneezing, nasal itch, postnasal drip, nasal discomfort, total nasal symptoms, nasal resistance, and eye symptoms and global ratings. Outcomes measured on different scales were combined to determine pooled odds ratios (categorical outcomes) or standardised mean differences (continuous outcomes). Assessment of heterogeneity between studies, and subgroup analyses of eye symptoms, were undertaken. Results Intranasal corticosteroids produced significantly greater relief than oral antihistamines of nasal blockage (standardised mean difference - 0.63, 95% confidence interval - 0.73 to - 0.53), nasal discharge (- 0.5, - 0.6 to - 0.4), sneezing (- 0.49, - 0.59 to - 0.39), nasal itch (- 0.38, - 0.49 to - 0.21), postnasal drip (- 0.24, - 0.42 to - 0.06), and total nasal symptoms (- 0.42, - 0.53 to - 0.32), and global ratings gave an odds ratio for deterioration of symptoms of 0.26 (0.08 to 0.8). There were no significant differences between treatments for nasal discomfort, nasal resistance, or eve symptoms. The effects on sneezing, total nasal symptoms, and eye symptoms were significantly heterogeneous between studies. Other combined outcomes Were homogeneous between studies. Subgroup analysis of the outcome of eye symptoms suggested that the duration of assessment (averaged mean score over the study period versus mean score at end of study period) might have accounted for the heterogeneity. Conclusion The results of this systematic review, together with data on safety and cost effectiveness, support the use of intranasal corticosteroids over oral antihistamines as first line treatment for allergic rhinitis.	Monash Univ, Dept Med, Melbourne, Vic 3181, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia; Monash Univ, Dept Allergy & Clin Immunol, Melbourne, Vic 3181, Australia	Monash University; Monash University; Monash University	Weiner, JM (corresponding author), Monash Univ, Dept Med, Melbourne, Vic 3181, Australia.	jmweiner@allergynet.com.au	Puy, Robert/AAU-6374-2020; Abramson, Michael/AAQ-2671-2020	Puy, Robert/0000-0001-7001-6313; Abramson, Michael/0000-0002-9954-0538; Weiner, John/0000-0001-5895-8973	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDERSSON M, 1993, CLIN OTOLARYNGOL, V18, P30, DOI 10.1111/j.1365-2273.1993.tb00805.x; Australian Bureau of Statistics, 1991, 1989 90 NAT HLTH SUR; BACKHOUSE CI, 1986, J INT MED RES, V14, P35; BENINCASA C, 1994, DRUG INVEST, V8, P225, DOI 10.1007/BF03258482; BERKA C, 1994, J ALLERGY CLIN IMMUN, V93, P165; Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; Brooks CD, 1996, AM J RHINOL, V10, P193, DOI 10.2500/105065896781794941; BUNNAG C, 1992, ALLERGY, V47, P313, DOI 10.1111/j.1398-9995.1992.tb02060.x; CALDERNZAPATA MA, 1997, ALLERGY ALLERGIC DIS; DARNELL R, 1994, CLIN EXP ALLERGY, V24, P1144, DOI 10.1111/j.1365-2222.1994.tb03320.x; Davies R. J., 1993, Rhinology (Utrecht), V31, P159; DICKSON DJ, 1984, BRIT J CLIN PRACT, V38, P416; Drouin MA, 1995, ADV THER, V12, P340; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FROLUND L, 1991, CLIN OTOLARYNGOL, V16, P527, DOI 10.1111/j.1365-2273.1991.tb00965.x; GAWCHIK SM, 1995, PEDIATR ASTHMA ALLER, V9, P25, DOI 10.1089/pai.1995.9.25; Gehanno P, 1997, ALLERGY, V52, P445, DOI 10.1111/j.1398-9995.1997.tb01027.x; HARDING SM, 1976, CLIN ALLERGY, V6, P369, DOI 10.1111/j.1365-2222.1976.tb01918.x; HILBERG O, 1995, ALLERGY, V50, P683, DOI 10.1111/j.1398-9995.1995.tb02586.x; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; Jordana G, 1996, J ALLERGY CLIN IMMUN, V97, P588, DOI 10.1016/S0091-6749(96)70303-2; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; Kozma CM, 1996, CLIN THER, V18, P334, DOI 10.1016/S0149-2918(96)80014-2; LANCER JM, 1987, J LARYNGOL OTOL, V101, P350; LAU SK, 1990, ASIAN PAC J ALLERGY, V8, P109; Lipworth BJ, 1997, THORAX, V52, P476, DOI 10.1136/thx.52.5.476; MARTINATI LC, 1993, CLIN EXP ALLERGY, V23, P986, DOI 10.1111/j.1365-2222.1993.tb00288.x; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; Munk ZM, 1996, ANN ALLERG ASTHMA IM, V77, P277, DOI 10.1016/S1081-1206(10)63320-0; Nathan RA, 1996, ANN ALLERG ASTHMA IM, V77, P255, DOI 10.1016/S1081-1206(10)63315-7; NEGRINI AC, 1995, CLIN EXP ALLERGY, V25, P60, DOI 10.1111/j.1365-2222.1995.tb01003.x; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; PIPKORN U, 1988, CLIN ALLERGY, V18, P253, DOI 10.1111/j.1365-2222.1988.tb02867.x; PRENNER BM, 1997, ALLERGY ASTHMA, V6, P8; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; RAMSDALE E H, 1991, Journal of Allergy and Clinical Immunology, V87, P298, DOI 10.1016/0091-6749(91)91918-J; ROBINSON AC, 1989, CLIN EXP ALLERGY, V19, P569, DOI 10.1111/j.1365-2222.1989.tb02437.x; SACKETT D, 1996, COCHRANE COLLABORATI; SCHOENWETTER W, 1995, CLIN THER, V17, P479, DOI 10.1016/0149-2918(95)80113-8; Selner JC, 1995, CLIN THER, V17, P1099, DOI 10.1016/0149-2918(95)80088-3; SIBBALD B, 1986, CLIN ALLERGY, V16, P203, DOI 10.1111/j.1365-2222.1986.tb00767.x; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SIMPSON RJ, 1994, ANN ALLERGY, V73, P497; STRICKER WE, 1994, ANN ALLERGY, V72, P86; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Vervloet D, 1997, CLIN DRUG INVEST, V13, P291, DOI 10.2165/00044011-199713060-00001; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOOD SF, 1986, CLIN ALLERGY, V16, P195, DOI 10.1111/j.1365-2222.1986.tb00766.x; ZIERING RW, 1989, POSTGRAD MED, V85, P183	57	393	409	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1998	317	7173					1624	1629		10.1136/bmj.317.7173.1624	http://dx.doi.org/10.1136/bmj.317.7173.1624			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848901	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077602100024
J	Clouse, WD; Hallett, JW; Schaff, HV				Clouse, WD; Hallett, JW; Schaff, HV			Improved prognosis of thoracic aortic aneurysms - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARFANS-SYNDROME; NATURAL-HISTORY; SIZE	Context.-Managing thoracic aortic aneurysms identified incidentally by increased use of computed tomography, echocardiography, and magnetic resonance imaging is problematic, especially in the elderly. Objective.-To ascertain whether the previously reported poor prognosis for individuals with thoracic aortic aneurysms has changed with better medical therapies and improved surgical techniques that can now be applied to aneurysm management. Design.-Population-based cohort study. Setting and Patients.-All 133 patients with the diagnosis of degenerative thoracic aortic aneurysms among Olmsted County, Minnesota, residents between 1980 and 1994 compared with a previously reported cohort of similar patients between 1951 and 1980. Main Outcome Measures.-The primary clinical end points were incidence, cumulative rupture risk, rupture risk as a function of aneurysm size, and survival. Results.-In contrast to abdominal aortic aneurysms, for which men are affected predominately, 51% of thoracic aortic aneurysms were identified in women who were considerably older at recognition than men (mean age, 75.9 vs 62.8 years, respectively; P = .01). The overall incidence rate of 10.4 per 100 000 person-years (95% confidence interval [CI], 8.6-12.2) between 1980 and 1994 was more than 3-fold higher than the rate from 1951 to 1980. The cumulative risk of rupture was 20% after 5 years. Seventy-nine percent of ruptures occurred in women (P = .01). The 5-year risk of rupture as a function of aneurysm size at recognition was 0% for aneurysms less than 4 cm in diameter, 16% (95% CI, 4%-28%) fd those 4 to 5.9 cm, and 31% (95% CI, 5%-56%) for aneurysms 6 cm or more. Overall 5-year survival improved to 56% (95% CI, 48%-66%) between 1980 and 1994 compared with only 19% between 1951 and 1980 (P < .01). Conclusions.-In this population, elderly women represent an increasing portion of all patients with clinically recognized thoracic aortic aneurysms and constitute the majority of patients whose aneurysm eventually ruptures. Overall survival for thoracic aortic aneurysms has improved significantly in the past 15 years.	Mayo Clin & Mayo Fdn, Div Vasc Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Cardiovasc Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Epidemiol Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Hallett, JW (corresponding author), Mayo Clin & Mayo Fdn, Div Vasc Res, 200 1st St SW, Rochester, MN 55905 USA.			Schaff, Hartzell/0000-0003-0994-027X	NIAMS NIH HHS [AR 30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERSTRALH EJ, 1992, MAYO CLIN TECHNICAL, V49; BICKERSTAFF L, 1986, SURGERY, V92, P1103; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Coady MA, 1997, J THORAC CARDIOV SUR, V113, P476, DOI 10.1016/S0022-5223(97)70360-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD ES, 1991, ANN SURG, V213, P417, DOI 10.1097/00000658-199105000-00006; CRAWFORD ES, 1989, J THORAC CARDIOV SUR, V98, P659; CRONENWETT JL, 1985, SURGERY, V98, P472; DAPUNT OE, 1994, J THORAC CARDIOV SUR, V107, P1323, DOI 10.1016/S0022-5223(94)70054-0; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; HALLETT JW, 1993, J VASC SURG, V18, P684, DOI 10.1016/0741-5214(93)90078-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; MCNAMARA JJ, 1978, ANN THORAC SURG, V26, P468, DOI 10.1016/S0003-4975(10)62927-X; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PERKO MJ, 1995, ANN THORAC SURG, V59, P1204, DOI 10.1016/0003-4975(95)00132-5; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SVENSSON LG, 1993, CHEST, V104, P1248, DOI 10.1378/chest.104.4.1248; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; TAHERNIA AC, 1993, SOUTH MED J, V86, P305, DOI 10.1097/00007611-199303000-00012	21	330	351	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1926	1929		10.1001/jama.280.22.1926	http://dx.doi.org/10.1001/jama.280.22.1926			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851478	Bronze			2022-12-28	WOS:000077364500037
J	Baxter, J; Crabtree, L; Hildreth, A; Gray, C; O'Connell, J				Baxter, J; Crabtree, L; Hildreth, A; Gray, C; O'Connell, J			Atrial fibrillation	LANCET			English	Letter							COMMUNITY		Sunderland Royal Hosp, Dept Med Elderly, Sunderland SR4 7TP, England; Univ Newcastle, Dept Geriatr Med, Sunderland SR4 7TP, England	Sunderland Royal Hospital; Newcastle University - UK	O'Connell, J (corresponding author), Sunderland Royal Hosp, Dept Med Elderly, Sunderland SR4 7TP, England.							OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Sudlow M, 1998, BRIT MED J, V317, P327, DOI 10.1136/bmj.317.7154.327; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1858	1858		10.1016/S0140-6736(05)79924-4	http://dx.doi.org/10.1016/S0140-6736(05)79924-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851411				2022-12-28	WOS:000077337900060
J	Low, AJ				Low, AJ			Comparison of effectiveness of direct recording scale and dial scale	LANCET			English	Article							MOTHERS		McGill Univ, Montreal, PQ H2V 4G7, Canada	McGill University	Low, AJ (corresponding author), McGill Univ, 5370 Pk Ave, Montreal, PQ H2V 4G7, Canada.			Low, Andrea/0000-0002-7088-4556				MCAULIFFE JF, 1993, J TROP PEDIATRICS, V39, P370, DOI 10.1093/tropej/39.6.370; Sohal H, 1997, LANCET, V350, P562, DOI 10.1016/S0140-6736(05)63138-8	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1832	1832		10.1016/S0140-6736(05)79895-0	http://dx.doi.org/10.1016/S0140-6736(05)79895-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851394				2022-12-28	WOS:000077337900022
J	Zandbergen, EGJ; de Haan, RJ; Stoutenbeek, CP; Koelman, JHTM; Hijdra, A				Zandbergen, EGJ; de Haan, RJ; Stoutenbeek, CP; Koelman, JHTM; Hijdra, A			Systematic review of early prediction of poor outcome in anoxic-ischaemic coma	LANCET			English	Article							SOMATOSENSORY EVOKED-POTENTIALS; HOSPITAL CARDIAC-ARREST; HYPOXIC-ISCHEMIC COMA; PROGNOSTIC VALUE; CARDIOPULMONARY-RESUSCITATION; MEDIAN NERVE; NONTRAUMATIC COMA; POSTANOXIC COMA; MIDAZOLAM; SURVIVORS	Background Studies to assess the prognostic value of early neurological and neurophysiological findings in patients with anoxic-ischaemic coma have not led to precise, generally accepted, prognostic rules. We did a systematic review of the relevant literature to assess whether such rules could be derived from the combined results of these studies. Methods From Medline and Embase databases we selected studies concerning patients older than 10 years with anoxic-ischaemic coma in which findings from early neurological examination, electroencephalogram (EEG), or somatosensory evoked potentials (SSEP) were related to poor outcome-defined as death dr survival in a vegetative state. We selected variables with a specificity of 100% for poor outcome in ail studies, and expressed the overall prognostic accuracy of these variables as pooled positive-likelihood ratios and as 95% Cls of the pooled false-positive test rates. Findings In 33 studies, 14 prognostic variables were studied, three of which had a specificity of 100%: absence of pupillary light reflexes on day 3 (pooled positive-likelihood ratio 10.5 [95% CI 2.1-52.4]; 95% CI pooled false-positive test rate 0-11.9%): absent motor response to pain on day 3 (16.8 [3.4-8.41]; 0-6.7%); and bilateral absence of early cortical SSEP within the first week (12.0 [5.3-27.6]; 0-2.0%). EEG recordings with an isoelectric or burst-suppression pattern had a specificity of 100% in five of six relevant studies (pooled positive-likelihood ratio 9.0 [2.5-33.1]; 95% CI pooled false-positive test rate 0.2-5.9%). These characteristics were present in 19%, 31%, 33%, and 33% of pooled patient populations, respectively. For the 11 SSEP studies, results did not significantly differ between studies in which the treating physicians were or were not masked from the test result, prospective and retrospective studies, studies with short and long follow-up periods, and studies with high or low overall poor outcome. Interpretation SSEP has the smallest CI of its pooled positive-likelihood ratio and its pooled false-positive test rate. Because evoked potentials are also the least susceptible to metabolic changes and drugs, recording of SSEP is the most useful method to predict poor outcome.	Univ Amsterdam, Acad Med Ctr, Dept Neurol & Clin Neurophysiol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Zandbergen, EGJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol & Clin Neurophysiol, POB 22660, NL-1100 DD Amsterdam, Netherlands.							AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ALLISON T, 1991, BRAIN, V114, P2465, DOI 10.1093/brain/114.6.2465; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; AUSTIN EJ, 1988, NEUROLOGY, V38, P773, DOI 10.1212/WNL.38.5.773; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; BASSETTI C, 1987, EEG-EMG-Z ELEK ELEKT, V18, P97; BASSETTI C, 1990, SCHWEIZ MED WSCHR, V120, P1425; BEREK K, 1995, STROKE, V26, P543, DOI 10.1161/01.STR.26.4.543; BERTINI G, 1989, CRIT CARE MED, V17, P627, DOI 10.1097/00003246-198907000-00006; BRIERLEY JB, 1971, LANCET, V2, P560; BRUNKO E, 1987, ELECTROENCEPHALOGR C, V66, P14; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CLOCHE R, 1968, ANESTH ANALG REANIM, V25, P579; COULTHARD P, 1993, BRIT J ORAL MAX SURG, V31, P28, DOI 10.1016/0266-4356(93)90093-C; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EDGREN E, 1987, CRIT CARE MED, V15, P820, DOI 10.1097/00003246-198709000-00004; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; HIJDRA A, 1984, NEUROLOGY, V34, P1501, DOI 10.1212/WNL.34.11.1501; HOCKADAY JM, 1965, ELECTROEN CLIN NEURO, V18, P575, DOI 10.1016/0013-4694(65)90075-1; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; JENNETT B, 1975, LANCET, V1, P480; KANO T, 1992, RESUSCITATION, V23, P235, DOI 10.1016/0300-9572(92)90007-Y; KOHT A, 1988, ANESTH ANALG, V67, P435; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; LEMI H, 1973, J NEUROL NEUROSUR PS, V36, P997; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MOLLER M, 1978, ACTA MED SCAND, V203, P31; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P177; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; SALTUARI L, 1994, LANCET, V343, P1052, DOI 10.1016/S0140-6736(94)90176-7; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SLOAN TB, 1990, BRIT J ANAESTH, V64, P590, DOI 10.1093/bja/64.5.590; SNYDER BD, 1980, NEUROLOGY, V30, P1292, DOI 10.1212/WNL.30.12.1292; SNYDER BD, 1980, NEUROLOGY, V30, P52, DOI 10.1212/WNL.30.1.52; SORENSEN K, 1978, J NEUROL NEUROSUR PS, V41, P840, DOI 10.1136/jnnp.41.9.840; THOMASSEN A, 1978, ACTA ANAESTH SCAND, V22, P483, DOI 10.1111/j.1399-6576.1978.tb01327.x; TSUBOKAWA T, 1990, Brain Injury, V4, P329, DOI 10.3109/02699059009026186; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; WIJDICKS EFM, 1994, ANN NEUROL, V35, P239, DOI 10.1002/ana.410350219; WILLOUGHBY JO, 1974, BMJ-BRIT MED J, V3, P437, DOI 10.1136/bmj.3.5928.437; YAMASHITA S, 1995, INTERNAL MED, V34, P71, DOI 10.2169/internalmedicine.34.71	49	339	356	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1808	1812		10.1016/S0140-6736(98)04076-8	http://dx.doi.org/10.1016/S0140-6736(98)04076-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851380				2022-12-28	WOS:000077337900008
J	LeRoy, G; Orphanides, G; Lane, WS; Reinberg, D				LeRoy, G; Orphanides, G; Lane, WS; Reinberg, D			Requirement of RSF and FACT for transcription of chromatin templates in vitro	SCIENCE			English	Article							RNA-POLYMERASE-II; REMODELING FACTOR; NUCLEOSOMAL DNA; PURIFICATION; BINDING; SEQUENCES; PROTEINS; COMPLEX; ISWI	Transcription of naked DNA in vitro requires the general transcription factors and RNA polymerase II. However, this minimal set of factors is not sufficient for transcription when the DNA template is packaged into chromatin. Here, a factor that facilitates activator-dependent transcription initiation on chromatin templates was purified. This factor, remodeling and spacing factor (RSF), has adenosine triphosphate-dependent nucleosome-remodeling and spacing activities. Polymerases that initiate transcription with RSF can only extend their transcripts in the presence of FACT (facilitates chromatin transcription). Thus, the minimal factor requirements for activator-dependent transcription on chromatin templates in vitro have been defined.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucleic Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbdf@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIHARA T, AB010882 DNA DAT BAN; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bulger M., 1994, METH MOL G, V5, P241; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; ORPHANIDES G, UNPUB; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587	25	249	259	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1900	1904		10.1126/science.282.5395.1900	http://dx.doi.org/10.1126/science.282.5395.1900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836642				2022-12-28	WOS:000077338100052
J	Yu, XM; Salter, MW				Yu, XM; Salter, MW			Gain control of NMDA-receptor currents by intracellular sodium	NATURE			English	Article							HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; CHANNEL ACTIVITY; CALCIUM; NA+; KINASE; INACTIVATION; PHOSPHATASES; ACTIVATION; TRANSPORT	The influx of Na+ is fundamental to electrical signalling in the nervous system and is essential for such basic signals as action potentials and excitatory postsynaptic potentials(1). During periods of bursting or high levels of discharge activity, large increases in intracellular Na+ concentration ([Na+](i)) are produced in neuronal soma and dendrites(2-4). However, the intracellular signalling function of raised postsynaptic: [Na+](i) is unknown. Here we show that [Na+](i) regulates the function of NMDA (N-methyl-D-aspartate) receptors, a principal subtype of glutamate receptor(5). NMDA-receptor-mediated whole-cell currents and NMDA-receptor single-channel activity were increased by raising [Na+](i) and channel activity decreased upon lowering [Na+](i); therefore. the activity of NMDA channels tracks changes in [Na+](i). We found that the sensitivity of the channel to Na+ was set by a Src kinase that is associated with the channel. Raising [Na+](i) selectively increased synaptic responses mediated by NMDA receptors, but not by non-NMDA receptors. Thus, the change in postsynaptic [Na+](i) that occurs during neuronal activity is a signal for controlling the gain of excitatory synaptic transmission. This mechanism may be important for NMDA-receptor-dependent plasticity and toxicity in the central nervous system.	Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Oral Physiol, Toronto, ON M5G 1G6, Canada; Clarke Inst Psychiat, Mol Neurobiol Sect, Toronto, ON M5T 1R8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Salter, MW (corresponding author), Hosp Sick Children, Programme Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; Callaway JC, 1997, J NEUROPHYSIOL, V77, P145, DOI 10.1152/jn.1997.77.1.145; Chidekel AS, 1997, EXP NEUROL, V146, P403, DOI 10.1006/exnr.1997.6544; Congar P, 1997, J NEUROSCI, V17, P5366; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.ph.58.030196.002025; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; Hille B., 1992, IONIC CHANNELS EXCIT; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; Medina I, 1996, J PHYSIOL-LONDON, V495, P411, DOI 10.1113/jphysiol.1996.sp021603; NOWAK LM, 1992, NEURON, V8, P181, DOI 10.1016/0896-6273(92)90119-X; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Parri HR, 1998, J NEUROSCI, V18, P854; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573, DOI 10.1113/jphysiol.1997.sp021951; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SANDEAUX R, 1982, BIOCHIM BIOPHYS ACTA, V684, P127, DOI 10.1016/0005-2736(82)90056-6; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	30	126	132	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					469	474		10.1038/24877	http://dx.doi.org/10.1038/24877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853755				2022-12-28	WOS:000077370100055
J	Edwards, G; Dora, KA; Gardener, MJ; Garland, CJ; Weston, AH				Edwards, G; Dora, KA; Gardener, MJ; Garland, CJ; Weston, AH			K+ is an endothelium-derived hyperpolarizing factor in rat arteries	NATURE			English	Article							SMOOTH-MUSCLE; POTASSIUM CHANNELS; DEPENDENT HYPERPOLARIZATION; MESENTERIC-ARTERY; CEREBRAL-ARTERIES; NITRIC-OXIDE; CORONARY; CELLS; RELAXATION; MECHANISMS	In arteries, muscarinic agonists such as acetylcholine release an unidentified, endothelium-derived hyperpolarizing factor (EDHF) which is neither prostacyclin nor nitric oxide(1-3). Here we show that EDHF-induced hyperpolarization of smooth muscle and relaxation of small resistance arteries are inhibited by ouabain plus Ba2+; ouabain is a blocker of Na+/K+ ATPase(4) and Ba2+ blocks inwardly rectifying K+ channels(5). Small increases in the amount of extracellular K+ mimic these effects of EDHF in a ouabain- and Ba2+-sensitive, but endothelium-independent, manner. Acetylcholine hyperpolarizes endothelial tells and increases the K+ concentration in the myoendothelial space; these effects are abolished by charybdotoxin plus apamin. Hyperpolarization of smooth muscle by EDHF is also abolished by this toxin combination, but these toxins do not affect the hyperpolarization of smooth muscle by added K+. These data show that EDHF is K+ that effluxes through charybdotoxin- and apamin-sensitive K+ channels on endothelial cells. The resulting increase in myoendothelial K+ concentration hyperpolarizes and relaxes adjacent smooth-muscle cells by activating Ba2+-sensitive K+ channels and Na+/K+ ATPase, These results show that fluctuations in K+ levels originating within the blood vessel itself are important in regulating mammalian blood pressure and flow.	Univ Manchester, Sch Biol Sci, Div Physiol Pharmacol & Toxicol, Manchester M13 9PT, Lancs, England; Univ Bristol, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Manchester; University of Bristol	Weston, AH (corresponding author), Univ Manchester, Sch Biol Sci, Div Physiol Pharmacol & Toxicol, G38 Stopford Bldg, Manchester M13 9PT, Lancs, England.	aweston@man.ac.uk	Garland, Christopher/O-1254-2015	Garland, Christopher/0000-0003-0848-6044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BOLTON TB, 1984, J PHYSIOL-LONDON, V351, P549, DOI 10.1113/jphysiol.1984.sp015262; BUENGER R, 1976, Pfluegers Archiv European Journal of Physiology, V363, P27; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chataigneau T, 1998, BRIT J PHARMACOL, V123, P574, DOI 10.1038/sj.bjp.0701629; Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x; Danker T, 1996, PFLUG ARCH EUR J PHY, V433, P71, DOI 10.1007/s004240050250; Dora KA, 1997, P NATL ACAD SCI USA, V94, P6529, DOI 10.1073/pnas.94.12.6529; EDWARDS FR, 1988, J PHYSIOL-LONDON, V404, P437, DOI 10.1113/jphysiol.1988.sp017298; Edwards G, 1997, Prog Drug Res, V49, P93; Edwards G, 1998, PROG DRUG RES, V50, P107; FEELISCH M, 1987, EUR J PHARMACOL, V142, P465, DOI 10.1016/0014-2999(87)90090-2; FELETOU M, 1988, BRIT J PHARMACOL, V93, P515, DOI 10.1111/j.1476-5381.1988.tb10306.x; GARCIA ML, 1995, AM J PHYSIOL-CELL PH, V269, pC1, DOI 10.1152/ajpcell.1995.269.1.C1; GARLAND CJ, 1992, BRIT J PHARMACOL, V105, P429, DOI 10.1111/j.1476-5381.1992.tb14270.x; GARLAND CJ, 1995, TRENDS PHARMACOL SCI, V16, P23, DOI 10.1016/S0165-6147(00)88969-5; GORDON JL, 1983, BRIT J PHARMACOL, V79, P531, DOI 10.1111/j.1476-5381.1983.tb11028.x; HOEFFNER U, 1989, AM J PHYSIOL, V257, pH330, DOI 10.1152/ajpheart.1989.257.1.H330; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KUSCHINSKY W, 1972, CIRC RES, V31, P240, DOI 10.1161/01.RES.31.2.240; Marchenko SM, 1996, J PHYSIOL-LONDON, V492, P53, DOI 10.1113/jphysiol.1996.sp021288; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902, DOI 10.1152/ajpheart.1990.259.3.H902; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; Paterson DJ, 1996, ACTA PHYSIOL SCAND, V156, P287, DOI 10.1046/j.1365-201X.1996.190000.x; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; Prior HM, 1998, CARDIOVASC RES, V37, P780, DOI 10.1016/S0008-6363(97)00237-X; WALDRON GJ, 1994, CAN J PHYSL PHARM S1, V72, P11; Wellman GC, 1996, PFLUG ARCH EUR J PHY, V432, P355, DOI 10.1007/s004240050144; Zygmunt PM, 1996, BRIT J PHARMACOL, V117, P1600, DOI 10.1111/j.1476-5381.1996.tb15327.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V122, P1679, DOI 10.1038/sj.bjp.0701601	30	910	930	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					269	272		10.1038/24388	http://dx.doi.org/10.1038/24388			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834033				2022-12-28	WOS:000077110400048
J	Merabet, L; Desautels, A; Minville, K; Casanova, C				Merabet, L; Desautels, A; Minville, K; Casanova, C			Motion integration in a thalamic visual nucleus	NATURE			English	Article							ANTERIOR ECTOSYLVIAN SULCUS; AREA MT; CAT; PULVINAR; STRIATE; ORGANIZATION; ORIENTATION; SELECTIVITY; DIRECTION; NEURONS	Thalamic nuclei have long been regarded as passive relay stations for sensory information en route to higher level processing in the cerebral cortex. Recently, physiological and theoretical studies have reassessed the role of the thalamus and it has been proposed that thalamic nuclei may actively participate with cortical areas in processing specific information(1-4). In support of this idea, we now show that a subset of neurons in an extrageniculate visual nucleus, the lateral-posterior pulvinar complex, can signal the true direction of motion of a plaid pattern, indicating that thalamic cells can integrate different motion signals into a coherent moving percept(5-8). This is the first time that these computations have been found to occur outside the higher-order cortical areas(5,6,9,10). Our fi(n)dings implicate extrageniculate cortico-thalamo-cortical loops in the dynamic processing of image motion, and, more generally, as basic computational modules involved in analysing specific features of complex visual scenes.	Univ Montreal, Sch Optometry, Visual Neurosci Lab, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Casanova, C (corresponding author), Univ Montreal, Sch Optometry, Visual Neurosci Lab, CP 6128,Succ Centreville, Montreal, PQ H3C 3J7, Canada.	casanovc@ere.umontreal.ca	Merabet, Lotfi B./V-2735-2017; merabet, lotfi/AAU-8259-2020	Merabet, Lotfi B./0000-0002-8094-9536; merabet, lotfi/0000-0002-8094-9536				ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; Bazhenov M, 1998, J NEUROSCI, V18, P6444; Casanova C, 1996, NEUROSCIENCE, V70, P439, DOI 10.1016/0306-4522(95)00359-2; CHALUPA LM, 1976, J NEUROPHYSIOL, V39, P354, DOI 10.1152/jn.1976.39.2.354; CHALUPA LM, 1991, VISION VISUAL DYSFUN, V4, P140; CREUTZFELDT OD, 1988, PROG BRAIN RES, V75, P307; Crick F, 1998, NATURE, V391, P245, DOI 10.1038/34584; CUSICK CG, 1993, J COMP NEUROL, V336, P1, DOI 10.1002/cne.903360102; FABRETHORPE M, 1986, EXP BRAIN RES, V62, P596; GIZZI MS, 1990, J NEUROPHYSIOL, V63, P1529, DOI 10.1152/jn.1990.63.6.1529; Guillery RW, 1995, J ANAT, V187, P583; HARTH E, 1987, SCIENCE, V237, P184, DOI 10.1126/science.3603015; MILLER R, 1996, BIOL CYBERN, V75, P623; Minville K, 1998, NEUROSCIENCE, V84, P699, DOI 10.1016/S0306-4522(97)00525-3; Movshon Adelson, 1985, PATTERN RECOGNITION, V54, P117, DOI 10.1098/rstb.1998.0333; MUCKE L, 1982, EXP BRAIN RES, V46, P1; MUMFORD D, 1991, BIOL CYBERN, V65, P135, DOI 10.1007/BF00202389; MUMFORD D, 1994, LARGE SCALE NEURONAL, P125; NOWLAN SJ, 1995, J NEUROSCI, V15, P1195; PALMER LA, 1978, J COMP NEUROL, V177, P237, DOI 10.1002/cne.901770205; PAYNE BR, 1993, CEREB CORTEX, V3, P1, DOI 10.1093/cercor/3.1.1; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; Scannell J. W., 1997, Society for Neuroscience Abstracts, V23, P1306; Scannell JW, 1996, J NEUROPHYSIOL, V76, P895, DOI 10.1152/jn.1996.76.2.895; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SINGER W, 1994, NATURE, V369, P444, DOI 10.1038/369444a0; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; STONER GR, 1994, VISUAL DETECTION MOT, P253	29	80	81	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1998	396	6708					265	268		10.1038/24382	http://dx.doi.org/10.1038/24382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834032				2022-12-28	WOS:000077110400047
J	Syngal, S; Weeks, JC; Schrag, D; Garber, JE; Kuntz, KM				Syngal, S; Weeks, JC; Schrag, D; Garber, JE; Kuntz, KM			Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations	ANNALS OF INTERNAL MEDICINE			English	Article						colonoscopy; colectomy; colorectal neoplasms, hereditary, nonpolyposis; quality of life; life expectancy	FAMILIAL ADENOMATOUS POLYPOSIS; POUCH-ANAL ANASTOMOSIS; QUALITY-OF-LIFE; COLON-CANCER; ILEORECTAL ANASTOMOSIS; ULCERATIVE-COLITIS; COST-EFFECTIVENESS; PULL-THROUGH; RISK; CARCINOMA	Background: Predisposition genetic testing is now possible for many hereditary cancer syndromes, including hereditary nonpolyposis colorectal cancer. The optimal management of the elevated risk for cancer in carriers of mutations for hereditary nonpolyposis colorectal cancer is unclear. Objective: To assess the life expectancy and quality-adjusted life expectancy benefits derived from endoscopic surveillance and prophylactic colectomy for persons who carry a mutation associated with hereditary nonpolyposis colorectal cancer. Design: Decision analysis model. Lifetime risk for colorectal cancer, efficacy of surveillance and colectomy, stage-specific colorectal cancer mortality, and quality of life were included in the model. Setting: Decision about a cancer prevention strategy at the time of a positive result on genetic testing. Patients: Carriers of a mutation for hereditary nonpolyposis colorectal cancer who were 25 years of age. Interventions: Immediate prophylactic colectomy; delayed colectomy on the basis of age, adenoma, or diagnosis of colorectal cancer; and endoscopic surveillance. Prophylactic surgical options were proctocolectomy with ileoanal anastomosis and subtotal colectomy with ileorectal anastomosis. Measurements: Life expectancy and quality-adjusted life expectancy. Results: All risk-reduction strategies led to large gains in life expectancy for carriers of a mutation for hereditary nonpolyposis colorectal cancer, with benefits ranging from 13.5 years for surveillance to 15.6 years for prophylactic proctocolectomy at 25 years of age compared with no intervention. The benefits of colectomy compared with surveillance decreased with increasing age and were minimal if colectomy was performed at the time of colorectal cancer diagnosis. When health-related quality of life was considered, surveillance led to the greatest quality-adjusted life expectancy benefit (3.2 years compared with proctocolectomy and 0.3 years compared with subtotal colectomy). Conclusions: Colonoscopic surveillance is an effective method of reducing risk far cancer in carriers of a mutation for hereditary nonpolyposis colorectal cancer. The individual patient's choice between prophylactic surgery and surveillance is a complex decision in which personal preferences weigh heavily.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Sch Hlth, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Anal, 718 Huntington Ave,2nd Floor, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R25CA057711] Funding Source: NIH RePORTER; NCI NIH HHS [5R25CA57711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; AMBROZE WL, 1992, DIS COLON RECTUM, V35, P12, DOI 10.1007/BF02053332; BESS MA, 1980, ARCH SURG-CHICAGO, V115, P460; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CORAN AG, 1990, ANN SURG, V212, P242, DOI 10.1097/00000658-199009000-00002; DECOSSE JJ, 1992, BRIT J SURG, V79, P1372, DOI 10.1002/bjs.1800791245; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FITZGIBBONS RJ, 1987, ANN SURG, V206, P289, DOI 10.1097/00000658-198709000-00007; FRUHMORGEN P, 1979, ENDOSCOPY, V11, P146; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; HOEHNER JC, 1994, DIS COLON RECTUM, V37, P824, DOI 10.1007/BF02050149; IWAMA T, 1994, DIS COLON RECTUM, V37, P1024, DOI 10.1007/BF02049317; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; JASS JR, 1992, EUR J GASTROEN HEPAT, V4, P523; KOHLER LW, 1991, GASTROENTEROLOGY, V101, P679; Kollmorgen CF, 1996, DIS COLON RECTUM, V39, P525, DOI 10.1007/BF02058705; LANSPA SJ, 1990, GASTROENTEROLOGY, V98, P1117, DOI 10.1016/0016-5085(90)90323-S; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIJONMARCK CE, 1990, DIS COLON RECTUM, V33, P195, DOI 10.1007/BF02134178; LOVE RR, 1986, SURG GYNECOL OBSTET, V162, P8; LYNCH HT, 1981, MED HYPOTHESES, V7, P1201, DOI 10.1016/0306-9877(81)90063-3; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P849, DOI 10.1007/BF02555362; MECKLIN JP, 1986, DIS COLON RECTUM, V29, P160, DOI 10.1007/BF02555012; *NAT CTR HLTH STAT, 1990, MON VITAL STAT REP, P39; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; *NIH, 1994, NIH PUBL; NUGENT KP, 1993, DIS COLON RECTUM, V36, P1059, DOI 10.1007/BF02047300; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEDERSEN T, 1990, ACTA ANAESTH SCAND, V34, P176, DOI 10.1111/j.1399-6576.1990.tb03066.x; PENNA C, 1994, DIS COLON RECTUM, V37, P157, DOI 10.1007/BF02047539; Provenzale D, 1997, GASTROENTEROLOGY, V113, P7, DOI 10.1016/S0016-5085(97)70074-X; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; ROUFFET F, 1994, DIS COLON RECTUM, V37, P651, DOI 10.1007/BF02054407; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; SettiCarraro P, 1996, BRIT J SURG, V83, P885, DOI 10.1002/bjs.1800830704; SITZMANN JV, 1995, SURGERY, V118, P797, DOI 10.1016/S0039-6060(05)80267-3; STELZNER M, 1989, SURG GYNECOL OBSTET, V169, P187; STEVENSON G, 1989, P PROF C SPONS ACR C; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; von Neumann J., 1953, THEORY GAMES EC BEHA; Wagner JL, 1996, PREVENTION EARLY DET, P321; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Weinstein MC, 1980, CLIN DECISION ANAL; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	54	136	146	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					787	+		10.7326/0003-4819-129-10-199811150-00007	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841584				2022-12-28	WOS:000076984800004
J	Britton, BJ; Evans, JG; Potter, JM				Britton, BJ; Evans, JG; Potter, JM		CRACKPOT Investigators	Does the fly matter? The CRACKPOT study in evidence based trout fishing	BRITISH MEDICAL JOURNAL			English	Article								Objective To investigate the importance of the type of dry fly (artificial floating fly) in catching trout (brown and rainbow) in an English chalkstream. Setting River Kennet, Berkshire. Design Five anglers on five separate occasions spent live hours using a randomly allocated ny from a sample of five types. Participants Five anglers of considerable but varying experience, determination, and opinion. Main outcome measures Number, weight and species of trout caught. Results One ny (Black Gnat) performed significantly worse than the others. The ny most successful in catching brown trout was the Cinnamon Sedge. Conclusion The possible prolongation of doctors' leisure time consequent on the use of unproductive trout flies has resource implications for the NHS. Urgent funding of a definitive, large multiriver trial is needed.	Radcliffe Infirm, Dept Clin Gerontol, Oxford OX2 6HE, England; John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Oxford Wadham Coll, Oxford OX1 3PN, England	Radcliffe Infirmary; University of Oxford; University of Oxford	Evans, JG (corresponding author), Radcliffe Infirm, Dept Clin Gerontol, Oxford OX2 6HE, England.							AELIAN C, 1959, ANIMALIUM NATURA; BERNERS J, 1880, BOKE ST ALBANS; BUCKLAND J, 1986, POCKET GUIDE TROUT S; Frost WE., 1967, TROUT; Halford Frederic, 1886, FLOATING FLIES DRESS; RONALDS A, 1836, FLYFISHERS ENTOMOLOG; Walton Izaak, 1653, COMPLEAT ANGLER	7	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1678	1680		10.1136/bmj.317.7174.1678	http://dx.doi.org/10.1136/bmj.317.7174.1678			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857122	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077742300008
J	Brown, P; Bradley, R				Brown, P; Bradley, R			1755 and all that: a historical primer of transmissible spongiform encephalopathy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PROTEIN; PRION; MICE		NINCDS, CNS Studies Lab, NIH, Bethesda, MD 20892 USA; MAFF, Cent Vet Lab, Addlestone KT15 3NB, Surrey, England	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Brown, P (corresponding author), NINCDS, CNS Studies Lab, NIH, Bldg 36,Room 5B20, Bethesda, MD 20892 USA.	pwb@codon.nih.gov						ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BESNOIT C, 1899, REV VET, V23, P307; Besnoit C., 1898, REV VET, V23, P397; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHANDLER RL, 1961, LANCET, V1, P1378; CUILLE J., 1936, Compte Rendu de l'Academie des Sciences, V203, P1552; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; GAJDUSEK DC, 1966, NATURE, V209, P794, DOI 10.1038/209794a0; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; Gordon W. S., 1946, VET REC, V58, P516; HADLOW WJ, 1959, LANCET, V2, P289; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KLATZO I, 1959, LAB INVEST, V8, P799; LEOPOLDT JG, 1759, NUTZLICHE ERFAHRUNG, P348; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; 1755, J HOUSE COMMONS, V27, P87	20	70	77	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 19	1998	317	7174					1688	1692		10.1136/bmj.317.7174.1688	http://dx.doi.org/10.1136/bmj.317.7174.1688			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857129	Green Published			2022-12-28	WOS:000077742300015
J	Craft, A				Craft, A			Will you present the prizes?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1739	1739		10.1136/bmj.317.7174.1739	http://dx.doi.org/10.1136/bmj.317.7174.1739			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857162	Green Published			2022-12-28	WOS:000077742300057
J	Tarduno, JA; Brinkman, DB; Renne, PR; Cottrell, RD; Scher, H; Castillo, P				Tarduno, JA; Brinkman, DB; Renne, PR; Cottrell, RD; Scher, H; Castillo, P			Evidence for extreme climatic warmth from Late Cretaceous Arctic vertebrates	SCIENCE			English	Article							STABLE ISOTOPIC EVIDENCE; SOUTHERN HIGH-LATITUDES; POLE THERMAL-GRADIENTS; SVERDRUP BASIN; UNITED-STATES; AGE; EVOLUTION; VOLCANISM; CANADA; ISLAND	A Late Cretaceous (92 to 86 million years ago) vertebrate assemblage from the high Canadian Arctic (Axel Heiberg Island) implies that polar climates were warm (mean annual temperature exceeding 14 degrees C) rather than near freezing. The assemblage includes Large (2.4 meters Long) champsosaurs, which are extinct crocodilelike reptiles. Magmatism at six Large igneous provinces at this time suggests that volcanic carbon dioxide emissions helped cause the global warmth.	Royal Tyrrell Museum Palaeontol, Drumheller, AB T0J 0Y0, Canada; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Scripps Inst Oceanog, Div Geol Res, La Jolla, CA 92093 USA	Berkeley Geochronolgy Center; University of California System; University of California San Diego; Scripps Institution of Oceanography	Tarduno, JA (corresponding author), Univ Rochester, Dept Earth & Environm Sci, 601 Elmwood Ave, Rochester, NY 14627 USA.		Scher, Howie/C-4927-2013	Scher, Howie/0000-0002-7778-6772; Tarduno, John/0000-0002-0490-0124; Renne, Paul/0000-0003-1769-5235; Cottrell, Rory/0000-0003-4174-6389				[Anonymous], 1974, NATL ATLAS CANADA, V4th; ARDUNO JA, 1996, T AM GEOPHYS UNION S, V77, P844; Baksi AK, 1997, J GEOL, V105, P629, DOI 10.1086/515966; BALKWILL HR, 1978, AAPG BULL, V62, P1004; Barron E.J., 1985, GEOPHYS MONOGR SER, V32, P546; BESSE J, 1991, J GEOPHYS RES-SOLID, V96, P4029, DOI 10.1029/90JB01916; BRINKMAN DB, 1990, PALAEOGEOGR PALAEOCL, V78, P37, DOI 10.1016/0031-0182(90)90203-J; CROWLEY TJ, 1995, GEOPHYS RES LETT, V22, P933, DOI 10.1029/95GL00799; Duncan R.A., 1991, PROC OCEAN DRILL SCI, V121, P507; Erickson B.R., 1972, Monograph Sci Mus Minn, V1, P1; Erickson B.R., 1985, Journal of Vertebrate Paleontology, V5, P111; EVANS S, 1990, ZOOL J LINN SOC-LOND, V90, P205; GRADSTEIN FM, 1994, J GEOPHYS RES-SOL EA, V99, P24051, DOI 10.1029/94JB01889; HARGRAVES RB, 1989, J GEOPHYS RES-SOLID, V94, P1851, DOI 10.1029/JB094iB02p01851; Herman AB, 1996, NATURE, V380, P330, DOI 10.1038/380330a0; HILLS LV, 1994, CAN J EARTH SCI, V31, P733, DOI 10.1139/e94-066; HUBER BT, 1995, GEOL SOC AM BULL, V107, P1164, DOI 10.1130/0016-7606(1995)107<1164:MLCCOT>2.3.CO;2; HUTCHISON JH, 1982, PALAEOGEOGR PALAEOCL, V37, P149, DOI 10.1016/0031-0182(82)90037-2; IVERSON JB, 1992, REVISED CHECKLIST DI; Kerr AC, 1996, LITHOS, V37, P245, DOI 10.1016/0024-4937(95)00039-9; KOWALLIS BJ, 1995, CRETACEOUS RES, V16, P109, DOI 10.1006/cres.1995.1007; Markwick PJ, 1998, PALAEOGEOGR PALAEOCL, V137, P205, DOI 10.1016/S0031-0182(97)00108-9; OCONNOR JM, 1990, J GEOPHYS RES-SOLID, V95, P17475, DOI 10.1029/JB095iB11p17475; PARRISH J M, 1987, Palaios, V2, P377, DOI 10.2307/3514763; Price GD, 1996, GEOL SOC AM BULL, V108, P1192, DOI 10.1130/0016-7606(1996)108<1192:MLCCOT>2.3.CO;2; Renne PR, 1998, CHEM GEOL, V149, P259, DOI 10.1016/S0009-2541(98)00047-3; SELLWOOD BW, 1994, NATURE, V370, P453, DOI 10.1038/370453a0; SPICER RA, 1990, J GEOL SOC LONDON, V147, P329, DOI 10.1144/gsjgs.147.2.0329; Stoll HM, 1996, SCIENCE, V272, P1771, DOI 10.1126/science.272.5269.1771; STOREY M, 1995, SCIENCE, V267, P852, DOI 10.1126/science.267.5199.852; Tarduno JA, 1997, J GEOPHYS RES-SOL EA, V102, P723, DOI 10.1029/96JB02850; Tejada MLG, 1996, J PETROL, V37, P361, DOI 10.1093/petrology/37.2.361; TRETTIN HP, 1987, CAN J EARTH SCI, V24, P257, DOI 10.1139/e87-027; VAREKAMP JC, 1992, TERRA NOVA, V4, P363, DOI 10.1111/j.1365-3121.1992.tb00825.x; WYNNE PJ, 1988, CAN J EARTH SCI, V25, P1220, DOI 10.1139/e88-119	35	192	213	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2241	2244		10.1126/science.282.5397.2241	http://dx.doi.org/10.1126/science.282.5397.2241			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856943				2022-12-28	WOS:000077645800041
J	Rodgers, A; MacMahon, S; Yee, T; Clark, T; Zhou, B; Zhang, H; Nakamura, M; Aoki, N; Liu, L; Xie, J; Ling, Y; Wang, SY; Wu, X; Wu, Y; Tamakoshi, A; Li, S; Fang, X; Chen, Z; Xu, Z; Horibe, H; Adachi, H; Koga, Y; Li, Z; Zhang, H; He, Y; Lam, TH; Suzuki, S; Sasaki, R; Bos, K				Rodgers, A; MacMahon, S; Yee, T; Clark, T; Zhou, B; Zhang, H; Nakamura, M; Aoki, N; Liu, L; Xie, J; Ling, Y; Wang, SY; Wu, X; Wu, Y; Tamakoshi, A; Li, S; Fang, X; Chen, Z; Xu, Z; Horibe, H; Adachi, H; Koga, Y; Li, Z; Zhang, H; He, Y; Lam, TH; Suzuki, S; Sasaki, R; Bos, K		Eastern Stroke Coronary Heart Dis Res Grp; Akabane Grp; Shirakawa Study Grp	Blood pressure, cholesterol, and stroke in eastern Asia	LANCET			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; RISK-FACTORS; HEMORRHAGIC STROKE; TRIALS; MEN; HYPERTENSION; POPULATION; REDUCTION; MORTALITY	Background Stroke is a major cause of death and disability in most populations of eastern Asia, and the incidence, particularly of haemorrhagic stroke, is generally higher than in western populations. This study aimed to assess the contributions of blood pressure and blood cholesterol concentrations to stroke risk in populations from eastern Asia. Methods The project included 13 cohorts from the People's Republic of China and five from Japan (124774 participants, 837 214 person-years of observation). All 18 cohorts provided data on blood pressure and 12 (69767 participants) provided data on cholesterol concentrations. Parametric and non-parametric analyses were done, with adjustments for several potential confounding factors. Analyses were based on estimated usual diastolic blood pressure and cholesterol concentration during follow-up, rather than baseline measurements, to avoid regression dilution bias. Findings Overall mean blood pressure was 124/78 mm Hg and mean cholesterol concentration was 4.5 mmol/L. 1798 strokes occurred; 751 (42%) were classified as haemorrhagic and 707 (39%) were confirmed by computed tomography or necropsy. Each 5 mm Hg lower usual diastolic blood pressure was associated with lower risk of. non-haemorrhagic stroke (odds ratio 0.61 [95% CI 0.57-0.66]) and lower risk of haemorrhagic stroke (0.54 [0.50-0.58]). With decreasing cholesterol concentrations there were trends towards a decrease in risk of non-haemorrhagic stroke (odds ratio for 0.6 mmol/L decrease, 0.77 [0.57-1.06]) and an increase in risk of haemorrhagic stroke (1.27 [0.84-1.91]). Overall, there was no clear evidence of any interaction between cholesterol and diastolic blood pressure. Interpretation Blood pressure is an important determinant of stroke risk in eastern Asian populations, whereas cholesterol concentration is less important, affecting the proportions of stroke subtypes more than overall stroke numbers. The association between blood pressure and stroke seems stronger than in western populations; a population-wide reduction of 3 mm Hg in diastolic blood pressure should eventually decrease the number of strokes by about a third.	Univ Auckland, Dept Med, Clin Trials Res Unit, Eastern Stroke & Coronary Heart Dis Collaborat, Auckland, New Zealand; Beijing Steelworkers, Beijing, Peoples R China; Shanghai Factory Workers, Shanghai, Peoples R China; Shanghai Stroke Risk Factors, Shanghai, Peoples R China	University of Auckland	Rodgers, A (corresponding author), Univ Auckland, Dept Med, Clin Trials Res Unit, Eastern Stroke & Coronary Heart Dis Collaborat, Auckland, New Zealand.		Tamakoshi, Akiko/D-5105-2012; Lam, Tai Hing/C-4317-2009	Clark, Taane/0000-0001-8985-9265; Rodgers, Anthony/0000-0003-1282-1896; Lam, Tai Hing/0000-0002-2033-9971				BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; CARROLL RJ, 1994, STAT MED, V13, P1265, DOI 10.1002/sim.4780131208; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COX DR, 1972, J R STAT SOC B, V34, P187; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Fagard RH, 1995, J HYPERTENS, V13, P1223, DOI 10.1097/00004872-199511000-00001; Gatchev O, 1993, Ann Epidemiol, V3, P403, DOI 10.1016/1047-2797(93)90068-F; Hashimoto R, 1995, J Atheroscler Thromb, V2, P53; He J, 1997, CURR OPIN CARDIOL, V12, P202, DOI 10.1097/00001573-199703000-00018; He Y., 1996, American Journal of Epidemiology, V143, pS48; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HOSMER DW, 1989, APPL LOGISTIC REGRES; Iribarren C, 1996, STROKE, V27, P1993, DOI 10.1161/01.STR.27.11.1993; Ito Y, 1997, J Epidemiol, V7, P1; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LI Z, 1996, AS PAC C VASC DIS PR, P49; LIN CH, 1984, STROKE, V15, P653, DOI 10.1161/01.STR.15.4.653; LIU Y, 1979, CHIN MED J, V92, P719; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON S, 1994, J VASC MED BIOL, V4, P265; Murray C.J.L., 1996, GLOBAL BURDEN DIS CO, P295; MURRAY CJL, 1996, GLOBAL PATTERN CAUSE; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; OKADA H, 1976, STROKE, V7, P599, DOI 10.1161/01.STR.7.6.599; Qizilbash N, 1995, LANCET, V346, P1647; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SUDLOW CLM, 1997, STROKE, V28, P41; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TAMAKOSHI A, 1993, J EPIDEMIOL, V3, P99; UEDA K, 1988, STROKE, V19, P48, DOI 10.1161/01.STR.19.1.48; Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624; WU XG, 1991, CHINESE CIRCULATION, V6, P127; XU Z, 1994, CHIN J EPIDEMIOL, V15, P94; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; ZHOU B, 1996, AS PAC C VASC DIS PR, P49	37	426	436	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1801	1807						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851379				2022-12-28	WOS:000077337900007
J	Dorale, JA; Edwards, RL; Ito, E; Gonzalez, LA				Dorale, JA; Edwards, RL; Ito, E; Gonzalez, LA			Climate and vegetation history of the midcontinent from 75 to 25 ka: A speleothem record from Crevice Cave, Missouri, USA	SCIENCE			English	Article							UPPER MISSISSIPPI VALLEY; ROXANA SILT; VALUES; AGES; ICE; ILLINOIS; ISOTOPE; CALCITE	Four Missouri stalagmites yield consistent overlapping records of oxygen and carbon isotopic changes and provide a climate and vegetation history with submillennial resolution from 75 to 25 thousand years ago (ka). The thorium-230-dated records reveal that between 75 and 55 ka, the midcontinental climate oscillated on millennial time scales between cold and warm, and vegetation alternated among forest, savanna, and prairie. Temperatures were highest and prairie vegetation peaked between 59 and 55 ka. Climate cooled and forest replaced grassland at 55 ka, when global ice sheets began to build during the early part of Marine Oxygen Isotope Stage 3.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Univ Iowa, Dept Geol, Iowa City, IA 52242 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Iowa	Dorale, JA (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.	dora0011@tcumn.edu	Edwards, R. Lawrence/I-3124-2014; Gonzalez, Luis/D-5476-2011	Edwards, R. Lawrence/0000-0002-7027-5881; Gonzalez, Luis/0000-0001-7600-8306; Ito, Emi/0000-0001-9401-243X				AMUNDSON DC, 1979, ECOL MONOGR, V49, P1, DOI 10.2307/1942569; Baker A, 1997, CHEM GEOL, V136, P263, DOI 10.1016/S0009-2541(96)00129-5; BAKER A, 1995, GEOLOGY, V23, P309, DOI 10.1130/0091-7613(1995)023<0309:PIOMSD>2.3.CO;2; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; BETTIS EA, 1996, IOWA GEOL SURV BUR G, V18, P95; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Curry B.B., 1992, GEOLOGICAL SOC AM SP, V270, P71; Curry BB, 1998, QUATERNARY RES, V50, P128, DOI 10.1006/qres.1998.1985; Curry BB, 1996, QUATERNARY RES, V46, P19, DOI 10.1006/qres.1996.0040; DANSGAARD W, 1964, TELLUS, V16, P436; DORALE JA, 1992, SCIENCE, V258, P1626, DOI 10.1126/science.258.5088.1626; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; EHLERINGER JR, 1986, OECOLOGIA, V70, P520, DOI 10.1007/BF00379898; FORMAN SL, 1992, PALAEOGEOGR PALAEOCL, V93, P71, DOI 10.1016/0031-0182(92)90184-7; Friedman I., 1977, DATA GEOCHEMISTRY; Gruger E., 1972, QUATERNARY RES, V2, P217; Harmon R., 1975, B NATL SPELEOL SOC, V37, P21; HENDY CH, 1971, GEOCHIM COSMOCHIM AC, V35, P801, DOI 10.1016/0016-7037(71)90127-X; HUDSON JD, 1977, Q J GEOL SOC LOND, V33, P637; JOHNSON WH, 1989, QUATERNARY RES, V31, P319, DOI 10.1016/0033-5894(89)90040-9; LEIGH DS, 1994, GEOL SOC AM BULL, V106, P430, DOI 10.1130/0016-7606(1994)106<0430:RSOTUM>2.3.CO;2; LEIGH DS, 1993, QUATERNARY RES, V39, P282, DOI 10.1006/qres.1993.1035; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; MEDINA E, 1991, OECOLOGIA, V87, P369, DOI 10.1007/BF00634593; Moore G.W., 1978, SPELEOLOGY STUDY CAV, V2nd, P150; RICHARDS DA, 1994, NATURE, V367, P357, DOI 10.1038/367357a0; Tieszen LL, 1989, STABLE ISOTOPES ECOL, P167; WHITTECAR GR, 1982, QUATERNARY RES, V17, P228, DOI 10.1016/0033-5894(82)90060-6; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; ZHU H, 1995, J PALEOLIMNOL, V14, P337, DOI 10.1007/BF00682432	31	263	306	6	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1871	1874		10.1126/science.282.5395.1871	http://dx.doi.org/10.1126/science.282.5395.1871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836633				2022-12-28	WOS:000077338100043
J	Wang, HS; Pan, ZM; Shi, WM; Brown, BS; Wymore, RS; Cohen, IS; Dixon, JE; McKinnon, D				Wang, HS; Pan, ZM; Shi, WM; Brown, BS; Wymore, RS; Cohen, IS; Dixon, JE; McKinnon, D			KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel	SCIENCE			English	Article							PARAVERTEBRAL SYMPATHETIC NEURONS; LINOPIRDINE DUP-996; K+ CHANNELS; M-CURRENTS; CONDUCTANCE; BLOCKADE; ENHANCER; GENE; ION	The M-current regulates the subthreshold electrical excitability of many neurons, determining their firing properties and responsiveness to synaptic input. To date, however, the genes that encode subunits of this important channel have not been identified. The biophysical properties, sensitivity to pharmacological blockade, and expression pattern of the KCNQ2 and KCNQ3 potassium channels were determined. It is concluded that both these subunits contribute to the native M-current.	SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Dupont Co, Pharmaceut, CNS Dis Res, Wilmington, DE 19880 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; DuPont	Dixon, JE (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, Stony Brook, NY 11794 USA.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				AIKEN SP, 1995, BRIT J PHARMACOL, V115, P1163, DOI 10.1111/j.1476-5381.1995.tb15019.x; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; BROWN DA, 1988, ION CHANNELS, P55; CASSELL JF, 1987, BRIT J PHARMACOL, V91, P259, DOI 10.1111/j.1476-5381.1987.tb10279.x; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; CONSTANTI A, 1987, J PHYSIOL-LONDON, V387, P173, DOI 10.1113/jphysiol.1987.sp016569; CONSTANTI A, 1981, NEUROSCI LETT, V24, P289, DOI 10.1016/0304-3940(81)90173-7; Costa AMN, 1997, NEUROPHARMACOLOGY, V36, P1747, DOI 10.1016/S0028-3908(97)00155-X; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dixon JE, 1996, EUR J NEUROSCI, V8, P183, DOI 10.1111/j.1460-9568.1996.tb01179.x; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Lamas JA, 1997, EUR J NEUROSCI, V9, P605, DOI 10.1111/j.1460-9568.1997.tb01637.x; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MARRION NV, 1992, P ROY SOC B-BIOL SCI, V248, P207, DOI 10.1098/rspb.1992.0063; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Shi WM, 1997, J NEUROSCI, V17, P9423; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Stansfeld C, 1997, TRENDS NEUROSCI, V20, P13, DOI 10.1016/S0166-2236(96)20058-X; STEINLEIN O, 1995, HUM GENET, V95, P411; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; WANG HS, 1995, J PHYSIOL-LONDON, V485, P319, DOI 10.1113/jphysiol.1995.sp020732; WANG HS, KNCQ2 KNCQ3 M1 MUSCA; WANG HS, RIBONUCLEASE RNASE P; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WOMBLE MD, 1992, J PHYSIOL-LONDON, V457, P93, DOI 10.1113/jphysiol.1992.sp019366; Yamada WM, 1989, METHODS NEURONAL MOD, P97; YANG, 1998, J BIOL SCI, V273, P19419; Zaczek R, 1998, J PHARMACOL EXP THER, V285, P724	30	982	1037	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1890	1893		10.1126/science.282.5395.1890	http://dx.doi.org/10.1126/science.282.5395.1890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836639				2022-12-28	WOS:000077338100049
J	Schott, D; Dempfle, CE; Beck, P; Liermann, A; Mohr-Pennert, A; Goldner, M; Mehlem, P; Azuma, H; Schuster, V; Mingers, AM; Schwarz, HP; Kramer, MD				Schott, D; Dempfle, CE; Beck, P; Liermann, A; Mohr-Pennert, A; Goldner, M; Mehlem, P; Azuma, H; Schuster, V; Mingers, AM; Schwarz, HP; Kramer, MD			Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	41st Annual Meeting of the Gesellschaft-fur-Thromboseforschung-und-Hamostaseforschung	FEB 22-25, 1997	VIENNA, AUSTRIA	Gesell Thromboseforsch & Hamostaseforsch			SEVERE THROMBOTIC TENDENCY; RISK FACTOR; MICE; GENE; OBSTRUCTION; FIBRINOGEN; DISRUPTION; MUTATION; KINDREDS; DISEASE		Univ Heidelberg, Klinikum Mannheim, Dept Pediat, Kinderklin, D-68167 Mannheim, Germany; Univ Heidelberg, Klinikum Mannheim, Dept Med 1, D-68167 Mannheim, Germany; Univ Heidelberg, Klinikum Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany; Hyland Immuno, Heidelberg, Germany; Univ Tokushima, Dept Internal Med, Tokushima 770, Japan; Univ Wurzburg, Dept Pediat, Wurzburg, Germany; Univ Heidelberg, Dept Immunol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Tokushima University; University of Wurzburg; Ruprecht Karls University Heidelberg	Schott, D (corresponding author), Univ Heidelberg, Klinikum Mannheim, Dept Pediat, Kinderklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.							AZUMA H, 1993, BLOOD, V82, P475; Azuma H, 1997, BLOOD, V89, P183, DOI 10.1182/blood.V89.1.183.183_183_190; BABCOCK MF, 1987, ANESTHESIOLOGY, V67, P819, DOI 10.1097/00000542-198711000-00037; Bateman J B, 1986, J Pediatr Ophthalmol Strabismus, V23, P137; Borel MG, 1933, B SOC OPHTALMOLOGIE B SOC OPHTALMOLOGIE, V46, P168; Bouisson M., 1847, ANN OCUL, V17, P100; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Chambers J D, 1969, Trans Am Acad Ophthalmol Otolaryngol, V73, P996; COHEN SR, 1990, ANN OTO RHINOL LARYN, V99, P509, DOI 10.1177/000348949009900702; COOPER TJ, 1979, CAN J OPHTHALMOL, V14, P57; Dempfle CE, 1997, THROMB HAEMOSTASIS, V77, P879; DIAMOND JP, 1991, BRIT J OPHTHALMOL, V75, P753, DOI 10.1136/bjo.75.12.753; DOLAN G, 1988, BRIT J HAEMATOL, V70, P417, DOI 10.1111/j.1365-2141.1988.tb02510.x; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; EAGLE RC, 1986, AM J OPHTHALMOL, V101, P493, DOI 10.1016/0002-9394(86)90658-6; FIRAT T, 1974, AM J OPHTHALMOL, V78, P679, DOI 10.1016/S0002-9394(14)76307-X; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; FRANCOIS J, 1968, AM J OPHTHALMOL, V65, P674, DOI 10.1016/0002-9394(68)94380-8; Freitag HJ, 1996, NEURORADIOLOGY, V38, P181; GIROLAMI A, 1986, ACTA HAEMATOL-BASEL, V75, P54, DOI 10.1159/000206083; GISSLER HM, 1992, BRIT J DERMATOL, V127, P272, DOI 10.1111/j.1365-2133.1992.tb00127.x; HIDAYAT AA, 1987, OPHTHALMOLOGY, V94, P949; Kao WWY, 1998, INVEST OPHTH VIS SCI, V39, P502; LEEBEEK FWG, 1989, AM J HEMATOL, V30, P32, DOI 10.1002/ajh.2830300107; Lijnen HR, 1996, BLOOD, V88, P870; MARCUS DM, 1990, ARCH OPHTHALMOL-CHIC, V108, P514, DOI 10.1001/archopht.1990.01070060062050; Mingers AM, 1997, SEMIN THROMB HEMOST, V23, P259, DOI 10.1055/s-2007-996099; MINGERS AM, 1996, 25 HAM S HAMB 1994 B, P96; Mirshahi S, 1996, FIBRINOLYSIS, V10, P255, DOI 10.1016/S0268-9499(96)80021-X; NUSSGENS Z, 1993, OPHTHALMIC PAED GEN, V14, P137, DOI 10.3109/13816819309087630; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Robbins K. C., 1970, METHOD ENZYMOL, V19, P184; SARTORI MT, 1994, BLOOD COAGUL FIBRIN, V5, P889, DOI 10.1097/00001721-199412000-00004; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; Schuster V, 1996, AM J MED GENET, V63, P318, DOI 10.1002/(SICI)1096-8628(19960503)63:1<318::AID-AJMG53>3.0.CO;2-N; SCHWARTZ GS, 1995, AM J OPHTHALMOL, V120, P253, DOI 10.1016/S0002-9394(14)72619-4; SCURRY J, 1993, J REPROD MED, V38, P407; SHAPIRO A, 1995, TRANSFUSION, V35, P204, DOI 10.1046/j.1537-2995.1995.35395184275.x; SHIGEKIYO T, 1992, THROMB HAEMOSTASIS, V67, P189; Tait RC, 1996, THROMB HAEMOSTASIS, V76, P1004	43	111	124	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1679	1686		10.1056/NEJM199812033392305	http://dx.doi.org/10.1056/NEJM199812033392305			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834305				2022-12-28	WOS:000077294800005
J	Lands, RH				Lands, RH			Medical practices disappearing in the south	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1823	1823		10.1001/jama.280.21.1823	http://dx.doi.org/10.1001/jama.280.21.1823			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846766				2022-12-28	WOS:000077176600011
J	Bradbury, J				Bradbury, J			Bad news for the young in AIDS epidemic update	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1760	1760		10.1016/S0140-6736(05)79835-4	http://dx.doi.org/10.1016/S0140-6736(05)79835-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848364				2022-12-28	WOS:000077246500027
J	Collier, J				Collier, J			Patient-information leaflets and prescriber competence	LANCET			English	Editorial Material									St George Hosp, Sch Med, Dept Clin Pharmacol, London SW17 0RE, England	St Georges University London	Collier, J (corresponding author), St George Hosp, Sch Med, Dept Clin Pharmacol, Cranmer Terrace, London SW17 0RE, England.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1724	1724		10.1016/S0140-6736(05)79823-8	http://dx.doi.org/10.1016/S0140-6736(05)79823-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848346				2022-12-28	WOS:000077246500005
J	Lamme, VAF; Spekreijse, H				Lamme, VAF; Spekreijse, H			Neuronal synchrony does not represent texture segregation	NATURE			English	Article							CAT VISUAL-CORTEX; MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC CONNECTIONS; MACAQUE MONKEY; RESPONSES; OSCILLATIONS; INTEGRATION	The visual environment is perceived as an organized whole of objects and their surroundings. In many visual cortical areas, however, neurons are typically activated when a stimulus is presented over a very limited portion of the visual field, the receptive field of that neuron(1-4). To bridge the gap between this piecewise neuronal analysis and our global visual percepts, it has been postulated that neurons representing elements of the same object fire in synchrony to represent the perceptual organization of a scene(5-10). Experiments with stimuli such as moving bars or gratings have provided evidence for this hypothesis(11-16). We have further tested this by presenting monkeys with various textured scenes consisting of a figure on a background, and recorded neuronal activity in the primary visual cortex (area V1). Our results show no systematic relationship between the synchrony of firing of pairs of neurons and the perceptual organization of the scene. Instead, pairs of recording sites representing elements of the same figure most commonly showed equal amounts of synchrony between them as did pairs of which one site represented the figure and the other the background. We conclude that synchrony in V1 does not reflect the binding of features that leads to texture segregation.	Univ Amsterdam, AMC, Dept Phys Med, Grad Sch Neurosci, NL-1100 AC Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Lamme, VAF (corresponding author), Univ Amsterdam, AMC, Dept Phys Med, Grad Sch Neurosci, POB 12141, NL-1100 AC Amsterdam, Netherlands.	v.lamme@amc.uva.nl						BOUR LJ, 1984, IEEE T BIO-MED ENG, V31, P419, DOI 10.1109/TBME.1984.325281; Brosch M, 1997, CEREB CORTEX, V7, P70, DOI 10.1093/cercor/7.1.70; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; Freiwald WA, 1995, NEUROREPORT, V6, P2348, DOI 10.1097/00001756-199511270-00018; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; KONIG P, 1995, NEURAL COMPUT, V7, P469, DOI 10.1162/neco.1995.7.3.469; Kreiter AK, 1996, J NEUROSCI, V16, P2381; KRUGER J, 1989, BRAIN RES, V477, P57, DOI 10.1016/0006-8993(89)91394-2; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Lamme VAF, 1998, P NATL ACAD SCI USA, V95, P3263, DOI 10.1073/pnas.95.6.3263; Livingstone MS, 1996, J NEUROPHYSIOL, V75, P2467, DOI 10.1152/jn.1996.75.6.2467; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; SCHILLER PH, 1976, J NEUROPHYSIOL, V39, P1288, DOI 10.1152/jn.1976.39.6.1288; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; TSO DY, 1986, J NEUROSCI, V6, P1160; van der Togt C, 1998, EUR J NEUROSCI, V10, P1490, DOI 10.1046/j.1460-9568.1998.00200.x; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113	29	102	103	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					362	366		10.1038/24608	http://dx.doi.org/10.1038/24608			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845071				2022-12-28	WOS:000077204000048
J	Handsfield, HH				Handsfield, HH			Screening asymptomatic women for Chlamydia trachomatis - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INFECTION; CRITERIA		Seattle King Cty Dept Publ Hlth, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Handsfield, HH (corresponding author), Seattle King Cty Dept Publ Hlth, Seattle, WA 98104 USA.							GENE M, 1996, ANN INTERN MED, V124, P1; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HANDSFIELD HH, 1997, SCREENING DIAGNOSING, P1; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840	7	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1800	1801		10.1001/jama.280.20.1800	http://dx.doi.org/10.1001/jama.280.20.1800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140HF	9842959				2022-12-28	WOS:000077081400040
J	Defesche, JC; Kastelein, JJP				Defesche, JC; Kastelein, JJP			Molecular epidemiology of familial hypercholesterolaemia	LANCET			English	Editorial Material							RECEPTOR GENE; MUTATIONS		Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Defesche, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands.		Kastelein, John/AAF-7950-2020					AALTOSETALA K, 1992, J INTERN MED, V231, P22; Lee WK, 1998, J MED GENET, V35, P573, DOI 10.1136/jmg.35.7.573; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; Varret M, 1997, NUCLEIC ACIDS RES, V25, P172, DOI 10.1093/nar/25.1.172; Vohl MC, 1997, CLIN GENET, V52, P1, DOI 10.1111/j.1399-0004.1997.tb02506.x	5	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1643	1644		10.1016/S0140-6736(05)61443-2	http://dx.doi.org/10.1016/S0140-6736(05)61443-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853432				2022-12-28	WOS:000077110300004
J	Ashcroft, FM				Ashcroft, FM			Ion channels - Exciting times for PIP2	SCIENCE			English	Editorial Material							SENSITIVE K+ CHANNELS; ATP; RECEPTOR		Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Ashcroft, FM (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	frances.ashcroft@physiol.ox.ac.uk						Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; NIKI I, 1989, FEBS LETT, V257, P361, DOI 10.1016/0014-5793(89)81572-8; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	9	32	33	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1059	1060		10.1126/science.282.5391.1059	http://dx.doi.org/10.1126/science.282.5391.1059			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9841452				2022-12-28	WOS:000076887700033
J	Coutts, A				Coutts, A			Chewing gum for extradural haemorrhage	BRITISH MEDICAL JOURNAL			English	Article									Gilbert Bain Hosp, Lerwick ZE1 0RB, Shetland, Scotland		Coutts, A (corresponding author), Gilbert Bain Hosp, Lerwick ZE1 0RB, Shetland, Scotland.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1687	1687		10.1136/bmj.317.7174.1687	http://dx.doi.org/10.1136/bmj.317.7174.1687			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857127	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077742300014
J	Chang, G; Spencer, RH; Lee, AT; Barclay, MT; Rees, DC				Chang, G; Spencer, RH; Lee, AT; Barclay, MT; Rees, DC			Structure of the MscL homolog from Mycobacterium tuberculosis: A gated mechanosensitive ion channel	SCIENCE			English	Article							RESTRAINED MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; ACETYLCHOLINE-RECEPTOR; PROTEIN STRUCTURES; PROGRAM; ARCHITECTURE; MOLSCRIPT; SUBUNITS	Mechanosensitive ion channels play a critical role in transducing physical stresses at the cell membrane into an electrochemical response. The MscL family of Large-conductance mechanosensitive channels is widely distributed among prokaryotes and may participate in the regulation of osmotic pressure changes within the cell. In an effort to better understand the structural basis for the function of these channels, the structure of the MscL homolog from Mycobacterium tuberculosis was determined by x-ray crystallography to 3.5 angstroms resolution. This channel is organized as a homopentamer, with each subunit containing two transmembrane cr helices and a third cytoplasmic alpha helix. From the extracellular side, a water-filled opening approximately 18 angstroms in diameter Leads into a pore Lined with hydrophilic residues which narrows at the cytoplasmic side to an occluded hydrophobic apex that may act as the channel gate. This structure may serve as a model for other mechanosensitive channels, as well as the broader class of pentameric ligand-gated ion channels exemplified by the nicotinic acetylcholine receptor.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Rees, DC (corresponding author), CALTECH, Howard Hughes Med Inst, 147-75CH, Pasadena, CA 91125 USA.	dcrees@caltech.edu			NIGMS NIH HHS [GM18486] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chang G.-H., UNPUB; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GROS P, 1990, SCIENCE, V249, P1149, DOI 10.1126/science.2396108; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; NUMA S, 1989, HARVEY LECT, V83, P121; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Pellegrini M, 1997, PROTEINS, V29, P426, DOI 10.1002/(SICI)1097-0134(199712)29:4<426::AID-PROT3>3.3.CO;2-J; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; Sigurdson WJ, 1997, BIOPHYS J, V72, pWP104; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; SPENCER RH, UNPUB; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	40	825	864	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2220	2226		10.1126/science.282.5397.2220	http://dx.doi.org/10.1126/science.282.5397.2220			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856938				2022-12-28	WOS:000077645800036
J	Wood, AJJ; Stein, CM; Woosley, R				Wood, AJJ; Stein, CM; Woosley, R			Making medicines safer the need for an independent drug safety board	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NIFEDIPINE; MORTALITY		Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Vanderbilt University; Georgetown University	Wood, AJJ (corresponding author), Vanderbilt Univ, Med Ctr, Rm 550 MRB 1, Nashville, TN 37232 USA.		Woosley, Raymond/AAE-4874-2020	Woosley, Raymond/0000-0002-2588-328X	NHLBI NIH HHS [HL 56251] Funding Source: Medline; NIGMS NIH HHS [GM 31304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angell M, 1996, NEW ENGL J MED, V334, P1513, DOI 10.1056/NEJM199606063342306; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; JOHANNES L, 1997, WALL STREET J   1211, V11, pA13; JOHANNES L, 1997, WALL STREET J   1001, pB1; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; LANGRETH R, 1997, WALL STREET J   1031, pB1; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MOORE SD, 1998, WALL STREET J   0609, pB1; MOORE SD, 1998, WALL STREET J   0609, pB25; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068	13	82	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1851	1854		10.1056/NEJM199812173392512	http://dx.doi.org/10.1056/NEJM199812173392512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854125				2022-12-28	WOS:000077545800012
J	Stockinger, Z				Stockinger, Z			Rupturing aneurysm of the posterior inferior cerebellar artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									US Naval Hosp, Okinawa, Japan		Stockinger, Z (corresponding author), US Naval Hosp, Okinawa, Japan.								0	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1758	1758		10.1056/NEJM199812103392406	http://dx.doi.org/10.1056/NEJM199812103392406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845711				2022-12-28	WOS:000077459700006
J	Martin, MP; Dean, M; Smith, MW; Winkler, C; Gerrard, B; Michael, NL; Lee, B; Doms, RW; Margolick, J; Buchbinder, S; Goedert, JJ; O'Brien, TR; Hilgartner, MW; Vlahov, D; O'Brien, SJ; Carrington, M				Martin, MP; Dean, M; Smith, MW; Winkler, C; Gerrard, B; Michael, NL; Lee, B; Doms, RW; Margolick, J; Buchbinder, S; Goedert, JJ; O'Brien, TR; Hilgartner, MW; Vlahov, D; O'Brien, SJ; Carrington, M			Genetic acceleration of AIDS progression by a promoter variant of CCR5	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR GENE; HIV-1 INFECTION; DISEASE PROGRESSION; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; MIP-1-ALPHA; MIP-1-BETA; RESISTANCE; RANTES	The CCR5 gene encodes a cell surface chemokine receptor molecule that serves as the principal coreceptor, with CD4, for macrophage-tropic (R5) strains of human immunodeficiency virus-type 1 (HIV-1). Genetic association analysis of five cohorts of people with acquired immunodeficiency syndrome (AIDS) revealed that infected individuals homozygous for a multisite haplotype of the CCR5 regulatory region containing the promoter allele, CCR5P1, progress to AIDS more rapidly than those with other CCR5 promoter genotypes, particularly in the early years after infection. Composite genetic epidemiologic analyses of genotypes bearing CCR5P1, CCR5-Delta 32, CCR2-641, and SDF1-3'A affirmed distinct regulatory influences for each gene on AIDS progression. An estimated 10 to 17 percent of patients who develop AIDS within 3.5 years of HIV-1 infection do so because they are homozygous for CCR5P1/P1, and 7 to 13 percent of all people carry this susceptible genotype. The cumulative and interactive influence of these AIDS restriction genes illustrates the multigenic nature of host factors Limiting AIDS disease progression.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Sci Applicat Int Corp, Frederick, MD 21702 USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA; NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA; Cornell Univ, Med Ctr, New York Hosp, Div Pediat Hematol & Oncol, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Pennsylvania; Johns Hopkins University; San Francisco Department of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cornell University; NewYork-Presbyterian Hospital	O'Brien, TR (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.	obrien@ncifcrf.gov	Smith, Michael/B-5341-2012; Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019; OBRIEN, STEPHEN/ABD-1346-2020	Dean, Michael C/0000-0003-2234-0631; OBRIEN, STEPHEN/0000-0001-7857-0757	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Allison PD, 1995, SURVIVAL ANAL USING, P155; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CARRINGTON M, UNPUB; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, PROPORTIONAL HAZARD; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Donefield SM, 1998, SCIENCE, V280, P1819, DOI 10.1126/science.280.5371.1815f; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HILGARTNER MW, 1993, AM J PEDIAT HEMATOL, V15, P208; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Ioannidis JPA, 1998, NAT MED, V4, P536, DOI 10.1038/nm0598-536; Khoury M, 1993, FUNDAMENTALS GENETIC; Kostrikis LG, 1998, NAT MED, V4, P350, DOI 10.1038/nm0398-350; Lee B, 1998, J VIROL, V72, P7450, DOI 10.1128/JVI.72.9.7450-7458.1998; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rizzardi GP, 1998, NAT MED, V4, P252, DOI 10.1038/nm0398-252; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHWEDER T, 1982, BIOMETRIKA, V69, P493; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1998, SCIENCE, V280, P1820; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; *US CDC, 1987, MORB MORTAL WKLY S1, V36; *US CDCP, 1992, MMWR-MORBID MORTAL W, V41, P1; van Rij RP, 1998, AIDS, V12, pF85, DOI 10.1097/00002030-199809000-00001; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; Weir BS, 1990, GENETIC DATA ANAL; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	48	369	383	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1907	1911		10.1126/science.282.5395.1907	http://dx.doi.org/10.1126/science.282.5395.1907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836644				2022-12-28	WOS:000077338100054
J	Williams, DM; Kasting, JF; Frakes, LA				Williams, DM; Kasting, JF; Frakes, LA			Low-latitude glaciation and rapid changes in the Earth's obliquity explained by obliquity-oblateness feedback	NATURE			English	Article							CLIMATE FRICTION; SOUTH-AUSTRALIA; SNOWBALL EARTH; ICE-AGE; PALEOLATITUDE; DEPOSITION; INSOLATION; INTERVALS; EVOLUTION; MARS	Palaeomagnetic data suggest that the Earth was glaciated at low latitudes during the Palaeoproterozoic(1,2) (about 2.4-2.2 Gyr ago) and Neoproterozoic(3-8) (about 820-550 Myr ago) eras, although some of the Neoproterozoic data are disputed(9,10). If the Earth's magnetic field was aligned more or less with its spin axis, as it is today, then either the polar ice caps must have extended well down into the tropics-the 'snowball Earth' hypothesis(8)-or the present zonation of climate with respect to latitude must have been reversed. Williams(11) has suggested that the Earth's obliquity may have been greater than 54 degrees during most of its history, which would have made the Equator the coldest part of the planet(12). But this would require a mechanism to bring the obliquity down to its present value of 23.5 degrees. Here we propose that obliquity-oblateness feedback(13) could have reduced the Earth's obliquity by tens of degrees in less than 100 Myr if the continents were situated so as to promote the formation of large polar ice sheets. A high obliquity for the early Earth may also provide a natural explanation for the present inclination of the lunar orbit with respect to the ecliptic (5 degrees), which is otherwise difficult to explain.	Penn State Univ, Behrend Coll, Sch Sci, Erie, PA 16563 USA; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Univ Adelaide, Dept Geol & Geophys, Adelaide, SA 5005, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Adelaide	Williams, DM (corresponding author), Penn State Univ, Behrend Coll, Sch Sci, Stn Rd, Erie, PA 16563 USA.		Kasting, James/AAF-6851-2020					AWRAMIK SM, 1986, SCIENCE, V231, P1279, DOI 10.1126/science.231.4743.1279; BILLS BG, 1994, GEOPHYS RES LETT, V21, P177, DOI 10.1029/93GL02024; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; EMBLETON BJJ, 1986, EARTH PLANET SC LETT, V79, P419, DOI 10.1016/0012-821X(86)90197-4; Evans DA, 1997, NATURE, V386, P262, DOI 10.1038/386262a0; Frakes L. A., 1979, CLIMATES THROUGHOUT; GOLDREIC.P, 1966, REV GEOPHYS, V4, P411, DOI 10.1029/RG004i004p00411; HECHT J, 1997, AGES EARTH; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Ida S, 1997, NATURE, V389, P353, DOI 10.1038/38669; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; ITO T, 1995, J GEOPHYS RES-SOL EA, V100, P15147, DOI 10.1029/95JB01061; LASKAR J, 1993, ASTRON ASTROPHYS, V270, P522; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; MEERT JG, 1994, EARTH PLANET SC LETT, V123, P1, DOI 10.1016/0012-821X(94)90253-4; Park JK, 1997, CAN J EARTH SCI, V34, P34, DOI 10.1139/e17-003; PELTIER WR, 1994, GEOPHYS RES LETT, V21, P2299, DOI 10.1029/94GL02058; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; ROCHESTER MG, 1976, GEOPHYS J ROY ASTR S, V46, P109, DOI 10.1111/j.1365-246X.1976.tb01635.x; RUBINCAM DP, 1975, J GEOPHYS RES, V80, P1537, DOI 10.1029/JB080i011p01537; RUBINCAM DP, 1993, J GEOPHYS RES-PLANET, V98, P10827, DOI 10.1029/93JE00999; RUBINCAM DP, 1995, PALEOCEANOGRAPHY, V10, P365, DOI 10.1029/95PA00578; SCHMIDT PW, 1995, EARTH PLANET SC LETT, V134, P107, DOI 10.1016/0012-821X(95)00106-M; TOUMA J, 1994, ASTRON J, V108, P1943, DOI 10.1086/117209; Touma J, 1998, ASTRON J, V115, P1653, DOI 10.1086/300312; VANYO JP, 1982, GEOPHYS RES LETT, V9, P1125, DOI 10.1029/GL009i010p01125; WALKER JCG, 1986, NATURE, V320, P600, DOI 10.1038/320600a0; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; WILLIAMS DM, 1998, STABILITY HABITABLE; WILLIAMS GE, 1993, EARTH-SCI REV, V34, P1, DOI 10.1016/0012-8252(93)90004-Q; WILLIAMS GE, 1995, EARTH PLANET SC LETT, V131, P115, DOI 10.1016/0012-821X(95)00004-V; Williams GE, 1997, EARTH PLANET SC LETT, V153, P157, DOI 10.1016/S0012-821X(97)00181-7; ZHANG HM, 1985, PRECAMBRIAN RES, V29, P65, DOI 10.1016/0301-9268(85)90060-9	33	72	78	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					453	455		10.1038/24845	http://dx.doi.org/10.1038/24845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853751				2022-12-28	WOS:000077370100050
J	Cabral, JHM; Lee, A; Cohen, SL; Chait, BT; Li, M; Mackinnon, R				Cabral, JHM; Lee, A; Cohen, SL; Chait, BT; Li, M; Mackinnon, R			Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain	CELL			English	Article							HUMAN INWARD RECTIFIER; CARDIAC-ARRHYTHMIA; ESCHERICHIA-COLI; PROTEIN; FAMILY; EAG; RECTIFICATION; INACTIVATION; DROSOPHILA; OXYGEN	The HERG voltage-dependent K+ channel plays a role in cardiac electrical excitability, and when defective, it underlies one form of the long QT syndrome. We have determined the crystal structure of the HERG K+ channel N-terminal domain and studied its role as a modifier of gating using electrophysiological methods. The domain is similar in structure to a bacterial light sensor photoactive yellow protein and provides the first three-dimensional model of a eukaryotic PAS domain. Scanning mutagenesis of the domain surface has allowed the identification of a hydrophobic "hot spot" forming a putative interface with the body of the K+ channel to which it tightly binds. The presence, of the domain attached to the channel slows the rate of deactivation. Given the roles of PAS domains in biology, we propose that the HERG N-terminal domain has a regulatory function.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Johns Hopkins University	Mackinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu	Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716	NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM47400] Funding Source: Medline; NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033324, R55NS033324] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BRUNGER AT, 1996, XPLOR VERSION 3 851; CHAIT BT, 1994, STRUCTURE, V2, P465, DOI 10.1016/S0969-2126(00)00047-2; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REPPERT SM, 1998, CELL, V21, P1; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	33	359	368	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					649	655		10.1016/S0092-8674(00)81635-9	http://dx.doi.org/10.1016/S0092-8674(00)81635-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845367	Bronze			2022-12-28	WOS:000077253700012
J	Huang, Z; Shilo, BZ; Kunes, S				Huang, Z; Shilo, BZ; Kunes, S			A retinal axon fascicle uses spitz, an EGF receptor ligand, to construct a synaptic cartridge in the brain of Drosophila	CELL			English	Article							CHICK OPTIC TECTUM; FAINT-LITTLE-BALL; VISUAL-SYSTEM; VENTRAL ECTODERM; SECRETED PROTEIN; GENE ENCODES; CELL FATE; EYE; HEDGEHOG; HOMOLOG	Photoreceptor axons arriving in the Drosophila brain organize their postsynaptic target field into a precise array of five neuron "cartridge" ensembles. Here we show that Hedgehog, an initial inductive; signal transported along retinal axons from the developing eye, induces postsynaptic precursor cells to express the Drosophila homolog of the epidermal growth factor receptor (EGFR). The EGFR ligand Spitz, a signal for ommatidial assembly in the compound eye, is transported to retinal axon termini in the brain where it acts as a local cue for the recruitment of five cells into a cartridge ensemble. Hedgehog and Spitz thus bring about the concerted assembly of ommatidial and synaptic cartridge units, imposing the "neurocrystalline" order of the compound eye on the postsynaptic target field.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Harvard University; Weizmann Institute of Science	Kunes, S (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			Shilo, Ben Zion/0000-0003-4903-8889	NEI NIH HHS [EY10112] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010112] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAITENBERG V, 1967, EXP BRAIN RES, V3, P271; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; CONTAMINE D, 1989, GENETICS, V123, P525; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRAZIADEI PPC, 1992, NEUROSCIENCE, V46, P617, DOI 10.1016/0306-4522(92)90149-V; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Huang Z, 1998, DEVELOPMENT, V125, P3753; JONES B, 1993, DEVELOPMENT, V117, P793; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KELLY JP, 1972, BRAIN RES, V42, P263, DOI 10.1016/0006-8993(72)90530-6; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; KUNES S, 1993, J NEUROSCI, V13, P752; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACAGNO ER, 1979, DEV BIOL, V73, P206, DOI 10.1016/0012-1606(79)90064-2; MARDON G, 1994, DEVELOPMENT, V120, P3473; Meinertzhagen Ian A., 1993, P1363; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; OLAND LA, 1987, J COMP NEUROL, V255, P196, DOI 10.1002/cne.902550204; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Pignoni F, 1997, DEVELOPMENT, V124, P271; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Queenan AM, 1997, DEVELOPMENT, V124, P3871; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SELLECK SB, 1992, NATURE, V355, P253, DOI 10.1038/355253a0; Tio M, 1997, DEVELOPMENT, V124, P343; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TRUJILLOCENOZ O, 1973, J ULTRA MOL STRUCT R, V42, P554, DOI 10.1016/S0022-5320(73)80027-9; XU T, 1993, DEVELOPMENT, V117, P1223; YAMAGATA M, 1995, J NEUROSCI, V15, P4556; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V; ZECCA M, 1995, DEVELOPMENT, V121, P2265	48	99	99	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					693	703		10.1016/S0092-8674(00)81639-6	http://dx.doi.org/10.1016/S0092-8674(00)81639-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845371	Bronze			2022-12-28	WOS:000077253700016
J	Vogelzang, NJ; Stadler, WM				Vogelzang, NJ; Stadler, WM			Kidney cancer	LANCET			English	Article							RENAL-CELL CARCINOMA; HIGH-DOSE INTERLEUKIN-2; ACTIVATED KILLER-CELLS; PROSPECTIVE RANDOMIZED TRIAL; PHASE-II; RECOMBINANT INTERLEUKIN-2; LEUKOCYTE INTERFERON; NATURAL-HISTORY; FOLLOW-UP; TUMOR	In the USA, the incidence of kidney cancer has increased 43% since 1973. The risk of the disorder is higher in men than in women and increases with age. The von Hippel-Lindau tumour-suppressor gene is inactivated in over 75% of sporadic cases. Metastatic disease is present in 20-30% of patients at diagnosis. Early-Stage kidney cancer is treated with a radical nephrectomy, but under certain circumstances a partial nephrectomy may be done. Tumour thrombus into the vena cava or right atrium requires thoracotomy and hypothermic circulatory arrest for successful removal of the tumour, but should not be done if extensive nodal or frank metastatic disease is present. Interleukin-2 is the systemic therapy of choice for metastatic disease at present, with long-term relapse-free survival of 5-8%. Several treatments including anti-angiogenesis drugs, cyclin-dependent kinase inhibitors, and differentiating agents are being actively investigated. Fluorouracil has a 10-15% response rate, and surgical excision of isolated metastases should always be considered. Therapy for metastatic renal cancer remains inadequate, but recent developments in basic and clinical research suggest future improvement.	Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center	Vogelzang, NJ (corresponding author), Univ Chicago, Med Ctr, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	njvogelz@mcis.bsd.uchicago.edu						ASO Y, 1992, J UROLOGY, V147, P340, DOI 10.1016/S0022-5347(17)37231-2; ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; ATZPODIEN J, 1997, P AN M AM SOC CLIN, V16, P3262; BLOM JHM, 1993, CURR OPIN UROL, V3, P359; BOSNIAK MA, 1996, J UROLOGY, V155, P584; Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H; Bukowski RM, 1997, CLEV CLIN J MED, V64, P413; CARLSON DL, 1995, J COMP PATHOL, V113, P277, DOI 10.1016/S0021-9975(05)80042-8; CHOYKE PL, 1992, AM J ROENTGENOL, V159, P1229, DOI 10.2214/ajr.159.6.1442389; Coughlin SS, 1997, CANCER-AM CANCER SOC, V79, P2171, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2171::AID-CNCR15>3.3.CO;2-5; DeMulder PHM, 1996, CANCER CHEMOTH PHARM, V37, P491, DOI 10.1007/s002800050417; Figlin RA, 1997, J UROLOGY, V158, P740, DOI 10.1016/S0022-5347(01)64304-0; FISHER RI, 1988, ANN INTERN MED, V108, P518, DOI 10.7326/0003-4819-108-4-518; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Galligioni E, 1996, CANCER, V77, P2560, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P; GELB AB, 1993, AM J SURG PATHOL, V17, P275, DOI 10.1097/00000478-199303000-00008; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Goey SH, 1996, ANN ONCOL, V7, P887, DOI 10.1093/oxfordjournals.annonc.a010790; GREEN DM, 1994, J CLIN ONCOL, V12, P2132, DOI 10.1200/JCO.1994.12.10.2132; Gronwald J, 1997, CANCER RES, V57, P481; GUINAN PD, 1995, J UROLOGY, V153, P901, DOI 10.1016/S0022-5347(01)67599-2; Hanninen EL, 1996, J UROLOGY, V155, P19, DOI 10.1016/S0022-5347(01)66527-3; Henriksson R, 1998, BRIT J CANCER, V77, P1311, DOI 10.1038/bjc.1998.218; Herring JC, 1997, J UROLOGY, V157, P2246, DOI 10.1016/S0022-5347(01)64734-7; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; Kavolius JP, 1998, J CLIN ONCOL, V16, P2261, DOI 10.1200/JCO.1998.16.6.2261; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kranenborg MHGC, 1997, CANCER-AM CANCER SOC, V80, P2390, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2390::AID-CNCR9>3.3.CO;2-X; KRIEGMAIR M, 1995, UROLOGY, V45, P758, DOI 10.1016/S0090-4295(99)80079-X; LATIF F, 1993, CANCER RES, V53, P861; Levy DA, 1998, J UROLOGY, V159, P1163, DOI 10.1016/S0022-5347(01)63541-9; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mani S, 1998, ANN ONCOL, V9, P165; Margolin K, 1997, CLIN CANCER RES, V3, P565; Marshall FF, 1997, CANCER, V80, P2167, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2167::AID-CNCR18>3.0.CO;2-X; McCaffrey JA, 1996, SEMIN ONCOL, V23, pR19; MCLAUGHLIN JK, 1996, CANC EPIDEMIOLOGY PR, P1442; MERTENS WC, 1993, ANN ONCOL, V4, P331, DOI 10.1093/oxfordjournals.annonc.a058494; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Motzer Robert J., 1997, P885; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; NELSON JF, 1996, COMPREHENSIVE TXB GE, P218; Nishikubo CY, 1996, CANCER-AM CANCER SOC, V78, P2421, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2421::AID-CNCR21>3.3.CO;2-H; NOVICK AC, 1998, CAMPBELLS UROLOGY, P2973; ODA H, 1995, CANCER RES, V55, P354; OSBAND ME, 1990, LANCET, V335, P994, DOI 10.1016/0140-6736(90)91064-H; PIZZOCARO G, 1997, P AN M AM SOC CLIN, V16, P1132; PYRHONAN S, 1996, P AN M AM SOC CLIN, V15, P614; QUESADA JR, 1983, CANCER RES, V43, P940; RIES LAG, 1997, NIH PUBLICATION; RITCHIE AWS, 1998, P AN M AM SOC CLIN, V17, P1194; ROBSON CJ, 1969, J UROLOGY, V101, P297, DOI 10.1016/S0022-5347(17)62331-0; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; SAWCZUK IS, 1997, P AN M AM SOC CLIN, V16, pA326; Schipper H, 1996, LANCET, V348, P1149, DOI 10.1016/S0140-6736(96)06184-3; SIEGEL JP, 1991, J CLIN ONCOL, V9, P694, DOI 10.1200/JCO.1991.9.4.694; Simons JW, 1997, CANCER RES, V57, P1537; Stadler WM, 1998, J CLIN ONCOL, V16, P1820, DOI 10.1200/JCO.1998.16.5.1820; STADLER WM, 1998, P AN M AM SOC CLIN, V17, P1192; STEINECK G, 1990, ACTA ONCOL, V29, P155, DOI 10.3109/02841869009126537; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; STUDER UE, 1990, J UROLOGY, V144, P243, DOI 10.1016/S0022-5347(17)39422-3; Theillet C, 1998, NAT MED, V4, P767, DOI 10.1038/nm0798-767; Tobe SW, 1995, CLIN CANCER RES, V1, P1611; Tourani JM, 1998, J CLIN ONCOL, V16, P2505, DOI 10.1200/JCO.1998.16.7.2505; TRUMP DL, 1996, P AN M AM SOC CLIN, V15, P648; Tzannis ST, 1996, P NATL ACAD SCI USA, V93, P5460, DOI 10.1073/pnas.93.11.5460; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; VANLEEUWEN FE, 1993, J CLIN ONCOL, V11, P415, DOI 10.1200/JCO.1993.11.3.415; VOGELZANG NJ, 1993, J CLIN ONCOL, V11, P1809, DOI 10.1200/JCO.1993.11.9.1809; VOGELZANG NJ, IN PRESS J UROL; Walther MM, 1997, J UROLOGY, V158, P1675, DOI 10.1016/S0022-5347(01)64091-6; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; YAGODA A, 1995, SEMIN ONCOL, V22, P42; YANG JC, 1994, J CLIN ONCOL, V12, P1572, DOI 10.1200/JCO.1994.12.8.1572	79	214	225	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1691	1696		10.1016/S0140-6736(98)01041-1	http://dx.doi.org/10.1016/S0140-6736(98)01041-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853456				2022-12-28	WOS:000077110300043
J	Melhus, H; Michaelsson, K; Kindmark, A; Bergstrom, R; Holmberg, L; Mallmin, H; Wolk, A; Ljunghall, S				Melhus, H; Michaelsson, K; Kindmark, A; Bergstrom, R; Holmberg, L; Mallmin, H; Wolk, A; Ljunghall, S			Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture	ANNALS OF INTERNAL MEDICINE			English	Article						hip fracture; bone density; vitamin A; hypervitaminosis A; osteoporosis	GREEN LEAFY VEGETABLES; RETINOIC ACID; BREAST-CANCER; A STATUS; RESORPTION; NORWAY; 9-CIS	Background: The highest incidence of osteoporotic fractures is found in northern Europe, where dietary intake of vitamin A (retinol) is unusually high. In animals, the most common adverse effect of toxic doses of retinol is spontaneous fracture. Objective: To investigate whether excessive dietary intake of vitamin A is associated with decreased bone mineral density and increased risk for hip fracture. Design: A cross-sectional study and a nested case-control study. Setting: Two counties in central Sweden. Participants: For the cross-sectional study, 175 women 28 to 74 years of age were randomly selected. For the nested case-control study, 247 women who had a first hip fracture within 2 to 64 months after enrollment and 873 age-matched controls were selected from a mammography study cohort of 66 651 women 40 to 76 years of age. Measurements: Retinol intake was estimated from dietary records and a food-frequency questionnaire. Bone mineral density was measured with dual-energy x-ray absorptiometry. Hip fracture was identified by using hospital discharge records and was confirmed by record review. Results: In multivariate analysis, retinol intake was negatively associated with bone mineral density. For every l-mg increase in daily intake of retinol, risk for hip fracture increased by 68% (95% CI, 18% to 140%; P for trend, 0.006). For intake greater than 1.5 mg/d compared with intake less than 0.5 mg/d, bone mineral density was reduced by 10% at the femoral neck (P = 0.05), 14% at the lumbar spine (P = 0.001), and 6% for the total body (P = 0.009) and risk for hip fracture was doubled (odds ratio, 2.1 [CI, 1.1 to 4.0]). Conclusion: High dietary intake of retinol seems to be associated with osteoporosis.	Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Univ Uppsala Hosp, Dept Surg, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Karolinska Institutet; Uppsala University; Uppsala University Hospital	Melhus, H (corresponding author), Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden.	Hakan.Melhus@medicin.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217				Ariens E., 1982, NUTR TOXICOL, V1, P17; ARMSTRONG R, 1994, RETINOIDS, V1, P545; BECKER W, 1989, FOOD HABITS NUTR INT; Belsley D., 1980, REGRESSION DIAGNOSIS; BLAND M, 1993, INTRO MED STAT; Bloch CE, 1924, AM J DIS CHILD, V28, P659; CRUZ JAA, 1991, EUR J CLIN NUTR, V45, P121; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; dePee S, 1996, EUR J CLIN NUTR, V50, pS38; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; DEQUEKER J, 1991, CLIN RHEUMATOL, V10, P49, DOI 10.1007/BF02208033; DIGIOVANNA JJ, 1995, ARCH DERMATOL, V131, P1263, DOI 10.1001/archderm.131.11.1263; FALCH JA, 1985, ACTA ORTHOP SCAND, V56, P12, DOI 10.3109/17453678508992970; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; *FAO, 1988, FAO FOOD NUTR SER, V23, P85; FELL HB, 1952, J PHYSIOL-LONDON, V116, P320, DOI 10.1113/jphysiol.1952.sp004708; FRISTEDT R, 1873, TELEOSTEI GADIDAE TX, P595; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; Hills, 1993, STAT MODELS EPIDEMIO; HOLMBERG L, 1994, ARCH INTERN MED, V154, P1805, DOI 10.1001/archinte.154.16.1805; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; *INT DAIR FED, 1995, ANN B INT DAIR FED, P14; Johansson L., 1997, Scandinavian Journal of Nutrition/Naringsforskning, V41, P63; JOHNELL O, 1992, OSTEOPOROSIS INT, V2, P298, DOI 10.1007/BF01623186; KAMM JJ, 1984, RETINOIDS, V2, P287; KINDMARK A, 1995, CALCIFIED TISSUE INT, V57, P242, DOI 10.1007/BF00310266; KINDMARK A, 1993, BIOCHEM BIOPH RES CO, V192, P1367, DOI 10.1006/bbrc.1993.1567; Maddala G.S., 1988, INTRO ECONOMETRICS; MATHEWSROTH MM, 1988, TOXICOL LETT, V41, P185, DOI 10.1016/0378-4274(88)90053-7; MCCOLLUM EV, 1957, HIST NUTR SEQUENCE I, P266; MELLANBY E, 1947, J PHYSIOL-LONDON, V105, P382, DOI 10.1113/jphysiol.1947.sp004178; Melton L III, 1995, OSTEOPOROSIS ETIOLOG, P225; MICHAELSSON K, 1995, CALCIFIED TISSUE INT, V57, P86, DOI 10.1007/BF00298425; MICHAELSSON K, 1995, INT J EPIDEMIOL, V24, P771, DOI 10.1093/ije/24.4.771; MOORE T, 1945, BIOCHEM J, V39, P222, DOI 10.1042/bj0390222; NIEMAN C, 1954, VITAM HORM, V12, P69; Okada Natsuko, 1994, Journal of Dermatology (Tokyo), V21, P308; Olson JA, 1990, PRESENT KNOWLEDGE NU, V6th, P96; REDDY V, 1995, LANCET, V346, P1634, DOI 10.1016/S0140-6736(95)91973-2; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; SCHEVEN BAA, 1990, BONE, V11, P53, DOI 10.1016/8756-3282(90)90072-7; TOGARI A, 1991, GEN PHARMACOL, V22, P287, DOI 10.1016/0306-3623(91)90450-K; [No title captured]	46	253	262	2	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					770	+		10.7326/0003-4819-129-10-199811150-00003	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841582				2022-12-28	WOS:000076984800002
J	de Silva, HA; Aronson, JK; Grahame-Smith, DG; Jobst, KA; Smith, AD				de Silva, HA; Aronson, JK; Grahame-Smith, DG; Jobst, KA; Smith, AD			Abnormal function of potassium channels in platelets of patients with Alzheimer's disease	LANCET			English	Article							MEDIAL TEMPORAL-LOBE; DIAGNOSIS; PRECURSOR; PROTEIN; ATROPHY; BLOOD; K+	Background Reports of abnormalities of potassium-channel function in various cultured cells of Alzheimer's disease patients led us to attempt to characterise the pharmacological characteristics of the abnormal channel. Methods We studied platelets from 14 patients with Alzheimer-type dementia and 14 non-demented controls matched for age and sex. The effects of specific inhibitors of K+ channels on the efflux of rubidium-86 ions, a radioactive analogue of K+, from the platelets were measured. Findings Normal platelets contain three types of K+ channel, sensitive to the inhibitory actions of apamin (small-conductance calcium-dependent potassium channels), charybdotoxin (of less specificity, but probably intermediate conductance calcium-dependent K+ channels), and alpha-dendrotoxin (voltage-sensitive K+ channels). However, Rb-86(+) efflux from the platelets of patients with Alzheimer-type dementia was not inhibited by either apamin or charybdotoxin. By contrast, inhibition by a-dendrotoxin did occur. Interpretation Our results suggest that calcium-dependent K+ channels in platelets are selectively impaired in Alzheimer's disease. A similar abnormality in neurons could contribute to the pathophysiology of the disorder.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; Univ Oxford, Dept Pharmacol, Oxford Project Investigate Memory & Ageing, Oxford OX1 3QT, England	Radcliffe Infirmary; University of Oxford; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.		Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSEN FL, 1991, TROP MED PARASITOL, V42, P1; CHEN M, 1995, BIOCHEM BIOPH RES CO, V213, P96, DOI 10.1006/bbrc.1995.2103; deAllie FA, 1996, BRIT J PHARMACOL, V117, P479, DOI 10.1111/j.1476-5381.1996.tb15215.x; deSilva HA, 1996, CLIN SCI, V91, P725, DOI 10.1042/cs0910725; deSilva HA, 1997, CLIN SCI, V93, P249, DOI 10.1042/cs0930249; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; HAJIMOHAMMADREZA I, 1990, BIOCHIM BIOPHYS ACTA, V1025, P208, DOI 10.1016/0005-2736(90)90099-A; IKEDA M, 1991, BRAIN RES, V567, P51, DOI 10.1016/0006-8993(91)91434-3; Jobst K A, 1997, Int Psychogeriatr, V9 Suppl 1, P191, DOI 10.1017/S1041610297004912; JOBST KA, 1994, J CLIN PSYCHIAT, V55, P22; JOBST KA, 1992, LANCET, V340, P1179; JOBST KA, 1992, J NEUROL NEUROSUR PS, V55, P190, DOI 10.1136/jnnp.55.3.190; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Roth M, 1988, CAMDEX CAMBRIDGE EXA; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384	19	40	42	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1590	1593		10.1016/S0140-6736(98)03200-0	http://dx.doi.org/10.1016/S0140-6736(98)03200-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843105				2022-12-28	WOS:000076998900012
J	Turelli, M				Turelli, M			Evolutionary genetics - The causes of Haldane's rule	SCIENCE			English	Editorial Material							DROSOPHILA		Univ Calif Davis, Ctr Populat Biol, Livermore, CA 95616 USA	University of California System; University of California Davis	Turelli, M (corresponding author), Univ Calif Davis, Ctr Populat Biol, Livermore, CA 95616 USA.							Coyne J.A., 1989, P180; Coyne JA, 1998, PHILOS T ROY SOC B, V353, P287, DOI 10.1098/rstb.1998.0210; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; DOBZHANSKY T, 1937, GENETICS ORIGIN SPEC, P256; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; Laurie CC, 1997, GENETICS, V147, P937; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1993, EVOLUTION, V47, P1606, DOI [10.2307/2410171, 10.1111/j.1558-5646.1993.tb02179.x]; Orr HA, 1997, ANNU REV ECOL SYST, V28, P195, DOI 10.1146/annurev.ecolsys.28.1.195; Presgraves DC, 1998, SCIENCE, V282, P952, DOI 10.1126/science.282.5390.952; TAYLOR DR, 1993, HEREDITY, V74, P518; True JR, 1996, GENETICS, V142, P819; TURELLI M, 1995, GENETICS, V140, P389; Turelli M, 1997, GENETICS, V147, P1799; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534	16	38	39	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					889	891		10.1126/science.282.5390.889	http://dx.doi.org/10.1126/science.282.5390.889			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9841436				2022-12-28	WOS:000076727300033
J	Westhof, E; Michel, F				Westhof, E; Michel, F			RNA structure - Ribozyme architectural diversity made visible	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; HAMMERHEAD RIBOZYME; TETRALOOP; BINDING; DOMAIN; MODEL		CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Westhof, E (corresponding author), CNRS, Inst Biol Mol & Cellulaire, 15 Rue R Descartes, F-67084 Strasbourg, France.	westhof@ibmc.u-strasbg.fr; michel@cgm-cnrs.fr						Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Feigon J, 1996, CHEM BIOL, V3, P611, DOI 10.1016/S1074-5521(96)90127-1; Ferre-D'Amare AR, 1998, J MOL BIOL, V279, P621, DOI 10.1006/jmbi.1998.1789; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; GESTELAND RF, 1993, RNA WORLD; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Patel DJ, 1997, J MOL BIOL, V272, P645, DOI 10.1006/jmbi.1997.1281; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3	15	2	2	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 9	1998	282	5387					251	252		10.1126/science.282.5387.251	http://dx.doi.org/10.1126/science.282.5387.251			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9841389				2022-12-28	WOS:000076370200035
J	Gale, C; Martyn, C				Gale, C; Martyn, C			Larks and owls and health, wealth, and wisdom	BRITISH MEDICAL JOURNAL			English	Article								Objective To test the validity of Benjamin Franklin's maxim "early to bed and early to rise makes a man healthy, wealthy, and wise." Design Cross sectional analysis of sleeping patterns in a nationally representative group of elderly people, and longitudinal investigation of mortality. Setting Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects 1229 men and women aged 65 and over who in 1973-4 had taken part in a survey funded by the Department of Health and Social Security and for whom data on sleeping patterns, health, socioeconomic circumstances, and cognitive function had been recorded Main outcome measures Self reported income, access to a car, standard of accommodation, performance on a test of cognitive function, state of health and mortality during 23 years of follow up. Results 356 people (29%) were defined as larks (to bed before 11 pm and up before 8 am) and 318 (26%) were defined as owls (to bed at or after 11 pm and up at or after 8 am). There was no indication that larks were richer than those with other sleeping patterns. On the contrary, owls had the largest mean income and were more likely to have access to a car. There was also no evidence that larks were superior to those with other sleeping patterns with regard to their cognitive performance or their state of health. Both larks and owls had a slightly reduced risk of death compared with the rest of the study sample, but this was accounted for by the fact that they spent less time in bed at night. In the study sample as a whole, longer periods of time in bed were associated with increased mortality. After adjustment for age, sex, the presence of illness, and other risk factors, people who spent 12 or more hours in bed had a relative risk of death of 1.7 (1.2 to 2.5) compared with those who were in bed for 9 hours. The lowest risk occurred in people who spent 8 hours in bed (adjusted relative risk 0.8; 0.7 to 1.0). Conclusion These findings do not support Franklin's claim. A "late to bed and late to rise" lifestyle does not seem to lead to socioeconomic, cognitive, or health disadvantage, but a longer time spent in bed may be associated with increased mortality.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Martyn, C (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							BOSWELL J, 1934, LIFE JOHNSON, V5, P299; EDISON TA, 1948, PHILOS LIBR, V52, P178; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Minors D, 1998, AGE AGEING, V27, P67, DOI 10.1093/ageing/27.1.67; Qureshi AI, 1997, NEUROLOGY, V48, P904, DOI 10.1212/WNL.48.4.904; RUIGOMEZ A, 1995, AGE AGEING, V24, P113, DOI 10.1093/ageing/24.2.113; SMITH CS, 1989, J APPL PSYCHOL, V74, P728, DOI 10.1037/0021-9010.74.5.728; WINGARD DL, 1982, AM J EPIDEMIOL, V116, P765, DOI 10.1093/oxfordjournals.aje.a113466	8	59	60	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1675	1677		10.1136/bmj.317.7174.1675	http://dx.doi.org/10.1136/bmj.317.7174.1675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857121	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000077742300007
J	Schott, GD				Schott, GD			Nan West's murals in the Royal National Orthopaedic Hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Natl Orthopaed Hosp, London W1N 6AD, England	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Schott, GD (corresponding author), Royal Natl Orthopaed Hosp, London W1N 6AD, England.							HONE J, 1939, LIFE H TONKS, P182; JOHNSON J, 1976, DICT BRIT ART, V5, P538; POWERS A, 1989, LAST ROMANTICS ROMAN, P62; WEST KA, 1949, COMMUNICATION   0101; WHISTLER L, 1985, LAUGHTER URN LIFE R, P93; 1927, TIMES           1116, P19; 1928, HOSP GAZETTE, V24, P68	7	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1736	1736		10.1136/bmj.317.7174.1736	http://dx.doi.org/10.1136/bmj.317.7174.1736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857159	Green Published			2022-12-28	WOS:000077742300054
J	Walton, J				Walton, J			Charles George Drake - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1596	1596		10.1136/bmj.317.7172.1596	http://dx.doi.org/10.1136/bmj.317.7172.1596			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836685	Green Published			2022-12-28	WOS:000077451700078
J	Waxman, R; Tennant, A; Helliwell, P				Waxman, R; Tennant, A; Helliwell, P			Community survey of factors associated with consultation for low back pain	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; MODEL; DEPRESSION; PREVALENCE; DISABILITY; SEEKING; BELIEFS	Objective To investigate the psychosocial factors associated with consultation for low back pain. Design Two phase cross sectional postal survey. Setting Bradford Metropolitan Health District. Subjects 1813 adults responding to the phase 1 questionnaire. 540 of the 782 with an episode of low back pain in the past 12 months completed the second questionnaire. Main outcome measures Six psychosocial constructs. Results 406 (52%) of the respondents reporting back pain in the past 12 months had not consulted a health professional. Logistic regression showed that consultation was associated with externalised beliefs regarding pain management (odds ratio 3.6; 95% confidence interval 2.1 to 6.0). Duration of pain affected the factors associated with consultation Consultation for episodes lasting less than two weeks (n = 290) was associated with greater than median pain (3.0; 1.7 to 5.5), consultation for episodes over two weeks (n = 243) was associated with increased disability (3.7; 1.5 to 9.0), and consultation for episodes over three months (n = 143) with increased depression (3.9; 1.3 to 11.8). Conclusions The results support a role for psychosocial factors in consultation for low back pain and suggest that the reasons for consultation vary with duration of pain. Duration of the episode may be a useful guide to management of non-specific low back pain.	Univ Leeds, Res Sch Med, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Waxman, R (corresponding author), Univ Leeds, Res Sch Med, Rheumatol & Rehabil Res Unit, Leeds LS2 9NZ, W Yorkshire, England.							ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; BADGER LW, 1994, PSYCHOSOM MED, V56, P128, DOI 10.1097/00006842-199403000-00008; Balint M., 1986, DOCTOR HIS PATIENT I; CAREY TS, 1995, SPINE, V20, P312, DOI 10.1097/00007632-199502000-00009; Carey TS, 1996, SPINE, V21, P339, DOI 10.1097/00007632-199602010-00018; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DODD T, 1997, PREVALENCE BACK PAIN; Hillman M, 1996, J EPIDEMIOL COMMUN H, V50, P347, DOI 10.1136/jech.50.3.347; Horal J, 1969, Acta Orthop Scand Suppl, V118, P1; MAIN CJ, 1991, PAIN, V46, P287, DOI 10.1016/0304-3959(91)90112-B; MAIN CJ, 1983, J PSYCHOSOM RES, V27, P503, DOI 10.1016/0022-3999(83)90040-5; Main CJ, 1984, CURR CONCEPTS PAIN, V2, P10; REKOLA KE, 1993, J EPIDEMIOL COMMUN H, V47, P153, DOI 10.1136/jech.47.2.153; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; RUDY TE, 1988, PAIN, V35, P129, DOI 10.1016/0304-3959(88)90220-5; SCHEMPER M, 1997, CONTROL CLIN TRIALS, V18, pS61; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; SZPALSKI M, 1995, SPINE, V20, P431, DOI 10.1097/00007632-199502001-00005; *U YORK NHS CTR RE, 1993, EFFECTIVE HLTH CARE, V5, P1; VONKORFF M, 1996, BRIT J PSYCHIAT, V168, pS101; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WRIGHT D, 1995, BRIT J RHEUMATOL, V34, P156; Zimmermann C, 1996, J PSYCHOSOM RES, V40, P351, DOI 10.1016/0022-3999(95)00536-6	26	58	58	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1564	1567		10.1136/bmj.317.7172.1564	http://dx.doi.org/10.1136/bmj.317.7172.1564			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146VC	9836660	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077451700027
J	Zhao, KJ; Wang, WD; Rando, OJ; Xue, YT; Swiderek, K; Kuo, A; Crabtree, GR				Zhao, KJ; Wang, WD; Rando, OJ; Xue, YT; Swiderek, K; Kuo, A; Crabtree, GR			Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling	CELL			English	Article							REMODELING FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; NUCLEAR MATRIX; HUMAN HOMOLOG; ACTIN; YEAST	Lymphocyte activation is accompanied by visible changes in chromatin structure. We find that antigen receptor signaling induces the rapid association of the BAF complex with chromatin. PIP2, which is regulated by activation stimuli, is sufficient in vitro to target the BAF complex to chromatin, but it has no effect on related chromatin remodeling complexes containing SNF2L or hISWI. Purification and peptide sequencing of the subunits of the complex revealed beta-actin as well as a novel actin-related protein, BAF53. beta-actin and BAF53 are required for maximal ATPase activity of BRG1 and are also required with BRG1 fair association of the complex with chromatin/matrix. This work indicates that membrane signals control the activity of the mammalian SWI/SNF or BAF complex and demonstrates a direct interface between signaling and chromatin regulation.	Stanford Univ, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	Howard Hughes Medical Institute; Stanford University; City of Hope; Beckman Research Institute of City of Hope	Crabtree, GR (corresponding author), Stanford Univ, Dept Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Wang, Weidong/AAV-2446-2021	Rando, Oliver/0000-0003-1516-9397; Wang, Weidong/0000-0002-0658-7928				BILLI AM, 1993, BIOCHEM BIOPH RES CO, V195, P8, DOI 10.1006/bbrc.1993.2001; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CRABTREE GR, 1989, SCIENCE, V243, P255; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MAZZOTTI G, 1995, J HISTOCHEM CYTOCHEM, V43, P181, DOI 10.1177/43.2.7822774; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	40	607	630	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					625	636		10.1016/S0092-8674(00)81633-5	http://dx.doi.org/10.1016/S0092-8674(00)81633-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845365	Bronze			2022-12-28	WOS:000077253700010
J	Branson, BM				Branson, BM			Home sample collection tests for HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Home sample collection (HSC) tests allow persons to test themselves for human immunodeficiency virus (HIV) infection at home without medical supervision. Characterizing the use of such tests can help assess their potential effect on public health efforts to prevent and control HIV. Objective.-To describe use of HIV HSC tests. Design.-Retrospective descriptive analysis from data collected by test manufacturers during 1996 and 1997. Setting.-United States. Participants.-Volunteer sample of consumers who used either of 2 HSC tests. Main Outcome Measures.-Demographic and behavioral aspects of users. Results.-During the first year of availability, 174316 HIV HSC tests were submitted to the manufacturers for analysis; 0.9% of the results were positive for HIV, and 97% of all users called to learn test results. Survey responses from 70 620 HIV-negative and 865 HIV-positive users revealed that most were men, white, and aged 25 to 34 years; HIV prevalence was highest among nonwhites, aged 35 to 44 years, men who have sex with men, and injection drug users. Bisexual men accounted for a large proportion of HIV-positive users. Nearly 60% of all users and 49% of those who tested HIV positive had never been tested before. Telephone counselors found that 23% of HIV-positive users already had a source of follow-up care, 65% accepted referrals, and 12% had tested themselves to evaluate the effects of antiretroviral therapy. Conclusions.-Home sample collection tests for HIV were used by persons who were at risk for HIV and by persons who did not use other testing. Most HIV-positive users either had a source of medical care or received referrals.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Branson, BM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Off Commun, Mailstop E-06, Atlanta, GA 30333 USA.							BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911; *CDCP, 1997, HIV COUNS TEST PUBL; COLFAX GJ, 1997, SOC GEN INT MED 20 A; HOXIE NJ, 1992, AM J PUBLIC HEALTH, V82, P1370, DOI 10.2105/AJPH.82.10.1370; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Kassler WJ, 1997, AIDS EDUC PREV, V9, P27; MALOR CJ, 1991, J INFECT DIS, V163, P699; SCHOPPER D, 1996, AIDS, V10, P1255; SCHULTZ WB, 1996, ADVISORY OPINION	9	49	51	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1699	1701		10.1001/jama.280.19.1699	http://dx.doi.org/10.1001/jama.280.19.1699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138PD	9832003				2022-12-28	WOS:000076980700037
J	Williams, RE				Williams, RE			De futuro urbanorum	BRITISH MEDICAL JOURNAL			English	Article																		ANGRIST SW, 1967, ORDER CHAOS LAWS EME; Brown P. L., 1972, ASTRONOMY COLOUR; Obert EF., 1973, INTERNAL COMBUSTION, V3rd ed.; Wilkie, 1968, MUSCLE; WILLIAMS RE, 1975, BRIT MED J, V4, P25, DOI 10.1136/bmj.4.5987.25	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1713	1713		10.1136/bmj.317.7174.1713	http://dx.doi.org/10.1136/bmj.317.7174.1713			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857139	Green Published			2022-12-28	WOS:000077742300029
J	Henning, T; Salama, F				Henning, T; Salama, F			Carbon - Carbon in the Universe	SCIENCE			English	Review							ULTRAVIOLET EXTINCTION CURVES; AMORPHOUS-CARBON; INTERSTELLAR CARBON; SILICON-CARBIDE; ELECTRONIC-STRUCTURE; AROMATIC-MOLECULES; ION IRRADIATION; GRAINS; GRAPHITE; DUST	Carbon is a major player In the evolutionary scheme of the universe because of its abundance and its ability to form complex species. It is also a key element in the evolution of prebiotic molecules. The different forms of cosmic carbon are reviewed ranging from carbon atoms and carbon-bearing molecules to complex, solid-state, carbonaceous structures. The current state of knowledge is assessed an the observational and laboratory fronts. Fundamental astrophysical implications are examined as well as the impact of these studies on the hitherto poorly understood physical and chemical properties of carbon materials in space.	Inst Astrophys, D-07745 Jena, Germany; Univ Sternwarte, D-07745 Jena, Germany; NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Henning, T (corresponding author), Inst Astrophys, Schillergasschen 2-3, D-07745 Jena, Germany.		Salama, Farid/A-8787-2009; Henning, Thomas K/O-4372-2018	Salama, Farid/0000-0002-6064-4401; Henning, Thomas K/0000-0002-1493-300X				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1998, IN PRESS ASTROPHYS J; ANDERS E, 1991, SPACE SCI REV, V56, P157, DOI 10.1007/BF00178405; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; Beegle LW, 1997, ASTROPHYS J, V487, P976, DOI 10.1086/304658; Bernatowicz TJ, 1996, ASTROPHYS J, V472, P760, DOI 10.1086/178105; BLANCO A, 1995, ASTROPHYS J, V448, P339, DOI 10.1086/175964; BURBIDGE EM, 1957, REV MOD PHYS, V29, P547, DOI 10.1103/RevModPhys.29.547; BUSS RH, 1990, ASTROPHYS J, V365, pL23, DOI 10.1086/185879; CALDWELL BJ, 1994, ASTROPHYS J, V429, P285; Cherchneff I., 1998, MOL ASTROPHYSICS STA, P265; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; Cruikshank D. P., 1997, STARDUST PLANETESIMA, V122, P315; DEHEER WA, 1993, CHEM PHYS LETT, V207, P480, DOI 10.1016/0009-2614(93)89033-E; DONNET JB, 1982, CARBON, V20, P267, DOI 10.1016/0008-6223(82)90002-1; Dorschner J, 1995, ASTRON ASTROPHYS REV, V6, P271, DOI 10.1007/BF00873686; Draine B., 1989, IAU S, V135, P313; FITZPATRICK EL, 1986, ASTROPHYS J, V307, P286, DOI 10.1086/164415; FITZPATRICK EL, 1988, ASTROPHYS J, V328, P734, DOI 10.1086/166332; FREIVOGEL P, 1994, ASTROPHYS J, V431, pL151, DOI 10.1086/187495; FRENKLACH M, 1989, NATURE, V339, P196, DOI 10.1038/339196a0; FURTON DG, 1993, ASTROPHYS J, V415, pL51, DOI 10.1086/187030; Garay G, 1998, ASTROPHYS J, V501, P699, DOI 10.1086/305852; Geballe T. R., 1997, Astronomical Society of the Pacific Conference Series, V122, P119; Gordon KD, 1998, ASTROPHYS J, V498, P522, DOI 10.1086/305571; Grevesse N., 1993, ORIGIN EVOLUTION ELE, P15; HECHT JH, 1991, ASTROPHYS J, V367, P635, DOI 10.1086/169658; HEIMANN RB, 1994, DIAM RELAT MATER, V3, P1151, DOI 10.1016/0925-9635(94)90161-9; HENNING T, 1998, IN PRESS SOLID INTER; HENNING T, 1998, IN PRESS LAB ASTROPH; HENRARD L, 1993, ASTROPHYS J, V406, P92, DOI 10.1086/172422; Henrard L, 1997, ASTROPHYS J, V487, P719, DOI 10.1086/304645; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; Hollenbach DJ, 1997, ANNU REV ASTRON ASTR, V35, P179, DOI 10.1146/annurev.astro.35.1.179; HUSS GR, 1995, GEOCHIM COSMOCHIM AC, V59, P115, DOI 10.1016/0016-7037(94)00376-W; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Ingalls JG, 1997, ASTROPHYS J, V479, P296, DOI 10.1086/303876; JAGER C, UNPUB; Joblin C, 1995, ASTROPHYS SPACE SC L, V202, P157, DOI 10.1007/978-94-011-0373-2_17; Jones AP, 1994, MORIOND AST, P35; Korpela EJ, 1998, ASTROPHYS J, V495, P317, DOI 10.1086/305274; Kozasa T, 1996, ASTRON ASTROPHYS, V307, P551; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; LEQUEUX J, 1996, ASTRON ASTROPHYS, P315; LIJIMA S, 1987, J PHYS CHEM-US, V91, P3466; MENNELLA V, 1995, ASTROPHYS J, V444, P288, DOI 10.1086/175603; Mennella V, 1996, ASTROPHYS J, V464, pL191, DOI 10.1086/310116; Mennella V, 1997, ASTROPHYS J, V481, P545, DOI 10.1086/304035; MENNELLA V, 1995, ASTROPHYS J SUPPL S, V100, P149, DOI 10.1086/192212; MESSENGER S, 1995, METEORITICS, V30, P546; Meyer DM, 1998, ASTROPHYS J, V493, P222, DOI 10.1086/305128; Meyer DM, 1997, AIP CONF PROC, P507, DOI 10.1063/1.53318; MUMMA MJ, 1997, STARDUST PLANETESIMA, V122, P369; MUSCHKE H, UNPUB ASTRON ASTROPH; Papoular R, 1996, ASTRON ASTROPHYS, V315, P222; Papoular R, 1998, ASTRON ASTROPHYS, V329, P1035; Pendleton Y. J., 1997, Astronomical Society of the Pacific Conference Series, V122, P179; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; ROBERTSON J, 1991, PROG SOLID STATE CH, V21, P199, DOI 10.1016/0079-6786(91)90002-H; Salama F, 1996, ASTROPHYS J, V458, P621, DOI 10.1086/176844; Salama F, 1998, ORIGINS LIFE EVOL B, V28, P349, DOI 10.1023/A:1006506620752; SALAMA F, 1998, IN PRESS SOLID INTER; SALAMA F, 1996, LOW TEMPERATURE MOL, P169; Sandford SA, 1996, METEORIT PLANET SCI, V31, P449, DOI 10.1111/j.1945-5100.1996.tb02088.x; SARRE PJ, 1995, SCIENCE, V269, P674, DOI 10.1126/science.269.5224.674; Schnaiter M, 1998, ASTROPHYS J, V498, P486, DOI 10.1086/305543; Scott A, 1997, ASTROPHYS J, V489, pL193, DOI 10.1086/316789; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; Sofia UJ, 1998, ASTROPHYS J, V504, pL47, DOI 10.1086/311566; Sofia UJ, 1997, ASTROPHYS J, V482, pL105, DOI 10.1086/310681; Speck AK, 1997, MON NOT R ASTRON SOC, V288, P431, DOI 10.1093/mnras/288.2.431; STECHER TP, 1965, ASTROPHYS J, V142, P1681, DOI 10.1086/148461; STOGNIENKO R, 1995, ASTRON ASTROPHYS, V296, P797; THADDEUS P, 1995, ASTROPHYS J, V448, P545; Tielens AGGM, 1995, ASTR SOC P, V73, P3; Tulej M, 1998, ASTROPHYS J, V506, pL69, DOI 10.1086/311637; UGARTE D, 1992, NATURE, V359, P707, DOI 10.1038/359707a0; van Dishoeck E.F., 1998, MOL ASTROPHYSICS STA, P53; Wesolowski P, 1997, APPL PHYS LETT, V71, P1948, DOI 10.1063/1.119990; ZINNER E, 1995, METEORITICS, V30, P209, DOI 10.1111/j.1945-5100.1995.tb01115.x; Zsargo J, 1997, ASTROPHYS J, V484, P820, DOI 10.1086/304377; [No title captured]	84	307	322	10	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2204	2210		10.1126/science.282.5397.2204	http://dx.doi.org/10.1126/science.282.5397.2204			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856936				2022-12-28	WOS:000077645800030
J	Low, L; King, S; Wilkie, T				Low, L; King, S; Wilkie, T			Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article								Objectives To gather empirical evidence on any discrimination based on genetic information shown by the insurance industry in the United Kingdom and to assess how society is likely to handle future genetic information from tests for polygenic multifactorial conditions. Design Postal questionnaire survey Subjects Sample (n = 7000) of members from seven British support groups for families with genetic disorders and a representative sample (n = 1033) of the general public who answered questions on applying for life insurance as part of an omnibus survey Main outcome measures Subjects were asked about their experiences with insurers, the medical profession, employers, and social services. Experiences with insurers are reported here. Results Altogether 33.4% of the study group had problems when applying for life insurance compared with 5% of applicants in the omnibus survey Thirteen per cent of Study respondents from subgroups who represented no adverse actuarial risk on genetic grounds reported that their treatment by insurers seemed to represent unjustified genetic discrimination. Conclusions Life insurers may not be operating a consistent policy for assessing genetic information or acting in accord with the actuarial risks brought to them. The inconsistency suggests error rather than a corporate policy of discrimination based on genetic characteristics. Any future proposals for genetic testing for common or multifactorial disorders should be examined carefully.	Wellcome Trust, Unit Policy Res Sci & Med, London NW1 2BE, England	University of London; University College London	Wilkie, T (corresponding author), Wellcome Trust, Unit Policy Res Sci & Med, London NW1 2BE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ASS BRIT INS, 1997, GEN TEST ABI COD PRA; *ASS BRIT INS, 1997, INS FACTS FIG TRENDS; *ASS BRIT INS, 1997, LIF INS GEN POL STAT; BERDIE D, 1989, MARKETING RES    SEP, P52; *DEP EMPL, 1996, DIS DISCR SERV PREM; *EC INT UN, 1997, HEALTHC INT 2 QUART; Geller Lisa N, 1996, Sci Eng Ethics, V2, P71, DOI 10.1007/BF02639319; GOYDER J, 1985, SOCIOLOGY, V19, P55, DOI 10.1177/0038038585019001006; *HOUS COMM SCI TEC, 1995, HC41 SCI TECHN COMM; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; Leslie L.L., 1972, SOC SCI RES, V9, P323, DOI [DOI 10.1016/0049-089X(72)90080-4, 10.1016/0049-089X(72)90080-4]; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MCEWEN JE, 1993, AM J HUM GENET, V53, P33; SHAPIRO D, 1997, FINANCIAL TIMES 0321, P16; Wilkie T, 1998, NAT GENET, V20, P119, DOI 10.1038/2416; WYNBRANDT J, 1991, ENCY GENETIC DISORDE	16	77	77	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1632	1635		10.1136/bmj.317.7173.1632	http://dx.doi.org/10.1136/bmj.317.7173.1632			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	149JW	9848905	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000077602100028
J	Clarke, ND; Berg, JM				Clarke, ND; Berg, JM			Zinc fingers in Caenorhabditis elegans: Finding families and probing pathways	SCIENCE			English	Review							TRANSCRIPTION FACTOR-IIIA; SEX-DETERMINING GENE; C-ELEGANS; BINDING PROPERTIES; PROTEINS; DOMAIN; DROSOPHILA; TRA-1; HUNCHBACK; REPEATS	More than 3 percent of the protein sequences inferred from the Caenorhabditis elegans genome contain sequence motifs characteristic of zinc-binding structural domains, and of these more than half are believed to be sequence-specific DNA-binding proteins. The distribution of these zinc-binding domains among the genomes of various organisms offers insights into the role of zinc-binding proteins in evolution. In addition, the complete genome sequence of C. elegans provides an opportunity to analyze, and perhaps predict, pathways of transcriptional regulation.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Clarke, ND (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.		Clarke, Neil/D-9613-2014; Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963				Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; Bohm S, 1997, NUCLEIC ACIDS RES, V25, P2464, DOI 10.1093/nar/25.12.2464; BOHM S, 1985, STUD BIOPHYS, V107, P237; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clarke N. M., UNPUB; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Erdman SE, 1996, GENETICS, V144, P1639; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN JA, 1977, GENETICS, V86, P275; Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Matsuda S, 1996, ONCOGENE, V12, P705; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; SCHEDL T, 1989, GENETICS, V123, P755; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZARKOWER D, COMMUNICATION	37	159	187	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2018	2022		10.1126/science.282.5396.2018	http://dx.doi.org/10.1126/science.282.5396.2018			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851917				2022-12-28	WOS:000077467100035
J	Peters, C; Mayer, A				Peters, C; Mayer, A			Ca2+/calmodulin signals the completion docking and triggers a late step of vacuole fusion	NATURE			English	Article							ADRENAL CHROMAFFIN CELLS; SACCHAROMYCES-CEREVISIAE; IN-VITRO; YEAST VACUOLES; GTPASE YPT7P; CALMODULIN; INHERITANCE; EXOCYTOSIS; CALCIUM; ENDOCYTOSIS	The basic reaction mechanisms for membrane fusion in the trafficking of intracellular membranes and in exocytosis are probably identical(5). But in contrast to regulated exocytosis, intracellular fusion reactions are referred to as 'constitutive' as no final Ca2+-dependent triggering step has been observed. Although transport from the endoplasmic reticulum to the Golgi apparatus in the cell depends on Ca2+ (ref. 6), as does endosome fusion(7) and assembly of the nuclear envelopes, it is unclear whether Ca2+ triggers these events. Membrane fusion involves several subreactions: priming, tethering and docking. Proteins that are needed for fusion include p115, SNAPs, NSF, SNAREs and small GTPases, which operate in these early reactions(1-3), but the machinery that catalyses the final mixing of biological membranes is still unknown. Here we show that Ca2+ is released from the vacuolar lumen following completion of the docking step. We have identified calmodulin as the putative Ca2+ sensor and as the fir component required in the post-docking phase of vacuole fusion. Calmodulin binds tightly to vacuoles upon Ca2+ release. Unlike synaptotagmin or syncollin in exocytosis(4), calmodulin does not act as a fusion damp but actively promotes bilayer mixing. Hence, activation of SNAREs is not sufficient to drive bilayer mixing between physiological membranes. We propose that Ca2+ control of the latest phase of membrane fusion maybe a conserved feature, relevant not only for exocytosis, but also for intracellular, 'constitutive' fusion reactions. However, the origin of the Ca2+ signal, its receptor and its mode of processing differ.	Max Planck Gesell, Friedrich Miescher Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Mayer, A (corresponding author), Max Planck Gesell, Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.		Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				APODACA G, 1994, J BIOL CHEM, V269, P19005; Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KIBBLE VA, 1996, EUR J PHYSL, V431, P464; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; STEINHARDT RA, 1982, NATURE, V295, P154, DOI 10.1038/295154a0; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WADA Y, 1992, J BIOL CHEM, V267, P18665; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	30	321	328	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					575	580		10.1038/25133	http://dx.doi.org/10.1038/25133			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859992				2022-12-28	WOS:000077466800058
J	Brezina, D				Brezina, D			Alton Small	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1902	1902		10.1001/jama.280.22.1902-b	http://dx.doi.org/10.1001/jama.280.22.1902-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851458				2022-12-28	WOS:000077364500012
J	Hackett, PH; Yarnell, PR; Hill, R; Reynard, K				Hackett, PH; Yarnell, PR; Hill, R; Reynard, K			High-altitude cerebral edema evaluated with magnetic resonance imaging - Clinical correlation and pathophysiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MOUNTAIN-SICKNESS; PULMONARY-EDEMA; BRAIN EDEMA; DEXAMETHASONE; HYPOTHESIS; FEATURES; LESIONS; ILLNESS; HYPOXIA	Context.-Because of its onset in generally remote environments, high-altitude cerebral edema (HACE) has received little scientific attention. Understanding the pathophysiology might have implications for prevention and treatment of both this disorder and the much more common acute mountain sickness. Objectives.-To identify a clinical imaging correlate for HACE and determine whether the edema is primarily vasogenic or cytotoxic. Design,Case-comparison study. Setting,Community hospitals accessed by helicopter from mountains in Colorado and Alaska, Patients.-A consecutive sample of 9 men with MACE, between 18 and 35 years old, 8 of whom also had pulmonary edema, were studied after evacuation from high-altitude locations; 5 were mountain climbers and 4 were skiers. The control group, matched for age, sex, and altitude exposure, consisted of 3 subjects with high-altitude pulmonary edema only and 3 who had been entirely well at altitude. Four patients with HACE were available for follow-up imaging after complete recovery. Main Outcome Measures.-Magnetic resonance imaging (MRI) of the brain during acute, convalescent, and recovered phases of HACE, and once in controls, immediately after altitude exposure. Results.-Seven of the 9 patients with HACE showed intense T-2 Signal in white matter areas, especially the splenium of the corpus callosum, and no gray matter abnormalities. Control subjects demonstrated no such abnormalities. All patients completely recovered; in the 4 available for follow-up MRI, the changes had resolved entirely. Conclusions.-We conclude that HACE is characterized on MRI by reversible white matter edema, with a predilection for the splenium of the corpus callosum. This finding provides a clinical imaging correlate useful for diagnosis. It also suggests that the predominant mechanism is vasogenic (movement of fluid and protein out of the vascular compartment) and, thus, that the blood-brain barrier may be important in MACE.	Univ Alaska, Sch Hlth Profess, Anchorage, AK USA; Alaska Reg Hosp, Dept Emergency Med, Anchorage, AK USA; Alaska Reg Hosp, Dept Radiol, Anchorage, AK USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; St Anthony Hosp, Denver, CO USA; Univ Colorado, Sch Med, Dept Med, Denver, CO USA	University of Alaska System; University of Alaska Anchorage; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hackett, PH (corresponding author), St Marys Hosp & Med Ctr, Dept Emergency Med, 2635 N 7th Ave, Grand Junct, CO 81502 USA.	phack@ruralhealth.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL040476] Funding Source: NIH RePORTER; NHLBI NIH HHS [R15 HL40476-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTSCH P, 1988, J APPL PHYSIOL, V65, P1929, DOI 10.1152/jappl.1988.65.5.1929; BAUMGARTNER RW, IN PRESS J APPL PHYS; BRADLEY WG, 1987, MAGNETIC RESONANCE I, P29; Cordoliani YS, 1998, AM J NEURORADIOL, V19, P871; DICKINSON J, 1983, THORAX, V38, P646, DOI 10.1136/thx.38.9.646; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; GARRIDO E, 1993, INT J SPORTS MED, V14, P232, DOI 10.1055/s-2007-1021169; GARRIDO E, 1995, EUR J APPL PHYSL, V70, P447; GREENWOOD J, 1995, NEW CONCEPTS BLOOD B; HACKETT PH, 1976, LANCET, V2, P1149; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; Hackett PH, 1995, WILDERNESS MED, P1; HANSEN JE, 1970, ARCH ENVIRON HEALTH, V21, P666; HAUSER RA, 1988, ARCH NEUROL-CHICAGO, V45, P1078, DOI 10.1001/archneur.1988.00520340032007; HOUSTON CS, 1975, LANCET, V2, P758; ITO T, 1995, AM J NEURORADIOL, V16, P1344; JOO F, 1989, Neurological Research, V11, P67; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOBAYASHI T, 1987, CHEST, V92, P814, DOI 10.1378/chest.92.5.814; KRASNEY J, 1997, HYPOXIA WOMEN ALTITU, P254; KRASNEY JA, 1994, MED SCI SPORT EXER, V26, P195, DOI 10.1249/00005768-199402000-00010; KRASNEY JA, 1997, KIDNEY INT S59, V51, pS69; LASSEN NA, 1975, LANCET, V2, P1154; LEBIHAN D, 1992, MAGNETIC RESONANCE I, P335; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; Matsuzawa Y, 1992, HIGH ALTITUDE MED, P300; MOODY DM, 1988, AM J NEURORADIOL, V9, P1051; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; OGAWA S, 1992, AM J PHYSIOL, V262, pC546, DOI 10.1152/ajpcell.1992.262.3.C546; PLATEEL M, 1995, J NEUROCHEM, V65, P2133; RAROQUE HG, 1990, NEUROLOGY, V40, P167, DOI 10.1212/WNL.40.1.167; RICHALET JP, 1991, RESP PHYSIOL, V85, P205, DOI 10.1016/0034-5687(91)90062-N; ROACH RC, 1998, HYPOXIA MOL MED, P272; SEVERINGHAUS JW, 1995, J APPL PHYSIOL, V79, P375, DOI 10.1152/jappl.1995.79.2.375; Simonson T. M., 1996, CLIN MAGNETIC RESONA, P767; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; SUTTON JR, 1979, B EUR PHYSIOPATH RES, V15, P1045; WOHNS RNW, 1981, CRIT CARE MED, V9, P880, DOI 10.1097/00003246-198112000-00017; YAFFE K, 1995, NEUROLOGY, V45, P104, DOI 10.1212/WNL.45.1.104; YAMAGUCHI S, 1992, HIGH ALTITUDE MED, P305; ZAVASKY D, 1995, WILD ENVIRON MED, V6, P229	43	205	220	2	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1920	1925		10.1001/jama.280.22.1920	http://dx.doi.org/10.1001/jama.280.22.1920			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851477	Bronze			2022-12-28	WOS:000077364500036
J	To, T; Agha, M; Dick, PT; Feldman, W				To, T; Agha, M; Dick, PT; Feldman, W			Cohort study on circumcision of newborn boys and subsequent risk of urinary-tract infection	LANCET			English	Article							ROUTINE NEONATAL CIRCUMCISION; DECREASED INCIDENCE; MALE INFANTS	Background A decrease in risk of urinary-tract infection is one of the most commonly given reasons for circumcision of newborn boys. Previous studies have reported rates of UTI to be 10-20 times higher in uncircumcised than in circumcised boys. This population-based cohort study followed neonates in Ontario, Canada, prospectively to study the relation between circumcision and subsequent UTI risk. Methods Eligible boys were born to residents of Ontario between April 1, 1993, and March 31, 1994. We used hospital discharge data to follow up boys until March 31; 1996. Findings Of 69100 eligible boys, 30105 (43.6%) were circumcised and 38995 (56.4%) uncircumcised. 888 boys circumcised after the first month of life were excluded. 29217 uncircumcised boys were matched to the remaining circumcised boys by date of birth. The 1-year probabilities of hospital admission for UTI were 1.88 per 1000 person-years of observation (83 cases up to end of follow-up) in the circumcised cohort and 7.02 per 1000 person-years (247 cases up to end of follow-up) in the uncircumcised cohort (p < 0.0001). The estimated relative risk of admission for UTI by first-year follow-up indicated a significantly higher risk for uncircumcised boys than for circumcised boys (3.7 [2.8-4.9]). 195 circumcisions would be needed to prevent one hospital admission for UTI in the first year of life. Interpretation Although our findings support the notion that circumcision may protect boys from UTI, the magnitude of this effect may be less than previously estimated.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Paediat Med, Paediat Outcomes Res Team, Toronto, ON M5G 1X8, Canada; Inst Clin Evaluat Sci Ontario, N York, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, N York, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Clin Epidemiol Unit, N York, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	To, T (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave,Rm 10222, Toronto, ON M5G 1X8, Canada.	teresa.to@sickkids.on.ca						Andrews W, 1996, CAN MED ASSOC J, V154, P769; Craig JC, 1996, J PEDIATR-US, V128, P23, DOI 10.1016/S0022-3476(96)70423-7; GINSBURG CM, 1982, PEDIATRICS, V69, P409; HERZOG LW, 1989, AM J DIS CHILD, V143, P348, DOI 10.1001/archpedi.1989.02150150106026; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; MUSTARD CA, 1995, AM J OBSTET GYNECOL, V172, P631, DOI 10.1016/0002-9378(95)90584-7; POLAND RL, 1990, NEW ENGL J MED, V322, P1312, DOI 10.1056/NEJM199005033221811; To T, 1996, PATTERNS HLTH CARE O, P294; WILLIAMS N, 1993, BRIT J SURG, V80, P1231, DOI 10.1002/bjs.1800801005; WISWELL TE, 1985, PEDIATRICS, V75, P901; WISWELL TE, 1990, AM FAM PHYSICIAN, V41, P859; WISWELL TE, 1993, CLIN PEDIATR, V32, P130, DOI 10.1177/000992289303200301; WISWELL TE, 1986, PEDIATRICS, V78, P96	13	118	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	1998	352	9143					1813	1816		10.1016/S0140-6736(98)02392-7	http://dx.doi.org/10.1016/S0140-6736(98)02392-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851381				2022-12-28	WOS:000077337900009
J	Braunwald, E				Braunwald, E			Evolution of the management of acute myocardial infarction: a 20th century saga	LANCET			English	Article							THROMBOLYTIC THERAPY; CORONARY-OCCLUSION		Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Braunwald, E (corresponding author), Harvard Univ, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; Burchell H B, 1974, Am J Cardiol, V34, P868, DOI 10.1016/0002-9149(74)90712-7; CHAZOV EI, 1976, TERAPEVT ARKH, V48, P8; DAY HW, 1963, DIS CHEST, V44, P423, DOI 10.1378/chest.44.4.423; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; FLETCHER AP, 1959, J CLIN INVEST, V38, P1111, DOI 10.1172/JCI103887; FYE WB, 1997, ACUTE MYOCARDIAL INF, P1; Gupta S, 1997, CIRCULATION, V96, P404; Harrison T.R., 1950, PRINCIPLES INTERNAL, P1285; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; HOWELL JD, 1984, B HIST MED, V58, P83; HUTCHINS GM, 1978, AM J CARDIOL, V41, P1127, DOI 10.1016/0002-9149(78)90869-X; JULIAN DG, 1961, LANCET, V2, P840; Kouwenhoven WB, 1960, JAMA-J AM MED ASSOC, V173, P94; Krehl L, 1901, EKRANKUNGEN HERZMUSK; Levine S, 1929, CORONARY THROMBOSIS; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; MAROKO PR, 1973, ANN INTERN MED, V79, P720, DOI 10.7326/0003-4819-79-5-720; OBRAZTSOV VP, 1910, Z KLIN MED, V71, P116; PANTRIDG.JF, 1967, LANCET, V2, P271; Parkinson J, 1928, LANCET, V1, P4; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; RENTROP K P, 1979, Clinical Cardiology, V2, P354; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SEDERHOLM M, 1984, NEW ENGL J MED, V310, P9; Stone GW, 1998, J AM COLL CARDIOL, V31, P23, DOI 10.1016/S0735-1097(97)00439-7; SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; VERSTRAETE M, 1972, TXB CORONARY CARE, P643; Wearn JT, 1923, AM J MED SCI, V165, P250, DOI 10.1097/00000441-192302000-00008; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093	36	51	54	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1998	352	9142					1771	1774		10.1016/S0140-6736(98)03212-7	http://dx.doi.org/10.1016/S0140-6736(98)03212-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848369				2022-12-28	WOS:000077246500044
J	Raju, TNK				Raju, TNK			The Nobel Chronicles - 1926: Johannes Andreas Grib Fibiger (1867-1928)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1635	1635		10.1016/S0140-6736(98)00067-1	http://dx.doi.org/10.1016/S0140-6736(98)00067-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843145				2022-12-28	WOS:000076998900073
J	Tonkin, A; Aylward, P; Colquhoun, D; Glasziou, P; Harris, P; MacMahon, S; Magnus, P; Newel, D; Nestel, P; Sharpe, N; Hunt, D; Shaw, J; Simes, RJ; Thompson, P; Thomson, A; West, M; White, H; Simes, S; Hague, W; Caleo, S; Hall, J; Martin, A; Mulray, S; Barter, P; Beilin, L; Collins, R; McNeil, J; Meier, P; Willimott, H; Smithers, D; Wallace, P; Sullivan, D; Keech, A				Tonkin, A; Aylward, P; Colquhoun, D; Glasziou, P; Harris, P; MacMahon, S; Magnus, P; Newel, D; Nestel, P; Sharpe, N; Hunt, D; Shaw, J; Simes, RJ; Thompson, P; Thomson, A; West, M; White, H; Simes, S; Hague, W; Caleo, S; Hall, J; Martin, A; Mulray, S; Barter, P; Beilin, L; Collins, R; McNeil, J; Meier, P; Willimott, H; Smithers, D; Wallace, P; Sullivan, D; Keech, A		Long-Term Intervention Pravastatin Ischaemic	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM-CHOLESTEROL; MYOCARDIAL-INFARCTION; LOWERING CHOLESTEROL; ARTERY DISEASE; INTERVENTION; POPULATION; MORTALITY; TRIALS; MEN	Background In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. Methods In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. Results Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P < 0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P < 0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P < 0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P < 0.001), stroke (a 19 percent reduction in risk, P = 0.048), and coronary revascularization (a 20 percent reduction in risk, P < 0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. Conclusions Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels. (C) 1998, Massachusetts Medical Society.	Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia; Clin Trials Res Unit, Auckland, New Zealand; Flinders Med Ctr, Cent Lipid Lab, Adelaide, SA, Australia	University of Sydney; Flinders Medical Centre	Tonkin, A (corresponding author), Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Mallett St Campus, Sydney, NSW 2006, Australia.		Meier, Petra/P-7504-2019; west, malcolm J/C-9425-2009; Hall, Jane P/I-3469-2014; Glasziou, Paul/A-7832-2008; Htut, Thien/H-5144-2011; Thompson, Peter L/P-1071-2014; Simes, Robert John/P-1497-2014; Hankey, Graeme J/H-4968-2014; McNeil, John/L-6440-2019; Colquhoun, David M/F-9078-2013	Meier, Petra/0000-0001-5354-1933; west, malcolm J/0000-0002-7629-5277; Glasziou, Paul/0000-0001-7564-073X; Hankey, Graeme J/0000-0002-6044-7328; McNeil, John/0000-0002-1049-5129; Coupland, Lucy/0000-0002-8912-9534; Davidson, Patricia M./0000-0003-2050-1534; Hall, Jane/0000-0002-2191-0543; Martin, Andrew/0000-0001-5804-2295; Watson, John/0000-0003-0988-2583				[Anonymous], 1997, Eur Heart J, V18, P1569; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; COX DR, 1972, J R STAT SOC B, V34, P187; EUROASPIRE Study Grp, 1998, EUR HEART J, V19, P356; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; KANNEL WB, 1995, AM J CARDIOL, V76, pC69, DOI 10.1016/S0002-9149(99)80474-3; KEECH A, 1992, POSTGRAD MED J, V68, P870; Keech A, 1998, ATHEROSCLEROSIS, V136, pS31; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; Lee E, 2013, STAT METHODS SURVIVA; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Pearson TA, 1996, J AM COLL CARDIOL, V27, P1039, DOI 10.1016/0735-1097(96)87736-9; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PETO R, 1985, CIRCULATION, V72, P451; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Simons LA, 1996, MED J AUSTRALIA, V164, P208, DOI 10.5694/j.1326-5377.1996.tb94138.x; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; THEROUX P, 1993, CURR PROB CARDIOLOGY, V18, P159; TONKIN A, 1995, AM J CARDIOL, V76, P474	24	4276	4383	1	106	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1998	339	19					1349	1357						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135BN	9841303				2022-12-28	WOS:000076780200002
J	Carey, S				Carey, S			Neuroscience - Knowledge of number: Its evolution and ontogeny	SCIENCE			English	Editorial Material									NYU, Dept Psychol, New York, NY 10003 USA	New York University	Carey, S (corresponding author), NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA.							Brannon EM, 1998, SCIENCE, V282, P746, DOI 10.1126/science.282.5389.746; Dehaene S., 1997, NUMBER SENSE; Gallistel C. R., 1990, ORG LEARNING; Hurford JamesR., 1987, LANGUAGE NUMBER; ULLER C, IN PRESS COGN DEV; WYNN K, 1992, COGNITIVE PSYCHOL, V24, P220, DOI 10.1016/0010-0285(92)90008-P; Wynn K, 1995, MATH COGNITION, V1, P35, DOI DOI 10.1016/S0010-0277(99)00066-9	7	37	37	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					641	642		10.1126/science.282.5389.641	http://dx.doi.org/10.1126/science.282.5389.641			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841416				2022-12-28	WOS:000076607500030
J	Golden, KM; Ackley, SF; Lytle, VI				Golden, KM; Ackley, SF; Lytle, VI			The percolation phase transition in sea ice	SCIENCE			English	Article							ELECTRICAL-RESISTIVITY; EXPONENT INEQUALITIES; PARTICLE-SIZE; WEDDELL-SEA; COMPOSITES; TRANSPORT; ALGAE; LAYER; FLUX	Sea ice exhibits a marked transition in its fluid transport properties at a critical brine volume fraction p(c) of about 5 percent, or temperature T-c of about -5 degrees C for salinity of 5 parts per thousand. For temperatures warmer than T-c, brine carrying heat and nutrients can move through the ice, whereas for colder temperatures the ice is impermeable. This transition plays a key role in the geophysics, biology, and remote sensing of sea ice. Percolation theory can be used to understand this critical behavior of transport in sea ice. The similarity of sea ice microstructure to compressed powders is used to theoretically predict p(c) of about 5 percent.	Univ Utah, Dept Math, Salt Lake City, UT 84112 USA; USA, Cold Reg Res & Engn Lab, Hanover, NH 03755 USA; Univ Tasmania, Antarctic Cooperat Res Ctr, Hobart, Tas 7001, Australia; Univ Tasmania, Australian Antarctic Div, Hobart, Tas 7001, Australia	Utah System of Higher Education; University of Utah; United States Department of Defense; United States Army; U.S. Army Corps of Engineers; U.S. Army Engineer Research & Development Center (ERDC); Cold Regions Research & Engineering Laboratory (CRREL); University of Tasmania; Australian Antarctic Division; University of Tasmania	Golden, KM (corresponding author), Univ Utah, Dept Math, Salt Lake City, UT 84112 USA.		Pepi, Milva/AAF-9693-2020					ACKLEY SF, 1995, ANTARCT J US, V30, P133; ARCONE SA, 1986, J GEOPHYS RES-OCEANS, V91, P14281, DOI 10.1029/JC091iC12p14281; Broadbent S.R., 1957, P CAMB PHILOS SOC, V53, P629, DOI [DOI 10.1017/S0305004100032680, 10.1017/S0305004100032680]; CHAYES JT, 1986, COMMUN MATH PHYS, V105, P133, DOI 10.1007/BF01212346; Cox C.F., 1975, 354 CRREL; DEBONDT S, 1992, J MATER SCI, V27, P1983, DOI 10.1007/BF01107228; DIECKMANN GS, 1991, POLAR BIOL, V11, P449; EICKEN H, 1992, POLAR BIOL, V12, P3; Frankenstein G, 1967, J GLACIOL, V6, P943, DOI 10.1017/s0022143000020244; FRITSEN CH, 1994, SCIENCE, V266, P782, DOI 10.1126/science.266.5186.782; GOLDEN K, 1990, PHYS REV LETT, V65, P2923, DOI 10.1103/PhysRevLett.65.2923; Golden KM, 1997, PHYS REV LETT, V78, P3935, DOI 10.1103/PhysRevLett.78.3935; Golden KM, 1998, IEEE T GEOSCI REMOTE, V36, P1655, DOI 10.1109/36.718637; GOLDEN KM, 1997, IMA VOLUMES MATH ITS, V96, P75; HOSSEINMOSTAFA AR, 1995, J ELECTROMAGNET WAVE, V9, P421; HUDIER EJJ, 1995, ATMOS OCEAN, V33, P569, DOI 10.1080/07055900.1995.9649545; KUSY RP, 1971, NATURE-PHYS SCI, V229, P58, DOI 10.1038/physci229058a0; KUSY RP, 1977, J APPL PHYS, V48, P5301, DOI 10.1063/1.323560; Lytle VI, 1996, J GEOPHYS RES-OCEANS, V101, P8853, DOI 10.1029/95JC03675; LYTLE VI, IN PRESS J GEOPHYS R; LYTLE VI, 1995, ANTARCT J US, V30, P125; MALLIARIS A, 1971, J APPL PHYS, V42, P614, DOI 10.1063/1.1660071; Maykut GA, 1995, J GEOPHYS RES-OCEANS, V100, P24691, DOI 10.1029/95JC02554; MCLACHLAN DS, 1990, J AM CERAM SOC, V73, P2187, DOI 10.1111/j.1151-2916.1990.tb07576.x; MCPHEE M, COMMUNICATION; McPhee MG, 1996, B AM METEOROL SOC, V77, P1221, DOI 10.1175/1520-0477(1996)077<1221:TAZFE>2.0.CO;2; ONO N, 1985, ANN GLACIOL, V6, P298, DOI 10.3189/1985AoG6-1-298-299; Stauffer D., 1992, INTRO PERCOLATION TH; WEEKS WF, 1982, CRREL MONOGRAPH, V821	29	339	344	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2238	2241		10.1126/science.282.5397.2238	http://dx.doi.org/10.1126/science.282.5397.2238			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856942				2022-12-28	WOS:000077645800040
J	Schwarz, JP; Robertson, DS; Niebauer, TM; Faller, LE				Schwarz, JP; Robertson, DS; Niebauer, TM; Faller, LE			A free-fall determination of the Newtonian constant of gravity	SCIENCE			English	Article							GRAVITATIONAL CONSTANT	Recent determinations of the Newtonian constant of gravity have produced values that differ by nearly 40 times their individual error estimates (more than 0.5%). In an attempt to help resolve this situation, an experiment that uses the gravity field of a one-half metric ton source mass to perturb the trajectory of a free-falling mass and laser interferometry to track the falling object was performed. This experiment does not suspend the test mass from a support system. It is therefore free of many systematic errors associated with supports. The measured value was G = (6.6873 +/- 0.0094) x 10(-11) m(3) kg(-1) sec(-2).	Univ Colorado, JILA, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Boulder, CO 80309 USA; NOAA, NOS, Natl Geodet Survey, Boulder, CO 80309 USA; CIRES, Boulder, CO 80309 USA; Colorado Sch Mines, Dept Geophys, Golden, CO 80401 USA	University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Geodetic Survey, NOAA; National Ocean Service, NOAA; University of Colorado System; University of Colorado Boulder; Colorado School of Mines	Schwarz, JP (corresponding author), Univ Colorado, JILA, Boulder, CO 80309 USA.		schwarz, joshua/G-4556-2013	schwarz, joshua/0000-0002-9123-2223				BANTEL MK, 1998, P CPEM 1998; BARTA G, 1985, P 10 INT S EARTHS TI; Brouwer D., 1961, METHODS CELESTIAL ME; FALLER J, 1996, GRAVITY GEOID MARINE, V117; FITZGERALD MP, 1995, IEEE T INSTRUM MEAS, V44, P494, DOI 10.1109/19.377890; Gillies GT, 1997, REP PROG PHYS, V60, P151, DOI 10.1088/0034-4885/60/2/001; KOLDEWYN WA, 1976, THESIS WESLEYAN U; KURODA K, 1995, PHYS REV LETT, V75, P2796, DOI 10.1103/PhysRevLett.75.2796; LUTHER GG, 1982, PHYS REV LETT, V48, P121, DOI 10.1103/PhysRevLett.48.121; Michaelis W, 1996, METROLOGIA, V32, P267, DOI 10.1088/0026-1394/32/4/4; NEWMAN RD, 1997, P 8 M GROSSM M GEN R; Niebauer T M, 1987, THESIS U COLORADO BO; Niebauer TM, 1995, METROLOGIA, V32, P159, DOI 10.1088/0026-1394/32/3/004; PRESS WH, 1992, NUMERICAL RECIPES; Robertson D, 1996, METROLOGIA, V33, P545, DOI 10.1088/0026-1394/33/6/4; ROBERTSON D, 1997, 1997 AGU CHAPM C MIC; SCHUMACHER A, 1998, P CPEM 1998; Schurr J, 1998, PHYS REV LETT, V80, P1142, DOI 10.1103/PhysRevLett.80.1142; SCHWARZ JP, 1998, THESIS U COLORADO BO; WALESCH H, 1995, IEEE T INSTRUM MEAS, V44, P491, DOI 10.1109/19.377889; ZUMBERGE MA, 1981, THESIS U COLORADO BO; 1995, MICROG SOLUTIONS FG5	22	55	59	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2230	2234		10.1126/science.282.5397.2230	http://dx.doi.org/10.1126/science.282.5397.2230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856940				2022-12-28	WOS:000077645800038
J	Al Odaib, A; Shneider, BL; Bennett, MJ; Pober, BR; Reyes-Mugica, M; Friedman, AL; Suchy, FJ; Rinaldo, P				Al Odaib, A; Shneider, BL; Bennett, MJ; Pober, BR; Reyes-Mugica, M; Friedman, AL; Suchy, FJ; Rinaldo, P			A defect in the transport of long-chain fatty acids associated with acute liver failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING-PROTEIN; BETA-OXIDATION; DEFICIENCY; MEMBRANE; FIBROBLASTS; DISORDERS; CHILDREN; CLONING; DISEASE		Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA	Yale University; Yale University; Yale University; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rinaldo, P (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Lab Genet, 200 1st St SW, Rochester, MN 55905 USA.		Reyes-Mugica, Miguel/C-2483-2008	Reyes-Mugica, Miguel/0000-0001-5698-3702				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ALONSO EM, 1995, J PEDIATR-US, V127, P888, DOI 10.1016/S0022-3476(95)70023-4; Bennett MJ, 1996, PEDIATR RES, V39, P185, DOI 10.1203/00006450-199601000-00031; BENNETT MJ, 1994, HUM PATHOL, V25, P742, DOI 10.1016/0046-8177(94)90241-0; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; Boles RG, 1998, J PEDIATR-US, V132, P924, DOI 10.1016/S0022-3476(98)70385-3; BOLES RG, 1994, HUM PATHOL, V25, P735, DOI 10.1016/0046-8177(94)90240-2; COUTURIER M, 1991, J INHERIT METAB DIS, V14, P215, DOI 10.1007/BF01800593; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fitscher BA, 1996, P SOC EXP BIOL MED, V212, P15; FUJII S, 1987, J BIOCHEM-TOKYO, V101, P679, DOI 10.1093/jb/101.3.679; GALL DG, 1975, J PEDIATR-US, V87, P869; Kamijo T, 1997, PEDIATR RES, V42, P569, DOI 10.1203/00006450-199711000-00002; LII YP, 1993, CHUNG HUA I HSUEH TS, V51, P154; LONGO N, 1997, P 7 INT C INB ERR ME, P219; MANNING NJ, 1990, J INHERIT METAB DIS, V13, P58, DOI 10.1007/BF01799333; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NYHAN WL, 1995, CLIN CHEM, V41, P10; PALMER AM, 1990, CLIN NEUROPHARMACOL, V13, P58, DOI 10.1097/00002826-199002000-00006; SAUDUBRAY JM, 1997, INT PEDIAT, V12, P34; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHIBAO K, 1990, Acta Paediatrica Japonica, V32, P399; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; Thompson GN, 1997, NEW ENGL J MED, V337, P1203, DOI 10.1056/NEJM199710233371704; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; WHITINGTON PF, 1994, LIVER DIS CHILDREN, P180; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	30	43	44	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1752	1757		10.1056/NEJM199812103392405	http://dx.doi.org/10.1056/NEJM199812103392405			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845710				2022-12-28	WOS:000077459700005
J	Salinsky, M				Salinsky, M			Torture continues in Turkey: findings of new report	LANCET			English	Editorial Material									Med Fdn, London NW5 3EJ, England		Salinsky, M (corresponding author), Med Fdn, 96-98 Grafton Rd, London NW5 3EJ, England.							*COUNC EUR, 1996, EUR COMM PREV TORT I; *PHYS HUM RIGHTS, 1996, TORT TURK ITS UNW AC, V5, P209; *US STAT DEP, 1998, TURK COUNTR REP HUM	3	4	4	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1854	1854		10.1016/S0140-6736(05)79918-9	http://dx.doi.org/10.1016/S0140-6736(05)79918-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851405				2022-12-28	WOS:000077337900051
J	Kehle, J; Beuchle, D; Treuheit, S; Christen, B; Kennison, JA; Bienz, M; Muller, J				Kehle, J; Beuchle, D; Treuheit, S; Christen, B; Kennison, JA; Bienz, M; Muller, J			dMi-2, a hunchback-interacting protein that functions in Polycomb repression	SCIENCE			English	Article							HOMEOTIC GENE-EXPRESSION; DROSOPHILA-MELANOGASTER; SEGMENTAL DETERMINATION; SPATIAL EXPRESSION; BITHORAX COMPLEX; MI-2 AUTOANTIGEN; ULTRABITHORAX; EMBRYOS; DOMAIN; REGION	Early in Drosophila embryogenesis, gap gene products directly repress transcription of homeotic (HOX) genes and thereby delimit HOX expression domains. Subsequently, Polycomb-group proteins maintain this repression. Currently, there is no known molecular Link between gap and Polycomb-group proteins. Here, dMi-2 is identified as a protein that binds to a domain in the gap protein Hunchback that is specifically required for the repression of HOX genes. Genetic analyses show that dMi-2 participates in both Hunchback and Polycomb repression in vivo. Hence, recruitment of dMi-2 may serve as a link between repression of HOX genes by Hunchback and Polycomb proteins.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	Max Planck Society; MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Muller, J (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35-3, D-72076 Tubingen, Germany.	juerg.mueller@tuebingen.mpg.de						AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BREEN TR, 1986, DEV BIOL, V118, P442, DOI 10.1016/0012-1606(86)90015-1; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HULSKAMP M, 1994, GENETICS, V138, P125; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LONIE A, 1994, DEVELOPMENT, V120, P2629; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOAZED D, 1992, DEVELOPMENT, V116, P805; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; MULLER J, 1995, DEVELOPMENT, V121, P2847; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PATTATUCCI AM, 1991, GENETICS, V129, P443; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SOMMER R, 1992, THESIS U MUNICH; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	39	297	302	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1897	1900		10.1126/science.282.5395.1897	http://dx.doi.org/10.1126/science.282.5395.1897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836641				2022-12-28	WOS:000077338100051
J	Stanewsky, R; Kaneko, M; Emery, P; Beretta, B; Wager-Smith, K; Kay, SA; Rosbash, M; Hall, JC				Stanewsky, R; Kaneko, M; Emery, P; Beretta, B; Wager-Smith, K; Kay, SA; Rosbash, M; Hall, JC			The cry(b) mutation identifies cryptochrome as a circadian photoreceptor in Drosophila	CELL			English	Article							CLOCK GENE; PERIOD LOCUS; DARK CYCLES; LIGHT; MELANOGASTER; MUTANTS; EXPRESSION; TIMELESS; TRANSCRIPTION; BEHAVIOR	A new rhythm mutation was isolated based on its elimination of per-controlled luciferase cycling. Levels of period or timeless clock gene products in the mutant are flat in daily light-dark cycles or constant darkness (although PER and TIM oscillate normally in temperature cycles). Consistent with the fact that light normally suppresses TIM, cry(b) is an apparent null mutation in a gene encoding Drosophila's version of the blue light receptor cryptochrome. Behaviorally cry(b) exhibits poor synchronization to light-dark cycles in genetic backgrounds that cause external blindness or demand several hours of daily rhythm resets, and it shows no response to brief light pulses. cry(b) flies are rhythmic in constant darkness, correlating with robust PER and TIM cycling in certain pacemaker neurons.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Natl Sci Fdn, Ctr Biol Timing, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Scripps Res Inst, La Jolla, CA 92037 USA; NSF, Ctr Biol Timing, La Jolla, CA 92037 USA	Brandeis University; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing; Brandeis University; Howard Hughes Medical Institute; Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing	Hall, JC (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.	hall@brandeis.edu	Stanewsky, Ralf/ABB-9193-2021; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; Kaneko, Maki/0000-0002-2489-6185; Stanewsky, Ralf/0000-0001-8238-6864	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33205] Funding Source: Medline; NIMH NIH HHS [MH-51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Campbell SS, 1998, SCIENCE, V279, P396, DOI 10.1126/science.279.5349.396; Cashmore AR, 1998, J PLANT RES, V111, P267, DOI 10.1007/BF02512182; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DOWSE HB, 1993, MOL GENETICS BIOL RH, P195; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE M, 1989, J NEUROGENET, V5, P229, DOI 10.3109/01677068909066210; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; HELFRICHFORSTER C, 1997, BIOL RHYTHM RES S, V28, P119; HOFBAUER A, 1989, NATURWISSENSCHAFTEN, V76, P335, DOI 10.1007/BF00368438; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kaneko M, 1997, J NEUROSCI, V17, P6745; Kaneko M, 1998, CURR OPIN NEUROBIOL, V8, P652, DOI 10.1016/S0959-4388(98)80095-0; KLEMM E, 1976, PHOTOCHEM PHOTOBIOL, V24, P369, DOI 10.1111/j.1751-1097.1976.tb06838.x; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LINDSLEY DL, 1992, GENETIC VARIATIONS D; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Ohata K, 1998, INT CONGR SER, V1152, P167; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAGE TL, 1982, EXPERIENTIA, V38, P1007, DOI 10.1007/BF01955344; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RAGOVOY J, 1971, CRY BABY PEARL ALBUM; ROBERTSON HM, 1988, GENETICS, V118, P461; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosato E, 1997, NUCLEIC ACIDS RES, V25, P455, DOI 10.1093/nar/25.3.455; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; RUTILA JE, 1998, IN PRESS J BIOL RHYT; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SCIENCE, V270, P801; SMITH H, 1982, ANNU REV PLANT PHYS, V33, P481, DOI 10.1146/annurev.pp.33.060182.002405; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006; Stanewsky R, 1997, J NEUROSCI, V17, P676; Stanewsky R, 1996, GENETICS, V143, P259; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; Yoshikawa T, 1998, COMP BIOCHEM PHYS B, V119, P65, DOI 10.1016/S0305-0491(97)00290-3; Yoshimura T, 1998, BRAIN RES, V779, P188, DOI 10.1016/S0006-8993(97)01122-0; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZERR DM, 1990, J NEUROSCI, V10, P2749; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	61	746	767	4	96	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					681	692		10.1016/S0092-8674(00)81638-4	http://dx.doi.org/10.1016/S0092-8674(00)81638-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845370	Bronze			2022-12-28	WOS:000077253700015
J	Bloor, M; Thomas, M; Hood, K; Abeni, D; Goujon, C; Hausser, D; Hubert, M; Kleiber, D; Nieto, JA				Bloor, M; Thomas, M; Hood, K; Abeni, D; Goujon, C; Hausser, D; Hubert, M; Kleiber, D; Nieto, JA			Differences in sexual risk behaviour between young men and women travelling abroad from the UK	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV; INFECTION; TRAVELERS	Background Identification of people who most frequently engage in sexual risk behaviour while travelling abroad would be useful for the design and targeting of health education and promotion campaigns. Methods Eligible participants were people living in the UK aged 18-34 years who had travelled abroad without a partner in the previous 2 years. Respondents were first screened for eligibility as part of representative face-to-face and telephone surveys by a market research company. Eligible individuals who agreed to take part then underwent a computer-assisted telephone interview. Reinterviewing continued until 400 eligible people had been contacted. We also interviewed a control group of 568 young people who had travelled abroad without a partner in the previous 2 years but who did not report a new sexual relationship during their travels. Findings One in ten of the eligible participants reported sexual intercourse with a new partner. Travellers who reported a new sexual relationship abroad were also likely to report large numbers of sexual partners at home. Of the 400 people who had a new sexual partner abroad, 300 (75%) used condoms on all occasions with the new partner. Logistic regression modelling showed differences between men and women in those factors linked to the practice of unsafe or safer sex while travelling. For men, patterns of condom use abroad with casual partners (p<0.001) reflected patterns of use at home (p<0.001), whereas for women, patterns of condom use varied according to their partners' backgrounds (p<0.001). Interpretation Condoms are widely used among young travellers, but patterns of use vary by sex. Campaigns about sexual health targeted at international travellers should continue, not least because young people who meet new sexual partners abroad may be a convenient proxy group for that minority of the population who report most sexual partners at home. Such campaigns should be designed differently for men and women.	Cardiff Univ, Sch Social Sci, Cardiff CF1 3AT, S Glam, Wales; Univ Wales Coll Med, Dept Med Comp & Stat, Cardiff CF4 4XN, S Glam, Wales; Ist Dermopatic Immacolata, Clin Epidemiol Unit, Rome, Italy; Hop Inst Pasteur, Dept Vaccinat, Paris, France; Swiss Fed Inst Technol, Inst Rech Environm Construit, Lausanne, Switzerland; Fac Univ St Louis, Ctr Etud Sociol, Brussels, Belgium; Free Univ Berlin, Dept Psychol, D-1000 Berlin, Germany; Univ Nacl Educ Distancia, Fdn Univ Empresa, E-28040 Madrid, Spain	Cardiff University; Cardiff University; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University Saint-Louis - Bruxelles; Free University of Berlin; Universidad Nacional de Educacion a Distancia (UNED)	Bloor, M (corresponding author), Cardiff Univ, Sch Social Sci, Cardiff CF1 3AT, S Glam, Wales.		Hood, Kerenza/C-2528-2008; Abeni, Damiano/AAA-1401-2019	Hood, Kerenza/0000-0002-5268-8631; Abeni, Damiano/0000-0002-0167-7617				BLOOR M, 1995, EC SOCIAL IMPACT AID; BLOOR M, 1997, FEASIBILITY STUDY CO; BONNEUX L, 1988, BRIT MED J, V297, P581, DOI 10.1136/bmj.297.6648.581; CHOI K, 1991, 7 INT C AIDS FLOR; DANIELS D, 1992, INT J STD AIDS, V3, P4337; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DEVINCENZI I, 1992, BRIT MED J, V304, P809; ELLIS CJ, 1990, BRIT MED J, V301, P984, DOI 10.1136/bmj.301.6758.984-c; GILLIES P, 1992, AIDS, V6, P339, DOI 10.1097/00002030-199203000-00020; HAUSSER D, 1991, 3 IUMSP; HAWKES S, 1994, AIDS, V8, P247, DOI 10.1097/00002030-199402000-00013; Houweling H, 1991, Int J STD AIDS, V2, P252; Hubert M., 1998, SEXUAL BEHAV HIV AID; KLEIBER D, 1995, AIDS EUROPE BEHAV AS, V2; Kleiber D, 1995, AIDS SEX TOURISMUS E; MCKEGANEY NP, 1994, AIDS, V8, P1215, DOI 10.1097/00002030-199409000-00002; Mendelsohn R, 1996, GENITOURIN MED, V72, P43; NOONE A, 1992, LANCET, V305, P892; SPIRA A, 1992, NATURE, V360, P407; Wellings K, 1994, SEXUAL BEHAV BRITAIN	20	62	62	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1664	1668		10.1016/S0140-6736(98)09414-8	http://dx.doi.org/10.1016/S0140-6736(98)09414-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853439				2022-12-28	WOS:000077110300011
J	Boyd, PA; Chamberlain, P; Hicks, NR				Boyd, PA; Chamberlain, P; Hicks, NR			6-year experience of prenatal diagnosis in an unselected population in Oxford, UK	LANCET			English	Article							FETAL NUCHAL TRANSLUCENCY; CONGENITAL-ANOMALIES; FIRST TRIMESTER; DOWNS-SYNDROME; ULTRASOUND; ABNORMALITIES	Background The benefits and harm associated with prenatal diagnosis are open to debate. We give a 6-year overview of the experience of one prenatal-diagnosis unit using a defined, unselected population. Methods All congenital malformations suspected prenatally and ail congenital malformations, including chromosome anomalies, confirmed at birth were identified from the local Congenital Malformation Register. All fetuses or infants of women booked for delivery at the Oxford Women's Centre who had an OX postcode and date of delivery between 1991 and 1996 were eligible for the study. Findings 725 (2%) of 33376 babies, were judged abnormal at delivery. 396 (55%) malformed fetuses and infants had been correctly identified prenatally. 174 fetuses had a suspected abnormality identified on scan and subsequently proved to be normal. 160 (92%) of these false-positive results were attributable to the reporting of so called ultrasound soft markers. Accuracy of ultrasound diagnosis was good for structural malformations. Ultrasound soft markers were responsible for a 4% increase in detection of malformations (from 51% to 55%) and a 12-fold increase in false-positive rate (one in 2332 to one in 188). 171 pregnancies (43% of prenatally diagnosed malformed babies) were terminated because of suspected abnormality. Suspicion of abnormality in these cases was first aroused after ultrasound scan in 136 (79%); chromosome analysis because of advanced maternal age, family history, or higher risk in biochemical screening test in 25 (15%); and molecular analysis of single gene defect because of family history in ten (6%). There was a 20% reduction in prevalence of conditions compatible with survival beyond the neonatal period because of termination of such pregnancies. Interpretation More than half of all malformed fetuses can be identified prenatally in routine practice, mostly following initial suspicion from ultrasound examination. Ultrasound soft markers lead to a small increase in detection of malformations but a large increase in false positives. Further research on the impact, including psychological, and Value of markers is required to determine whether the benefits of reporting them exceeds the harm. Because methods and techniques continually change, ongoing surveillance of prenatal diagnostic services is vital.	Oxford Radcliffe NHS Trust, Womens Ctr, Prenatal Diag Unit, Oxford OX3 9DU, England; Oxford Radcliffe NHS Trust, Womens Ctr, Ultrasound Unit, Oxford OX3 9DU, England; Oxfordshire Hlth Author, Dept Publ Hlth & Hlth Policy, Oxford OX3 9DZ, England		Boyd, PA (corresponding author), Oxford Radcliffe NHS Trust, Womens Ctr, Prenatal Diag Unit, Oxford OX3 9DU, England.			Hicks, Nicholas/0000-0002-7214-9678				Chitty LS, 1995, PRENATAL DIAG, V15, P1241, DOI 10.1002/pd.1970151306; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; Ewigman BG, 1993, NEW ENGL J MED, V169, P483; LECK I, 1993, OXFORD MONOGRPAHS ME, V27, P65; LEHA C, 1995, J MED SCREEN, V2, P67; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; MARTEAU TM, 1992, PRENATAL DIAGNOSIS S, P663; Neilson JP, 1997, LANCET, V350, P754, DOI 10.1016/S0140-6736(05)62562-7; NEILSON JP, 1998, COCHRANE LIB; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; RENWICK M, 1992, ARCH DIS CHILD-FETAL, V67, P770; ROBERTS LJ, 1995, BRIT J OBSTET GYNAEC, V102, P381, DOI 10.1111/j.1471-0528.1995.tb11289.x; SAARIKEMPPAINEN A, 1994, J PERINAT MED, V22, P279, DOI 10.1515/jpme.1994.22.4.279; Soothill P, 1997, LANCET, V350, P1629, DOI 10.1016/S0140-6736(05)64046-9; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; STOLL C, 1995, PRENATAL DIAG, V15, P791, DOI 10.1002/pd.1970150902; Wald N J, 1997, J Med Screen, V4, P181; Whittle M, 1997, BRIT MED J, V314, P918, DOI 10.1136/bmj.314.7085.918; Zimmer EZ, 1997, PRENATAL DIAG, V17, P623, DOI 10.1002/(SICI)1097-0223(199707)17:7<623::AID-PD123>3.0.CO;2-J; 1997, CONGENITAL MALFO MB3	20	103	105	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1577	1581		10.1016/S0140-6736(98)03202-4	http://dx.doi.org/10.1016/S0140-6736(98)03202-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843102				2022-12-28	WOS:000076998900009
J	Steinhorn, RH				Steinhorn, RH			Prenatal ultrasonography: first do no harm?	LANCET			English	Editorial Material									SUNY Coll Buffalo, Dept Pediat Gynecol & Obstet, Buffalo, NY 14222 USA	State University of New York (SUNY) System; Buffalo State College	Steinhorn, RH (corresponding author), SUNY Coll Buffalo, Dept Pediat Gynecol & Obstet, Buffalo, NY 14222 USA.		Steinhorn, Robin/A-4248-2010					BUTCHER HC, 1993, BRIT MED J, V307, P13; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; GONCALVES LF, 1994, AM J OBSTET GYNECOL, V171, P1606, DOI 10.1016/0002-9378(94)90411-1; Leslie KK, 1996, J MATERN-FETAL INVES, V6, P132; Lewis DA, 1997, J PEDIATR SURG, V32, P352, DOI 10.1016/S0022-3468(97)90209-8	5	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1998	352	9140					1568	1569		10.1016/S0140-6736(05)61038-0	http://dx.doi.org/10.1016/S0140-6736(05)61038-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843098				2022-12-28	WOS:000076998900004
J	Grill, E; Ziegler, H				Grill, E; Ziegler, H			Botany - A plant's dilemma	SCIENCE			English	Editorial Material							ACID SIGNAL-TRANSDUCTION; VACUOLAR ION-CHANNEL; SLOW ANION CHANNELS; CYCLIC ADP-RIBOSE; ABSCISIC-ACID; PROTEIN PHOSPHATASE; GUARD-CELLS; DEHYDRATION TOLERANCE; K+ CHANNELS; WILD-TYPE		Tech Univ Munich, Lehrstuhl Bot, D-80333 Munich, Germany	Technical University of Munich	Grill, E (corresponding author), Tech Univ Munich, Lehrstuhl Bot, D-80333 Munich, Germany.	grill@botanik.biologie.tu-muenchen.de						ALLEN GJ, 1995, PLANT CELL, V7, P1473; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; [Anonymous], UNPUB; ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; Bertauche N, 1996, EUR J BIOCHEM, V241, P193, DOI 10.1111/j.1432-1033.1996.0193t.x; Bethke PC, 1997, PLANT J, V11, P1227, DOI 10.1046/j.1365-313X.1997.11061227.x; Blatt MR, 1997, PHYSIOL PLANTARUM, V100, P481, DOI 10.1034/j.1399-3054.1997.1000309.x; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Furini A, 1997, EMBO J, V16, P3599, DOI 10.1093/emboj/16.12.3599; GAFF DF, 1971, SCIENCE, V174, P1033, DOI 10.1126/science.174.4013.1033; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; GRILL E, IN PRESS CURR OPIN P; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; LECKIE CP, COMMUNICATION; Leube MP, 1998, FEBS LETT, V424, P100, DOI 10.1016/S0014-5793(98)00149-5; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mori IC, 1997, PLANT PHYSIOL, V113, P833, DOI 10.1104/pp.113.3.833; Muir SR, 1996, FEBS LETT, V395, P39, DOI 10.1016/0014-5793(96)01000-9; Pedron J, 1998, EUR J BIOCHEM, V252, P385, DOI 10.1046/j.1432-1327.1998.2520385.x; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; RADEMACHER W, 1989, STRUCTURAL AND FUNCTIONAL RESPONSES TO ENVIRONMENTAL STRESSES : WATER SHORTAGE, P147; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; SCHROEDER JI, 1993, PLANT CELL, V5, P1831, DOI 10.1105/tpc.5.12.1831; Schultz TF, 1997, PLANT SCI, V130, P63, DOI 10.1016/S0168-9452(97)00204-5; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Walther P, 1997, SCANNING, V19, P343, DOI 10.1002/sca.4950190501; Willmer C., 1996, STOMATA, DOI DOI 10.1007/978-94-011-0579-8; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Zeiger E, 1987, STOMATAL FUNCTION; Zhou DF, 1997, PLANT J, V12, P921, DOI 10.1046/j.1365-313X.1997.12040921.x	36	37	42	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					252	253		10.1126/science.282.5387.252	http://dx.doi.org/10.1126/science.282.5387.252			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9841390				2022-12-28	WOS:000076370200036
J	Moloo, J; Jackson, KL; Waller, JL; McKeown, RE; Addy, CL; Cuffe, SP; Garrison, CZ				Moloo, J; Jackson, KL; Waller, JL; McKeown, RE; Addy, CL; Cuffe, SP; Garrison, CZ			Xenotransmission of the socioeconomic gradient in health? A population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ S Carolina, Sch Med, Dept Med, Columbia, SC 29203 USA; Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Dept Neuropsychiat & Behav Sci, Columbia, SC 29203 USA; Univ Louisville, Off Provost, Louisville, KY 40202 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Louisville	Moloo, J (corresponding author), Univ S Carolina, Sch Med, Dept Med, 2 Med Pk,Room 506, Columbia, SC 29203 USA.			McKeown, Robert/0000-0002-8829-5784	NIMH NIH HHS [MH40363] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AM PET PROD MAN A, 1997, 1996 1997 APPMA NAT; Black D., 1982, BLACK REPORT; EVANS RG, 1994, ARE SOME PEOPLE HLTH, P3; HAMM TE, 1983, ATHEROSCLEROSIS, V48, P221, DOI 10.1016/0021-9150(83)90040-0; SMITH GD, 1992, BRIT MED J, V305, P1554, DOI 10.1136/bmj.305.6868.1554	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1686	1686		10.1136/bmj.317.7174.1686	http://dx.doi.org/10.1136/bmj.317.7174.1686			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857126	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077742300013
J	Yang, PD; Deng, T; Zhao, DY; Feng, PY; Pine, D; Chmelka, BF; Whitesides, GM; Stucky, GD				Yang, PD; Deng, T; Zhao, DY; Feng, PY; Pine, D; Chmelka, BF; Whitesides, GM; Stucky, GD			Hierarchically ordered oxides	SCIENCE			English	Article							MESOPOROUS SILICA; COLLOIDAL CRYSTALLIZATION; GROWTH	Porous silica, niobia, and titania with three-dimensional structures patterned over multiple Length scales were prepared by combining micromolding, polystyrene sphere templating, and cooperative assembly of inorganic set-gel species with amphiphilic triblock copolymers. The resulting materials show hierarchical ordering over several discrete and tunable Length scales ranging from 10 nanometers to several micrometers. The respective ordered structures can be independently modified by choosing different mold patterns, latex spheres, and block copolymers. The examples presented demonstrate the compositional and structural diversities that are possible with this simple approach.	Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; Harvard University; University of California System; University of California Santa Barbara	Stucky, GD (corresponding author), Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA.		Pine, David J/B-7740-2016; , 赵东元/E-5796-2010	Pine, David J/0000-0002-3304-6684; , 赵东元/0000-0002-1642-2510				Antonietti M, 1998, ADV MATER, V10, P154, DOI 10.1002/(SICI)1521-4095(199801)10:2<154::AID-ADMA154>3.0.CO;2-I; Bu XH, 1997, SCIENCE, V278, P2080, DOI 10.1126/science.278.5346.2080; Firouzi A, 1997, J AM CHEM SOC, V119, P9466, DOI 10.1021/ja971267+; Gimon-Kinsel ME, 1998, STUD SURF SCI CATAL, V117, P111; Holland BT, 1998, SCIENCE, V281, P538, DOI 10.1126/science.281.5376.538; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; Huo QS, 1997, ADV MATER, V9, P974, DOI 10.1002/adma.19970091210; Keller SL, 1998, PHYS REV LETT, V80, P2725, DOI 10.1103/PhysRevLett.80.2725; Kim E, 1996, ADV MATER, V8, P245, DOI 10.1002/adma.19960080313; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Marzolin C, 1998, ADV MATER, V10, P571, DOI 10.1002/(SICI)1521-4095(199805)10:8<571::AID-ADMA571>3.0.CO;2-P; Park SH, 1998, ADV MATER, V10, P1045, DOI 10.1002/(SICI)1521-4095(199809)10:13<1045::AID-ADMA1045>3.3.CO;2-U; Round F. E., 1990, DIATOMS BIOL MORPHOL; Tolbert SH, 1997, SCIENCE, V278, P264, DOI 10.1126/science.278.5336.264; Trau M, 1997, NATURE, V390, P674, DOI 10.1038/37764; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Velev OD, 1997, NATURE, V389, P447, DOI 10.1038/38921; Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yang H, 1997, ADV MATER, V9, P811, DOI 10.1002/adma.19970091010; Yang PD, 1998, NATURE, V396, P152; Yang PD, 1998, CHEM MATER, V10, P2033, DOI 10.1021/cm980201q; Zakhidov AA, 1998, SCIENCE, V282, P897, DOI 10.1126/science.282.5390.897; Zhao D, 1998, ADV MATER, V10, P1380, DOI 10.1002/(SICI)1521-4095(199811)10:16<1380::AID-ADMA1380>3.0.CO;2-8; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	25	928	978	14	537	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2244	2246		10.1126/science.282.5397.2244	http://dx.doi.org/10.1126/science.282.5397.2244			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856944	Green Submitted			2022-12-28	WOS:000077645800042
J	Blaxter, M				Blaxter, M			Caenorhabditis elegans is a nematode	SCIENCE			English	Review							DETERMINING DIVERGENCE TIMES; ONCHOCERCA-VOLVULUS; PROTEIN CLOCK; SEQUENCES; GENE; ORGANISMS; ALLERGEN; FAMILIES; HOMOLOGS; ANIMALS	Caenorhabditis elegans is a rhabditid nematode. What relevance does this have for the interpretation of the complete genome sequence, and how will it affect the exploitation of the sequence for scientific and social ends? Nematodes are only distantly related to humans and other animal groups; will this Limit the universality of the C, elegans story? Many nematodes are parasites; can knowledge of the C. elegans sequence aid in the prevention and treatment of disease?	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Blaxter, M (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019	Blaxter, Mark L/0000-0003-2861-949X; 				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aleshin VV, 1998, RUSS J NEMATOL, V6, P175; [Anonymous], 1896, COMMUNICATION; BLAXTER M, 1997, C ELEGANS, V2, P851; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BLUMENTHAL T, 1997, C ELEGANS, V2, P115; Boucher G, 1995, CONSERV BIOL, V9, P1594, DOI 10.1046/j.1523-1739.1995.09061594.x; BRITTON C, 1995, MOL BIOCHEM PARASIT, V72, P77, DOI 10.1016/0166-6851(95)00088-I; Brusca R.C., 1990, INVERTEBRATES; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHERVITZ SA, SCIENCE, V282, P2022; CLARKE ND, SCIENCE, V282, P2018; DAUB J, UNPUB; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; *FIL GEN PROJ, IN PRESS PARASITOL T; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; FITCH DHA, 1997, C ELEGANS, V2, P815; FULTON LL, 1996, MODERN BIOL ANAL ORG, P571; Gems D, 1996, P NATL ACAD SCI USA, V93, P1665, DOI 10.1073/pnas.93.4.1665; GERRITS D, UNPUB; Goldstein B, 1998, CURR BIOL, V8, P157, DOI 10.1016/S0960-9822(98)70062-4; GUILIANO D, COMMUNICATION; GUILLIANO D, UNPUB; Haeckel Ernst, 1866, GENERELLE MORPHOLOGI; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HESCHL MFP, 1990, J MOL EVOL, V31, P3, DOI 10.1007/BF02101786; HODGKIN J, UNPUB; HOPE IA, 1991, DEVELOPMENT, V113, P399; HULTER H, COMMUNICATION; Kampfer S, 1998, INVERTEBR BIOL, V117, P29, DOI 10.2307/3226849; Kennedy MW, 1997, J BIOL CHEM, V272, P29442, DOI 10.1074/jbc.272.47.29442; Kohara Y, 1996, Tanpakushitsu Kakusan Koso, V41, P715; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA P, 1994, NUCLEIC ACIDS RES, V22, P159; LAMBSHEAD PJD, 1993, OCEANIS S D, V19, P5; Lawton JH, 1998, NATURE, V391, P72, DOI 10.1038/34166; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Malakhov V. V., 1994, NEMATODES STRUCTURE; Martin RJ, 1997, PARASITOLOGY, V114, pS111, DOI 10.1017/S0031182097001029; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; MCREYNOLDS LA, 1993, PARASITOL TODAY, V9, P403, DOI 10.1016/0169-4758(93)90046-I; MOORE JS, UNPUB; Moore TA, 1996, MOL BIOCHEM PARASIT, V79, P243, DOI 10.1016/0166-6851(96)02659-X; MORRIS SC, 1994, DEVELOPMENT, P1; Mushegian AR, 1998, GENOME RES, V8, P590, DOI 10.1101/gr.8.6.590; Nielsen C., 1995, ANIMAL EVOLUTION INT; PASTRANA DV, IN PRESS INFECT IMMU; PHILIPPE H, 1994, DEVELOPMENT, P15; Platonova T. A., 1976, NEMATODES THEIR ROLE; Platt H. M., 1994, PHYLOGENETIC SYSTEMA; PRICHARD R, 1994, VET PARASITOL, V54, P259, DOI 10.1016/0304-4017(94)90094-9; Raff R. A., 1996, SHAPE LIFE GENES DEV; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; Riddle DL, 1997, C ELEGANS; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; SONNHAMMER ELL, 1994, PROTEIN SCI, V3, P482; SPENCE HJ, 1993, MOL BIOCHEM PARASIT, V57, P339, DOI 10.1016/0166-6851(93)90210-O; Swofford David L., 1996, P407; TREE TIM, 1995, MOL BIOCHEM PARASIT, V69, P185, DOI 10.1016/0166-6851(94)00204-Z; VANFLETEREN JR, 1994, MOL PHYLOGENET EVOL, V3, P92, DOI 10.1006/mpev.1994.1012; Voronov DA, 1998, NATURE, V395, P28, DOI 10.1038/25637; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Wray GA, 1996, SCIENCE, V274, P568, DOI 10.1126/science.274.5287.568	70	231	240	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2041	2046		10.1126/science.282.5396.2041	http://dx.doi.org/10.1126/science.282.5396.2041			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851921				2022-12-28	WOS:000077467100039
J	Griffith, CA; Yelle, RV; Marley, MS				Griffith, CA; Yelle, RV; Marley, MS			The dusty atmosphere of the brown dwarf Gliese 229B	SCIENCE			English	Article							INFRARED-ABSORPTION; SOLAR-SYSTEM; DARK-MATTER; SPECTRA; MODELS; TITAN; BAND; STAR; TEMPERATURES; ULTRAVIOLET	The brown dwarf Gliese 229B has an observable atmosphere too warm to contain ice clouds Like those on Jupiter and too cool to contain silicate clouds Like those on Low-mass stars. These unique conditions permit visibility to higher pressures than possible in cool stars or planets. Gliese 229B's 0.85- to 1.0- micrometer spectrum indicates particulates deep in the atmosphere (10 to 50 bars) having optical properties of neither ice nor silicates. Their reddish color suggests an organic composition characteristic of aerosols in planetary stratospheres. The particles' mass fraction (10(-7)) agrees with a photochemical origin caused by incident radiation from the primary star and suggests the occurrence of processes native to planetary stratospheres.	No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA; Boston Univ, Ctr Space Phys, Boston, MA 02215 USA; New Mexico State Univ, Dept Astron, Las Cruces, NM 88003 USA	Northern Arizona University; Boston University; New Mexico State University	Griffith, CA (corresponding author), No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA.		Marley, Mark S/I-4704-2013					Allard F, 1996, ASTROPHYS J, V465, pL123, DOI 10.1086/310143; [Anonymous], 1987, ADSPR, DOI [DOI 10.1016/0273-1177(87)90362-0, 10.1016/0273-1177(87)90362-0]; BORYSOW A, 1990, ASTROPHYS J, V348, pL41, DOI 10.1086/185626; BYRNE PB, 1985, MON NOT R ASTRON SOC, V214, P119, DOI 10.1093/mnras/214.2.119; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CHAMBERLAIN JW, 1987, THEORY PLAENTARY ATM; Clarke DW, 1997, ICARUS, V127, P158, DOI 10.1006/icar.1996.5667; COLL P, 1995, ADV SPACE RES, V16, P93, DOI 10.1016/0273-1177(95)00197-M; CONRATH BJ, 1984, ICARUS, V57, P184, DOI 10.1016/0019-1035(84)90065-4; Cronin JR., 1988, ORGANIC MATTER CARBO, P819; CRUIKSHANK DP, 1989, ADV SPACE RES, V9, P65; FEGLEY B, 1994, ICARUS, V110, P117, DOI 10.1006/icar.1994.1111; Fegley B, 1996, ASTROPHYS J, V472, pL37, DOI 10.1086/310356; FRENKLACH M, 1989, ASTROPHYS J, V341, P372, DOI 10.1086/167501; Geballe TR, 1996, ASTROPHYS J, V467, pL101, DOI 10.1086/310203; GIARMPAPA MS, 1989, ASTROPHYS J, V345, P53; GUILLOT T, 1997, ASTRONOMICAL BIOCH O, P343; HOLTON JR, 1986, J GEOPHYS RES-ATMOS, V91, P2681, DOI 10.1029/JD091iD02p02681; Houdebine ER, 1996, ASTRON ASTROPHYS, V305, P209; HOUDEBINE ER, 1990, THESIS U ORSAY PARIS; JONES JRA, 1996, ASTRON ASTROPHYS, V480, pL39; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; KOIKE C, 1995, ICARUS, V114, P203, DOI 10.1006/icar.1995.1055; LEWIS JS, 1984, SPACE SCI REV, V39, P163, DOI 10.1007/BF00173673; MARCY GW, 1995, 6251 IAU; Marley MS, 1996, SCIENCE, V272, P1919, DOI 10.1126/science.272.5270.1919; MATTHEWS CN, 1992, ORIGINS LIFE EVOL B, V21, P421; Matthews K, 1996, ASTRON J, V112, P1678, DOI 10.1086/118133; MCDONALD GD, 1994, ICARUS, V108, P137, DOI 10.1006/icar.1994.1046; McKay CP, 1996, PLANET SPACE SCI, V44, P741, DOI 10.1016/0032-0633(96)00009-8; MOULD J, 1987, ASTROPHYS J, V226, P923; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; Noll KS, 1997, ASTROPHYS J, V489, pL87, DOI 10.1086/310954; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; OSSENKOPF V, 1992, ASTRON ASTROPHYS, V261, P567; OWEN T, 1995, ADV SPACE RES-SERIES, V16, P41, DOI 10.1016/0273-1177(95)00192-H; Palik E D, 1985, HDB OPTICAL CONSTANT; PANAGI PM, 1993, ASTRON ASTROPHYS SUP, V100, P343; Partridge H, 1997, J CHEM PHYS, V106, P4618, DOI 10.1063/1.473987; Ragent B, 1998, J GEOPHYS RES-PLANET, V103, P22891, DOI 10.1029/98JE00353; Schiavon RP, 1997, ASTROPHYS J, V484, P499, DOI 10.1086/304332; Schultz AB, 1998, ASTROPHYS J, V492, pL181, DOI 10.1086/311103; Scott A, 1996, ASTROPHYS J SUPPL S, V105, P401, DOI 10.1086/192321; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; Tsuji T, 1996, ASTRON ASTROPHYS, V308, pL29; TSUJI T, 1996, ASTRON ASTROPHYS, V305, P91; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963; ZHENG C, 1995, ICARUS, V113, P84, DOI 10.1006/icar.1995.1006	52	49	49	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2063	2067		10.1126/science.282.5396.2063	http://dx.doi.org/10.1126/science.282.5396.2063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851924				2022-12-28	WOS:000077467100042
J	Yaron, A; Hatzubai, A; Davis, M; Lavon, I; Amit, S; Manning, AM; Andersen, JS; Mann, M; Mercurio, F; Ben-Neriah, Y				Yaron, A; Hatzubai, A; Davis, M; Lavon, I; Amit, S; Manning, AM; Andersen, JS; Mann, M; Mercurio, F; Ben-Neriah, Y			Identification of the receptor component of the I kappa B alpha-ubiquitin ligase	NATURE			English	Article							PROTEASOME PATHWAY; PHOSPHORYLATION; COMPLEX; KINASE; DEGRADATION; PROTEINS; ACTIVATION; INHIBITOR; BETA	NF-kappa B, a ubiquitous, inducible transcription factor involved in immune, inflammatory, stress and developmental processes, is retained in a latent form in the cytoplasm of non-stimulated cells by inhibitory molecules, I kappa Bs(1-3). It, activation is a paradigm for a signal-transduction cascade that integrates an inducible kinase and the ubiquitin-proteasome system to eliminate inhibitory regulators. Here we isolate the pI kappa B alpha-ubiquitin ligase (pI kappa B alpha-E3) that attaches ubiquitin, a small protein which marks other proteins for degradation by the proteasome system, to the phosphorylated NF-kappa B inhibitor pI kappa B alpha. Taking advantage of its high affinity to pI kappa B alpha, we isolate this ligase from HeLa cells by single-step immunoaffinity purification. Using nanoelectrospray mass spectrometry, we identify the specific component of the ligase that recognizes the pI kappa B alpha degradation motif as an F-box/WD-domain protein belonging to a recently distinguished family of beta-TrCP/Slimb proteins. This component, which we denote E3RS(I kappa B) (pI kappa B alpha-E3 receptor subunit), binds specifically to pI kappa B alpha and promotes its in vitro ubiquitination in the presence of two other ubiquitin-system enzymes, El and UBC5C, one of many known E2 enzymes. An F-box-deletion mutant of E3RS(I kappa B), which tightly binds pI kappa B alpha but does not support its ubiquitination, acts in vivo as a dominant-negative molecule, inhibiting the degradation of pI kappa B alpha and consequently NF-kappa B activation. E3RS(I kappa B) represents a family of receptor proteins that are core components of a class of ubiquitin ligases. When these receptor components recognize their specific ligand, which is a conserved, phosphorylation-based sequence motif, they target regulatory proteins containing this motif for proteasomal degradation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; Signal Pharmaceut Inc, San Diego, CA 92121 USA; Protana AS, DK-5230 Odense M, Denmark	Hebrew University of Jerusalem	Ben-Neriah, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel.	yinon@cc.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019; Andersen, Jens S/L-2100-2015; Lavon, Iris/ABE-6651-2021; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Mann, Matthias/0000-0003-1292-4799				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Paul M, 1997, VIROLOGY, V232, P207, DOI 10.1006/viro.1997.8541; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	26	549	578	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					590	594		10.1038/25159	http://dx.doi.org/10.1038/25159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859996				2022-12-28	WOS:000077466800062
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - Survival probabilities (the Kaplan-Meier method)	BRITISH MEDICAL JOURNAL			English	Review									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England	St Georges University London; University of Oxford	Bland, JM (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Altman DG, 1998, BRIT MED J, V317, P468; LUTHRA P, 1982, BMJ-BRIT MED J, V284, P1013, DOI 10.1136/bmj.284.6321.1013; PARMAR MKB, SURVIVAL ANAL PRACTI, P37	3	491	498	1	32	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1572	1572		10.1136/bmj.317.7172.1572	http://dx.doi.org/10.1136/bmj.317.7172.1572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836663	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077451700030
J	Swinn, M; Emberton, M; Ralph, D; Smith, M; Serhal, P				Swinn, M; Emberton, M; Ralph, D; Smith, M; Serhal, P			Ethical dilemma - Retrieving semen from a dead patient - Utilitarianism in the absence of definitive guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Urol & Nephrol, London W1P 7PN, England; UCL Hosp, Assisted Concept Unit, London WC1E 6DB, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Swinn, M (corresponding author), Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.		Smith, Martin/B-2616-2009; Lichterman, Boleslav/B-5205-2018	Lichterman, Boleslav/0000-0002-3453-4380					0	10	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1583	1583		10.1136/bmj.317.7172.1583	http://dx.doi.org/10.1136/bmj.317.7172.1583			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836668	Green Published			2022-12-28	WOS:000077451700039
J	Cassileth, PA; Harrington, DP; Appelbaum, FR; Lazarus, HM; Rowe, JM; Paietta, E; Willman, C; Hurd, DD; Bennett, JM; Blume, KG; Head, DR; Wiernik, PH				Cassileth, PA; Harrington, DP; Appelbaum, FR; Lazarus, HM; Rowe, JM; Paietta, E; Willman, C; Hurd, DD; Bennett, JM; Blume, KG; Head, DR; Wiernik, PH			Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; 1ST REMISSION; INTENSIVE CHEMOTHERAPY; POSTREMISSION THERAPY; 4-HYDROPEROXYCYCLOPHOSPHAMIDE; CLASSIFICATION	Background In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission improves the long-term outcome, but the role of bone marrow transplantation is uncertain. We compared high-dose cytarabine with autologous or allogeneic marrow transplantation during the first remission of acute myeloid leukemia. Methods Previously untreated adolescents and adults 16 to 55 years of age who had acute myeloid leukemia received standard induction chemotherapy. After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were administered. Patients with histocompatible siblings were offered allogeneic marrow transplantation, whereas the remaining patients were randomly assigned to receive a single course of high-dose cytarabine or transplantation of autologous marrow treated with perfosfamide (4-hydroperoxycyclophosphamide). Oral busulfan and intravenous cyclophosphamide were used as preparative regimens for both allogeneic and autologous marrow transplantation. The end points were survival from the time of complete remission and disease-free survival. Results In an intention-to-treat analysis, we found no significant differences in disease-free survival among patients receiving high-dose chemotherapy, those undergoing autologous bone marrow transplantation, and those undergoing allogeneic marrow transplantation. The median follow-up was four years. Survival after complete remission was somewhat better after chemotherapy than after autologous marrow transplantation (P = 0.05). There was a marginal advantage in terms of overall survival with chemotherapy as compared with allogeneic marrow transplantation (P = 0.04). Conclusions A postinduction course of high-dose cytarabine can provide equivalent disease-free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia. (N Engl J Med 1998;339:1649-56.) (C)1998, Massachusetts Medical Society.	Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA; Univ Rochester, Ctr Canc, Rochester, NY USA; Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA; Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA; Stanford Univ Hosp, Stanford, CA 94305 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	University of Miami; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center; Case Western Reserve University; University of Rochester; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of New Mexico; Wake Forest University; Stanford University; St Jude Children's Research Hospital	Cassileth, PA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.				NATIONAL CANCER INSTITUTE [U10CA014548, U10CA023318, U10CA038926] Funding Source: NIH RePORTER; NCI NIH HHS [CA14548, CA38926, CA23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERKSON J, 1952, J AM STAT ASSOC, V47, P501, DOI 10.2307/2281318; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; CASSILETH PA, 1988, J CLIN ONCOL, V6, P583, DOI 10.1200/JCO.1988.6.4.583; CASSILETH PA, 1993, J CLIN ONCOL, V11, P314, DOI 10.1200/JCO.1993.11.2.314; CASSILETH PA, 1992, BLOOD, V79, P1924; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; COPELAN EA, 1991, BLOOD, V78, P838, DOI 10.1182/blood.V78.3.838.838; Cox DR., 1989, ANAL BINARY DATA; DASTUGUE N, 1995, LEUKEMIA, V9, P1491; DINSMORE R, 1984, BLOOD, V63, P649; Harousseau JL, 1997, BLOOD, V90, P2978; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Leith CP, 1997, BLOOD, V89, P3323; Linker C. A., 1995, Blood, V86, p99A; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PRENTICE RL, 1978, BIOMETRIKA, V65, P167, DOI 10.1093/biomet/65.1.167; Ravindranath Y, 1996, NEW ENGL J MED, V334, P1428, DOI 10.1056/NEJM199605303342203; ROSENFELD C, 1989, BLOOD, V74, P1159; SANZ MA, 1993, J CLIN ONCOL, V11, P1661, DOI 10.1200/JCO.1993.11.9.1661; Schiller G., 1995, Blood, V86, p99A; SCHILLER G, 1992, BLOOD, V80, P2977; SCHILLER GJ, 1992, J CLIN ONCOL, V10, P41, DOI 10.1200/JCO.1992.10.1.41; Sierra J, 1996, J CLIN ONCOL, V14, P1353, DOI 10.1200/JCO.1996.14.4.1353; Stein AS, 1996, J CLIN ONCOL, V14, P2206, DOI 10.1200/JCO.1996.14.8.2206; WEINSTEIN HJ, 1995, BLOOD PRINCIPLES PRA, P543; WOODS WG, 1996, P AN M AM SOC CLIN, V15, pA368; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	33	469	486	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1649	1656		10.1056/NEJM199812033392301	http://dx.doi.org/10.1056/NEJM199812033392301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834301				2022-12-28	WOS:000077294800001
J	Stern, DL				Stern, DL			A role of Ultrabithorax in morphological differences between Drosophila species	NATURE			English	Article							BITHORAX COMPLEX; GENE ULTRABITHORAX; BODY PLANS; HOX GENES; EVOLUTION; MELANOGASTER; EXPRESSION; PRODUCTS; PROTEINS	The mechanisms underlying the evolution of morphology are poorly understood(1,2). Distantly related taxa sometimes exhibit correlations between morphological differences and patterns of gene expression(3-8), but such comparisons cannot establish how mechanisms evolve to generate diverse morphologies. Answers to these questions require resolution of the nature of developmental evolution within and between closely related species. Here I show how the detailed regulation of the Hox gene Ultrabithorax patterns trichomes on the posterior femur of the second leg in Drosophila melanogaster, and that evolution of Ultrabithorax has contributed to divergence of this feature among closely related species, The cis-regulatory regions of Ultrabithorax, and not the protein itself, appear to have evolved. This study provides experimental evidence that cis-regulatory evolution is one way in which conserved proteins have promoted morphological diversity(1).	Wellcome CRC Inst, Cambridge CB2 1QR, England		Stern, DL (corresponding author), Univ Cambridge, Museum Zool, Lab Dev & Evolut, Downing St, Cambridge CB2 3EJ, England.			Stern, David/0000-0002-1847-6483	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063622, R01 GM063622-01] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; Akam M, 1998, INT J DEV BIOL, V42, P445; Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Castelli-Gair J, 1998, INT J DEV BIOL, V42, P437; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; Davis AW, 1996, NATURE, V380, P157, DOI 10.1038/380157a0; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lowe CJ, 1997, NATURE, V389, P718, DOI 10.1038/39580; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MORATA G, 1981, NATURE, V290, P778, DOI 10.1038/290778a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; SANCHEZHERRERO E, 1985, COLD SPRING HARB SYM, V50, P165, DOI 10.1101/SQB.1985.050.01.022; WARREN RW, 1994, NATURE, V372, P458, DOI 10.1038/372458a0; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2	21	191	198	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					463	466		10.1038/24863	http://dx.doi.org/10.1038/24863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853753	Green Accepted			2022-12-28	WOS:000077370100053
J	Gearhart, J				Gearhart, J			Cell biology - New potential for human embryonic stem cells	SCIENCE			English	Editorial Material							PRIMORDIAL GERM-CELLS; IN-VITRO; MOUSE EMBRYOS; ES CELLS; CULTURE; DIFFERENTIATION; ESTABLISHMENT; NEURONS; LINE		Dept Gynecol & Obstet, Baltimore, MD 21287 USA		Gearhart, J (corresponding author), Dept Gynecol & Obstet, Baltimore, MD 21287 USA.	gearhart@jhmi.edu						BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; DOETSCHMAN T, 1988, DEV BIOL, V127, P224, DOI 10.1016/0012-1606(88)90204-7; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1996, J NEUROSCI, V16, P1056; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; Piedrahita JA, 1998, BIOL REPROD, V58, P1321, DOI 10.1095/biolreprod58.5.1321; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; SHAMBLOTT MJ, IN PRESS P NATL ACAD; Shim H, 1997, BIOL REPROD, V57, P1089, DOI 10.1095/biolreprod57.5.1089; SMITH AG, IN PRESS CURR BIOL; Solter D, 1998, NATURE, V394, P315, DOI 10.1038/28485; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Tada M, 1997, EMBO J, V16, P6510, DOI 10.1093/emboj/16.21.6510; Thomson JA, 1998, CURR TOP DEV BIOL, V38, P133; Thomson JA, 1996, BIOL REPROD, V55, P254, DOI 10.1095/biolreprod55.2.254; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WILES MV, 1991, DEVELOPMENT, V111, P259	27	137	183	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 6	1998	282	5391					1061	1062		10.1126/science.282.5391.1061	http://dx.doi.org/10.1126/science.282.5391.1061			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9841453				2022-12-28	WOS:000076887700034
J	Greenfield, S				Greenfield, S			Brain drugs of the future	BRITISH MEDICAL JOURNAL			English	Review									Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Greenfield, S (corresponding author), Univ Oxford, Dept Pharmacol, S Parks Rd, Oxford OX1 3QT, England.							Cragg SJ, 1997, J NEUROSCI, V17, P5738; GEARY J, 1997, TIME            0505, P46; Greenfield S, 1996, NEUROCHEM INT, V28, P485, DOI 10.1016/0197-0186(95)00100-X; Greenfield S., 1995, JOURNEY CTR MIND SCI; Greenfield SA, 1992, ESSAYS BIOCHEM, V27, P103; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JONES SA, 1995, CELL TISSUE RES, V279, P323, DOI 10.1007/BF00318488; LEMIN GR, 1996, ANNU REV NEUROSCI, V19, P289; MARSHALL LH, 1998, DISCOVERIES HUMAN BR; Pert C., 1997, PERT; Toga A.W., 1996, BRAIN MAPPING METHOD; WOOLF NJ, 1990, BRAIN CHOLINERGIC SY, P387; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	13	2	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1698	1701		10.1136/bmj.317.7174.1698	http://dx.doi.org/10.1136/bmj.317.7174.1698			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857132	Green Published			2022-12-28	WOS:000077742300019
J	Towey, R; Kimaro, E				Towey, R; Kimaro, E			Only if she has a fishing rod!	BRITISH MEDICAL JOURNAL			English	Article									Burgando Med Ctr, Dept Anaesthesia, Mwanza, Tanzania		Towey, R (corresponding author), Burgando Med Ctr, Dept Anaesthesia, POB 1370, Mwanza, Tanzania.								0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1711	1711		10.1136/bmj.317.7174.1711	http://dx.doi.org/10.1136/bmj.317.7174.1711			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857137	Green Published			2022-12-28	WOS:000077742300026
J	Sun, PQ; Dong, P; Dai, K; Hannon, GJ; Beach, D				Sun, PQ; Dong, P; Dai, K; Hannon, GJ; Beach, D			p53-independent role of MDM2 in TGF-beta 1 resistance	SCIENCE			English	Article							GROWTH-FACTOR-BETA; P53 GENE-MUTATIONS; RETINOBLASTOMA PROTEIN; BREAST-CARCINOMA; IN-VITRO; EXPRESSION; CELLS; OVEREXPRESSION; ONCOPROTEIN; INHIBITION	Transforming growth factor-beta (TGF-beta) inhibits cell proliferation, and acquisition of TGF-beta resistance has been Linked to tumorigenesis, A genetic screen was performed to identify complementary DNAs that abrogated TGF-beta sensitivity in mink lung epithelial cells, Ectopic expression of murine double minute 2 rescued TGF-beta-induced growth arrest in a p53-independent manner by interference with retinoblastoma susceptibility gene product (Rb)/E2F function. In human breast tumor cells, increased MDM2 expression Levels correlated with TGF-beta resistance. Thus, MDM2 may confer TGF-beta resistance in a subset of tumors and may promote tumorigenesis by interference with two independent tumor suppressors, p53 and Rb.	Inst Child Hlth, London WC1N, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Beach, D (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N, England.		Hannon, Gregory/AAB-3568-2019					ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Boyer SN, 1996, CANCER RES, V56, P4620; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; Gunther T, 1997, J CANCER RES CLIN, V123, P388, DOI 10.1007/s004320050076; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRASAGAKIS K, 1994, ANTICANCER RES, V14, P2565; Kulkarni S, 1996, CELL GROWTH DIFFER, V7, P501; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nowell PC, 1998, IMMUNOL RES, V17, P171, DOI 10.1007/BF02786442; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POREMBA C, 1995, ONCOL RES, V7, P331; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; SUN P, UNPUB; Teti A, 1997, INT J CANCER, V72, P1013; Wagner SN, 1998, BRIT J DERMATOL, V138, P13; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	32	190	191	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2270	2272		10.1126/science.282.5397.2270	http://dx.doi.org/10.1126/science.282.5397.2270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856953				2022-12-28	WOS:000077645800051
J	Goyder, E; Irwig, L				Goyder, E; Irwig, L			Screening for diabetes: what are we really doing?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RAISED BLOOD-PRESSURE; ANTIHYPERTENSIVE THERAPY; NEW-ZEALAND; MELLITUS; NIDDM; COMPLICATIONS; RISK; HYPERTENSION; MANAGEMENT; GUIDELINES		Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia	University of Sydney	Goyder, E (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Sheffield S1 4DA, S Yorkshire, England.	e.goyder@sheffield.ac.uk	Goyder, Elizabeth E/A-2146-2010	Goyder, Elizabeth E/0000-0003-3691-1888				[Anonymous], 1997, ARCH INTERN MED, V157, P2413; Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360; Begg EJ, 1996, NEW ZEAL MED J, V109, P237; Canadian Task Force on the Periodic Health Examination, 1994, CAN GUID CLIN PREV H; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Davies M, 1994, J Med Screen, V1, P78; DAVIES M, 1991, BRIT MED J, V303, P696, DOI 10.1136/bmj.303.6804.696; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; FULLER J, 1998, ANTIHYPERTENSIVE THE; Gaster B, 1998, ARCH INTERN MED, V158, P134, DOI 10.1001/archinte.158.2.134; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOLDNER MG, 1971, J AMER MED ASSOC, V218, P1400, DOI 10.1001/jama.218.9.1400; HANEFELD M, 1991, DIABETES CARE, V14, P308, DOI 10.2337/diacare.14.4.308; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JACKSON R, 1998, ABSOLUTE 5 YEAR RISK; JARRETT RJ, 1977, BRIT MED J, V2, P861, DOI 10.1136/bmj.2.6091.861; Kerbel D, 1997, J Med Screen, V4, P128; KOSKINEN P, 1992, DIABETES CARE, V15, P820, DOI 10.2337/diacare.15.7.820; MacMahon S, 1996, J HYPERTENS, V14, P691, DOI 10.1097/00004872-199606000-00003; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PATERSON KR, 1993, DIABETIC MED, V10, P777, DOI 10.1111/j.1464-5491.1993.tb00164.x; PYLORALA K, 1997, DIABETES CARE, V20, P614; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMMONS D, 1995, NEW ZEAL MED J, V108, P464; Simpson FO, 1996, J HYPERTENS, V14, P683, DOI 10.1097/00004872-199606000-00002; Swales JD, 1996, J HYPERTENS, V14, P813, DOI 10.1097/00004872-199607000-00002; *WHO, 1994, TECHN REP SER WHO, V844; WORRALL G, 1991, J FAM PRACTICE, V33, P155; Zanchetti A, 1996, J HYPERTENS, V14, P681, DOI 10.1097/00004872-199606000-00001	33	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1998	317	7173					1644	1646		10.1136/bmj.317.7173.1644	http://dx.doi.org/10.1136/bmj.317.7173.1644			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848909	Green Published			2022-12-28	WOS:000077602100032
J							C elegans Sequencing Consortium	Genome sequence of the nematode C-elegans: A platform for investigating biology	SCIENCE			English	Review							TRANSFER-RNA GENES; CAENORHABDITIS-ELEGANS; DNA-SEQUENCES; ORGANIZATION; FAMILIES; PROGRAM; YEAST; CONSTRUCTION; TRANSPOSON; INSERTS	The 97-megabase genomic sequence of the nematode Caenorhabditis elegans reveals over 19,000 genes. More than 40 percent of the predicted protein products find significant matches in other organisms. There is a variety of repeated sequences, both local and dispersed. The distinctive distribution of some repeats and highly conserved genes provides evidence for a regional organization of the chromosomes.	Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Sanger Ctr, Hinxton CB10 1SA, Cambs, England	Washington University (WUSTL); Wellcome Trust Sanger Institute	C elegans Sequencing Consortium (corresponding author), Washington Univ, Genome Sequencing Ctr, Box 8501,4444 Forest Pk Pkwy, St Louis, MO 63108 USA.		Wilson, Richard K./AAF-4139-2019; Smith, Andy/A-7512-2011; Jones, Steven J/C-3621-2009; Isobe, Toshiaki/Q-9279-2017; Maggi, Leonard/L-5217-2019; Palau, Francesc/A-9391-2014	Wilson, Richard K./0000-0002-1992-1358; Smith, Andy/0000-0001-8580-278X; Jones, Steven J/0000-0003-3394-2208; Maggi, Leonard/0000-0003-0138-0984; Steward, Charles/0000-0001-8829-5349; Lindsay, Sarah/0000-0002-0965-3070; Palau, Francesc/0000-0002-8635-5421; Schultz, Brian/0000-0003-4964-976X; Lawson, Daniel/0000-0001-7765-983X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], UNPUB; BARNES TM, 1995, GENETICS, V141, P159; Bernardi G, 1995, ANNU REV GENET, V29, P445, DOI 10.1146/annurev.ge.29.120195.002305; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cooper ML, 1996, GENOME RES, V6, P1110, DOI 10.1101/gr.6.11.1110; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; Dear S, 1998, GENOME RES, V8, P260, DOI 10.1101/gr.8.3.260; Devine SE, 1997, GENOME RES, V7, P551, DOI 10.1101/gr.7.5.551; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; Green Paul, COMMUNICATION; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; HAMER L, 1995, P NATL ACAD SCI USA, V92, P11706, DOI 10.1073/pnas.92.25.11706; Heiner CR, 1998, GENOME RES, V8, P557, DOI 10.1101/gr.8.5.557; HERMAN RK, 1988, NEMATODE CAENORHABDI, P17; Ketting RF, 1997, NUCLEIC ACIDS RES, V25, P4041, DOI 10.1093/nar/25.20.4041; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; KOHARA Y, 1996, PNE PROTEIN NUCL ACI, V41, P715; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; OKIMOTO R, 1992, GENETICS, V130, P471; Parsons JD, 1995, COMPUT APPL BIOSCI, V11, P615; Robertson HM, 1998, GENOME RES, V8, P449, DOI 10.1101/gr.8.5.449; *SANG CTR WASH U G, IN PRESS GENOME RES; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; SONNHAMMER ELL, 1994, P 2 INT C INT SYST M, P363; SULTSON J, 1992, NATURE, V356, P37; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670; WARD S, 1988, J MOL BIOL, V199, P1, DOI 10.1016/0022-2836(88)90374-9; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WATERSTON R, 1995, P NATL ACAD SCI USA, V92, P10836, DOI 10.1073/pnas.92.24.10836; Wendl MC, 1998, GENOME RES, V8, P975, DOI 10.1101/gr.8.9.975; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wilson RK, 1997, GENOME ANAL, V1, P397	56	4219	8802	21	359	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2012	2018		10.1126/science.282.5396.2012	http://dx.doi.org/10.1126/science.282.5396.2012			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851916				2022-12-28	WOS:000077467100034
J	Zuber, MT; Smith, DE; Solomon, SC; Abshire, JB; Afzal, RS; Aharonson, O; Fishbaugh, K; Ford, PG; Frey, HV; Garvin, JB; Head, JW; Ivanov, AB; Johnson, CL; Muhleman, DO; Neumann, GA; Pettengill, GH; Phillips, RJ; Sun, ZL; Zwally, HJ; Banerdt, WB; Duxbury, TC				Zuber, MT; Smith, DE; Solomon, SC; Abshire, JB; Afzal, RS; Aharonson, O; Fishbaugh, K; Ford, PG; Frey, HV; Garvin, JB; Head, JW; Ivanov, AB; Johnson, CL; Muhleman, DO; Neumann, GA; Pettengill, GH; Phillips, RJ; Sun, ZL; Zwally, HJ; Banerdt, WB; Duxbury, TC			Observations of the north polar region of Mars from the Mars Orbiter Laser Altimeter	SCIENCE			English	Article							PLANETARY CONDITIONS; WATER-VAPOR; ICE; BEHAVIOR; MODEL	Elevations from the Mars Orbiter Laser Altimeter (MOLA) have been used to construct a precise topographic map of the martian north polar region. The northern ice cap has a maximum elevation of 3 kilometers above its surroundings but Lies within a 5-kilometer-deep hemispheric depression that is contiguous with the area into which most outflow channels emptied, Polar cap topography displays evidence of modification by ablation, flow, and wind and is consistent with a primarily H2O composition. Correlation of topography with images suggests that the cap was more spatially extensive in the past. The cap volume of 1.2 x 10(6) to 1.7 x 10(6) cubic kilometers is about half that of the Greenland ice cap. Clouds observed over the polar cap are Likely composed of CO2 that condensed out of the atmosphere during northern hemisphere winter. Many clouds exhibit dynamical structure Likely caused by the interaction of propagating wave fronts with surface topography.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; CALTECH, Pasadena, CA 91125 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Massachusetts Institute of Technology (MIT); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Brown University; California Institute of Technology; Washington University (WUSTL); Carnegie Institution for Science; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Zuber, MT (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	zuber@tharsis.gsfc.nasa.gov	Abshire, James/I-2800-2013; Sun, Xiaoli/B-5120-2013; Neumann, Gregory A/I-5591-2013; Banerdt, William/Q-7324-2019	Neumann, Gregory A/0000-0003-0644-9944; Banerdt, William/0000-0003-3125-1542; Aharonson, Oded/0000-0001-9930-2495				ABSHIRE JB, UNPUB; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BLASIUS KR, 1982, ICARUS, V50, P140, DOI 10.1016/0019-1035(82)90122-1; BUDD WF, 1970, J GLACIOL, V9, P29; CLARK BR, 1976, ICARUS, V27, P215, DOI 10.1016/0019-1035(76)90005-1; CLIFFORD SM, 1987, J GEOPHYS RES-SOLID, V92, P9135, DOI 10.1029/JB092iB09p09135; CLIFFORD SM, 1993, J GEOPHYS RES-PLANET, V98, P10973, DOI 10.1029/93JE00225; Davies ME, 1995, CELEST MECH DYN ASTR, V63, P127, DOI 10.1007/BF00693410; Drewry D. J., 1982, ANN GLACIOL, V3, P83, DOI DOI 10.1017/S0260305500002573; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; DURHAM WB, 1992, J GEOPHYS RES-PLANET, V97, P20883, DOI 10.1029/92JE02326; DURHAM WB, 1998, 1 INT C MARS POL SCI, P8; DZURISIN D, 1975, J GEOPHYS RES, V80, P3286, DOI 10.1029/JB080i023p03286; Fanale F.P., 1992, MARS, P1135; FANALE FP, 1986, ICARUS, V67, P1, DOI 10.1016/0019-1035(86)90170-3; FARMER CB, 1979, J GEOPHYS RES, V84, P2881, DOI 10.1029/JB084iB06p02881; FISHER DA, 1993, ICARUS, V105, P501, DOI 10.1006/icar.1993.1144; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GARVIN JB, IN PRESS GEOPHYS RES; Greeley R., 1992, MARS, P730; Haefeli R., 1961, J GLACIOL, V3; HEAD JW, INPRESS GEOPHYS RES; Holton J. R., 1992, INTRO DYNAMIC METEOR; HOWARD A, 1980, 82385 TM; HOWARD AD, 1982, ICARUS, V50, P161, DOI 10.1016/0019-1035(82)90123-3; Jakosky B. M., 1992, MARS, P969; JAKOSKY BM, 1982, J GEOPHYS RES, V87, P2999, DOI 10.1029/JB087iB04p02999; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LANCASTER N, 1990, J GEOPHYS RES-SOLID, V95, P10921, DOI 10.1029/JB095iB07p10921; LEOVY CB, 1982, ADV SPACE RES, V2, P19, DOI DOI 10.1016/0273-1177(82)90103-X; MALIN MC, UNPUB; MUHLEMAN DO, 1998, 1 INT C MARS POL SCI, P28; ROWLANDS DD, 1993, GEODYN 2 SYSTEM DESC; ROWLANDS DQ, UNPUB; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SMITH WHF, 1990, GEOPHYSICS, V55, P293, DOI 10.1190/1.1442837; Thomas P., 1992, MARS, P767; TILLMAN JE, 1988, J GEOPHYS RES-ATMOS, V93, P9433, DOI 10.1029/JD093iD08p09433; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; TSOAR H, 1979, J GEOPHYS RES, V84, P8167, DOI 10.1029/JB084iB14p08167; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]; Zuber M., 1998, 1 INT C MARS POL SCI, P45; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; ZUBER MT, IN PRESS GEOPHYS RES; ZUBER MT, 1998, EOS, V79, pF486; ZWALLY HJ, 1989, SCIENCE, V246, P1587, DOI 10.1126/science.246.4937.1587	49	211	212	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2053	2060		10.1126/science.282.5396.2053	http://dx.doi.org/10.1126/science.282.5396.2053			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851922				2022-12-28	WOS:000077467100040
J	Leon, MB; Baim, DS; Popma, JJ; Gordon, PC; Cutlip, DE; Ho, KKL; Giambartolome, A; Diver, DJ; Lasorda, DM; Williams, DO; Pocock, SJ; Kuntz, RE				Leon, MB; Baim, DS; Popma, JJ; Gordon, PC; Cutlip, DE; Ho, KKL; Giambartolome, A; Diver, DJ; Lasorda, DM; Williams, DO; Pocock, SJ; Kuntz, RE		Stent Anticoagulation Restenosis Study	A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; ANTIPLATELET THERAPY; COMBINED TICLOPIDINE; ULTRASOUND GUIDANCE; FRENCH-MULTICENTER; ASPIRIN THERAPY; IMPLANTATION; ANTICOAGULATION; PLACEMENT; DISEASE	Background Antithrombotic drugs are used after coronary-artery stenting to prevent stent thrombosis. We compared the efficacy and safety of th ree antithrombotic-drug regimens - aspirin alone, aspirin and warfarin, and aspirin and ticlopidine - after coronary stenting. Methods Of 1965 patients who underwent coronary stenting at 50 centers, 1653 (84.1 percent) met angiographic criteria for successful placement of the stent and were randomly assigned to one of three regimens: aspirin alone (557 patients), aspirin and warfarin (550 patients), or aspirin and ticlopidine (546 patients). All clinical events reflecting stent thrombosis were included in the prespecified primary end point: death, revascularization of the target lesion, angiographically evident thrombosis, or myocardial infarction within 30 days. Results The primary end point was observed in 38 patients: 20 (3.6 percent) assigned to receive aspirin alone, 15 (2.7 percent) assigned to receive aspirin and warfarin, and 3 (0.5 percent) assigned to receive aspirin and ticlopidine (P = 0.001 for the comparison of all three groups). Hemorrhagic complications occurred in 10 patients (1.8 percent) who received aspirin alone, 34 (6.2 percent) who received aspirin and warfarin, and 30 (5.5 percent) who received aspirin and ticlopidine (P<0.001 for the comparison of all three groups); the incidence of vascular surgical complications was 0.4 percent (2 patients), 2.0 percent(ll patients), and 2.0 percent (11 patients), respectively (P = 0.02). There were no significant differences in the incidence of neutropenia or thrombocytopenia (overall incidence, 0.3 percent) among the three treatment groups. Conclusions As compared with aspirin alone and a combination of aspirin and warfarin, treatment with, aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone. After coronary stenting, aspirin and ticlopidine should be considered for the prevention of the serious complication of stent thrombosis. (N Engl J Med 1998;339:1665-71.) (C)1998, Massachusetts Medical Society.	Washington Hosp Ctr, Cardiol Res Fdn, Washington, DC 20010 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Miriam Hosp, Providence, RI 02906 USA; St Josephs Hosp, Syracuse, NY USA; Georgetown Med Ctr, Washington, DC USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Rhode Isl Hosp, Providence, RI USA; London Sch Hyg & Trop Med, London WC1, England	MedStar Washington Hospital Center; Harvard University; Beth Israel Deaconess Medical Center; Lifespan Health Rhode Island; Miriam Hospital; Georgetown University; Allegheny General Hospital; Lifespan Health Rhode Island; Rhode Island Hospital; University of London; London School of Hygiene & Tropical Medicine	Leon, MB (corresponding author), Washington Hosp Ctr, Cardiol Res Fdn, 110 Irving St NW,Suite 4B-1, Washington, DC 20010 USA.			Ho, Kalon/0000-0001-5946-6428				Albiero R, 1997, CIRCULATION, V95, P1145; Baim DS, 1997, CIRCULATION, V95, P1098; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Bennett CL, 1998, LANCET, V352, P1036, DOI 10.1016/S0140-6736(05)60079-7; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; COHEN DJ, 1995, CIRCULATION, V92, P2480, DOI 10.1161/01.CIR.92.9.2480; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hall P, 1996, CIRCULATION, V93, P215, DOI 10.1161/01.CIR.93.2.215; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; MORICE MC, 1995, CATHETER CARDIO DIAG, V35, P1, DOI 10.1002/ccd.1810350102; *SAS I, 1990, SAS STAT US GUID, V2, P1071; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801	18	1378	1417	1	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1665	1671		10.1056/NEJM199812033392303	http://dx.doi.org/10.1056/NEJM199812033392303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834303				2022-12-28	WOS:000077294800003
J	Kao, AC; Green, DC; Zaslavsky, AM; Koplan, JP; Cleary, PD				Kao, AC; Green, DC; Zaslavsky, AM; Koplan, JP; Cleary, PD			The relationship between method of physician payment and patient trust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE PHYSICIANS; FEE-FOR-SERVICE; MANAGED-CARE; HEALTH-CARE; FINANCIAL INCENTIVES; NATIONAL SURVEY; QUALITY; PLANS; ARRANGEMENTS; CAPITATION	Context.-Trust is the cornerstone of the patient-physician relationship. Payment methods that place physicians at financial risk have raised concerns about patients' trust in physicians to act in patients' best interests. Objective.-To evaluate the extent to which methods of physician payment are related to patient trust. Design.-Cross-sectional telephone interview survey done between January and June 1997. Setting.-Health plans of a large national insurer in Atlanta, Ga, the Baltimore, Md-Washington, DC, area, and Orlando, Fla. Participants.-A total of 2086 adult managed care and indemnity patients. Main Outcome Measure.-A 10-item scale (alpha =.94) assessing patients' trust in physicians. Results.-More fee-for-service (FFS) indemnity patients (94%) completely or mostly trust their physicians to "put their health and well-being above keeping down the health plan's costs" than salary (77%), capitated (33%), or FFS managed care patients (85%) (P<.001 for pairwise comparisons). In multivariate analyses that adjusted for potentially confounding factors, FFS indemnity patients also had higher scores on the 10-item;trust scale than salary (P<.001), capitated (P<.001), or FFS managed care patients (P<.01). The effects of payment method on patient trust were reduced when a measure based on patients' reports about physician behavior leg, Does your physician take enough time to answer your questions?) was included in the regression analyses, but the differences remained statistically significant, except for the comparison between FFS managed care and FFS indemnity patients (P=.08). Patients' perceptions of how their physicians were paid were not independently associated with trust, but the 37.7% who said they did not know how their physicians were paid had higher levels of trust than other patients (P<.01). A total of 30.2% of patients were incorrect about their physicians' method of payment. Conclusions.-Most patients trusted their physicians, but FFS indemnity patients have higher levels of trust than salary, capitated, or FFS managed care patients. Patients' reports of physician behavior accounted for part of the variation in patients' trust in physicians who are paid differently. The impact of payment methods on patient trust may be mediated partly by physician behavior.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA; Prudential Ctr Hlth Care Res, Atlanta, GA USA	Harvard University; Harvard Medical School; American Medical Association	Cleary, PD (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	cleary@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019					ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; BARR DA, 1995, ANN INTERN MED, V122, P353, DOI 10.7326/0003-4819-122-5-199503010-00006; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; BLENDON RJ, 1995, JAMA-J AM MED ASSOC, V273, P341, DOI 10.1001/jama.273.4.341; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; Cleary P D, 1992, QRB Qual Rev Bull, V18, P53; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; ELLSBURY K, 1987, J FAM PRACTICE, V6, P616; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; EPSTEIN AM, 1986, AM J MED, V80, P865, DOI 10.1016/0002-9343(86)90630-3; Fox BC, 1996, JAMA-J AM MED ASSOC, V276, P1635, DOI 10.1001/jama.276.20.1635; Fox BC, 1996, CLIN INFECT DIS, V23, P616, DOI 10.1093/clinids/23.3.616; GARSKE JP, 1976, PSYCHOL REP, V39, P349; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Gray B, 1997, J COMMUN HEALTH, V22, P247, DOI 10.1023/A:1025148302636; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; Grimaldi P L, 1996, Nurs Manage, V27, P49; GURTMAN MB, 1992, J PERS SOC PSYCHOL, V62, P989, DOI 10.1037/0022-3514.62.6.989; Halm EA, 1997, JAMA-J AM MED ASSOC, V278, P1677, DOI 10.1001/jama.278.20.1677; Herschberg S, 1992, Qual Assur Util Rev, V7, P54; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; Institute of Medicine, 1989, CONTR COSTS CHANG PA; JANOFFBULMAN R, 1989, SOC COGNITION, V7, P113, DOI 10.1521/soco.1989.7.2.113; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Katz J., 1984, SILENT WORLD DOCTOR; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kerr EA, 1997, JAMA-J AM MED ASSOC, V278, P308, DOI 10.1001/jama.278.4.308; Kleinbaum D, 1988, APPL REGRESSION ANAL; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; Kramer Roderick M., 1995, TRUST ORG FRONTIERS; Landon BE, 1998, JAMA-J AM MED ASSOC, V279, P1377, DOI 10.1001/jama.279.17.1377; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; LEVY DR, 1985, PEDIATRICS, V75, P639; Lipset Martin, 1987, CONFIDENCE GAP BUSIN; LUPTON D, 1991, SOC SCI MED, V33, P559, DOI 10.1016/0277-9536(91)90213-V; MACKLIN R, 1993, ENEMIES PATIENTS; Manian FA, 1996, JAMA-J AM MED ASSOC, V275, P145; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MORREIM EH, 1991, J LEGAL MED, V12, P275, DOI 10.1080/01947649109510858; RELMAN AS, 1988, NEW ENGL J MED, V319, P784, DOI 10.1056/NEJM198809223191209; Remler DK, 1997, INQUIRY-J HEALTH CAR, V34, P196; RODWIN M, 1993, MED MONEY MORALS; RODWIN MA, 1995, AM J LAW MED, V21, P241; ROEMER MI, 1962, J HEALTH HUM BEHAV, V3, P4, DOI 10.2307/2948736; Schlesinger MJ, 1997, HEALTH AFFAIR, V16, P106, DOI 10.1377/hlthaff.16.1.106; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; STACK LC, 1978, TRUST; STEARNS SC, 1992, INQUIRY-J HEALTH CAR, V29, P416; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; Thom DH, 1997, J FAM PRACTICE, V44, P169; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Weissman JS., 1994, FALLING SAFETY NET I; Weyrauch K F, 1996, J Am Board Fam Pract, V9, P31; Wrightsman LS, 1991, MEASURES PERSONALITY; Zucker L., 1986, RES ORGAN BEHAV, V8, P1840, DOI DOI 10.1023/A	64	284	287	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1708	1714		10.1001/jama.280.19.1708	http://dx.doi.org/10.1001/jama.280.19.1708			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	138PD	9832007	Bronze			2022-12-28	WOS:000076980700041
J	Galweiler, L; Guan, CH; Muller, A; Wisman, E; Mendgen, K; Yephremov, A; Palme, K				Galweiler, L; Guan, CH; Muller, A; Wisman, E; Mendgen, K; Yephremov, A; Palme, K			Regulation of polar auxin transport by AtPIN1 in Arabidopsis vascular tissue	SCIENCE			English	Article							THALIANA; PROTEINS; PLANTS; ACID; CELLS; STEM	Polar auxin transport controls multiple developmental processes in plants, including the formation of vascular tissue. Mutations affecting the PIN-FORMED (PIN1) gene diminish polar auxin transport in Arabidopsis thaliana inflorescence axes. The AtPIN1 gene was found to encode a 67-kilodalton protein with similarity to bacterial and eukaryotic carrier proteins, and the AtPIN1 protein was detected at the basal end of auxin transport-competent cells in vascular tissue. AtPIN1 may act as a transmernbrane component of the auxin efflux carrier.	Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; Max Planck Inst Zuchtungsforsch, Abt Mol Pflanzengenet, D-50829 Cologne, Germany; Univ Konstanz, Fak Biol Phytopathol, D-78457 Constance, Germany	Max Planck Society; Max Planck Society; University of Konstanz	Palme, K (corresponding author), Max Planck Gesell, Max Delbruck Lab, Carl von Linne Weg 10, D-50829 Cologne, Germany.	palme@mpiz-koeln.mpg.de	Palme, Klaus/A-9524-2013	Palme, Klaus/0000-0002-2728-3835				Aloni Roni, 1995, P531; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; CARDON GH, 1993, PLANT J, V3, P773, DOI 10.1111/j.1365-313X.1993.00773.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; DARWIN C, 1980, POWER MOVEMENTS PLAN; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Frey M, 1998, PLANT J, V13, P717, DOI 10.1046/j.1365-313X.1998.00091.x; GALWEILER L, UNPUB; GIERL A, 1985, EMBO J, V4, P579, DOI 10.1002/j.1460-2075.1985.tb03669.x; GOLDSMITH MHM, 1977, ANNU REV PLANT PHYS, V28, P439, DOI 10.1146/annurev.pp.28.060177.002255; GU J, 1994, BIOTECHNIQUES, V17, P257; JACOBS M, 1983, SCIENCE, V220, P1297, DOI 10.1126/science.220.4603.1297; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; KLEE HJ, 1987, GENE DEV, V1, P86, DOI 10.1101/gad.1.1.86; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logan H, 1997, PHYSIOL PLANTARUM, V100, P1, DOI 10.1034/j.1399-3054.1997.1000101.x; Lomax Terri L., 1995, P509; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Mendgen K., 1991, Electron microscopy of plant pathogens., P31; MORRIS DA, 1978, J EXP BOT, V29, P147, DOI 10.1093/jxb/29.1.147; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; OKADA K, 1991, PLANT CELL, V3, P677, DOI 10.1105/tpc.3.7.677; Reinold S, 1996, PLANT PHYSIOL, V112, P131, DOI 10.1104/pp.112.1.131; Sachs T., 1991, PATTERN FORMATION PL, P101; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Teichmann T, 1997, EUR J BIOCHEM, V247, P826, DOI 10.1111/j.1432-1033.1997.00826.x; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; VANDERWEIJ GH, 1934, REC TRAV BOT NEERL, V31, P810; WENT F. W., 1928, REC TRAV BOT NEERL, V25, P1; Wisman E, 1998, PLANT MOL BIOL, V37, P989, DOI 10.1023/A:1006082009151; ZETTL R, 1994, P NATL ACAD SCI USA, V91, P689, DOI 10.1073/pnas.91.2.689	36	1123	1183	15	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2226	2230		10.1126/science.282.5397.2226	http://dx.doi.org/10.1126/science.282.5397.2226			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856939	Green Submitted			2022-12-28	WOS:000077645800037
J	Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ				Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ			Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FULL-TERM INFANTS; CEREBRAL-PALSY; NEONATAL ENCEPHALOPATHY; BIRTH-WEIGHT; ASPHYXIA; ANTECEDENTS; PREGNANCY	Objective To ascertain antepartum predictors of newborn encephalopathy in term infants. Design Population based, unmatched case-control study. Setting Metropolitan area of Western Australia,June 1993 to September 1995. Subjects All 164 term infants with moderate or severe newborn encephalopathy; 400 randomly selected controls. Main outcome measures Adjusted odds ratio estimates. Results The birth prevalence of moderate or severe newborn encephalopathy was 3.8/1000 term live births. The neonatal fatality was 9.1%. The risk of newborn encephalopathy increased with increasing maternal age and decreased with increasing parity. There was an increased risk associated with having a mother who was unemployed (odds ratio 3.60), an unskilled manual worker (3.84), or a housewife (2.48). Other risk factors from before conception were not having private health insurance (3.46), a family history of seizures (2.55), a family history of neurological disease (2.73), and infertility treatment (4.43). Risk factors during pregnancy were maternal thyroid disease (9.7), severe pre-eclampsia (6.30), moderate or severe bleeding (3.57), a clinically diagnosed viral illness (2.97), not having drunk alcohol (2.91); and placenta described at delivery as abnormal (2.07). Factors related to the baby were birth weight adjusted for gestational age between the third and ninth centile (4.37) or below the third centile (38.23). The risk relation with gestational age was J shaped with 38 and 39 weeks having the lowest risk. Conclusions The causes of newborn encephalopathy are heterogeneous and many of the causal pathways start before birth.	TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia; Hornsby Ku Ring Gai Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Western Australia, Dept Paediat, Nedlands, WA 6907, Australia; Princess Margaret Hosp Children, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Badawi, N (corresponding author), Royal Alexandra Hosp Children, New Childrens Hosp, Dept Neonatol, POB 3515, Parramatta, NSW 2124, Australia.	nadiaB@nch.edu.au	Burton, Paul R/H-7527-2016; Badawi, Nadia/A-3179-2014					ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Blair E, 1993, Paediatr Perinat Epidemiol, V7, P272, DOI 10.1111/j.1365-3016.1993.tb00405.x; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR EM, 1985, INTRAUTERINE GROWTH; BROWN MA, 1993, MED J AUSTRALIA, V158, P700; DENNIS J, 1978, DEV MED CHILD NEUROL, V20, P143; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GAFFNEY G, 1994, ARCH DIS CHILD-FETAL, V70, pF195, DOI 10.1136/fn.70.3.F195; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HAGBERG G, 1976, ACTA PAEDIATR SCAND, V65, P403, DOI 10.1111/j.1651-2227.1976.tb04906.x; HALPERIN LR, 1978, LANCET, V2, P212; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; KURINCZUK JJ, 1995, PAEDIATR PERINAT EP, V9, pA9; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P553; MALLARD EC, 1994, AM J OBSTET GYNECOL, V170, P206; NELSON KB, 1985, AM J DIS CHILD, V139, P1031, DOI 10.1001/archpedi.1985.02140120077032; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x	28	392	401	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1549	1553		10.1136/bmj.317.7172.1549	http://dx.doi.org/10.1136/bmj.317.7172.1549			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836652	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077451700020
J	Hoyer, AP; Grandjean, P; Jorgensen, T; Brock, JW; Hartvig, HB				Hoyer, AP; Grandjean, P; Jorgensen, T; Brock, JW; Hartvig, HB			Organochlorine exposure and risk of breast cancer	LANCET			English	Article							IN-VITRO; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; PESTICIDES; CHEMICALS; GROWTH	Background Some organochlorine compounds may have. weak oestrogenic effects and are, therefore, suspected of increasing the risk of breast cancer. We assessed prospectively the risk of breast cancer in relation to serum concentrations of several organochlorine compounds. Methods In 1976, serum samples from 7712 women were obtained from participants in the Copenhagen City Heart Study as part of physical examinations and interviews about lifestyle factors. During 17 years of follow-up, 268 women developed invasive breast cancer. Each woman with breast cancer was matched with two breast-cancer-free women from the remaining cohort. We analysed in 1996-97 the serum samples from 240 women with breast cancer and 477 controls. Findings Dieldrin was associated with a significantly increased dose-related risk of breast cancer (adjusted odds ratio 2.05 [95% CI 1.17-3.57], p for trend 0.01). beta-hexachlorocyclohexane increased risk slightly but not significantly (p for trend 0.24). There was no overall association between risk of breast cancer and p,p'-dichlorodiphenyltrichloroethane or metabolites or for polychlorinated biphenyls. Exclusion of women with breast cancer diagnosed within 5 years of blood sampling strengthened the result for dieldrin, but did not affect the other results. Interpretation These findings support the hypothesis that exposure to xeno-oestrogens may increase the risk of breast cancer.	Copenhagen Ctr Prospect Populat Studies, Copenhagen, Denmark; Odense Univ, Inst Community Hlth, Odense, Denmark; KAS Glostrup, Ctr Prevent Med, Glostrup, Denmark; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark	University of Southern Denmark; Centers for Disease Control & Prevention - USA; University of Copenhagen	Hoyer, AP (corresponding author), Harsdoffrej 1B,2tr, DK-1874 Frederiksberg C, Denmark.		Jørgensen, Torben/Z-1335-2018	Jorgensen, Torben/0000-0001-9453-2830	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07381] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHLBORG UG, 1995, CRIT REV TOXICOL, V25, P463, DOI 10.3109/10408449509017924; APPLEYARD M, 1987, SCAND J SOC MED S, V41; Arnold SF, 1997, ENVIRON HEALTH PERSP, V105, P615, DOI 10.2307/3433379; BRESLOW NE, IARC SCI PUBLICATION, V32; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; BROWN JF, 1989, CHEMOSPHERE, V19, P829, DOI 10.1016/0045-6535(89)90417-7; BUSTOS S, 1988, B ENVIRON CONTAM TOX, V1, P91; CULOTTA E, 1995, SCIENCE, V267, P330, DOI 10.1126/science.7824930; *DAN NAT BOARD HLT, 1983, 3 DAN NAT BOARD HLTH; GIERTHY JF, 1993, CANCER RES, V53, P3149; HOLCOMB M, 1994, CANCER LETT, V82, P43, DOI 10.1016/0304-3835(94)90144-9; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; JENSEN AA, 1988, DRUGS HUMAN LACTATIO, P551; Jensen G., 1984, ACTA MED SCAND S, V682; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KREIGER N, 1994, J NATL CANCER I, V86, P589; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; MORGAN DP, 1971, ARCH ENVIRON HEALTH, V22, P301, DOI 10.1080/00039896.1971.10665848; Oksbjerg S, 1997, Ugeskr Laeger, V159, P7134; Osterlind A, 1985, Ugeskr Laeger, V147, P2483; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P171; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SOTO AM, 1992, ADV MOD ENV, V21, P295; WHELAN S, 1990, ARC SCI PUBLICATIONS, V102; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOLFF MS, 1983, AM J IND MED, V4, P259, DOI 10.1002/ajim.4700040120	29	225	232	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1816	1820		10.1016/S0140-6736(98)04504-8	http://dx.doi.org/10.1016/S0140-6736(98)04504-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851382				2022-12-28	WOS:000077337900010
J	Paulose, KP				Paulose, KP			A memorable patient - Never fully examined	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1567	1567		10.1136/bmj.317.7172.1567	http://dx.doi.org/10.1136/bmj.317.7172.1567			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836661	Green Published			2022-12-28	WOS:000077451700028
J	Brett, AS				Brett, AS			New guidelines for coding physicians' services - A step backward	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGEMENT		Univ S Carolina, Columbia, SC 29203 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Brett, AS (corresponding author), Univ S Carolina, Columbia, SC 29203 USA.							American Medical Association and Health Care Financing Administration, 1997, DOC GUID EV MAN SERV; BRAUN P, 1992, MED CARE, V30, pNS13, DOI 10.1097/00005650-199211001-00002; BRAUN P, 1988, JAMA-J AM MED ASSOC, V260, P2409, DOI 10.1001/jama.260.16.2409; BRAUN P, 1988, JAMA-J AM MED ASSOC, V260, P2390, DOI 10.1001/jama.260.16.2390; *CHIC AM MED ASS, 1991, CPT 1992 PHYS CURR P; *CICC AM MED ASS, 1990, CPT 1991 PHYS CURR P; GESENSWAY D, 1998, ACP OBSERVER     APR, P1; Hand RW, 1998, CHEST, V113, P1432, DOI 10.1378/chest.113.6.1432; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; LEVY JM, 1992, MED CARE, V30, pNS80, DOI 10.1097/00005650-199211001-00007; MARTIN S, 1998, AM MED NEWS     0209, P12; MARTIN S, 1998, AM MED NEWS     0223, P7; MRTIN S, 1998, AM MED NEWS     0309, P3; O'Donohue WJ, 1998, CHEST, V113, P1431, DOI 10.1378/chest.113.6.1431-a; *PHYS PAYM REV COM, 1988, ANN REP C; Werner MJ, 1998, ANN INTERN MED, V128, P678, DOI 10.7326/0003-4819-128-8-199804150-00012; ZUBER TJ, 1992, AM FAM PHYSICIAN, V45, P703	18	37	37	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1705	1708		10.1056/NEJM199812033392312	http://dx.doi.org/10.1056/NEJM199812033392312			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834312				2022-12-28	WOS:000077294800012
J	Marci, CD; Roberts, TC				Marci, CD; Roberts, TC			The increasing debt of medical students: How much is too much	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPECIALTY CHOICES		Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University	Marci, CD (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.							*AM MED ASS CTR HL, 1998, PHYS MARK STAT 1997; KASSEBAUM DG, 1992, ACAD MED, V67, P700, DOI 10.1097/00001888-199210000-00018; KASSEBAUM DG, 1994, ACAD MED, V69, P164; Kassebaum DG, 1996, ACAD MED, V71, P1123; Krol D, 1998, ACAD MED, V73, P313, DOI 10.1097/00001888-199803000-00020; Medical Group Management Association, 1998, PHYS COMP PROD SURV; PETERSDORF RG, 1991, ACAD MED, V66, P61, DOI 10.1097/00001888-199102000-00001; Schnipper J, 1995, JAMA, V273, P80, DOI 10.1001/jama.273.1.80	8	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1879	1880						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846787				2022-12-28	WOS:000077176600040
J	Naradzay, JF				Naradzay, JF			Into the deep well: The evolution of medical school loan debt	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Loan Informat Network Co, Watertown, NY USA		Naradzay, JF (corresponding author), Loan Informat Network Co, Watertown, NY USA.							EASTAUGH SR, 1981, MED EC HLTH FINANCE; Flexner A., 1910, MEDICAL ED US CANADA; Fox W, 1984, DANDY J HOPKINS; HELMS LB, 1986, ACAD MED, V61, P555; JOHNSON DG, 1983, PHYSICIANS MAKING PE; Kassebaum DG, 1996, ACAD MED, V71, P1124, DOI 10.1097/00001888-199610000-00024; Lloyd G.E.R., 1970, EARLY GREEK SCI THAL; Morais Herbert M., 1968, HIST NEGRO MED; Regan-Smith MG, 1998, ACAD MED, V73, P505, DOI 10.1097/00001888-199805000-00014; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; STOCKWELL A, 1997, GUERRILLA GUIDE MAST; 1946, CUSHING BIOGRAPHY	12	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1881	+						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846788				2022-12-28	WOS:000077176600041
J	Nightingale, SL				Nightingale, SL			Jurisdiction over cloning technology to create human beings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-28	WOS:000077176600007
J	Pinedo, HM; Verheul, HMW; D'Amato, RJ; Folkman, J				Pinedo, HM; Verheul, HMW; D'Amato, RJ; Folkman, J			Involvement of platelets in tumour angiogenesis?	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; RELEASE; DISEASE; CELLS	Preclinical and clinical research show that tumour growth is dependent on angiogenesis. Activation of the coagulation cascade is commonly found in patients with cancer. We propose that platelets contribute to tumour-induced angiogenesis. The basis of our hypothesis Is that platelets are a rich source of stimulators and inhibitors of angiogenesis and their interaction with the endothelium. Presumably, the antithrombotic state of normal endothelium is disturbed by endothelial stimuli derived from tumour cells. This hypothesis may explain the suggested clinical benefits of anticoagulants in cancer and implies that targeting of platelet interaction with tumour vasculature will inhibit angiogenesis.	Free Univ Amsterdam, Acad Hosp, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cellular Biol, Boston, MA 02115 USA	Vrije Universiteit Amsterdam; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Pinedo, HM (corresponding author), Free Univ Amsterdam, Acad Hosp, Dept Med Oncol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.		Verheul, Henk/V-6462-2019; Verheul, Henk M.W./J-9775-2013	Verheul, Henk/0000-0001-5981-922X; 				BRIDGES JM, 1966, NATURE, V210, P1364, DOI 10.1038/2101364a0; BROCK TA, 1991, AM J PATHOL, V138, P213; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1996, NAT MED, V2, P67; Folkman Judah, 1997, P3075; Gasparini G, 1996, EUR J CANCER, V32A, P2485, DOI 10.1016/S0959-8049(96)00376-0; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; HEILMANN E, 1994, J CELL PHYSIOL, V161, P23, DOI 10.1002/jcp.1041610104; KAKKAR AK, 1995, BRIT J SURG, V82, P724, DOI 10.1002/bjs.1800820603; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Monreal M, 1998, THROMB HAEMOSTASIS, V79, P916; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pedersen LM, 1996, EUR RESPIR J, V9, P1826; SUN NCJ, 1979, AM J CLIN PATHOL, V71, P10; Verheul HMW, 1997, CLIN CANCER RES, V3, P2187; Zacharski LR, 1998, THROMB HAEMOSTASIS, V80, P10	21	292	300	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1775	1777		10.1016/S0140-6736(98)05095-8	http://dx.doi.org/10.1016/S0140-6736(98)05095-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848370				2022-12-28	WOS:000077246500045
J	Suzuki, Y; Yasunaga, T; Ohkura, R; Wakabayashi, T; Sutoh, K				Suzuki, Y; Yasunaga, T; Ohkura, R; Wakabayashi, T; Sutoh, K			Swing of the lever arm of a myosin motor at the isomerization and phosphate-release steps	NATURE			English	Article							GREEN-FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; X-RAY STRUCTURES; DICTYOSTELIUM-DISCOIDEUM; MUSCLE-CONTRACTION; BERYLLIUM FLUORIDE; ALUMINUM FLUORIDE; COMPLEXES; DOMAIN; SUBFRAGMENT-1	In muscle, the myosin head ('crossbridge') performs the 'working stroke: in which ATP is hydrolysed to generate the sliding of actin and myosin filaments.. The myosin head consists of a globular motor domain and a long lever-arm domain. The 'lever-arm hypothesis'(1-5) predicts that during the working stroke, the lever-arm domain tilts against the motor domain, which is bound to actin in a fixed orientation, To detect this working stroke in operation, we constructed fusion proteins by connecting Aequorea victoria green fluorescent protein and blue fluorescent protein(6-8) to the amino and carboxyl termini of the motor domain of myosin II of Dictyostelium discoideum, a soil amoeba, and measured the fluorescence resonance energy transfer between the two fluorescent proteins, We show here that the carboxy-terminal fluorophore swings at the isomerization step of the ATP hydrolysis cycle, and then swings back at the subsequent step in which inorganic phosphate is released, thereby mimicking the suing of the lever arm, The swing at the phosphate-release step may correspond to the working stroke, and the swing at the isomerization step to the recovery stroke.	Univ Tokyo, Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan; Univ Tokyo, Sch Sci, Dept Phys, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Sch Arts & Sci, Dept Life Sci, Komaba 3-8-1, Tokyo 153, Japan.	cksutoh@komaba.ecc.u-tkyo.ac.jp	Yasunaga, Takuo/C-8316-2009	Yasunaga, Takuo/0000-0002-2494-9603				BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuhlman PA, 1998, J MUSCLE RES CELL M, V19, P491, DOI 10.1023/A:1005304408812; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARUTA S, 1993, J BIOL CHEM, V268, P7093; MIKI M, 1991, BIOCHEMISTRY-US, V30, P10878, DOI 10.1021/bi00109a011; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; Yasunaga T, 1996, J STRUCT BIOL, V116, P155, DOI 10.1006/jsbi.1996.0025	26	156	157	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1998	396	6709					380	383		10.1038/24640	http://dx.doi.org/10.1038/24640			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845076				2022-12-28	WOS:000077204000053
J	Ni, M; Tepperman, JM; Quail, PH				Ni, M; Tepperman, JM; Quail, PH			PIF3, a phytochrome-interacting factor necessary for normal photoinduced signal transduction, is a novel basic helix-loop-helix protein	CELL			English	Article							ARABIDOPSIS-THALIANA; G-BOX; GENE-EXPRESSION; LIGHT; MUTANTS; FAMILY; SEQUENCES; PATHWAYS; PLANTS; BINDS	The mechanism by which the phytochrome (phy) photoreceptor family transduces informational light signals to photoresponsive genes is unknown. Using a yeast two-hybrid screen, we have identified a phytochrome-interacting factor, PIF3, a basic helix-loop-helix protein containing a PAS domain. PIF3 binds to wild-type C-terminal domains of both phyA and phyB, but less strongly to signaling-defective, missense mutant-containing domains. Expression of sense or antisense PIF3 sequences in transgenic Arabidopsis perturbs photoresponsiveness in a manner indicating that PIF3 functions in both phyA and phyB signaling pathways in vivo. PIF3 localized to the nucleus in transient transfection experiments, indicating a potential role in controlling gene expression. Together, the data suggest that phytochrome signaling to photoregulated genes includes a direct pathway involving physical interaction between the photoreceptor and a transcriptional regulator.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	quail@nature.berkeley.edu	Ni, Maria/GVT-4942-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47475] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Anderson SL, 1997, PLANT CELL, V9, P1727, DOI 10.1105/tpc.9.10.1727; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; dePater S, 1997, PLANT MOL BIOL, V34, P169, DOI 10.1023/A:1005898823105; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; Hirschfeld M, 1998, GENETICS, V149, P523; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Kawagoe Y, 1996, PLANT SCI, V116, P47, DOI 10.1016/0168-9452(96)04366-X; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; Mancinelli Alberto L., 1994, P211; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Pratt Lee H., 1994, P163; Quail Peter H., 1994, P71; Quail PH, 1997, BIOESSAYS, V19, P571, DOI 10.1002/bies.950190708; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; Schafer E, 1997, PLANT CELL ENVIRON, V20, P722, DOI 10.1046/j.1365-3040.1997.d01-98.x; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Smith H, 1997, PLANT CELL ENVIRON, V20, P840, DOI 10.1046/j.1365-3040.1997.d01-104.x; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Tobin Elaine M., 1994, Seminars in Cell Biology, V5, P335, DOI 10.1006/scel.1994.1040; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wei N, 1996, PLANT PHYSIOL, V112, P871, DOI 10.1104/pp.112.3.871; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757	53	546	600	10	91	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					657	667		10.1016/S0092-8674(00)81636-0	http://dx.doi.org/10.1016/S0092-8674(00)81636-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845368	Bronze			2022-12-28	WOS:000077253700013
J	Tesfaye, S; Achari, V; Yang, YC; Harding, S; Bowden, A; Vora, JP				Tesfaye, S; Achari, V; Yang, YC; Harding, S; Bowden, A; Vora, JP			Pregnant, vomiting, and going blind	LANCET			English	Article							ENCEPHALOPATHY		Royal Liverpool Hosp, Dept Med, Liverpool L7 8XP, Merseyside, England; Royal Liverpool Hosp, Dept Ophthalmol, Liverpool L7 8XP, Merseyside, England; Royal Liverpool Hosp, Dept Neurol, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	Tesfaye, S (corresponding author), Royal Hallamshire Hosp, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Harding, Simon/0000-0003-4676-1158; Tesfaye, Solomon/0000-0003-1190-1472				DAVIS RE, 1983, ADV CLIN CHEM, V23, P93, DOI 10.1016/S0065-2423(08)60399-6; Kril JJ, 1996, METAB BRAIN DIS, V11, P9, DOI 10.1007/BF02080928; OHKOSHI N, 1994, EUR NEUROL, V34, P177, DOI 10.1159/000117034; TIMMINGS PL, 1993, NEW ZEAL MED J, V106, P159; VICTOR M, 1971, WERNICKEKORSAKOFF SY	5	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1594	1594		10.1016/S0140-6736(98)08325-1	http://dx.doi.org/10.1016/S0140-6736(98)08325-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843106				2022-12-28	WOS:000076998900013
J	Druss, RG				Druss, RG			The magic white coat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Columbia P&S, New York, NY 10128 USA	Columbia University	Druss, RG (corresponding author), Columbia P&S, 180 E End Ave, New York, NY 10128 USA.								0	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					743	743		10.7326/0003-4819-129-9-199811010-00014	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841610				2022-12-28	WOS:000076785200012
J	Haselkorn, R				Haselkorn, R			Development - How Cyanobacteria count to 10	SCIENCE			English	Editorial Material							HETEROCYST DIFFERENTIATION; ANABAENA; PCC-7120		Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Haselkorn, R (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.							BUIKEMA W, UNPUB; BUIKEMA WJ, 1991, GENE DEV, V5, P321, DOI 10.1101/gad.5.2.321; FATH MJ, UNPUB; GOLDEN JW, 1985, NATURE, V314, P419, DOI 10.1038/314419a0; LIANG J, 1992, P NATL ACAD SCI USA, V89, P5655, DOI 10.1073/pnas.89.12.5655; McCartney B, 1997, J BACTERIOL, V179, P2314, DOI 10.1128/jb.179.7.2314-2318.1997; WEI TF, 1994, J BACTERIOL, V176, P4473, DOI 10.1128/JB.176.15.4473-4482.1994; Yoon HS, 1998, SCIENCE, V282, P935, DOI 10.1126/science.282.5390.935; ZHANG CC, 1993, P NATL ACAD SCI USA, V90, P11840, DOI 10.1073/pnas.90.24.11840; Zhou RB, 1998, P NATL ACAD SCI USA, V95, P4959, DOI 10.1073/pnas.95.9.4959	10	19	19	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					891	892		10.1126/science.282.5390.891	http://dx.doi.org/10.1126/science.282.5390.891			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9841437				2022-12-28	WOS:000076727300034
J	Goodman, NW				Goodman, NW			Clinical governance	BRITISH MEDICAL JOURNAL			English	Article									Southmead Gen Hosp, Dept Anaesthesia, Bristol BS10 5NB, Avon, England	Southmead Hospital	Goodman, NW (corresponding author), Southmead Gen Hosp, Dept Anaesthesia, Bristol BS10 5NB, Avon, England.							[Anonymous], 1993, OXFORD ENGLISH DICT; BAMJI A, 1993, BRIT MED J, V307, P944; Barber P, 1997, LANCET, V350, P974, DOI 10.1016/S0140-6736(05)64065-2; BYWATER M, 1998, OBSERVER        0719, P28; GOODMAN NW, 1996, ANAESTHESIA POINTS W, V29, P33; MILLER P, 1993, BRIT MED J, V306, P156, DOI 10.1136/bmj.306.6871.156; OWEN AV, 1995, BRIT MED J, V310, P648; Power M., 1997, AUDIT SOC RITUALS VE, P183; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61	10	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1725	1727		10.1136/bmj.317.7174.1725	http://dx.doi.org/10.1136/bmj.317.7174.1725			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857149	Green Published			2022-12-28	WOS:000077742300039
J	Zeman, A				Zeman, A			The consciousness of sight	BRITISH MEDICAL JOURNAL			English	Review							MONKEYS; CORTEX		Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Zeman, A (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Zeman, Adam/0000-0003-4875-658X				Chalmers D., 1996, REALITY VIRTUAL WORL; COWEY A, 1995, NATURE, V373, P247, DOI 10.1038/373247a0; DOUGLAS RJ, 1993, BAILLIERE CLIN NEUR, V2, P206; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; Milner A. D., 1995, VISUAL BRAIN ACTION; Morris JS, 1998, NATURE, V393, P467, DOI 10.1038/30976; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; WEIKRANTZ L, 1997, CONSCIOUSNESS LOST F; ZEKI S, 1993, P ROY SOC B-BIOL SCI, V252, P215, DOI 10.1098/rspb.1993.0068; Zeki S., 1993, VISION BRAIN; Zeman AZJ, 1997, J NEUROL NEUROSUR PS, V62, P549, DOI 10.1136/jnnp.62.6.549	11	1	1	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1696	1697		10.1136/bmj.317.7174.1696	http://dx.doi.org/10.1136/bmj.317.7174.1696			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857131	Green Published			2022-12-28	WOS:000077742300018
J	Boyes, J; Byfield, P; Nakatani, Y; Ogryzko, V				Boyes, J; Byfield, P; Nakatani, Y; Ogryzko, V			Regulation of activity of the transcription factor GATA-1 by acetylation	NATURE			English	Article							DNA-BINDING DOMAIN; HISTONE ACETYLTRANSFERASE; MEGAKARYOCYTIC DIFFERENTIATION; ZINC-FINGER; ACTIVATION; CHROMATIN; COMPLEX; CGATA-1; PROTEIN; CELLS	Modification of histones, DNA-binding proteins found in chromatin, by addition of acetyl groups occurs to a greater degree when the histones are associated with transcriptionally active DNA(1,2). A breakthrough in understanding how this acetylation is mediated was the discovery that various transcriptional co-activator proteins have intrinsic histone acetyltransferase activity (for example, Gcn5p (ref. 3), PCAF(4), TAF(II)250 (ref. 5) and p300/ CBp(6,7)). These acetyltransferases also modify certain transcription factors (TFIIE beta, TFIIF, EKLF and p53 (refs 8-10)). GATA-1 is an important transcription factor in the haematopoietic lineage(11) and is essential for terminal differentiation of erythrocytes and megakaryocytes(12,13). It is associated in vivo with the acetyltransferase p300/CBP14, sere we report that GATA-1 is acetylated in vitro by p300. This significantly increases the amount of GATA-1 bound to DNA and alters the mobility of GATA-1-DNA complexes, suggestive of a conformational change in GATA-1. GATA-1 is also acetylated in vivo and acetylation directly stimulates GATA-1-dependent transcription. Mutagenesis of important acetylated residues shows that there is a relationship between the acetylation and in viva function of GATA-1. We propose that acetylation of transcription factors can alter interactions between these factors and DNA and among different transcription factors, and is an integral part of transcription and differentiation processes.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Boyes, J (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389; Boyes, Joan/0000-0002-8705-9827				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Briegel K, 1996, DEVELOPMENT, V122, P3839; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V68, P597; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pikaart MJ, 1996, PROTEIN EXPRES PURIF, V8, P469, DOI 10.1006/prep.1996.0126; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	27	614	633	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1998	396	6711					594	598		10.1038/25166	http://dx.doi.org/10.1038/25166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859997				2022-12-28	WOS:000077466800063
J	Peters, JW; Lanzilotta, WN; Lemon, BJ; Seefeldt, LC				Peters, JW; Lanzilotta, WN; Lemon, BJ; Seefeldt, LC			X-ray crystal structure of the Fe-only hydrogenase (Cpl) from Clostridium pasteurianum to 1.8 angstrom resolution	SCIENCE			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; IRON-SULFUR CLUSTERS; RESONANCE RAMAN; CARBON-MONOXIDE; ACTIVE-SITE; PROTEIN; GENE; PROGRAM; SPECTROSCOPY; ACTIVATION	A three-dimensional structure for the monomeric iron-containing hydrogenase (Cpl) from Clostridium pasteurianum was determined to 1.8 angstrom resolution by x-ray crystallography using multiwavelength anomalous dispersion (MAD) phasing. Cpl, an enzyme that catalyzes the two-electron reduction of two protons to yield dihydrogen, was found to contain 20 gram atoms of iron per mole of protein, arranged into five distinct [Fe-S] clusters. The probable active-site cluster, previously termed the H-cluster, was found to be an unexpected arrangement of six iron atoms existing as a [4Fe-4S] cubane subcluster covalently bridged by a cysteinate thiol to a [2Fe] subcluster. The iron atoms of the [2Fe] subcluster both exist with an octahedral coordination geometry and are bridged to each other by three non-protein atoms, assigned as two sulfide atoms and one carbonyl or cyanide molecule. This structure provides insights into the mechanism of biological hydrogen activation and has broader implications for [Fe-S] cluster structure and function in biological systems.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Peters, JW (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	petersj@cc.usu.edu		Peters, John/0000-0001-9117-9568				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ADAMS MWW, 1987, J BIOL CHEM, V262, P15054; ADAMS MWW, 1989, P NATL ACAD SCI USA, V86, P4932, DOI 10.1073/pnas.86.13.4932; ADAMS MWW, 1980, BIOCHIM BIOPHYS ACTA, V594, P105, DOI 10.1016/0304-4173(80)90007-5; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BRUNGER AT, 1987, SCIENCE, V235, P258; CHEN JS, 1974, BIOCHIM BIOPHYS ACTA, V371, P283, DOI 10.1016/0005-2795(74)90025-7; Cotton F. A., 1988, ADV INORGANIC CHEM; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; FERNANDEZ VM, 1983, ANAL BIOCHEM, V130, P54, DOI 10.1016/0003-2697(83)90648-6; FontecillaCamps JC, 1996, J BIOL INORG CHEM, V1, P91, DOI 10.1007/s007750050027; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gorwa MF, 1996, J BACTERIOL, V178, P2668, DOI 10.1128/jb.178.9.2668-2675.1996; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaasjager VE, 1998, ANGEW CHEM INT EDIT, V37, P1668, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1668::AID-ANIE1668>3.0.CO;2-J; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KOWAL AT, 1989, J BIOL CHEM, V264, P4342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, CCP4 ESF EACMB NEWSL, P26; LESLIE AGW, 1994, ACTA CRYSTALLOGR D, V50, P760; MACOR KA, 1987, J BIOL CHEM, V262, P9945; MALKI S, 1995, J BACTERIOL, V177, P2628, DOI 10.1128/jb.177.10.2628-2636.1995; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER J, 1991, BIOCHEMISTRY-US, V30, P9697, DOI 10.1021/bi00104a018; Moulis JM, 1996, PROTEIN SCI, V5, P1765, DOI 10.1002/pro.5560050902; OTWINOWSKI Z, 1991, DATA COLLECTION PROC, P56; PETERS JP, UNPUB; PRYZBYLA AE, 1992, FEMS MICROBIOL REV, V88, P109; SANTANGELO JD, 1995, MICROBIOL-UK, V141, P171, DOI 10.1099/00221287-141-1-171; Stephens PJ, 1996, CHEM REV, V96, P2491, DOI 10.1021/cr950045w; STOKKERMANS J, 1989, FEMS MICROBIOL LETT, V58, P217; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; THAUER RK, 1974, EUR J BIOCHEM, V42, P447, DOI 10.1111/j.1432-1033.1974.tb03358.x; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; THOMANN H, 1991, J AM CHEM SOC, V113, P7044, DOI 10.1021/ja00018a057; VanderSpek TM, 1996, EUR J BIOCHEM, V237, P629; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g; VOORDOUW G, 1989, J BACTERIOL, V171, P3881, DOI 10.1128/jb.171.7.3881-3889.1989; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Xia JQ, 1997, J AM CHEM SOC, V119, P8301, DOI 10.1021/ja971025+	51	1675	1704	8	291	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1853	1858		10.1126/science.282.5395.1853	http://dx.doi.org/10.1126/science.282.5395.1853			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836629				2022-12-28	WOS:000077338100039
J	Craddock, N; Lendon, C				Craddock, N; Lendon, C			New susceptibility gene for Alzheimer's disease on chromosome 12?	LANCET			English	Editorial Material							APOLIPOPROTEIN-E; ASSOCIATION		Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Neurosci, Birmingham B15 2QZ, W Midlands, England	University of Birmingham	Craddock, N (corresponding author), Univ Birmingham, Queen Elizabeth Psychiat Hosp, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.							Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1720	1721		10.1016/S0140-6736(98)00075-0	http://dx.doi.org/10.1016/S0140-6736(98)00075-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848343				2022-12-28	WOS:000077246500002
J	Dobbie, I; Linari, M; Piazzesi, G; Reconditi, M; Koubassova, N; Ferenczi, MA; Lombardi, V; Irving, M				Dobbie, I; Linari, M; Piazzesi, G; Reconditi, M; Koubassova, N; Ferenczi, MA; Lombardi, V; Irving, M			Elastic bending and active tilting of myosin heads during muscle contraction	NATURE			English	Article							X-RAY-DIFFRACTION; RABBIT SKELETAL-MUSCLE; MUSCULAR-CONTRACTION; FORCE GENERATION; STRIATED-MUSCLE; THIN-FILAMENTS; FIBERS; EXTENSIBILITY; STIFFNESS; KINETICS	Muscle contraction is driven by a change in shape of the myosin head reg;ion that links the actin and myosin filaments(1,2). Tilting of the light-chain domain of the head with respect to its actin-bound catalytic domain is thought to be coupled to the ATPase cycle(3-6). Here, using X-ray diffraction and mechanical data from isolated muscle fibres, we characterize an elastic bending of the heads that is independent of the presence of ATP. Together, the tilting and bending motions can explain force generation in isometric muscle, when filament sliding is prevented. The elastic strain in the head is 2.0-2.7 nm under these conditions, contributing 40-50% of the compliance of the muscle sarcomere. We present an atomic model for changes in head conformation that accurately reproduces the changes in the X-ray diffraction pattern seen when rapid length changes are applied to muscle fibres both in active contraction and in the absence of ATP. The model predictions are relatively independent of which parts of the head are assumed to bend or tilt, but depend critically on the measured values of filament sliding and elastic strain.	Univ London Kings Coll, Randall Inst, London WC2B 5RL, England; Univ Florence, Dipartimento Sci Fisiol, I-50134 Florence, Italy; Natl Inst Med Res, London NW7 1AA, England; Moscow MV Lomonosov State Univ, Inst Mech, Moscow 119899, Russia	University of London; King's College London; University of Florence; MRC National Institute for Medical Research; Lomonosov Moscow State University	Irving, M (corresponding author), Univ London Kings Coll, Randall Inst, London WC2B 5RL, England.		Koubassova, Natalia/AAI-6490-2021; Ferenczi, Michael/F-9510-2015	Koubassova, Natalia/0000-0002-0238-4920; Ferenczi, Michael/0000-0002-0349-331X; RECONDITI, MASSIMO/0000-0001-5065-924X; LINARI, MARCO/0000-0001-6512-4897; Dobbie, Ian/0000-0002-5531-5865				Bershitsky S, 1996, BIOPHYS J, V71, P1462, DOI 10.1016/S0006-3495(96)79347-5; CECCHI G, 1982, SCIENCE, V217, P70, DOI 10.1126/science.6979780; COOKE R, 1980, BIOCHEMISTRY-US, V19, P2265, DOI 10.1021/bi00551a042; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; Irving M, 1997, NEWS PHYSIOL SCI, V12, P249; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; LOVELL SJ, 1981, NATURE, V293, P664, DOI 10.1038/293664a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; Piazzesi G, 1997, J PHYSIOL-LONDON, V498, P3, DOI 10.1113/jphysiol.1997.sp021837; Piazzesi G., 1995, Biophysical Journal, V68, P92; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; Yagi N, 1996, J SYNCHROTRON RADIAT, V3, P305, DOI 10.1107/S0909049596008928	30	128	131	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					383	387		10.1038/24647	http://dx.doi.org/10.1038/24647			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845077	Green Submitted			2022-12-28	WOS:000077204000054
J	Oro, AE; Scott, MP				Oro, AE; Scott, MP			Splitting hairs: Dissecting roles of signaling systems in epidermal development	CELL			English	Review							HEDGEHOG		Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Oro, AE (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.							CHIANG C, 1998, IN PRESS DEV BIOL; Chuong C-M, 1998, MOL BASIS EPITHELIAL; COOPER PH, 1983, J AM ACAD DERMATOL, V8, P639, DOI 10.1016/S0190-9622(83)70071-X; Crowe R, 1998, DEVELOPMENT, V125, P767; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; MILLAR S, 1998, IN PRESS DEV BIOL; Morgan BA, 1998, DEV BIOL, V201, P1, DOI 10.1006/dbio.1998.8969; Noramly S, 1998, DEVELOPMENT, V125, P3775; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Song HK, 1996, P NATL ACAD SCI USA, V93, P10246, DOI 10.1073/pnas.93.19.10246; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Viallet JP, 1998, MECH DEVELOP, V72, P159, DOI 10.1016/S0925-4773(98)00027-6; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; ZHOU P, 1995, GENE DEV, V9, P570	20	130	144	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					575	578		10.1016/S0092-8674(00)81624-4	http://dx.doi.org/10.1016/S0092-8674(00)81624-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845357	Bronze			2022-12-28	WOS:000077253700001
J	Pellizzoni, L; Kataoka, N; Charroux, B; Dreyfuss, G				Pellizzoni, L; Kataoka, N; Charroux, B; Dreyfuss, G			A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing	CELL			English	Article							MOTOR-NEURON GENE; SMALL NUCLEAR RIBONUCLEOPROTEIN; WERDNIG-HOFFMANN DISEASE; MESSENGER-RNA PRECURSORS; HELICASE-LIKE PROTEIN; COILED BODY; MOLECULAR ANALYSIS; MAMMALIAN NUCLEI; SNRNP PROTEINS; SURVIVAL	Spinal muscular atrophy (SMA) is a common motor neuron degenerative disease that results from reduced levels of, or mutations in, the Survival of Motor Neurons (SMN) protein. SMN is found in the cytoplasm and the nucleus where it is concentrated in gems. SMN interacts with spliceosomal snRNP proteins and is critical for snRNP assembly in the cytoplasm. We show that a dominant-negative mutant SMN (SMN Delta N27) causes a dramatic reorganization of snRNPs in the nucleus. Furthermore, SMN Delta N27 inhibits pre-mRNA splicing in vitro, while wild-type SMN stimulates splicing. SMN mutants found in SMA patients cannot stimulate splicing. These findings demonstrate that SMN plays a crucial role in the generation of the pre-mRNA splicing machinery and thus in mRNA biogenesis, and they link the function of SMN in this pathway to SMA.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013; Kataoka, Naoyuki/H-6298-2019	Dreyfuss, Gideon/0000-0001-8129-8774; Kataoka, Naoyuki/0000-0002-4498-7420; Pellizzoni, Livio/0000-0002-9168-5628				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHANG JG, 1995, AM J HUM GENET, V57, P1503; COBBEN JM, 1995, AM J HUM GENET, V57, P805; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1988, NUCLEIC ACIDS RES, V16, P9415, DOI 10.1093/nar/16.20.9415; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mattaj IW, 1998, CURR BIOL, V8, pR93, DOI 10.1016/S0960-9822(98)70055-7; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJIW, 1988, STRUCTURE FUNCTION M, P100; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; Ohno M, 1996, GENE DEV, V10, P997, DOI 10.1101/gad.10.8.997; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PADGETT RA, 1983, CELL, V35, P101, DOI 10.1016/0092-8674(83)90212-X; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; ROTH MB, 1995, CURR OPIN CELL BIOL, V7, P325, DOI 10.1016/0955-0674(95)80086-7; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	58	457	468	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					615	624		10.1016/S0092-8674(00)81632-3	http://dx.doi.org/10.1016/S0092-8674(00)81632-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845364	hybrid			2022-12-28	WOS:000077253700009
J	Salecker, I; Clandinin, TR; Zipursky, SL				Salecker, I; Clandinin, TR; Zipursky, SL			Hedgehog and spitz: Making a match between photoreceptor axons and their targets	CELL			English	Review							VISUAL-SYSTEM; DROSOPHILA; NEUROGENESIS		Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Salecker, I (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.		Salecker, Iris/V-1228-2018	Salecker, Iris/0000-0003-3775-7763; Zipursky, Stephen/0000-0001-5630-7181				DAVIS RE, 1990, BRAIN RES, V512, P46, DOI 10.1016/0006-8993(90)91168-G; Freeman M, 1997, DEVELOPMENT, V124, P261; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GONG QH, 1995, NEURON, V14, P91, DOI 10.1016/0896-6273(95)90243-0; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; Huang Z, 1998, CELL, V95, P693, DOI 10.1016/S0092-8674(00)81639-6; Huang Z, 1998, DEVELOPMENT, V125, P3753; Jensen AM, 1997, DEVELOPMENT, V124, P363; Meinertzhagen I.A., 1993, DEV DROSOPHILA MELAN; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SELLECK SB, 1992, NATURE, V355, P253, DOI 10.1038/355253a0; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WOLFF T, 1997, MOL CELLULAR APPROAC, P474	16	12	12	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					587	590		10.1016/S0092-8674(00)81627-X	http://dx.doi.org/10.1016/S0092-8674(00)81627-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845360	Bronze			2022-12-28	WOS:000077253700004
J	Bishai, WR; Graham, NMH; Harrington, S; Pope, DS; Hooper, N; Astemborski, J; Sheely, L; Vlahov, D; Glass, GE; Chaisson, RE				Bishai, WR; Graham, NMH; Harrington, S; Pope, DS; Hooper, N; Astemborski, J; Sheely, L; Vlahov, D; Glass, GE; Chaisson, RE			Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; POPULATION; IDENTIFICATION; COMMUNITY; PTBN12	Context.-Recent studies suggest that one third of tuberculosis cases in urban areas result from recent transmission. Improved tuberculosis control measures such as uniform implementation of directly observed therapy might reduce the proportion of cases resulting from recent transmission. Objective.-To determine patterns of tuberculosis transmission in Baltimore, Md, after 15 years of community-based directly observed therapy. Design.-A 30-month (January 1994-June 1996), prospective, city-wide study of all cases of tuberculosis using traditional contact investigations, geographic information systems data, and molecular epidemiologic comparison of Mycobacterium tuberculosis isolates with 2 DNA probes. Patients.-One hundred eighty-two patients with culture-positive tuberculosis. Main Outcome Measures.-Proportion of disease defined as recently transmitted based on epidemiologic linkage by traditional contact tracing and molecular, linkage by DNA fingerprint analysis of isolates; geographic foci of transmission based on linkage of residences by geographic information systems data. Results.-Of the 182 patients who had isolates of M tuberculosis available, 84 (46%) showed molecular clustering with 58 (32%) defined as being recently transmitted. Only 20 (24%) of 84 cases with clustered DNA fingerprints had epidemiologic evidence of recent contact. Geographic analysis showed significant spatial aggregation of the 20 clustered cases with epidemiologic links (P<.001), occurring in areas of low socioeconomic status and high drug use, The 64 cases with clustered DNA fingerprints but without epidemiologic links shared common risk factors and demographic features with the 20 clustered patients who did have epidemiologic links. Conclusions.-Recently transmitted tuberculosis accounts for a high proportion of tuberculosis cases in Baltimore. Recently transmitted cases occur in geographically distinct areas of Baltimore, and location-based control efforts may be more effective than contact tracing for the early identification of cases.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Baltimore City Dept Hlth, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene	Bishai, WR (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	wbishai@jhsph.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036973, R29AI036973, R01AI040605] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36973, AI40605] Funding Source: Medline; NIDA NIH HHS [DA07061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Altman D.G., 1991, PRACTICAL STAT MED R; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Bishai WR, 1996, NEW ENGL J MED, V334, P1573, DOI 10.1056/NEJM199606133342404; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Braden CR, 1997, INFECT DIS CLIN PRAC, V6, P89, DOI 10.1097/00019048-199702000-00004; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P253; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Chaulk CP, 1997, CLIN CHEST MED, V18, P149, DOI 10.1016/S0272-5231(05)70364-6; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; CUZICK J, 1990, J ROY STAT SOC B MET, V52, P73; Etkind S, 1991, Semin Respir Infect, V6, P273; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Fujiwara PI, 1997, CLIN CHEST MED, V18, P135, DOI 10.1016/S0272-5231(05)70363-4; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; HERMANS PWM, 1995, J INFECT DIS, V171, P1504, DOI 10.1093/infdis/171.6.1504; Michele TM, 1997, JAMA-J AM MED ASSOC, V278, P1093, DOI 10.1001/jama.278.13.1093; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064, DOI 10.1128/JCM.33.5.1064-1069.1995	33	130	135	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1679	1684		10.1001/jama.280.19.1679	http://dx.doi.org/10.1001/jama.280.19.1679			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831999	Bronze			2022-12-28	WOS:000076980700033
J	Go, AS; Barron, HV; Rundle, AC; Ornato, JP; Avins, AL				Go, AS; Barron, HV; Rundle, AC; Ornato, JP; Avins, AL		Natl Registry Myocardial Infarction 2 Investiga	Bundle-branch block and in-hospital mortality in acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; bundle-branch block; mortality; thrombolytic therapy; comorbidity	LONG-TERM SURVIVAL; CLINICAL SIGNIFICANCE; PROGNOSTIC-SIGNIFICANCE; THROMBOLYTIC THERAPY; CONDUCTION DEFECTS	Background: Left bundle-branch block (BBB) is considered an important predictor of poor outcome in patients with acute myocardial infarction, but the consequences of right BBB are not well understood. Objectives: To 1) estimate the prevalence of left and right BBB in patients with myocardial infarction; 2) compare the clinical characteristics of and treatments received by patients with left, right, or no BBB; and 3) determine the independent association of left BBB and right BBB with in-hospital death. Design: Retrospective cohort study. Setting: Multicenter registry of 1571 U.S. hospitals. Patients: 297 832 patients with acute myocardial infarction who had left, right, or no BBB on initial electrocardiography. Measurements: Presence and type of BBB, clinical characteristics of patients, therapies given, and in-hospital death. Results: Patients with left BBB (n = 19 967; 6.7%) or right BBB (n = 18 354; 6.2%) were older and had more comorbid illness and congestive heart failure than patients with no BBB. Among patients for whom thrombolytic therapy was clearly indicated, fewer patients with left or right BBB (16.6% and 32.0%, respectively) than patients with no BBB (66.5%) received this therapy (P < 0.001). Fewer patients with left or right BBB (60.6% and 67.3%, respectively) than patients with no BBB (75.6%) received aspirin within the first 24 hours (P < 0.001), and fewer patients with left or right BBB (23.9% and 31.8%, respectively) than patients with no BBB (40.4%) received p-blockers within the first 24 hours (P < 0.001). Unadjusted in-hospital mortality rates were almost twice as high for patients with left or right BBB (22.6% and 23.0%, respectively) as for patients with no BBB (13.1%) (P < 0.001). Compared with no BBB and no ST-segment elevation, left BBB was associated with a 34% increase (odds ratio, 1.34 [95% Cl, 1.28 to 1.39]) and right BBB was associated with a 64% increase (odds ratio, 1.64 [Cl, 1.57 to 1.71]) in the risk for in-hospital death, after adjustment for potential confounders. Conclusions: In patients with acute myocardial infarction, prevalences of right and left BBB are similar. Patients with BBB have more comorbid conditions, are less likely to receive therapy, and have an increased risk for in-hospital death compared with patients with no BBB. Compared with left BBB, right BBB seems to be a stronger independent predictor of in-hospital death.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Genentech Inc, San Francisco, CA 94080 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Kaiser Permanente; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Roche Holding; Genentech; Virginia Commonwealth University	Go, AS (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3503 Broadway St,12th Floor, Oakland, CA 94611 USA.	axg@dor.kaiser.org	Go, Alan S./AAE-7745-2019					APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BAUER GE, 1965, BRIT HEART J, V27, P724; BECKER AE, 1978, BRIT HEART J, V40, P773; BENNETT JC, 1996, TXB MED; Braunwald E., 1997, HEART DIS TXB CARDIO, V5th; DUBOIS C, 1988, CLIN CARDIOL, V11, P292, DOI 10.1002/clc.4960110504; Every NR, 1998, J AM COLL CARDIOL, V31, p173A, DOI 10.1016/S0735-1097(97)84464-6; GANN D, 1975, CHEST, V67, P298, DOI 10.1378/chest.67.3.298; GODMAN MJ, 1970, NEW ENGL J MED, V282, P237, DOI 10.1056/NEJM197001292820502; GOLDBERGER AL, 1990, CLIN ELECTROCARDIOGR; GOULD L, 1972, J AMER MED ASSOC, V219, P502, DOI 10.1001/jama.219.4.502; GOULD L, 1973, JAMA-J AM MED ASSOC, V225, P625, DOI 10.1001/jama.225.6.625; HAUER RNW, 1982, AM J CARDIOL, V49, P1581, DOI 10.1016/0002-9149(82)90231-4; HINDMAN MC, 1978, CIRCULATION, V58, P689, DOI 10.1161/01.CIR.58.4.689; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; HOD H, 1995, EUR HEART J, V16, P471, DOI 10.1093/oxfordjournals.eurheartj.a060938; HOLLANDER G, 1983, AM HEART J, V105, P738, DOI 10.1016/0002-8703(83)90234-X; ISSELBACHER KJ, 1994, HARRISONS PRINCIPLES; JONES ME, 1977, AM HEART J, V94, P163, DOI 10.1016/S0002-8703(77)80275-5; KONES RJ, 1980, ACTA CARDIOL, V35, P469; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MelgarejoMoreno A, 1997, CIRCULATION, V96, P1139, DOI 10.1161/01.CIR.96.4.1139; Newby KH, 1996, CIRCULATION, V94, P2424, DOI 10.1161/01.CIR.94.10.2424; NIMETZ AA, 1975, AM HEART J, V90, P439, DOI 10.1016/0002-8703(75)90423-8; NORRIS RM, 1970, AM HEART J, V79, P728, DOI 10.1016/0002-8703(70)90359-5; OKABE M, 1993, JPN HEART J, V34, P121; OTTERSTAD JE, 1978, ACTA MED SCAND, V203, P529; RICOU F, 1991, J AM COLL CARDIOL, V17, P858, DOI 10.1016/0735-1097(91)90865-7; RICOU F, 1991, AM J CARDIOL, V67, P1143, DOI 10.1016/0002-9149(91)90882-L; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SCHEIDT S, 1972, J AMER MED ASSOC, V222, P919, DOI 10.1001/jama.222.8.919; Sgarbossa EB, 1998, J AM COLL CARDIOL, V31, P105, DOI 10.1016/S0735-1097(97)00446-4; Stein JJ, 1994, INTERNAL MED; SUAREZ G, 1995, CHEST, V108, P83, DOI 10.1378/chest.108.1.83; TIERNEY L, 1998, CURRENT MED DIAGNOSI	38	123	124	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					690	+		10.7326/0003-4819-129-9-199811010-00003	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841600				2022-12-28	WOS:000076785200002
J	Berendsen, HJC				Berendsen, HJC			Protein folding - A glimpse of the holy grail?	SCIENCE			English	Editorial Material									Univ Groningen, Dept Biophys Chem, NL-9700 AB Groningen, Netherlands; Univ Groningen, BIOSON Res Inst, NL-9700 AB Groningen, Netherlands	University of Groningen; University of Groningen	Berendsen, HJC (corresponding author), Univ Groningen, Dept Biophys Chem, NL-9700 AB Groningen, Netherlands.	berendsen@chem.rug.nl						Brooks CL, 1998, CURR OPIN STRUC BIOL, V8, P222, DOI 10.1016/S0959-440X(98)80043-2; *CASP, 1997, PROTEINS S, V1; Crippen GM, 1998, PROTEINS, V32, P425, DOI 10.1002/(SICI)1097-0134(19980901)32:4<425::AID-PROT3>3.0.CO;2-F; Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; MATTHEWS J, 1981, GRAIL QUEST ETERNAL, P72; *US RES DEV PROGR, 1993, GRAND CHALL 1993 HIG; vanderSpoel D, 1996, J BIOMOL NMR, V8, P229, DOI 10.1007/BF00410322; Venclovas C, 1997, PROTEINS, P7	9	44	429	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					642	643		10.1126/science.282.5389.642	http://dx.doi.org/10.1126/science.282.5389.642			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841417				2022-12-28	WOS:000076607500031
J	McColl, K; Murray, L; El-Omar, E; Dickson, A; El-Nujumi, A; Wirz, A; Kelman, A; Penny, C; Knill-Jones, R; Hilditch, T				McColl, K; Murray, L; El-Omar, E; Dickson, A; El-Nujumi, A; Wirz, A; Kelman, A; Penny, C; Knill-Jones, R; Hilditch, T			Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DUODENAL-ULCER; PEPTIC-ULCER; FUNCTIONAL DYSPEPSIA; DISEASE	Background The eradication of Helicobacter pylori infection is beneficial in patients with gastric or duodenal ulcers. The value of eradicating the infection in patients with dyspepsia and no evidence of ulcer disease is not known. Methods We performed a randomized, placebo-controlled trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin), and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms of dyspepsia in patients with H. pylori infection but no evidence of ulcer disease on upper gastrointestinal endoscopy. Symptoms were assessed with the Glasgow Dyspepsia Severity Score, with resolution of symptoms defined as a score of 0 or 1 in the preceding six months (maximal score, 20). One year later the patients were assessed to determine the frequency of the resolution of symptoms. Results One month after the completion of treatment, 132 of 150 patients (88 percent) in the group assigned to receive omeprazole and antibiotics had a negative test for H. pylori, as compared with 7 of 152 (5 percent) in the group assigned to receive omeprazole alone. One year later, dyspepsia had resolved in 33 of 154 patients (21 percent) in the group given omeprazole and antibiotics, as compared with 11 of 154 (7 percent) in the group given omeprazole alone (95 percent confidence interval for the difference, 7 to 22 percent; P<0.001). Among the patients in the group given omeprazole and antibiotics, the symptoms resolved in 26 of the 98 patients (27 percent) who had had symptoms for five years or less, as compared with 7 of the 56 patients (12 percent) who had had symptoms for more than five years (P = 0.03). Conclusions In patients with H. pylori infection and nonulcer, or functional, dyspepsia, treatment with omeprazole and antibiotics to eradicate the infection is more likely to resolve symptoms than treatment with omeprazole alone. (N Engl J Med 1998;339:1869-74.) (C) 1998, Massachusetts Medical Society.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Clin Phys, Glasgow G11 6NT, Lanark, Scotland; Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	McColl, K (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland.		El-Omar, Emad/AAT-7780-2021	El-Omar, Emad/0000-0002-0011-3924				Armstrong D, 1996, SCAND J GASTROENTERO, V31, P38, DOI 10.3109/00365529609094532; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; COLINJONES DG, 1988, LANCET, V1, P576; COVER TL, 1995, J CLIN MICROBIOL, V33, P1496, DOI 10.1128/JCM.33.6.1496-1500.1995; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; ElOmar EM, 1996, EUR J GASTROEN HEPAT, V8, P967, DOI 10.1097/00042737-199610000-00006; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Gillen D, 1998, GASTROENTEROLOGY, V114, P50, DOI 10.1016/S0016-5085(98)70632-8; Gilvarry J, 1997, SCAND J GASTROENTERO, V32, P535, DOI 10.3109/00365529709025095; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; JEBBINK HJA, 1993, SCAND J GASTROENTERO, V28, P8, DOI 10.3109/00365529309101568; JOHANNESSEN T, 1990, SCAND J GASTROENTERO, V25, P689, DOI 10.3109/00365529008997594; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; MARSHALL BJ, 1988, LANCET, V2, P1437; MATYSIAKBUDNIK T, 1992, IR J MED SCI S10, V161, P37; McColl KEL, 1997, GUT, V40, P302, DOI 10.1136/gut.40.3.302; McColl KEL, 1998, GUT, V42, P618, DOI 10.1136/gut.42.5.618; MEARIN F, 1991, GASTROENTEROLOGY, V101, P999, DOI 10.1016/0016-5085(91)90726-2; Megraud F, 1996, SCAND J GASTROENTERO, V31, P57, DOI 10.3109/00365529609094536; Nyren O, 1992, Pharmacoeconomics, V1, P312; ORIORDAN T, 1990, GUT, V31, P999, DOI 10.1136/gut.31.9.999; Phull PS, 1996, BRIT MED J, V312, P349, DOI 10.1136/bmj.312.7027.349; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; REILLY TG, 1995, ALIMENT PHARM THERAP, V9, P483; TALLEY NJ, 1992, GASTROENTEROLOGY, V102, P1259; Talley NJ, 1996, SCAND J GASTROENTERO, V31, P19, DOI 10.3109/00365529609094745; Talley NJ, 1997, GASTROENTEROLOGY, V113, pS67, DOI 10.1016/S0016-5085(97)80016-9; TALLEY NJ, 1995, ALIMENT PHARM THER, V9, P107; XIANG Z, 1993, EUR J CLIN MICROBIOL, V12, P739, DOI 10.1007/BF02098460	29	426	435	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1869	1874		10.1056/NEJM199812243392601	http://dx.doi.org/10.1056/NEJM199812243392601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862941				2022-12-28	WOS:000077696600001
J	Fergusson, E; Li, J; Taylor, B				Fergusson, E; Li, J; Taylor, B			Grandmothers' role in preventing unnecessary accident and emergency attendances: cohort study	BRITISH MEDICAL JOURNAL			English	Article							CARE; GRANDCHILDREN; MOTHERS		Royal Free Hosp, London NW3 2QG, England; UCL, Royal Free & Univ Coll Med Sch, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London	Fergusson, E (corresponding author), Maudsley Hosp & Inst Psychiat, Dept Child Psychiat, London SE5 8AZ, England.	E.Fergusson@iop.bpmf.ac.uk						ELLEN JM, 1995, PEDIATR EMERG CARE, V11, P223, DOI 10.1097/00006565-199508000-00008; Halfon N, 1996, PEDIATRICS, V98, P28; HORWITZ SM, 1985, MED CARE, V23, P946, DOI 10.1097/00005650-198508000-00002; TOMLIN AM, 1991, PSYCHOL AGING, V6, P182, DOI 10.1037/0882-7974.6.2.182; TOMLIN AM, 1989, PSYCHOL AGING, V4, P119, DOI 10.1037/0882-7974.4.1.119	5	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1685	1685		10.1136/bmj.317.7174.1685	http://dx.doi.org/10.1136/bmj.317.7174.1685			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	151VX	9857125	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000077742300012
J	Grunig, G; Warnock, M; Wakil, AE; Venkayya, R; Brombacher, F; Rennick, DM; Sheppard, D; Mohrs, M; Donaldson, DD; Locksley, RM; Corry, DB				Grunig, G; Warnock, M; Wakil, AE; Venkayya, R; Brombacher, F; Rennick, DM; Sheppard, D; Mohrs, M; Donaldson, DD; Locksley, RM; Corry, DB			Requirement for IL-13 independently of IL-4 in experimental asthma	SCIENCE			English	Article							AIRWAY HYPERREACTIVITY; T-LYMPHOCYTES; MICE; INTERLEUKIN-4; EXPRESSION; MODEL; LUNG; INFLAMMATION; EOSINOPHILIA; INDUCTION	The pathogenesis of asthma reflects, in part, the activity of T cell cytokines. Murine models support participation of interleukin-4 (IL-4) and the IL-4 receptor in asthma. Selective neutralization of IL-13, a cytokine related to IL-4 that also binds to the alpha chain of the IL-4 receptor, ameliorated the asthma phenotype, including airway hyperresponsiveness, eosinophil recruitment, and mucus overproduction. Administration of either IL-13 or IL-4 conferred an asthma-like phenotype to nonimmunized T cell-deficient mice by an IL-4 receptor alpha chain-dependent pathway. This pathway may underlie the genetic associations of asthma with both the human 5q31 Locus and the IL-4 receptor.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Lung Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Dept Transplantat, San Francisco, CA 94115 USA; Univ Cape Town, Groote Schuur Hosp, Dept Immunol, ZA-7700 Rondebosch, South Africa; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA; Genet Inst, Cambridge, MA 02140 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; University of Cape Town; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Corry, DB (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, T32HL007185, K08HL003344] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL003344, P50 HL056385, T32 HL007185, T32 HL07185] Funding Source: Medline; PHS HHS [03344, 47412] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bancroft AJ, 1998, J IMMUNOL, V160, P3453; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; COHN L, 1997, J EXP MED, V186, P1727; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GOLDSTEIN RA, 1994, ANN INTERN MED, V121, P698, DOI 10.7326/0003-4819-121-9-199411010-00011; GRUNIG G, UNPUB; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hogan SP, 1998, J IMMUNOL, V161, P1501; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; NobenTrauth N, 1996, TRANSGENIC RES, V5, P487, DOI 10.1007/BF01980214; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; Watanabe A, 1997, AM J RESP CELL MOL, V16, P69, DOI 10.1165/ajrcmb.16.1.8998081	32	1598	1696	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2261	2263		10.1126/science.282.5397.2261	http://dx.doi.org/10.1126/science.282.5397.2261			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856950	Green Accepted			2022-12-28	WOS:000077645800048
J	Cohn, JN; Goldstein, SO; Greenberg, BH; Lorell, BH; Bourge, RC; Jaski, BE; Gottlieb, SO; McGrew, F; DeMets, DL; White, BG				Cohn, JN; Goldstein, SO; Greenberg, BH; Lorell, BH; Bourge, RC; Jaski, BE; Gottlieb, SO; McGrew, F; DeMets, DL; White, BG		Vesnarinone Trial Investigators	A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INOTROPIC AGENT OPC-8212; DRUG	Background Vesnarinone, an inotropic drug, was shown in a short-term placebo-controlled trial to improve survival markedly in patients with severe heart failure when given at a dose of 60 mg per day, but there was a trend toward an adverse effect on survival when the dose was 120 mg per day. In a longer-term study, we evaluated the effects of daily doses of 60 mg or 30 mg of vesnarinone, as compared with placebo, on mortality and morbidity. Methods We enrolled 3833 patients who had symptoms of New York Heart Association class III or IV heart failure and a left ventricular ejection fraction of 30 percent or less despite optimal treatment. The mean follow-up was 286 days. Results There were significantly fewer deaths in the placebo group (242 deaths, or 18.9 percent) than in the 60-mg vesnarinone group (292 deaths, or 22.9 percent) and longer survival (P=0.02). The increase in mortality with vesnarinone was attributed to an increase in sudden death, presumed to be due to arrhythmia. The quality of life had improved significantly more in the 60-mg vesnarinone group than in the placebo group at 8 weeks (P<0.001) and 16 weeks (P=0.003) after randomization. Trends in mortality and in measures of the quality of life in the 30-mg vesnarinone group were similar to those in the 60-mg group but not significantly different from those in the placebo group. Agranulocytosis occurred in 1.2 percent of the patients given 60 mg of vesnarinone per day and 0.2 percent of those given 30 mg of vesnarinone. Conclusions Vesnarinone is associated with a dose-dependent increase in mortality among patients with severe heart failure, an increase that is probably related to an increase in deaths due to arrhythmia. A short-term benefit in terms of the quality of life raises issues about the appropriate therapeutic goal in treating heart failure. (N Engl J Med 1998;339:1810-6.) (C) 1998, Massachusetts Medical Society.	Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA; Henry Ford Hosp, Dept Med, Div Cardiovasc Med, Detroit, MI 48202 USA; Univ Calif San Diego, Ctr Med, Dept Cardiol, San Diego, CA 92103 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA USA; Univ Alabama Birmingham, Dept Med, Div Cardiol, Birmingham, AL 35294 USA; San Diego Cardiac Ctr Med Grp, San Diego, CA USA; Univ Maryland Hosp, Dept Med, Div Cardiol, Baltimore, MD 21201 USA; Stern Cardiovasc Ctr, Memphis, TN USA; Univ Wisconsin, Sch Med, Dept Stat & Biostat, Madison, WI USA; Clin Cardiovasc Res, Mclean, VA USA	University of Minnesota System; University of Minnesota Twin Cities; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Diego; Harvard University; Beth Israel Deaconess Medical Center; University of Alabama System; University of Alabama Birmingham; University System of Maryland; University of Maryland Baltimore; University of Wisconsin System; University of Wisconsin Madison	Cohn, JN (corresponding author), Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Box 508 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.							ASANOI H, 1989, CLIN CARDIOL, V12, P133, DOI 10.1002/clc.4960120304; ASANOI H, 1987, J AM COLL CARDIOL, V9, P865, DOI 10.1016/S0735-1097(87)80243-7; Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; Cavusoglu E, 1995, J Card Fail, V1, P249, DOI 10.1016/1071-9164(95)90030-6; CINTRON G, 1993, CIRCULATION, V87, P17; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; Cohn JN, 1999, J CARD FAIL, V5, P1, DOI 10.1016/S1071-9164(99)90017-9; FELDMAN AM, 1988, AM HEART J, V116, P771, DOI 10.1016/0002-8703(88)90336-5; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; JUST H, 1995, CIRCULATION S1, V92, P722; KUBO SH, 1988, CARDIOVASC DRUG THER, V2, P653, DOI 10.1007/BF00054205; LATHROP DA, 1985, EUR J PHARMACOL, V117, P391, DOI 10.1016/0014-2999(85)90016-0; MATSUMORI A, 1994, CIRCULATION, V89, P955, DOI 10.1161/01.CIR.89.3.955; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Rector T S, 1995, J Card Fail, V1, P201, DOI 10.1016/1071-9164(95)90025-X; RECTOR TS, 1993, AM J CARDIOL, V71, P1106, DOI 10.1016/0002-9149(93)90582-W; RYDEN L, 1990, LANCET, V336, P1; SASAYAMA S, 1986, Heart and Vessels, V2, P23, DOI 10.1007/BF02060240; *SEV HEART FAIL ST, 1990, LANCET, V336, P698; TAIRA N, 1984, ARZNEIMITTEL-FORSCH, V34-1, P347; YATANI A, 1989, J CARDIOVASC PHARM, V13, P812, DOI 10.1097/00005344-198906000-00002	22	460	478	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1810	1816		10.1056/NEJM199812173392503	http://dx.doi.org/10.1056/NEJM199812173392503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854116	Bronze			2022-12-28	WOS:000077545800003
J	Ronning, F; Kim, C; Feng, DL; Marshall, DS; Loeser, AG; Miller, LL; Eckstein, JN; Bozovic, I; Shen, ZX				Ronning, F; Kim, C; Feng, DL; Marshall, DS; Loeser, AG; Miller, LL; Eckstein, JN; Bozovic, I; Shen, ZX			Photoemission evidence for a remnant fermi surface and a d-wave-like dispersion in insulating Ca2CuO2Cl2	SCIENCE			English	Article							T-J MODEL; ANGLE-RESOLVED PHOTOEMISSION; QUASI-PARTICLE DISPERSION; COPPER-OXIDE SR2CUO2CL2; ELECTRONIC-STRUCTURE; QUANTUM ANTIFERROMAGNETS; CUPRATE SUPERCONDUCTORS; C SUPERCONDUCTORS; BAND-STRUCTURE; HUBBARD-MODEL	An angle-resolved photoemission study is reported on Ca2CUO2Cl2, a parent compound of high-T-c superconductors. Analysis of the electron occupation probability, n(k), from the spectra shows a steep drop in spectral intensity across a contour that is close to the Fermi surface predicted by the band calculation. This analysis reveals a Fermi surface remnant, even though Ca2CuO2Cl2 is a Mott insulator. The Lowest energy peak exhibits a dispersion with approximately the \cosk(x)a - cosk(y)a\ form along this remnant Fermi surface. Together with the data from Dy-doped Bi2Sr2CaCu2O8+delta, these results suggest that this d-wave-like dispersion of the insulator is the underlying reason for the pseudo gap in the underdoped regime.	Dept Phys, Stanford, CA 94305 USA; Dept Appl Phys, Stanford, CA 94305 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; Motorola Inc, Phoenix Corp Res Lab, Tempe, AZ 85284 USA; Iowa State Univ, Dept Phys, Ames, IA 50011 USA; Varian Associates Inc, Ginzton Res Ctr, Palo Alto, CA 94304 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Iowa State University	Shen, ZX (corresponding author), Dept Phys, Stanford, CA 94305 USA.	shen@ee.stanford.edu	Feng, Donglai/R-1615-2018	Feng, Donglai/0000-0001-9370-5357				ANDERSON PW, 1987, SCIENCE, V235, P1996; BATTLOG B, 1996, SCIENCE, V382, P20; Birgeneau R. J., 1989, Physical properties of high temperature superconductors I, P151; BULUT N, 1994, PHYS REV LETT, V73, P748, DOI 10.1103/PhysRevLett.73.748; CHAKRAVARTY S, 1988, PHYS REV LETT, V60, P1057, DOI 10.1103/PhysRevLett.60.1057; Chubukov AV, 1996, PHILOS MAG B, V74, P563; DAGATTO E, 1994, REV MOD PHYS, V66, P763; DESAMELO CAR, 1993, PHYS REV LETT, V71, P3202; DESSAU DS, 1993, PHYS REV LETT, V71, P2781, DOI 10.1103/PhysRevLett.71.2781; Dessau DS, 1998, PHYS REV LETT, V81, P192, DOI 10.1103/PhysRevLett.81.192; Ding H, 1997, PHYS REV LETT, V78, P2628, DOI 10.1103/PhysRevLett.78.2628; Ding H, 1996, NATURE, V382, P51, DOI 10.1038/382051a0; DONIACH S, 1990, PHYS REV B, V41, P6668, DOI 10.1103/PhysRevB.41.6668; EDER R, 1994, PHYS REV LETT, V72, P2816, DOI 10.1103/PhysRevLett.72.2816; Eder R, 1997, PHYS REV B, V55, pR3414, DOI 10.1103/PhysRevB.55.R3414; Eskes H., 1989, Mechanisms of High Temperature Superconductivity. Proceedings of the 2nd NEC Symposium, P20; GOODING RJ, 1994, PHYS REV B, V50, P12866, DOI 10.1103/PhysRevB.50.12866; HIROI Z, 1995, PHYSICA C, V255, P61; Hufner S., 1995, PHOTOELECTRON SPECTR; Janko B, 1997, PHYS REV B, V56, P11407, DOI 10.1103/PhysRevB.56.R11407; Kim C, 1998, PHYS REV LETT, V80, P4245, DOI 10.1103/PhysRevLett.80.4245; KIVELSON SA, 1987, PHYS REV B, V35, P8865, DOI 10.1103/PhysRevB.35.8865; KOTLIAR G, 1988, PHYS REV B, V38, P5142, DOI 10.1103/PhysRevB.38.5142; Kyung B, 1996, PHYS REV B, V54, P10125, DOI 10.1103/PhysRevB.54.10125; LaRosa S, 1997, PHYS REV B, V56, pR525, DOI 10.1103/PhysRevB.56.R525; Laughlin RB, 1997, PHYS REV LETT, V79, P1726, DOI 10.1103/PhysRevLett.79.1726; Lee PA, 1997, PHYS REV LETT, V78, P4111, DOI 10.1103/PhysRevLett.78.4111; Lee TK, 1997, PHYS REV B, V55, P5983, DOI 10.1103/PhysRevB.55.5983; Leung PW, 1997, PHYS REV B, V56, P6320, DOI 10.1103/PhysRevB.56.6320; Levi BG, 1996, PHYS TODAY, V49, P19, DOI 10.1063/1.2807756; LEVI BG, 1993, PHYS TODAY, V46, P17; Levi BG, 1996, PHYS TODAY, V49, P17, DOI 10.1063/1.881544; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Marshall DS, 1996, PHYS REV LETT, V76, P4841, DOI 10.1103/PhysRevLett.76.4841; MILLER LL, 1990, PHYS REV B, V41, P1921, DOI 10.1103/PhysRevB.41.1921; Millis AJ, 1995, J PHYS CHEM SOLIDS, V56, P1641, DOI 10.1016/0022-3697(95)00140-9; NAZARENKO A, 1995, PHYS REV B, V51, P8676, DOI 10.1103/PhysRevB.51.8676; NOVIKOV DL, 1995, PHYS REV B, V51, P6675, DOI 10.1103/PhysRevB.51.6675; PREUSS R, 1995, PHYS REV LETT, V75, P1344, DOI 10.1103/PhysRevLett.75.1344; RANDERIA M, 1995, PHYS REV LETT, V74, P4951, DOI 10.1103/PhysRevLett.74.4951; Schmalian J, 1998, PHYS REV LETT, V80, P3839, DOI 10.1103/PhysRevLett.80.3839; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; Shen ZX, 1997, PHYS REV LETT, V78, P1771, DOI 10.1103/PhysRevLett.78.1771; SUZUMURA Y, 1988, J PHYS SOC JPN, V57, P2768, DOI 10.1143/JPSJ.57.2768; TANAMOTO T, 1993, J PHYS SOC JPN, V62, P717, DOI 10.1143/JPSJ.62.717; TANAMOTO T, 1992, J PHYS SOC JPN, V61, P1886, DOI 10.1143/JPSJ.61.1886; TOHYAMA T, 1994, PHYS REV B, V49, P3596, DOI 10.1103/PhysRevB.49.3596; TOHYAMA T, COMMUNICATION; TRIVEDI N, 1995, PHYS REV LETT, V75, P312, DOI 10.1103/PhysRevLett.75.312; UEMURA Y, 1994, HIGH TC SUPERCONDUCT; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; WELLS BO, 1995, PHYS REV LETT, V74, P964, DOI 10.1103/PhysRevLett.74.964; White PJ, 1996, PHYS REV B, V54, P15669, DOI 10.1103/PhysRevB.54.R15669; Xiang T, 1996, PHYS REV B, V54, P12653, DOI 10.1103/PhysRevB.54.R12653; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089	57	247	248	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2067	2072		10.1126/science.282.5396.2067	http://dx.doi.org/10.1126/science.282.5396.2067			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851925	Green Submitted			2022-12-28	WOS:000077467100043
J	Welsh, J				Welsh, J			Truth and reconciliation ... and justice	LANCET			English	Editorial Material									Amnesty Int, Med Programme, London WC1X 8DJ, England		Welsh, J (corresponding author), Amnesty Int, Med Programme, 1 Easton St, London WC1X 8DJ, England.							*NOTR DAM CTR CIV, 1993, REP NAT TRUTH REC CO; *ROM STAT INT CRIM, 1998, ACONF1839 UN ROM STA; South African Truth and Reconciliation Commission, 1998, FIN REP, pV; STOVER E, 1987, OPEN SECRET TORTURE, P65; *UN, 1976, A31253 UN	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1852	1853		10.1016/S0140-6736(98)10541-X	http://dx.doi.org/10.1016/S0140-6736(98)10541-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851403				2022-12-28	WOS:000077337900049
J	Hong, M; Zhukareva, V; Vogelsberg-Ragaglia, V; Wszolek, Z; Reed, L; Miller, BI; Geschwind, DH; Bird, TD; McKeel, D; Goate, A; Morris, JC; Wilhelmsen, KC; Schellenberg, GD; Trojanowski, JQ; Lee, VMY				Hong, M; Zhukareva, V; Vogelsberg-Ragaglia, V; Wszolek, Z; Reed, L; Miller, BI; Geschwind, DH; Bird, TD; McKeel, D; Goate, A; Morris, JC; Wilhelmsen, KC; Schellenberg, GD; Trojanowski, JQ; Lee, VMY			Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; SR PROTEINS; PHOSPHORYLATION; LOCALIZATION; SEQUENCES; DEMENTIA	Tau proteins aggregate as cytoplasmic inclusions in a number of neurodegenerative diseases, including Alzheimer's disease and hereditary frontotemporal dementia and parkinsonism Linked to chromosome 17 (FTDP-17). Over 10 exonic and intronic mutations in the tau gene have been identified in about 20 FTDP-17 families. Analyses of soluble and insoluble tau proteins from brains of FTDP-17 patients indicated that different pathogenic mutations differentially altered distinct biochemical properties and stoichiometry of brain tau isoforms, Functional assays of recombinant tau proteins with different FTDP-17 missense mutations implicated all but one of these mutations in disease pathogenesis by reducing the ability of tau to bind microtubules and promote microtubule assembly.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Mayo Clin Jacksonville, Dept Neurol, Jacksonville, FL 32224 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Reed Neurol Res Ctr, Program Neurogenet, Dept Neurol, Los Angeles, CA 90095 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA; Ernest Gallo Clin & Res Ctr, San Francisco, CA 94110 USA; Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Pennsylvania; Pennsylvania Medicine; Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of Washington; University of Washington Seattle	Lee, VMY (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.		Morris, John C/A-1686-2012; Wszolek, Zbigniew K./AAB-1431-2019					ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; LAVIGUER A, 1993, SCIENCE, V260, P219; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1998, J NEUROPATH EXP NEUR, V57, P588, DOI 10.1097/00005072-199806000-00006; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	21	781	794	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1914	1917		10.1126/science.282.5395.1914	http://dx.doi.org/10.1126/science.282.5395.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836646				2022-12-28	WOS:000077338100056
J	Erbel, R; Haude, M; Hopp, HW; Franzen, D; Rupprecht, HJ; Heublein, B; Fischer, K; De Jaegere, P; Serruys, P; Rutsch, W; Probst, P				Erbel, R; Haude, M; Hopp, HW; Franzen, D; Rupprecht, HJ; Heublein, B; Fischer, K; De Jaegere, P; Serruys, P; Rutsch, W; Probst, P		Restenosis Stent Study Grp	Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALMAZ-SCHATZ STENTS; ANGIOGRAPHIC FOLLOW-UP; INTRACORONARY IMPLANTATION; ULTRASOUND GUIDANCE; EXPERIENCE; PLACEMENT; ANTIPLATELET; MULTICENTER; THERAPY; DISEASE	Background Intracoronary stenting reduces the rate of restenosis after angioplasty in patients with new coronary lesions. We conducted a prospective, randomized, multicenter study to determine whether intracoronary stenting, as compared with standard balloon angioplasty, reduces the recurrence of luminal narrowing in restenotic lesions. Method; A total of 383 patients who had undergone at least one balloon angioplasty and who had clinical and angiographic evidence of restenosis after the procedure were randomly assigned to undergo standard balloon angioplasty (192 patients) or intracoronary stenting with a Palmaz-Schatz stent (191 patients). The primary end point was angiographic evidence of restenosis (defined as stenosis of more than 50 percent of the luminal diameter) at six months. The secondary end points were death, Q-wave myocardial infarction, bypass surgery, and revascularization of the target vessel. Results The rate of restenosis was significantly higher in the angioplasty group than in the stent group (32 percent as compared with 18 percent, P = 0.03). Revascularization of the target vessel at six months was required in 27 percent of the angioplasty group but in only 10 percent of the stent group (P = 0.001). This difference resulted from a smaller mean (+/-SD) minimal luminal diameter in the angioplasty group (1.85+/-0.56 mm) than in the stent group (2.04+/-0.66 mm), with a mean difference of 0.19 mm (P = 0.01) at follow-up. Subacute thrombosis occurred in 0.6 percent of the angioplasty group and in 3.9 percent of the stent group. The rate of event-free survival at 250 days was 72 percent in the angioplasty group and 84 percent in the stent group (P = 0.04). Conclusions Elective coronary stenting was effective in the treatment of restenosis after balloon angioplasty. Stenting resulted in a lower rate of recurrent stenosis despite a higher incidence of subacute thrombosis. (N Engl J Med 1998;339:1672-8,) (C)1998, Massachusetts Medical Society.	Univ Essen Gesamthsch, Dept Cardiol, D-45122 Essen, Germany; Univ Cologne, Dept Med 3, Cologne, Germany; Johannes Gutenberg Univ Mainz, Med Clin 2, D-6500 Mainz, Germany; Hannover Med Sch, Dept Cardiothorac Surg, D-3000 Hannover, Germany; Erasmus Univ, Ctr Thorax, Dept Cardiol, NL-3000 DR Rotterdam, Netherlands; Univ Clin Charite, Dept Cardiol, Berlin, Germany; Univ Vienna, Dept Cardiol, Vienna, Austria	University of Duisburg Essen; University of Cologne; Johannes Gutenberg University of Mainz; Hannover Medical School; Erasmus University Rotterdam; Erasmus MC; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Vienna	Erbel, R (corresponding author), Univ Essen Gesamthsch, Dept Cardiol, Hufelandstr 55, D-45122 Essen, Germany.		Fischer, Kathelijn/M-2395-2017					BAUTERS C, 1992, J AM COLL CARDIOL, V20, P845, DOI 10.1016/0735-1097(92)90182-M; BOURASSA MG, 1991, J AM COLL CARDIOL, V18, P368, DOI 10.1016/0735-1097(91)90588-Z; Colombo A, 1996, J AM COLL CARDIOL, V28, P830, DOI 10.1016/S0735-1097(96)00266-5; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; CURRIER JW, 1995, J AM COLL CARDIOL, V25, P516, DOI 10.1016/0735-1097(95)98445-J; Debbas NMG, 1996, J INVASIVE CARDIOL, V8, P241; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; ELLIS SG, 1992, CIRCULATION, V86, P1836, DOI 10.1161/01.CIR.86.6.1836; ERBEL R, 1989, Z KARDIOL, V78, P71; FAXON DP, 1984, AM J CARDIOL, V53, pC72, DOI 10.1016/0002-9149(84)90751-3; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GARDNER MJ, 1992, STAT CONFIDENCE CONF, P50; HAUDE M, 1991, AM J CARDIOL, V67, P691, DOI 10.1016/0002-9149(91)90523-N; HAUDE M, 1993, J AM COLL CARDIOL, V21, P26, DOI 10.1016/0735-1097(93)90713-B; HAUDE M, 1994, J INTERV CARDIOL, V7, P341, DOI 10.1111/j.1540-8183.1994.tb00467.x; HAUDE M, 1993, AM HEART J, V126, P15, DOI 10.1016/S0002-8703(07)80005-6; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KUNTZ RE, 1993, CIRCULATION, V88, P1310, DOI 10.1161/01.CIR.88.3.1310; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; MUDRA H, 1994, CIRCULATION, V90, P1252, DOI 10.1161/01.CIR.90.3.1252; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; QUIGLEY PJ, 1989, AM J CARDIOL, V63, P409, DOI 10.1016/0002-9149(89)90309-3; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RUPPRECHT HJ, 1990, CATHETER CARDIO DIAG, V19, P151, DOI 10.1002/ccd.1810190302; SAVAGE MP, 1996, STRATEGIC APPROACHES, P361; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; Schmitz HJ, 1996, AM HEART J, V131, P884, DOI 10.1016/S0002-8703(96)90169-6; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SERRUYS PW, 1993, AM HEART J, V126, P1243, DOI 10.1016/0002-8703(93)90689-7; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; SRIDHAR K, 1996, STRATEGIC APPROACHES, P618; TEIRSTEIN PS, 1987, J AM COLL CARDIOL, V9, pA63; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002	38	228	235	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1672	1678		10.1056/NEJM199812033392304	http://dx.doi.org/10.1056/NEJM199812033392304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834304	Bronze			2022-12-28	WOS:000077294800004
J	Pretre, R; Turina, MI				Pretre, R; Turina, MI			Facts, at last, on management of small infrarenal aortic aneurysms	LANCET			English	Editorial Material									Univ Zurich Hosp, Dept Cardiovasc Surg, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Pretre, R (corresponding author), Univ Zurich Hosp, Dept Cardiovasc Surg, CH-8091 Zurich, Switzerland.							[Anonymous], 1995, Eur J Vasc Endovasc Surg, V9, P42; CRAIG SR, 1993, BRIT J SURG, V80, P450, DOI 10.1002/bjs.1800800413; Dardik A, 1998, J VASC SURG, V28, P413, DOI 10.1016/S0741-5214(98)70126-0; HEINEMANN M, 1990, ANN THORAC SURG, V49, P580, DOI 10.1016/0003-4975(90)90304-O; MAGEE TR, 1992, BRIT J SURG, V79, P1014, DOI 10.1002/bjs.1800791009; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3	6	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1642	1643		10.1016/S0140-6736(98)00069-5	http://dx.doi.org/10.1016/S0140-6736(98)00069-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853430				2022-12-28	WOS:000077110300002
J	Keller, MB; Kocsis, JH; Thase, ME; Gelenberg, AJ; Rush, AJ; Koran, L; Schatzberg, A; Russell, J; Hirschfeld, R; Klein, D; McCullough, JP; Fawcett, JA; Kornstein, S; LaVange, L; Harrison, W				Keller, MB; Kocsis, JH; Thase, ME; Gelenberg, AJ; Rush, AJ; Koran, L; Schatzberg, A; Russell, J; Hirschfeld, R; Klein, D; McCullough, JP; Fawcett, JA; Kornstein, S; LaVange, L; Harrison, W		Sertraline Chronic Depression Study Grp	Maintenance phase efficacy of sertraline for chronic depression - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECURRENT DEPRESSION; MAJOR DEPRESSION; DRUG-THERAPY; CONTINUATION; PREVENTION; DISABILITY; DISORDERS; OUTCOMES; BURDEN	Context.-The chronic form of major depression is associated with a high rate of prevalence and disability, but no controlled research has examined the impact of long-term treatment on the course and burden of illness. Objective.-To determine if maintenance therapy with sertraline hydrochloride can effectively prevent recurrence of depression in the high-risk group of patients experiencing chronic major depression or major depression with antecedent dysthymic disorder ("double depression"). Design.-A 76-week randomized, double-blind, parallel-group study, conducted from September 1993 to November 1996, Setting.-Outpatient psychiatric clinics at 10 academic medical centers and 2 clinical research centers. Intervention.-Maintenance treatment with either sertraline hydrochloride (n = 77) in flexible doses up to 200 mg or placebo (n = 84), Patients.-A total of 161 outpatients with chronic major or double depression who responded to sertraline in a 12-week, double-blind, acute-phase treatment trial and continued to have a satisfactory therapeutic response during a subsequent 4-month continuation phase. Main Outcome Measure.-Time to recurrence of major depression. Results.-Sertraline afforded significantly greater prophylaxis against recurrence than did placebo (5 [6%] of 77 in the sertraline group vs 19 [23%] of 84 in the placebo group; P = .002 for the log-rank test of time-to-recurrence distributions). Clinically significant depressive symptoms reemerged in 20 (26%) of 77 patients treated with sertraline vs 42 (50%) of 84 patients who received placebo (P=.001), With use of a Cox proportional hazards model, patients receiving placebo were 4.07 times more likely (95% CI, 1.51-10.95; P=.005) to experience a depression recurrence, after adjustment for study site, type of depression, and randomization strata. Conclusions.-Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients.	Brown Univ, Butler Hosp, Dept Psychiat, Providence, RI 02912 USA; Cornell Univ, Sch Med, Dept Psychiat, New York, NY 10021 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA; Univ Arizona, Dept Psychiat, Tucson, AZ USA; Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX USA; Stanford Univ, Sch Med, Dept Psychiat, Stanford, CA 94305 USA; Univ Texas, Med Branch, Dept Psychiat, Galveston, TX 77550 USA; SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Richmond, VA 23298 USA; Rush Inst Mental Well Being, Dept Psychiat, Chicago, IL USA; Quintiles, Dept Psychiat, Res Triangle Pk, NC USA; Pfizer Inc, Dept Psychiat, New York, NY USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Brown University; Butler Hospital Rhode Island; Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of Arizona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; University of Texas System; University of Texas Medical Branch Galveston; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Virginia Commonwealth University; Rush University; IQVIA; Pfizer; Columbia University	Keller, MB (corresponding author), Brown Univ, Butler Hosp, Dept Psychol & Human Behav, 345 Blackstone Blvd, Providence, RI 02906 USA.		Howland, Robert H/K-6937-2015	Howland, Robert H/0000-0002-6533-6010; Rush, Augustus/0000-0003-2004-2382	NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH061590] Funding Source: NIH RePORTER; NIMH NIH HHS [U01 MH061590] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1993, DEPR GUID PAN DEPR P, V2; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BERNSTEIN MJ, 1985, AM J PSYCHIAT, V142, P469; COPPEN A, 1986, PHARMACOTHERAPY DEPR; DILSAVER SC, 1994, DRUG SAFETY, V10, P103, DOI 10.2165/00002018-199410020-00002; DOOGAN DP, 1992, BRIT J PSYCHIAT, V160, P217, DOI 10.1192/bjp.160.2.217; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Guy W., 1976, DHEW PUBL; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540; KELLER MB, 1998, J CLIN PSYCHIAT, V59, P560; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KLERMAN GL, 1992, ARCH GEN PSYCHIAT, V49, P831; KUPFER DJ, 1992, ARCH GEN PSYCHIAT, V49, P769; Littrell J, 1994, EXP CLIN PSYCHOPHARM, V2, P82; MAJ M, 1992, AM J PSYCHIAT, V149, P795; Mason Barbara J., 1995, P73; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; MONTGOMERY SA, 1988, BRIT J PSYCHIAT, V153, P69; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; PRIEN RF, 1984, ARCH GEN PSYCHIAT, V41, P1096; PRIEN RF, 1986, AM J PSYCHIAT, V143, P18; Robins L., 1991, PSYCHIAT DISORDER AM; ROBINSON DS, 1991, PSYCHOPHARMACOL BULL, V27, P31; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	28	157	160	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1665	1672		10.1001/jama.280.19.1665	http://dx.doi.org/10.1001/jama.280.19.1665			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9831997	Bronze			2022-12-28	WOS:000076980700031
J	Kelner, KL				Kelner, KL			Note bene: Triplet repeat diseases - Innocent inclusions	SCIENCE			English	Editorial Material																		Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1	2	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					643	643						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841418				2022-12-28	WOS:000076607500032
J	Chaloner, J				Chaloner, J			The new Victorians: community care in the 1990s	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1738	1738		10.1136/bmj.317.7174.1738	http://dx.doi.org/10.1136/bmj.317.7174.1738			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857161	Green Published			2022-12-28	WOS:000077742300056
J	Beecham, L				Beecham, L			NHS in Wales being reshaped	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1663	1663						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848927				2022-12-28	WOS:000077602100079
J	Eisner, MD; Smith, AK; Blanc, PD				Eisner, MD; Smith, AK; Blanc, PD			Bartenders' respiratory health after establishment of smoke-free bars and taverns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; INDOOR AIR-POLLUTION; BRONCHIAL SYMPTOMS QUESTIONNAIRE; PASSIVE SMOKING; PULMONARY-FUNCTION; LUNG-FUNCTION; YOUNG-ADULTS; OCCUPATIONAL EXPOSURE; HEART-DISEASE; FOLLOW-UP	Context.-The association between environmental tobacco smoke (ETS) exposure and respiratory symptoms has not been well established in adults. Objective.-To study the respiratory health of bartenders before and after legislative prohibition of smoking in all bars and taverns by the state of California. Design.-Cohort of bartenders interviewed before and after smoking prohibition. Setting and Participants.-Bartenders at a random sample of bars and taverns in San Francisco. Main Outcome Measures.-Interviews assessed respiratory symptoms, sensory irritation symptoms, ETS exposure, personal smoking, and recent upper respiratory tract infections. Spirometric assessment included forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) measurements. Results.-Fifty-three of 67 eligible bartenders were interviewed. At baseline, all 53 bartenders reported workplace ETS exposure. After the smoking ban, self-reported ETS exposure at work declined from a median of 28 to 2 hours per week (P<.001). Thirty-nine bartenders (74%) initially reported respiratory symptoms. Of those symptomatic at baseline, 23 (59%) no longer had symptoms at follow-up (P<.001). Forty-one bartenders (77%) initially reported sensory irritation symptoms. At follow-up, 32 (78%) of these subjects had resolution of symptoms (P<.001). After prohibition of workplace smoking, we observed improvement in mean FVC (0.189 L; 95% confidence interval [CI], 0.082-0.296 L; 4.2% change) and, to a lesser extent, mean FEV1 (0.039 L; 95% CI, -0.030 to 0.107 L; 1.2% change). Complete cessation of workplace ETS exposure (compared with continued exposure) was associated with improved mean FVC (0.287 L; 95% CI, 0.088-0.486; 6.8% change) and mean FEV1 (0.142 L; 95% CI, 0.020-0.264 L; 4.5% change), after controlling for personal smoking and recent upper respiratory tract infections. Conclusion.-Establishment of smoke-free bars and taverns was associated with a rapid improvement of respiratory health.	Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA; Univ Calif San Francisco, Div Environm & Occupat Med, San Francisco, CA USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Blanc, PD (corresponding author), 350 Parnassus Ave,Suite 609, San Francisco, CA 94143 USA.	blancp@itsa.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007185, K04HL003225] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07185, KO4 HL03225] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbar-Khanzadeh F, 1996, Med Lav, V87, P122; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BAKE B, 1977, SCAND J RESPIR DIS, V58, P311; BECKER DM, 1989, JAMA-J AM MED ASSOC, V262, P799, DOI 10.1001/jama.262.6.799; Bergman TA, 1996, AM IND HYG ASSOC J, V57, P746, DOI 10.1202/0002-8894(1996)057<0746:OEONNM>2.0.CO;2; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; BRODER I, 1993, CAN J PUBLIC HEALTH, V84, P254; BRUNEKREEF B, 1985, INT J EPIDEMIOL, V14, P227, DOI 10.1093/ije/14.2.227; BUIST AS, 1979, AM REV RESPIR DIS, V120, P953; BURCHFIEL CM, 1995, AM J RESP CRIT CARE, V151, P1778, DOI 10.1164/ajrccm.151.6.7767520; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; *CAL ENV PROT AG, 1997, HLTH EFF EXP ENV TOB; COMSTOCK GW, 1981, AM REV RESPIR DIS, V124, P143; DAYAL HH, 1994, ENVIRON RES, V65, P161, DOI 10.1006/enrs.1994.1029; DELFINO RJ, 1993, EUR RESPIR J, V6, P1104; Diggle P. J., 1996, ANAL LONGITUDINAL DA; DIMICHWARD H, 1998, AM J RESP CRIT CARE, V157, pA505; EMMONS KM, 1994, PREV MED, V23, P35, DOI 10.1006/pmed.1994.1005; Gerlach K K, 1997, Tob Control, V6, P199; GILLIS CR, 1984, EUR J RESPIR DIS, V65, P121; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HOWARD G, 1988, JAMA-J AM MED ASSOC, V279, P119; Jaakkola MS, 1996, J CLIN EPIDEMIOL, V49, P581, DOI 10.1016/0895-4356(96)00004-2; JAAKKOLA MS, 1995, J CLIN EPIDEMIOL, V48, P317, DOI 10.1016/0895-4356(94)00157-L; JARVIS MJ, 1992, BRIT J ADDICT, V87, P111; JARVIS MJ, 1983, THORAX, V38, P829, DOI 10.1136/thx.38.11.829; KAUFFMANN F, 1989, INT J EPIDEMIOL, V18, P334, DOI 10.1093/ije/18.2.334; Kawachi I, 1997, CIRCULATION, V95, P2374, DOI 10.1161/01.CIR.95.10.2374; LAW MR, 1977, BMJ-BRIT MED J, V315, P973; LEADERER BP, 1994, AM J RESP CRIT CARE, V150, P1216, DOI 10.1164/ajrccm.150.5.7952542; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222, DOI 10.1164/ajrccm.150.5.7952544; Macdonald H R, 1997, Tob Control, V6, P41; MASI MA, 1988, AM REV RESPIR DIS, V138, P296, DOI 10.1164/ajrccm/138.2.296; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; MILLAR WJ, 1988, CAN J PUBLIC HEALTH, V79, P379; MORRIS PD, 1995, ENVIRON RES, V68, P3, DOI 10.1006/enrs.1995.1002; NG TP, 1993, J EPIDEMIOL COMMUN H, V47, P454, DOI 10.1136/jech.47.6.454; Ott W, 1996, J AIR WASTE MANAGE, V46, P1120, DOI 10.1080/10473289.1996.10467548; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; REPACE JL, 1980, SCIENCE, V208, P464, DOI 10.1126/science.7367873; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; SCHOENBERG JB, 1987, J NATL CANCER I, V79, P13; SCHWARTZ J, 1990, AM REV RESPIR DIS, V141, P62, DOI 10.1164/ajrccm/141.1.62; SHERRILL DL, 1994, AM J RESP CRIT CARE, V149, P591, DOI 10.1164/ajrccm.149.3.8118623; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; SINGLETON J, 1989, COMS 2 CALIFORNIA OC; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715; THOMPSON B, 1995, J OCCUP ENVIRON MED, V37, P1086, DOI 10.1097/00043764-199509000-00009; United States Environmental Protection Agency, 1992, US EPA PUBL; *VIT HLTH STAT, 1988, VIT HLTH STAT, V10, P1; Wells AJ, 1998, J AM COLL CARDIOL, V31, P1, DOI 10.1016/S0735-1097(97)00432-4; WESTERN B, 1994, SOC FORCES, V73, P497, DOI 10.2307/2579818; WHITE JR, 1980, NEW ENGL J MED, V302, P720, DOI 10.1056/NEJM198003273021304; WHITE JR, 1991, CHEST, V100, P39, DOI 10.1378/chest.100.1.39; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; XU XP, 1995, AM J RESP CRIT CARE, V151, P41, DOI 10.1164/ajrccm.151.1.7812570	64	253	259	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1909	1914		10.1001/jama.280.22.1909	http://dx.doi.org/10.1001/jama.280.22.1909			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851475	Bronze			2022-12-28	WOS:000077364500034
J	Michael, WM; Newport, J				Michael, WM; Newport, J			Coupling of mitosis to the completion of S phase through Cdc34-mediated degradation of Wee 1	SCIENCE			English	Article							CELL-CYCLE; DNA-REPLICATION; F-BOX; UBIQUITIN; KINASE; PROTEOLYSIS; XENOPUS; PROTEIN; CDC2; SYSTEM	The dependence of mitosis on the completion of the period of DNA replication in the cell cycle [synthesis (S) phase] ensures that chromosome segregation occurs only after the genome has been fully duplicated. A key negative regulator of mitosis, the protein kinase Wee1, was degraded in a Cdc34-dependent fashion in Xenopus egg extra cts. Th is proteolysis event was required for a timely entrance into mitosis and was inhibited when DNA replication was blocked. Therefore, the DNA replication checkpoint can prevent mitosis by suppressing the proteolysis of Wee1 during 5 phase.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Michael, WM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	wmichael@biomail.ucsd.edu	McDermott, Michael Francis/GZM-5330-2022		NIGMS NIH HHS [R01GM44656] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044656] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MICHAEL WM, UNPUB; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murakami MS, 1998, DEVELOPMENT, V125, P237; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	25	127	134	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1886	1889		10.1126/science.282.5395.1886	http://dx.doi.org/10.1126/science.282.5395.1886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836638				2022-12-28	WOS:000077338100048
J	Adams, JN; Trent, RJ				Adams, JN; Trent, RJ			Aortic complications of Marfan's syndrome	LANCET			English	Editorial Material							BETA-ADRENERGIC-BLOCKADE; LIFE EXPECTANCY; DISTENSIBILITY; ROOT; DILATATION; SURVIVAL; DILATION		Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Adams, JN (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.							ADAMS JN, 1995, BRIT HEART J, V73, P265; BRUNO L, 1984, BRIT HEART J, V51, P220; FINKBOHNER R, 1995, CIRCULATION, V91, P728, DOI 10.1161/01.CIR.91.3.728; Groenink M, 1998, HEART, V80, P163, DOI 10.1136/hrt.80.2.163; Groenink M, 1998, AM J CARDIOL, V82, P203, DOI 10.1016/S0002-9149(98)00315-4; HABBAL MHE, 1992, AM HEART J, V123, P752; Haouzi A, 1997, AM HEART J, V133, P60, DOI 10.1016/S0002-8703(97)70248-5; JEREMY RW, 1994, AM J CARDIOL, V74, P369, DOI 10.1016/0002-9149(94)90405-7; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; REED CM, 1992, AM J CARDIOL, V70, P541, DOI 10.1016/0002-9149(92)91207-K; ROMAN MJ, 1993, J AM COLL CARDIOL, V22, P1470, DOI 10.1016/0735-1097(93)90559-J; SALIM MA, 1994, AM J CARDIOL, V74, P629, DOI 10.1016/0002-9149(94)90762-5; SAVOLAINEN A, 1992, AM J CARDIOL, V70, P691, DOI 10.1016/0002-9149(92)90215-K; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; SILVERMAN DI, 1995, J AM COLL CARDIOL, V26, P1062, DOI 10.1016/0735-1097(95)00258-0; TREASURE T, 1993, BRIT HEART J, V69, P101	17	33	34	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1722	1723		10.1016/S0140-6736(05)79822-6	http://dx.doi.org/10.1016/S0140-6736(05)79822-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848345				2022-12-28	WOS:000077246500004
J	Burgner, D; McDonald, D; Watson, M; Pike, M				Burgner, D; McDonald, D; Watson, M; Pike, M			A 6-year-old child with vacant episodes and unilateral convulsions	LANCET			English	Article							HERPES-SIMPLEX ENCEPHALITIS; POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; DIAGNOSIS; MANAGEMENT; DISEASE		Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Burgner, D (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.			Burgner, David/0000-0002-8304-4302				Cinque P, 1996, J NEUROL NEUROSUR PS, V61, P339, DOI 10.1136/jnnp.61.4.339; Kimberlin DW, 1996, J INFECT DIS, V174, P1162, DOI 10.1093/infdis/174.6.1162; KOSKINIEMI M, 1984, REV INFECT DIS, V6, P608; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857	4	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1750	1750		10.1016/S0140-6736(98)09176-4	http://dx.doi.org/10.1016/S0140-6736(98)09176-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848352				2022-12-28	WOS:000077246500011
J	MacDonald, NE; Halperin, SA; Law, BJ; Forrest, B; Danzig, LE; Granoff, DM				MacDonald, NE; Halperin, SA; Law, BJ; Forrest, B; Danzig, LE; Granoff, DM			Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	37th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 28-OCT 03, 1997	TORONTO, CANADA				INFLUENZAE TYPE-B; MENINGITIDIS SEROGROUP-B; NEISSERIA-MENINGITIDIS; GROUP-A; CAPSULAR POLYSACCHARIDE; ANTIBODY-RESPONSES; CHILDREN; IMMUNOGENICITY; INFANTS; IMMUNIZATION	Context.-Meningococcal polysaccharide vaccines are not used routinely in infants and toddlers, the groups at highest risk of invasive disease, because of poor immunologic responses to the Neisseria meningitidis serogroup C polysaccharide in these age groups. Meningococcal C conjugate vaccines offer the prospect of circumventing this problem. Objective.-To assess the immunogenicity and the induction of immunologic memory in toddlers by meningococcal C conjugate vaccine. Design.-A multicenter, randomized, observer-blinded controlled trial. Setting.-Urban and suburban family medicine or pediatric practices, Participants.-Two hundred eleven healthy toddlers aged 15 to 23 months. Intervention.-Two injections at 2 months apart of meningococcal C conjugate (group 1, n = 69), plain meningococcal polysaccharide (group 2, n = 72), or hepatitis B virus vaccine (group 3, n = 70). All toddlers received a follow-up dose of plain meningococcal polysaccharide vaccine 12 months later. Main Outcome Measures.-IgG meningococcal C anticapsular antibody concentrations determined by enzyme-linked immunosorbent assay and complement-mediated bactericidal antibody. Results.-In group 1, the magnitude of the IgG response to meningococcal C conjugate vaccine was more than 4-fold higher after dose 1 and more than 10-fold higher after dose 2 compared with meningococcal polysaccharide vaccine (group 2) (P<.001). Higher titers persisted in the meningococcal C conjugate group for at least 12 months (P<.001). Group 1, primed with meningococcal C conjugate, had 25-fold higher IgG responses to the meningococcal polysaccharide 1-year booster dose than the controls who had received hepatitis B virus vaccine initially and were given meningococcal polysaccharide vaccine 1 year later for the first time (P<.001). In contrast, group 2, primed with meningococcal polysaccharide, had a 2-fold lower response to the 1-year booster meningococcal polysaccharide dose than the hepatitis B virus control group (P=.006), Serum bactericidal responses paralleled the enzyme-linked immunosorbent assay responses. Conclusions.-Immunization of toddlers with meningococcal C conjugate vaccine induces high titers of anticapsular and bactericidal antibody. Furthermore, this vaccine induces immunologic memory to meningococcal C polysaccharide. In contrast, meningococcal polysaccharide vaccine is less immunogenic than the conjugate vaccine and also induces a hyporesponsive state that persists for at least 12 months.	Univ Ottawa, Ottawa, ON, Canada; Dalhousie Univ, Halifax, NS, Canada; Univ Manitoba, Winnipeg, MB, Canada; Chiron Corp, Chiron Vaccines, Emeryville, CA USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of Ottawa; Dalhousie University; University of Manitoba; Novartis; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	MacDonald, NE (corresponding author), Childrens Hosp Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	macdonald_n@cheo.on.ca		Halperin, Scott/0000-0003-0525-589X				Amato Neto V, 1974, Rev Inst Med Trop Sao Paulo, V16, P149; Fairley CK, 1996, J INFECT DIS, V174, P1360, DOI 10.1093/infdis/174.6.1360; GOLD R, 1977, J INFECT DIS, V136, pS31, DOI 10.1093/infdis/136.Supplement.S31; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1973, J INFECT DIS, V128, P769, DOI 10.1093/infdis/128.6.769; Granoff DM, 1998, J INFECT DIS, V178, P870, DOI 10.1086/515346; Granoff DM, 1998, CLIN DIAGN LAB IMMUN, V5, P479, DOI 10.1128/CDLI.5.4.479-485.1998; GRANOFF DM, 1995, CLIN DIAGN LAB IMMUN, V2, P574, DOI 10.1128/CDLI.2.5.574-582.1995; Granoff DM, 1997, INFECT IMMUN, V65, P1710, DOI 10.1128/IAI.65.5.1710-1715.1997; Hall CB, 1996, PEDIATRICS, V97, P404; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; JAFARI HS, 1997, MMWR-MORBID MORTAL W, V46, P1; King WJ, 1996, J PEDIATR-US, V128, P196, DOI 10.1016/S0022-3476(96)70389-X; KING WJ, 1995, J PEDIATR-US, V126, P937, DOI 10.1016/S0022-3476(95)70214-8; Leach A, 1997, J INFECT DIS, V175, P200, DOI 10.1093/infdis/175.1.200; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; MACLENNAN J, 1997, 15 ANN M EUR SOC PAE; MANDRELL RE, 1995, J INFECT DIS, V172, P1279, DOI 10.1093/infdis/172.5.1279; PELTOLA H, 1985, PEDIATRICS, V76, P91; Ramsay M, 1997, Commun Dis Rep CDR Rev, V7, pR49; Robbins JB, 1996, JAMA-J AM MED ASSOC, V276, P1181, DOI 10.1001/jama.276.14.1181; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982	23	169	175	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1685	1689		10.1001/jama.280.19.1685	http://dx.doi.org/10.1001/jama.280.19.1685			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9832000	Bronze			2022-12-28	WOS:000076980700034
J	Strom, BL; Abrutyn, E; Berlin, JA; Kinman, JL; Feldman, RS; Stolley, PD; Levison, ME; Korzeniowski, OM; Kaye, D				Strom, BL; Abrutyn, E; Berlin, JA; Kinman, JL; Feldman, RS; Stolley, PD; Levison, ME; Korzeniowski, OM; Kaye, D			Dental and cardiac risk factors for infective endocarditis - A population-based, case-control study	ANNALS OF INTERNAL MEDICINE			English	Article						endocarditis, bacterial; heart valve disease; dental care; antibiotics; risk factors	MITRAL-VALVE PROLAPSE; AMERICAN-HEART-ASSOCIATION; BACTERIAL-ENDOCARDITIS; ANTIBIOTIC-PROPHYLAXIS; PREVENTION; CRITERIA; RECOMMENDATIONS; EFFICACY	Background: Although antibiotic prophylaxis against infective endocarditis is recommended, the true risk factors for infective endocarditis are unclear. Objective: To quantitate the risk for endocarditis from dental treatment and cardiac abnormalities. Design: Population-based, case-control study Setting: 54 hospitals in the Philadelphia area. Patients: Persons with community-acquired infective endocarditis not associated with intravenous drug use were compared with community residents, matched by age, sex, and neighborhood of residence. Measurements: Information on demographic characteristics, host risk factors, and dental treatment was obtained from structured telephone interviews, dental records, and medical records. Results: During the preceding 3 months, dental treatment was no more frequent among case-patients than controls (adjusted odds ratio, 0.8 [95% CI, 0.4 to 1.5]). Of 273 case-patients, 104 (38%) knew of previous cardiac lesions compared with 17 controls (6%) (adjusted odds ratio, 16.7 [Cl, 7.4 to 37.4]). Case-patients more often had a history of mitral valve prolapse (adjusted odds ratio, 19.4 [Cl, 6.4 to 58.4]), congenital heart disease (adjusted odds ratio, 6.7 [Cl, 2.3 to 19.4]), cardiac valvular surgery (adjust ed odds ratio 74.6 [CI, 12.5 to 447]), rheumatic fever (adjusted odds ratio, 13.4 [CI, 4.5 to 39.5]), and heart murmur without other known cardiac abnormalities (adjusted odds ratio, 4.2 [CI, 2.0 to 8.9]). Among case-patients with known cardiac lesions-the target of prophylaxis - dental therapy was significantly (P = 0.03) less common than among controls (adjusted odds ratio, 0.2 [Cl, 0.04 to 0.7] over 3 months). Few participants received prophylactic antibiotics. Conclusions: Dental treatment does not seem to be a risk factor for infective endocarditis, even in patients with valvular abnormalities, but cardiac valvular abnormalities are strong risk factors. Few cases of infective endocarditis would be preventable with antibiotic prophylaxis, even with 100% effectiveness assumed. Current policies for prophylaxis should be reconsidered.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Allegheny Univ Hlth Sci, Dept Med, Philadelphia, PA 19102 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA; Univ Maryland, Baltimore, MD 21201 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University; Drexel University; University System of Maryland; University of Maryland Baltimore	Strom, BL (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	bstrom@cceb.med.upenn.edu			NHLBI NIH HHS [R01 HL 39000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLIN JA, 1994, AM J CARDIOL, V73, P887, DOI 10.1016/0002-9149(94)90816-8; BERLIN JA, 1995, AM J CARDIOL, V76, P933, DOI 10.1016/S0002-9149(99)80264-1; BOR DH, 1984, AM J MED, V76, P711, DOI 10.1016/0002-9343(84)90300-0; CHERUBIN CE, 1971, AM J MED, V51, P83, DOI 10.1016/0002-9343(71)90326-3; CLEMENS JD, 1982, NEW ENGL J MED, V307, P776, DOI 10.1056/NEJM198209233071302; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DANCHIN N, 1989, LANCET, V1, P743; DENTON C, 1957, CIRCULATION, V15, P525, DOI 10.1161/01.CIR.15.4.525; DOWLING JN, 1974, ANN INTERN MED, V81, P641, DOI 10.7326/0003-4819-81-5-641; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; GOULD IM, 1993, BRIT HEART J, V70, P79; HARFORD CG, 1974, ARCH INTERN MED, V134, P116, DOI 10.1001/archinte.134.1.116; HICKEY AJ, 1985, AM HEART J, V109, P431, DOI 10.1016/0002-8703(85)90543-5; HOSMER DW, 1989, APPL LOGISTIC REGRES; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; KAYE D, 1991, ANN INTERN MED, V114, P803, DOI 10.7326/0003-4819-114-9-803; Lacassin F, 1995, EUR HEART J, V16, P1968, DOI 10.1093/oxfordjournals.eurheartj.a060855; LERNER PI, 1966, NEW ENGL J MED, V274, P199, DOI 10.1056/NEJM196601272740407; MACMAHON SW, 1987, AM HEART J, V113, P1291, DOI 10.1016/0002-8703(87)90957-4; MACMAHON SW, 1987, AM J CARDIOL, V59, P105, DOI 10.1016/S0002-9149(87)80080-2; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Rothman K, 1986, MODERN EPIDEMIOLOGY; Sekeres MA, 1997, CLIN INFECT DIS, V24, P1185, DOI 10.1086/513657; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WEINSTEIN L, 1996, INFECT ENDOCARDITIS	29	310	321	3	80	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					761	+		10.7326/0003-4819-129-10-199811150-00002	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841581				2022-12-28	WOS:000076984800001
J	Hampton, JR				Hampton, JR			The primacy of primary health care	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Nottingham NG7 2UH, England	University of Nottingham	Hampton, JR (corresponding author), Univ Nottingham Hosp, Nottingham NG7 2UH, England.								0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1724	1725		10.1136/bmj.317.7174.1724	http://dx.doi.org/10.1136/bmj.317.7174.1724			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857148	Green Published			2022-12-28	WOS:000077742300038
J	Le Fanu, J				Le Fanu, J			The need for political correctness in scientific writing	BRITISH MEDICAL JOURNAL			English	Article									Mawbey Brough Hlth Ctr, London SW8 2UD, England		Le Fanu, J (corresponding author), Mawbey Brough Hlth Ctr, London SW8 2UD, England.							Black D., 1982, INEQUALITIES HLTH BL; SPENCE JC, 1954, 1000 FAMILIES NEWCAS	2	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1721	1722		10.1136/bmj.317.7174.1721	http://dx.doi.org/10.1136/bmj.317.7174.1721			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857145	Green Published			2022-12-28	WOS:000077742300035
J	Goldblatt, D				Goldblatt, D			How to get a grant funded	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Inst Child Hlth, London WC1N 1EH, England; Univ London, Great Ormond St Hosp Children NHS Trust, London WC1N 1EH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Goldblatt, D (corresponding author), Univ London, Inst Child Hlth, London WC1N 1EH, England.		Goldblatt, David/C-5972-2008	Goldblatt, David/0000-0002-0769-5242					0	4	4	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1647	1648		10.1136/bmj.317.7173.1647	http://dx.doi.org/10.1136/bmj.317.7173.1647			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848911	Green Published			2022-12-28	WOS:000077602100034
J	Cao, W; Henry, MD; Borrow, P; Yamada, H; Elder, JH; Ravkov, EV; Nichol, ST; Compans, RW; Campbell, KP; Oldstone, MBA				Cao, W; Henry, MD; Borrow, P; Yamada, H; Elder, JH; Ravkov, EV; Nichol, ST; Compans, RW; Campbell, KP; Oldstone, MBA			Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; MEMBRANE; DISEASE; MICE	A peripheral membrane protein that is interactive with Lymphocytic choriomeningitis virus (LCMV) was purified from cells permissive to infection. Tryptic peptides from this protein were determined to be alpha-dystroglycan (alpha-DG). Several strains of LCMV and other arenaviruses, including Lassa fever virus (LFV), Oliveros, and Mobala, bound to purified alpha-DG protein. Soluble alpha-DG blocked both LCMV and LFV infection. Cells bearing a null mutation of the gene encoding DG were resistant to LCMV infection, and reconstitution of DC expression in null mutant cells restored susceptibility to LCMV infection. Thus, alpha-DG is a cellular receptor for both LCMV and LFV.	Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Univ Iowa, Coll Med, Dept Phys & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Edward Jenner Inst Vaccine Res, Newbury RG20 7NN, Berks, England; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Ctr Dis Control, Atlanta, GA 30333 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of Iowa; Scripps Research Institute; Emory University; Centers for Disease Control & Prevention - USA	Oldstone, MBA (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Virol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu	Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X; Campbell, Kevin/0000-0003-2066-5889; Borrow, Persephone/0000-0002-3877-9780; Cao, Wei/0000-0002-8952-9159; Henry, Michael/0000-0002-7871-245X	NIAID NIH HHS [AI 09484] Funding Source: Medline; NIA NIH HHS [AG 00080] Funding Source: Medline; NIDDK NIH HHS [DK09712] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009712] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORROW P, 1992, J VIROL, V66, P7270, DOI 10.1128/JVI.66.12.7270-7281.1992; BORROW P, UNPUB; Borrow Persephone, 1997, P593; Bowen MD, 1996, VIROLOGY, V219, P285, DOI 10.1006/viro.1996.0248; BURNS JW, 1991, VIROLOGY, V183, P620, DOI 10.1016/0042-6822(91)90991-J; CAO WQ, UNPUB; CLEGG JCS, 1993, ARENAVIRIDAE, P175; DELATORRE JC, UNPUB; Durbeej M, 1998, J HISTOCHEM CYTOCHEM, V46, P449, DOI 10.1177/002215549804600404; Fabiyi A, 1976, Bull Pan Am Health Organ, V10, P335; FAZAKERLEY JK, 1991, J GEN VIROL, V72, P1611, DOI 10.1099/0022-1317-72-7-1611; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAY SD, 1991, J BIOL CHEM, V266, P3287; MCCORMICK JB, 1987, J INFECT DIS, V155, P437, DOI 10.1093/infdis/155.3.437; Oldstone M B, 1980, Prog Med Virol, V26, P45; Peters C.J., 1996, FIELDS VIROLOGY, P1521; ROWE WP, 1954, NAVAL MED RES I BETH, V12, P167; SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Yamada H, 1996, J NEUROCHEM, V66, P1518; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173; Zinkernagel RM, 1997, SCAND J IMMUNOL, V46, P423, DOI 10.1046/j.1365-3083.1997.d01-161.x	24	512	525	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2079	2081		10.1126/science.282.5396.2079	http://dx.doi.org/10.1126/science.282.5396.2079			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851928				2022-12-28	WOS:000077467100046
J	Dong, C; Yang, DD; Wysk, M; Whitmarsh, AJ; Davis, RJ; Flavell, RA				Dong, C; Yang, DD; Wysk, M; Whitmarsh, AJ; Davis, RJ; Flavell, RA			Defective T cell differentiation in the absence of Jnk1	SCIENCE			English	Article							LYMPHOCYTES; EXPRESSION; MICE	The c-Jun NH2-terminal kinase (JNK) signaling pathway has been implicated in the immune response that is mediated by the activation and differentiation of CD4 helper T (T-H) cells into T(H)1 and T(H)2 effector cells. JNK activity observed in wild-type activated T-H cells was severely reduced in T-H cells from Jnk1(-/-) mice. The Jnk1(-/-) T cells hyperproliferated, exhibited decreased activation-induced cell death, and preferentially differentiated to T(H)2 cells. The enhanced production of T(H)2 cytokines by Jnk1(-/-) cells was associated with increased nuclear accumulation of the transcription factor NFATc. Thus, the JNK1 signaling pathway plays a key role in T cell receptor-initiated T-H cell proliferation, apoptosis, and differentiation.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Program Mol Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.		dong, chen/B-3181-2009	dong, chen/0000-0002-0084-9130; Whitmarsh, Alan/0000-0003-1184-6610	NATIONAL CANCER INSTITUTE [R01CA065861, P01CA072009] Funding Source: NIH RePORTER; NCI NIH HHS [CA65861, CA72009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DONG CH, UNPUB, P12720; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Murphy KM, 1998, CURR OPIN IMMUNOL, V10, P226, DOI 10.1016/S0952-7915(98)80253-7; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rincon Mercedes, 1997, Genes and Function, V1, P51; RONEY JW, 1995, IMMUNITY, V2, P473; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Timmerman LA, 1997, J IMMUNOL, V159, P2735; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	27	515	530	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2092	2095		10.1126/science.282.5396.2092	http://dx.doi.org/10.1126/science.282.5396.2092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851932				2022-12-28	WOS:000077467100050
J	Frishman, WH				Frishman, WH			Carvedilol	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC HEART-FAILURE; IDIOPATHIC DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTOR ANTAGONIST; LEFT-VENTRICULAR FUNCTION; DOUBLE-BLIND; CONGESTIVE CARDIOMYOPATHY; EXERCISE CAPACITY; RANDOMIZED TRIAL; CLINICAL PHARMACOKINETICS; PLASMA NOREPINEPHRINE		New York Med Coll, Westchester Cty Med Ctr, Dept Med, Valhalla, NY 10595 USA; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	New York Medical College; Westchester Medical Center; New York Medical College	Frishman, WH (corresponding author), New York Med Coll, Westchester Cty Med Ctr, Dept Med, Munger Pavil, Valhalla, NY 10595 USA.							ANDERSON JL, 1985, AM J CARDIOL, V55, P471, DOI 10.1016/0002-9149(85)90396-0; *AUSTR NZ HEART FA, 1998, AM J MED, V104, P163; BARTSCH W, 1982, THERAPIEWOCHE, V32, P5714; Basu S, 1997, CIRCULATION, V96, P183; BAUM T, 1983, AM J MED, V75, P15, DOI 10.1016/0002-9343(83)90132-8; Bohm M, 1997, J AM COLL CARDIOL, V30, P992, DOI 10.1016/S0735-1097(97)00248-9; Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; BRISTOW MR, 1994, CIRCULATION, V89, P1632, DOI 10.1161/01.CIR.89.4.1632; Cohn J N, 1997, J Card Fail, V3, P173, DOI 10.1016/S1071-9164(97)90013-0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Colucci WS, 1996, CIRCULATION, V94, P2800, DOI 10.1161/01.CIR.94.11.2800; DALY PA, 1990, CIRCULATION, V82, P35; DEITCHMAN D, 1980, EUR J PHARMACOL, V61, P263, DOI 10.1016/0014-2999(80)90128-4; DEMEY C, 1990, BRIT J CLIN PHARMACO, V29, P486; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; Dunn CJ, 1997, DRUGS, V54, P161, DOI 10.2165/00003495-199754010-00015; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FISHER ML, 1994, J AM COLL CARDIOL, V23, P943, DOI 10.1016/0735-1097(94)90641-6; FRANCIS GS, 1982, AM HEART J, V104, P725, DOI 10.1016/0002-8703(82)90003-5; FREEDMAN SB, 1987, AM J CARDIOL, V60, P499, DOI 10.1016/0002-9149(87)90293-1; FRISHMAN WH, 1983, NEW ENGL J MED, V308, P940; FRISHMAN WH, 1983, CIRCULATION, V67, P11; FRISHMAN WH, 1997, CARDIOVASCULAR PHARM, P1561; FRISHMAN WH, 1996, ATHEROSCLEROSIS CORO, V2, P1205; FRISHMAN WH, 1997, CARDIOVASCULAR PHARM, P59; FUJIMAKI M, 1994, DRUG METAB DISPOS, V22, P700; FUJIMAKI M, 1990, J PHARM SCI, V79, P568, DOI 10.1002/jps.2600790704; Gilbert EM, 1996, CIRCULATION, V94, P2817, DOI 10.1161/01.CIR.94.11.2817; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HALL S, 1991, J CARDIOVASC PHARM, V18, pS35; HAUFZACHARIOU U, 1993, EUR J CLIN PHARMACOL, V45, P95, DOI 10.1007/BF00315487; HENDERSON EB, 1988, CIRCULATION, V78, P1192, DOI 10.1161/01.CIR.78.5.1192; Hjalmarson A, 1997, DRUGS, V54, P501, DOI 10.2165/00003495-199754040-00001; IKRAM H, 1981, LANCET, V2, P490; KRAMER BK, 1992, EUR J CLIN PHARMACOL, V43, P85, DOI 10.1007/BF02280760; KRUM H, 1995, CIRCULATION, V92, P1499, DOI 10.1161/01.CIR.92.6.1499; LANGDON CG, 1991, J CARDIOVASC PHARM, V18, pS51; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; LEUNG WH, 1990, AM HEART J, V119, P884, DOI 10.1016/S0002-8703(05)80327-8; LOUIS W J, 1987, Journal of Cardiovascular Pharmacology, V10, pS89, DOI 10.1097/00005344-198706111-00016; MacMahon S, 1997, LANCET, V349, P375; METRA M, 1994, J AM COLL CARDIOL, V24, P1678, DOI 10.1016/0735-1097(94)90174-0; MIKI S, 1991, J CARDIOVASC PHARM, V18, pS62; MORGAN T, 1994, CLIN PHARMACOKINET, V26, P335, DOI 10.2165/00003088-199426050-00002; Moser M, 1998, AM J HYPERTENS, V11, p15S, DOI 10.1016/S0895-7061(97)00424-X; NEUGEBAUER G, 1987, Journal of Cardiovascular Pharmacology, V10, pS85; Neugebauer G, 1988, DRUGS S6, V36, P148, DOI DOI 10.2165/00003495-198800366-00026; NICHOLS AJ, 1991, FUNDAM CLIN PHARM, V5, P25, DOI 10.1111/j.1472-8206.1991.tb00698.x; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; OLLIVIER JP, 1990, EUR J CLIN PHARMACOL, V38, pS164, DOI 10.1007/BF01409489; OLSEN SL, 1995, J AM COLL CARDIOL, V25, P1225, DOI 10.1016/0735-1097(95)00012-S; PACKER M, 1987, CIRCULATION, V75, P80; PACKER M, 1986, AM J MED, V80, P23, DOI 10.1016/0002-9343(86)90337-2; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pfeffer MA, 1996, NEW ENGL J MED, V334, P1396, DOI 10.1056/NEJM199605233342109; PODRID PJ, 1990, CIRCULATION, V82, P103; Rector TS, 1987, HEART FAIL, V3, P198; Roden DM, 1997, CIRCULATION, V95, P2335, DOI 10.1161/01.CIR.95.10.2335; RUFFOLO RR, 1990, EUR J CLIN PHARMACOL, V38, pS112, DOI 10.1007/BF01409477; SacknerBerstein JD, 1996, JAMA-J AM MED ASSOC, V275, P686; SHAMMAS FV, 1988, CLIN PHARMACOKINET, V15, P94, DOI 10.2165/00003088-198815020-00002; Tenero D., 1996, Clinical Pharmacology and Therapeutics, V59, P201, DOI 10.1038/sj.clpt.1996.304; Tomlinson B, 1988, Drugs, V36 Suppl 6, P37; VANDERDOES R, 1991, EUR HEART J, V12, P60, DOI 10.1093/oxfordjournals.eurheartj.a059826; VIQUERAT CE, 1985, AM J MED, V78, P455, DOI 10.1016/0002-9343(85)90338-9; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; Weiss R, 1998, AM J CARDIOL, V82, P927, DOI 10.1016/S0002-9149(98)00507-4; Yancy C., 1997, Journal of the American College of Cardiology, V29, p284A; YOUNG PH, 1992, J CARDIOVASC PHARM, V19, pS82, DOI 10.1097/00005344-199219001-00016; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Zarembski DG, 1996, AM J CARDIOL, V77, P1247, DOI 10.1016/S0002-9149(96)00175-0; ZHOU HH, 1995, CLIN PHARMACOL THER, V57, P518, DOI 10.1016/0009-9236(95)90036-5; ZIMMER HG, 1995, CARDIOSCIENCE, V6, P47	76	220	232	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1759	1765		10.1056/NEJM199812103392407	http://dx.doi.org/10.1056/NEJM199812103392407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845712				2022-12-28	WOS:000077459700007
J	Dunin-Borkowski, RE; McCartney, MR; Frankel, RB; Bazylinski, DA; Posfai, M; Buseck, PR				Dunin-Borkowski, RE; McCartney, MR; Frankel, RB; Bazylinski, DA; Posfai, M; Buseck, PR			Magnetic microstructure of magnetotactic bacteria by electron holography	SCIENCE			English	Article							BIOGENIC MAGNETITE; FORCE MICROSCOPY; MORPHOLOGY; MARINE; MAGNETOSOMES; FIELD	Off-axis electron holography in the transmission electron microscope was used to correlate the physical and magnetic microstructure of magnetite nanocrystals in magnetotactic bacteria. The magnetite crystals were all single magnetic domains, and the magnetization directions of small superparamagnetic crystals were constrained by magnetic interactions with larger crystals in the chains. Shape anisotropy was found to dominate magnetocrystalline anisotropy in elongated crystals. A coercive field between 300 and 450 oersted was determined for one chain.	Arizona State Univ, Ctr Solid State Sci, Tempe, AZ 85287 USA; Calif Polytech State Univ San Luis Obispo, Dept Phys, San Luis Obispo, CA 93407 USA; Iowa State Univ, Dept Microbiol, Ames, IA 50011 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Arizona State Univ, Dept Chem Biochem, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; California State University System; California Polytechnic State University San Luis Obispo; Iowa State University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Dunin-Borkowski, RE (corresponding author), Arizona State Univ, Ctr Solid State Sci, Tempe, AZ 85287 USA.		Dunin-Borkowski, Rafal/G-5597-2012; Pósfai, Mihály/C-1792-2012	Dunin-Borkowski, Rafal/0000-0001-8082-0647; Pósfai, Mihály/0000-0001-9355-3533				BAZYLINSKI DA, 1988, NATURE, V334, P518, DOI 10.1038/334518a0; BAZYLINSKI DA, 1994, MICROSC RES TECHNIQ, V27, P389, DOI 10.1002/jemt.1070270505; BAZYLINSKI DA, 1997, GEOMICROBIOLOGY INTE, P181; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; Dunin-Borkowski RE, 1998, ULTRAMICROSCOPY, V74, P61, DOI 10.1016/S0304-3991(98)00023-0; Dunlop D. J., 1997, ROCK MAGNETISM FUNDA; Egerton R.F., 2011, ELECT ENERGY LOSS SP; Fabian K, 1996, GEOPHYS J INT, V124, P89, DOI 10.1111/j.1365-246X.1996.tb06354.x; FARINA M, 1994, J MICROSC-OXFORD, V173, P1, DOI 10.1111/j.1365-2818.1994.tb03423.x; Frankel RB, 1997, BIOPHYS J, V73, P994, DOI 10.1016/S0006-3495(97)78132-3; FRANKEL RB, 1984, ANNU REV BIOPHYS BIO, V13, P85; HSU CY, 1994, SCIENCE, V265, P95, DOI 10.1126/science.265.5168.95; JACOBS IS, 1955, PHYS REV, V100, P1060, DOI 10.1103/PhysRev.100.1060; KIRSCHVINK JL, 1981, BIOSYSTEMS, V13, P181, DOI 10.1016/0303-2647(81)90060-5; KUO PC, 1988, J APPL PHYS, V64, P5071, DOI 10.1063/1.342527; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1988, J EXP BIOL, V140, P35; MANN S, 1984, NATURE, V310, P405, DOI 10.1038/310405a0; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MELDRUM FC, 1993, P ROY SOC B-BIOL SCI, V251, P231, DOI 10.1098/rspb.1993.0034; MOSKOWITZ BM, 1988, J MAGN MAGN MATER, V73, P273, DOI 10.1016/0304-8853(88)90093-5; MOSKOWITZ BM, REV GEOPHYS S, P123; ORCHOWSKI A, 1995, PHYS REV LETT, V74, P399, DOI 10.1103/PhysRevLett.74.399; PENNINGA I, 1995, J MAGN MAGN MATER, V149, P279, DOI 10.1016/0304-8853(95)00078-X; Posfai M, 1998, SCIENCE, V280, P880, DOI 10.1126/science.280.5365.880; PROKSCH RB, 1995, APPL PHYS LETT, V66, P2582, DOI 10.1063/1.113508; SMITH DJ, 1988, INTRO ELECT HOLOGRAP; SPARKS NHC, 1990, EARTH PLANET SC LETT, V98, P14, DOI 10.1016/0012-821X(90)90084-B; TONOMURA A, 1992, ADV PHYS, V41, P59, DOI 10.1080/00018739200101473; Walker MM, 1997, NATURE, V390, P371, DOI 10.1038/37057; WINKLHOFER M, 1998, EOS, V79, pS68	31	325	337	5	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1868	1870		10.1126/science.282.5395.1868	http://dx.doi.org/10.1126/science.282.5395.1868			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836632	Green Submitted			2022-12-28	WOS:000077338100042
J	Holmes, WC; Slap, GB				Holmes, WC; Slap, GB			Sexual abuse of boys - Definition, prevalence, correlates, sequelae, and management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ILLICIT DRUG-USE; CHEMICALLY DEPENDENT ADOLESCENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; JUVENILE DETENTION CENTER; CHILD-ABUSE; GENDER DIFFERENCES; RISK-FACTORS; SUBSTANCE-ABUSE; PHYSICAL ABUSE; GENERAL-POPULATION	Objective.-To clarify the definition of sexual abuse of boys, update estimates of its prevalence, and explore critically its reported correlates, sequelae, and management. Data Sources.-Studies from 1985 to 1997 were identified using OVID-MEDLINE and OVID-CINAHL. The search terms used were sexual abuse, sexual victimization, and sexual assault. Constraints applied included English language, human male subjects, age younger than 19 years, and North American samples. Study Selection.-Publications were included for review if they appeared in peer-reviewed journals; had clear research designs; reported results for at least 20 male subjects; and were not reviews, perspectives, theoretical treatises, editorials, or letters. Data Extraction.-Study types and sampling methods were categorized using well-established definitions. Preference was given to studies with large samples, with case-control or cohort designs, and/or with adjustment for effect modifiers or confounders. Data Synthesis.-We identified 166 studies representing 149 sexual abuse samples. Studies were methodologically limited and definitions of sexual abuse varied widely. Prevalence estimates varied widely (by definition used and population studied), ranging from 4% to 76%. Boys at highest risk were younger than 13 years, nonwhite, of low socioeconomic status, and not living with their fathers. Perpetrators tended to be known but unrelated males. Abuse frequently occurred outside the home, involved penetration, and occurred more than once. Sequelae included psychological distress, substance abuse, and sexually related problems. Evaluation of management strategies was limited. Conclusions.-Sexual abuse of boys appears to be common, underreported, underrecognized, and undertreated. Future study requires clearer definitions of abuse, improved sampling, more rigorous data collection, more sophisticated data analyses, and better assessment of management and treatment strategies. Regardless, health care professionals should be more aware of and sensitive to the possibility of sexual abuse in their male patients.	Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Leonard Davis Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Craig Dalsimer Program Adolescent Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Craig Dalsimer Program Adolescent Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Holmes, WC (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.							BAGLEY C, 1991, PERCEPT MOTOR SKILL, V72, P287, DOI 10.2466/PMS.72.1.287-288; Bagley C, 1995, Crisis, V16, P126, DOI 10.1027/0227-5910.16.3.126; BARTHOLOW BN, 1994, CHILD ABUSE NEGLECT, V18, P747; BECKER J, 1991, INT J LAW PSYCHIAT, V14, P85, DOI 10.1016/0160-2527(91)90026-J; BECKER JV, 1989, J PSYCHOPATHOL BEHAV, V11, P353, DOI 10.1007/BF00961533; Bernstein DP, 1997, J AM ACAD CHILD PSY, V36, P340, DOI 10.1097/00004583-199703000-00012; BONEYMCCOY S, 1995, CHILD ABUSE NEGLECT, V19, P1401, DOI 10.1016/0145-2134(95)00104-9; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037/0022-006X.63.5.726; BOUDEWYN AC, 1995, J TRAUMA STRESS, V8, P445, DOI 10.1007/BF02102969; BOYD CJ, 1993, J PSYCHOACTIVE DRUGS, V25, P301, DOI 10.1080/02791072.1993.10472287; BRIERE J, 1988, AM J ORTHOPSYCHIAT, V58, P457, DOI 10.1111/j.1939-0025.1988.tb01606.x; BRIERE J, 1994, CHILD ABUSE NEGLECT, V18, P131, DOI 10.1016/0145-2134(94)90115-5; BROUSSARD SD, 1988, CHILD ABUSE NEGLECT, V12, P563, DOI 10.1016/0145-2134(88)90073-7; BROWN GR, 1991, AM J PSYCHIAT, V148, P55; Brown LK, 1997, J AM ACAD CHILD PSY, V36, P316, DOI 10.1097/00004583-199703000-00009; BURGESS AW, 1988, ANN NY ACAD SCI, V528, P277, DOI 10.1111/j.1749-6632.1988.tb50871.x; BURGESS AW, 1987, AM J PSYCHIAT, V144, P1431; CAPPELLERI JC, 1993, AM J PUBLIC HEALTH, V83, P1622, DOI 10.2105/AJPH.83.11.1622; CARBALLODIEGUEZ A, 1995, CHILD ABUSE NEGLECT, V19, P595, DOI 10.1016/0145-2134(95)00018-4; CLAYDEN GS, 1988, ARCH DIS CHILD, V63, P832, DOI 10.1136/adc.63.7.832; CLAYTOR RN, 1989, CLIN PEDIATR, V28, P419, DOI 10.1177/000992288902800909; COLE C, 1988, CLIN SOC WORK J, V16, P33, DOI 10.1007/BF00753406; CUPOLI JM, 1988, CHILD ABUSE NEGLECT, V12, P151, DOI 10.1016/0145-2134(88)90023-3; DEMBO R, 1988, INT J ADDICT, V23, P351, DOI 10.3109/10826088809039203; DEMBO R, 1990, INT J ADDICT, V25, P1341, DOI 10.3109/10826089009056224; Dembo R, 1989, Violence Vict, V4, P121; DEMBO R, 1987, J ADOLESCENCE, V10, P13, DOI 10.1016/S0140-1971(87)80030-1; DEMBO R, 1988, INT J ADDICT, V23, P1101, DOI 10.3109/10826088809056189; DESENCLOS JCA, 1992, AM J PUBLIC HEALTH, V82, P426, DOI 10.2105/AJPH.82.3.426; DEYKIN EY, 1992, AM J PSYCHIAT, V149, P1341; DEYKIN EY, 1994, AM J PUBLIC HEALTH, V84, P634, DOI 10.2105/AJPH.84.4.634; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; DITOMASSO MJ, 1993, CHILD ABUSE NEGLECT, V17, P477, DOI 10.1016/0145-2134(93)90022-W; DOLL LS, 1992, CHILD ABUSE NEGLECT, V16, P855, DOI 10.1016/0145-2134(92)90087-8; DUBE R, 1988, CHILD ABUSE NEGLECT, V12, P321, DOI 10.1016/0145-2134(88)90045-2; DUBOWITZ H, 1992, AM J DIS CHILD, V146, P688, DOI 10.1001/archpedi.1992.02160180046015; ECKENRODE J, 1988, CHILD ABUSE NEGLECT, V12, P311, DOI 10.1016/0145-2134(88)90044-0; EISENBERG N, 1987, CHILD ABUSE NEGLECT, V11, P109, DOI 10.1016/0145-2134(87)90039-1; Ellason JW, 1996, B MENNINGER CLIN, V60, P39; ELLIOTT DM, 1995, J TRAUMA STRESS, V8, P629, DOI 10.1007/BF02102892; Embree BG, 1997, SOC BIOL, V44, P42; ERICKSON PI, 1991, J ADOLESCENT HEALTH, V12, P319, DOI 10.1016/0197-0070(91)90007-9; FALLER KC, 1988, CHILD WELFARE, V67, P389; FALLER KC, 1989, CHILD ABUSE NEGLECT, V13, P281, DOI 10.1016/0145-2134(89)90015-X; FEITEL B, 1992, HOSP COMMUNITY PSYCH, V43, P155; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Finkelhor D., 1984, CHILD SEXUAL ABUSE N, P150; FREUND K, 1990, ARCH SEX BEHAV, V19, P557, DOI 10.1007/BF01542465; Friedrich W. N., 1988, J INTERPERS VIOLENCE, V3, P21, DOI 10.1177/088626088003001002; FRIEDRICH WN, 1992, J INTERPERS VIOLENCE, V7, P396, DOI 10.1177/088626092007003008; FRIEDRICH WN, 1995, J PEDIATR PSYCHOL, V20, P661, DOI 10.1093/jpepsy/20.5.661; Fromuth M E, 1987, Violence Vict, V2, P241; FROMUTH ME, 1991, J INTERPERS VIOLENCE, V6, P376, DOI 10.1177/088626091006003009; FROMUTH ME, 1989, CHILD ABUSE NEGLECT, V13, P533, DOI 10.1016/0145-2134(89)90057-4; FUTTERMAN D, 1993, PEDIATRICS, V91, P730; GELLERT GA, 1993, PEDIATRICS, V91, P39; GIBBYSMITH BM, 1995, PSYCHOL REP, V77, P619, DOI 10.2466/pr0.1995.77.2.619; Golding JM, 1997, HEALTH PSYCHOL, V16, P417, DOI 10.1037/0278-6133.16.5.417; Gordon M, 1990, J FAMILY VIOLENCE, V5, P321, DOI DOI 10.1007/BF00979068; Gould D A, 1994, Arch Fam Med, V3, P252, DOI 10.1001/archfami.3.3.252; GREENBERG DM, 1993, J FORENSIC SCI, V38, P432; Harrison PA, 1997, CHILD ABUSE NEGLECT, V21, P529, DOI 10.1016/S0145-2134(97)00013-6; HARRISON PA, 1990, J ADOLESC CHEM DEPEN, V1, P53, DOI DOI 10.1300/J272V01N01_04; HARTMAN CR, 1987, HOSP COMMUNITY PSYCH, V38, P292; HASKETT ME, 1991, CHILD ABUSE NEGLECT, V15, P467, DOI 10.1016/0145-2134(91)90030-H; HAUGAARD JJ, 1989, CHILD ABUSE NEGLECT, V13, P89, DOI 10.1016/0145-2134(89)90032-X; HERNANDEZ JT, 1993, J NATL MED ASSOC, V85, P593; HIBBARD RA, 1988, AM J DIS CHILD, V142, P326, DOI 10.1001/archpedi.1988.02150030100031; HIBBARD RA, 1990, PEDIATRICS, V86, P896; HIBBARD RA, 1992, CHILD ABUSE NEGLECT, V16, P533, DOI 10.1016/0145-2134(92)90069-4; HIBBARD RA, 1992, CHILD ABUSE NEGLECT, V16, P755, DOI 10.1016/0145-2134(92)90112-5; Holmes WC, 1997, J ADOLESCENT HEALTH, V20, P414, DOI 10.1016/S1054-139X(96)00278-9; HUNT JE, 1992, LUPUS, V1, P75, DOI 10.1177/096120339200100204; HUNTER JA, 1991, J INTERPERS VIOLENCE, V6, P205, DOI 10.1177/088626091006002005; HUSSEY DL, 1992, CHILD ADOLESC SOC WO, V9, P491; HUSTON RL, 1995, CHILD ABUSE NEGLECT, V19, P165, DOI 10.1016/0145-2134(94)00114-A; HUTCHINGS PS, 1993, COMMUNITY MENT HLT J, V29, P59, DOI 10.1007/BF00760631; JACKSON H, 1993, CHILD ABUSE NEGLECT, V17, P127, DOI 10.1016/0145-2134(93)90013-U; JACOBSON A, 1990, HOSP COMMUNITY PSYCH, V41, P154; Janikowski TP, 1997, ADDICT BEHAV, V22, P447, DOI 10.1016/S0306-4603(97)84428-0; JANUS MD, 1987, ADOLESCENCE, V22, P405; JENNY C, 1994, PEDIATRICS, V94, P41; JOHNSON RL, 1987, AM J PSYCHIAT, V144, P650; JOHNSON RL, 1985, J ADOLESCENT HEALTH, V6, P372, DOI 10.1016/S0197-0070(85)80005-X; JOHNSON TC, 1988, CHILD ABUSE NEGLECT, V12, P219, DOI 10.1016/0145-2134(88)90030-0; KAPLAN MS, 1991, J INTERPERS VIOLENCE, V6, P3, DOI 10.1177/088626091006001001; KELLOGG ND, 1995, CHILD ABUSE NEGLECT, V19, P1457, DOI 10.1016/0145-2134(95)00094-9; KELSEY JL, 1986, METHODS OBSERVATIONA; KENDALLTACKETT KA, 1992, J FAM VIOLENCE, V7, P57, DOI 10.1007/BF00978724; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Koegel P, 1995, AM J PUBLIC HEALTH, V85, P1642, DOI 10.2105/AJPH.85.12.1642; KOHAN MJ, 1987, AM J ORTHOPSYCHIAT, V57, P258, DOI 10.1111/j.1939-0025.1987.tb03536.x; Langevin R., 1989, SEXUAL ABUSE, V2, P227; LANKTREE C, 1991, CHILD ABUSE NEGLECT, V15, P447, DOI 10.1016/0145-2134(91)90028-C; Lenderking WR, 1997, J GEN INTERN MED, V12, P250, DOI 10.1046/j.1525-1497.1997.012004250.x; LIVINGSTON R, 1993, J AM ACAD CHILD PSY, V32, P948, DOI 10.1097/00004583-199309000-00009; Lodico MA, 1996, J ADOLESCENT HEALTH, V18, P211, DOI 10.1016/1054-139X(95)00167-Q; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; MacMillan HL, 1997, JAMA-J AM MED ASSOC, V278, P131, DOI 10.1001/jama.278.2.131; MARSHALL WN, 1988, AM J DIS CHILD, V142, P664, DOI 10.1001/archpedi.1988.02150060098041; MCCANN J, 1989, CHILD ABUSE NEGLECT, V13, P179, DOI 10.1016/0145-2134(89)90005-7; MCCLELLAN J, 1995, CHILD ABUSE NEGLECT, V19, P1245, DOI 10.1016/0145-2134(95)00087-O; McClellan J, 1997, J AM ACAD CHILD PSY, V36, P959, DOI 10.1097/00004583-199707000-00018; MCCORMACK A, 1986, CHILD ABUSE NEGLECT, V10, P387, DOI 10.1016/0145-2134(86)90014-1; MCCORMACK A, 1992, J FAM VIOLENCE, V7, P219, DOI 10.1007/BF00979029; MCFADDEN RD, 1997, NY TIMES        0224, pA1; MCKELVEY RS, 1995, CHILD ABUSE NEGLECT, V19, P545, DOI 10.1016/0145-2134(95)00014-Y; Melchert TP, 1997, CHILD ABUSE NEGLECT, V21, P125, DOI 10.1016/S0145-2134(96)00138-X; MIAN M, 1986, CHILD ABUSE NEGLECT, V10, P223, DOI 10.1016/0145-2134(86)90083-9; Moisan PA, 1997, CHILD ABUSE NEGLECT, V21, P473, DOI 10.1016/S0145-2134(97)00007-0; MOORE KA, 1989, FAM PLANN PERSPECT, V21, P110, DOI 10.2307/2135660; Morris P A, 1991, J Child Adolesc Psychiatr Ment Health Nurs, V4, P49, DOI 10.1111/j.1744-6171.1991.tb00489.x; MURAM D, 1991, CHILD ABUSE NEGLECT, V15, P523, DOI 10.1016/0145-2134(91)90036-D; NAGY S, 1994, PEDIATRICS, V93, P570; Neisen J. H., 1990, J PSYCHOL HUMAN SEXU, V3, P151; NELSON DE, 1994, J SCHOOL HEALTH, V64, P413, DOI 10.1111/j.1746-1561.1994.tb03264.x; NUTTALL R, 1994, CHILD ABUSE NEGLECT, V18, P455, DOI 10.1016/0145-2134(94)90030-2; OKAMI P, 1991, ARCH SEX BEHAV, V20, P437, DOI 10.1007/BF01542407; OLIVARDIA R, 1995, AM J PSYCHIAT, V152, P1279; PARIS J, 1994, J NERV MENT DIS, V182, P375, DOI 10.1097/00005053-199407000-00002; PIERCE R, 1985, CHILD ABUSE NEGLECT, V9, P191, DOI 10.1016/0145-2134(85)90011-0; POWERS JL, 1988, CHILD ABUSE NEGLECT, V12, P189, DOI 10.1016/0145-2134(88)90027-0; PRIEST R, 1992, AM J ORTHOPSYCHIAT, V62, P475, DOI 10.1037/h0079353; Raiha NK, 1997, CHILD ABUSE NEGLECT, V21, P759, DOI 10.1016/S0145-2134(97)00037-9; REINHART MA, 1987, CLIN PEDIATR, V26, P470, DOI 10.1177/000992288702600907; REINHART MA, 1987, CHILD ABUSE NEGLECT, V11, P229, DOI 10.1016/0145-2134(87)90062-7; REMAFEDI G, 1991, PEDIATRICS, V87, P869; RESNICK MD, 1994, PEDIATRICS, V94, P907; Rew L, 1991, Arch Psychiatr Nurs, V5, P331, DOI 10.1016/0883-9417(91)90034-3; Rhynard J, 1997, J SCHOOL HEALTH, V67, P89, DOI 10.1111/j.1746-1561.1997.tb03419.x; RICHARDSON MF, 1993, J FAM VIOLENCE, V8, P89, DOI 10.1007/BF00986995; Risin L. I., 1987, J INTERPERS VIOLENCE, V2, P309, DOI [10.1177/088626087002003006, DOI 10.1177/088626087002003006]; ROANE TH, 1992, CHILD WELFARE, V71, P231; Robin RW, 1997, PSYCHIAT SERV, V48, P826; Robin RW, 1997, CHILD ABUSE NEGLECT, V21, P769, DOI 10.1016/S0145-2134(97)00038-0; ROESLER TA, 1994, J NERV MENT DIS, V182, P145, DOI 10.1097/00005053-199403000-00003; ROHSENOW DJ, 1988, J SUBST ABUSE TREAT, V5, P13, DOI 10.1016/0740-5472(88)90032-3; ROSE SM, 1991, COMMUNITY MENT HLT J, V27, P255, DOI 10.1007/BF00757260; ROSE SM, 1991, HOSP COMMUNITY PSYCH, V42, P499; Rosen LN, 1996, MIL MED, V161, P342, DOI 10.1093/milmed/161.6.342; ROSENTHAL JA, 1988, CHILD ABUSE NEGLECT, V12, P263, DOI 10.1016/0145-2134(88)90034-8; ROSENTHAL JA, 1991, CHILD ABUSE NEGLECT, V15, P249, DOI 10.1016/0145-2134(91)90069-P; ROSSETTI SJ, 1995, CHILD ABUSE NEGLECT, V19, P1469, DOI 10.1016/0145-2134(95)00100-1; RUBINSTEIN M, 1993, AM J PSYCHIAT, V150, P262; Ryan G, 1996, J AM ACAD CHILD PSY, V35, P17, DOI 10.1097/00004583-199601000-00008; SABOTTA EE, 1992, CHILD ABUSE NEGLECT, V16, P627, DOI 10.1016/0145-2134(92)90101-V; SANSONNETHAYDEN H, 1987, J AM ACAD CHILD PSY, V26, P753, DOI 10.1097/00004583-198709000-00023; Sarwer DB, 1997, CHILD ABUSE NEGLECT, V21, P649, DOI 10.1016/S0145-2134(97)00030-6; SCHULTE JG, 1995, J NERV MENT DIS, V183, P111, DOI 10.1097/00005053-199502000-00010; Sher KJ, 1997, J STUD ALCOHOL, V58, P414, DOI 10.15288/jsa.1997.58.414; SHRIER D, 1988, J NATL MED ASSOC, V80, P1189; SIEGEL JM, 1987, AM J EPIDEMIOL, V126, P1141, DOI 10.1093/oxfordjournals.aje.a114752; SIMPSON TL, 1994, J SUBST ABUSE TREAT, V11, P347, DOI 10.1016/0740-5472(94)90045-0; Sobsey D, 1997, CHILD ABUSE NEGLECT, V21, P707, DOI 10.1016/S0145-2134(97)00033-1; SPENCER MJ, 1986, PEDIATRICS, V78, P133; Stein MB, 1996, AM J PSYCHIAT, V153, P275; Stevenson M. R., 1992, J PSYCHOL HUM SEX, V4, P57, DOI [10.1300/J056v04n04_05, DOI 10.1300/J056V04N04_05]; SULLIVAN PM, 1991, ANN OTO RHINOL LARYN, V100, P188, DOI 10.1177/000348949110000304; SWETT C, 1990, AM J PSYCHIAT, V147, P632; Tingus KD, 1996, CHILD ABUSE NEGLECT, V20, P63, DOI 10.1016/0145-2134(95)00116-6; TJADEN PG, 1992, CHILD ABUSE NEGLECT, V16, P807, DOI 10.1016/0145-2134(92)90083-4; VERMUND SH, 1990, J ADOLESCENT HEALTH, V11, P449, DOI 10.1016/0197-0070(90)90094-I; VIOLATO C, 1993, PSYCHOL REP, V72, P767, DOI 10.2466/pr0.1993.72.3.767; WALLEN J, 1992, J SUBST ABUSE TREAT, V9, P243, DOI 10.1016/0740-5472(92)90067-X; WEBER FT, 1992, J ADOLESCENT HEALTH, V13, P600, DOI 10.1016/1054-139X(92)90374-K; Weine SM, 1997, J TRAUMA STRESS, V10, P291; WELLMAN MM, 1993, CHILD ABUSE NEGLECT, V17, P539, DOI 10.1016/0145-2134(93)90028-4; Whiffen VE, 1997, BRIT J CLIN PSYCHOL, V36, P185, DOI 10.1111/j.2044-8260.1997.tb01406.x; WINDLE M, 1995, AM J PSYCHIAT, V152, P1322; WOLFE DA, 1994, CHILD ABUSE NEGLECT, V18, P37, DOI 10.1016/0145-2134(94)90094-9; WORLING JR, 1995, CHILD ABUSE NEGLECT, V19, P633, DOI 10.1016/0145-2134(95)00021-Y; WORLING JR, 1995, J ABNORM PSYCHOL, V104, P610, DOI 10.1037/0021-843X.104.4.610; WURTELE SK, 1990, CLIN J PAIN, V6, P110; Young E A, 1997, Depress Anxiety, V5, P66, DOI 10.1002/(SICI)1520-6394(1997)5:2<66::AID-DA2>3.0.CO;2-3; ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572; 1998, NY TIMES        0407, pA18	176	291	295	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1855	1862		10.1001/jama.280.21.1855	http://dx.doi.org/10.1001/jama.280.21.1855			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	141ZZ	9846781				2022-12-28	WOS:000077176600032
J	Qizilbash, N; Whitehead, A; Higgins, J; Wilcock, G; Schneider, L; Farlow, M				Qizilbash, N; Whitehead, A; Higgins, J; Wilcock, G; Schneider, L; Farlow, M		Dementia Trialists Collaboration	Cholinesterase inhibition for Alzheimer disease - A meta-analysis of the tacrine trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DOUBLE-BLIND; CLINICAL-TRIALS; RATING-SCALE; TETRAHYDROAMINOACRIDINE; LECITHIN; MULTICENTER; THA; METAANALYSIS; CROSSOVER; EFFICACY	Objectives.-To determine the effects of cholinesterase inhibition with tacrine hydrochloride for the symptoms of Alzheimer disease in terms of cognitive performance, clinical global impression, behavior, and functional autonomy. Data Sources.-The Cochrane Dementia Group registry of trials. Study Selection.-Unconfounded, randomized, double-blind, placebo-controlled trials in which tacrine had been given for more than 1 day and that were completed before January 1, 1996. Data Extraction.-Two reviewers independently selected trials for inclusion and individual patient data were sought. Data Synthesis.-Data were analyzed from 12 trials that included 1984 patients with Alzheimer disease. At 12 weeks, cognitive performance, as measured by the Mini-Mental State Examination (score range, 0-30), was better in patients receiving tacrine than in patients receiving placebo by 0.62 points (95% confidence interval [CI], 0.23-1.00; P = .002). Compared with similar untreated patients who would be expected to deteriorate by 0.50 to 1.00 points on the Mini-Mental State Examination during 12 weeks, the progress of patients receiving tacrine would be expected to range between an improvement of 0.12 and a deterioration of 0.38 points. The odds ratio for improvement on the Clinical Global Impression of Change scale (range, 1-7) for patients receiving tacrine compared with those receiving placebo was 1.58 (95% CI, 1.18-2.1 1; P = .002). The behavioral noncognitive subscale of the Alzheimer's Disease Assessment Scale (range, 0-50) showed a difference in favor of tacrine of 0.58 points (95% CI, 0.17-1.00; P = .006). Improvement on the Progressive Deterioration Scale, largely an index of functional activities, was not significant (0.75; 95% CI, -0.43 to 1.93; P = .21). Age, severity of dementia, and exposure to tacrine prior to randomization had no clear influence on the treatment effect. There was a nonsignificant trend toward increasing effect with increasing dose for cognitive function and the Clinical Global impression of Change. For patients without prior exposure to tacrine, the odds of patients' withdrawing during the study while they were receiving tacrine compared with placebo was 3.63 (95% CI, 2.80-4.71; P < .001). Eleven (95% CI, 7-31) patients would need to be treated to achieve any improvement on the Clinical Global Impression scale, and 42 (95% CI, 23-125) to achieve a moderate or marked improvement. One patient would be expected to withdraw for every 4 (95% CI, 3-5) patients treated. Conclusions.-Cholinesterase inhibition with tacrine appears to reduce deterioration in cognitive performance during the first 3 months and increase the odds of global clinical improvement. Effects observed on measures of behavioral disturbance were of questionable clinical significance, and functional autonomy was not significantly affected. The clinical relevance of the benefits of cholinesterase inhibition remains controversial, and long-term trials with clinically relevant end points are required.	Univ Oxford, Radcliffe Infirm, Dept Clin Geratol, Cochrane Dementia Grp,Dementia Trialists Collabor, Oxford OX2 6HE, England; Univ Reading, MPS Res Unit, Reading RG6 2AH, Berks, England; Inst Child Hlth, Systemat Reviews TRaining Unit, London, England; Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England; Univ So Calif, Sch Med, Dept Psychiat, Los Angeles, CA USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA	Radcliffe Infirmary; University of Oxford; University of Reading; University of London; University College London; University of Southern California; Indiana University System; Indiana University-Purdue University Indianapolis	Qizilbash, N (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Geratol, Cochrane Dementia Grp,Dementia Trialists Collabor, Oxford OX2 6HE, England.	nawab.qizilbash@geratology.ox.ac.uk	Higgins, Julian PT/H-4008-2011	Higgins, Julian PT/0000-0002-8323-2514				CHATELLIER G, 1990, BRIT MED J, V300, P495, DOI 10.1136/bmj.300.6723.495; DAVIES B, 1990, INT J GERIATR PSYCH, V5, P317, DOI 10.1002/gps.930050508; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DAVIS KL, 1995, LANCET, V345, P625, DOI 10.1016/S0140-6736(95)90526-X; DEJONG R, 1989, CLIN THER, V11, P545; EAGGER S, 1992, INT J GERIATR PSYCH, V7, P115, DOI 10.1002/gps.930070208; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; FARLOW MR, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P283; Ferris SH, 1997, ALZ DIS ASSOC DIS, V11, pS1; FITTEN LJ, 1990, AM J PSYCHIAT, V147, P239; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORETTE F, 1995, EUR J NEUROL, V2, P1; Foster NL, 1996, DEMENTIA, V7, P260, DOI 10.1159/000106890; GAUTHIER S, 1990, NEW ENGL J MED, V322, P1272, DOI 10.1056/NEJM199005033221804; Guy W, 1976, PUBLICATION ADM, V76-338, P218; IQBAL K, 1991, ALZHEIMERS DIS BASIC, P522; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; KNOPMAN DS, 1994, NEUROLOGY, V44, P2315, DOI 10.1212/WNL.44.12.2315; MALTBY N, 1994, BMJ-BRIT MED J, V308, P879, DOI 10.1136/bmj.308.6933.879; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MINTHON L, 1993, DEMENTIA, V4, P32, DOI 10.1159/000107293; MOLLOY DW, 1991, CAN MED ASSOC J, V144, P29; MORRIS JC, IN PRESS NEUROLOGY; NORDBERG A, 1992, NEUROBIOL AGING, V13, P747, DOI 10.1016/0197-4580(92)90099-J; QIZILBASH N, 1997, DEMENTIA MODULE COCH, P3; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, J AM GERIATR SOC, V45, P923, DOI 10.1111/j.1532-5415.1997.tb02960.x; Smith F, 1996, J Biopharm Stat, V6, P59, DOI 10.1080/10543409608835122; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; WHITEHEAD A, 1994, STAT MED, V13, P2503, DOI 10.1002/sim.4780132313; WILCOCK GK, 1993, AGE AGEING, V22, P316, DOI 10.1093/ageing/22.5.316; WOOD PC, 1994, INT J GERIATR PSYCH, V9, P649, DOI 10.1002/gps.930090809	34	119	120	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1777	1782		10.1001/jama.280.20.1777	http://dx.doi.org/10.1001/jama.280.20.1777			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842955				2022-12-28	WOS:000077081400035
J	Ghooi, RB; Ghooi, SR				Ghooi, RB; Ghooi, SR			A mother in pain	LANCET			English	Editorial Material											Ghooi, RB (corresponding author), 697 Pocket A,Sarita Vihar,Mathura Rd, New Delhi 110044, India.								0	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1998	352	9140					1625	1625		10.1016/S0140-6736(98)07150-5	http://dx.doi.org/10.1016/S0140-6736(98)07150-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843124				2022-12-28	WOS:000076998900048
J	Merzenich, M				Merzenich, M			Neuroscience - Long-term change of mind	SCIENCE			English	Editorial Material							MASSIVE CORTICAL REORGANIZATION; UPPER-LIMB AMPUTATION; MOTOR REORGANIZATION; MAGNETIC STIMULATION; SOMATOSENSORY CORTEX; MONKEYS; MAPS		Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Merzenich, M (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA.							Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; CRONHOLM B, 1951, Acta Psychiatr Neurol Scand Suppl, V72, P1; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FUHR P, 1992, ELECTROEN CLIN NEURO, V85, P53, DOI 10.1016/0168-5597(92)90102-H; Haber WB, 1955, J PSYCHOL, V40, P115, DOI 10.1080/00223980.1955.9712969; HENDERSON WR, 1948, J NEUROL NEUROSUR PS, V11, P88, DOI 10.1136/jnnp.11.2.88; Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121; KEW JJM, 1994, J NEUROPHYSIOL, V72, P2517, DOI 10.1152/jn.1994.72.5.2517; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PALCA J, 1991, SCIENCE, V252, P1789, DOI 10.1126/science.2063191; PascualLeone A, 1996, NEUROREPORT, V7, P2068, DOI 10.1097/00001756-199609020-00002; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	17	43	45	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 6	1998	282	5391					1062	1063		10.1126/science.282.5391.1062	http://dx.doi.org/10.1126/science.282.5391.1062			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136YY	9841454				2022-12-28	WOS:000076887700035
J	Jasny, BR; Hines, PJ				Jasny, BR; Hines, PJ			A genome sampler	SCIENCE			English	Editorial Material																			0	1	1	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					651	651		10.1126/science.282.5389.651	http://dx.doi.org/10.1126/science.282.5389.651			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9841419				2022-12-28	WOS:000076607500033
J	Ferguson, AD; Hofmann, E; Coulton, JW; Diederichs, K; Welte, W				Ferguson, AD; Hofmann, E; Coulton, JW; Diederichs, K; Welte, W			Siderophore-mediated iron transport: Crystal structure of FhuA with bound lipopolysaccharide	SCIENCE			English	Article							ESCHERICHIA-COLI K-12; OUTER-MEMBRANE; ANOMALOUS DIFFRACTION; CELL-ENVELOPE; PROTEIN; RECEPTOR; CHANNEL; BINDING; ENERGY; TONB	FhuA, the receptor for ferrichrome-iron in Escherichia coli, is a member of a family of integral outer membrane proteins, which, together with the energy-transducing protein TonB, mediate the active transport of ferric siderophores across the outer membrane of Cram-negative bacteria. The three-dimensional structure of FhuA is presented here in two conformations: with and without ferrichrome-iron at resolutions of 2.7 and 2.5 angstroms, respectively. FhuA is a beta barrel composed of 22 antiparallel beta strands. In contrast to the typical trimeric arrangement found in porins, FhuA is monomeric. Located within the beta barrel is a structurally distinct domain, the "cork," which mainly consists of a four-stranded beta sheet and four short alpha helices. A single Lipopolysaccharide molecule is noncovalently associated with the membrane-embedded region of the protein. Upon binding of ferrichrome-iron, conformational changes are transduced to the periplasmic pocket of FhuA, signaling the Ligand-Loaded status of the receptor. Sequence homologies and mutagenesis data are used to propose a structural mechanism for TonB-dependent siderophore-mediated transport across the outer membrane.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	University of Konstanz; McGill University	Welte, W (corresponding author), Univ Konstanz, Fak Biol, M656, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de	Hofmann, Eckhard/GPF-5024-2022	Hofmann, Eckhard/0000-0003-4874-372X				Adam G., 1968, STRUCTURAL CHEM MOL, P198; ANGYAL SJ, 1995, CARBOHYD RES, V266, P143, DOI 10.1016/0008-6215(94)00253-C; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR 3 1; BUTCHER D, 1995, PEPT BIOPOLYM, V35, P109; CARMEL G, 1990, J BACTERIOL, V172, P1861, DOI 10.1128/jb.172.4.1861-1869.1990; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; COWTAN K, 1994, ACTA CRYSTALLOGR D, V50, P760; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; DOUBLIE S, METHODS ENZYMOL, V276, P52397; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ghosh A, 1996, CHEM BIOL, V3, P1011, DOI 10.1016/S1074-5521(96)90167-2; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARPLUS PA, UNPUB; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; Killmann H, 1998, J BACTERIOL, V180, P3845, DOI 10.1128/JB.180.15.3845-3852.1998; Killmann H, 1996, J BACTERIOL, V178, P6913, DOI 10.1128/jb.178.23.6913-6920.1996; KILLMANN H, 1992, J BACTERIOL, V174, P3479, DOI 10.1128/JB.174.11.3479-3486.1992; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LOCHER K, 1997, EUR J BIOCHEM, V247, P779; Mademidis A, 1997, MOL MICROBIOL, V26, P1109, DOI 10.1046/j.1365-2958.1997.6592008.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; NEILANDS JB, 1952, J AM CHEM SOC, V74, P4846, DOI 10.1021/ja01139a033; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; WELTE W, 1995, KIDNEY INT, V48, P930, DOI 10.1038/ki.1995.374; WELTE W, 1998, P NATO ADV WORKSH NE, P239; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502	49	646	665	4	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2215	2220		10.1126/science.282.5397.2215	http://dx.doi.org/10.1126/science.282.5397.2215			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856937	Green Submitted			2022-12-28	WOS:000077645800035
J	Yu, ZC; Eicher, U				Yu, ZC; Eicher, U			Abrupt climate oscillations during the last deglaciation in central North America	SCIENCE			English	Article							STABLE-ISOTOPE; SOUTHERN ONTARIO; LAKE-SEDIMENTS; ICE-CORE; HOLOCENE; ATLANTIC; HISTORY; RECORDS; OXYGEN; INSTABILITY	Evidence from stable isotopes and a variety of proxies from two Ontario Lakes demonstrate that many of the Late glacial-to-early Holocene events that are well known from the North Atlantic seaboard, such as the Gerzensee-Killarney Oscillation (also known as the Intra-Allerod Cold Period), Younger Dryas, and Preboreal Oscillation, also occurred in central North America. These results thus imply that climatic forcing acted in the same manner in both regions and that atmospheric circulation played an important role in the propagation of these events.	Royal Ontario Museum, Ctr Biodivers & Conservat Biol, Toronto, ON M5S 2C6, Canada; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	Royal Ontario Museum; University of Bern; University of Toronto	Yu, ZC (corresponding author), Canadian Forest Serv, 5320 122 St, Edmonton, AB T6H 3S5, Canada.	zyu@nrcan.gc.ca	Yu, Zicheng/D-4108-2012	Yu, Zicheng/0000-0003-2358-2712				Ahlberg K, 1996, BOREAS, V25, P257, DOI 10.1111/j.1502-3885.1996.tb00641.x; Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; BARNETT PJ, 1979, CAN J EARTH SCI, V16, P568, DOI 10.1139/e79-051; BECKER B, 1991, NATURE, V353, P647, DOI 10.1038/353647a0; BENNETT KD, 1987, CAN J BOT, V65, P1792, DOI 10.1139/b87-248; Bjorck S, 1996, SCIENCE, V274, P1155, DOI 10.1126/science.274.5290.1155; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1964, TELLUS, V16, P436; EICHER U, 1976, Boreas (Oslo), V5, P109; EICHER U, 1987, GEOGR HELV, V2, P99; Eicher U., 1980, MITTEILUNGEN NATURFO, V37, P65; Elias SA, 1996, J QUATERNARY SCI, V11, P417; Friedman I, 1977, COMPILATION STABLE I; FRITZ P, 1975, SCIENCE, V190, P267, DOI 10.1126/science.190.4211.267; FRITZ P, 1987, PALAEOGEOGR PALAEOCL, V58, P183, DOI 10.1016/0031-0182(87)90059-9; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HAJDAS I, 1993, CLIM DYNAM, V9, P107, DOI 10.1007/BF00209748; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; KUTZBACH JE, 1988, SCIENCE, V241, P1043, DOI 10.1126/science.241.4869.1043; LEHMAN SJ, 1992, NATURE, V356, P757, DOI 10.1038/356757a0; Levesque AJ, 1997, NATURE, V385, P423, DOI 10.1038/385423a0; LEVESQUE AJ, 1993, NATURE, V361, P623, DOI 10.1038/361623a0; Lewis CFM, 1992, CLIM DYNAM, V6, P241, DOI 10.1007/BF00193537; LOTTER AF, 1992, J QUATERNARY SCI, V7, P187; MCANDREWS JH, 1981, QUATERNARY PALEOCLIM, P319; MCCREA JM, 1950, J CHEM PHYS, V18, P849, DOI 10.1063/1.1747785; MOTT RJ, 1978, CAN J EARTH SCI, V15, P1101, DOI 10.1139/e78-116; REA DK, 1994, GEOLOGY, V22, P1059, DOI 10.1130/0091-7613(1994)022<1059:GLPCIO>2.3.CO;2; SHANE LCK, 1987, BOREAS, V16, P1; Shemesh A, 1998, GEOPHYS RES LETT, V25, P1935, DOI 10.1029/98GL01443; SIEGENTHALER U, 1984, ANN GLACIOL, V5, P149, DOI 10.3189/1984AoG5-1-149-152; SIEGENTHALER U, 1986, HDB HOLOCENE PALAEOE, P407; Stager JC, 1997, SCIENCE, V276, P1834, DOI 10.1126/science.276.5320.1834; STUIVER M, 1970, J GEOPHYS RES, V75, P5247, DOI 10.1029/JC075i027p05247; STUIVER M, 1968, SCIENCE, V162, P994, DOI 10.1126/science.162.3857.994; SZEICZ JM, 1991, CAN J BOT, V69, P1507, DOI 10.1139/b91-195; TERASMAE J, 1980, CAN J EARTH SCI, V17, P1087, DOI 10.1139/e80-107; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210; Webb Thompson III, 1993, P514; WRIGHT HE, 1989, QUATERNARY SCI REV, V8, P295, DOI 10.1016/0277-3791(89)90033-4; YU Z, 1997, THESIS U TORONTO; Yu ZC, 1997, GEOLOGY, V25, P251, DOI 10.1130/0091-7613(1997)025<0251:MHDCCB>2.3.CO;2; Yu ZY, UNPUB	46	118	127	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1998	282	5397					2235	2238		10.1126/science.282.5397.2235	http://dx.doi.org/10.1126/science.282.5397.2235			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856941				2022-12-28	WOS:000077645800039
J	Rodien, P; Bremont, C; Parma, J; Van Sande, J; Costagliola, S; Luton, JP; Vassart, G; Duprez, L				Rodien, P; Bremont, C; Parma, J; Van Sande, J; Costagliola, S; Luton, JP; Vassart, G; Duprez, L			Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPEREMESIS GRAVIDARUM; THYROID-FUNCTION; THYROTOXICOSIS; PREGNANCY; HORMONE; PROTEINS; CELLS; TSH		Free Univ Brussels, Fac Med, Inst Rech Interdisciplinaire, Brussels, Belgium; Free Univ Brussels, Fac Med, Serv Genet Med, Brussels, Belgium; Hop Cochin, Serv Endocrinol Malad Metab, F-75674 Paris, France; CNRS, UPR 1524, Paris, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Vassart, G (corresponding author), IRIBHN, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		costagliola, sabine/D-4864-2012; Rodien, Patrice/AAT-7909-2021					BOUILLON R, 1982, AM J OBSTET GYNECOL, V143, P922, DOI 10.1016/0002-9378(82)90475-6; BURROW GN, 1993, ENDOCR REV, V14, P194, DOI 10.1210/er.14.2.194; Costagliola S, 1998, J IMMUNOL, V160, P1458; DEPUE RH, 1987, AM J OBSTET GYNECOL, V156, P1137, DOI 10.1016/0002-9378(87)90126-8; EVANS AJ, 1986, BRIT J OBSTET GYNAEC, V93, P520, DOI 10.1111/j.1471-0528.1986.tb08667.x; Glinoer D, 1997, ENDOCR REV, V18, P404, DOI 10.1210/er.18.3.404; Goodwin TM, 1997, CLIN OBSTET GYNECOL, V40, P32, DOI 10.1097/00003081-199703000-00006; GOODWIN TM, 1992, J CLIN ENDOCR METAB, V75, P1333, DOI 10.1210/jc.75.5.1333; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; HARADA A, 1979, J CLIN ENDOCR METAB, V48, P793, DOI 10.1210/jcem-48-5-793; HOERMANN R, 1991, ENDOCRINOLOGY, V128, P1129; JEFFCOATE WJ, 1985, BRIT J OBSTET GYNAEC, V92, P413, DOI 10.1111/j.1471-0528.1985.tb01117.x; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KIMURA M, 1993, CLIN ENDOCRINOL, V38, P345, DOI 10.1111/j.1365-2265.1993.tb00512.x; KRENTZ AJ, 1994, BRIT J CLIN PRACT, V48, P75; LUDGATE M, 1990, MOL CELL ENDOCRINOL, V73, P13; MRABET NT, 1992, BIOCHEMISTRY-US, V31, P2239, DOI 10.1021/bi00123a005; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; ROSENTHAL FD, 1976, BRIT MED J, V2, P209, DOI 10.1136/bmj.2.6029.209; STEWART HJ, 1988, J REPROD FERTIL, V83, P1, DOI 10.1530/jrf.0.0830001; SWAMINATHAN R, 1989, ACTA ENDOCRINOL-COP, V120, P155, DOI 10.1530/acta.0.1200155; TSURUTA E, 1995, J CLIN ENDOCR METAB, V80, P350, DOI 10.1210/jc.80.2.350; WILSON R, 1992, CLIN ENDOCRINOL, V37, P331, DOI 10.1111/j.1365-2265.1992.tb02333.x; YOSHIMURA M, 1993, J CLIN ENDOCR METAB, V77, P1009, DOI 10.1210/jc.77.4.1009	25	174	178	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1823	1826		10.1056/NEJM199812173392505	http://dx.doi.org/10.1056/NEJM199812173392505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854118				2022-12-28	WOS:000077545800005
J	Quinn, N				Quinn, N			Charles David Marsden - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1661	1661		10.1136/bmj.317.7173.1661	http://dx.doi.org/10.1136/bmj.317.7173.1661			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848926	Green Published			2022-12-28	WOS:000077602100066
J	Bargmann, CI				Bargmann, CI			Neurobiology of the Caenorhabditis elegans genome	SCIENCE			English	Review							NUCLEOTIDE-GATED CHANNEL; GLR-1 GLUTAMATE-RECEPTOR; NEMATODE ASCARIS-SUUM; C-ELEGANS; CHEMOSENSORY RECEPTORS; INHIBITORY MOTONEURONS; NEURONAL DEGENERATION; CHLORIDE CHANNEL; NERVOUS-SYSTEM; GENE	Neurotransmitter receptors, neurotransmitter synthesis and release pathways, and heterotrimeric GTP-binding protein (G protein)-coupled second messenger pathways are highly conserved between Caenorhabditis elegans and mammals, but gap junctions and chemosensory receptors have independent origins in vertebrates and nematodes. Most ion channels are similar to vertebrate channels but there are no predicted voltage-activated sodium channels. The C. elegans genome encodes at least 80 potassium channels, 90 neurotransmitter-gated ion channels, 50 peptide receptors, and up to 1000 orphan receptors that may be chemoreceptors, For many gene families, C. elegans has both conventional members and divergent outliers with weak homology to known genes; these outliers may provide insights into previously unknown functions of conserved protein families.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618				ALFONSO A, 1994, J NEUROSCI, V14, P2290; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ANDERSON PAV, 1993, P NATL ACAD SCI USA, V90, P7419, DOI 10.1073/pnas.90.15.7419; [Anonymous], COMMUNICATION; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Barger AJ, 1998, J NEUROSCI, V18, P2871; Barnes TM, 1997, J NEUROCHEM, V69, P2251; Barnes TM, 1996, J NEUROCHEM, V67, P46; BIRNBY D, UNPUB; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; Colbert HA, 1997, J NEUROSCI, V17, P8259; COWDEN C, 1993, J COMP NEUROL, V333, P455, DOI 10.1002/cne.903330311; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DAVIS RE, 1989, J NEUROSCI, V9, P403; DAVIS RE, 1989, J NEUROSCI, V9, P415; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Elkes DA, 1997, NEURON, V19, P165, DOI 10.1016/S0896-6273(00)80356-6; Fleming JT, 1997, J NEUROSCI, V17, P5843; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUANG MX, 1995, NATURE, V378, P292, DOI 10.1038/378292a0; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; JOHNSON CD, 1981, GENETICS, V97, P261; Johnstone DB, 1997, NEURON, V19, P151, DOI 10.1016/S0896-6273(00)80355-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Jorgensen Erik M., 1995, Seminars in Developmental Biology, V6, P207, DOI 10.1016/S1044-5781(06)80030-7; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Korswagen HC, 1997, GENE DEV, V11, P1493, DOI 10.1101/gad.11.12.1493; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; Li HY, 1997, P NATL ACAD SCI USA, V94, P5912, DOI 10.1073/pnas.94.11.5912; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Maryon EB, 1996, J CELL BIOL, V134, P885, DOI 10.1083/jcb.134.4.885; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1998, J NEUROSCI, V18, P70; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Olde B, 1997, J MOL NEUROSCI, V8, P53, DOI 10.1007/BF02736863; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Phelan P, 1998, NATURE, V391, P181, DOI 10.1038/34426; RAIZEN DM, 1995, GENETICS, V141, P1365; Rand JB, 1995, METHOD CELL BIOL, V48, P187; RANKIN CH, 1990, BEHAV BRAIN RES, V37, P89, DOI 10.1016/0166-4328(90)90074-O; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Robertson HM, 1998, GENOME RES, V8, P449, DOI 10.1101/gr.8.5.449; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; Sakube Y, 1997, J MOL BIOL, V267, P849, DOI 10.1006/jmbi.1997.0910; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; STARICH TA, 1993, GENETICS, V133, P527; STRETTON AOW, 1991, PARASITOLOGY, V102, pS107, DOI 10.1017/S0031182000073339; STRETTON AOW, 1985, TRENDS NEUROSCI, V8, P294, DOI 10.1016/0166-2236(85)90105-5; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tavernarakis N, 1997, NEURON, V18, P107, DOI 10.1016/S0896-6273(01)80050-7; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WALROND JP, 1985, J NEUROSCI, V5, P9; WALROND JP, 1985, J NEUROSCI, V5, P1; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wen JYM, 1997, BEHAV NEUROSCI, V111, P354, DOI 10.1037/0735-7044.111.2.354; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zwaal RR, 1997, GENETICS, V145, P715; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	87	665	727	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2028	2033		10.1126/science.282.5396.2028	http://dx.doi.org/10.1126/science.282.5396.2028			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851919				2022-12-28	WOS:000077467100037
J	Poltorak, A; He, XL; Smirnova, I; Liu, MY; Van Huffel, C; Du, X; Birdwell, D; Alejos, E; Silva, M; Galanos, C; Freudenberg, M; Ricciardi-Castagnoli, P; Layton, B; Beutler, B				Poltorak, A; He, XL; Smirnova, I; Liu, MY; Van Huffel, C; Du, X; Birdwell, D; Alejos, E; Silva, M; Galanos, C; Freudenberg, M; Ricciardi-Castagnoli, P; Layton, B; Beutler, B			Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene	SCIENCE			English	Article							LIPOPOLYSACCHARIDE BINDING-PROTEIN; TUMOR NECROSIS FACTOR; C-JUN; ENDOTOXIN; DROSOPHILA; CELLS; TOLL; CD14; 18-WHEELER; CACHECTIN	Mutations of the gene Lps selectively impede Lipopolysaccharide (LPS) signal transduction in C3H/HeJ and C57BL/10ScCr mice, rendering them resistant to endotoxin yet highly susceptible to Gram-negative infection. The codominant Lps(d) allele of C3H/HeJ mice was shown to correspond to a missense mutation in the third exon of the Toll-Like receptor-4 gene (Tlr4), predicted to replace proline with histidine at position 712 of the polypeptide chain. C57BL/10ScCr mice are homozygous for a null mutation of Tlr4, Thus, the mammalian Tlr4 protein has been adapted primarily to subserve the recognition of LPS and presumably transduces the LPS signal across the plasm a mem bra ne. Destructive mutations of Tlr4 predispose to the development of Gram-negative sepsis, Leaving most aspects of immune function intact.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; CNR, Cellular & Mol Pharmacol Ctr, I-20133 Milan, Italy; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Consiglio Nazionale delle Ricerche (CNR); Max Planck Society	Beutler, B (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Castagnoli, Paola/E-8288-2010; Eckhardt, Erik/G-1567-2010	Van Huffel, Christophe/0000-0001-6127-3027; Freudenberg, Marina Alexandra/0000-0001-5894-1805				APTE RN, 1977, J IMMUNOL, V119, P1898; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; CHIANG C, 1994, MECH DEVELOP, V47, P225; COUTINHO A, 1977, EUR J IMMUNOL, V7, P325, DOI 10.1002/eji.1830070517; COUTINHO A, 1978, IMMUNOGENETICS, V7, P17, DOI 10.1007/BF01843983; ELDON E, 1994, DEVELOPMENT, V120, P885; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hu JX, 1997, GENOME RES, V7, P693, DOI 10.1101/gr.7.7.693; Kuhns DB, 1997, J IMMUNOL, V158, P3959; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MICHALEK SM, 1980, J INFECT DIS, V141, P55, DOI 10.1093/infdis/141.1.55; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; POLTORAK A, UNPUB; ROSENSTREICH DL, 1978, J IMMUNOL, V121, P1664; ROSENSTREICH DL, 1977, J INFECT DIS, V136, pS239, DOI 10.1093/infdis/136.Supplement.S239; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VOGEL SN, 1979, J IMMUNOL, V122, P619; VOGEL SN, 1992, TUMOR NECROSIS FACTO, P485; WATSON J, 1977, J IMMUNOL, V118, P2088; WATSON J, 1977, J IMMUNOL, V120, P422; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	34	6094	6435	6	589	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2085	2088		10.1126/science.282.5396.2085	http://dx.doi.org/10.1126/science.282.5396.2085			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851930				2022-12-28	WOS:000077467100048
J	Baloh, RW				Baloh, RW			Vertigo	LANCET			English	Article							PAROXYSMAL POSITIONING VERTIGO; FAMILIAL HEMIPLEGIC MIGRAINE; INNER-EAR; MANAGEMENT; DISEASE; DIZZINESS; HEARING	Vertigo is a subtype of dizziness, which results from an imbalance within the vestibular system. This seminar focuses on three common presentations of vertigo: prolonged spontaneous vertigo, recurrent attacks of vertigo, and positional vertigo. The patient's history is usually the key to differentiation of peripheral and central causes of vertigo. The most common cause of vertigo, benign paroxysmal positional vertigo, can be cured with a simple positional manoeuvre. Other common causes of vertigo include vestibular neuritis, Meniere's syndrome, migraine, and vertebrobasilar insufficiency, Treatment should be directed at the underlying cause whenever possible, but antivertiginous and antiemetic drugs can suppress symptoms when a specific cause cannot be found. These drugs are generally not indicated for long-term daily use, however, since they may interfere with the normal compensation process.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baloh, RW (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Box 951769, Los Angeles, CA 90095 USA.	rwbaloh@ucla.edu						ARIYASU L, 1990, ARCH OTOLARYNGOL, V116, P700; Baloh R.W., 1990, CLIN NEUROPHYSIOL; Baloh R. W, 1998, DIZZINESS HEARING LO; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Baloh RW, 1997, HEADACHE, V37, P615, DOI 10.1046/j.1526-4610.1997.3710615.x; BALOH RW, 1996, DISORDERS VESTIBULAR, P418; BARTH A, 1993, ANN NEUROL, V33, P451, DOI 10.1002/ana.410330507; Beynon GJ, 1997, BRIT J AUDIOL, V31, P11, DOI 10.3109/03005364000000005; BLOCH DB, 1995, ARCH OTOLARYNGOL, V121, P1167; BOGOUSSLAVSKY J, 1986, STROKE, V17, P929, DOI 10.1161/01.STR.17.5.929; Brandt T, 1996, Eur J Med Res, V1, P361; Brandt T, 1993, J Vestib Res, V3, P373; Brandt T., 1991, VERTIGO ITS MULTISEN; CAPLAN LR, 1993, NEUROLOGY, V43, P1281, DOI 10.1212/WNL.43.7.1281; CAPLAN LR, 1986, STROKE PATHOPHYSIOLO, P549; Cappello M, 1995, Eur J Emerg Med, V2, P201, DOI 10.1097/00063110-199512000-00006; Claes J, 1997, ACTA OTO-LARYNGOL, P37; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; FISHER CM, 1967, ARCHIV OTOLARYNGOL, V85, P529; Fitzgerald DC, 1997, ANN OTO RHINOL LARYN, V106, P830, DOI 10.1177/000348949710601005; FOSTER CA, 1995, CONNS CURRENT THERAP, P837; Furman JM, 1997, NEUROLOGY, V48, P1161, DOI 10.1212/WNL.48.5.1161; Furman JM., 1996, BALANCE DISORDERS CA; Gibson WPR, 1997, OTOLARYNG CLIN N AM, V30, P961; GOWER D, 1983, LARYNGOSCOPE, V93, P1028; GRAND W, 1971, NEUROLOGY, V21, P1157, DOI 10.1212/WNL.21.11.1157; HAAN J, 1995, CEPHALALGIA, V15, P477, DOI 10.1046/j.1468-2982.1995.1506477.x; HALMAGYI GM, 1996, DISORDERS VESTIBULAR, P171; HARKER LA, 1987, OTOLARYNG HEAD NECK, V96, P239, DOI 10.1177/019459988709600303; HARRIS JP, 1998, OTOLARYNGOLOGY HEAD, P3172; Herdman S., 1996, DISORDERS VESTIBULAR, P583; Herdman SJ, 1997, PHYS THER, V77, P602, DOI 10.1093/ptj/77.6.602; HUANG CY, 1985, J NEUROL NEUROSUR PS, V48, P263, DOI 10.1136/jnnp.48.3.263; HUGHES GB, 1986, ANN OTO RHINOL LARYN, V95, P250, DOI 10.1177/000348948609500308; Johnson GD, 1998, LARYNGOSCOPE, V108, P1, DOI 10.1097/00005537-199801001-00001; KAYAN A, 1984, BRAIN, V107, P1123, DOI 10.1093/brain/107.4.1123; Lanska DJ, 1997, NEUROLOGY, V48, P1167, DOI 10.1212/WNL.48.5.1167; Luxon LM, 1997, J LARYNGOL OTOL, V111, P1114, DOI 10.1017/S0022215100139507; Luxon LM, 1996, BRIT J HOSP MED, V56, P519; MARK AS, 1994, BAILLIERE CLIN NEUR, V3, P515; NORRVING B, 1995, ACTA NEUROL SCAND, V91, P43; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PAPARELLA MM, 1980, ANN OTO RHINOL LARYN, V89, P249, DOI 10.1177/00034894800890S358; SANTOS PM, 1993, OTOLARYNG HEAD NECK, V109, P680, DOI 10.1177/019459989310900408; Schuknecht H, 1974, PATHOLOGY EAR; SCHUKNECHT HF, 1978, ANN OTO RHINOL LARYN, V87, P743, DOI 10.1177/000348947808700601; SCHUKNECHT HF, 1985, HEARING LOSS DIZZINE, P1; Sloane PD, 1996, CLIN GERIATR MED, V12, P785; Telian SA, 1998, OTOLARYNGOLOGY HEAD, P2731; Tumarkin A, 1936, BRIT MED J, V1936, P175; Weber PC, 1997, OTOLARYNG CLIN N AM, V30, P977	52	84	90	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	1998	352	9143					1841	1846		10.1016/S0140-6736(98)05430-0	http://dx.doi.org/10.1016/S0140-6736(98)05430-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851400				2022-12-28	WOS:000077337900046
J	Starobinski, M; Salomon, D				Starobinski, M; Salomon, D			Acute febrile neutrophilic dermatosis in acute myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland	University of Geneva	Starobinski, M (corresponding author), Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1998	339	23					1687	1687		10.1056/NEJM199812033392306	http://dx.doi.org/10.1056/NEJM199812033392306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144BX	9834306				2022-12-28	WOS:000077294800006
J	Holstege, FCP; Jennings, EG; Wyrick, JJ; Lee, TI; Hengartner, CJ; Green, MR; Golub, TR; Lander, ES; Young, RA				Holstege, FCP; Jennings, EG; Wyrick, JJ; Lee, TI; Hengartner, CJ; Green, MR; Golub, TR; Lander, ES; Young, RA			Dissecting the regulatory circuitry of a eukaryotic genome	CELL			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR IIE; TATA-BINDING PROTEIN; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; GENE-EXPRESSION; NUCLEOSOMAL DNA; MESSENGER-RNAS; IN-VIVO	Genome-wide expression analysis was used to identify genes whose expression depends on the functions of key components of the transcription initiation machinery in yeast. Components of the RNA polymerase II holoenzyme, the general transcription factor TFIID, and the SAGA chromatin modification complex were found to have roles in expression of distinct sets of genes. The results reveal an unanticipated level of regulation which is superimposed on that due to gene-specific transcription factors, a novel mechanism for coordinate regulation of specific sets of genes when cells encounter limiting nutrients, and evidence that the ultimate targets of signal transduction pathways can be identified within the initiation apparatus.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Martinez, Octavio/B-7375-2009; Hengartner, Christoph/AAF-5132-2021; Young, Richard A/F-6495-2012; Holstege, Frank/AAM-9944-2021	Young, Richard A/0000-0001-8855-8647; 				Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DeRisi J, 1996, NAT GENET, V14, P457; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1997, MOL CELL BIOL, V17, P4622, DOI 10.1128/MCB.17.8.4622; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Madhani HD, 1998, TRENDS CELL BIOL, V8, P348, DOI 10.1016/S0962-8924(98)01298-7; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUN X, 1998, MOL CELL, V2, P1; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Tijerina P, 1998, J BIOL CHEM, V273, P1107, DOI 10.1074/jbc.273.2.1107; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yin ZK, 1996, MOL MICROBIOL, V20, P751, DOI 10.1111/j.1365-2958.1996.tb02514.x	65	1546	1591	0	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					717	728		10.1016/S0092-8674(00)81641-4	http://dx.doi.org/10.1016/S0092-8674(00)81641-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845373	Bronze			2022-12-28	WOS:000077253700018
J	Harrison, PJ; Eastwood, SL				Harrison, PJ; Eastwood, SL			Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia	LANCET			English	Article							PRESYNAPTIC PROTEINS; HIPPOCAMPUS; EXPRESSION; SYNAPTOPHYSIN; SIZE; NEUROPATHOLOGY; DYSFUNCTION; SYNAPSES; BRAINS; CORTEX	Background The anatomical basis of schizophrenia involves the cytoarchitecture of the cerebral cortex, but the phenotype;of the affected neurons and synapses remains unclear. In mice, the presynaptic protein complexin I is a marker of axosomatic (inhibitory) synapses, whereas complexin II is a marker of axodendritic (mainly excitatory) synapses. These findings suggest that the complexins might be useful in the investigation of the synaptic pathology of schizophrenia. Methods We characterised the expression of the complexins in tissue taken at necropsy from human medial temporal lobe (hippocampus, parahippocampal gyrus) and cerebellum using in-situ hybridisation and immunoautoradiography. We then measured the concentrations of the complexins and their messenger RNAs (mRNAs) in the medial temporal lobe of 11 patients with schizophrenia and 11 non-schizophrenic controls. Findings The distribution of complexin I and II was consistent with the data on mice, with predominant expression of complexin I by inhibitory neurons, and complexin II by excitatory neurons. The amounts of both complexin mRNAs were lower in schizophrenic than in control patients (p<0.001), but the difference of complexin II mRNA was greater. The amount of complexin I protein was unchanged in schizophrenia, but complexin II protein was decreased (p<0.001). For both mRNA and protein, the complexin II/complexin I ratio was lower in schizophrenia, confirming the relatively greater loss of the excitatory marker. The findings did not seem attributable to medication. Interpretation The synaptic pathology of schizophrenia, at least in medial temporal robe, primarily affects excitatory (glutamatergic) neurons. The inferred imbalance between excitatory and inhibitory circuitry may contribute to the involvement of this region in the pathophysiology of the disorder.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England	University of Oxford; Radcliffe Infirmary; University of Oxford	Harrison, PJ (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.			Harrison, Paul/0000-0002-6719-1126	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNOLD SE, 1995, AM J PSYCHIAT, V152, P738; Arnold SE, 1996, ACTA NEUROPATHOL, V92, P217, DOI 10.1007/s004010050512; ARNOLD SE, 1991, P NATL ACAD SCI USA, V88, P1050; BENES FM, 1991, SCHIZOPHRENIA BULL, V17, P597, DOI 10.1093/schbul/17.4.597; BROWNING MD, 1993, BIOL PSYCHIAT, V34, P529, DOI 10.1016/0006-3223(93)90195-J; Cotter D, 1997, BRAIN RES, V765, P238, DOI 10.1016/S0006-8993(97)00575-1; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; EASTWOOD SL, 1995, NEUROSCIENCE, V69, P339, DOI 10.1016/0306-4522(95)00324-C; EASTWOOD SL, 1995, NEUROSCIENCE, V66, P309, DOI 10.1016/0306-4522(94)00586-T; Gabriel SM, 1997, ARCH GEN PSYCHIAT, V54, P559; Garey LJ, 1998, J NEUROL NEUROSUR PS, V65, P446, DOI 10.1136/jnnp.65.4.446; HARRISON PJ, 1991, LANCET, V337, P450, DOI 10.1016/0140-6736(91)93392-M; Harrison PJ, 1995, NEUROSCI LETT, V200, P151, DOI 10.1016/0304-3940(95)12102-A; HECKERS S, 1991, ARCH GEN PSYCHIAT, V48, P1002; Krimer LS, 1997, CEREB CORTEX, V7, P732, DOI 10.1093/cercor/7.8.732; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; McGuire PK, 1996, PSYCHOL MED, V26, P663, DOI 10.1017/S0033291700037673; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Peters A, 1996, J NEUROCYTOL, V25, P687, DOI 10.1007/BF02284835; Porter RHP, 1997, BRAIN RES, V751, P217, DOI 10.1016/S0006-8993(96)01404-7; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6; Woo TU, 1998, P NATL ACAD SCI USA, V95, P5341, DOI 10.1073/pnas.95.9.5341; Young CE, 1998, CEREB CORTEX, V8, P261, DOI 10.1093/cercor/8.3.261; Zaidel DW, 1997, AM J PSYCHIAT, V154, P812; Zaidel DW, 1997, PSYCHOL MED, V27, P703, DOI 10.1017/S0033291796004618	28	118	125	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1669	1673		10.1016/S0140-6736(98)03341-8	http://dx.doi.org/10.1016/S0140-6736(98)03341-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140VX	9853440				2022-12-28	WOS:000077110300012
J	Cho, KO; Choi, KW				Cho, KO; Choi, KW			Fringe is essential for mirror symmetry and morphogenesis in the Drosophila eye	NATURE			English	Article							LIMB DEVELOPMENT; GENE-EXPRESSION; COMPOUND EYE; DORSAL; FURROW; INITIATION; PROPAGATION; ACTIVATION; INDUCTION; BOUNDARY	An early event in Drosophila eye development is the division of the eye disc into dorsoventral domains. The dorsoventral pattern is displayed in the adult compound eye as a distinct mirror symmetry across the dorsoventral midline or equator(1,2). The dorsoventral axis is also implicated in organizing early development of the eye, as retinal differentiation is initiated at the posterior dorsoventral midline(3). Here we show that Fringe is expressed specifically in the ventral half of the undifferentiated eye disc, thus creating a dorsoventral boundary. Ectopic Fringe borders that are generated by clones of fringe(-) cells can reverse the planar polarity of photoreceptor clusters, indicating that the Fringe boundary is crucial for the induction of mirror symmetry. Lack of a Fringe boundary disrupts equatorial expression of Notch signalling proteins and causes a complete failure of eye development. Our results indicate that the formation of the Fringe boundary and subsequent Notch signalling at the equator are essential for organizing mirror symmetry and eye morphogenesis.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Dept Ophthalmol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Choi, KW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Choi, Kwang-Wook/C-1707-2011; Cho, Kyung-Ok/C-1705-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Cho, Kyung-Ok/0000-0002-0760-2560				Blair SS, 1997, CURR BIOL, V7, pR686, DOI 10.1016/S0960-9822(06)00356-3; Borod ER, 1998, DEV BIOL, V197, P187, DOI 10.1006/dbio.1998.8888; BRAND AH, 1993, DEVELOPMENT, V118, P401; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Chanut F, 1997, DEVELOPMENT, V124, P559; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; Dominguez M, 1997, GENE DEV, V11, P3254, DOI 10.1101/gad.11.23.3254; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Heberlein U, 1998, DEVELOPMENT, V125, P567; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Kehl BT, 1998, DEVELOPMENT, V125, P1217; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; MA CY, 1995, DEVELOPMENT, V121, P2279; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; Netter S, 1998, GENETICS, V149, P257; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pignoni F, 1997, DEVELOPMENT, V124, P271; Royet J, 1997, DEVELOPMENT, V124, P4793; SUN YH, 1995, GENETICS, V141, P1075; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WOLFF T, 1991, DEVELOPMENT, V113, P841; XU T, 1993, DEVELOPMENT, V117, P1223; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	29	147	149	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					272	276		10.1038/24394	http://dx.doi.org/10.1038/24394			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834034				2022-12-28	WOS:000077110400049
J	Wang, HY; Oster, G				Wang, HY; Oster, G			Energy transduction in the F-1 motor of ATP synthase	NATURE			English	Article							F1-ATPASE; MECHANISM; ROTATION; CATALYSIS; TRANSPORT; SUBUNIT	ATP synthase is the universal enzyme that manufactures ATP from ADP and phosphate by using the energy derived from a transmembrane protonmotive gradient. It can also reverse itself and hydrolyse ATP to pump protons against an electrochemical gradient. ATP synthase carries out both its synthetic and hydrolytic cycles by a rotary methanism(1-4). This has been confirmed in the direction of hydrolysis(5,6) after isolation of the soluble F-1 portion of the protein and visualization of the actual rotation of the central 'shaft' of the enzyme with respect to the rest of the molecule, making ATP synthase the world's smallest rotary engine. Here we present a model for this engine that accounts for its mechanochemical behaviour in both the hydrolysing and synthesizing directions. We conclude that the pi motor achieves its high mechanical torque and almost 100% efficiency because it converts the free energy of ATP binding into elastic strain, which is then released by a coordinated kinetic and tightly coupled conformational mechanism to create a rotary torque.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Coll Nat Resources, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12954, DOI 10.1021/bi971477z; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1997, J EXP BIOL, V200, P217; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GERSTEIN M, 1996, PROTEIN MOTIONS, P81; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Rojnuckarin A, 1998, P NATL ACAD SCI USA, V95, P4288, DOI 10.1073/pnas.95.8.4288; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; Yasuda R, 1998, BIOPHYS J, V74, pA1	19	362	367	3	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1998	396	6708					279	282		10.1038/24409	http://dx.doi.org/10.1038/24409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140VY	9834036				2022-12-28	WOS:000077110400051
J	Zhang, J; Yu, KF				Zhang, J; Yu, KF			What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Logistic regression is used frequently in cohort studies and clinical trials. When the incidence of an outcome of interest is common in the study population (>10%), the adjusted odds ratio derived from the logistic regression can no longer approximate the risk ratio. The more frequent the outcome, the more the odds ratio overestimates the risk ratio when it is more than 1 or underestimates it when it is less than 1. We propose a simple method to approximate a risk ratio from the adjusted odds ratio and derive an estimate of an association or treatment effect that better represents the true relative risk.	NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, J (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bldg 6100,Room 7B03, Bethesda, MD 20892 USA.		Trajman, Anete/C-7679-2016	Trajman, Anete/0000-0002-4000-4984				HOSMER DW, 1989, APPL LOGISTIC REGRES; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; MANTEL N, 1959, J NATL CANCER I, V22, P719; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212	6	2900	2939	3	74	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1998	280	19					1690	1691		10.1001/jama.280.19.1690	http://dx.doi.org/10.1001/jama.280.19.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138PD	9832001	Bronze			2022-12-28	WOS:000076980700035
J	Hadjivassiliou, M; Grunewald, R; Chattopadhyay, AK; Davies-Jones, GAB; Gibson, A; Jarratt, JA; Kandler, RH; Lobo, A; Powell, T; Smith, CML				Hadjivassiliou, M; Grunewald, R; Chattopadhyay, AK; Davies-Jones, GAB; Gibson, A; Jarratt, JA; Kandler, RH; Lobo, A; Powell, T; Smith, CML			Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia	LANCET			English	Article							ADULT CELIAC-DISEASE; VITAMIN-E-DEFICIENCY; CEREBELLAR SYNDROME; SPINOCEREBELLAR DEGENERATION; MALABSORPTION	Background Ataxia is the commonest neurological manifestation of coeliac disease. Some individuals with genetic susceptibility to the disease have serological evidence of gluten sensitivity without overt gastrointestinal symptoms or evidence of small-bower inflammation. The sole manifestation of disease in such patients may be ataxia. We describe the clinical, radiological, and neurophysiological features of this disorder. Methods Patients with ataxia attending the neurology outpatient clinics at the royal Hallamshire Hospital, Sheffield, UK, were screened for gluten sensitivity as shown by the titre of antibody to gliadin. Those with other causes of ataxia were excluded. we carried out clinical, neurophysiological, neuroradiological, and, in two cases, neuropathological examinations. Findings 28 patients with gluten ataxia were identified. All had gait ataxia and most had limb ataxia. Those with more severe gait ataxia had longer disease duration. No patient had tremor or other extrapyramidal features. 19 patients showed some form of peripheral neuropathy on neurophysiological examination. 16 patients had no gastrointestinal symptoms. Distal duodenal biopsy showed lymphocytic infiltration in two patients, and changes compatible with coeliac disease in 11. Six patients had evidence of cerebellar atrophy on magnetic-resonance imaging. Necropsy was done on two patients who died; there was lymphocytic infiltration of the cerebellum, damage to the posterior columns of the spinal cord, and sparse infiltration of the peripheral nerves. Interpretation Gluten sensitivity is an important cause of apparently idiopathic ataxia and may be progressive. The ataxia is a result of immunological damage to the cerebellum, to the posterior columns of the spinal cord, and to peripheral nerves. We propose the term gluten ataxia to describe this disorder.	Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Clin Neurophysiol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neuroradiol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Gastroenterol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neuropathol, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield	Hadjivassiliou, M (corresponding author), Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England.							Beversdorf D, 1996, LANCET, V347, P446, DOI 10.1016/S0140-6736(96)90014-8; BHATIA KP, 1995, BRAIN, V118, P1087, DOI 10.1093/brain/118.5.1087; CATASSI C, 1996, P 7 INT S COEL DIS S; Chinnery PF, 1997, NEUROLOGY, V49, P1131, DOI 10.1212/WNL.49.4.1131; COOKE WT, 1966, BRAIN, V89, P683, DOI 10.1093/brain/89.4.683; DICK DJ, 1995, POSTGRAD MED J, V71, P186, DOI 10.1136/pgmj.71.833.186; Elders C, 1925, LANCET, V1, P75; FINELLI PF, 1980, NEUROLOGY, V30, P245, DOI 10.1212/WNL.30.3.245; Ghezzi A, 1997, NEUROLOGY, V49, P1447, DOI 10.1212/WNL.49.5.1447; Hadjivassiliou M, 1997, J NEUROL NEUROSUR PS, V63, P770, DOI 10.1136/jnnp.63.6.770; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HADJIVASSILIOU M, 1997, J NEUROL NEUROSUR PS, V63, P267; HARDING AE, 1981, J NEUROL SCI, V51, P259, DOI 10.1016/0022-510X(81)90104-0; HARDING AE, 1982, ANN NEUROL, V12, P419, DOI 10.1002/ana.410120503; HERMASZEWSKI RA, 1991, POSTGRAD MED J, V67, P1023, DOI 10.1136/pgmj.67.793.1023; KAPLAN JG, 1988, NEUROLOGY, V38, P642, DOI 10.1212/WNL.38.4.642; KINNEY HC, 1982, J NEUROL SCI, V53, P9, DOI 10.1016/0022-510X(82)90076-4; KRISTOFERITSCH W, 1987, J NEUROL, V234, P116, DOI 10.1007/BF00314115; Lu C S, 1986, Mov Disord, V1, P209, DOI 10.1002/mds.870010306; MARSH MN, 1995, Q J MED, V85, P9; MAURO A, 1991, ACTA NEUROL SCAND, V84, P167, DOI 10.1111/j.1600-0404.1991.tb04927.x; Muller AF, 1996, AM J GASTROENTEROL, V91, P1430; Mumford CJ, 1996, J NEUROL NEUROSUR PS, V60, P225, DOI 10.1136/jnnp.60.2.225; WARD ME, 1985, NEUROLOGY, V35, P1199, DOI 10.1212/WNL.35.8.1199	24	285	291	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1582	1585		10.1016/S0140-6736(98)05342-2	http://dx.doi.org/10.1016/S0140-6736(98)05342-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843103				2022-12-28	WOS:000076998900010
J	Parmar, MKB; Torri, V; Bonaventura, A; Bonazzi, C; Colombo, N; Delaloye, JF; Marsoni, S; Mangioni, C; Sandercock, J; Sessa, C; Williams, C; Tinazzi, A; Flann, M; Geiser, K; Scorpiglione, N; Stewart, JF; Chaves, J; Palmeiro, E; Curtain, A; McCormack, T; Gennatas, C; Marras, F; Oppo, TG; Balestrino, M; Malzoni, C; Malzoni, M; Belli, M; Geminiani, ML; Crestani, G; Monaco, A; Vavala, V; Piatto, E; Barattini, G; Fornara, PG; Chetri, MC; Santeufemia, G; Artioli, F; Carone, D; Fanizza, G; Trentadue, R; Priolo, D; Scollo, P; Nigro, SC; Petrina, M; Mastrantonio, P; Spanna, GD; Zagni, R; Belloni, C; Colleoni, R; Redaelli, L; Cavagnini, A; Di Costanzo, G; Perroni, D; Arienti, S; Orfanotti, G; Cantoni, FM; Secli, R; Bianchi, A; Martinello, R; Mollica, G; Maizzi, D; Picchiarelli, ME; Fiorini, G; Borsani, M; Colombo, E; Garsia, S; Melgrati, L; Paggi, G; Brunenghi, GM; Casini, M; Isa, L; Algeri, R; Prozio, G; Belfiore, G; Angelini, F; D'Aprile, M; Moreschi, M; Mauri, ML; Natale, N; Senzani, FM; Pavanato, G; Poggi, G; Garuti, G; Luerti, M; Cruciani, G; Pagano, F; Baccolo, M; Poddi, ER; Bocciolone, L; Sabelli, MA; Maggi, R; Restelli, C; D'Antona, A; Locatelli, MC; Pessi, A; Raina, A; Chiari, S; Gabriele, A; Pittelli, MR; Iacobelli, P; Dogliotti, L; Gorzegno, G; Musso, P; Vegna, G; Coco, G; Alletti, DG; Picciotto, F; Lucchese, V; Epis, A; di Palumbo, VS; Drudi, G; Ravaioli, A; Zampella, D; Morandi, MG; Gorga, G; Zucchelli, C; Cariello, S; Galletto, L; Sussio, M; Massacesi, L; Massacesi, M; Carli, A; Tucci, E; Tajani, E; Corrado, G; Bumma, S; Durando, A; Massobrio, M; Sberveglieri, M; Biasio, M; Guercio, E; Jura, R; Danese, S; Wierdis, T; Farnelli, C; Tarantino, G; Grassi, R; Repetti, F; Rocchi, B; Grampa, M; Ercoli, A; Griso, C; Signori, E; Zanini, L; Presti, M; Klimek, M; Urbanski, K; Biswas, A; Viegas, O; Kochli, O; Dreher, E; Fey, M; Beck, G; Ludin, J; Bonnefoi, H; Krauer, F; Bauer, J; Delmore, G; Furrer, C; Lorenz, U; Thurlimann, B; Lorenz, U; Bronz, L; Sanna, P; Wyss, D; Goldhirsch, A; Gyr, T; Leidi, L; Pastorelli, G; Pagani, O; Rey, P; Hailer, U; Benz, J; Kaye, SB; Reed, NS; Symonds, RP; Atkinson, RJ; Axford, AT; Rustin, G; Seckl, MJ; Green, JA; Scott, IV; Guthrie, D; Harper, PG; Calman, F; Dobbs, HJ; Weir, P; Cassoni, A; Lederman, JA; Souhami, RL; Bozzino, J; Adab, F; Redman, CWE; Scoble, JE; Paterson, M; Daniel, F; Cowley, N; Williams, CJ; Spooner, D; Hong, A; McIllmurray, M; Hendy-Ibbs, P; Hall, V; Iveson, TJ; Whitehouse, JMA; Garry, R; Lamont, A; Robinson, A; Trask, CW; Clubb, AW; Murrell, D; Newman, G; Wilkins, M; Goldthorp, WO; Roberts, JK; Radstone, DJ; Whipp, MJ; Ledermann, JA; Pater, J; Buyse, M; Omura, G				Parmar, MKB; Torri, V; Bonaventura, A; Bonazzi, C; Colombo, N; Delaloye, JF; Marsoni, S; Mangioni, C; Sandercock, J; Sessa, C; Williams, C; Tinazzi, A; Flann, M; Geiser, K; Scorpiglione, N; Stewart, JF; Chaves, J; Palmeiro, E; Curtain, A; McCormack, T; Gennatas, C; Marras, F; Oppo, TG; Balestrino, M; Malzoni, C; Malzoni, M; Belli, M; Geminiani, ML; Crestani, G; Monaco, A; Vavala, V; Piatto, E; Barattini, G; Fornara, PG; Chetri, MC; Santeufemia, G; Artioli, F; Carone, D; Fanizza, G; Trentadue, R; Priolo, D; Scollo, P; Nigro, SC; Petrina, M; Mastrantonio, P; Spanna, GD; Zagni, R; Belloni, C; Colleoni, R; Redaelli, L; Cavagnini, A; Di Costanzo, G; Perroni, D; Arienti, S; Orfanotti, G; Cantoni, FM; Secli, R; Bianchi, A; Martinello, R; Mollica, G; Maizzi, D; Picchiarelli, ME; Fiorini, G; Borsani, M; Colombo, E; Garsia, S; Melgrati, L; Paggi, G; Brunenghi, GM; Casini, M; Isa, L; Algeri, R; Prozio, G; Belfiore, G; Angelini, F; D'Aprile, M; Moreschi, M; Mauri, ML; Natale, N; Senzani, FM; Pavanato, G; Poggi, G; Garuti, G; Luerti, M; Cruciani, G; Pagano, F; Baccolo, M; Poddi, ER; Bocciolone, L; Sabelli, MA; Maggi, R; Restelli, C; D'Antona, A; Locatelli, MC; Pessi, A; Raina, A; Chiari, S; Gabriele, A; Pittelli, MR; Iacobelli, P; Dogliotti, L; Gorzegno, G; Musso, P; Vegna, G; Coco, G; Alletti, DG; Picciotto, F; Lucchese, V; Epis, A; di Palumbo, VS; Drudi, G; Ravaioli, A; Zampella, D; Morandi, MG; Gorga, G; Zucchelli, C; Cariello, S; Galletto, L; Sussio, M; Massacesi, L; Massacesi, M; Carli, A; Tucci, E; Tajani, E; Corrado, G; Bumma, S; Durando, A; Massobrio, M; Sberveglieri, M; Biasio, M; Guercio, E; Jura, R; Danese, S; Wierdis, T; Farnelli, C; Tarantino, G; Grassi, R; Repetti, F; Rocchi, B; Grampa, M; Ercoli, A; Griso, C; Signori, E; Zanini, L; Presti, M; Klimek, M; Urbanski, K; Biswas, A; Viegas, O; Kochli, O; Dreher, E; Fey, M; Beck, G; Ludin, J; Bonnefoi, H; Krauer, F; Bauer, J; Delmore, G; Furrer, C; Lorenz, U; Thurlimann, B; Lorenz, U; Bronz, L; Sanna, P; Wyss, D; Goldhirsch, A; Gyr, T; Leidi, L; Pastorelli, G; Pagani, O; Rey, P; Hailer, U; Benz, J; Kaye, SB; Reed, NS; Symonds, RP; Atkinson, RJ; Axford, AT; Rustin, G; Seckl, MJ; Green, JA; Scott, IV; Guthrie, D; Harper, PG; Calman, F; Dobbs, HJ; Weir, P; Cassoni, A; Lederman, JA; Souhami, RL; Bozzino, J; Adab, F; Redman, CWE; Scoble, JE; Paterson, M; Daniel, F; Cowley, N; Williams, CJ; Spooner, D; Hong, A; McIllmurray, M; Hendy-Ibbs, P; Hall, V; Iveson, TJ; Whitehouse, JMA; Garry, R; Lamont, A; Robinson, A; Trask, CW; Clubb, AW; Murrell, D; Newman, G; Wilkins, M; Goldthorp, WO; Roberts, JK; Radstone, DJ; Whipp, MJ; Ledermann, JA; Pater, J; Buyse, M; Omura, G		ICON Collaborators	ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer	LANCET			English	Article							SURVIVAL; STAGE	Background A series of meta-analyses of randomised controlled trials raised the question of whether the three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) was more or less effective than optimal-dose single-agent carboplatin for women with advanced ovarian cancer. Methods We carried out an international, multicentre, randomised trial to compare CAP with single-agent carboplatin in women with ovarian cancer requiring chemotherapy. 1526 patients were entered from 132 centres in nine countries. Analyses were by intention to treat. Findings 728 patients have died (368/766 allocated CAP vs 360/760 allocated carboplatin) and the survival curves show no evidence of a difference between CAP and carboplatin (hazard ratio 1.00 [95% CI 0.86-1.16]; p = 0.98). The results indicate a median survival of 33 months and a 2-year survival of 60% for both groups. We found no evidence that CAP or carboplatin were more or less effective in different subgroups defined by age, stage, residual disease, differentiation, histology, and coordinating centre. CAP was substantially more toxic than carboplatin, causing more alopecia, leucopenia, and nausea. More thrombocytopenia occurred with carboplatin. Interpretation Single-agent carboplatin, with the dose calculated by the area-under-the-curve method, is a safe, effective, and appropriate standard of treatment for women with advanced ovarian cancer.	Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Parmar, MKB (corresponding author), Ist Ric Farmacol Mario Negri, Via Eritrea 62, I-20157 Milan, Italy.		Scollo, Paolo/AAU-5274-2021; Colombo, Nicoletta/AAB-8319-2019; Danese, Silvio/ABH-9571-2020; Rustin, Gordon J. S./J-9763-2019; Pagani, Olivia/ABF-3164-2020; Torri, Valter/H-7550-2015	Danese, Silvio/0000-0001-7341-1351; Torri, Valter/0000-0001-9541-9354; Sandercock, Josie/0000-0001-7337-8635; Buyse, Marc/0000-0002-4559-0994; Marsoni, Silvia/0000-0002-5361-7122				AHERN RP, 1995, J CLIN ONCOL, V13, P726, DOI 10.1200/JCO.1995.13.3.726; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BUYSE M, 1991, J CLIN ONCOL, V9, P1668; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CALVERT AH, 1991, SEMIN ONCOL, V18, P28; GHERSI D, 1992, EUR J CANCER, V28A, P1297, DOI 10.1016/0959-8049(92)90497-P; HAND R, 1993, JAMA-J AM MED ASSOC, V269, P1119, DOI 10.1001/jama.269.9.1119; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MUGGIA FM, 1997, P AN M AM SOC CLIN, V16, pA352; PARMAR M, 1995, SURVIVAL ANAL PRACTI; PETTERSSON F, 1995, ANN REPORT RESULTS T, V22; QAZI F, 1995, CA-CANCER J CLIN, V45, P88, DOI 10.3322/canjclin.45.2.88; Skarlos DV, 1996, EUR J CANCER, V32A, P421, DOI 10.1016/0959-8049(95)00537-4; STEWART LA, 1991, BRIT MED J, V303, P884; STUART G, 1998, P AN M AM SOC CLIN, V17, pA361; YANCIK R, 1993, CANCER, V71, P517	16	129	132	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1571	1576						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843101				2022-12-28	WOS:000076998900008
J	Werk, LN; Alpert, JJ				Werk, LN; Alpert, JJ			Solid feeding guidelines	LANCET			English	Editorial Material									Boston Univ, Sch Med, Dept Gen Pediat, Boston, MA 02118 USA	Boston University	Werk, LN (corresponding author), Boston Univ, Sch Med, Dept Gen Pediat, Boston, MA 02118 USA.		Werk, Lloyd/AAI-3704-2020	Werk, Lloyd/0000-0001-9892-898X				*AM AC PED, 1998, PED NUTR HDB; BIRKBECK J, 1992, NEW ZEAL MED J, V105, P221; *DEP HLTH, 1994, REP HLTH SOC SUBJ V4; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; HENDRICKS KM, 1992, NUTR REV, V50, P125, DOI 10.1111/j.1753-4887.1992.tb01303.x; Mehta KC, 1998, PEDIATRICS, V102, P569, DOI 10.1542/peds.102.3.569; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21	9	4	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1569	1570		10.1016/S0140-6736(05)61039-2	http://dx.doi.org/10.1016/S0140-6736(05)61039-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843099				2022-12-28	WOS:000076998900005
J	Blum, AL; Talley, NJ; O'Morain, C; van Zanten, SV; Labenz, J; Stolte, M; Louw, JA; Stubberod, A; Theodors, A; Sundin, M; Bolling-Sternevald, E; Junghard, O				Blum, AL; Talley, NJ; O'Morain, C; van Zanten, SV; Labenz, J; Stolte, M; Louw, JA; Stubberod, A; Theodors, A; Sundin, M; Bolling-Sternevald, E; Junghard, O		Omeprazole Plus Clarithromycin Amoxicillin Effe	Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASTROINTESTINAL SYMPTOMS; DUODENAL-ULCER; GASTRITIS; TRIALS; ENDOSCOPY; QUALITY; LIFE	Background It is uncertain whether treatment of Helicobacter pylori infection relieves symptoms in patients with nonulcer, or functional, dyspepsia. Methods We conducted a double-blind, multicenter trial of patients with H. pylori infection and dyspeptic symptoms (moderate-to-very-severe pain and discomfort centered in the upper abdomen). Patients were excluded if they had a history of peptic ulcer disease or gastroesophageal reflux disease and had abnormal findings on upper endoscopy. Patients were randomly assigned to seven days of treatment with 20 mg of omeprazole twice daily, 1000 mg of amoxicillin twice daily, and 500 mg of clarithromycin twice daily or with omeprazole alone and then followed up for one year. Treatment success was defined as the absence of dyspeptic symptoms or the presence of minimal symptoms on any of the 7 days preceding the 12-month visit. Results Twenty of the 348 patients were excluded after randomization because they were not infected with H. pylori, were not treated, or had no data available. For the remaining 328 patients (164 in each group), treatment was successful for 27.4 percent of those assigned to receive omeprazole and antibiotics and 20.7 percent of those assigned to receive omeprazole alone (P = 0.17; absolute difference between groups, 6.7 percent; 95 percent confidence interval, -2.6 to 16.0). After 12 months, gastritis had healed in 75.0 percent of the patients in the group given omeprazole and antibiotics and in 3.0 percent of the patients in the omeprazole group (P<0.001); the respective rates of H. pylori eradication were 79 percent and 2 percent. In the group given omeprazole and antibiotics, the rate of treatment success among patients with persistent H. pylori infection was similar to that among patients in whom the infection was eradicated (26 percent vs. 31 percent). There were no significant differences between the groups in the quality of life after treatment. Conclusions In patients with nonulcer dyspepsia, the eradication of H. pylori infection is not likely to relieve symptoms. (N Engl J Med 1998;339:1875-81.) (C) 1998, Massachusetts Medical Society.	CHU Vaudois, Div Gastroenterol, CH-1011 Lausanne, Switzerland; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Nepean Hosp, Sydney, NSW, Australia; Trinity Coll Dublin, Meath Hosp, Dept Gastroenterol, Dublin, Ireland; Trinity Coll Dublin, Adelaide Hosp, Dept Gastroenterol, Dublin, Ireland; Queen Elizabeth 2 Hlth Sci Ctr, Div Gastroenterol, Halifax, NS, Canada; Univ Klin Otto von Guericke, Magdeburg, Germany; Klinikum Bayreuth, Inst Pathol, Bayreuth, Germany; Univ Cape Town, Dept Gastroenterol, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Varnamo Hosp, Dept Surg, Varnamo, Sweden; St Josphs Hosp, Div Gastroenterol, Hafnarfjordur, Iceland; Astra Hassle AB, Dept Clin Res, Molndal, Sweden; Astra Hassle AB, Dept Stat, Molndal, Sweden; Linkoping Hosp, Dept Biomed & Surg, Linkoping, Sweden	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Sydney; Nepean Hospital; Trinity College Dublin; Trinity College Dublin; Queen Elizabeth II Health Sciences Centre; University Hospital Magdeburg; Klinikum Bayreuth; University of Cape Town; University of Cape Town	Blum, AL (corresponding author), CHU Vaudois, Div Gastroenterol, CH-1011 Lausanne, Switzerland.		Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				Agresti A., 1996, INTRO CATEGORICAL DA; Armstrong D, 1996, SCAND J GASTROENTERO, V31, P38, DOI 10.3109/00365529609094532; BERNERSEN B, 1992, BRIT MED J, V304, P1276, DOI 10.1136/bmj.304.6837.1276; Blum AL, 1997, GASTROENTEROLOGY, V112, pA73; Bytzer P, 1996, GASTROENTEROLOGY, V110, P302, DOI 10.1053/gast.1996.v110.agast960302; DIMENAS E, 1995, SCAND J GASTROENTERO, V30, P1046, DOI 10.3109/00365529509101605; DIMENAS E, 1993, SCAND J GASTROENTERO, V28, P681, DOI 10.3109/00365529309098272; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DominguezMunoz JE, 1997, GUT, V40, P459, DOI 10.1136/gut.40.4.459; Goh KL, 1996, EUR J GASTROEN HEPAT, V8, P1157, DOI 10.1097/00042737-199612000-00004; HEADING RC, 1991, SCAND J GASTROENTERO, V26, P1, DOI 10.3109/00365529109109529; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JUNGHARD O, IN PRESS EUR J SURG; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; LIND T, 1997, GUT               S1, V41, pA189; Pantoflickova D, 1998, BAILLIERE CLIN GASTR, V12, P503, DOI 10.1016/S0950-3528(98)90021-5; SCHUBERT TT, 1992, GASTROINTEST ENDOSC, V38, P357, DOI 10.1016/S0016-5107(92)70432-5; Sontag SJ, 1997, AM J GASTROENTEROL, V92, P1255; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; Talley NJ, 1998, GASTROENTEROLOGY, V114, pA305; Talley NJ, 1997, GASTROENTEROLOGY, V113, pS67, DOI 10.1016/S0016-5085(97)80016-9; Toothaker LE, 1991, MULTIPLE COMP RES; vanZanten SJOV, 1997, ALIMENT PHARM THERAP, V11, P63, DOI 10.1046/j.1365-2036.11.s1.15.x; VANZANTEN SJOV, 1993, J CLIN EPIDEMIOL, V46, P273, DOI 10.1016/0895-4356(93)90075-C; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; Verdu EF, 1996, SCAND J GASTROENTERO, V31, P1151, DOI 10.3109/00365529609036903; WENGER NK, 1984, AM J CARDIOL, V54, P908, DOI 10.1016/S0002-9149(84)80232-5; WIKLUND I, 1995, QUAL LIFE RES, V4, P503	31	410	418	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1998	339	26					1875	1881		10.1056/NEJM199812243392602	http://dx.doi.org/10.1056/NEJM199812243392602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	150ZN	9862942	Green Published			2022-12-28	WOS:000077696600002
J	Davies, S				Davies, S			A memorable patient - A Christmas carol	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1732	1732		10.1136/bmj.317.7174.1732	http://dx.doi.org/10.1136/bmj.317.7174.1732			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857157	Green Published			2022-12-28	WOS:000077742300045
J	Gregory, R				Gregory, R			Snapshots from the decade of the brain - Brainy mind	BRITISH MEDICAL JOURNAL			English	Review									Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England	University of Bristol	Gregory, R (corresponding author), Univ Bristol, Dept Expt Psychol, Bristol BS8 1TN, Avon, England.							Crick F., 1994, ASTONISHING HYPOTHES; DARWIN C, 1872, EXPESSION EMOTIONS M; GREGORY RL, 1980, PHILOS T ROY SOC B, V290, P181, DOI 10.1098/rstb.1980.0090; Gregory RL, 1997, PHILOS T ROY SOC B, V352, P1121, DOI 10.1098/rstb.1997.0095; Gregory RL, 1981, MIND SCI; Humphrey N., 1992, HIST MIND; HUXLEY A, 1968, COMPLETE WORKS A HUX; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; KOSSLYN SM, 1995, NATURE, V378, P496, DOI 10.1038/378496a0; LURIA A, 1969, MIND MEMONIST LITTLE; MACH E, 1959, ANAL SENSATION; Posner M. I., 1994, IMAGES MIND; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; SILLITO A, 1995, ARTFUL EYE, P294; Zeki S., 1993, VISION BRAIN	15	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1693	1695		10.1136/bmj.317.7174.1693	http://dx.doi.org/10.1136/bmj.317.7174.1693			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857130	Green Published			2022-12-28	WOS:000077742300017
J	Hastings, M				Hastings, M			The brain, circadian rhythms, and clock genes	BRITISH MEDICAL JOURNAL			English	Review									Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Hastings, M (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		anand, amit/A-7222-2009					Arendt J., 1995, MELATONIN MAMMALIAN; Aschoff J., 1981, HDB BEHAV NEUROBIOLO, V4; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; HALL JC, 1990, ANNU REV GENET, V24, P659; HASTINGS MH, 1995, NATO ADV SCI INST SE, V277, P95; Hastings MH, 1997, TRENDS NEUROSCI, V20, P459, DOI 10.1016/S0166-2236(97)01087-4; Klein D.C., 1991, SUPRACHIASMATIC NUCL; PICE JL, 1998, CELL, V94, P83; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; SMITH L, 1994, LANCET, V344, P1137, DOI 10.1016/S0140-6736(94)90636-X; WEHR TA, 1991, J CLIN ENDOCR METAB, V73, P1276, DOI 10.1210/jcem-73-6-1276; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	16	53	55	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1704	1707		10.1136/bmj.317.7174.1704	http://dx.doi.org/10.1136/bmj.317.7174.1704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857134	Green Published			2022-12-28	WOS:000077742300022
J	Alberio, L; Lammle, B				Alberio, L; Lammle, B			Images in clinical medicine - Capnocytophaga canimorsus Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Alberio, L (corresponding author), Univ Hosp Bern, CH-3010 Bern, Switzerland.		Laemmle, Bernhard/AAJ-1216-2020	Laemmle, Bernhard/0000-0003-4538-5154; Alberio, Lorenzo/0000-0001-9686-9920					0	13	13	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1827	1827		10.1056/NEJM199812173392506	http://dx.doi.org/10.1056/NEJM199812173392506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854119				2022-12-28	WOS:000077545800006
J	Zhang, H; Dornadula, G; Beumont, M; Livornese, L; Van Uitert, B; Henning, K; Pomerantz, RJ				Zhang, H; Dornadula, G; Beumont, M; Livornese, L; Van Uitert, B; Henning, K; Pomerantz, RJ			Human immunodeficiency virus type I in the semen of men receiving highly active antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; POLYMERASE CHAIN-REACTION; ANTIVIRAL TREATMENT; DISEASE STAGE; HIV-1; INFECTION; CELLS; IDENTIFICATION; TRANSMISSION; SPERMATOZOA	Background Highly active antiretroviral therapy can effectively decrease the revels of human immunodeficiency virus type 1 (HIV-1) virions in peripheral plasma and seminal fluid of infected men. Whether the genital tract of HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable virus in the peripheral plasma harbors replication-competent virus is not known. Methods We collected peripheral-blood and semen samples from seven men with HIV-1 infection who were receiving highly active antiretroviral therapy and who had no detectable viral RNA (fewer than 50 copies per milliliter) in plasma and analyzed the samples for cell-associated proviral DNA using a quantitative polymerase-chain-reaction assay. Replication-competent viruses were evaluated by cell-coculture assays. Proviral DNA and replication-competent virus obtained from peripheral-blood and seminal cells were also analyzed by sequencing relevant viral genes. Results Despite the long-term suppression of HIV-1 RNA in the plasma of the seven men, proviral DNA was detected in seminal cells in four. Replication-competent viruses were recovered from peripheral-blood cells in three men and from the seminal cells in two of these three men. The viruses recovered from the seminal cells had no genotypic mutations suggestive of resistance to antiretroviral drugs and were macrophage-tropic, a feature that is characteristic of HIV-1 strains that are capable of being sexually transmitted. Conclusions In HIV-1-infected men who are receiving highly active antiretroviral therapy and who have no detectable levels of viral RNA in plasma, the virus may be present in seminal cells and therefore may be capable of being transmitted sexually. (N Engl J Med 1998;339:1803-9.) (C) 1998, Massachusetts Medical Society.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol,Dorrance H Hamilton Labs, Philadelphia, PA 19107 USA	Jefferson University	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Human Virol,Dorrance H Hamilton Labs, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.				NIAID NIH HHS [AI38666, AI33810] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038666, R01AI033810] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903; BAGASRA O, 1994, AIDS, V8, P1669, DOI 10.1097/00002030-199412000-00005; Cavert W, 1997, SCIENCE, V276, P1321; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Gil T, 1995, HUM REPROD, V10, P2923, DOI 10.1093/oxfordjournals.humrep.a135821; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1998, J VIROL, V72, P2422; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HINZI D, 1998, CELL, V93, P665; HO DD, 1987, NEW ENGL J MED, V317, P278; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; NUOVO GJ, 1994, AM J PATHOL, V144, P1142; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang H, 1996, J VIROL, V70, P628, DOI 10.1128/JVI.70.1.628-634.1996; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	38	349	356	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1998	339	25					1803	1809		10.1056/NEJM199812173392502	http://dx.doi.org/10.1056/NEJM199812173392502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148RJ	9854115				2022-12-28	WOS:000077545800002
J	Dean, J				Dean, J			ABC of sexual health - Examination of patients with sexual problems	BRITISH MEDICAL JOURNAL			English	Article																			0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1641	+		10.1136/bmj.317.7173.1641	http://dx.doi.org/10.1136/bmj.317.7173.1641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848908	Green Published			2022-12-28	WOS:000077602100031
J	Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ				Badawi, N; Kurinczuk, JJ; Keogh, JM; Alessandri, LM; O'Sullivan, F; Burton, PR; Pemberton, PJ; Stanley, FJ			Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FULL-TERM INFANTS; NEONATAL ENCEPHALOPATHY; CEREBRAL-PALSY; BIRTH ASPHYXIA; BABIES; WEIGHT	Objective To identify intrapartum predictors of newborn encephalopathy in term infants. Design Population based, unmatched case-control study. Setting Metropolitan area of Western Australia-June 1993 to September 1995. Subjects All 164 term infants with moderate or ne newborn encephalopathy; 400 randomly selected controls. Main outcome measures Adjusted odds ratio estimates. Results The birth prevalence of moderate or severe newborn encephalopathy vias 3.8/1000 term live births. The neonatal fatality was 9.1%. Maternal pyrexia (odds ratio 3.82), a persistent occipitoposterior position (4.29), and an acute intrapartum event (4.44) were all risk factors for newborn encephalopathy. More case infants than control infants were induced (41.5% and 30.5%, respectively) and fewer case infants were delivered by caesarean section without labour (3.7% and 14.5%, respectively). Operative vaginal delivery (2.34) and emergency caesarean section (2.17) were both associated with an increased risk. There was an inverse relation between elective caesarean section (0.17) and newborn encephalopathy. After application of a set of consensus criteria for elective caesarean section only three (7%) eligible case mothers compared with 33 (65%) eligible control mothers were sectioned electively. Of all the case infants, 113 (69%) had only antepartum risk factors for newborn encephalopathy identified; 39 (24%) had antepartum and intrapartum factors; eight (5%) had only intrapartum factors; and four (2%) had no recognised antepartum or intrapartum factors. Conclusions The causes of newborn encephalopathy are heterogeneous and many relate to the antepartum period. Elective caesarean section has an inverse association with newborn encephalopathy. Intrapartum hypoxia alone accounts for only a small proportion of newborn encephalopathy. These results question the view that most risk factors for newborn encephalopathy lie in the intrapartum period.	TVW Telethon Inst Child Hlth Res, W Perth, WA 6872, Australia; Hornsby Ku Ring Gai Hosp, Dept Obstet & Gynaecol, Hornsby, NSW 2077, Australia; Univ Western Australia, Dept Paediat, Nedlands, WA 6907, Australia; Princess Margaret Hosp Children, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Badawi, N (corresponding author), Royal Alexandra Hosp Children, New Childrens Hosp, Dept Neonatol, POB 3515, Parramatta, NSW 2124, Australia.	nadiaB@nch.edu.au	Burton, Paul R/H-7527-2016; Badawi, Nadia/A-3179-2014					ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; BERG AT, 1989, EARLY HUM DEV, V19, P271, DOI 10.1016/0378-3782(89)90062-5; DESOUZA SW, 1978, ARCH DIS CHILD, V53, P564, DOI 10.1136/adc.53.7.564; ERGANDER U, 1983, ACTA PAEDIATR SCAND, V72, P321, DOI 10.1111/j.1651-2227.1983.tb09722.x; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; GEE V, 1995, 12 HLTH DEP W AUSTR; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P553; LUMLEY J, 1985, CONTROL CLIN TRIALS, V6, P120, DOI 10.1016/0197-2456(85)90117-5; Murphy DJ, 1997, BMJ-BRIT MED J, V314, P404, DOI 10.1136/bmj.314.7078.404; NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034; Oh W, 1996, PEDIATRICS, V98, P141; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Spencer JAD, 1997, BRIT J OBSTET GYNAEC, V104, P25, DOI 10.1111/j.1471-0528.1997.tb10643.x; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; vanHam MAPC, 1997, EUR J OBSTET GYN R B, V74, P1, DOI 10.1016/S0301-2115(97)02725-5; ZIEGLER AL, 1976, HELV PAEDIATR ACTA, V31, P299	20	434	450	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1554	1558		10.1136/bmj.317.7172.1554	http://dx.doi.org/10.1136/bmj.317.7172.1554			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836653	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000077451700021
J	de Rooij, J; Zwartkruis, FJT; Verheijen, MHG; Cool, RH; Nijman, SMB; Wittinghofer, A; Bos, JL				de Rooij, J; Zwartkruis, FJT; Verheijen, MHG; Cool, RH; Nijman, SMB; Wittinghofer, A; Bos, JL			Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT; DOMAIN; CELLS; GENE; C3G	Rap1 is a small, Ras-like GTPase that was first identified as a protein that could suppress the oncogenic transformation of cells by Ras', Rap1 is activated by several extracellular stimuli(2-7) and may be involved in cellular processes such as cell proliferations(8), cell differentiation(4), T-cell anergy(2) and platelet activation(7). At least three different second messengers, namely diacylglycerol, calcium and cyclic AMP(5-7,9), able to activate Rap1 by promoting its release of the guanine nucleotide GDP and its binding to GTP. Here we report that activation of Rap1 by forskolin and cAMP occurs independently of protein kinase A (also known as cAMP-abivated protein kinase). We have cloned the gene encoding a guanine-nucleotide-exchange factor (GEF) which we have named Epac (exchange protein directly activated by cAMP). This protein contains a cAMP-binding site and a domain that is homologous to domains of known GEFs for pas and Rap1, Epac binds cAMP in vitro and exhibits in vivo and in vitro GEF activity towards Rap1, cAMP strongly induces the GEF activity of Epac towards Rap1 both in vivo and in vitro. We conclude that Epac is a GEF for Rapl that is regulated directly by cAMP and that Epac is a new target protein for cAMP.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany	Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Max Planck Society	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		Verheijen, Mark/AAD-8112-2019; Verheijen, Mark/GQY-5157-2022; de rooij, johan/C-1325-2019	Verheijen, Mark/0000-0002-3739-3755; Cool, Robbert/0000-0002-9845-2202				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Herberg FW, 1997, PROTEIN SCI, V6, P569; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SINGH TJ, 1985, J BIOL CHEM, V260, P3927; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; VOSSLER MR, 1997, CELL, V89, P74; WOLFHUIS RM, 1998, MOL CELL BIOL, V18, P2486; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	25	1536	1568	1	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					474	477		10.1038/24884	http://dx.doi.org/10.1038/24884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853756				2022-12-28	WOS:000077370100056
J	DeBuono, BA; Osten, WM				DeBuono, BA; Osten, WM			The medical resident workload: The case of New York State	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									New York State Dept Hlth, Albany, NY 12237 USA	State University of New York (SUNY) System								*DIV HLTH CAR STAN, 1998, RES ASS COMPL WORK H; LUCETTE L, 1998, WALL STREET J   0519, pB5; New York State Department of Health Ad Hoc Advisory Committee on Emergency Services, 1987, FIN REP NEW YORK STA; *NY STAT DEP HLTH, 1988, SECT 405 4 LTD RES W; *NY SUPR COURT NY, 1986, REP 4 GRAND JUR APR; *OFF PUBL AFF, 1998, NYU HOSP FIN VIOL RE; *OFF PUBL AFF, 1998, HLTH DEP REL RES REV; *OFF PUBL AFF, 1998, BROOKL HOSP CTR FIN	8	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1882	1883						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846789				2022-12-28	WOS:000077176600042
J	Jick, H; Garcia-Rodriguez, LA; Perez-Gutthann, S				Jick, H; Garcia-Rodriguez, LA; Perez-Gutthann, S			Principles of epidemiological research on adverse and beneficial drug effects	LANCET			English	Review							CALCIUM-CHANNEL BLOCKERS; HORMONE REPLACEMENT THERAPY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NEURAL-TUBE DEFECTS; VENOUS THROMBOEMBOLISM; ORAL-CONTRACEPTIVES; ALZHEIMERS-DISEASE; RISK; CANCER; ESTROGEN		Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA; Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain; Novartis Farmaceut SA, Clin Dev & Regulatory Affairs, Global Phamacoepidemiol, Barcelona, Spain	Boston University; Novartis	Jick, H (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02173 USA.		rodriguez, luis a garcia/B-1980-2010	Perez-Gutthann, Susana/0000-0001-5798-3691; Jick, Hershel/0000-0003-4270-5992				ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 1974, BMJ-BRIT MED J, V1, P440; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; *BOST COLL DRUG SU, 1974, JAMA-J AM MED ASSOC, V228, P68; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; Cuthbertson BH, 1997, BRIT MED J, V314, P690, DOI 10.1136/bmj.314.7082.690; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer RDT, 1997, LANCET, V349, P732, DOI 10.1016/S0140-6736(05)60175-4; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Garrett JE, 1996, THORAX, V51, P1093, DOI 10.1136/thx.51.11.1093; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; HELMRICH SP, 1984, J NATL CANCER I, V72, P617; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1978, AM J EPIDEMIOL, V107, P1; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1997, LANCET, V349, P1699, DOI 10.1016/S0140-6736(05)62672-4; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; Jick H, 1996, PHARMACOTHERAPY, V16, P321; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick H, 1997, LANCET, V349, P731, DOI 10.1016/S0140-6736(05)60173-0; JICK H, 1995, PHARMACOTHERAPY, V15, P428; KLEMETTI A, 1967, AM J PUBLIC HEALTH N, V57, P2071, DOI 10.2105/AJPH.57.12.2071; Kritchevsky SB, 1997, LANCET, V349, P1400, DOI 10.1016/S0140-6736(05)63246-1; LIDEGAARD O, 1998, WHO TECHN REP SER, V877; Lindberg G, 1998, BMJ-BRIT MED J, V316, P741, DOI 10.1136/bmj.316.7133.741; Meier CR, 1998, BRIT J CLIN PHARMACO, V45, P608, DOI 10.1046/j.1365-2125.1998.00733.x; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Poulter NR, 1997, LANCET, V349, P732, DOI 10.1016/S0140-6736(05)60174-2; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; RODRIGUEZ LAG, 1992, EPIDEMIOLOGY, V3, P337, DOI 10.1097/00001648-199207000-00008; Rosenberg L, 1998, JAMA-J AM MED ASSOC, V279, P1000, DOI 10.1001/jama.279.13.1000; ROSENBERG L, 1980, NEW ENGL J MED, V303, P546, DOI 10.1056/NEJM198009043031002; Rothman K., 1998, MODERN EPIDEMIOLOGY; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Vandenbroucke JP, 1997, LANCET, V349, P1113, DOI 10.1016/S0140-6736(05)63015-2; Vandenbroucke JP, 1997, LANCET, V349, P731, DOI 10.1016/S0140-6736(05)60172-9; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651	52	62	64	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1998	352	9142					1767	1770		10.1016/S0140-6736(98)04350-5	http://dx.doi.org/10.1016/S0140-6736(98)04350-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848368	hybrid			2022-12-28	WOS:000077246500043
J	Kadyrov, M; Kosanke, G; Kingdom, J; Kaufmann, P				Kadyrov, M; Kosanke, G; Kingdom, J; Kaufmann, P			Increased fetoplacental angiogenesis during first trimester in anaemic women	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN PLACENTA; IRON-DEFICIENCY; MATERNAL ANEMIA; PREGNANT-WOMEN; FETAL; HYPERTENSION; LIFE	Background epidemiological studies describe an association between relative size of the placenta at delivery and cardiovascular morbidity and mortality during adult life. Some determinants of placental size, such as maternal anaemia, have been acknowledged, but no plausible mechanism has been advanced to explain the initial of postnatal disease. Methods Placental villous vascularisation in anaemic women (Hb<90 g/L) was assessed in the first and third trimesters of pregnancy by immunohistochemical identification bf villous capillaries and compared with that of gestational age-matched groups of women with normal (Hb>110 g/L; control group) concentrations of haemoglobin, and an intermediate group (Hb 90-110 g/L). Findings Anaemia, especially in the first trimester, was associated with increased numbers of capillaries per villous cross section (mean 11.70 [SE 0.35] vs 4.14 [0.27]) located mainly in the outer third of the stroma beneath the trophoblast (94% [1.15] vs 67% [1.82]) and with increased numbers of villous macrophages and of proliferating MIB-1-positive cells compared with the control group. Interpretation Maternal anaemia in early pregnancy seems to influence the pattern of placental vascularisation. Such changes might alter placental vascular impedance during early fetal life, thereby exerting important effects on cardiovascular development.	Aachen Tech Univ, Dept Anat, Fac Med, D-52057 Aachen, Germany; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev Fetal Hlth, Toronto, ON, Canada	RWTH Aachen University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Kaufmann, P (corresponding author), Aachen Tech Univ, Dept Anat, Fac Med, Wendligweg 2, D-52057 Aachen, Germany.		Kingdom, John/AAF-2145-2020; Kingdom, John/A-3247-2013					AHMED A, 1995, GROWTH FACTORS, V12, P235, DOI 10.3109/08977199509036883; Allen LH, 1997, NUTR REV, V55, P91, DOI 10.1111/j.1753-4887.1997.tb06460.x; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENIRSCHKA K, 1995, PATHOLOGY HUMAN PLAC; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; CROWE C, 1995, J PHYSIOL-LONDON, V488, P515, DOI 10.1113/jphysiol.1995.sp020986; GUIDOZZI F, 1995, S AFR MED J, V85, P170; Hustin J, 1988, TROPHOBLAST RES, V3, P49; Jaffe R, 1997, AM J OBSTET GYNECOL, V176, P695, DOI 10.1016/S0002-9378(97)70572-6; KAUFMANN P, 1998, IN PRESS MORPHOGENES; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Lao TT, 1997, PLACENTA, V18, P593, DOI 10.1016/0143-4004(77)90015-7; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; RESHETNIKOVA OS, 1995, AM J OBSTET GYNECOL, V173, P724, DOI 10.1016/0002-9378(95)90330-5; SHARKEY AM, 1993, J REPROD FERTIL, V99, P609; Shore VH, 1997, PLACENTA, V18, P657, DOI 10.1016/S0143-4004(97)90007-2; Singla PN, 1997, J TROP PEDIATRICS, V43, P89, DOI 10.1093/tropej/43.2.89; SUHARNO D, 1993, LANCET, V342, P1325, DOI 10.1016/0140-6736(93)92246-P; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864	20	95	100	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1747	1749						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GH	9848351				2022-12-28	WOS:000077246500010
J	Emery, P; So, WV; Kaneko, M; Hall, JC; Rosbash, M				Emery, P; So, WV; Kaneko, M; Hall, JC; Rosbash, M			CRY, a Drosophila clock and light-regulated cryptochrome, is a major contributor to circadian rhythm resetting and photosensitivity	CELL			English	Article							MESSENGER-RNA LEVELS; PERIOD GENE; SUPRACHIASMATIC NUCLEUS; PHOTORECEPTOR FAMILY; BEHAVIORAL RHYTHMS; VISUAL-SYSTEM; PROTEIN; TIMELESS; MELANOGASTER; EXPRESSION	Light is a major environmental signal for circadian rhythms. We have identified and analyzed cry, a novel Drosophila cryptochrome gene. All characterized family members are directly photosensitive and include plant blue light photoreceptors. We show that cry transcription is under circadian regulation, influenced by the Drosophila clock genes period, timeless, Clock, and cycle. We also show that cry protein levels are dramatically affected by light exposure. Importantly, circadian photosensitivity is increased in a cry-overexpressing strain. These physiological and genetic data therefore link a specific photoreceptor molecule to circadian rhythmicity. Taken together with the data in the accompanying paper, we propose that CRY is a major Drosophila photoreceptor dedicated to the resetting of circadian rhythms.	Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Brandeis Univ, NSF, Ctr Biol Timing, Waltham, MA 02454 USA	Brandeis University; Brandeis University; Howard Hughes Medical Institute; Brandeis University; National Science Foundation (NSF); NSF - Center for Biological Timing	Rosbash, M (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02454 USA.	rosbash@brandeis.edu		Kaneko, Maki/0000-0002-2489-6185				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1965, CIRCADIAN CLOCKS, P94; BAER ME, 1993, J BIOL CHEM, V268, P16717; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BRAND AH, 1994, ECTOPIC EXPRESSION D, P635; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Ding JM, 1998, NATURE, V394, P381, DOI 10.1038/28639; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Giebultowicz JM, 1997, NATURE, V386, P664, DOI 10.1038/386664a0; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; Kaneko M, 1997, J NEUROSCI, V17, P6745; KLEMM E, 1976, PHOTOCHEM PHOTOBIOL, V24, P369, DOI 10.1111/j.1751-1097.1976.tb06838.x; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNER J, 1992, FORUM PSYCHOANAL, V8, P1; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; LINC, 1998, P NATL ACAD SCI USA, V95, P2686; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PAIETTA J, 1981, P NATL ACAD SCI-BIOL, V78, P5573, DOI 10.1073/pnas.78.9.5573; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutila JE, 1996, NEURON, V17, P921, DOI 10.1016/S0896-6273(00)80223-8; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; RUTILA JE, 1998, IN PESS J BIOL RHYTH; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SCHWARTZ WJ, 1994, NEUROSCIENCE, V58, P573, DOI 10.1016/0306-4522(94)90082-5; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Shimomura K, 1998, J BIOL RHYTHM, V13, P305, DOI 10.1177/074873098129000147; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZIMMERMAN WF, 1971, SCIENCE, V171, P1167, DOI 10.1126/science.171.3976.1167; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	87	666	686	4	115	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	1998	95	5					669	679		10.1016/S0092-8674(00)81637-2	http://dx.doi.org/10.1016/S0092-8674(00)81637-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845369	Bronze			2022-12-28	WOS:000077253700014
J	Lurie, P; Miller, S; Hecht, F; Chesney, M; Lo, B				Lurie, P; Miller, S; Hecht, F; Chesney, M; Lo, B			Postexposure prophylaxis after nonoccupational HIV exposure - Clinical, ethical, and policy considerations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; SEXUAL ASSAULT; EMERGENCY CONTRACEPTION; ZIDOVUDINE TREATMENT; DRUG-USERS; TRANSMISSION; INFECTION; RISK; MODEL	In the wake of recent breakthroughs in antiviral therapies and Centers far Disease Control and Prevention (CDC) recommendations advocating occupational postexposure prophylaxis (PEP), health care workers are increasingly receiving inquiries about PEP following exposures to the human immunodeficiency virus (HIV) through sex and injection drug use. The probability of HIV transmission by certain sexual or injection drug exposures is of the same order of magnitude as percutaneous occupational exposures for which the CDC recommends PEP. In such cases, if the exposure is sporadic, it seems appropriate to extrapolate from the data on occupational PEP and recommend prophylaxis. However, for individuals with continuing or low-risk exposures, we instead recommend referrals to state-of-the-art risk reduction programs. Clinicians, using local HIV seroprevalence data and their knowledge of transmission probabilities, can help exposed patients make an informed decision regarding PEP. Because of the large number of risky encounters that will not be treated prophylactically, even after significant outreach efforts, public health interventions that emphasize PEP as part of a comprehensive HIV prevention program should be confined to cities with highest HIV prevalences.	Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, AIDS Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr AIDS Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, Program Med Eth, San Francisco, CA 94143 USA; Publ Citizens Hlth Res Grp, Washington, DC USA; Univ Calif Berkeley, Sch Publ Hlth, Maternal & Child Hlth Program, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Lo, B (corresponding author), Room C126,521 Parnassus Ave, San Francisco, CA 94143 USA.	Bernie@itsa.ucsf.edu		Hecht, Frederick/0000-0002-5782-1171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAGSHAW SN, 1988, AUST NZ J OBSTET GYN, V28, P137, DOI 10.1111/j.1479-828X.1988.tb01643.x; BASHAM T, 1990, J INFECT DIS, V161, P1006, DOI 10.1093/infdis/161.5.1006; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; BROWN WF, 1998, MAYORS SUMMIT AIDS H; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468; *CDCP, 1995, NAT HIV SER SUMM UPD, V3; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; CHESNEY M, IN PRESS SEXUALLY TR; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CRAIB KJP, 1995, GENITOURIN MED, V71, P150, DOI 10.1136/sti.71.3.150; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; ELLERTSON C, 1995, STUD FAMILY PLANN, V26, P251, DOI 10.2307/2138011; EMERY T, 1997, BOSTON GLOBE    0113, pC1; Emini EA, 1995, ADV EXP MED BIOL, V390, P187; FABIAN R, 1994, VALUING HLTH POLICY, P118; Fishbein M., 1994, PREVENTING AIDS THEO, P61; Freeman RC, 1996, AIDS EDUC PREV, V8, P58; GAUGHWIN MD, 1991, AIDS, V5, P1025, DOI 10.1097/00002030-199108000-00016; GAYLE HD, 1990, NEW ENGL J MED, V323, P1538, DOI 10.1056/NEJM199011293232206; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P1116; Katz MH, 1998, ANN INTERN MED, V128, P306, DOI 10.7326/0003-4819-128-4-199802150-00012; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; LEBLANC S, 1996, YOUR MONEY YOUR LIFE; Ledray L E, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P180; Leland J, 1996, Newsweek, V128, P64; Li RW, 1997, NEW ENGL J MED, V337, P499, DOI 10.1056/NEJM199708143370714; Lipsky JJ, 1996, LANCET, V348, P800, DOI 10.1016/S0140-6736(95)12333-4; LO B, 1995, RESOLVING ETHICAL DI; Martin JP, 1998, 38 INT C ANT AG CHEM; Mastro T D, 1996, AIDS, V10 Suppl A, pS75, DOI 10.1097/00002030-199601001-00011; Mayer KH, 1995, INFECT AGENT DIS, V4, P273; Montoya ID, 1996, J ACQ IMMUN DEF SYND, V13, P169, DOI 10.1097/00042560-199610010-00008; *NAT VICT CTR, 1992, NAT WOM STUD RAP AM; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; OKIE S, 1997, WASHINGTON POST 0204, pZ13; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; PADIAN NS, 1995, J INFECT DIS, V172, P1084, DOI 10.1093/infdis/172.4.1084; PAINTER K, 1997, US TODAY        1103, pD1; PERLMAN D, 1997, SAN FRANCISCO C 1014, pA2; Pinkerton SD, 1997, NEW ENGL J MED, V337, P500; RAMBOW B, 1992, ANN EMERG MED, V21, P727, DOI 10.1016/S0196-0644(05)82788-X; ROSENSTOCK S, 1994, PREVENTING AIDS THEO, P5; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; SEIDLIN M, 1993, AIDS, V7, P1247, DOI 10.1097/00002030-199309000-00015; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; SMITH LFP, 1995, BRIT J GEN PRACT, V45, P409; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P52; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P84; SULLIVAN A, 1996, NY TIMES MAGAZI 1110, P77; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Vanchieri C, 1996, ANN INTERN MED, V125, pI61; YOUNG WW, 1992, OBSTET GYNECOL, V80, P878	61	62	62	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1769	1773		10.1001/jama.280.20.1769	http://dx.doi.org/10.1001/jama.280.20.1769			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842953				2022-12-28	WOS:000077081400033
J	Newacheck, PW; Pearl, M; Hughes, DC; Halfon, N				Newacheck, PW; Pearl, M; Hughes, DC; Halfon, N			The role of Medicaid in ensuring children's access to care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-INCOME CHILDREN; HEALTH-CARE; MANAGED CARE; SERVICES; POOR; BARRIERS; EQUITY; YOUTH; HMO	Context.-Congress enacted a series of laws beginning in the mid 1980s to expand Medicaid eligibility for children, especially those in poor families. As a result, Medicaid enrollment of children has nearly doubled over the past decade. Objective.-To assess the effectiveness of Medicaid in improving access to and use of health services by poor children. Design-Analysis of cross-sectional survey data from the 1995 National Health Interview Survey. Poor children with Medicaid were compared to poor children without insurance and nonpoor children with private insurance. Setting and Participants.-A total of 29711 children younger than 18 years (3716 poor children with Medicaid, 1329 poor children without insurance, 14 609 nonpoor children with private insurance, and 10 057 children with other combinations of poverty and insurance status) included in a nationally representative stratified probability sample of the US noninstitutionalized population. Main Outcome Measures.-Usual source of care, access to a regular clinician, unmet health needs, and use of physician services. Results.-Poor children with Medicaid compared to poor children without health insurance experienced superior access across all measured dimensions of health care, including presence of a usual source of care (95.6% vs 73.8%), frequency of unmet health needs (2.1% vs 5.9%), and use of medical services (eg, greater than or equal to 1 physician contact in past year) (83.9% vs 60.7%). Poor children with Medicaid compared to nonpoor children with private insurance used similar levels of physician services (83.9% vs 84%), but were more likely to have unmet health needs (2.1% vs 0.6%) and were less likely to have a usual source of care (95.6% vs 97.4%). Conclusion.-Medicaid is associated with improvements in access to care and use of services. However, there remains room for improvement when Medicaid is judged against private health insurance. The Balanced Budget Act of 1997 contains several Medicaid provisions that could stimulate further improvements in access for poor children.	Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94109 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94109 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Newacheck, PW (corresponding author), Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, 1388 Sutter St,11th Floor, San Francisco, CA 94109 USA.							ADAY LA, 1981, MED CARE, V19, P4, DOI 10.1097/00005650-198112001-00004; Aday LA, 1975, DEV INDICES ACCESS M; ANDERSEN RA, 1998, RES SERIES CTR HLTH, V25; BUTLER JA, 1985, PEDIATRICS, V76, P495; COHEN JW, 1995, HEALTH AFFAIR, V14, P255, DOI 10.1377/hlthaff.14.1.255; Coughlin Teresa A., 1994, MEDICAID 1980 COSTS; HALFON N, 1995, ANNU REV PUBL HEALTH, V16, P447, DOI 10.1146/annurev.pu.16.050195.002311; HUGHES DC, 1995, PEDIATRICS, V95, P591; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; LAMISONWHITE L, 1997, CURENT POPULATION RE; LEVEY LA, 1986, AM J PUBLIC HEALTH, V76, P1000, DOI 10.2105/AJPH.76.8.1000; LIEU TA, 1994, AM J PUBLIC HEALTH, V84, P1621, DOI 10.2105/AJPH.84.10.1621; MARGOLIS PA, 1995, ARCH PEDIAT ADOL MED, V149, P541, DOI 10.1001/archpedi.1995.02170180071011; Marquis MS, 1996, HEALTH SERV RES, V30, P791; MAULDON J, 1994, AM J PUBLIC HEALTH, V84, P899, DOI 10.2105/AJPH.84.6.899; MCMANUS M, 1991, PEDIATRICS, V87, P909; Millman M., 1993, ACCESS HLTH CARE AM; NEWACHECK PW, 1994, PEDIATRICS, V93, P497; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWACHECK PW, 1988, PEDIATRICS, V82, P462; NEWACHECK PW, 1995, JAMA-J AM MED ASSOC, V274, P1468, DOI 10.1001/jama.274.18.1468; NEWACHECK PW, 1989, PEDIATRICS, V84, P1056; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; Selden TM, 1998, HEALTH AFFAIR, V17, P192, DOI 10.1377/hlthaff.17.3.192; SHAH BV, 1992, SUDAAN USERS MANUAL; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; SIMPSON G, 1997, VITAL HLTH STAT, V10; STPETER RF, 1992, JAMA-J AM MED ASSOC, V267, P2760, DOI 10.1001/jama.267.20.2760; *US DEP HHS, 1997, PUBL US DEP HLTH HUM; VBENSON V, 1997, VIT HLTH STAT, V10; WEISSMAN JS, 1993, ANNU REV PUBL HEALTH, V14, P243; [No title captured]	33	85	85	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1998	280	20					1789	1793		10.1001/jama.280.20.1789	http://dx.doi.org/10.1001/jama.280.20.1789			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	140HF	9842958				2022-12-28	WOS:000077081400039
J	Rose, SPR				Rose, SPR			Neurogenetic determinism and the new euphenics	BRITISH MEDICAL JOURNAL			English	Review							BEHAVIOR		Open Univ, Brain & Behav Res Grp, Milton Keynes MK7 6AA, Bucks, England	Open University - UK	Rose, SPR (corresponding author), Open Univ, Brain & Behav Res Grp, Milton Keynes MK7 6AA, Bucks, England.							[Anonymous], 1997, LIFELINES BIOL FREED; Breggin PR, 1998, TALKING BACK RITALIN; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; ROSE S, 1995, NATURE, V373, P380, DOI 10.1038/373380a0	5	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1707	1708		10.1136/bmj.317.7174.1707	http://dx.doi.org/10.1136/bmj.317.7174.1707			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857135	Green Published			2022-12-28	WOS:000077742300023
J	Kato, Y; Tani, T; Sotomaru, Y; Kurokawa, K; Kato, JY; Doguchi, H; Yasue, H; Tsunoda, Y				Kato, Y; Tani, T; Sotomaru, Y; Kurokawa, K; Kato, JY; Doguchi, H; Yasue, H; Tsunoda, Y			Eight calves cloned from somatic cells of a single adult	SCIENCE			English	Article							FETAL	Eight carves were derived from differentiated cells of a single adult cow, five from cumulus cells and three from oviductal cells out of 10 embryos transferred to surrogate cows (80 percent success). ALL carves were visibly normal, but four died at or soon after birth from environmental causes, and postmortem analysis revealed no abnormality. These results show that bovine cumulus and oviductal epithelial cells of the adult have the genetic content to direct the development of newborn carves.	Kinki Univ, Coll Agr, Lab Anim Reprod, Nara 6318505, Japan; Kinki Univ, Res Inst Anim Dev Biotechnol, Nara 6318505, Japan; Minist Agr Forestry & Fisheries, Natl Inst Anim Ind, Dept Anim Breeding & Genet, Tsukuba, Ibaraki 3050901, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan	Tsunoda, Y (corresponding author), Kinki Univ, Coll Agr, Lab Anim Reprod, 3327-204 Nakamachi, Nara 6318505, Japan.		Kurokawa, Kazuo/E-9130-2013; tani, tetsuya/AAR-7581-2021	Kurokawa, Kazuo/0000-0003-3549-4795; tani, tetsuya/0000-0001-5276-8941				BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BRIGS R, 1960, DEV BIOL, V2, P252, DOI 10.1016/0012-1606(60)90008-7; CIBELLI JB, 1998, NATURE, V280, P1256; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI; DORLAND M, 1997, J REPROD FERTIL, V20, P31; Garry FB, 1996, THERIOGENOLOGY, V45, P141, DOI 10.1016/0093-691X(95)00363-D; Inoue-Murayama Miho, 1997, Animal Science and Technology, V68, P443; JOSHI MS, 1988, J REPROD FERTIL, V83, P249, DOI 10.1530/jrf.0.0830249; Kato Y., UNPUB; REIK W, 1993, DEVELOPMENT, V119, P933; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROSENKRANS C F JR, 1991, Theriogenology, V35, P266, DOI 10.1016/0093-691X(91)90242-6; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	15	783	932	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2095	2098		10.1126/science.282.5396.2095	http://dx.doi.org/10.1126/science.282.5396.2095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851933				2022-12-28	WOS:000077467100051
J	Ungermann, C; Sato, K; Wickner, W				Ungermann, C; Sato, K; Wickner, W			Defining the functions of trans-SNARE pairs	NATURE			English	Article							MEMBRANE-FUSION COMPLEX; VACUOLE INHERITANCE; IN-VITRO; CLOSTRIDIAL NEUROTOXINS; VESICLE FUSION; YEAST VACUOLES; ALPHA-SNAP; DOCKING; NSF; SYNAPTOBREVIN	The homotypic fusion of yeast vacuoles includes a 'docking' step, which we show here to consist of two sequential reactions: a reversible 'tethering' mediated by the GTPase Ypt7, and 'SNARE pairing', in which SNARE proteins from opposite membranes form a complex in trans. The function of this trans-SNARE complex must be transient, as the complex can be disassembled by excess Sec18 in the presence of Sec17 and ATP without influencing the fusion rate. These data Indicate that SNARE pairing may transiently signal to downstream factors, leading to fusion.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Ungermann, C (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Christian.Ungermann@Dartmouth.edu						BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9	34	286	290	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					543	548		10.1038/25069	http://dx.doi.org/10.1038/25069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859990				2022-12-28	WOS:000077466800048
J	Kiselyov, K; Xu, X; Mozhayeva, G; Kuo, T; Pessah, I; Mignery, G; Zhu, X; Birnbaumer, L; Muallem, S				Kiselyov, K; Xu, X; Mozhayeva, G; Kuo, T; Pessah, I; Mignery, G; Zhu, X; Birnbaumer, L; Muallem, S			Functional interaction between InsP(3) receptors and store-operated Htrp3 channels	NATURE			English	Article							INTRACELLULAR CA2+ STORES; CALCIUM-ENTRY; INOSITOL PHOSPHATE; PLASMA-MEMBRANE; CELLS; DEPLETION; EXPRESSION; RELEASE; INFLUX	Calcium ions are released from intracellular stores in response to agonist-stimulated production of inositol 1,4,5-trisphosphate (InsP(3)), a second messenger generated at the cell membrane. Depletion of Ca2+ from internal stores triggers a capacitative influx of extracellular Ca2+ across the plasma membrane(1,2). The influx of Ca2+ can be recorded as store-operated channels (SOC) in the plasma membrane or as a current known as the Ca2+-release-activated current (I-crac)(3-5). A critical question in cell signalling is how SOC and I-crac sense and respond to Ca2+-store depletion: in one model, a messenger molecule is generated that activates Ca2+ entry in response to store depletion(1,6); in an alternative model(7), InsP(3) receptors in the stores are coupled to SOC and I-crac. The mammalian Htrp3 protein(8) forms a well defined store-operated channel(8,9) and so provides a suitable system for studying the effect of Ca2+-store depletion on SOC and I-crac. We show here that Htrp3 channels stably expressed in HEK293 cells are in a tight functional interaction with the InsP(3) receptors. Htrp3 channels present in the same plasma membrane patch can be activated by Ca2+ mobilization in intact cells and by InsP(3) in excised patches. This activation of Htrp3 by InsP(3) is lost on extensive washing of excised patches but is restored by addition of native or recombinant InsP(3)-bound InsP(3) receptors. Our results provide evidence for the coupling hypothesis(7), in which InsP(3) receptors activated by InsP(3) interact with SOC and regulate I-crac.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia; Wayne State Univ, Detroit, MI 48201 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43216 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43216 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90049 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Wayne State University; University of California System; University of California Davis; Loyola University Chicago; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	smuall@mednet.swmed.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X; Kiselyov, Kirill/0000-0001-6683-2895				Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; KISELYOV KI, IN PRESS PFLUEGERS A; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MIGNERY GA, 1990, J BIOL CHEM, V265, P12579; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAMOSFRANCO J, IN PRESS BIOPHYS J; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHARP AH, 1993, J NEUROSCI, V13, P3051; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	25	530	545	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1998	396	6710					478	482		10.1038/24890	http://dx.doi.org/10.1038/24890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853757				2022-12-28	WOS:000077370100057
J	O'Brien, E; Bouchier-Hayes, D; Fitzgerald, D; Atkins, N				O'Brien, E; Bouchier-Hayes, D; Fitzgerald, D; Atkins, N			The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic	LANCET			English	Editorial Material									Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland		O'Brien, E (corresponding author), Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland.			Atkins, Neil/0000-0002-9575-4686				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Atkins N, 1998, J HYPERTENS, V16, pS198; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Fagerberg B, 1998, AM J HYPERTENS, V11, P14, DOI 10.1016/S0895-7061(97)00363-4; Gensini GF, 1998, EUR HEART J, V19, pA53; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Hasnain S, 1998, J HUM HYPERTENS, V12, P469, DOI 10.1038/sj.jhh.1000648; MOHER M, 1997, BMJ-BRIT MED J, V515, P69; Ramsay LE, 1998, AM J HYPERTENS, V11, p79S, DOI 10.1016/S0895-7061(98)00063-6; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Simon A, 1997, AM J HYPERTENS, V10, P813, DOI 10.1016/S0895-7061(97)00118-0; Stephens N, 1997, LANCET, V349, P1710, DOI 10.1016/S0140-6736(97)22024-6; Webster MWI, 1997, LANCET, V350, pSI23	13	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1700	1702		10.1016/S0140-6736(97)09026-0	http://dx.doi.org/10.1016/S0140-6736(97)09026-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853458				2022-12-28	WOS:000077110300045
J	Heffner, JE; Barbieri, C				Heffner, JE; Barbieri, C			Compliance with do-not-resuscitate orders for hospitalized patients transported to radiology departments	ANNALS OF INTERNAL MEDICINE			English	Article							DNR ORDERS	Background: Little is known about the effectiveness of do-not-resuscitate (DNR) orders during transport of hospitalized patients away from their rooms. Objective: To determine compliance with DNR orders in radiology departments. Design: Observational study. Setting: 248 hospital-based radiology departments. Participants: 248 radiology department representatives. Measurements: 10-item questionnaire examining the response of radiology personnel to patients with DNR orders who experience cardiopulmonary arrest. Results: Written DNR protocols and structured procedures for communicating DNR status were used by 18.5% (CI, 13.7% to 23.4%) and 18.1% (CI, 13.3% to 23.0%) of departments, respectively. Medical chart review was the only source of information on DNR status for 41.5% (CI, 35.4% to 47.7%) of departments. It was found that 20.2% of respondents (CI, 15.2% to 25.2%) would resuscitate patients with DNR orders and that 38.3% (CI, 32.3% to 44.4%) had resuscitated patients with DNR orders in the past. Conclusions: Most radiology departments do not have formal procedures to prevent patients from undergoing unwanted or inappropriate resuscitative interventions, and DNR orders are frequently overruled.	St Josephs Hosp, Mercy Hlth Serv Res Grp, Phoenix, AZ 85001 USA	St. Joseph's Hospital and Medical Center	Heffner, JE (corresponding author), Med Univ S Carolina, Dept Med, Room 812 CSB,171 Ashley Ave, Charleston, SC 29425 USA.							*AM COLL SURG, 1994, AM COLL SURG B, V79, P29; *AM HOSP ASS, 1996, AM HOSP ASS GUID HLT; *AM MED ASS, 1997, GRAD MED ED DIR 1997; *AM SOC AN, 1994, ETH GUID AN CAR PAT, P746; Casarett D, 1997, NEW ENGL J MED, V336, P1908, DOI 10.1056/NEJM199706263362611; CLEMENCY MV, 1993, ANESTH ANALG, V76, P394; *DHEW, 1995, DHEW PUBL; EVANS AL, 1985, JAMA-J AM MED ASSOC, V253, P2236, DOI 10.1001/jama.253.15.2236; Heffner JE, 1996, ARCH INTERN MED, V156, P793, DOI 10.1001/archinte.156.7.793; Heffner JE, 1998, ARCH INTERN MED, V158, P1090, DOI 10.1001/archinte.158.10.1090; Heffner JE, 1997, ARCH INTERN MED, V157, P685, DOI 10.1001/archinte.157.6.685; Jacobson JA, 1996, RADIOLOGY, V198, P21, DOI 10.1148/radiology.198.1.8539381; LAPUMA J, 1988, ARCH INTERN MED, V148, P2193, DOI 10.1001/archinte.148.10.2193; MCDERMOTT VGM, 1993, BRIT J RADIOL, V66, P667, DOI 10.1259/0007-1285-66-788-667; MITTELBERGER JA, 1993, ARCH INTERN MED, V153, P228, DOI 10.1001/archinte.153.2.228; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; Terry PB, 1996, RADIOLOGY, V198, P17, DOI 10.1148/radiology.198.1.8539372; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; WALL SD, 1991, AM J ROENTGENOL, V157, P911, DOI 10.2214/ajr.157.5.1927808; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056	20	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1998	129	10					801	805		10.7326/0003-4819-129-10-199811150-00010	http://dx.doi.org/10.7326/0003-4819-129-10-199811150-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138QW	9841586				2022-12-28	WOS:000076984800006
J	Keitz, S				Keitz, S			Blue	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vet Affairs Med Ctr, Ambulatory Care Serv IIC, Durham, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Keitz, S (corresponding author), Vet Affairs Med Ctr, Ambulatory Care Serv IIC, 508 Fulton St, Durham, NC 27705 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					744	745		10.7326/0003-4819-129-9-199811010-00015	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841611				2022-12-28	WOS:000076785200013
J	Wear, D				Wear, D			On white coats and professional development: The formal and the hidden curricula	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN	White coat ceremonies are a recent phenomenon in medical education. Selected as a symbol by the Arnold P. Gold Foundation to impress upon medical students the importance of compassion and humility, the white coat has had a long association with all things medical, scientific, and healing. It is also associated with the attributes of purity and goodness traditionally symbolized by the color white. Thus, its selection as the material focus of the white coat ceremony seems natural. This article situates the white coat ceremony as a curricular event and suggests that, in addition to having the meanings cited above, the white coat has other meanings that fall into the realm of the hidden curriculum-it can symbolize caregiving hierarchies and spheres of practice, the social and economic privilege of physicians, and medicine's well-established practices of determining membership in the profession. Finally, this paper suggests several other ceremonies or rituals that may be better than the white coat ceremony for encouraging compassion and humility in medical students.	Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Rootstown, OH 44272 USA	Northeast Ohio Medical University (NEOMED)	Wear, D (corresponding author), Northeastern Ohio Univ Coll Med & Pharm, Coll Med, 4209 State Route 44,POB 95, Rootstown, OH 44272 USA.	dw@neoucom.edu						APPLE MW, 1975, CURRICULUM THEORIZIN, P95; Bird Frederick, 1980, RITUALS CEREMONIES P, P19; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; Browne RayBroadus., 1980, RITUALS CEREMONIES P; COLT HG, 1989, ANN EMERG MED, V18, P145, DOI 10.1016/S0196-0644(89)80104-0; Jackson P., 1990, LIFE CLASSROOMS; Joseph Nathan., 1986, UNIFORMS NONUNIFORMS; KAIER S, 1990, SOCIAL PYSCHOL CLOTH; LOWES R, 1996, NEW PHYSICIAN    SEP, P27; Mahowald Mary Briody, 1996, FEMINISM BIOETHICS R, P95; MCLAREN P, 1989, LIFE SCH INTRO CRITI; Sherwin S., 1996, FEMINISM BIOETHICS R, P47; 1997, AAMC REPORTER, P4	13	123	126	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					734	737		10.7326/0003-4819-129-9-199811010-00010	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841607				2022-12-28	WOS:000076785200009
J	Sandler, DA				Sandler, DA			Boom ditty boom ditty boom ditty boom (goodness gracious me)	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Hosp, Derby S44 5BL, England		Sandler, DA (corresponding author), Royal Hosp, Derby S44 5BL, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1742	1742		10.1136/bmj.317.7174.1742	http://dx.doi.org/10.1136/bmj.317.7174.1742			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857165	Green Published			2022-12-28	WOS:000077742300060
J	Beecham, L				Beecham, L			All GPs must have full insurance	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1663	1663						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848927				2022-12-28	WOS:000077602100078
J	Li, FZ; Ambrosini, G; Chu, EY; Plescia, J; Tognin, S; Marchisio, PC; Altieri, DC				Li, FZ; Ambrosini, G; Chu, EY; Plescia, J; Tognin, S; Marchisio, PC; Altieri, DC			Control of apoptosis and mitotic spindle checkpoint by survivin	NATURE			English	Article							CELL-CYCLE; PROTEINS; MICROTUBULES; EXPRESSION; FAMILY; DEATH; BCL-2; GENES; IAP	Progression of the cell cycle and control of apoptosis (programmed cell death) are thought to be intimately linked processes(1), acting to preserve homeostasis and developmental morphogenesis(2). Although proteins that regulate apoptosis have been implicated in restraining cell-cycle entry(3) and controlling ploidy (chromosome number)(4), the effector molecules at the interface between cell proliferation and cell survival have remained elusive. Here we show that a new inhibitor of apoptosis (IAP) protein(5,6), survivin(7), is expressed in the G2/M phase of the cell cycle in a cycle-regulated manner. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle in a specific and saturable reaction that is regulated by microtubule dynamics(8). Disruption of survivin-microtubule interactions results in loss of survivin's anti-apoptosis function and increased caspase-3 activity, a mechanism involved in cell death, during mitosis. These results indicate that survivin may counteract a default induction of apoptosis in G2/M phase. The overexpression of survivin in cancer(7) may overcome this apoptotic checkpoint and favour aberrant progression of transformed cells through mitosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy	Yale University; Vita-Salute San Raffaele University; University of Turin	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, 295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu	Li, Fengzhi/GXF-0115-2022		Telethon [496] Funding Source: Medline	Telethon(Fondazione Telethon)		Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lu CD, 1998, CANCER RES, V58, P1808; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; TAMM I, IN PRESS CANC RES; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	24	1605	1887	1	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1998	396	6711					580	584		10.1038/25141	http://dx.doi.org/10.1038/25141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147AY	9859993				2022-12-28	WOS:000077466800059
J	Jayawant, S; Rawlinson, A; Gibbon, F; Price, J; Schulte, J; Sharples, P; Sibert, JR; Kemp, AM				Jayawant, S; Rawlinson, A; Gibbon, F; Price, J; Schulte, J; Sharples, P; Sibert, JR; Kemp, AM			Subdural haemorrhages in infants: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEAD-INJURY; SHAKEN; ABUSE; BABY	Objectives. To identify the incidence, clinical outcome, and associated factors of subdural haemorrhage in children under 2 years of age, and to determine how such cases were investigated and how many were due to child abuse. Design Population based case series. Setting South Wales and south west England. Subjects Children under 2 years of age who had a subdural haemorrhage, We excluded neonates developed subdural haemorrhage during their stay on a neonatal unit and infants who developed a subdural haemorrhage after infection or neurosurgical intervention. Main outcome measures Incidence and clinical outcome of subdural haemorrhage in infants, the number of cases caused by child abuse, the investigations such children received, and associated risk factors. Results Thirty three children (23 boys and 10 girls) were identified with subdural haemorrhage. The incidence was 12.8/100 000 children/year (95% confidence interval 5.4 to 20.2). Twenty eight cases (85%) were under 1 year of age. The incidence of subdural haemorrhage in children under 1 year of age was 21.0/100 000 children/year and was therefore higher than in the older children. The clinical outcome was poor: nine infants died and 15 had profound disability. Only 22 infants had the basic investigations of a full blood count, coagulation screen, computed tomography or magnetic resonance imaging, skeletal survey or bone scan, and ophthalmological examination. In retrospect, 27 cases (82%) were highly suggestive of abuse. Conclusion Subdural haemorrhage is common in infancy and carries a poor prognosis; three quarters of such infants die or have profound disability. Most cases are due to child abuse, but in a few the cause is unknown. Some children with subdural haemorrhage do not undergo appropriate investigations. We believe the clinical investigation of such children should include a full multidisciplinary social assessment, an ophthalmic examination, a skeletal survey supplemented with a bone scan or a skeletal survey repeated at around 10 days, a coagulation screen, and computed tomography or magnetic resonance imaging. Previous physical abuse in an infant is a significant risk factor for subdural haemorrhage and must be taken seriously by child protection agencies.	Univ Wales, Coll Med, Dept Child Hlth, Llandough Hosp,Acad Ctr, Penarth CF64 2XX, Vale Glamorgan, Wales; Southmead Gen Hosp, Dept Child Hlth, Bristol BS10 5NB, Avon, England; Frenchay Hosp, Bristol BS16 1LE, Avon, England	Southmead Hospital	Kemp, AM (corresponding author), Univ Wales, Coll Med, Dept Child Hlth, Llandough Hosp,Acad Ctr, Penarth CF64 2XX, Vale Glamorgan, Wales.	kempam@cardiff.acuk						ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; *BRIT PAED SURV UN, 1991, 6 BRIT PAED ASS; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CARTY H, 1995, BRIT MED J, V310, P344, DOI 10.1136/bmj.310.6976.344; Department of Health, 1996, CONF ENQ STILLB DEAT; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HALLER J D, 1991, Pediatrics, V87, P262; KAUR B, 1992, SURV OPHTHALMOL, V37, P1, DOI 10.1016/0039-6257(92)90002-B; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; OHARE AE, 1984, ARCH DIS CHILD, V59, P860, DOI 10.1136/adc.59.9.860; SALMAN M, 1997, PAEDIAT TODAY, V5, P42; SHOWERS J, 1992, CHILD ABUSE NEGLECT, V16, P11, DOI 10.1016/0145-2134(92)90004-B; TARDIEU A, 1860, ANN HYG PUBLIQUE MED, V13, P361, DOI DOI 10.3917/EP.039.0174; Wilkins B, 1997, ARCH DIS CHILD, V76, P393, DOI 10.1136/adc.76.5.393	23	196	201	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1998	317	7172					1558	+		10.1136/bmj.317.7172.1558	http://dx.doi.org/10.1136/bmj.317.7172.1558			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836654	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000077451700022
J	Himanen, JP; Henkemeyer, M; Nikolov, DB				Himanen, JP; Henkemeyer, M; Nikolov, DB			Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2	NATURE			English	Article							NEURAL CREST MIGRATION; TRANSMEMBRANE LIGANDS; COMMISSURAL AXONS; NUK; GUIDANCE; COMPLEX; PATTERN	The Eph receptors, which bind a group of cell-membrane-anchored ligands known as ephrins, represent the largest subfamily of receptor tyrosine kinases (RTKs)(1). They are predominantly expressed in the developing and adult nervous system(2) and are important in contact-mediated axon guidance(3-6), axon fasciculation(5,7) and cell migations(8-11). Eph receptors are unique among other RTKs in that they fall into two subclasses with distinct Ligand specificities(12), and in that they can themselves function as ligands to activate bidirectional cell-cell signalling(4,13,14). We report here the crystal structure at 2.9 Angstrom resolution of the amino-terminal ligand-binding domain of the EphB2 receptor (also known as NUk)(15-17). Th, domain folds into a compact jellyroll beta-sandwich composed of 11 antiparallel beta-strands. Using structure-based mutagenesis, we have identified an extended loop that is important for ligand binding and class specificity. This loop, which is conserved within but not between Eph RTK subclasses, packs against the concave beta-sandwich surface near positions at which missense mutations cause signalling defects(18), localizing the ligand-binding region on the surface of the receptor.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA	Memorial Sloan Kettering Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nikolov, DB (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Dimitar@ximpact3.number.lnuk		Henkemeyer, Mark/0000-0002-7525-1061				[Anonymous], 1997, Cell, V90, P403; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BRUNGER AT, 1993, XPLOR V 3 1 MANUAL; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WU Q, 1995, DEVELOPMENT, V121, P4005	30	87	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1998	396	6710					486	491		10.1038/24904	http://dx.doi.org/10.1038/24904			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853759				2022-12-28	WOS:000077370100059
J	Rutherford, SL; Lindquist, S				Rutherford, SL; Lindquist, S			Hsp90 as a capacitor for morphological evolution	NATURE			English	Article							STEROID-RECEPTOR; TYROSINE KINASE; PROTEIN-KINASE; IN-VIVO; DROSOPHILA; NEUTRALITY; MUTATIONS; HSP83	The heat-shock protein Hsp90 supports diverse but specific signal transducers and lies at the interface of several developmental pathways. We report here that when Drosophila Hsp90 is mutant or pharmacologically Impaired, phenotypic variation affecting nearly any adult structure is produced, with specific variants depending on the genetic background and occurring both in laboratory strains and in wild populations. Multiple, previously silent, genetic determinants produced these variants and, when enriched by selection, they rapidly became independent of the Hsp90 mutation, Therefore, widespread variation affecting morphogenic pathways exists in nature, but is usually silent; Hsp90 buffers this variation, allowing it to accumulate under neutral conditions, When Hsp90 buffering is compromised, for example by temperature, cryptic variants are expressed and selection can lead to the continued expression of these traits, even when Hsp90 function is restored. This provides a plausible mechanism for promoting evolutionary change in otherwise entrenched developmental processes.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Calif Irvine, Ctr Dev Biol, 4205 Biol Sci 2, Irvine, CA 92697 USA.							Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DEJONG G, 1976, GENETICS, V84, P77; Dickson BJ, 1996, GENETICS, V142, P163; DYKHUIZEN D, 1980, GENETICS, V96, P801; Falconer DS, 1996, INTRO QUANTITATIVE G; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Futuyama D.J., 1998, EVOLUTIONARY BIOL; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Kauffman S.A., 1993, ORIGINS ORDER; Kimura M., 1983, NEUTRAL THEORY MOL E; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Polaczyk PJ, 1998, DEV GENES EVOL, V207, P462, DOI 10.1007/s004270050137; Raff R. A., 1996, SHAPE LIFE GENES DEV; RENDEL JM, 1965, GENETICS, V52, P1137; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WADDINGTON CH, 1956, EVOLUTION, V10, P1, DOI 10.2307/2406091; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747; Wade MJ, 1997, GENETICS, V147, P1235; WAGNER GP, 1984, BIOSYSTEMS, V17, P51, DOI 10.1016/0303-2647(84)90015-7; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; XU Y, IN PRESS P NATL ACAD; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	37	1602	1677	1	215	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1998	396	6709					336	342		10.1038/24550	http://dx.doi.org/10.1038/24550			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	142MJ	9845070				2022-12-28	WOS:000077204000040
J	Usui, T; Ohta, T; Oshiumi, H; Tomizawa, J; Ogawa, H; Ogawa, T				Usui, T; Ohta, T; Oshiumi, H; Tomizawa, J; Ogawa, H; Ogawa, T			Complex formation and functional versatility of Mre11 of budding yeast in recombination	CELL			English	Article							DOUBLE-STRAND BREAKS; MEIOTIC CHROMOSOME SYNAPSIS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; INITIATION SITE; CELL-CYCLE; DNA-REPAIR; MEIOSIS; GENE; PROTEIN	Meiotic recombination of S. cerevisiae contains two temporally coupled processes, formation and processing of double-strand breaks (DSBs). Mre11 forms a complex with Rad50 and Xrs2, acting as the binding core, and participates in DSB processing. Although these proteins are also involved in DSB formation, Mre11 is not necessarily holding them. The C-terminal region of Mre11 is required only for DSB formation and binds to some meiotic proteins. The N-terminal half specifies nuclease activities that are collectively required for DSB processing. Mre11 has a DNA-binding site for DSB formation and another site for DSB processing. It has two regions to bind to Rad50. Mre11 repairs methyl methanesulfonate-induced DSBs by reactions that require the nuclease activities and those that do not.	Natl Inst Genet, Shizuoka 4118540, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Osaka University	Ohta, T (corresponding author), Natl Inst Genet, Shizuoka 4118540, Japan.		Oshiumi, Hiroyuki/G-1645-2012	Oshiumi, Hiroyuki/0000-0003-1567-8722				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BHARGAVA J, 1992, GENETICS, V130, P59; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; DEMASSY B, 1995, EMBO J, V14, P4589, DOI 10.1002/j.1460-2075.1995.tb00138.x; DETLOFF P, 1992, GENETICS, V132, P113; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McKee AHZ, 1997, GENETICS, V146, P797; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Prinz S, 1997, GENETICS, V146, P781; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x	35	290	300	2	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 25	1998	95	5					705	716		10.1016/S0092-8674(00)81640-2	http://dx.doi.org/10.1016/S0092-8674(00)81640-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	143KD	9845372	Bronze			2022-12-28	WOS:000077253700017
J	Lang, SM; Schiffl, H				Lang, SM; Schiffl, H			Losartan and anaemia of end-stage renal disease	LANCET			English	Letter									Univ Munich, Med Klin, Klinikum Innenstadt, D-80336 Munich, Germany	University of Munich	Lang, SM (corresponding author), Univ Munich, Med Klin, Klinikum Innenstadt, Ziemssenstr 1, D-80336 Munich, Germany.							Schwarzbeck A, 1998, LANCET, V352, P286, DOI 10.1016/S0140-6736(05)60259-0; SHAND BI, 1995, J HUM HYPERTENS, V9, P233; Toto R, 1998, HYPERTENSION, V31, P684, DOI 10.1161/01.HYP.31.2.684	3	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1708	1708		10.1016/S0140-6736(05)61486-9	http://dx.doi.org/10.1016/S0140-6736(05)61486-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853467	Bronze			2022-12-28	WOS:000077110300058
J	Morrison, PJ				Morrison, PJ			Implications of genetic testing for insurance in the UK	LANCET			English	Editorial Material									Belfast City Hosp Trust, Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital	Morrison, PJ (corresponding author), Belfast City Hosp Trust, Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland.							*ASS BRIT INS, 1997, GEN TEST ABI COD PRA; *DEP TRAD IND OFF, 1998, IMPL GEN TEST INS; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; Kleinert S, 1998, LANCET, V352, P1608, DOI 10.1016/S0140-6736(05)61064-1; McNally D, 1997, ULSTER MED J, V66, P134; Morrison PJ, 1998, CLIN GENET, V54, P375; MORRISON PJ, 1998, AM J HUM GENET S, V63, pA12; 1996, NAT GENET, V13, P1	8	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 21	1998	352	9141					1647	1648		10.1016/S0140-6736(05)61446-8	http://dx.doi.org/10.1016/S0140-6736(05)61446-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853435				2022-12-28	WOS:000077110300007
J	Wolkenstein, P; Latarjet, J; Roujeau, JC; Duguet, C; Boudeau, S; Vaillant, L; Maignan, M; Schuhmacher, MH; Milpied, B; Pilorget, A; Bocquet, H; Brun-Buisson, C; Revuz, J				Wolkenstein, P; Latarjet, J; Roujeau, JC; Duguet, C; Boudeau, S; Vaillant, L; Maignan, M; Schuhmacher, MH; Milpied, B; Pilorget, A; Bocquet, H; Brun-Buisson, C; Revuz, J			Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis	LANCET			English	Article							STEVENS-JOHNSON SYNDROME; NECROSIS-FACTOR-ALPHA; TNF-ALPHA	Background Toxic epidermal necrolysis (TEN) is associated with a 30% death rate. Tumour necrosis factor alpha (TNF-alpha) has been implicated in the pathogenesis of TEN. Thalidomide is a potent inhibitor of TNF-a action. We did a double-blind, randomised, placebo-controlled study of thalidomide in TEN. Methods The patients received a 5-day course of thalidomide 400 mg daily or placebo. The main endpoint was the progression of skin detachment after day 7. Secondary endpoints were the severity of the disease, evaluated with the simplified acute physiology score (SAPS), and the mortality. TNF-alpha and interleukin 6 were measured. Findings The study was stopped because there was excess mortality in the thalidomide group-ten of 12 patients died compared with three of ten in the placebo group (Fisher's exact test with Katz's approximation, relative risk = 2.78, p = 0.03). After adjustment for SAPS, mortality remained significantly higher in the thalidomide group than in the placebo group (exact logistic regression mid-p = 0.007; 95% CI for odds ratio 2.7 to infinity). Plasma TNF-alpha concentration was higher in the thalidomide group than the placebo group on day 2, though the difference was not significant (Wilcoxon rank-sum test p = 0.07), Interpretation Even though few patients were included, our data suggest that thalidomide is detrimental in TEN, possibly because of a paradoxical enhancement of TNF-a production.	Univ Paris 12, Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France; Univ Paris 12, Hop Henri Mondor, Dept Intens Care, F-94010 Creteil, France; Hop St Luc, Burn Unit, Lyon, France; Labs Laphal, Dept Clin Res, Paris, France; Hop Trousseau, Dept Dermatol, Tours, France; Hop Brabois, Dept Infect Dis, Vandoeuvre Nancy, France; Hotel Dieu, Dept Dermatol, Nantes, France; Hotel Dieu, Burn Unit, Nantes, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Tours; CHU de Nancy; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Revuz, J (corresponding author), Univ Paris 12, Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France.	jean.revuz@hmn.ap-hop-paris.fr						BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Chao N J, 1996, Biol Blood Marrow Transplant, V2, P86; CORREIA O, 1993, DERMATOLOGY, V186, P32, DOI 10.1159/000247299; FISHER CJ, 1996, NEW ENGL J MED, V334, P1698; GUNSLER V, 1992, DRUG SAFETY, V7, P116; HALEBIAN PH, 1986, ANN SURG, V204, P503, DOI 10.1097/00000658-198611000-00001; HENG MCY, 1991, J AM ACAD DERMATOL, V25, P778, DOI 10.1016/S0190-9622(08)80969-3; HEWITT J, 1992, CLIN EXP DERMATOL, V17, P264, DOI 10.1111/j.1365-2230.1992.tb02163.x; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; KAMANABROO D, 1985, ARCH DERMATOL, V121, P1548, DOI 10.1001/archderm.121.12.1548; KELEMEN JJ, 1995, J AM COLL SURGEONS, V180, P273; Kim PS, 1983, J BURN CARE REHABIL, V4, P91; Klausner JD, 1996, CLIN IMMUNOL IMMUNOP, V81, P219, DOI 10.1006/clin.1996.0181; Klausner JD, 1996, J ACQ IMMUN DEF SYND, V11, P247, DOI 10.1097/00042560-199603010-00005; LEGALL JR, 1984, CRIT CARE MED, V12, P975; Lund CC., SURG GYNECOL OBSTET, V79, P352; MEHTA CR, 1995, STAT MED, V14, P2143, DOI 10.1002/sim.4780141908; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; NISHIMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P455, DOI 10.1006/bbrc.1994.1250; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Redondo P, 1997, BRIT J DERMATOL, V136, P645, DOI 10.1111/j.1365-2133.1997.tb02175.x; REVUZ J, 1987, ARCH DERMATOL, V123, P1160, DOI 10.1001/archderm.123.9.1160; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Shannon EJ, 1996, IMMUNOPHARM IMMUNOT, V18, P59, DOI 10.3109/08923979609007110; SHERERTZ EF, 1985, J AM ACAD DERMATOL, V12, P178, DOI 10.1016/S0190-9622(85)80012-8; VOGELSANG GB, 1992, NEW ENGL J MED, V326, P1055, DOI 10.1056/NEJM199204163261604; Zwingenberger K, 1996, J INFLAMM, V46, P177	28	283	301	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1586	1589		10.1016/S0140-6736(98)02197-7	http://dx.doi.org/10.1016/S0140-6736(98)02197-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843104				2022-12-28	WOS:000076998900011
J	Chinitz, D; Shalev, C; Galai, N; Israeli, A				Chinitz, D; Shalev, C; Galai, N; Israeli, A			Israel's basic basket of health services: the importance of being explicitly implicit	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd International Conference on Priorities in Health Care	OCT 08-10, 1998	LONDON, ENGLAND				REFORM		Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth, IL-91120 Jerusalem, Israel; Hadassah Med Org, IL-91120 Jerusalem, Israel; Gertner Hlth Policy Inst, Unit Hlth Rights & Eth, IL-52621 Tel Hashomer, Israel; Ben Gurion Univ Negev, Dept Epidemiol, IL-84105 Beer Sheva, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Ben Gurion University	Chinitz, D (corresponding author), Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth, IL-91120 Jerusalem, Israel.		Galai, Noya/HII-8086-2022					BINNUN G, 1997, TRENDS NATL EXPENDIT; Chinitz D, 1995, J HEALTH POLIT POLIC, V20, P909, DOI 10.1215/03616878-20-4-909; Chinitz D, 1997, HEALTH AFFAIR, V16, P205, DOI 10.1377/hlthaff.16.5.205; COHEN A, 1997, MAARIV          1210; HUNTER DJ, 1995, BRIT MED J, V311, P811, DOI 10.1136/bmj.311.7008.811; Mechanic D, 1997, HEALTH AFFAIR, V16, P83, DOI 10.1377/hlthaff.16.5.83; PELED A, 1997, MAARIV          1210, P9; SHALEV C, 1997, LESSONS LEARNED 3 YE; Shalev C, 1997, DALHOUSIE LAW J, V20, P553	9	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					1005	1007						3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129EA	9841023				2022-12-28	WOS:000076449300034
J	Calman, K				Calman, K			Lessons from Whitehall	BRITISH MEDICAL JOURNAL			English	Article									Univ Durham, Durham DH1 3HP, England	Durham University	Calman, K (corresponding author), Univ Durham, Durham DH1 3HP, England.		Calman, Kenneth C/C-9855-2010						0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1718	1720		10.1136/bmj.317.7174.1718	http://dx.doi.org/10.1136/bmj.317.7174.1718			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857142	Green Published			2022-12-28	WOS:000077742300032
J	Orchard, D				Orchard, D			Doctors' autonomy	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1730	1731		10.1136/bmj.317.7174.1730	http://dx.doi.org/10.1136/bmj.317.7174.1730			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857152	Green Published			2022-12-28	WOS:000077742300043
J	Tanaka, S; Kunath, T; Hadjantonakis, AK; Nagy, A; Rossant, J				Tanaka, S; Kunath, T; Hadjantonakis, AK; Nagy, A; Rossant, J			Promotion of trophoblast stem cell proliferation by FGF4	SCIENCE			English	Article							PLACENTAL LACTOGEN-I; TRANSCRIPTION FACTOR; MOUSE EMBRYOS; EXPRESSION; BLASTOCYST; LOCALIZATION; GENE	The trophoblast cell Lineage is essential for the survival of the mammalian embryo in utero. This lineage is specified before implantation into the uterus and is restricted to form the fetal portion of the placenta. A culture of mouse blastocysts or early postimplantation trophoblasts in the presence of fibroblast growth factor 4 (FGF4) permitted the isolation of permanent trophoblast stem cell Lines. These cell Lines differentiated to other trophoblast subtypes in vitro in the absence of FGF4 and exclusively contributed to the trophoblast Lineage in vivo in chimeras.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Rossant, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	rossant@mshri.on.ca	Nagy, Andras/G-6465-2013	Nagy, Andras/0000-0003-4311-0413; Hadjantonakis, Anna-Katerina/0000-0002-7580-5124; Tanaka, Satoshi/0000-0002-4745-550X				Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Chai N, 1998, DEV BIOL, V198, P105, DOI 10.1016/S0012-1606(98)80031-6; CIRUNA B, UNPUB; COLOSI P, 1987, MOL ENDOCRINOL, V1, P767, DOI 10.1210/mend-1-11-767; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DARZYNKIEWICZ Z, 1997, CURRENT PROTOCOLS CY; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FLECHON JE, 1995, PLACENTA, V16, P643, DOI 10.1016/0143-4004(95)90033-0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARDNER RL, 1972, J EMBRYOL EXP MORPH, V28, P279; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HOGAN B, 1994, MANIPULATING MOUSE E, P265; IOANNIS D, 1998, DEVELOPMENT, V125, P1529; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; MacAuley A, 1998, MOL BIOL CELL, V9, P795, DOI 10.1091/mbc.9.4.795; NGY A, 1993, GENE TARGETING, P147; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PARTANEN J, UNPUB; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Pownall ME, 1998, CURR BIOL, V8, P673, DOI 10.1016/S0960-9822(98)70257-X; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSSANT J, 1978, J EMBRYOL EXP MORPH, V48, P239; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Rossant J., 1986, EXPT APPROACHES MAMM, P97; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	40	1008	1034	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2072	2075		10.1126/science.282.5396.2072	http://dx.doi.org/10.1126/science.282.5396.2072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851926				2022-12-28	WOS:000077467100044
J	Tong, S; Baghurst, PA; Sawyer, MG; Burns, J; McMichael, AJ				Tong, S; Baghurst, PA; Sawyer, MG; Burns, J; McMichael, AJ			Declining blood lead levels and changes in cognitive function during childhood - The Port Pirie Cohort Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AGE 2 YEARS; ENVIRONMENTAL EXPOSURE; CHILDRENS INTELLIGENCE; PRESCHOOL-CHILDREN; IRON-DEFICIENCY; ADULT MONKEYS; PERFORMANCE; ATTAINMENT; BEHAVIOR	Context.-Many studies have found a significant inverse association between early exposure to environmental lead and cognitive function in childhood. Whether these effects are reversible when exposure is reduced is not clear. Objective.-To assess the reversibility of the apparent effects of lead on cognitive abilities in early childhood by testing whether declines in blood lead concentrations beyond the age of 2 years are associated with improvements in cognition. Setting.-Urban and rural communities surrounding a large lead smelter in Port Pirie, South Australia. Participants.-A total of 375 children followed up from birth to the age of 11 to 13 years. Design.-Long-term prospective cohort study. Main Outcome Measures.-The Bayley Mental Development Index at age 2 years, the McCarthy General Cognitive Index at age 4 years, and IQs from the Wechsler Intelligence Scale (revised version) at ages 7 and 11 to 13 years. Results.-Mean blood lead concentrations in the children decreased from 1.02 mu mol/L (21.2 mu g/dL) at age 2 years to 0.38 mu mol/L (7.9 mu g/dl) at age 11 to 13 years, but cognitive scores in children whose blood lead concentration declined most were generally not improved relative to the scores of children whose blood lead levels declined least. Changes in IQ and declines in blood lead levels that occurred between the ages of 7 and 11 to 13 years (r = 0.12, P = .09) suggested slightly better cognition among children whose blood lead levels declined most. Conclusion.-The cognitive deficits associated with exposure to environmental lead in early childhood appear to be only partially reversed by a subsequent decline in blood lead level.	Queensland Univ Technol, Ctr Publ Hlth Res, Brisbane, Qld 4059, Australia; Adelaide Womens & Childrens Hosp, Adelaide, SA, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; London Sch Hyg & Trop Med, London WC1, England	Queensland University of Technology (QUT); Womens & Childrens Hospital Australia; Royal Children's Hospital Melbourne; University of London; London School of Hygiene & Tropical Medicine	Tong, S (corresponding author), Queensland Univ Technol, Ctr Publ Hlth Res, Brisbane, Qld 4059, Australia.	s.tong@qut.edu.au						BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BINDER S, 1993, JAMA-J AM MED ASSOC, V269, P1679, DOI 10.1001/jama.269.13.1679; Caldwell BM, 1985, HOME OBSERVATION MEA; COONEY GH, 1989, DEV MED CHILD NEUROL, V31, P640; CUNNINGHAM RD, 1993, JAMA-J AM MED ASSOC, V270, P828, DOI 10.1001/jama.1993.03510070049021; DANIEL A, 1984, COMMUNITY HEALTH ST, V8, P218; DIETRICH KN, 1991, NEUROTOXICOL TERATOL, V13, P203, DOI 10.1016/0892-0362(91)90012-L; ERNHART CB, 1993, JAMA-J AM MED ASSOC, V270, P827, DOI 10.1001/jama.1993.03510070049019; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FERGUSSON DM, 1993, INT J EPIDEMIOL, V22, P891, DOI 10.1093/ije/22.5.891; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; HARVEY PG, 1984, SCI TOTAL ENVIRON, V40, P45, DOI 10.1016/0048-9697(84)90341-3; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; McCarthy D., 1972, MANUAL MCCARTHY SCAL; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; RICE DC, 1993, NEUROTOXICOLOGY, V14, P167; RICE DC, 1988, NEUROTOXICOL TERATOL, V10, P207, DOI 10.1016/0892-0362(88)90019-0; RUFF HA, 1993, JAMA-J AM MED ASSOC, V269, P1641, DOI 10.1001/jama.269.13.1641; Ruff HA, 1996, ENVIRON HEALTH PERSP, V104, P180, DOI 10.2307/3432787; SCHINDLER AM, 1993, JAMA-J AM MED ASSOC, V270, P828, DOI 10.1001/jama.1993.03510070049020; SCHROEDER SR, 1985, ENVIRON RES, V38, P144, DOI 10.1016/0013-9351(85)90080-5; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; *STAND ASS AUSTR, 1985, 2787 STAND ASS AUSTR; Tong SL, 1996, BRIT MED J, V312, P1569, DOI 10.1136/bmj.312.7046.1569; U.S. Agency for Toxic Substances and Disease Registry, 1988, NAT EXT LEAD POIS CH; *US EPA, 1990, 600889049F EPA; *US EPA, AIR QUAL CRIT LEAD S; WASSERMAN G, 1992, J PEDIATR-US, V121, P695, DOI 10.1016/S0022-3476(05)81895-5; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755	39	101	111	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1998	280	22					1915	1919		10.1001/jama.280.22.1915	http://dx.doi.org/10.1001/jama.280.22.1915			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	145HF	9851476	Bronze			2022-12-28	WOS:000077364500035
J	Bhushan, M; McElhone, K; Griffiths, CEM				Bhushan, M; McElhone, K; Griffiths, CEM			GMDP and psoriasis	LANCET			English	Letter									Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England	University of Manchester	Griffiths, CEM (corresponding author), Univ Manchester, Hope Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England.		Griffiths, Christopher E.M./P-5448-2014	Griffiths, Christopher E.M./0000-0001-5371-4427				Andronova TM, 1991, SOV MED REV D, V4, P1; KOGA T, 1986, MICROBIOL IMMUNOL, V30, P717, DOI 10.1111/j.1348-0421.1986.tb02997.x; Marks R, 1996, J DERMATOL TREAT, V7, pS7, DOI 10.3109/09546639609080596; vandeKerkhof PCM, 1997, BRIT J DERMATOL, V137, P661; WILLIAMSOND, 1998, LANCET, V352, P545	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1857	1857		10.1016/S0140-6736(05)79923-2	http://dx.doi.org/10.1016/S0140-6736(05)79923-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851410				2022-12-28	WOS:000077337900056
J	Levinsky, NG				Levinsky, NG			Can we afford medical care for Alice C?	LANCET			English	Editorial Material									Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University	Levinsky, NG (corresponding author), Boston Univ, Sch Med, 715 Albany St,Room 102, Boston, MA 02118 USA.							Callahan D., 1987, MED GOALS AGEING SOC; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; Daniels N, 1988, AM I MY PARENTS KEEP; EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; LAMM RD, 1984, COMMUNICATION   0327; LEVINSKY NG, IN PRESS J AM GERIAT; LOVE AA, 1998, BOSTON GLOBE    0421, pC1; PETTERSON PG, 1997, POLICY OPTIONS REFOR; SANDERS D, 1968, UCLA LAW REV, V15, P357; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; VEATCH RM, 1988, HASTINGS CENT REP, V18, P34, DOI 10.2307/3563234	13	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1849	1851		10.1016/S0140-6736(98)07555-2	http://dx.doi.org/10.1016/S0140-6736(98)07555-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144WE	9851402				2022-12-28	WOS:000077337900048
J	Morris, K				Morris, K			Treating HIV/AIDS information overload	LANCET			English	Editorial Material									Lancet, London, England		Morris, K (corresponding author), Lancet, London, England.								0	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 5	1998	352	9143					1866	1866		10.1016/S0140-6736(05)79940-2	http://dx.doi.org/10.1016/S0140-6736(05)79940-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851425				2022-12-28	WOS:000077337900074
J	Lu, HP; Xun, LY; Xie, XS				Lu, HP; Xun, LY; Xie, XS			Single-molecule enzymatic dynamics	SCIENCE			English	Article							BREVIBACTERIUM-STEROLICUM; CHOLESTEROL OXIDASE; ELECTRON-TRANSFER; KINETICS; FLUCTUATIONS; SPECTROSCOPY; BEHAVIOR; ENERGY; TRANSITIONS; DIFFUSION	Enzymatic turnovers of single cholesterol oxidase molecules were observed in real time by monitoring the emission from the enzyme's fluorescent active site, flavin adenine dinucleotide (FAD), Statistical analyses of single-molecule trajectories revealed a significant and slow fluctuation in the rate of cholesterol oxidation by FAD. The static disorder and dynamic disorder of reaction rates, which are essentially indistinguishable in ensemble-averaged experiments, were determined separately by the real-time single-molecule approach. A molecular memory phenomenon, in which an enzymatic turnover was not independent of its previous turnovers because of a slow fluctuation of protein conformation, was evidenced by spontaneous spectral fluctuation of FAD.	Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; Washington State Univ, Dept Microbiol, Pullman, WA 99164 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Washington State University	Xie, XS (corresponding author), Pacific NW Natl Lab, William R Wiley Environm Mol Sci Lab, Richland, WA 99352 USA.	xsxie@pnl.gov						AGMON N, 1983, J CHEM PHYS, V78, P6947, DOI 10.1063/1.444643; CHANDLER D, 1987, INTRO MODERN STAT ME, pCH8; Colquhoun David, 1995, P397; Craig DB, 1996, J AM CHEM SOC, V118, P5245, DOI 10.1021/ja9540839; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Edman L, 1996, P NATL ACAD SCI USA, V93, P6710, DOI 10.1073/pnas.93.13.6710; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEHLEN JN, 1994, SCIENCE, V263, P499, DOI 10.1126/science.263.5146.499; Geva E, 1998, CHEM PHYS LETT, V288, P225, DOI 10.1016/S0009-2614(98)00322-4; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Ha T, 1998, PHYS REV LETT, V80, P2093, DOI 10.1103/PhysRevLett.80.2093; Ha T, 1996, PHYS REV LETT, V77, P3979, DOI 10.1103/PhysRevLett.77.3979; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; Jia YW, 1997, P NATL ACAD SCI USA, V94, P7932, DOI 10.1073/pnas.94.15.7932; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; Lu HP, 1997, J PHYS CHEM B, V101, P2753, DOI 10.1021/jp9634518; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; MANSFIELD E, 1986, BASIC STAT APPL, pCH11; MULLER F, 1992, CHEM BIOCH FLAVOENZY, V1; Neet K E, 1980, Methods Enzymol, V64, P192; Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PALMER T, 1991, UNDERSTANDING ENZYME, pCH9; RICARD J, 1974, EUR J BIOCHEM, V49, P195, DOI 10.1111/j.1432-1033.1974.tb03825.x; SCHENTER G, UNPUB; SCHMIDT T, 1995, J PHYS CHEM-US, V99, P17662, DOI 10.1021/j100049a030; UWAJIMA T, 1974, AGR BIOL CHEM TOKYO, V38, P1149, DOI 10.1080/00021369.1974.10861299; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Van Kampen NG, 1992, STOCHASTIC PROCESSES; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; Vasudevan PT, 1996, APPL BIOCHEM BIOTECH, V60, P63, DOI 10.1007/BF02788060; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; WANG J, 1995, PHYS REV LETT, V74, P4317, DOI 10.1103/PhysRevLett.74.4317; Wennmalm S, 1997, P NATL ACAD SCI USA, V94, P10641, DOI 10.1073/pnas.94.20.10641; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; ZWANZIG R, 1990, ACCOUNTS CHEM RES, V23, P148, DOI 10.1021/ar00173a005	44	1247	1292	9	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1877	1882		10.1126/science.282.5395.1877	http://dx.doi.org/10.1126/science.282.5395.1877			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836635				2022-12-28	WOS:000077338100045
J	Matsuoka, S; Huang, MX; Elledge, SJ				Matsuoka, S; Huang, MX; Elledge, SJ			Linkage of ATM to cell cycle regulation by the Chk2 protein kinase	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; S-PHASE; YEAST; SERINE-216; PATHWAY; MITOSIS; CDC25C	In response to DNA damage and replication blocks, coils prevent cell cycle progression through the control of critical cell cycle regulators, We identified Chk2, the mammalian homolog of the Saccharomyces cerevisiae Rad53 and Schizosaccharomyces pombe Cds1 protein kinases required for the DNA damage and replication checkpoints. Chk2 was rapidly phosphorylated and activated in response to replication blocks and DNA damage; the response to DNA damage occurred in an ataxia telangiectasia mutated (ATM)-dependent manner. In vitro, Chk2 phosphorylated Cdc25C on serine-216, a site known to be involved in negative regulation of Cdc25C. This is the same site phosphorylated by the protein kinase Chk1, which suggests that, in response to DNA damage and DNA replicational stress, Chk1 and Chk2 may phosphorylate Cdc25C to prevent entry into mitosis.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.				NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JB, 1994, GENE DEV, V8, P2416; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Goggins M, 1996, CANCER RES, V56, P5360; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; OGG S, 1994, J BIOL CHEM, V269, P30461; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Tomlinson GE, 1998, CANCER RES, V58, P3237; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	21	1072	1117	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 4	1998	282	5395					1893	1897		10.1126/science.282.5395.1893	http://dx.doi.org/10.1126/science.282.5395.1893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	144WG	9836640				2022-12-28	WOS:000077338100050
J	Cassels, A; Janovsky, K				Cassels, A; Janovsky, K			Better health in developing countries: are sector-wide approaches the way of the future?	LANCET			English	Editorial Material									WHO, Div Anal Res & Assessment, CH-1211 Geneva 27, Switzerland; Hatfield Lodge, Canterbury, Kent, England	World Health Organization	Janovsky, K (corresponding author), WHO, Div Anal Res & Assessment, CH-1211 Geneva 27, Switzerland.							Cassels A, 1997, SOC SCI MED, V44, P1073, DOI 10.1016/S0277-9536(96)00363-2; Cassels A, 1996, HEALTH POLICY PLANN, V11, P354, DOI 10.1093/heapol/11.4.354; HARROLD P, 1995, AFRICA TECHNICAL DEP, V302; Janovsky Katja., 1996, HLTH POLICY SYSTEMS, P11; Peters D, 1998, INT J HEALTH PLAN M, V13, P177, DOI 10.1002/(SICI)1099-1751(199804/06)13:2<177::AID-HPM504>3.0.CO;2-T	5	64	65	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 28	1998	352	9142					1777	1779		10.1016/S0140-6736(98)05350-1	http://dx.doi.org/10.1016/S0140-6736(98)05350-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	143GH	9848371				2022-12-28	WOS:000077246500046
J	Sack, RB; Siddique, AK				Sack, RB; Siddique, AK			Corpses and the spread of cholera	LANCET			English	Editorial Material							EPIDEMIC		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	Johns Hopkins University; International Centre for Diarrhoeal Disease Research (ICDDR)	Sack, RB (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.							Glass Roger I., 1992, P129; Gunnlaugsson G, 1998, EPIDEMIOL INFECT, V120, P7, DOI 10.1017/S0950268897008170; Rodrigues A, 1997, AM J TROP MED HYG, V57, P601, DOI 10.4269/ajtmh.1997.57.601; Swerdlow David L., 1994, P297; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418	5	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	NOV 14	1998	352	9140					1570	1570		10.1016/S0140-6736(05)61040-9	http://dx.doi.org/10.1016/S0140-6736(05)61040-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138XT	9843100	hybrid			2022-12-28	WOS:000076998900006
J	Roddie, I				Roddie, I			Coming to terms with death	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1737	1737		10.1136/bmj.317.7174.1737	http://dx.doi.org/10.1136/bmj.317.7174.1737			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857160	Green Published			2022-12-28	WOS:000077742300055
J	Bacon, A				Bacon, A			A memorable mistake - Please come back - the patient won't take her cotton wool	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1646	1646		10.1136/bmj.317.7173.1646	http://dx.doi.org/10.1136/bmj.317.7173.1646			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848910	Green Published			2022-12-28	WOS:000077602100033
J	Schultz, PH; Zarate, M; Hames, W; Camilion, C; King, J				Schultz, PH; Zarate, M; Hames, W; Camilion, C; King, J			A 3.3-Ma impact in Argentina and possible consequences	SCIENCE			English	Article							BUENOS-AIRES PROVINCE; POLARITY TIME SCALE; CRATER FIELD; RIO-CUARTO; PLIOCENE; INTERCALIBRATION; METAMORPHISM; DELTA-O-18; BOUNDARY; ATLANTIC	Enigmatic glassy materials (escorias) and red bricklike materials (tierras cocidas) occur at a restricted stratigraphic Level (the top of the Chapadmalal Formation). Materials from one Locality near Mar del Plata are attributed to a mid-Pliocene impact event with a radiometric and magnetostratigraphic age of 3.3 million years ago (Ma), An extinction of endemic fauna (including the glyptodonts and flightless cariamid birds) correlates with the unit containing the impact glasses, Moreover, the age of the glasses is coincident within dating uncertainties with a pulselike change in the oxygen isotope marine record in the Atlantic and Pacific Oceans just before the tate Pliocene deterioration of the climate.	Brown Univ, Providence, RI 02912 USA; Consejo Nacl Invest Cient & Tecn, Inst Argentino Nivol & Glaciol, Ctr Reg Invest Cientif & Tecn, RA-5500 Mendoza, Argentina; Auburn Univ, Dept Geol, Auburn, AL 36849 USA; Natl Univ La Plata, Ctr Nacl Invest Cientif & Tecn, RA-1900 La Plata, Argentina; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	Brown University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Auburn University System; Auburn University; National University of La Plata; University of Rhode Island	Schultz, PH (corresponding author), Brown Univ, Providence, RI 02912 USA.							AMEGHINO F, 1910, ANALES MUSEO NACL BU, V13, P39; Baksi AK, 1996, CHEM GEOL, V129, P307, DOI 10.1016/0009-2541(95)00154-9; BLOOM A, 1992, GEOL SOC AM ABSTR, V24, pA136; BOUSKA V, 1981, METEORITICS, V16, P171, DOI 10.1111/j.1945-5100.1981.tb00541.x; Cione AL, 1996, J S AM EARTH SCI, V9, P221, DOI 10.1016/0895-9811(96)00008-9; CORTELEZZI CR, 1971, REV MUSEO PLATA G, V7, P233; ELGORESY A, 1965, J GEOPHYS RES, V70, P3453, DOI 10.1029/JZ070i014p03453; FELDMAN VI, 1980, IMPACTITES, P70; Flynn J.J., 1995, SEPM SPECIAL PUBLICA, P317, DOI DOI 10.2110/PEC.95.04.0317; HEUSSER JC, 1865, NEUE DENK ALLGEMEINE, V21; HILGEN FJ, 1991, EARTH PLANET SC LETT, V104, P226, DOI 10.1016/0012-821X(91)90206-W; HILGEN FJ, 1991, EARTH PLANET SC LETT, V107, P349, DOI 10.1016/0012-821X(91)90082-S; HODELL DA, 1985, GEOL SOC AM BULL, V96, P495, DOI 10.1130/0016-7606(1985)96<495:LPRODV>2.0.CO;2; Hodell DA, 1986, PALEOCEANOGRAPHY, V1, P285, DOI 10.1029/PA001i003p00285; HODGES KV, 1994, CONTRIB MINERAL PETR, V117, P151, DOI 10.1007/BF00286839; KIEFFER SW, 1971, J GEOPHYS RES, V76, P5449, DOI 10.1029/JB076i023p05449; Kraglievich J.L., 1952, REV MUSEO MUNICIPAL, V1, P8; ORGEIRA MJ, 1990, PHYS EARTH PLANET IN, V64, P121, DOI 10.1016/0031-9201(90)90032-S; OUTES F, 1908, REV MUSEO PLATA, V15, P138; Pohl J., 1977, IMPACT EXPLOSION CRA, P343; PRELL WL, 1984, SCIENCE, V226, P692, DOI 10.1126/science.226.4675.692; RENNE PR, 1994, GEOLOGY, V22, P783, DOI 10.1130/0091-7613(1994)022<0783:IOAART>2.3.CO;2; SCHULTZ PH, 1994, GEOLOGY, V22, P889, DOI 10.1130/0091-7613(1994)022<0889:GTFOIP>2.3.CO;2; SCHULTZ PH, 1992, NATURE, V355, P234, DOI 10.1038/355234a0; Stu┬ffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; Teruggi M.E., 1957, J SEDIMENT RES, V27, P322; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; TONNI EP, 1992, PALAEOGEOGR PALAEOCL, V95, P179, DOI 10.1016/0031-0182(92)90140-Z; YORK D, 1969, EARTH PLANET SC LETT, V5, P320; YRIGOYEN M, 1975, RELATORIO GEOLOGIA P, P139; ZARATE MA, 1989, PALAEOGEOGR PALAEOCL, V72, P27, DOI 10.1016/0031-0182(89)90130-2; ZARATE MA, 1993, QUAT INT, V17, P115; ZARATE MA, 1989, THESIS MUSEO PLATA	33	64	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1998	282	5396					2061	2063		10.1126/science.282.5396.2061	http://dx.doi.org/10.1126/science.282.5396.2061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851923				2022-12-28	WOS:000077467100041
J	Shintani, D; DellaPenna, D				Shintani, D; DellaPenna, D			Elevating the vitamin E content of plants through metabolic engineering	SCIENCE			English	Article							PROTEIN LOCALIZATION SITES; TOCOPHEROLS; GENES; BIOSYNTHESIS; PURIFICATION; TOCOTRIENOLS; CELLS; FATS; OILS; CDNA	alpha-Tocopherol (vitamin E) is a Lipid-soluble antioxidant synthesized only by photosynthetic organisms. alpha-Tocopherol is an essential component of mammalian diets, and intakes in excess of the U.S. recommended daily allowance are correlated with decreased incidence of a number of degenerative human diseases. Plant oils, the main dietary source of tocopherols, typically contain alpha-tocopherol as a minor component and high Levels of its biosynthetic precursor, gamma-tocopherol, A genomics-based approach was used to clone the final enzyme in alpha-tocopherol synthesis, gamma-tocopherol methyltransferase. Overexpression of gamma-tocopherol methyltransferase in Arabidopsis seeds shifted oil compositions in favor of alpha-tocopherol. Similar increases in agricultural oil crops would increase vitamin E Levels in the average U.S. diet.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	DellaPenna, D (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 200, Reno, NV 89557 USA.	delta_d@med.unr.edu	Shintani, David/A-8790-2011	Shintani, David/0000-0001-9557-0476				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; BECHTOLD N, 1993, CR HEBD ACAD SCI, V1144, P204; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DHARLINGUE A, 1985, J BIOL CHEM, V260, P5200; Eitenmiller RR, 1997, FOOD TECHNOL-CHICAGO, V51, P78; ERIN AN, 1985, BIOCHIM BIOPHYS ACTA, V815, P209, DOI 10.1016/0005-2736(85)90291-3; FRYER MJ, 1992, PLANT CELL ENVIRON, V15, P381, DOI 10.1111/j.1365-3040.1992.tb00988.x; Garcia I, 1997, BIOCHEM J, V325, P761, DOI 10.1042/bj3250761; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; Kaneko T, 1996, DNA Res, V3, P109; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; *NAT RES COUNC FOO, 1989, NAS NRC REC DIET ALL; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Norris SR, 1995, PLANT CELL, V7, P2139, DOI 10.1105/tpc.7.12.2139; Norris SR, 1998, PLANT PHYSIOL, V117, P1317, DOI 10.1104/pp.117.4.1317; SEFFENS WS, 1990, DEV GENET, V11, P65, DOI 10.1002/dvg.1020110108; SOLL J, 1985, ARCH BIOCHEM BIOPHYS, V238, P290, DOI 10.1016/0003-9861(85)90167-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYVAOJA EL, 1986, J AM OIL CHEM SOC, V63, P328, DOI 10.1007/BF02546039; TAYLOR LA, 1988, NUCLEIC ACIDS RES, V16, P358, DOI 10.1093/nar/16.1.358; TAYLOR P, 1981, CHEM IND-LONDON, P722; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; TRELFALL DR, 1971, ASPECTS TERPENOID CH, P357; *VERIS INF SERV, 1994, VIT E FACT BOOK; WHISTANC.GR, 1970, BIOCHEM J, V117, P593, DOI 10.1042/bj1170593; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	30	394	482	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1998	282	5396					2098	2100		10.1126/science.282.5396.2098	http://dx.doi.org/10.1126/science.282.5396.2098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147BB	9851934				2022-12-28	WOS:000077467100052
J	Bolsin, SN				Bolsin, SN			The Wisheart affairs: responses to Dunn - The Bristol cardiac disaster	BRITISH MEDICAL JOURNAL			English	Article									Dept Perioperat Med, Geelong, Vic 3220, Australia		Bolsin, SN (corresponding author), Dept Perioperat Med, POB 281, Geelong, Vic 3220, Australia.							Dunn PM, 1998, BRIT MED J, V317, P1144; JOFFE HS, 1995, BRIT MED J, V310, P1195, DOI 10.1136/bmj.310.6988.1195b; TREASURE T, 1996, REPORT ADULT CARDIAC	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1579	1580		10.1136/bmj.317.7172.1579	http://dx.doi.org/10.1136/bmj.317.7172.1579			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836666	Green Published			2022-12-28	WOS:000077451700034
J	Krieger, DW				Krieger, DW			Evoked potentials not just to confirm hopelessness in anoxic brain injury	LANCET			English	Editorial Material							HOSPITAL CARDIAC-ARREST; COMA		Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Krieger, DW (corresponding author), Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA.							Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; DESMEDT JE, 1981, ELECTROEN CLIN NEURO, V52, P553, DOI 10.1016/0013-4694(81)91430-9; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; KARKELA J, 1992, CRIT CARE MED, V20, P378; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Marion DW, 1996, CRIT CARE MED, V24, pS81; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473	10	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	1998	352	9143					1796	1797		10.1016/S0140-6736(98)00081-6	http://dx.doi.org/10.1016/S0140-6736(98)00081-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	144WE	9851374				2022-12-28	WOS:000077337900002
J	Backonja, M; Beydoun, A; Edwards, KR; Schwartz, SL; Fonseca, V; Hes, M; LaMoreaux, L; Garofalo, E				Backonja, M; Beydoun, A; Edwards, KR; Schwartz, SL; Fonseca, V; Hes, M; LaMoreaux, L; Garofalo, E		Gabapentin Diabetic Neuropathy Study Grp	Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGED SEVERITY; TESTS; RAT; AMITRIPTYLINE; DESIPRAMINE; MANAGEMENT; MEXILETINE; DIAGNOSIS; CRITERIA; EFFICACY	Context.-Pain is the most disturbing symptom of diabetic peripheral neuropathy. As many as 45% of patients with diabetes mellitus develop peripheral neuropathies. Objective.-To evaluate the effect of gabapentin monotherapy on pain associated with diabetic peripheral neuropathy. Design.-Randomized, double-blind, placebo-controlled, 8-week trial conducted between July 1996 and March 1997, Setting.-Outpatient clinics at 20 sites. Patients.-The 165 patients enrolled had a 1- to 5-year history of pain attributed to diabetic neuropathy and a minimum 40-mm pain score on the Short-Form McGill Pain Questionnaire visual analogue scale. Intervention.-Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage) or placebo. Main Outcome Measures.-The primary efficacy measure was daily pain severity as measured on an 11-point Likert scale (0, no pain; 10, worst possible pain), Secondary measures included sleep interference scores, the Short-Form McGill Pain Questionnaire scores, Patient Global impression of Change and Clinical Global Impression of Change, the Short Form-36 Quality of Life Questionnaire scores, and the Profile of Mood States results. Results.-Eighty-four patients received gabapentin and 70 (83%) completed the study; 81 received placebo and 65 (80%) completed the study. By intent-to-treat analysis, gabapentin-treated patients' mean daily pain score at the study end point (baseline, 6.4; end point, 3.9; n = 82) was significantly lower (P<.001) compared with the placebo-treated patients' end-point score (baseline, 6.5; end point, 5.1; n = 80). All secondary outcome measures of pain were significantly better in the gabapentin group than in the placebo group. Additional statistically significant differences favoring gabapentin treatment were observed in measures of quality of life (Short Form-36 Quality of Life Questionnaire and Profile of Mood States). Adverse events experienced significantly more frequently in the gabapentin group were dizziness (20 [24%] in the gabapentin group vs 4 [4.9%] in the control group; P<.001) and somnolence (19 [23%] in the gabapentin group vs 5 [6%] in the control group; P = .003). Confusion was also more frequent in the gabapentin group (7 [8%] vs 1 [1.2%]; P = .06). Conclusion.-Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.	Univ Wisconsin, Dept Neurol, Madison, WI 53792 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI USA; Parke Davis Pharmaceut Res, Ann Arbor, MI USA; Neurol Consultants PC, Bennington, VT USA; Diabet & Glandular Dis Clin, San Antonio, TX USA; Univ Arkansas Med Sci, Diabet Program, Little Rock, AR 72205 USA	University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan; Pfizer; University of Arkansas System; University of Arkansas Medical Sciences	Backonja, M (corresponding author), 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	backonja@neurology.wisc.edu	Backonja, Miroslav/L-6268-2019; Beydoun, Ahmad/ABE-8111-2021	Backonja, Miroslav/0000-0001-5465-6935; Beydoun, Ahmad/0000-0002-9047-1185				Albers JW, 1995, ANN NEUROL, V38, P869, DOI 10.1002/ana.410380607; ALBERS JW, 1995, ANN NEUROL, V38, P478; Albers JW, 1996, NEUROLOGY, V46, P85, DOI 10.1212/WNL.46.1.85; [Anonymous], 1988, DIABETES, V37, P1000; [Anonymous], 1992, NEUROLOGY, V42, P1823; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; CALISSI PT, 1995, ANN PHARMACOTHER, V29, P769, DOI 10.1177/106002809502907-820; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dejgaard A, 1998, DIABETIC MED, V15, P97, DOI 10.1002/(SICI)1096-9136(199802)15:2<97::AID-DIA523>3.0.CO;2-5; DYCK PJ, 1992, NEUROLOGY, V42, P1164, DOI 10.1212/WNL.42.6.1164; DYCK PJ, 1991, NEUROLOGY, V41, P799, DOI 10.1212/WNL.41.6.799; DYCK PJ, 1995, NEUROLOGY, V45, P1115, DOI 10.1212/WNL.45.6.1115; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; Dyck PJ, 1997, DIABETES, V46, pS5, DOI 10.2337/diab.46.2.S5; Fedele D, 1997, DRUGS, V54, P414, DOI 10.2165/00003495-199754030-00004; FELDMAN EL, 1994, DIABETES CARE, V17, P1281, DOI 10.2337/diacare.17.11.1281; FELDMAN EL, 1994, ADV ENDOCRINOLOGY ME, P393; FIELDS HL, 1987, PAIN, P133; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; JOHNSON PC, 1986, ANN NEUROL, V19, P450, DOI 10.1002/ana.410190505; Kingery WS, 1997, PAIN, V73, P123, DOI 10.1016/S0304-3959(97)00049-3; Max MB, 1995, PAIN FORUM, V4, P248, DOI 10.1016/S1082-3174(11)80029-2; MAX MB, 1991, PAIN, V45, P3, DOI 10.1016/0304-3959(91)90157-S; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; McNair DM, 1981, PROFILE MOOD STATES; MCQUAY H, 1995, BRIT MED J, V311, P1047, DOI 10.1136/bmj.311.7012.1047; *MED EC CO INC, 1995, PHYS DESK REF, P1856; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; OJEMANN LM, 1988, EPILEPSIA, V29, P694; Oskarsson P, 1997, DIABETES CARE, V20, P1594, DOI 10.2337/diacare.20.10.1594; Pfeifer MA, 1997, DIABETES, V46, pS82, DOI 10.2337/diab.46.2.S82; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; Rosner H, 1996, CLIN J PAIN, V12, P56, DOI 10.1097/00002508-199603000-00010; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shimoyama N, 1997, NEUROSCI LETT, V222, P65, DOI 10.1016/S0304-3940(97)13331-6; STACEY BR, 1996, REGION ANESTH S, V2, P65; STRACKE H, 1992, DIABETES CARE, V15, P1550, DOI 10.2337/diacare.15.11.1550; Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; Ware J. E., 1993, SF36 HLTH SURVEY MAN; Xiao W.-H., 1995, Society for Neuroscience Abstracts, V21, P897	43	1054	1102	1	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1831	1836		10.1001/jama.280.21.1831	http://dx.doi.org/10.1001/jama.280.21.1831			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846777	Bronze			2022-12-28	WOS:000077176600028
J	Levinson, W; Altkorn, D				Levinson, W; Altkorn, D			Primary prevention of postmenopausal osteoporosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HORMONE REPLACEMENT THERAPY; BONE-MINERAL DENSITY; BREAST-CANCER; WOMEN; ESTROGEN; RISK; MORTALITY; DISEASE; OLDER		Univ Chicago, Gen Internal Med Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Levinson, W (corresponding author), Univ Chicago, Gen Internal Med Sect, Dept Med, 5841 S Maryland Ave,MC 6098, Chicago, IL 60637 USA.							Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; Schneider DL, 1997, JAMA-J AM MED ASSOC, V277, P543, DOI 10.1001/jama.277.7.543; Sellers TA, 1997, ANN INTERN MED, V127, P973, DOI 10.7326/0003-4819-127-11-199712010-00004; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P509; 1998, SCI AM MED, V15, pR11; 1998, OSTEOPOROSIS INT S4, V8, pS1	17	17	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1821	1822		10.1001/jama.280.21.1821	http://dx.doi.org/10.1001/jama.280.21.1821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846765				2022-12-28	WOS:000077176600010
J	Nightingale, SL				Nightingale, SL			New alcohol warning required for OTC analgesic/antipyretic products	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1998	280	21					1817	1817		10.1001/jama.280.21.1817	http://dx.doi.org/10.1001/jama.280.21.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	141ZZ	9846762				2022-12-28	WOS:000077176600004
J	McCally, M; Haines, A; Fein, O; Addington, W; Lawrence, RS; Cassel, CK				McCally, M; Haines, A; Fein, O; Addington, W; Lawrence, RS; Cassel, CK			Poverty and ill health: Physicians can, and should, make a difference	ANNALS OF INTERNAL MEDICINE			English	Article							FACTOR INTERVENTION TRIAL; SOCIOECONOMIC DIFFERENTIALS; MORTALITY RISK; UNITED-STATES; INEQUALITIES; INCOME; PERSPECTIVE; CHILDREN; PATTERN; IMPACT	A growing body of research confirms the existence of a powerful connection between socioeconomic status and health. This research has implications for both clinical practice and public policy and deserves to be more widely understood by physicians. Absolute poverty, which implies a lack of resources deemed necessary for survival, is self-evidently associated with poor health, particularly in less developed countries. Over the past two decades, economic decline or stagnation has reduced the incomes of 1.6 billion people. Strong evidence now indicates that relative poverty, which is defined in relation to the average resources available in a society, is also a major determinant of health in industrialized countries. For example, persons in U.S. states with income distributions that are more equitable have longer life expectancies than persons in less egalitarian states. There are numerous possible approaches to improving the health of poor populations. The most essential task is to ensure the satisfaction of basic human needs: shelter, clean air, safe drinking water, and adequate nutrition. Other approaches include reducing barriers to the adoption of healthier modes of living and improving access to appropriate and effective health and social services. Physicians as clinicians, educators, research scientists, and advocates for policy change can contribute to all of these approaches. Physicians and other health professionals should understand poverty and its effects on health and should endeavor to influence policymakers nationally and internationally to reduce the burden of ill health that is a consequence of poverty.	Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA; Cornell Univ, Coll Med, New York, NY USA; Royal Free Sch Med, London, England; UCL, Sch Med, London W1N 8AA, England; Rush Sch Med, Chicago, IL USA; Johns Hopkins Sch Publ Hlth, Baltimore, MD USA	Icahn School of Medicine at Mount Sinai; Cornell University; University of London; University College London; University of London; University College London; UCL Medical School; Rush University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	McCally, M (corresponding author), Mt Sinai Sch Med, Dept Community & Prevent Med, Box 1043, New York, NY 10029 USA.	mm6@doc.mssm.edu		Haines, Andy/0000-0002-8053-4605				AguirreMolina M, 1996, ANNU REV PUBL HEALTH, V17, P337, DOI 10.1146/annurev.pu.17.050196.002005; *AM COLL PHYS UN C, 1996, UN COV REN CALL ACT; AMUNDSEN DW, 1995, ENCY BIOETHICS, P1522; [Anonymous], [No title captured]; Arblaster L, 1996, J Health Serv Res Policy, V1, P93; Benzeval M, 1995, TACKLING INEQUALITIE; BLACK D, 1982, INEQUALITIES HLTH CA; BROWN LR, 1996, DIVIDING WATERS STAT; BRUNDTLAND GH, 1998, BMJ-BRIT MED J, V316, P13; Creese A, 1997, BRIT MED J, V315, P202, DOI 10.1136/bmj.315.7102.202; Evans R. G., 1994, WHY ARE SOME PEOPLE; Ewert A, 1996, ECOSYST HEALTH, V2, P271; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; FRANK JW, 1994, DAEDALUS, V123, P1; Gepkens A., 1996, European Journal of Public Health, V6, P218, DOI 10.1093/eurpub/6.3.218; GRAUBARD SR, 1994, DAEDALUS, V123, pR5; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; Jamison D.T., 1993, DIS CONTROL PRIORITI; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JONSEN AR, 1977, J MED PHILOS, V2, P376, DOI 10.1093/jmp/2.4.376; JUDGE K, 1993, BRIT MED J, V306, P677, DOI 10.1136/bmj.306.6879.677; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; KEHRER BH, 1979, J HUM RESOUR, V14, P434, DOI 10.2307/145316; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kitagawa EM, 1973, DIFFERENTIAL MORTALI; Logie DE, 1997, BRIT MED J, V315, P1444, DOI 10.1136/bmj.315.7120.1444; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1994, DAEDALUS-US, V123, P197; MARMOT MG, 1984, LANCET, V1, P1003; MCCALLY M, 1995, CRITICAL CONDITION H; MCKEE M, 1993, BRIT MED J, V307, P1575, DOI 10.1136/bmj.307.6919.1575; RAIK B, 1995, ACAD MED, V70, P1047, DOI 10.1097/00001888-199511000-00027; Rainwater L., 1974, WHAT MONEY BUYS INEQ; Ringen S, 1987, POSSIBILITY POLITICS; Rosen G., 1974, MED POLICE SOCIAL ME; RUSH D, 1988, AM J CLIN NUTR, V48, P389; SCHORR EB, 1988, OUR REACH BREAKING C; SHAHI GS, 1997, INT PERSPECTIVES ENV; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P497, DOI 10.2105/AJPH.86.4.497; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; SMITH T, 1994, SCOT MED J, V39, P144, DOI 10.1177/003693309403900507; Townsend P., 1993, INT ANAL POVERTY; Townsend PP., 1988, HLTH DEPRIVATION INE; United Nations Development Program, 1996, HUM DEV REP 1996; United Nations Development Programme, 1994, HUM DEV REP 1994; *US BUR CENS, 1993, INC POV; VONSCHIRNDING Y, 1997, INTERSECTORAL ACTION; Watt GCM, 1996, BRIT MED J, V312, P1026; Whitehead M., 1992, INEQUALITIES HLTH; *WHO, 1978, PRIM HLTH CAR; WILKINSON RG, 1992, AM J PUBLIC HEALTH, V82, P1082, DOI 10.2105/AJPH.82.8.1082; WILKINSON RG, 1994, BRIT MED J, V308, P1113, DOI 10.1136/bmj.308.6937.1113; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Commission on Environment and Development (WCED), 1987, A42427 UN; World Health Organization, 1995, WORLD HLTH REP 1995	57	55	55	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					726	733		10.7326/0003-4819-129-9-199811010-00009	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	135DH	9841606				2022-12-28	WOS:000076785200008
J	Heath, I				Heath, I			A seamless service	BRITISH MEDICAL JOURNAL			English	Article									Caversham Grp Practice, London NW5 2UP, England		Heath, I (corresponding author), Caversham Grp Practice, London NW5 2UP, England.							*CTR ADV INT ED, 1996, PRINC INT ED; NEAL MM, 1992, NEEDLEWORK SCH	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1723	1724		10.1136/bmj.317.7174.1723	http://dx.doi.org/10.1136/bmj.317.7174.1723			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857147	Green Published			2022-12-28	WOS:000077742300037
J	Johnson, JC				Johnson, JC			Alastair MacIntosh MacLachlainn (1892-1959): an unusual career	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1998	317	7174					1714	1715		10.1136/bmj.317.7174.1714	http://dx.doi.org/10.1136/bmj.317.7174.1714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151VX	9857140	Green Published			2022-12-28	WOS:000077742300030
J	Kondru, RK; Wipf, P; Beratan, DN				Kondru, RK; Wipf, P; Beratan, DN			Atomic contributions to the optical rotation angle as a quantitative probe of molecular chirality	SCIENCE			English	Article								Chiral molecules are characterized by a specific rotation angle, the angle through which plane-polarized Light is rotated on passing through an enantiomerically enriched solution. Recent developments in methodology allow computation of both the sign and the magnitude of these rotation angles. However, a general strategy for assigning the individual contributions that atoms and functional groups make to the optical rotation angle and, more generally, to the molecular chirality has remained elusive, Here, a method to determine the atomic contributions to the optical rotation angle is reported. This approach Links chemical structure with optical rotation angle and provides a quantitative measure of molecular asymmetry propagation from a center, axis, or plane of chirality.	Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kondru, RK (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.		Beratan, David N/C-5098-2011; Wipf, Peter/AAG-1771-2021	Beratan, David N/0000-0003-4758-8676; Wipf, Peter/0000-0001-7693-5863	NIGMS NIH HHS [GM 55433-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055433] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS RD, 1982, CHEM PHYS LETT, V87, P23, DOI 10.1016/0009-2614(82)83545-8; AMOS RD, 1987, CAMBRIDGE ANAL DERIV; APPLEQUI.J, 1973, J CHEM PHYS, V58, P4251, DOI 10.1063/1.1678981; BAK KL, 1995, THEOR CHIM ACTA, V90, P441, DOI 10.1007/BF01113546; Born M, 1935, PROC R SOC LON SER-A, V150, P0084, DOI 10.1098/rspa.1935.0090; BREWSTER JH, 1961, TETRAHEDRON, V13, P106, DOI 10.1016/S0040-4020(01)92206-9; Costante J, 1997, ANGEW CHEM INT EDIT, V36, P885, DOI 10.1002/anie.199708851; Eliel EL., 1994, STEREOCHEMISTRY ORGA; FIRSCH MJ, 1995, GAUSSIAN 94; Freudenberg K, 1933, LIEBIGS ANN CHEM, V501, P199; GOULD RR, 1970, J AM CHEM SOC, V92, P1813, DOI 10.1021/ja00710a001; HELGAKER T, 1997, DALTON ABINITIO ELEC; Jung TA, 1997, NATURE, V386, P696, DOI 10.1038/386696a0; Kirkwood JG, 1937, J CHEM PHYS, V5, P479, DOI 10.1063/1.1750060; Kondru RK, 1998, J AM CHEM SOC, V120, P2204, DOI 10.1021/ja973690o; Kondru RK, 1997, CHIRALITY, V9, P469, DOI 10.1002/(SICI)1520-636X(1997)9:5/6<469::AID-CHIR13>3.0.CO;2-M; KUHN W, 1933, STEREOCHEMIE, V8, P394; LAKHTAKIA A, 1990, SELECTED PAPERS N MS, V15; Le Bel JA, 1874, B SOC CHIM FR, V22, P337; McKendry R, 1998, NATURE, V391, P566, DOI 10.1038/35339; MOFFITT W, 1956, J CHEM PHYS, V25, P467, DOI 10.1063/1.1742946; MOSCOWITZ A, 1962, ADV CHEM PHYS, V4, P67, DOI 10.1002/9780470143506.ch2; MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588; MULLIKEN RS, 1962, J CHEM PHYS, V36, P3428, DOI 10.1063/1.1732476; Nakanishi K., 1994, CIRCULAR DICHROISM P; PAO YH, 1966, J AM CHEM SOC, V88, P4157, DOI 10.1021/ja00970a008; Polavarapu PL, 1997, TETRAHEDRON-ASYMMETR, V8, P3397, DOI 10.1016/S0957-4166(97)00453-9; Polavarapu PL, 1998, J AM CHEM SOC, V120, P6160, DOI 10.1021/ja980838a; Pople JA., 1970, APPROXIMATE MOL ORBI; RAUK A, 1977, CHEM PHYS, V25, P409, DOI 10.1016/0301-0104(77)85151-3; Rosenfeld L., 1928, Z PHYS, V52, P161, DOI DOI 10.1007/BF01342393; RUCH E, 1972, ACCOUNTS CHEM RES, V5, P49, DOI 10.1021/ar50050a002; SATYANARAYANA BK, 1987, J ORG CHEM, V52, P3170; Snatzke G., 1991, CHIRALITY WEAK BOSON, P59, DOI 10.1007/978-3-642-76569-8_4; TINOCO I, 1963, J CHEM PHYS, V40, P160; van't Hoff JH., 1894, LAGERUNG ATOME RAUME, V2nd ed., P30; VANTHOFF JH, 1874, ARCH NEERL SCI EXACT, V9, P455; WALDEN P, 1894, Z PHYS CHEM, V15, P196; WROBLEWSKI AE, 1988, J AM CHEM SOC, V110, P4144, DOI 10.1021/ja00221a008	39	115	118	3	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 18	1998	282	5397					2247	2250		10.1126/science.282.5397.2247	http://dx.doi.org/10.1126/science.282.5397.2247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	150CR	9856945				2022-12-28	WOS:000077645800043
J	Barr, ML; Meiser, BM; Eisen, HJ; Roberts, RF; Livi, U; Dall'Amico, R; Dorent, R; Rogers, JG; Radovancevic, B; Taylor, DO; Jeevanandam, V; Marboe, CC; Franco, EL; Ventura, HO; Michler, RE; Griffith, BP; Boyce, SW; Reichart, B; Gandjbakhch, I				Barr, ML; Meiser, BM; Eisen, HJ; Roberts, RF; Livi, U; Dall'Amico, R; Dorent, R; Rogers, JG; Radovancevic, B; Taylor, DO; Jeevanandam, V; Marboe, CC; Franco, EL; Ventura, HO; Michler, RE; Griffith, BP; Boyce, SW; Reichart, B; Gandjbakhch, I		Photopheresis Transplantation Study Grp	Photopheresis for the prevention of rejection in cardiac transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							T-CELL LYMPHOMA; EXTRACORPOREAL PHOTOCHEMOTHERAPY; HEART-TRANSPLANTATION; SYSTEMIC-SCLEROSIS; IMMUNOMODULATION; RECIPIENTS; DISEASE	Background Photopheresis is an immunoregulatory technique in which lymphocytes are reinfused after exposure to a photoactive compound (methox-salen) and ultraviolet A light. We performed a preliminary study to assess the safety and efficacy of photopheresis in the prevention of acute rejection of cardiac allografts. Methods A total of 60 consecutive eligible recipients of primary cardiac transplants were randomly assigned to standard triple-drug immunosuppressive therapy (cyclosporine, azathioprine, and prednisone) alone or in conjunction with photopheresis. The photopheresis group received a total of 24 photopheresis treatments, each pair of treatments given on two consecutive days, during the first six months after transplantation. The regimen for maintenance immunosuppression, the definition and treatment of rejection episodes, the use of prophylactic antibiotics, and the schedule for cardiac biopsies were standardized among all 12 study centers. All the cardiac-biopsy samples were graded in a blinded manner at a central pathology laboratory. Plasma from the subgroup of 34 patients (57 percent) who were enrolled at the nine U.S. centers was analyzed by polymerase-chain-reaction amplification for cytomegalovirus DNA. Results After six months of follow-up, the mean (+/-SD) number of episodes of acute rejection per patient was 1.44+/-1.0 in the standard-therapy group, as compared with 0.91+/-1.0 in the photopheresis group (P=0.04). Significantly more patients in the photopheresis group had one rejection episode or none (27 of 33) than in the standard-therapy group (14 of 27), and significantly fewer patients in the photopheresis group had two or more rejection episodes (6 of 33) than in the standard-therapy group (13 of 27, P=0.02). There was no significant difference in the time to a first episode of rejection, the incidence of rejection associated with hemodynamic compromise, or survival at 6 and 12 months. Although there were no significant differences in the rates or types of infection, cytomegalovirus DNA was detected significantly less frequently in the photopheresis group than in the standard-therapy group (P=0.04). Conclusions In this pilot study, the addition of photopheresis to triple-drug immunosuppressive therapy significantly decreased the risk of cardiac rejection without increasing the incidence of infection. (N Engl J Med 1998;339:1744-51.) (C) 1998, Massachusetts Medical Society.	Univ So Calif, Div Cardiothorac Surg, Dept Surg, Los Angeles, CA 90033 USA; Univ Munich, D-80539 Munich, Germany; Univ Padua, I-35100 Padua, Italy; Texas Heart Inst, Houston, TX 77025 USA; Temple Univ, Dept Med, Philadelphia, PA 19122 USA; Hop La Pitie Salpetriere, Dept Med, Paris, France; Washington Univ, St Louis, MO 63130 USA; Univ Utah, Salt Lake City, UT 84112 USA; Columbia Univ, Dept Pathol, New York, NY 10027 USA	University of Southern California; University of Munich; University of Padua; Texas Heart Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Sorbonne Universite; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Columbia University	Barr, ML (corresponding author), Univ So Calif, Div Cardiothorac Surg, Dept Surg, 1510 San Pablo St, Los Angeles, CA 90033 USA.			LIVI, Ugolino/0000-0003-1394-736X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARR ML, 1995, TRANSPLANT P, V27, P1993; Barr ML, 1996, ARTIF ORGANS, V20, P971, DOI 10.1111/j.1525-1594.1996.tb04580.x; Billingham M E, 1990, J Heart Transplant, V9, P587; COSTANZONORDIN MR, 1992, CIRCULATION, V86, P242; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; GOODRICH RP, 1994, P NATL ACAD SCI USA, V91, P5552, DOI 10.1073/pnas.91.12.5552; KHAVARI PA, 1988, CLIN RES, V36, pA662; KNOBLER RM, 1993, J AM ACAD DERMATOL, V28, P580, DOI 10.1016/0190-9622(93)70077-7; KNOBLER RM, 1992, ARTHRITIS RHEUM, V35, P319, DOI 10.1002/art.1780350311; LEE KH, 1989, YALE J BIOL MED, V62, P621; MALAWISTA SE, 1991, ARTHRITIS RHEUM, V34, P646, DOI 10.1002/art.1780340604; MEISER BM, 1994, TRANSPLANTATION, V57, P563; PEPINO P, 1989, EUR SURG RES, V21, P105, DOI 10.1159/000129010; PEREZ M, 1989, J INVEST DERMATOL, V92, P669, DOI 10.1111/1523-1747.ep12696853; ROOK AH, 1990, ANN INTERN MED, V112, P303, DOI 10.7326/0003-4819-112-4-303; ROOK AH, 1992, ARCH DERMATOL, V128, P337, DOI 10.1001/archderm.128.3.337; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, P746; ROSTAMI A M, 1990, Neurology, V40, P393; VOWELS BR, 1992, J INVEST DERMATOL, V98, P686, DOI 10.1111/1523-1747.ep12499907; WOLF DG, 1993, TRANSPLANTATION, V56, P330, DOI 10.1097/00007890-199308000-00014; WOLFE JT, 1994, ARTIF ORGANS, V18, P888, DOI 10.1111/j.1525-1594.1994.tb03340.x; Yoo EK, 1996, J INVEST DERMATOL, V107, P235, DOI 10.1111/1523-1747.ep12329711	22	229	250	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1998	339	24					1744	1751		10.1056/NEJM199812103392404	http://dx.doi.org/10.1056/NEJM199812103392404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146XU	9845709				2022-12-28	WOS:000077459700004
J	Tononi, G; Edelman, GM				Tononi, G; Edelman, GM			Neuroscience - Consciousness and complexity	SCIENCE			English	Review							VISUAL AWARENESS; CORTICAL AREAS; THALAMOCORTICAL SYSTEM; UNCONSCIOUS PERCEPTION; NEURONAL INTERACTIONS; BINOCULAR-RIVALRY; NEURAL DYNAMICS; CEREBRAL-CORTEX; WORKING-MEMORY; BRAIN ACTIVITY	Conventional approaches to understanding consciousness are generally concerned with the contribution of specific brain areas or groups of neurons. By contrast, it : is considered here what kinds of neural processes can account for key properties of conscious experience. Applying measures of neural integration and complexity, together with an analysis of extensive neurological data, leads to a testable proposal-the dynamic core hypothesis-about the properties of the neural substrate of consciousness.	Inst Neurosci, San Diego, CA 92121 USA		Tononi, G (corresponding author), Inst Neurosci, 10640 John J Hopkins Dr, San Diego, CA 92121 USA.	tononi@nsi.edu						[Anonymous], 1993, BRAIN ACTIVATION; Baars B. J., 1988, COGNITIVE THEORY CON; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Bergman H, 1998, TRENDS NEUROSCI, V21, P32, DOI 10.1016/S0166-2236(97)01151-X; BIEDERMA.I, 1972, SCIENCE, V177, P77, DOI 10.1126/science.177.4043.77; Blumenthal A, 1977, PROCESS COGNITION; BOGEN JE, 1995, CONSCIOUS COGN, V4, P52, DOI 10.1006/ccog.1995.1003; Bradley DC, 1998, NATURE, V392, P714, DOI 10.1038/33688; Braun AR, 1998, SCIENCE, V279, P91, DOI 10.1126/science.279.5347.91; BRESSLER SL, 1995, BRAIN RES REV, V20, P288, DOI 10.1016/0165-0173(94)00016-I; Cauller L, 1995, BEHAV BRAIN RES, V71, P163, DOI 10.1016/0166-4328(95)00032-1; CRICK F, 1990, COLD SH Q B, V55, P953; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; EDELMAN GM, IN PRESS CONSCIOUSNE; EDLEMAN GM, 1989, REMEMBERED PRESENT; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; Flohr H, 1995, BEHAV BRAIN RES, V71, P157, DOI 10.1016/0166-4328(95)00033-X; Frackowiak RS., 1997, HUMAN BRAIN FUNCTION; Friston KJ, 1995, HUM BRAIN MAPP, V3, P302, DOI 10.1002/hbm.460030405; Friston KJ, 1998, P NATL ACAD SCI USA, V95, P796, DOI 10.1073/pnas.95.3.796; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; Gevins A, 1996, ELECTROEN CLIN NEURO, V98, P327, DOI 10.1016/0013-4694(96)00288-X; Goldman-Rakic P. S., 1994, Society for Neuroscience Abstracts, V20, P808; Gur M, 1997, VISION RES, V37, P377, DOI 10.1016/S0042-6989(96)00183-6; HAIER RJ, 1992, BRAIN RES, V570, P134, DOI 10.1016/0006-8993(92)90573-R; He S, 1996, NATURE, V383, P334, DOI 10.1038/383334a0; HE S, 1995, INVEST OPHTH VIS SCI, V36, pS438; HOLTZMAN JD, 1985, NEUROPSYCHOLOGIA, V23, P315, DOI 10.1016/0028-3932(85)90018-1; HOREL JA, 1967, SCIENCE, V158, P394, DOI 10.1126/science.158.3799.394; INTRAUB H, 1981, J EXP PSYCHOL HUMAN, V7, P604, DOI 10.1037/0096-1523.7.3.604; Jackendoff R, 1987, CONSCIOUSNESS COMPUT; Jacoby L. L., 1993, ATTENTION SELECTION, P261; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; Kahn D, 1997, NEUROSCIENCE, V78, P13; KIHLSTROM JF, 1992, CONSCIOUS COGN, V1, P47, DOI 10.1016/1053-8100(92)90044-B; Kolb B, 1996, FUNDAMENTALS HUMAN N; KOLB FC, 1995, NATURE, V377, P336, DOI 10.1038/377336a0; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; LIBET B, 1993, CIBA F SYMP, V174, P123; LLINAS R, 1994, TEMPORAL CODING BRAI; Lumer ED, 1997, CEREB CORTEX, V7, P228, DOI 10.1093/cercor/7.3.228; Lumer ED, 1997, CEREB CORTEX, V7, P207, DOI 10.1093/cercor/7.3.207; Macknik SL, 1998, NAT NEUROSCI, V1, P144, DOI 10.1038/393; Maquet P, 1996, NATURE, V383, P163, DOI 10.1038/383163a0; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P238, DOI 10.1016/0010-0285(83)90010-5; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Meador KJ, 1998, NEUROLOGY, V51, P721, DOI 10.1212/WNL.51.3.721; MERIKLE PM, 1992, AM PSYCHOL, V47, P792, DOI 10.1037/0003-066X.47.6.792; Milner A. D., 1995, VISUAL BRAIN ACTION; MILNER AD, 1995, NEUROPSYCHOLOGIA, V33, P1117, DOI 10.1016/0028-3932(95)00052-5; Mountcastle V.B., 1978, MINDFUL BRAIN CORTIC, P7; NEWMAN J, 1995, CONSCIOUS COGN, V4, P172, DOI 10.1006/ccog.1995.1024; Papoulis A., 1991, PROBABILITY RANDOM V; PASHLER H, 1994, PSYCHOL BULL, V116, P220, DOI 10.1037/0033-2909.116.2.220; Penfield W., 1958, EXCITABLE CORTEX CON; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; PICTON TW, 1994, CURR OPIN NEUROBIOL, V4, P256, DOI 10.1016/0959-4388(94)90082-5; Pigarev IN, 1997, NEUROREPORT, V8, P2557, DOI 10.1097/00001756-199707280-00027; Posner M. I., 1994, IMAGES MIND; Ryle G., 1949, CONCEPT MIND, DOI 10.4324/9780203875858; SCHACTER DL, 1992, P NATL ACAD SCI USA, V89, P11113, DOI 10.1073/pnas.89.23.11113; SCHNEIDER W, 1994, CURR OPIN NEUROBIOL, V4, P177, DOI 10.1016/0959-4388(94)90069-8; Seidemann E, 1996, J NEUROSCI, V16, P752; Sengpiel F, 1997, CURR BIOL, V7, pR447, DOI 10.1016/S0960-9822(06)00215-6; Shannon C.E., 1963, MATH THEORY COMMUNIC; Shenberg DL, 1997, P NATL ACAD SCI USA, V94, P3408, DOI 10.1073/pnas.94.7.3408; Shiffrin RM, 1997, CARN S COGN, P49; Simons DJ, 1997, TRENDS COGN SCI, V1, P261, DOI 10.1016/S1364-6613(97)01080-2; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Solms M., 1997, NEUROPSYCHOLOGY DREA; Srinivasan R., 1998, Society for Neuroscience Abstracts, V24, P433; Steriade M, 1997, CEREB CORTEX, V7, P583, DOI 10.1093/cercor/7.6.583; Taylor JL, 1996, EXP BRAIN RES, V110, P62; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; TONONI G, 1992, CEREB CORTEX, V2, P310, DOI 10.1093/cercor/2.4.310; Tononi G, 1996, P NATL ACAD SCI USA, V93, P3422, DOI 10.1073/pnas.93.8.3422; Tononi G, 1998, P NATL ACAD SCI USA, V95, P3198, DOI 10.1073/pnas.95.6.3198; TONONI G, 1998, CONSCIOUSNESS, P245; TONONI G, UNPUB; TONONI G, IN PRESS TRENDS COGN; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; Zeki S, 1998, P ROY SOC B-BIOL SCI, V265, P1583, DOI 10.1098/rspb.1998.0475; [No title captured]	87	933	957	5	156	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1998	282	5395					1846	1851		10.1126/science.282.5395.1846	http://dx.doi.org/10.1126/science.282.5395.1846			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	144WG	9836628				2022-12-28	WOS:000077338100038
J	Van Doren, M; Broihier, HT; Moore, LA; Lehmann, R				Van Doren, M; Broihier, HT; Moore, LA; Lehmann, R			HMG-CoA reductase guides migrating primordial germ cells	NATURE			English	Article							COENZYME-A REDUCTASE; DROSOPHILA-MELANOGASTER; EXPRESSION; PHENOTYPES; MESODERM	The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is best known for catalysing a rate-limiting step in cholesterol biosynthesis, but it also participates in the production of a wide variety of other compounds'. Some clinical benefits attributed to inhibitors of HMG-CoA reductase are now thought to be independent of any serum cholesterol-lowering effect(2,3). Here we describe a new cholesterol-independent role for HMG-CoA reductase, in regulating a developmental process: primordial germ cell migration. We show that in Drosophila this enzyme is highly expressed in the somatic gonad and that it is necessary for primordial germ cells to migrate to this tissue. Misexpression of HMG-CoA reductase is sufficient to attract primordial germ cells to tissues other than the gonadal mesoderm. We conclude that the regulated expression of HMG-CoA reductase has a critical developmental function in providing spatial information to guide migrating primordial germ cells.	NYU, Med Ctr, Skirball Inst, Dev Genet Program, New York, NY 10016 USA; NYU, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University	Lehmann, R (corresponding author), NYU, Med Ctr, Skirball Inst, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.	lehmann@saturn.med.nyu.edu		Broihier, Heather/0000-0003-1363-3088; Lehmann, Ruth/0000-0002-8454-5651				Boyle M, 1997, DEVELOPMENT, V124, P971; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROLHIER HT, 1998, DEVELOPMENT, V125, P655; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; CLAYTON RB, 1964, J LIPID RES, V5, P3; Corsini A, 1996, CARDIOLOGY, V87, P458, DOI 10.1159/000177139; CUNNINGHAM FM, 1994, LIPID MEDIATORS; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMPERTS M, 1994, CIBA F SYMP, V182, P121; KATZNELSON S, 1995, KIDNEY INT S, V52, P112; KIM SY, 1995, KIDNEY INT, V48, P363, DOI 10.1038/ki.1995.304; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Moore LA, 1998, DEVELOPMENT, V125, P667; Perrimon N, 1996, GENETICS, V144, P1681; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Van Doren M, 1998, CURR BIOL, V8, P243; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	20	137	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1998	396	6710					466	469		10.1038/24871	http://dx.doi.org/10.1038/24871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145KL	9853754				2022-12-28	WOS:000077370100054
J	Roy-Byrne, PP; Cowley, DS				Roy-Byrne, PP; Cowley, DS			Search for pathophysiology of panic disorder	LANCET			English	Editorial Material							SENSITIVITY		Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Roy-Byrne, PP (corresponding author), Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, 325 9Th Ave, Seattle, WA 98104 USA.		roy-byrne, peter/AAC-9130-2019; Roy-Byrne, Peter/AAV-2991-2020					Bellodi L, 1998, AM J PSYCHIAT, V155, P1184, DOI 10.1176/ajp.155.9.1184; Bisaga A, 1998, AM J PSYCHIAT, V155, P1178, DOI 10.1176/ajp.155.9.1178; CHARNEY DS, 1984, ARCH GEN PSYCHIAT, V41, P751; Coplan JD, 1997, ARCH GEN PSYCHIAT, V54, P643; COWLEY DS, 1990, ARCH GEN PSYCHIAT, V47, P277; Crowe RR, 1997, AM J PSYCHIAT, V154, P1096; DAGER SR, 1994, AM J PSYCHIAT, V151, P57; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; Kent JM, 1996, PSYCHIAT RES, V64, P83, DOI 10.1016/0165-1781(96)02840-5; KLEIN DF, 1964, PSYCHOPHARMACOLOGIA, V5, P397, DOI 10.1007/BF02193476; KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306; Knowles JA, 1998, AM J MED GENET, V81, P139, DOI 10.1002/(SICI)1096-8628(19980328)81:2<139::AID-AJMG4>3.0.CO;2-R; LEDOUX JE, 1993, BEHAV BRAIN RES, V58, P69, DOI 10.1016/0166-4328(93)90091-4; Malizia AL, 1998, ARCH GEN PSYCHIAT, V55, P715, DOI 10.1001/archpsyc.55.8.715; NORDAHL TE, 1990, NEUROPSYCHOPHARMACOL, V3, P261; NUTT DJ, 1990, ARCH GEN PSYCHIAT, V47, P917; Papp LA, 1997, AM J PSYCHIAT, V154, P1557; REIMAN EM, 1986, AM J PSYCHIAT, V143, P469; ROYBYRNE PP, 1990, ARCH GEN PSYCHIAT, V47, P534; Smoller JW, 1998, AM J PSYCHIAT, V155, P1152, DOI 10.1176/ajp.155.9.1152; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Wilkinson DJC, 1998, ARCH GEN PSYCHIAT, V55, P511, DOI 10.1001/archpsyc.55.6.511	22	15	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 21	1998	352	9141					1646	1647		10.1016/S0140-6736(05)61445-6	http://dx.doi.org/10.1016/S0140-6736(05)61445-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	140VX	9853434				2022-12-28	WOS:000077110300006
J	Krijnen, P; van Jaarsveld, BC; Steyerberg, EW; 't Veld, AJM; Schalekamp, MADH; Habbema, JDF				Krijnen, P; van Jaarsveld, BC; Steyerberg, EW; 't Veld, AJM; Schalekamp, MADH; Habbema, JDF			A clinical prediction rule for renal artery stenosis	ANNALS OF INTERNAL MEDICINE			English	Article						renal artery obstruction; angiography; prediction rule; hypertension, renovascular; creatine	RENOVASCULAR HYPERTENSION; ANGIOGRAPHY; DIAGNOSIS; INTERVENTION; MODELS; TESTS	Background: Renal artery stenosis is a rare cause of hypertension. The gold standard for diagnosing renal artery stenosis, renal angiography, is invasive and costly. Objective: To develop a prediction rule for renal artery stenosis from clinical characteristics that can be used to select patients for renal angiography. Design: Logistic regression analysis of data from a prospective cohort of patients suspected of having renal artery stenosis. A prediction rule was derived from the regression model for use in clinical practice. Setting: 26 hypertension clinics in the Netherlands. Patients: 477 hypertensive patients who underwent renal angiography because they had drug-resistant hypertension or an increase in serum creatinine concentration during therapy with angiotensin-converting enzyme inhibitors. Results: Age, sex, atherosclerotic vascular disease, recent onset of hypertension, smoking history, body mass index, presence of an abdominal bruit, serum creatinine concentration, and serum cholesterol level were selected as predictors. The regression model was reliable (goodness-of-fit test, P > 0.2) and discriminated well between patients with stenosis and those with essential hypertension (area under the receiver-operating characteristic curve, 0.84). The diagnostic accuracy of the regression model was similar to that of renal scintigraphy, which had a sensitivity of 72% and a specificity of 90%. Conclusions: In the diagnostic workup of patients suspected of having renal artery stenosis, the clinical prediction rule can be considered as an alternative to renal scintigraphy. It can help to select patients for renal angiography in an efficient manner by reducing the number of angiographic procedures without the risk for missing many renal artery stenoses.	Erasmus Univ, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Univ Hosp Dijkzigt, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Krijnen, P (corresponding author), Erasmus Univ, Dept Publ Hlth, Ctr Clin Decis Sci, Room EE2085,Box 1738, NL-3000 DR Rotterdam, Netherlands.	krijnen@ckb.fgg.eur.nl	; Steyerberg, Ewout/C-1509-2018	van Jaarsveld, Brigit/0000-0001-5871-4952; Steyerberg, Ewout/0000-0002-7787-0122				Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; ANDERSON GH, 1988, AM J HYPERTENS, V1, P301, DOI 10.1093/ajh/1.3.301; [Anonymous], 1987, ARCH INTERN MED, V147, P820; Bijlstra PJ, 1996, J HYPERTENS, V14, P1033; DAVIS BA, 1979, NEW ENGL J MED, V301, P1273, DOI 10.1056/NEJM197912063012307; DERKX FHM, 1994, LANCET, V344, P237, DOI 10.1016/S0140-6736(94)93002-3; DUNNICK NR, 1991, RADIOL CLIN N AM, V29, P497; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; EIPPER DF, 1976, AM J CARDIOL, V37, P48, DOI 10.1016/0002-9149(76)90498-7; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; GRANERUS G, 1992, J INTERN MED, V232, P15, DOI 10.1111/j.1365-2796.1992.tb00545.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HARRELL FE, 1997, DESIGN S PLUS FUNCTI; HESSEL SJ, 1981, RADIOLOGY, V138, P273, DOI 10.1148/radiology.138.2.7455105; HOSMER DW, 1989, APPL LOGISTIC REGRES, P135; KAPLAN NM, 1994, CLIN HYPERTENSION, P1; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; NICHOLSON JP, 1983, LANCET, V2, P765; PICKERING TG, 1991, CLIN CHEM, V37, P1831; Pickering TG, 1996, J HYPERTENS, V14, P1265, DOI 10.1097/00004872-199611000-00002; PICKERING TG, 1991, CIRCULATION, V83, P147; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RUDNICK MR, 1994, AM J KIDNEY DIS, V24, P713, DOI 10.1016/S0272-6386(12)80235-6; RUTTIMAN S, 1993, ANN INTERN MED, V118, P905, DOI 10.7326/0003-4819-118-11-199306010-00015; SIMON N, 1972, J AMER MED ASSOC, V220, P1209, DOI 10.1001/jama.220.9.1209; SVETKEY LP, 1990, SOUTHERN MED J, V83, P743, DOI 10.1097/00007611-199007000-00005; TEGTMEYER CJ, 1996, RENAL VASCULAR DIS, P363; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; vanJaarsveld BC, 1996, CONTRIB NEPHROL, V119, P54; vanJaarsveld BC, 1997, ARCH INTERN MED, V157, P1226, DOI 10.1001/archinte.157.11.1226; VANJAARSVELD BC, 1995, J NEPHROL, V8, P5; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	36	144	154	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1998	129	9					705	+		10.7326/0003-4819-129-9-199811010-00005	http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	135DH	9841602				2022-12-28	WOS:000076785200004
J	Harrison, R; Burr, M				Harrison, R; Burr, M			Secondary prevention in acute myocardial infarction - Diet containing oil-rich fish confers more benefit than some pharmacological regimens	BRITISH MEDICAL JOURNAL			English	Letter									Wigan & Bolton Hlth Author, Wigan WN1 1AH, England; Univ Wales Coll Med, Ctr Appl Publ Hlth Med, Cardiff CF1 3NW, S Glam, Wales	Cardiff University	Harrison, R (corresponding author), Wigan & Bolton Hlth Author, Wigan WN1 1AH, England.							BURR ML, 1989, LANCET, V2, P757; Mehta RH, 1998, BMJ-BRIT MED J, V316, P838, DOI 10.1136/bmj.316.7134.838	2	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1153	1153						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9841050				2022-12-28	WOS:000076755100047
J	Shortman, K; Maraskovsky, E				Shortman, K; Maraskovsky, E			Immunology - Developmental options	SCIENCE			English	Editorial Material							DENDRITIC CELL-DEVELOPMENT; COLONY-STIMULATING FACTOR; PATHWAYS; BLOOD		Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Ludwig Inst Canc Res, Oncol Unit, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research	Shortman, K (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.							Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; D'Amico G, 1998, BLOOD, V92, P207, DOI 10.1182/blood.V92.1.207.413a02_207_214; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; MARASKOVSKY E, DENDRITIC CELLS BIOL; Metcalf D, 1997, P NATL ACAD SCI USA, V94, P11552, DOI 10.1073/pnas.94.21.11552; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Rescigno M, 1998, P NATL ACAD SCI USA, V95, P5229, DOI 10.1073/pnas.95.9.5229; Saunders D, 1996, J EXP MED, V184, P2185, DOI 10.1084/jem.184.6.2185; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; SHORTMAN K, DENDRITIC CELLS BIOL; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; Vremec D, 1997, EUR J IMMUNOL, V27, P40, DOI 10.1002/eji.1830270107; Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903	19	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					424	425		10.1126/science.282.5388.424	http://dx.doi.org/10.1126/science.282.5388.424			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9841399				2022-12-28	WOS:000076479600037
J	Beecham, L				Beecham, L			Lords criticise government's response to cannabis report	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1663	1663						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848927				2022-12-28	WOS:000077602100077
J	Beecham, L				Beecham, L			Consultants issue guidance on professional advisory panels	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1998	317	7173					1663	1663						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	149JW	9848927				2022-12-28	WOS:000077602100076
J	Boettcher, B				Boettcher, B			Fatal episodes in medical history	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1998	317	7172					1603	1603						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	146VC	9836691				2022-12-28	WOS:000077451700090
J	Kandela, P				Kandela, P			Road-traffic accidents	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1912, LANCET          0720, P166; 1896, LANCET          1121, P1484; 1912, LANCET          0210, P396; 1913, LANCET          1025, P1227; 1902, LANCET          1213, P1641; 1866, LANCET          0407, P376; 1902, LANCET          0705, P46; 1896, LANCET          0425, P1143	8	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 31	1998	352	9138					1483	1483		10.1016/S0140-6736(05)61321-9	http://dx.doi.org/10.1016/S0140-6736(05)61321-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134AJ	9841274				2022-12-28	WOS:000076719500071
